Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).
If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelsystem.org.

Sentinel

Overview for Request: cder_mpl1p_wp066

Request ID: cder_mpl1p_wp066_nsdp_v01

Request Description: In this report, we estimated rates of valsartan utilization and patient follow-up time, by N-nitrosodimethylamine (NDMA) contamination categories. We additionally summarized the cumulative exposed duration and cumulative exposed dose for valsartan products by NDMA contamination categories in the Sentinel Distributed Database (SDD).
Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) module, version 11.3.0, with custom programming
Data Source: We distributed this query to six Sentinel Data Partners on June 23, 2023. This report presents data from a subset of five Data Partners, including the nationally-representative commercial insurers and Medicare. The study period included data from May 1, 2012 through December 31, 2022. See Appendix A for the of dates of available data for each Data Partner.
Study Design: We identified individuals with prevalent and new use of NDMA-contaminated and non-contaminated valsartan, among a cohort who were 18+ years of age with no prior evidence of cancer. We present counts of patients and treatment episodes overall and further stratified by year-month and year-month by age group. We additionally described available follow-up time and reasons for censoring per cohort, and estimated cumulative treatment episode duration, cumulative filled treatment dose, and cumulative dose stratified by episode duration. This was a Type 2 and Type 5 analysis in the Query Request Package (QRP) documentation.
Exposure of Interest: We defined the exposure of interest, valsartan, from outpatient dispensing data using National Drug Codes (NDCs). We defined new valsartan use as no evidence of any valsartan product in the 365 days prior to the qualifying exposure (index); we had no washout requirement for our definition of prevalent valsartan use. Each qualifying dispensing of valsartan was identified per patient; cohort re-entry was allowed. Please see Appendix B for a list of generic and brand names of medical products used to define exposures in this request.

NDMA Contamination Evaluation: Valsartan exposure was classified as NDMA contaminated and non-contaminated. Contaminated valsartan products were defined using a list of Abbreviated New Drug Application (ANDA) numbers that had NDMA contaminant detected, which then mapped to corresponding NDCs for valsartan. Products with no NDMA were classified as non-contaminated. The manufacturing process that introduced the NDMA contamination was resolved as of January 1, 2019. Therefore, from January 1, 2019 all NDCs that were previously classified as contaminated products were now treated as non-contaminated valsartan products for any new dispensings on or after that date.

Cohort Eligibility Criteria: We required members to be enrolled in health plans with medical and drug coverage in the 365 days prior to their index date in order to be included in the cohort; a gap in coverage of up to 45 days was allowed and treated as continuous enrollment. The following age groups were included in the cohort: 18-44, 45-64, 65-74, 75-84, and 85+ years.

Exclusion Criteria: We excluded index exposure episodes with evidence of a cancer diagnosis or cancer related treatment (chemotherapy, radiation therapy, or cancer-specific surgery) in the 365 days prior to exposure. Please see Appendices C, D, and D.1 for a list of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS), Current Procedural Terminology (CPT), Health Care Procedure Coding System (HCPCS), and NDC codes used to define the exclusion criteria in this request.

Follow-up Time: We created exposure episodes based on the number of days of valsartan supplied per dispensing in the outpatient pharmacy dispensing data. We bridged together episodes less than 30 days apart and added 30 days to the end of each episode. Follow-up began on the day of the index dispensing and continued until the first occurrence of any censoring reason. Based on the NDMA contamination category, we created sensitivity analysis cohorts that evaluated the following combinations of censoring reasons:

Overview for Request: cder_mpl1p_wp066

Follow-up Time, continued:

Any valsartan:

1) a) disenrollment; b) death; c) the end of the data provided by each Data Partner; d) the end of the query period; e) end of exposure episode; f) switch to another anti-hypertensive agent.

Contaminated valsartan:

1) a) disenrollment; b) death; c) the end of the data provided by each Data Partner; d) the end of the query period; e) end of exposure episode; f) switch to another anti-hypertensive agent; g) switch to non-contaminated valsartan; h) switch to unclassified valsartan.

2) a) disenrollment; b) death; c) the end of the data provided by each Data Partner; d) the end of the query period

3) a) disenrollment; b) death; c) the end of the data provided by each Data Partner; d) the end of the query period; e) switch to non-contaminated valsartan; f) switch to unclassified valsartan.

Non-contaminated valsartan:

1) a) disenrollment; b) death; c) the end of the data provided by each Data Partner; d) the end of the query period; e) end of exposure episode; f) switch to another anti-hypertensive agent; g) switch to contaminated valsartan; h) switch to unclassified valsartan.

2) a) disenrollment; b) death; c) the end of the data provided by each Data Partner; d) the end of the query period

3) a) disenrollment; b) death; c) the end of the data provided by each Data Partner; d) the end of the query period; e) switch to contaminated valsartan; f) switch to unclassified valsartan.

Please see Appendix E for a list of generic and brand names of medical products used to define censoring criteria in this request.

Cumulative Dose Evaluation: Cumulative dose was calculated after dispensings were bridged into treatment episodes by multiplying the drug strength by the amount dispensed in each dispensing, and summing over all dispensings identified by the relevant NDC codes within that episode. Cumulative dose categories were determined by using 80mg as a maximum daily dose for combination products and 320 mg as a maximum daily dose for single valsartan products, and assuming <6, 6-12, 13-18, 19-24 and 25+ exposure months, to correspond to our episode duration categories of interest.

Please see Appendices F-H for the specifications defining parameters in this request and a design diagram of cohort entry requirements.

Limitations: Algorithms used to define exposures and exclusion criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelsystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (https://dev.sentinelsystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse).

Sentinel

Table of Contents

Glossary List of Terms to Define the Cohort Identification and Descriptive Analysis (CIDA) Found in this Report

Table 1 Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

Table 2 Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

Table 3 Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

Table 4 Summary of Time to End of At-Risk Period for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

Table 5 Summary of Reasons for End of At-Risk Period for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

Table 6a Summary of Time to End of At-Risk Period due to End of Exposure Episode for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

Table 6b Summary of Time to End of At-Risk Period due to Evidence of Death for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

Table 6c Summary of Time to End of At-Risk Period due to Disenrollment for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

Table 6d Summary of Time to End of At-Risk Period due to End of Data for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

Table 6e Summary of Time to End of At-Risk Period due to End of Study Period for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

Table 6f Summary of Time to End of At-Risk Period due to Switch to Other Antihypertensive for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

Table 6g Summary of Time to End of At-Risk Period due to Switch to Contaminated Product for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

Table 6h Summary of Time to End of At-Risk Period due to Switch to Non-Contaminated Product for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

Table 6i Summary of Time to End of At-Risk Period due to Switch to Unclassified Product for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

Table 7a Categorical Summary of Patients' Cumulative Treatment Episode Durations for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

Table 7b Continuous Summary of Patients' Cumulative Treatment Episode Durations for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

Table 8a Summary of Cumulative Filled Dose in All Treatment Episodes for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

Sentinel

Table of Contents

Table 8b	Summary of Cumulative Filled Dose in All Treatment Episodes for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Cumulative Episode Duration
Table 9a	Summary of Cumulative Filled Dose in Each Patient's First Treatment Episode for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022
Table 9b	Summary of Cumulative Filled Dose in Each Patient's First Treatment Episode for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Episode Duration
Table 10	Summary of Episode Level Cohort Attrition in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022
Appendix A	Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (June 23, 2023)
Appendix B	List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request
Appendix C	List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request
Appendix D	Appendix D. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Exclusion Criteria in this Request
Appendix E	List of Generic and Brand Names of Medical Products Used to Define Exposure Censoring Criteria in this Request
Appendix F	Specifications Defining Type 2 Parameters Used in this Request
Appendix G	Specifications Defining Type 5 Parameters Used in this Request
Appendix H	Design Diagram of Cohort Entry Requirements and Index Exposure

Sentinel

Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module*

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

- **Ambulatory Visit (AV) -** includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.
- **Emergency Department (ED) -** includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.
- **Inpatient Hospital Stay (IP) -** includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.
- **Non-Acute Institutional Stay (IS) -** includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.
- **Other Ambulatory Visit (OA) -** includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a “continuously enrolled” sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Sentinel

Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module*

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.
Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.
Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.
Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.
Query Period - period in which the modular program looks for exposures and outcomes of interest.
Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).
Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.
Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.
Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.
Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.
Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.
Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.
Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.
*all terms may not be used in this report

Sentinel

Table 1. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
Prevalent Use - All Censoring Options					
Any valsartan product	1,771,282	3,060,902	112,034,263	158.10	291,859,190.6
Contaminated valsartan	1,054,228	1,663,906	112,034,263	94.10	291,859,190.6
Non-contaminated valsartan	1,698,545	2,817,719	112,034,263	151.61	291,859,190.6
New Use - All Censoring Options					
Any valsartan product	1,071,474	1,107,774	110,677,579	96.81	284,837,293.4
Contaminated valsartan	265,082	267,426	110,677,579	23.95	284,837,293.4
Non-contaminated valsartan	749,276	764,735	110,677,579	67.70	284,837,293.4
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death					
Contaminated valsartan	1,054,228	1,056,944	112,034,263	94.10	291,859,190.6
New Use - Censoring on Query/Data End Date, Disenrollment, or Death					
Contaminated valsartan	265,082	265,115	110,677,579	23.95	284,837,293.4
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan					
Contaminated valsartan	1,054,228	1,314,531	112,034,263	94.10	291,859,190.6
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan					
Contaminated valsartan	265,082	265,415	110,677,579	23.95	284,837,293.4
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan					
Non-contaminated valsartan	1,698,545	2,050,473	112,034,263	151.61	291,859,190.6
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan					
Non-contaminated valsartan	749,276	753,576	110,677,579	67.70	284,837,293.4

[1]Eligible Members and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.

Sentinel

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
Prevalent Use - All Censoring Options					
Any valsartan product					
2012					
May	32,699	32,699	25,037,571	13.06	2,059,417.0
June	30,257	30,257	25,189,032	12.01	1,995,720.7
July	30,453	30,453	25,114,413	12.13	2,064,209.9
August	30,441	30,441	25,201,684	12.08	2,067,790.3
September	27,984	27,984	25,226,516	11.09	2,004,250.1
October	31,608	31,608	25,197,209	12.54	2,076,404.4
November	30,291	30,291	25,154,995	12.04	2,012,049.3
December	28,935	28,935	26,907,071	10.75	2,085,152.1
2013					
January	33,793	33,793	25,515,562	13.24	2,102,004.1
February	28,753	28,753	25,116,637	11.45	1,895,241.6
March	28,443	28,443	25,202,977	11.29	2,100,368.5
April	29,180	29,180	25,164,004	11.60	2,030,426.9
May	27,862	27,862	25,172,091	11.07	2,098,248.5
June	25,558	25,558	25,186,373	10.15	2,032,360.1
July	27,128	27,128	25,258,408	10.74	2,107,216.5
August	26,056	26,056	25,323,784	10.29	2,109,684.6
September	25,020	25,020	25,307,914	9.89	2,041,118.5
October	26,187	26,187	25,279,522	10.36	2,106,888.1
November	23,297	23,297	25,225,095	9.24	2,036,767.4
December	23,829	23,829	25,174,242	9.47	2,100,586.5
2014					
January	28,828	28,828	27,849,194	10.35	2,319,398.7
February	25,677	25,677	27,723,842	9.26	2,091,197.3
March	26,981	26,981	27,720,463	9.73	2,310,506.0
April	25,091	25,091	27,677,987	9.07	2,231,167.4
May	24,189	24,189	27,611,963	8.76	2,299,220.3
June	23,178	23,178	27,551,141	8.41	2,221,475.0
July	24,404	24,404	27,692,802	8.81	2,307,748.1
August	24,500	24,500	27,623,875	8.87	2,300,664.1

Sentinel

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
September	24,944	24,944	27,576,759	9.05	2,224,207.8
October	26,684	26,684	27,623,755	9.66	2,299,679.7
November	22,398	22,398	27,537,785	8.13	2,223,127.0
December	24,158	24,158	27,534,200	8.77	2,292,244.4
2015					
January	25,966	25,966	28,507,219	9.11	2,373,852.2
February	23,446	23,446	28,418,228	8.25	2,141,385.8
March	26,137	26,137	28,479,015	9.18	2,372,262.6
April	24,598	24,598	28,551,083	8.62	2,301,006.8
May	22,915	22,915	28,619,932	8.01	2,382,922.5
June	23,696	23,696	28,627,068	8.28	2,307,484.0
July	23,298	23,298	28,638,197	8.14	2,386,027.6
August	22,848	22,848	28,669,043	7.97	2,388,587.9
September	23,468	23,468	28,711,596	8.17	2,315,183.8
October	23,960	23,960	28,755,162	8.33	2,392,177.7
November	22,712	22,712	28,673,735	7.92	2,312,926.5
December	24,345	24,345	28,695,749	8.48	2,388,795.3
2016					
January	26,350	26,350	29,111,959	9.05	2,422,941.4
February	25,690	25,690	29,466,686	8.72	2,266,279.3
March	27,279	27,279	29,524,831	9.24	2,427,638.3
April	25,083	25,083	29,522,157	8.50	2,347,907.8
May	25,073	25,073	29,519,741	8.49	2,428,156.6
June	25,172	25,172	29,650,174	8.49	2,350,686.9
July	23,480	23,480	29,617,388	7.93	2,432,498.5
August	25,904	25,904	29,656,132	8.73	2,433,403.9
September	25,082	25,082	29,720,103	8.44	2,359,272.9
October	25,783	25,783	29,667,284	8.69	2,443,280.5
November	25,709	25,709	29,757,217	8.64	2,366,224.3
December	26,497	26,497	32,616,611	8.12	2,456,669.2
2017					
January	28,330	28,330	29,791,025	9.51	2,451,826.8
February	25,899	25,899	29,375,850	8.82	2,211,700.2

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
March	28,987	28,987	29,469,628	9.84	2,450,910.7
April	25,546	25,546	29,439,693	8.68	2,370,876.0
May	27,699	27,699	29,437,367	9.41	2,448,578.1
June	26,751	26,751	29,439,216	9.09	2,371,334.5
July	24,904	24,904	29,432,901	8.46	2,452,827.3
August	26,895	26,895	29,534,567	9.11	2,456,479.8
September	25,223	25,223	29,559,696	8.53	2,381,655.9
October	27,463	27,463	29,645,849	9.26	2,466,918.1
November	27,121	27,121	29,629,508	9.15	2,388,292.8
December	26,785	26,785	29,735,072	9.01	2,474,523.9
2018					
January	30,879	30,879	29,618,242	10.43	2,462,898.6
February	28,404	28,404	29,532,855	9.62	2,223,085.3
March	30,967	30,967	29,610,227	10.46	2,462,430.8
April	29,822	29,822	29,551,740	10.09	2,379,778.9
May	29,668	29,668	29,522,512	10.05	2,455,191.5
June	27,613	27,613	29,504,915	9.36	2,376,073.2
July	19,617	19,617	29,463,164	6.66	2,454,418.3
August	11,749	11,749	29,532,183	3.98	2,456,352.4
September	12,060	12,060	29,522,364	4.09	2,378,819.7
October	16,978	16,978	29,566,733	5.74	2,457,726.3
November	17,631	17,631	29,544,015	5.97	2,380,611.4
December	15,755	15,755	29,583,424	5.33	2,462,259.0
2019					
January	19,490	19,490	29,268,809	6.66	2,432,776.2
February	19,094	19,094	29,161,945	6.55	2,195,559.8
March	27,365	27,365	29,212,707	9.37	2,429,142.7
April	27,145	27,145	29,135,284	9.32	2,344,370.3
May	26,544	26,544	29,078,440	9.13	2,417,645.1
June	20,921	20,921	29,020,841	7.21	2,336,645.1
July	22,118	22,118	29,020,146	7.62	2,415,666.3
August	21,688	21,688	29,045,845	7.47	2,415,286.6
September	22,743	22,743	29,035,322	7.83	2,338,348.1

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
October	31,319	31,319	29,058,781	10.78	2,415,321.8
November	23,450	23,450	29,025,430	8.08	2,338,127.8
December	21,625	21,625	29,064,420	7.44	2,419,678.3
2020					
January	24,732	24,732	28,945,159	8.54	2,404,497.1
February	21,759	21,759	29,134,820	7.47	2,246,785.9
March	24,906	24,906	29,181,132	8.53	2,403,523.4
April	18,254	18,254	29,325,560	6.22	2,350,041.9
May	16,209	16,209	29,776,772	5.44	2,456,946.0
June	18,438	18,438	30,147,554	6.12	2,395,082.4
July	19,463	19,463	30,228,019	6.44	2,482,123.8
August	18,455	18,455	30,299,161	6.09	2,489,338.2
September	18,947	18,947	30,321,956	6.25	2,408,978.8
October	19,880	19,880	30,372,379	6.55	2,499,283.0
November	18,765	18,765	30,441,235	6.16	2,428,868.9
December	20,382	20,382	33,253,737	6.13	2,529,190.1
2021					
January	21,935	21,935	31,018,435	7.07	2,553,395.9
February	20,679	20,679	30,803,057	6.71	2,316,300.2
March	25,424	25,424	30,840,728	8.24	2,569,539.9
April	22,789	22,789	30,385,816	7.50	2,460,336.9
May	21,083	21,083	30,065,301	7.01	2,508,556.9
June	22,329	22,329	29,895,294	7.47	2,408,769.7
July	20,930	20,930	29,746,280	7.04	2,477,228.6
August	21,237	21,237	29,616,594	7.17	2,466,125.7
September	21,024	21,024	29,481,144	7.13	2,377,386.9
October	21,735	21,735	29,406,455	7.39	2,447,263.4
November	21,374	21,374	29,277,168	7.30	2,361,627.3
December	22,331	22,331	29,192,796	7.65	2,433,417.9
2022					
January	27,581	27,581	28,581,401	9.65	2,383,511.1
February	25,611	25,611	28,429,449	9.01	2,144,248.0
March	27,565	27,565	28,455,494	9.69	2,367,948.4

Sentinel

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
April	21,956	21,956	28,381,100	7.74	2,285,829.1
May	22,013	22,013	28,353,217	7.76	2,358,361.3
June	22,080	22,080	28,360,943	7.79	2,283,088.1
July	20,698	20,698	28,305,787	7.31	2,355,205.7
August	22,554	22,554	28,380,202	7.95	2,356,117.3
September	19,932	19,932	23,978,858	8.31	1,929,836.1
October	5,131	5,131	10,783,931	4.76	900,782.5
November	1,611	1,611	3,643,475	4.42	295,032.8
December	1,565	1,565	3,662,240	4.27	306,370.9
Contaminated valsartan					
2012					
May	0	0	25,037,571	0.00	2,059,417.0
June	0	0	25,189,032	0.00	1,995,720.7
July	0	0	25,114,413	0.00	2,064,209.9
August	0	0	25,201,684	0.00	2,067,790.3
September	5,903	5,903	25,226,516	2.34	2,004,250.1
October	34,684	34,684	25,197,209	13.77	2,076,404.4
November	17,532	17,532	25,154,995	6.97	2,012,049.3
December	12,012	12,012	26,907,071	4.46	2,085,152.1
2013					
January	11,389	11,389	25,515,562	4.46	2,102,004.1
February	7,564	7,564	25,116,637	3.01	1,895,241.6
March	7,054	7,054	25,202,977	2.80	2,100,368.5
April	19,816	19,816	25,164,004	7.87	2,030,426.9
May	19,484	19,484	25,172,091	7.74	2,098,248.5
June	15,978	15,978	25,186,373	6.34	2,032,360.1
July	13,949	13,949	25,258,408	5.52	2,107,216.5
August	10,791	10,791	25,323,784	4.26	2,109,684.6
September	10,555	10,555	25,307,914	4.17	2,041,118.5
October	9,637	9,637	25,279,522	3.81	2,106,888.1
November	9,954	9,954	25,225,095	3.95	2,036,767.4
December	9,065	9,065	25,174,242	3.60	2,100,586.5
2014					

Sentinel

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
January	10,711	10,711	27,849,194	3.85	2,319,398.7
February	11,438	11,438	27,723,842	4.13	2,091,197.3
March	14,756	14,756	27,720,463	5.32	2,310,506.0
April	12,824	12,824	27,677,987	4.63	2,231,167.4
May	10,457	10,457	27,611,963	3.79	2,299,220.3
June	8,893	8,893	27,551,141	3.23	2,221,475.0
July	11,563	11,563	27,692,802	4.18	2,307,748.1
August	11,948	11,948	27,623,875	4.33	2,300,664.1
September	11,068	11,068	27,576,759	4.01	2,224,207.8
October	19,306	19,306	27,623,755	6.99	2,299,679.7
November	14,706	14,706	27,537,785	5.34	2,223,127.0
December	16,848	16,848	27,534,200	6.12	2,292,244.4
2015					
January	23,996	23,996	28,507,219	8.42	2,373,852.2
February	29,664	29,664	28,418,228	10.44	2,141,385.8
March	27,916	27,916	28,479,015	9.80	2,372,262.6
April	25,129	25,129	28,551,083	8.80	2,301,006.8
May	24,128	24,128	28,619,932	8.43	2,382,922.5
June	30,366	30,366	28,627,068	10.61	2,307,484.0
July	31,455	31,455	28,638,197	10.98	2,386,027.6
August	27,377	27,377	28,669,043	9.55	2,388,587.9
September	22,996	22,996	28,711,596	8.01	2,315,183.8
October	20,287	20,287	28,755,162	7.06	2,392,177.7
November	21,011	21,011	28,673,735	7.33	2,312,926.5
December	25,264	25,264	28,695,749	8.80	2,388,795.3
2016					
January	31,198	31,198	29,111,959	10.72	2,422,941.4
February	33,388	33,388	29,466,686	11.33	2,266,279.3
March	37,230	37,230	29,524,831	12.61	2,427,638.3
April	43,027	43,027	29,522,157	14.57	2,347,907.8
May	43,445	43,445	29,519,741	14.72	2,428,156.6
June	38,502	38,502	29,650,174	12.99	2,350,686.9
July	34,284	34,284	29,617,388	11.58	2,432,498.5

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
August	38,030	38,030	29,656,132	12.82	2,433,403.9
September	37,168	37,168	29,720,103	12.51	2,359,272.9
October	33,917	33,917	29,667,284	11.43	2,443,280.5
November	28,615	28,615	29,757,217	9.62	2,366,224.3
December	26,224	26,224	32,616,611	8.04	2,456,669.2
2017					
January	27,371	27,371	29,791,025	9.19	2,451,826.8
February	24,425	24,425	29,375,850	8.31	2,211,700.2
March	25,944	25,944	29,469,628	8.80	2,450,910.7
April	22,270	22,270	29,439,693	7.56	2,370,876.0
May	24,323	24,323	29,437,367	8.26	2,448,578.1
June	25,880	25,880	29,439,216	8.79	2,371,334.5
July	30,534	30,534	29,432,901	10.37	2,452,827.3
August	32,181	32,181	29,534,567	10.90	2,456,479.8
September	27,200	27,200	29,559,696	9.20	2,381,655.9
October	26,844	26,844	29,645,849	9.05	2,466,918.1
November	26,261	26,261	29,629,508	8.86	2,388,292.8
December	26,157	26,157	29,735,072	8.80	2,474,523.9
2018					
January	29,480	29,480	29,618,242	9.95	2,462,898.6
February	27,131	27,131	29,532,855	9.19	2,223,085.3
March	28,469	28,469	29,610,227	9.61	2,462,430.8
April	26,122	26,122	29,551,740	8.84	2,379,778.9
May	26,296	26,296	29,522,512	8.91	2,455,191.5
June	26,392	26,392	29,504,915	8.94	2,376,073.2
July	18,093	18,093	29,463,164	6.14	2,454,418.3
August	8,475	8,475	29,532,183	2.87	2,456,352.4
September	8,880	8,880	29,522,364	3.01	2,378,819.7
October	12,924	12,924	29,566,733	4.37	2,457,726.3
November	14,070	14,070	29,544,015	4.76	2,380,611.4
December	13,682	13,682	29,583,424	4.62	2,462,259.0
2019					
January	0	0	29,268,809	0.00	2,432,776.2

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
February	0	0	29,161,945	0.00	2,195,559.8
March	0	0	29,212,707	0.00	2,429,142.7
April	0	0	29,135,284	0.00	2,344,370.3
May	0	0	29,078,440	0.00	2,417,645.1
June	0	0	29,020,841	0.00	2,336,645.1
July	0	0	29,020,146	0.00	2,415,666.3
August	0	0	29,045,845	0.00	2,415,286.6
September	0	0	29,035,322	0.00	2,338,348.1
October	0	0	29,058,781	0.00	2,415,321.8
November	0	0	29,025,430	0.00	2,338,127.8
December	0	0	29,064,420	0.00	2,419,678.3
2020					
January	0	0	28,945,159	0.00	2,404,497.1
February	0	0	29,134,820	0.00	2,246,785.9
March	0	0	29,181,132	0.00	2,403,523.4
April	0	0	29,325,560	0.00	2,350,041.9
May	0	0	29,776,772	0.00	2,456,946.0
June	0	0	30,147,554	0.00	2,395,082.4
July	0	0	30,228,019	0.00	2,482,123.8
August	0	0	30,299,161	0.00	2,489,338.2
September	0	0	30,321,956	0.00	2,408,978.8
October	0	0	30,372,379	0.00	2,499,283.0
November	0	0	30,441,235	0.00	2,428,868.9
December	0	0	33,253,737	0.00	2,529,190.1
2021					
January	0	0	31,018,435	0.00	2,553,395.9
February	0	0	30,803,057	0.00	2,316,300.2
March	0	0	30,840,728	0.00	2,569,539.9
April	0	0	30,385,816	0.00	2,460,336.9
May	0	0	30,065,301	0.00	2,508,556.9
June	0	0	29,895,294	0.00	2,408,769.7
July	0	0	29,746,280	0.00	2,477,228.6
August	0	0	29,616,594	0.00	2,466,125.7

Sentinel

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
September	0	0	29,481,144	0.00	2,377,386.9
October	0	0	29,406,455	0.00	2,447,263.4
November	0	0	29,277,168	0.00	2,361,627.3
December	0	0	29,192,796	0.00	2,433,417.9
2022					
January	0	0	28,581,401	0.00	2,383,511.1
February	0	0	28,429,449	0.00	2,144,248.0
March	0	0	28,455,494	0.00	2,367,948.4
April	0	0	28,381,100	0.00	2,285,829.1
May	0	0	28,353,217	0.00	2,358,361.3
June	0	0	28,360,943	0.00	2,283,088.1
July	0	0	28,305,787	0.00	2,355,205.7
August	0	0	28,380,202	0.00	2,356,117.3
September	0	0	23,978,858	0.00	1,929,836.1
October	0	0	10,783,931	0.00	900,782.5
November	0	0	3,643,475	0.00	295,032.8
December	0	0	3,662,240	0.00	306,370.9
Non-contaminated valsartan					
2012					
May	32,699	32,699	25,037,571	13.06	2,059,417.0
June	30,257	30,257	25,189,032	12.01	1,995,720.7
July	30,453	30,453	25,114,413	12.13	2,064,209.9
August	30,441	30,441	25,201,684	12.08	2,067,790.3
September	27,492	27,492	25,226,516	10.90	2,004,250.1
October	28,772	28,772	25,197,209	11.42	2,076,404.4
November	28,212	28,212	25,154,995	11.22	2,012,049.3
December	27,600	27,600	26,907,071	10.26	2,085,152.1
2013					
January	32,431	32,431	25,515,562	12.71	2,102,004.1
February	27,988	27,988	25,116,637	11.14	1,895,241.6
March	28,244	28,244	25,202,977	11.21	2,100,368.5
April	29,538	29,538	25,164,004	11.74	2,030,426.9
May	27,766	27,766	25,172,091	11.03	2,098,248.5

Sentinel

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
June	25,032	25,032	25,186,373	9.94	2,032,360.1
July	25,901	25,901	25,258,408	10.25	2,107,216.5
August	24,719	24,719	25,323,784	9.76	2,109,684.6
September	24,101	24,101	25,307,914	9.52	2,041,118.5
October	25,697	25,697	25,279,522	10.17	2,106,888.1
November	22,284	22,284	25,225,095	8.83	2,036,767.4
December	23,194	23,194	25,174,242	9.21	2,100,586.5
2014					
January	27,661	27,661	27,849,194	9.93	2,319,398.7
February	23,846	23,846	27,723,842	8.60	2,091,197.3
March	23,239	23,239	27,720,463	8.38	2,310,506.0
April	21,060	21,060	27,677,987	7.61	2,231,167.4
May	20,303	20,303	27,611,963	7.35	2,299,220.3
June	22,582	22,582	27,551,141	8.20	2,221,475.0
July	20,166	20,166	27,692,802	7.28	2,307,748.1
August	19,978	19,978	27,623,875	7.23	2,300,664.1
September	19,658	19,658	27,576,759	7.13	2,224,207.8
October	23,677	23,677	27,623,755	8.57	2,299,679.7
November	20,657	20,657	27,537,785	7.50	2,223,127.0
December	22,072	22,072	27,534,200	8.02	2,292,244.4
2015					
January	21,012	21,012	28,507,219	7.37	2,373,852.2
February	17,162	17,162	28,418,228	6.04	2,141,385.8
March	21,695	21,695	28,479,015	7.62	2,372,262.6
April	23,639	23,639	28,551,083	8.28	2,301,006.8
May	26,932	26,932	28,619,932	9.41	2,382,922.5
June	28,443	28,443	28,627,068	9.94	2,307,484.0
July	25,567	25,567	28,638,197	8.93	2,386,027.6
August	21,678	21,678	28,669,043	7.56	2,388,587.9
September	20,035	20,035	28,711,596	6.98	2,315,183.8
October	21,904	21,904	28,755,162	7.62	2,392,177.7
November	25,350	25,350	28,673,735	8.84	2,312,926.5
December	25,301	25,301	28,695,749	8.82	2,388,795.3

Sentinel

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2016					
January	24,987	24,987	29,111,959	8.58	2,422,941.4
February	21,035	21,035	29,466,686	7.14	2,266,279.3
March	18,389	18,389	29,524,831	6.23	2,427,638.3
April	14,871	14,871	29,522,157	5.04	2,347,907.8
May	15,238	15,238	29,519,741	5.16	2,428,156.6
June	17,095	17,095	29,650,174	5.77	2,350,686.9
July	17,160	17,160	29,617,388	5.79	2,432,498.5
August	15,797	15,797	29,656,132	5.33	2,433,403.9
September	12,799	12,799	29,720,103	4.31	2,359,272.9
October	12,447	12,447	29,667,284	4.20	2,443,280.5
November	12,285	12,285	29,757,217	4.13	2,366,224.3
December	12,233	12,233	32,616,611	3.75	2,456,669.2
2017					
January	14,231	14,231	29,791,025	4.78	2,451,826.8
February	12,618	12,618	29,375,850	4.30	2,211,700.2
March	13,539	13,539	29,469,628	4.59	2,450,910.7
April	11,232	11,232	29,439,693	3.82	2,370,876.0
May	15,500	15,500	29,437,367	5.27	2,448,578.1
June	15,368	15,368	29,439,216	5.22	2,371,334.5
July	17,374	17,374	29,432,901	5.90	2,452,827.3
August	18,553	18,553	29,534,567	6.28	2,456,479.8
September	16,966	16,966	29,559,696	5.74	2,381,655.9
October	16,657	16,657	29,645,849	5.62	2,466,918.1
November	15,368	15,368	29,629,508	5.19	2,388,292.8
December	14,198	14,198	29,735,072	4.77	2,474,523.9
2018					
January	15,728	15,728	29,618,242	5.31	2,462,898.6
February	12,781	12,781	29,532,855	4.33	2,223,085.3
March	14,508	14,508	29,610,227	4.90	2,462,430.8
April	14,920	14,920	29,551,740	5.05	2,379,778.9
May	15,132	15,132	29,522,512	5.13	2,455,191.5
June	13,308	13,308	29,504,915	4.51	2,376,073.2

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
July	20,586	20,586	29,463,164	6.99	2,454,418.3
August	16,359	16,359	29,532,183	5.54	2,456,352.4
September	15,457	15,457	29,522,364	5.24	2,378,819.7
October	17,834	17,834	29,566,733	6.03	2,457,726.3
November	13,550	13,550	29,544,015	4.59	2,380,611.4
December	15,239	15,239	29,583,424	5.15	2,462,259.0
2019					
January	66,133	66,133	29,268,809	22.60	2,432,776.2
February	41,714	41,714	29,161,945	14.30	2,195,559.8
March	47,467	47,467	29,212,707	16.25	2,429,142.7
April	31,664	31,664	29,135,284	10.87	2,344,370.3
May	27,250	27,250	29,078,440	9.37	2,417,645.1
June	20,779	20,779	29,020,841	7.16	2,336,645.1
July	21,483	21,483	29,020,146	7.40	2,415,666.3
August	22,149	22,149	29,045,845	7.63	2,415,286.6
September	24,075	24,075	29,035,322	8.29	2,338,348.1
October	33,194	33,194	29,058,781	11.42	2,415,321.8
November	24,611	24,611	29,025,430	8.48	2,338,127.8
December	26,421	26,421	29,064,420	9.09	2,419,678.3
2020					
January	31,324	31,324	28,945,159	10.82	2,404,497.1
February	26,057	26,057	29,134,820	8.94	2,246,785.9
March	26,186	26,186	29,181,132	8.97	2,403,523.4
April	16,957	16,957	29,325,560	5.78	2,350,041.9
May	15,514	15,514	29,776,772	5.21	2,456,946.0
June	18,849	18,849	30,147,554	6.25	2,395,082.4
July	19,488	19,488	30,228,019	6.45	2,482,123.8
August	17,968	17,968	30,299,161	5.93	2,489,338.2
September	19,033	19,033	30,321,956	6.28	2,408,978.8
October	21,828	21,828	30,372,379	7.19	2,499,283.0
November	20,595	20,595	30,441,235	6.77	2,428,868.9
December	21,882	21,882	33,253,737	6.58	2,529,190.1
2021					

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
January	21,936	21,936	31,018,435	7.07	2,553,395.9
February	20,403	20,403	30,803,057	6.62	2,316,300.2
March	25,329	25,329	30,840,728	8.21	2,569,539.9
April	23,047	23,047	30,385,816	7.58	2,460,336.9
May	21,225	21,225	30,065,301	7.06	2,508,556.9
June	22,273	22,273	29,895,294	7.45	2,408,769.7
July	24,499	24,499	29,746,280	8.24	2,477,228.6
August	26,866	26,866	29,616,594	9.07	2,466,125.7
September	28,998	28,998	29,481,144	9.84	2,377,386.9
October	28,164	28,164	29,406,455	9.58	2,447,263.4
November	26,411	26,411	29,277,168	9.02	2,361,627.3
December	26,791	26,791	29,192,796	9.18	2,433,417.9
2022					
January	30,595	30,595	28,581,401	10.70	2,383,511.1
February	27,616	27,616	28,429,449	9.71	2,144,248.0
March	28,852	28,852	28,455,494	10.14	2,367,948.4
April	22,354	22,354	28,381,100	7.88	2,285,829.1
May	21,517	21,517	28,353,217	7.59	2,358,361.3
June	21,544	21,544	28,360,943	7.60	2,283,088.1
July	19,808	19,808	28,305,787	7.00	2,355,205.7
August	21,498	21,498	28,380,202	7.57	2,356,117.3
September	19,289	19,289	23,978,858	8.04	1,929,836.1
October	5,087	5,087	10,783,931	4.72	900,782.5
November	1,637	1,637	3,643,475	4.49	295,032.8
December	1,579	1,579	3,662,240	4.31	306,370.9
New Use - All Censoring Options					
Any valsartan product					
2012					
May	7,421	7,421	24,166,365	3.07	1,986,971.9
June	6,700	6,700	24,323,602	2.75	1,926,342.0
July	6,624	6,624	24,260,241	2.73	1,993,110.0
August	6,694	6,694	24,352,392	2.75	1,997,306.8
September	5,977	5,977	24,384,282	2.45	1,936,602.1

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
October	7,597	7,597	24,361,535	3.12	2,006,972.4
November	7,379	7,379	24,325,872	3.03	1,945,262.4
December	6,699	6,699	26,031,525	2.57	2,016,435.2
2013					
January	8,063	8,063	24,677,951	3.27	2,032,383.3
February	7,193	7,193	24,296,400	2.96	1,833,030.6
March	6,959	6,959	24,387,599	2.85	2,032,154.1
April	7,074	7,074	24,356,762	2.90	1,965,085.5
May	6,389	6,389	24,371,620	2.62	2,031,348.9
June	5,644	5,644	24,391,675	2.31	1,968,132.0
July	6,226	6,226	24,469,382	2.54	2,041,208.8
August	5,855	5,855	24,539,935	2.39	2,044,235.2
September	5,453	5,453	24,530,405	2.22	1,978,257.9
October	5,921	5,921	24,507,861	2.42	2,042,447.9
November	5,141	5,141	24,462,746	2.10	1,975,082.9
December	4,945	4,945	24,419,612	2.03	2,037,414.1
2014					
January	6,294	6,294	27,013,090	2.33	2,249,532.2
February	5,593	5,593	26,901,209	2.08	2,028,834.5
March	5,856	5,856	26,906,058	2.18	2,242,365.8
April	5,340	5,340	26,871,388	1.99	2,165,995.6
May	4,725	4,725	26,815,313	1.76	2,232,803.8
June	4,438	4,438	26,764,766	1.66	2,158,006.7
July	4,681	4,681	26,913,066	1.74	2,242,641.3
August	4,824	4,824	26,852,855	1.80	2,236,342.8
September	5,071	5,071	26,813,640	1.89	2,162,572.9
October	5,655	5,655	26,866,714	2.10	2,236,555.7
November	4,888	4,888	26,790,399	1.82	2,162,655.4
December	5,425	5,425	26,794,311	2.02	2,230,440.6
2015					
January	6,510	6,510	27,758,950	2.35	2,311,266.7
February	6,425	6,425	27,684,932	2.32	2,085,730.0
March	7,240	7,240	27,754,240	2.61	2,311,514.4

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
April	6,739	6,739	27,833,258	2.42	2,242,901.1
May	6,215	6,215	27,907,509	2.23	2,323,452.0
June	6,422	6,422	27,920,253	2.30	2,250,375.6
July	6,426	6,426	27,935,424	2.30	2,327,348.8
August	6,125	6,125	27,969,348	2.19	2,330,156.0
September	6,638	6,638	28,013,672	2.37	2,258,821.1
October	7,187	7,187	28,058,011	2.56	2,334,100.4
November	6,935	6,935	27,982,387	2.48	2,256,933.6
December	7,695	7,695	28,009,720	2.75	2,331,344.2
2016					
January	9,191	9,191	28,421,595	3.23	2,365,048.1
February	9,457	9,457	28,778,677	3.29	2,212,572.9
March	10,078	10,078	28,837,859	3.49	2,370,578.1
April	9,250	9,250	28,835,149	3.21	2,292,770.7
May	9,068	9,068	28,831,585	3.15	2,371,145.9
June	8,768	8,768	28,958,336	3.03	2,295,372.4
July	7,929	7,929	28,925,439	2.74	2,375,165.1
August	8,958	8,958	28,961,102	3.09	2,375,887.9
September	8,788	8,788	29,022,773	3.03	2,303,422.5
October	9,350	9,350	28,967,662	3.23	2,385,311.6
November	9,764	9,764	29,055,104	3.36	2,309,890.2
December	9,998	9,998	31,868,695	3.14	2,398,069.1
2017					
January	11,151	11,151	29,089,780	3.83	2,393,670.2
February	10,780	10,780	28,677,979	3.76	2,158,952.1
March	11,937	11,937	28,766,224	4.15	2,392,202.9
April	10,270	10,270	28,731,704	3.57	2,313,752.3
May	11,181	11,181	28,725,904	3.89	2,389,230.8
June	10,351	10,351	28,724,143	3.60	2,313,609.3
July	9,055	9,055	28,714,609	3.15	2,392,832.2
August	10,263	10,263	28,811,737	3.56	2,396,220.1
September	9,185	9,185	28,832,993	3.19	2,323,017.3
October	10,432	10,432	28,915,208	3.61	2,406,007.5

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
November	10,809	10,809	28,895,873	3.74	2,329,036.1
December	10,692	10,692	28,996,351	3.69	2,412,892.5
2018					
January	12,833	12,833	28,878,209	4.44	2,401,157.7
February	12,353	12,353	28,788,619	4.29	2,166,886.5
March	13,497	13,497	28,857,955	4.68	2,399,655.9
April	12,816	12,816	28,793,206	4.45	2,318,534.1
May	12,795	12,795	28,758,375	4.45	2,391,456.0
June	11,504	11,504	28,735,519	4.00	2,313,980.5
July	6,419	6,419	28,690,181	2.24	2,389,954.0
August	2,709	2,709	28,757,908	0.94	2,392,169.4
September	2,628	2,628	28,753,009	0.91	2,317,018.5
October	3,948	3,948	28,799,308	1.37	2,394,149.0
November	5,051	5,051	28,781,661	1.75	2,319,287.6
December	4,558	4,558	28,822,491	1.58	2,399,029.8
2019					
January	7,215	7,215	28,522,880	2.53	2,370,820.6
February	8,047	8,047	28,420,202	2.83	2,139,645.1
March	14,529	14,529	28,469,921	5.10	2,367,061.4
April	13,998	13,998	28,390,403	4.93	2,284,099.3
May	14,306	14,306	28,333,866	5.05	2,355,257.3
June	10,454	10,454	28,281,656	3.70	2,276,599.9
July	10,930	10,930	28,331,772	3.86	2,355,510.9
August	11,348	11,348	28,448,053	3.99	2,361,944.9
September	13,118	13,118	28,503,979	4.60	2,292,768.2
October	20,651	20,651	28,567,496	7.23	2,372,314.7
November	14,307	14,307	28,539,004	5.01	2,297,908.7
December	11,646	11,646	28,581,869	4.07	2,378,636.7
2020					
January	12,527	12,527	28,469,978	4.40	2,364,312.1
February	11,078	11,078	28,657,036	3.87	2,209,370.9
March	11,859	11,859	28,701,263	4.13	2,363,344.8
April	8,742	8,742	28,837,459	3.03	2,310,365.2

Sentinel

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
May	7,342	7,342	29,276,287	2.51	2,415,238.9
June	8,346	8,346	29,639,375	2.82	2,354,274.3
July	8,206	8,206	29,716,730	2.76	2,439,661.0
August	7,274	7,274	29,783,518	2.44	2,446,600.4
September	7,692	7,692	29,802,868	2.58	2,367,378.5
October	8,545	8,545	29,849,701	2.86	2,455,962.8
November	8,174	8,174	29,917,245	2.73	2,386,633.4
December	8,980	8,980	32,693,989	2.75	2,485,193.1
2021					
January	9,610	9,610	30,484,813	3.15	2,509,050.6
February	9,706	9,706	30,269,601	3.21	2,275,899.8
March	12,688	12,688	30,306,426	4.19	2,524,467.4
April	11,901	11,901	29,860,354	3.99	2,417,225.6
May	10,861	10,861	29,547,296	3.68	2,464,767.8
June	11,203	11,203	29,380,469	3.81	2,366,843.1
July	10,279	10,279	29,232,125	3.52	2,434,050.5
August	10,167	10,167	29,100,784	3.49	2,422,898.4
September	10,035	10,035	28,963,681	3.46	2,335,433.2
October	10,568	10,568	28,885,445	3.66	2,403,671.7
November	10,354	10,354	28,753,408	3.60	2,319,106.2
December	10,964	10,964	28,665,871	3.82	2,389,213.7
2022					
January	15,373	15,373	28,055,579	5.48	2,339,221.9
February	14,814	14,814	27,896,606	5.31	2,103,662.1
March	15,402	15,402	27,912,328	5.52	2,322,319.5
April	11,093	11,093	27,829,527	3.99	2,241,198.1
May	10,594	10,594	27,796,473	3.81	2,311,846.3
June	10,313	10,313	27,799,615	3.71	2,237,720.5
July	8,975	8,975	27,739,415	3.24	2,307,920.2
August	9,972	9,972	27,810,090	3.59	2,308,525.1
September	8,906	8,906	23,440,097	3.80	1,886,307.5
October	2,191	2,191	10,651,574	2.06	889,659.2
November	708	708	3,592,262	1.97	290,865.7

Sentinel

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
December	666	666	3,611,835	1.84	302,104.2
Contaminated valsartan					
2012					
May	0	0	24,166,365	0.00	1,986,971.9
June	0	0	24,323,602	0.00	1,926,342.0
July	0	0	24,260,241	0.00	1,993,110.0
August	0	0	24,352,392	0.00	1,997,306.8
September	76	76	24,384,282	0.03	1,936,602.1
October	590	590	24,361,535	0.24	2,006,972.4
November	666	666	24,325,872	0.27	1,945,262.4
December	603	603	26,031,525	0.23	2,016,435.2
2013					
January	824	824	24,677,951	0.33	2,032,383.3
February	718	718	24,296,400	0.30	1,833,030.6
March	713	713	24,387,599	0.29	2,032,154.1
April	918	918	24,356,762	0.38	1,965,085.5
May	951	951	24,371,620	0.39	2,031,348.9
June	858	858	24,391,675	0.35	1,968,132.0
July	1,001	1,001	24,469,382	0.41	2,041,208.8
August	1,022	1,022	24,539,935	0.42	2,044,235.2
September	921	921	24,530,405	0.38	1,978,257.9
October	1,059	1,059	24,507,861	0.43	2,042,447.9
November	911	911	24,462,746	0.37	1,975,082.9
December	859	859	24,419,612	0.35	2,037,414.1
2014					
January	1,314	1,314	27,013,090	0.49	2,249,532.2
February	1,140	1,140	26,901,209	0.42	2,028,834.5
March	1,292	1,292	26,906,058	0.48	2,242,365.8
April	1,119	1,119	26,871,388	0.42	2,165,995.6
May	1,000	1,000	26,815,313	0.37	2,232,803.8
June	896	896	26,764,766	0.33	2,158,006.7
July	896	896	26,913,066	0.33	2,242,641.3
August	834	834	26,852,855	0.31	2,236,342.8

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
September	872	872	26,813,640	0.33	2,162,572.9
October	1,133	1,133	26,866,714	0.42	2,236,555.7
November	989	989	26,790,399	0.37	2,162,655.4
December	1,106	1,106	26,794,311	0.41	2,230,440.6
2015					
January	1,809	1,809	27,758,950	0.65	2,311,266.7
February	2,088	2,088	27,684,932	0.75	2,085,730.0
March	2,431	2,431	27,754,240	0.88	2,311,514.4
April	2,217	2,217	27,833,258	0.80	2,242,901.1
May	2,169	2,169	27,907,509	0.78	2,323,452.0
June	2,357	2,357	27,920,253	0.84	2,250,375.6
July	2,520	2,520	27,935,424	0.90	2,327,348.8
August	2,420	2,420	27,969,348	0.87	2,330,156.0
September	2,655	2,655	28,013,672	0.95	2,258,821.1
October	2,806	2,806	28,058,011	1.00	2,334,100.4
November	2,749	2,749	27,982,387	0.98	2,256,933.6
December	3,168	3,168	28,009,720	1.13	2,331,344.2
2016					
January	4,095	4,095	28,421,595	1.44	2,365,048.1
February	4,507	4,507	28,778,677	1.57	2,212,572.9
March	4,939	4,939	28,837,859	1.71	2,370,578.1
April	5,226	5,226	28,835,149	1.81	2,292,770.7
May	5,524	5,524	28,831,585	1.92	2,371,145.9
June	5,368	5,368	28,958,336	1.85	2,295,372.4
July	4,848	4,848	28,925,439	1.68	2,375,165.1
August	5,726	5,726	28,961,102	1.98	2,375,887.9
September	5,805	5,805	29,022,773	2.00	2,303,422.5
October	6,264	6,264	28,967,662	2.16	2,385,311.6
November	6,547	6,547	29,055,104	2.25	2,309,890.2
December	6,670	6,670	31,868,695	2.09	2,398,069.1
2017					
January	7,500	7,500	29,089,780	2.58	2,393,670.2
February	7,214	7,214	28,677,979	2.52	2,158,952.1

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
March	7,906	7,906	28,766,224	2.75	2,392,202.9
April	6,634	6,634	28,731,704	2.31	2,313,752.3
May	7,147	7,147	28,725,904	2.49	2,389,230.8
June	6,720	6,720	28,724,143	2.34	2,313,609.3
July	6,136	6,136	28,714,609	2.14	2,392,832.2
August	7,094	7,094	28,811,737	2.46	2,396,220.1
September	6,265	6,265	28,832,993	2.17	2,323,017.3
October	7,150	7,150	28,915,208	2.47	2,406,007.5
November	7,508	7,508	28,895,873	2.60	2,329,036.1
December	7,616	7,616	28,996,351	2.63	2,412,892.5
2018					
January	8,939	8,939	28,878,209	3.10	2,401,157.7
February	8,740	8,740	28,788,619	3.04	2,166,886.5
March	9,457	9,457	28,857,955	3.28	2,399,655.9
April	8,848	8,848	28,793,206	3.07	2,318,534.1
May	8,781	8,781	28,758,375	3.05	2,391,456.0
June	7,977	7,977	28,735,519	2.78	2,313,980.5
July	3,692	3,692	28,690,181	1.29	2,389,954.0
August	558	558	28,757,908	0.19	2,392,169.4
September	613	613	28,753,009	0.21	2,317,018.5
October	1,223	1,223	28,799,308	0.42	2,394,149.0
November	2,025	2,025	28,781,661	0.70	2,319,287.6
December	1,494	1,494	28,822,491	0.52	2,399,029.8
2019					
January	0	0	28,522,880	0.00	2,370,820.6
February	0	0	28,420,202	0.00	2,139,645.1
March	0	0	28,469,921	0.00	2,367,061.4
April	0	0	28,390,403	0.00	2,284,099.3
May	0	0	28,333,866	0.00	2,355,257.3
June	0	0	28,281,656	0.00	2,276,599.9
July	0	0	28,331,772	0.00	2,355,510.9
August	0	0	28,448,053	0.00	2,361,944.9
September	0	0	28,503,979	0.00	2,292,768.2

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
October	0	0	28,567,496	0.00	2,372,314.7
November	0	0	28,539,004	0.00	2,297,908.7
December	0	0	28,581,869	0.00	2,378,636.7
2020					
January	0	0	28,469,978	0.00	2,364,312.1
February	0	0	28,657,036	0.00	2,209,370.9
March	0	0	28,701,263	0.00	2,363,344.8
April	0	0	28,837,459	0.00	2,310,365.2
May	0	0	29,276,287	0.00	2,415,238.9
June	0	0	29,639,375	0.00	2,354,274.3
July	0	0	29,716,730	0.00	2,439,661.0
August	0	0	29,783,518	0.00	2,446,600.4
September	0	0	29,802,868	0.00	2,367,378.5
October	0	0	29,849,701	0.00	2,455,962.8
November	0	0	29,917,245	0.00	2,386,633.4
December	0	0	32,693,989	0.00	2,485,193.1
2021					
January	0	0	30,484,813	0.00	2,509,050.6
February	0	0	30,269,601	0.00	2,275,899.8
March	0	0	30,306,426	0.00	2,524,467.4
April	0	0	29,860,354	0.00	2,417,225.6
May	0	0	29,547,296	0.00	2,464,767.8
June	0	0	29,380,469	0.00	2,366,843.1
July	0	0	29,232,125	0.00	2,434,050.5
August	0	0	29,100,784	0.00	2,422,898.4
September	0	0	28,963,681	0.00	2,335,433.2
October	0	0	28,885,445	0.00	2,403,671.7
November	0	0	28,753,408	0.00	2,319,106.2
December	0	0	28,665,871	0.00	2,389,213.7
2022					
January	0	0	28,055,579	0.00	2,339,221.9
February	0	0	27,896,606	0.00	2,103,662.1
March	0	0	27,912,328	0.00	2,322,319.5

Sentinel

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
April	0	0	27,829,527	0.00	2,241,198.1
May	0	0	27,796,473	0.00	2,311,846.3
June	0	0	27,799,615	0.00	2,237,720.5
July	0	0	27,739,415	0.00	2,307,920.2
August	0	0	27,810,090	0.00	2,308,525.1
September	0	0	23,440,097	0.00	1,886,307.5
October	0	0	10,651,574	0.00	889,659.2
November	0	0	3,592,262	0.00	290,865.7
December	0	0	3,611,835	0.00	302,104.2
Non-contaminated valsartan					
2012					
May	7,421	7,421	24,166,365	3.07	1,986,971.9
June	6,700	6,700	24,323,602	2.75	1,926,342.0
July	6,624	6,624	24,260,241	2.73	1,993,110.0
August	6,694	6,694	24,352,392	2.75	1,997,306.8
September	5,901	5,901	24,384,282	2.42	1,936,602.1
October	7,010	7,010	24,361,535	2.88	2,006,972.4
November	6,713	6,713	24,325,872	2.76	1,945,262.4
December	6,098	6,098	26,031,525	2.34	2,016,435.2
2013					
January	7,243	7,243	24,677,951	2.94	2,032,383.3
February	6,478	6,478	24,296,400	2.67	1,833,030.6
March	6,247	6,247	24,387,599	2.56	2,032,154.1
April	6,157	6,157	24,356,762	2.53	1,965,085.5
May	5,444	5,444	24,371,620	2.23	2,031,348.9
June	4,790	4,790	24,391,675	1.96	1,968,132.0
July	5,227	5,227	24,469,382	2.14	2,041,208.8
August	4,838	4,838	24,539,935	1.97	2,044,235.2
September	4,534	4,534	24,530,405	1.85	1,978,257.9
October	4,865	4,865	24,507,861	1.99	2,042,447.9
November	4,231	4,231	24,462,746	1.73	1,975,082.9
December	4,087	4,087	24,419,612	1.67	2,037,414.1
2014					

Sentinel

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
January	4,977	4,977	27,013,090	1.84	2,249,532.2
February	4,425	4,425	26,901,209	1.64	2,028,834.5
March	4,377	4,377	26,906,058	1.63	2,242,365.8
April	3,888	3,888	26,871,388	1.45	2,165,995.6
May	3,333	3,333	26,815,313	1.24	2,232,803.8
June	3,113	3,113	26,764,766	1.16	2,158,006.7
July	3,360	3,360	26,913,066	1.25	2,242,641.3
August	3,563	3,563	26,852,855	1.33	2,236,342.8
September	3,655	3,655	26,813,640	1.36	2,162,572.9
October	3,935	3,935	26,866,714	1.46	2,236,555.7
November	3,422	3,422	26,790,399	1.28	2,162,655.4
December	3,744	3,744	26,794,311	1.40	2,230,440.6
2015					
January	3,899	3,899	27,758,950	1.40	2,311,266.7
February	3,341	3,341	27,684,932	1.21	2,085,730.0
March	3,674	3,674	27,754,240	1.32	2,311,514.4
April	3,450	3,450	27,833,258	1.24	2,242,901.1
May	3,238	3,238	27,907,509	1.16	2,323,452.0
June	3,309	3,309	27,920,253	1.19	2,250,375.6
July	3,188	3,188	27,935,424	1.14	2,327,348.8
August	3,058	3,058	27,969,348	1.09	2,330,156.0
September	3,323	3,323	28,013,672	1.19	2,258,821.1
October	3,675	3,675	28,058,011	1.31	2,334,100.4
November	3,726	3,726	27,982,387	1.33	2,256,933.6
December	4,100	4,100	28,009,720	1.46	2,331,344.2
2016					
January	4,674	4,674	28,421,595	1.64	2,365,048.1
February	4,506	4,506	28,778,677	1.57	2,212,572.9
March	4,463	4,463	28,837,859	1.55	2,370,578.1
April	3,304	3,304	28,835,149	1.15	2,292,770.7
May	2,963	2,963	28,831,585	1.03	2,371,145.9
June	2,857	2,857	28,958,336	0.99	2,295,372.4
July	2,658	2,658	28,925,439	0.92	2,375,165.1

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
August	2,814	2,814	28,961,102	0.97	2,375,887.9
September	2,608	2,608	29,022,773	0.90	2,303,422.5
October	2,663	2,663	28,967,662	0.92	2,385,311.6
November	2,794	2,794	29,055,104	0.96	2,309,890.2
December	2,873	2,873	31,868,695	0.90	2,398,069.1
2017					
January	3,181	3,181	29,089,780	1.09	2,393,670.2
February	3,119	3,119	28,677,979	1.09	2,158,952.1
March	3,486	3,486	28,766,224	1.21	2,392,202.9
April	3,186	3,186	28,731,704	1.11	2,313,752.3
May	3,561	3,561	28,725,904	1.24	2,389,230.8
June	3,208	3,208	28,724,143	1.12	2,313,609.3
July	2,533	2,533	28,714,609	0.88	2,392,832.2
August	2,795	2,795	28,811,737	0.97	2,396,220.1
September	2,514	2,514	28,832,993	0.87	2,323,017.3
October	2,773	2,773	28,915,208	0.96	2,406,007.5
November	2,798	2,798	28,895,873	0.97	2,329,036.1
December	2,591	2,591	28,996,351	0.89	2,412,892.5
2018					
January	3,267	3,267	28,878,209	1.13	2,401,157.7
February	3,048	3,048	28,788,619	1.06	2,166,886.5
March	3,409	3,409	28,857,955	1.18	2,399,655.9
April	3,350	3,350	28,793,206	1.16	2,318,534.1
May	3,344	3,344	28,758,375	1.16	2,391,456.0
June	2,939	2,939	28,735,519	1.02	2,313,980.5
July	2,384	2,384	28,690,181	0.83	2,389,954.0
August	2,056	2,056	28,757,908	0.71	2,392,169.4
September	1,935	1,935	28,753,009	0.67	2,317,018.5
October	2,525	2,525	28,799,308	0.88	2,394,149.0
November	2,740	2,740	28,781,661	0.95	2,319,287.6
December	2,715	2,715	28,822,491	0.94	2,399,029.8
2019					
January	6,718	6,718	28,522,880	2.36	2,370,820.6

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
February	7,442	7,442	28,420,202	2.62	2,139,645.1
March	13,424	13,424	28,469,921	4.72	2,367,061.4
April	12,712	12,712	28,390,403	4.48	2,284,099.3
May	12,888	12,888	28,333,866	4.55	2,355,257.3
June	9,037	9,037	28,281,656	3.20	2,276,599.9
July	9,200	9,200	28,331,772	3.25	2,355,510.9
August	9,772	9,772	28,448,053	3.44	2,361,944.9
September	11,823	11,823	28,503,979	4.15	2,292,768.2
October	18,923	18,923	28,567,496	6.62	2,372,314.7
November	13,056	13,056	28,539,004	4.57	2,297,908.7
December	10,986	10,986	28,581,869	3.84	2,378,636.7
2020					
January	12,133	12,133	28,469,978	4.26	2,364,312.1
February	10,774	10,774	28,657,036	3.76	2,209,370.9
March	10,665	10,665	28,701,263	3.72	2,363,344.8
April	7,113	7,113	28,837,459	2.47	2,310,365.2
May	6,069	6,069	29,276,287	2.07	2,415,238.9
June	6,784	6,784	29,639,375	2.29	2,354,274.3
July	6,871	6,871	29,716,730	2.31	2,439,661.0
August	6,425	6,425	29,783,518	2.16	2,446,600.4
September	6,869	6,869	29,802,868	2.30	2,367,378.5
October	7,637	7,637	29,849,701	2.56	2,455,962.8
November	7,155	7,155	29,917,245	2.39	2,386,633.4
December	7,664	7,664	32,693,989	2.34	2,485,193.1
2021					
January	8,166	8,166	30,484,813	2.68	2,509,050.6
February	8,353	8,353	30,269,601	2.76	2,275,899.8
March	10,988	10,988	30,306,426	3.63	2,524,467.4
April	10,396	10,396	29,860,354	3.48	2,417,225.6
May	9,418	9,418	29,547,296	3.19	2,464,767.8
June	9,777	9,777	29,380,469	3.33	2,366,843.1
July	9,272	9,272	29,232,125	3.17	2,434,050.5
August	9,210	9,210	29,100,784	3.16	2,422,898.4

Sentinel

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
September	9,305	9,305	28,963,681	3.21	2,335,433.2
October	9,866	9,866	28,885,445	3.42	2,403,671.7
November	9,804	9,804	28,753,408	3.41	2,319,106.2
December	10,568	10,568	28,665,871	3.69	2,389,213.7
2022					
January	14,823	14,823	28,055,579	5.28	2,339,221.9
February	14,372	14,372	27,896,606	5.15	2,103,662.1
March	14,967	14,967	27,912,328	5.36	2,322,319.5
April	10,624	10,624	27,829,527	3.82	2,241,198.1
May	9,909	9,909	27,796,473	3.56	2,311,846.3
June	9,724	9,724	27,799,615	3.50	2,237,720.5
July	8,302	8,302	27,739,415	2.99	2,307,920.2
August	9,255	9,255	27,810,090	3.33	2,308,525.1
September	8,364	8,364	23,440,097	3.57	1,886,307.5
October	2,087	2,087	10,651,574	1.96	889,659.2
November	690	690	3,592,262	1.92	290,865.7
December	646	646	3,611,835	1.79	302,104.2
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death					
Contaminated valsartan					
2012					
May	0	0	25,037,571	0.00	2,059,417.0
June	0	0	25,189,032	0.00	1,995,720.7
July	0	0	25,114,413	0.00	2,064,209.9
August	0	0	25,201,684	0.00	2,067,790.3
September	5,903	5,903	25,226,516	2.34	2,004,250.1
October	34,683	34,683	25,197,209	13.76	2,076,404.4
November	17,477	17,477	25,154,995	6.95	2,012,049.3
December	11,290	11,290	26,907,071	4.20	2,085,152.1
2013					
January	10,122	10,122	25,515,562	3.97	2,102,004.1
February	5,969	5,969	25,116,637	2.38	1,895,241.6
March	5,080	5,080	25,202,977	2.02	2,100,368.5
April	16,983	16,983	25,164,004	6.75	2,030,426.9

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
May	16,789	16,789	25,172,091	6.67	2,098,248.5
June	13,408	13,408	25,186,373	5.32	2,032,360.1
July	11,043	11,043	25,258,408	4.37	2,107,216.5
August	7,735	7,735	25,323,784	3.05	2,109,684.6
September	7,305	7,305	25,307,914	2.89	2,041,118.5
October	6,021	6,021	25,279,522	2.38	2,106,888.1
November	6,200	6,200	25,225,095	2.46	2,036,767.4
December	5,220	5,220	25,174,242	2.07	2,100,586.5
2014					
January	6,930	6,930	27,849,194	2.49	2,319,398.7
February	7,423	7,423	27,723,842	2.68	2,091,197.3
March	9,083	9,083	27,720,463	3.28	2,310,506.0
April	7,481	7,481	27,677,987	2.70	2,231,167.4
May	5,870	5,870	27,611,963	2.13	2,299,220.3
June	4,826	4,826	27,551,141	1.75	2,221,475.0
July	6,280	6,280	27,692,802	2.27	2,307,748.1
August	6,435	6,435	27,623,875	2.33	2,300,664.1
September	5,768	5,768	27,576,759	2.09	2,224,207.8
October	14,467	14,467	27,623,755	5.24	2,299,679.7
November	10,268	10,268	27,537,785	3.73	2,223,127.0
December	11,443	11,443	27,534,200	4.16	2,292,244.4
2015					
January	18,648	18,648	28,507,219	6.54	2,373,852.2
February	25,023	25,023	28,418,228	8.81	2,141,385.8
March	22,723	22,723	28,479,015	7.98	2,372,262.6
April	19,386	19,386	28,551,083	6.79	2,301,006.8
May	17,650	17,650	28,619,932	6.17	2,382,922.5
June	22,082	22,082	28,627,068	7.71	2,307,484.0
July	22,534	22,534	28,638,197	7.87	2,386,027.6
August	18,417	18,417	28,669,043	6.42	2,388,587.9
September	14,165	14,165	28,711,596	4.93	2,315,183.8
October	11,900	11,900	28,755,162	4.14	2,392,177.7
November	13,238	13,238	28,673,735	4.62	2,312,926.5

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
December	15,952	15,952	28,695,749	5.56	2,388,795.3
2016					
January	19,504	19,504	29,111,959	6.70	2,422,941.4
February	20,772	20,772	29,466,686	7.05	2,266,279.3
March	23,821	23,821	29,524,831	8.07	2,427,638.3
April	29,652	29,652	29,522,157	10.04	2,347,907.8
May	29,678	29,678	29,519,741	10.05	2,428,156.6
June	25,169	25,169	29,650,174	8.49	2,350,686.9
July	20,681	20,681	29,617,388	6.98	2,432,498.5
August	21,913	21,913	29,656,132	7.39	2,433,403.9
September	20,959	20,959	29,720,103	7.05	2,359,272.9
October	18,608	18,608	29,667,284	6.27	2,443,280.5
November	15,522	15,522	29,757,217	5.22	2,366,224.3
December	13,775	13,775	32,616,611	4.22	2,456,669.2
2017					
January	15,273	15,273	29,791,025	5.13	2,451,826.8
February	13,501	13,501	29,375,850	4.60	2,211,700.2
March	14,333	14,333	29,469,628	4.86	2,450,910.7
April	11,868	11,868	29,439,693	4.03	2,370,876.0
May	12,980	12,980	29,437,367	4.41	2,448,578.1
June	13,646	13,646	29,439,216	4.64	2,371,334.5
July	17,332	17,332	29,432,901	5.89	2,452,827.3
August	18,388	18,388	29,534,567	6.23	2,456,479.8
September	14,952	14,952	29,559,696	5.06	2,381,655.9
October	14,371	14,371	29,645,849	4.85	2,466,918.1
November	14,057	14,057	29,629,508	4.74	2,388,292.8
December	14,004	14,004	29,735,072	4.71	2,474,523.9
2018					
January	16,652	16,652	29,618,242	5.62	2,462,898.6
February	15,541	15,541	29,532,855	5.26	2,223,085.3
March	16,122	16,122	29,610,227	5.44	2,462,430.8
April	14,535	14,535	29,551,740	4.92	2,379,778.9
May	14,238	14,238	29,522,512	4.82	2,455,191.5

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
June	13,838	13,838	29,504,915	4.69	2,376,073.2
July	8,478	8,478	29,463,164	2.88	2,454,418.3
August	3,251	3,251	29,532,183	1.10	2,456,352.4
September	3,384	3,384	29,522,364	1.15	2,378,819.7
October	5,007	5,007	29,566,733	1.69	2,457,726.3
November	6,008	6,008	29,544,015	2.03	2,380,611.4
December	5,911	5,911	29,583,424	2.00	2,462,259.0
2019					
January	0	0	29,268,809	0.00	2,432,776.2
February	0	0	29,161,945	0.00	2,195,559.8
March	0	0	29,212,707	0.00	2,429,142.7
April	0	0	29,135,284	0.00	2,344,370.3
May	0	0	29,078,440	0.00	2,417,645.1
June	0	0	29,020,841	0.00	2,336,645.1
July	0	0	29,020,146	0.00	2,415,666.3
August	0	0	29,045,845	0.00	2,415,286.6
September	0	0	29,035,322	0.00	2,338,348.1
October	0	0	29,058,781	0.00	2,415,321.8
November	0	0	29,025,430	0.00	2,338,127.8
December	0	0	29,064,420	0.00	2,419,678.3
2020					
January	0	0	28,945,159	0.00	2,404,497.1
February	0	0	29,134,820	0.00	2,246,785.9
March	0	0	29,181,132	0.00	2,403,523.4
April	0	0	29,325,560	0.00	2,350,041.9
May	0	0	29,776,772	0.00	2,456,946.0
June	0	0	30,147,554	0.00	2,395,082.4
July	0	0	30,228,019	0.00	2,482,123.8
August	0	0	30,299,161	0.00	2,489,338.2
September	0	0	30,321,956	0.00	2,408,978.8
October	0	0	30,372,379	0.00	2,499,283.0
November	0	0	30,441,235	0.00	2,428,868.9
December	0	0	33,253,737	0.00	2,529,190.1

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2021					
January	0	0	31,018,435	0.00	2,553,395.9
February	0	0	30,803,057	0.00	2,316,300.2
March	0	0	30,840,728	0.00	2,569,539.9
April	0	0	30,385,816	0.00	2,460,336.9
May	0	0	30,065,301	0.00	2,508,556.9
June	0	0	29,895,294	0.00	2,408,769.7
July	0	0	29,746,280	0.00	2,477,228.6
August	0	0	29,616,594	0.00	2,466,125.7
September	0	0	29,481,144	0.00	2,377,386.9
October	0	0	29,406,455	0.00	2,447,263.4
November	0	0	29,277,168	0.00	2,361,627.3
December	0	0	29,192,796	0.00	2,433,417.9
2022					
January	0	0	28,581,401	0.00	2,383,511.1
February	0	0	28,429,449	0.00	2,144,248.0
March	0	0	28,455,494	0.00	2,367,948.4
April	0	0	28,381,100	0.00	2,285,829.1
May	0	0	28,353,217	0.00	2,358,361.3
June	0	0	28,360,943	0.00	2,283,088.1
July	0	0	28,305,787	0.00	2,355,205.7
August	0	0	28,380,202	0.00	2,356,117.3
September	0	0	23,978,858	0.00	1,929,836.1
October	0	0	10,783,931	0.00	900,782.5
November	0	0	3,643,475	0.00	295,032.8
December	0	0	3,662,240	0.00	306,370.9
New Use - Censoring on Query/Data End Date, Disenrollment, or Death					
Contaminated valsartan					
2012					
May	0	0	24,166,365	0.00	1,986,971.9
June	0	0	24,323,602	0.00	1,926,342.0
July	0	0	24,260,241	0.00	1,993,110.0
August	0	0	24,352,392	0.00	1,997,306.8

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
September	76	76	24,384,282	0.03	1,936,602.1
October	590	590	24,361,535	0.24	2,006,972.4
November	666	666	24,325,872	0.27	1,945,262.4
December	603	603	26,031,525	0.23	2,016,435.2
2013					
January	824	824	24,677,951	0.33	2,032,383.3
February	718	718	24,296,400	0.30	1,833,030.6
March	713	713	24,387,599	0.29	2,032,154.1
April	918	918	24,356,762	0.38	1,965,085.5
May	951	951	24,371,620	0.39	2,031,348.9
June	858	858	24,391,675	0.35	1,968,132.0
July	1,001	1,001	24,469,382	0.41	2,041,208.8
August	1,022	1,022	24,539,935	0.42	2,044,235.2
September	921	921	24,530,405	0.38	1,978,257.9
October	1,059	1,059	24,507,861	0.43	2,042,447.9
November	911	911	24,462,746	0.37	1,975,082.9
December	859	859	24,419,612	0.35	2,037,414.1
2014					
January	1,314	1,314	27,013,090	0.49	2,249,532.2
February	1,138	1,138	26,901,209	0.42	2,028,834.5
March	1,291	1,291	26,906,058	0.48	2,242,365.8
April	1,118	1,118	26,871,388	0.42	2,165,995.6
May	999	999	26,815,313	0.37	2,232,803.8
June	890	890	26,764,766	0.33	2,158,006.7
July	890	890	26,913,066	0.33	2,242,641.3
August	833	833	26,852,855	0.31	2,236,342.8
September	866	866	26,813,640	0.32	2,162,572.9
October	1,124	1,124	26,866,714	0.42	2,236,555.7
November	983	983	26,790,399	0.37	2,162,655.4
December	1,096	1,096	26,794,311	0.41	2,230,440.6
2015					
January	1,803	1,803	27,758,950	0.65	2,311,266.7
February	2,080	2,080	27,684,932	0.75	2,085,730.0

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
March	2,417	2,417	27,754,240	0.87	2,311,514.4
April	2,206	2,206	27,833,258	0.79	2,242,901.1
May	2,160	2,160	27,907,509	0.77	2,323,452.0
June	2,346	2,346	27,920,253	0.84	2,250,375.6
July	2,506	2,506	27,935,424	0.90	2,327,348.8
August	2,412	2,412	27,969,348	0.86	2,330,156.0
September	2,643	2,643	28,013,672	0.94	2,258,821.1
October	2,786	2,786	28,058,011	0.99	2,334,100.4
November	2,726	2,726	27,982,387	0.97	2,256,933.6
December	3,154	3,154	28,009,720	1.13	2,331,344.2
2016					
January	4,077	4,077	28,421,595	1.43	2,365,048.1
February	4,476	4,476	28,778,677	1.56	2,212,572.9
March	4,917	4,917	28,837,859	1.71	2,370,578.1
April	5,194	5,194	28,835,149	1.80	2,292,770.7
May	5,500	5,500	28,831,585	1.91	2,371,145.9
June	5,330	5,330	28,958,336	1.84	2,295,372.4
July	4,815	4,815	28,925,439	1.66	2,375,165.1
August	5,684	5,684	28,961,102	1.96	2,375,887.9
September	5,764	5,764	29,022,773	1.99	2,303,422.5
October	6,225	6,225	28,967,662	2.15	2,385,311.6
November	6,511	6,511	29,055,104	2.24	2,309,890.2
December	6,625	6,625	31,868,695	2.08	2,398,069.1
2017					
January	7,448	7,448	29,089,780	2.56	2,393,670.2
February	7,171	7,171	28,677,979	2.50	2,158,952.1
March	7,848	7,848	28,766,224	2.73	2,392,202.9
April	6,588	6,588	28,731,704	2.29	2,313,752.3
May	7,075	7,075	28,725,904	2.46	2,389,230.8
June	6,644	6,644	28,724,143	2.31	2,313,609.3
July	6,077	6,077	28,714,609	2.12	2,392,832.2
August	7,020	7,020	28,811,737	2.44	2,396,220.1
September	6,194	6,194	28,832,993	2.15	2,323,017.3

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
October	7,075	7,075	28,915,208	2.45	2,406,007.5
November	7,419	7,419	28,895,873	2.57	2,329,036.1
December	7,520	7,520	28,996,351	2.59	2,412,892.5
2018					
January	8,839	8,839	28,878,209	3.06	2,401,157.7
February	8,641	8,641	28,788,619	3.00	2,166,886.5
March	9,346	9,346	28,857,955	3.24	2,399,655.9
April	8,739	8,739	28,793,206	3.04	2,318,534.1
May	8,672	8,672	28,758,375	3.02	2,391,456.0
June	7,877	7,877	28,735,519	2.74	2,313,980.5
July	3,617	3,617	28,690,181	1.26	2,389,954.0
August	537	537	28,757,908	0.19	2,392,169.4
September	593	593	28,753,009	0.21	2,317,018.5
October	1,178	1,178	28,799,308	0.41	2,394,149.0
November	1,972	1,972	28,781,661	0.69	2,319,287.6
December	1,436	1,436	28,822,491	0.50	2,399,029.8
2019					
January	0	0	28,522,880	0.00	2,370,820.6
February	0	0	28,420,202	0.00	2,139,645.1
March	0	0	28,469,921	0.00	2,367,061.4
April	0	0	28,390,403	0.00	2,284,099.3
May	0	0	28,333,866	0.00	2,355,257.3
June	0	0	28,281,656	0.00	2,276,599.9
July	0	0	28,331,772	0.00	2,355,510.9
August	0	0	28,448,053	0.00	2,361,944.9
September	0	0	28,503,979	0.00	2,292,768.2
October	0	0	28,567,496	0.00	2,372,314.7
November	0	0	28,539,004	0.00	2,297,908.7
December	0	0	28,581,869	0.00	2,378,636.7
2020					
January	0	0	28,469,978	0.00	2,364,312.1
February	0	0	28,657,036	0.00	2,209,370.9
March	0	0	28,701,263	0.00	2,363,344.8

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
April	0	0	28,837,459	0.00	2,310,365.2
May	0	0	29,276,287	0.00	2,415,238.9
June	0	0	29,639,375	0.00	2,354,274.3
July	0	0	29,716,730	0.00	2,439,661.0
August	0	0	29,783,518	0.00	2,446,600.4
September	0	0	29,802,868	0.00	2,367,378.5
October	0	0	29,849,701	0.00	2,455,962.8
November	0	0	29,917,245	0.00	2,386,633.4
December	0	0	32,693,989	0.00	2,485,193.1
2021					
January	0	0	30,484,813	0.00	2,509,050.6
February	0	0	30,269,601	0.00	2,275,899.8
March	0	0	30,306,426	0.00	2,524,467.4
April	0	0	29,860,354	0.00	2,417,225.6
May	0	0	29,547,296	0.00	2,464,767.8
June	0	0	29,380,469	0.00	2,366,843.1
July	0	0	29,232,125	0.00	2,434,050.5
August	0	0	29,100,784	0.00	2,422,898.4
September	0	0	28,963,681	0.00	2,335,433.2
October	0	0	28,885,445	0.00	2,403,671.7
November	0	0	28,753,408	0.00	2,319,106.2
December	0	0	28,665,871	0.00	2,389,213.7
2022					
January	0	0	28,055,579	0.00	2,339,221.9
February	0	0	27,896,606	0.00	2,103,662.1
March	0	0	27,912,328	0.00	2,322,319.5
April	0	0	27,829,527	0.00	2,241,198.1
May	0	0	27,796,473	0.00	2,311,846.3
June	0	0	27,799,615	0.00	2,237,720.5
July	0	0	27,739,415	0.00	2,307,920.2
August	0	0	27,810,090	0.00	2,308,525.1
September	0	0	23,440,097	0.00	1,886,307.5
October	0	0	10,651,574	0.00	889,659.2

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
November	0	0	3,592,262	0.00	290,865.7
December	0	0	3,611,835	0.00	302,104.2
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan					
Contaminated valsartan					
2012					
May	0	0	25,037,571	0.00	2,059,417.0
June	0	0	25,189,032	0.00	1,995,720.7
July	0	0	25,114,413	0.00	2,064,209.9
August	0	0	25,201,684	0.00	2,067,790.3
September	5,903	5,903	25,226,516	2.34	2,004,250.1
October	34,683	34,683	25,197,209	13.76	2,076,404.4
November	17,491	17,491	25,154,995	6.95	2,012,049.3
December	11,459	11,459	26,907,071	4.26	2,085,152.1
2013					
January	10,451	10,451	25,515,562	4.10	2,102,004.1
February	6,298	6,298	25,116,637	2.51	1,895,241.6
March	5,504	5,504	25,202,977	2.18	2,100,368.5
April	18,155	18,155	25,164,004	7.21	2,030,426.9
May	17,942	17,942	25,172,091	7.13	2,098,248.5
June	14,424	14,424	25,186,373	5.73	2,032,360.1
July	12,089	12,089	25,258,408	4.79	2,107,216.5
August	8,642	8,642	25,323,784	3.41	2,109,684.6
September	8,249	8,249	25,307,914	3.26	2,041,118.5
October	7,092	7,092	25,279,522	2.81	2,106,888.1
November	7,527	7,527	25,225,095	2.98	2,036,767.4
December	6,504	6,504	25,174,242	2.58	2,100,586.5
2014					
January	8,210	8,210	27,849,194	2.95	2,319,398.7
February	9,137	9,137	27,723,842	3.30	2,091,197.3
March	12,232	12,232	27,720,463	4.41	2,310,506.0
April	10,436	10,436	27,677,987	3.77	2,231,167.4
May	8,029	8,029	27,611,963	2.91	2,299,220.3
June	6,532	6,532	27,551,141	2.37	2,221,475.0

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
July	8,782	8,782	27,692,802	3.17	2,307,748.1
August	9,205	9,205	27,623,875	3.33	2,300,664.1
September	8,145	8,145	27,576,759	2.95	2,224,207.8
October	16,607	16,607	27,623,755	6.01	2,299,679.7
November	12,217	12,217	27,537,785	4.44	2,223,127.0
December	14,037	14,037	27,534,200	5.10	2,292,244.4
2015					
January	21,084	21,084	28,507,219	7.40	2,373,852.2
February	27,090	27,090	28,418,228	9.53	2,141,385.8
March	24,817	24,817	28,479,015	8.71	2,372,262.6
April	21,900	21,900	28,551,083	7.67	2,301,006.8
May	20,827	20,827	28,619,932	7.28	2,382,922.5
June	26,445	26,445	28,627,068	9.24	2,307,484.0
July	27,394	27,394	28,638,197	9.57	2,386,027.6
August	23,168	23,168	28,669,043	8.08	2,388,587.9
September	18,506	18,506	28,711,596	6.45	2,315,183.8
October	15,661	15,661	28,755,162	5.45	2,392,177.7
November	16,568	16,568	28,673,735	5.78	2,312,926.5
December	20,342	20,342	28,695,749	7.09	2,388,795.3
2016					
January	26,392	26,392	29,111,959	9.07	2,422,941.4
February	28,660	28,660	29,466,686	9.73	2,266,279.3
March	31,913	31,913	29,524,831	10.81	2,427,638.3
April	37,935	37,935	29,522,157	12.85	2,347,907.8
May	37,990	37,990	29,519,741	12.87	2,428,156.6
June	32,609	32,609	29,650,174	11.00	2,350,686.9
July	28,112	28,112	29,617,388	9.49	2,432,498.5
August	30,630	30,630	29,656,132	10.33	2,433,403.9
September	29,617	29,617	29,720,103	9.97	2,359,272.9
October	25,965	25,965	29,667,284	8.75	2,443,280.5
November	20,623	20,623	29,757,217	6.93	2,366,224.3
December	17,754	17,754	32,616,611	5.44	2,456,669.2
2017					

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
January	19,015	19,015	29,791,025	6.38	2,451,826.8
February	16,740	16,740	29,375,850	5.70	2,211,700.2
March	17,297	17,297	29,469,628	5.87	2,450,910.7
April	14,455	14,455	29,439,693	4.91	2,370,876.0
May	15,878	15,878	29,437,367	5.39	2,448,578.1
June	17,384	17,384	29,439,216	5.91	2,371,334.5
July	22,453	22,453	29,432,901	7.63	2,452,827.3
August	23,802	23,802	29,534,567	8.06	2,456,479.8
September	19,121	19,121	29,559,696	6.47	2,381,655.9
October	18,142	18,142	29,645,849	6.12	2,466,918.1
November	17,801	17,801	29,629,508	6.01	2,388,292.8
December	17,791	17,791	29,735,072	5.98	2,474,523.9
2018					
January	20,728	20,728	29,618,242	7.00	2,462,898.6
February	19,134	19,134	29,532,855	6.48	2,223,085.3
March	19,736	19,736	29,610,227	6.67	2,462,430.8
April	17,708	17,708	29,551,740	5.99	2,379,778.9
May	17,777	17,777	29,522,512	6.02	2,455,191.5
June	18,375	18,375	29,504,915	6.23	2,376,073.2
July	12,298	12,298	29,463,164	4.17	2,454,418.3
August	5,554	5,554	29,532,183	1.88	2,456,352.4
September	6,108	6,108	29,522,364	2.07	2,378,819.7
October	8,796	8,796	29,566,733	2.97	2,457,726.3
November	9,976	9,976	29,544,015	3.38	2,380,611.4
December	10,478	10,478	29,583,424	3.54	2,462,259.0
2019					
January	0	0	29,268,809	0.00	2,432,776.2
February	0	0	29,161,945	0.00	2,195,559.8
March	0	0	29,212,707	0.00	2,429,142.7
April	0	0	29,135,284	0.00	2,344,370.3
May	0	0	29,078,440	0.00	2,417,645.1
June	0	0	29,020,841	0.00	2,336,645.1
July	0	0	29,020,146	0.00	2,415,666.3

Sentinel

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
August	0	0	29,045,845	0.00	2,415,286.6
September	0	0	29,035,322	0.00	2,338,348.1
October	0	0	29,058,781	0.00	2,415,321.8
November	0	0	29,025,430	0.00	2,338,127.8
December	0	0	29,064,420	0.00	2,419,678.3
2020					
January	0	0	28,945,159	0.00	2,404,497.1
February	0	0	29,134,820	0.00	2,246,785.9
March	0	0	29,181,132	0.00	2,403,523.4
April	0	0	29,325,560	0.00	2,350,041.9
May	0	0	29,776,772	0.00	2,456,946.0
June	0	0	30,147,554	0.00	2,395,082.4
July	0	0	30,228,019	0.00	2,482,123.8
August	0	0	30,299,161	0.00	2,489,338.2
September	0	0	30,321,956	0.00	2,408,978.8
October	0	0	30,372,379	0.00	2,499,283.0
November	0	0	30,441,235	0.00	2,428,868.9
December	0	0	33,253,737	0.00	2,529,190.1
2021					
January	0	0	31,018,435	0.00	2,553,395.9
February	0	0	30,803,057	0.00	2,316,300.2
March	0	0	30,840,728	0.00	2,569,539.9
April	0	0	30,385,816	0.00	2,460,336.9
May	0	0	30,065,301	0.00	2,508,556.9
June	0	0	29,895,294	0.00	2,408,769.7
July	0	0	29,746,280	0.00	2,477,228.6
August	0	0	29,616,594	0.00	2,466,125.7
September	0	0	29,481,144	0.00	2,377,386.9
October	0	0	29,406,455	0.00	2,447,263.4
November	0	0	29,277,168	0.00	2,361,627.3
December	0	0	29,192,796	0.00	2,433,417.9
2022					
January	0	0	28,581,401	0.00	2,383,511.1

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
February	0	0	28,429,449	0.00	2,144,248.0
March	0	0	28,455,494	0.00	2,367,948.4
April	0	0	28,381,100	0.00	2,285,829.1
May	0	0	28,353,217	0.00	2,358,361.3
June	0	0	28,360,943	0.00	2,283,088.1
July	0	0	28,305,787	0.00	2,355,205.7
August	0	0	28,380,202	0.00	2,356,117.3
September	0	0	23,978,858	0.00	1,929,836.1
October	0	0	10,783,931	0.00	900,782.5
November	0	0	3,643,475	0.00	295,032.8
December	0	0	3,662,240	0.00	306,370.9
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan					
Contaminated valsartan					
2012					
May	0	0	24,166,365	0.00	1,986,971.9
June	0	0	24,323,602	0.00	1,926,342.0
July	0	0	24,260,241	0.00	1,993,110.0
August	0	0	24,352,392	0.00	1,997,306.8
September	76	76	24,384,282	0.03	1,936,602.1
October	590	590	24,361,535	0.24	2,006,972.4
November	666	666	24,325,872	0.27	1,945,262.4
December	603	603	26,031,525	0.23	2,016,435.2
2013					
January	824	824	24,677,951	0.33	2,032,383.3
February	718	718	24,296,400	0.30	1,833,030.6
March	713	713	24,387,599	0.29	2,032,154.1
April	918	918	24,356,762	0.38	1,965,085.5
May	951	951	24,371,620	0.39	2,031,348.9
June	858	858	24,391,675	0.35	1,968,132.0
July	1,001	1,001	24,469,382	0.41	2,041,208.8
August	1,022	1,022	24,539,935	0.42	2,044,235.2
September	921	921	24,530,405	0.38	1,978,257.9
October	1,059	1,059	24,507,861	0.43	2,042,447.9

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
November	911	911	24,462,746	0.37	1,975,082.9
December	859	859	24,419,612	0.35	2,037,414.1
2014					
January	1,314	1,314	27,013,090	0.49	2,249,532.2
February	1,138	1,138	26,901,209	0.42	2,028,834.5
March	1,291	1,291	26,906,058	0.48	2,242,365.8
April	1,118	1,118	26,871,388	0.42	2,165,995.6
May	999	999	26,815,313	0.37	2,232,803.8
June	892	892	26,764,766	0.33	2,158,006.7
July	891	891	26,913,066	0.33	2,242,641.3
August	833	833	26,852,855	0.31	2,236,342.8
September	866	866	26,813,640	0.32	2,162,572.9
October	1,124	1,124	26,866,714	0.42	2,236,555.7
November	984	984	26,790,399	0.37	2,162,655.4
December	1,098	1,098	26,794,311	0.41	2,230,440.6
2015					
January	1,803	1,803	27,758,950	0.65	2,311,266.7
February	2,080	2,080	27,684,932	0.75	2,085,730.0
March	2,419	2,419	27,754,240	0.87	2,311,514.4
April	2,206	2,206	27,833,258	0.79	2,242,901.1
May	2,162	2,162	27,907,509	0.77	2,323,452.0
June	2,347	2,347	27,920,253	0.84	2,250,375.6
July	2,506	2,506	27,935,424	0.90	2,327,348.8
August	2,413	2,413	27,969,348	0.86	2,330,156.0
September	2,645	2,645	28,013,672	0.94	2,258,821.1
October	2,790	2,790	28,058,011	0.99	2,334,100.4
November	2,730	2,730	27,982,387	0.98	2,256,933.6
December	3,157	3,157	28,009,720	1.13	2,331,344.2
2016					
January	4,077	4,077	28,421,595	1.43	2,365,048.1
February	4,481	4,481	28,778,677	1.56	2,212,572.9
March	4,918	4,918	28,837,859	1.71	2,370,578.1
April	5,197	5,197	28,835,149	1.80	2,292,770.7

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
May	5,505	5,505	28,831,585	1.91	2,371,145.9
June	5,335	5,335	28,958,336	1.84	2,295,372.4
July	4,817	4,817	28,925,439	1.67	2,375,165.1
August	5,689	5,689	28,961,102	1.96	2,375,887.9
September	5,765	5,765	29,022,773	1.99	2,303,422.5
October	6,230	6,230	28,967,662	2.15	2,385,311.6
November	6,519	6,519	29,055,104	2.24	2,309,890.2
December	6,632	6,632	31,868,695	2.08	2,398,069.1
2017					
January	7,455	7,455	29,089,780	2.56	2,393,670.2
February	7,177	7,177	28,677,979	2.50	2,158,952.1
March	7,862	7,862	28,766,224	2.73	2,392,202.9
April	6,593	6,593	28,731,704	2.29	2,313,752.3
May	7,086	7,086	28,725,904	2.47	2,389,230.8
June	6,655	6,655	28,724,143	2.32	2,313,609.3
July	6,082	6,082	28,714,609	2.12	2,392,832.2
August	7,035	7,035	28,811,737	2.44	2,396,220.1
September	6,206	6,206	28,832,993	2.15	2,323,017.3
October	7,087	7,087	28,915,208	2.45	2,406,007.5
November	7,432	7,432	28,895,873	2.57	2,329,036.1
December	7,528	7,528	28,996,351	2.60	2,412,892.5
2018					
January	8,849	8,849	28,878,209	3.06	2,401,157.7
February	8,654	8,654	28,788,619	3.01	2,166,886.5
March	9,364	9,364	28,857,955	3.24	2,399,655.9
April	8,751	8,751	28,793,206	3.04	2,318,534.1
May	8,685	8,685	28,758,375	3.02	2,391,456.0
June	7,885	7,885	28,735,519	2.74	2,313,980.5
July	3,626	3,626	28,690,181	1.26	2,389,954.0
August	540	540	28,757,908	0.19	2,392,169.4
September	595	595	28,753,009	0.21	2,317,018.5
October	1,185	1,185	28,799,308	0.41	2,394,149.0
November	1,979	1,979	28,781,661	0.69	2,319,287.6

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
December	1,443	1,443	28,822,491	0.50	2,399,029.8
2019					
January	0	0	28,522,880	0.00	2,370,820.6
February	0	0	28,420,202	0.00	2,139,645.1
March	0	0	28,469,921	0.00	2,367,061.4
April	0	0	28,390,403	0.00	2,284,099.3
May	0	0	28,333,866	0.00	2,355,257.3
June	0	0	28,281,656	0.00	2,276,599.9
July	0	0	28,331,772	0.00	2,355,510.9
August	0	0	28,448,053	0.00	2,361,944.9
September	0	0	28,503,979	0.00	2,292,768.2
October	0	0	28,567,496	0.00	2,372,314.7
November	0	0	28,539,004	0.00	2,297,908.7
December	0	0	28,581,869	0.00	2,378,636.7
2020					
January	0	0	28,469,978	0.00	2,364,312.1
February	0	0	28,657,036	0.00	2,209,370.9
March	0	0	28,701,263	0.00	2,363,344.8
April	0	0	28,837,459	0.00	2,310,365.2
May	0	0	29,276,287	0.00	2,415,238.9
June	0	0	29,639,375	0.00	2,354,274.3
July	0	0	29,716,730	0.00	2,439,661.0
August	0	0	29,783,518	0.00	2,446,600.4
September	0	0	29,802,868	0.00	2,367,378.5
October	0	0	29,849,701	0.00	2,455,962.8
November	0	0	29,917,245	0.00	2,386,633.4
December	0	0	32,693,989	0.00	2,485,193.1
2021					
January	0	0	30,484,813	0.00	2,509,050.6
February	0	0	30,269,601	0.00	2,275,899.8
March	0	0	30,306,426	0.00	2,524,467.4
April	0	0	29,860,354	0.00	2,417,225.6
May	0	0	29,547,296	0.00	2,464,767.8

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
June	0	0	29,380,469	0.00	2,366,843.1
July	0	0	29,232,125	0.00	2,434,050.5
August	0	0	29,100,784	0.00	2,422,898.4
September	0	0	28,963,681	0.00	2,335,433.2
October	0	0	28,885,445	0.00	2,403,671.7
November	0	0	28,753,408	0.00	2,319,106.2
December	0	0	28,665,871	0.00	2,389,213.7
2022					
January	0	0	28,055,579	0.00	2,339,221.9
February	0	0	27,896,606	0.00	2,103,662.1
March	0	0	27,912,328	0.00	2,322,319.5
April	0	0	27,829,527	0.00	2,241,198.1
May	0	0	27,796,473	0.00	2,311,846.3
June	0	0	27,799,615	0.00	2,237,720.5
July	0	0	27,739,415	0.00	2,307,920.2
August	0	0	27,810,090	0.00	2,308,525.1
September	0	0	23,440,097	0.00	1,886,307.5
October	0	0	10,651,574	0.00	889,659.2
November	0	0	3,592,262	0.00	290,865.7
December	0	0	3,611,835	0.00	302,104.2
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan					
Non-contaminated valsartan					
2012					
May	32,699	32,699	25,037,571	13.06	2,059,417.0
June	30,242	30,242	25,189,032	12.01	1,995,720.7
July	28,323	28,323	25,114,413	11.28	2,064,209.9
August	26,328	26,328	25,201,684	10.45	2,067,790.3
September	21,724	21,724	25,226,516	8.61	2,004,250.1
October	21,477	21,477	25,197,209	8.52	2,076,404.4
November	19,955	19,955	25,154,995	7.93	2,012,049.3
December	18,775	18,775	26,907,071	6.98	2,085,152.1
2013					
January	22,649	22,649	25,515,562	8.88	2,102,004.1

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
February	18,807	18,807	25,116,637	7.49	1,895,241.6
March	18,778	18,778	25,202,977	7.45	2,100,368.5
April	19,552	19,552	25,164,004	7.77	2,030,426.9
May	17,841	17,841	25,172,091	7.09	2,098,248.5
June	15,725	15,725	25,186,373	6.24	2,032,360.1
July	15,829	15,829	25,258,408	6.27	2,107,216.5
August	14,605	14,605	25,323,784	5.77	2,109,684.6
September	14,116	14,116	25,307,914	5.58	2,041,118.5
October	15,160	15,160	25,279,522	6.00	2,106,888.1
November	12,839	12,839	25,225,095	5.09	2,036,767.4
December	13,078	13,078	25,174,242	5.19	2,100,586.5
2014					
January	17,639	17,639	27,849,194	6.33	2,319,398.7
February	14,768	14,768	27,723,842	5.33	2,091,197.3
March	14,202	14,202	27,720,463	5.12	2,310,506.0
April	12,633	12,633	27,677,987	4.56	2,231,167.4
May	11,902	11,902	27,611,963	4.31	2,299,220.3
June	14,605	14,605	27,551,141	5.30	2,221,475.0
July	11,656	11,656	27,692,802	4.21	2,307,748.1
August	11,656	11,656	27,623,875	4.22	2,300,664.1
September	11,120	11,120	27,576,759	4.03	2,224,207.8
October	15,299	15,299	27,623,755	5.54	2,299,679.7
November	13,683	13,683	27,537,785	4.97	2,223,127.0
December	14,584	14,584	27,534,200	5.30	2,292,244.4
2015					
January	14,475	14,475	28,507,219	5.08	2,373,852.2
February	11,781	11,781	28,418,228	4.15	2,141,385.8
March	15,790	15,790	28,479,015	5.54	2,372,262.6
April	18,345	18,345	28,551,083	6.43	2,301,006.8
May	22,069	22,069	28,619,932	7.71	2,382,922.5
June	23,622	23,622	28,627,068	8.25	2,307,484.0
July	20,958	20,958	28,638,197	7.32	2,386,027.6
August	16,857	16,857	28,669,043	5.88	2,388,587.9

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
September	14,950	14,950	28,711,596	5.21	2,315,183.8
October	16,612	16,612	28,755,162	5.78	2,392,177.7
November	20,263	20,263	28,673,735	7.07	2,312,926.5
December	19,926	19,926	28,695,749	6.94	2,388,795.3
2016					
January	19,773	19,773	29,111,959	6.79	2,422,941.4
February	16,178	16,178	29,466,686	5.49	2,266,279.3
March	13,702	13,702	29,524,831	4.64	2,427,638.3
April	11,133	11,133	29,522,157	3.77	2,347,907.8
May	11,635	11,635	29,519,741	3.94	2,428,156.6
June	13,612	13,612	29,650,174	4.59	2,350,686.9
July	14,034	14,034	29,617,388	4.74	2,432,498.5
August	12,625	12,625	29,656,132	4.26	2,433,403.9
September	10,010	10,010	29,720,103	3.37	2,359,272.9
October	9,613	9,613	29,667,284	3.24	2,443,280.5
November	9,489	9,489	29,757,217	3.19	2,366,224.3
December	9,344	9,344	32,616,611	2.86	2,456,669.2
2017					
January	11,347	11,347	29,791,025	3.81	2,451,826.8
February	10,075	10,075	29,375,850	3.43	2,211,700.2
March	10,548	10,548	29,469,628	3.58	2,450,910.7
April	8,554	8,554	29,439,693	2.91	2,370,876.0
May	12,580	12,580	29,437,367	4.27	2,448,578.1
June	12,408	12,408	29,439,216	4.21	2,371,334.5
July	14,734	14,734	29,432,901	5.01	2,452,827.3
August	15,909	15,909	29,534,567	5.39	2,456,479.8
September	14,371	14,371	29,559,696	4.86	2,381,655.9
October	13,771	13,771	29,645,849	4.65	2,466,918.1
November	12,599	12,599	29,629,508	4.25	2,388,292.8
December	11,311	11,311	29,735,072	3.80	2,474,523.9
2018					
January	12,362	12,362	29,618,242	4.17	2,462,898.6
February	9,918	9,918	29,532,855	3.36	2,223,085.3

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
March	11,272	11,272	29,610,227	3.81	2,462,430.8
April	11,705	11,705	29,551,740	3.96	2,379,778.9
May	11,825	11,825	29,522,512	4.01	2,455,191.5
June	10,106	10,106	29,504,915	3.43	2,376,073.2
July	17,604	17,604	29,463,164	5.97	2,454,418.3
August	13,688	13,688	29,532,183	4.63	2,456,352.4
September	12,643	12,643	29,522,364	4.28	2,378,819.7
October	14,605	14,605	29,566,733	4.94	2,457,726.3
November	10,422	10,422	29,544,015	3.53	2,380,611.4
December	12,290	12,290	29,583,424	4.15	2,462,259.0
2019					
January	61,811	61,811	29,268,809	21.12	2,432,776.2
February	38,057	38,057	29,161,945	13.05	2,195,559.8
March	43,213	43,213	29,212,707	14.79	2,429,142.7
April	26,878	26,878	29,135,284	9.23	2,344,370.3
May	21,940	21,940	29,078,440	7.55	2,417,645.1
June	15,089	15,089	29,020,841	5.20	2,336,645.1
July	14,872	14,872	29,020,146	5.12	2,415,666.3
August	15,443	15,443	29,045,845	5.32	2,415,286.6
September	17,240	17,240	29,035,322	5.94	2,338,348.1
October	25,530	25,530	29,058,781	8.79	2,415,321.8
November	17,849	17,849	29,025,430	6.15	2,338,127.8
December	18,930	18,930	29,064,420	6.51	2,419,678.3
2020					
January	22,509	22,509	28,945,159	7.78	2,404,497.1
February	18,172	18,172	29,134,820	6.24	2,246,785.9
March	16,758	16,758	29,181,132	5.74	2,403,523.4
April	10,290	10,290	29,325,560	3.51	2,350,041.9
May	9,101	9,101	29,776,772	3.06	2,456,946.0
June	11,605	11,605	30,147,554	3.85	2,395,082.4
July	11,470	11,470	30,228,019	3.79	2,482,123.8
August	10,224	10,224	30,299,161	3.37	2,489,338.2
September	11,271	11,271	30,321,956	3.72	2,408,978.8

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
October	13,961	13,961	30,372,379	4.60	2,499,283.0
November	13,296	13,296	30,441,235	4.37	2,428,868.9
December	14,181	14,181	33,253,737	4.26	2,529,190.1
2021					
January	14,088	14,088	31,018,435	4.54	2,553,395.9
February	13,276	13,276	30,803,057	4.31	2,316,300.2
March	16,858	16,858	30,840,728	5.47	2,569,539.9
April	15,652	15,652	30,385,816	5.15	2,460,336.9
May	14,150	14,150	30,065,301	4.71	2,508,556.9
June	14,586	14,586	29,895,294	4.88	2,408,769.7
July	16,916	16,916	29,746,280	5.69	2,477,228.6
August	19,013	19,013	29,616,594	6.42	2,466,125.7
September	21,088	21,088	29,481,144	7.15	2,377,386.9
October	20,028	20,028	29,406,455	6.81	2,447,263.4
November	18,330	18,330	29,277,168	6.26	2,361,627.3
December	18,148	18,148	29,192,796	6.22	2,433,417.9
2022					
January	21,655	21,655	28,581,401	7.58	2,383,511.1
February	19,623	19,623	28,429,449	6.90	2,144,248.0
March	19,970	19,970	28,455,494	7.02	2,367,948.4
April	14,507	14,507	28,381,100	5.11	2,285,829.1
May	13,447	13,447	28,353,217	4.74	2,358,361.3
June	13,192	13,192	28,360,943	4.65	2,283,088.1
July	11,650	11,650	28,305,787	4.12	2,355,205.7
August	12,687	12,687	28,380,202	4.47	2,356,117.3
September	11,355	11,355	23,978,858	4.74	1,929,836.1
October	2,959	2,959	10,783,931	2.74	900,782.5
November	987	987	3,643,475	2.71	295,032.8
December	926	926	3,662,240	2.53	306,370.9
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan					
Non-contaminated valsartan					
2012					
May	7,421	7,421	24,166,365	3.07	1,986,971.9

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
June	6,700	6,700	24,323,602	2.75	1,926,342.0
July	6,624	6,624	24,260,241	2.73	1,993,110.0
August	6,694	6,694	24,352,392	2.75	1,997,306.8
September	5,901	5,901	24,384,282	2.42	1,936,602.1
October	7,010	7,010	24,361,535	2.88	2,006,972.4
November	6,713	6,713	24,325,872	2.76	1,945,262.4
December	6,098	6,098	26,031,525	2.34	2,016,435.2
2013					
January	7,243	7,243	24,677,951	2.94	2,032,383.3
February	6,478	6,478	24,296,400	2.67	1,833,030.6
March	6,247	6,247	24,387,599	2.56	2,032,154.1
April	6,157	6,157	24,356,762	2.53	1,965,085.5
May	5,444	5,444	24,371,620	2.23	2,031,348.9
June	4,789	4,789	24,391,675	1.96	1,968,132.0
July	5,217	5,217	24,469,382	2.13	2,041,208.8
August	4,822	4,822	24,539,935	1.96	2,044,235.2
September	4,514	4,514	24,530,405	1.84	1,978,257.9
October	4,833	4,833	24,507,861	1.97	2,042,447.9
November	4,195	4,195	24,462,746	1.71	1,975,082.9
December	4,046	4,046	24,419,612	1.66	2,037,414.1
2014					
January	4,931	4,931	27,013,090	1.83	2,249,532.2
February	4,381	4,381	26,901,209	1.63	2,028,834.5
March	4,314	4,314	26,906,058	1.60	2,242,365.8
April	3,835	3,835	26,871,388	1.43	2,165,995.6
May	3,280	3,280	26,815,313	1.22	2,232,803.8
June	3,052	3,052	26,764,766	1.14	2,158,006.7
July	3,293	3,293	26,913,066	1.22	2,242,641.3
August	3,483	3,483	26,852,855	1.30	2,236,342.8
September	3,562	3,562	26,813,640	1.33	2,162,572.9
October	3,872	3,872	26,866,714	1.44	2,236,555.7
November	3,354	3,354	26,790,399	1.25	2,162,655.4
December	3,656	3,656	26,794,311	1.36	2,230,440.6

Sentinel

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2015					
January	3,815	3,815	27,758,950	1.37	2,311,266.7
February	3,285	3,285	27,684,932	1.19	2,085,730.0
March	3,593	3,593	27,754,240	1.29	2,311,514.4
April	3,368	3,368	27,833,258	1.21	2,242,901.1
May	3,173	3,173	27,907,509	1.14	2,323,452.0
June	3,250	3,250	27,920,253	1.16	2,250,375.6
July	3,133	3,133	27,935,424	1.12	2,327,348.8
August	2,994	2,994	27,969,348	1.07	2,330,156.0
September	3,243	3,243	28,013,672	1.16	2,258,821.1
October	3,602	3,602	28,058,011	1.28	2,334,100.4
November	3,636	3,636	27,982,387	1.30	2,256,933.6
December	4,004	4,004	28,009,720	1.43	2,331,344.2
2016					
January	4,592	4,592	28,421,595	1.62	2,365,048.1
February	4,419	4,419	28,778,677	1.54	2,212,572.9
March	4,381	4,381	28,837,859	1.52	2,370,578.1
April	3,241	3,241	28,835,149	1.12	2,292,770.7
May	2,906	2,906	28,831,585	1.01	2,371,145.9
June	2,821	2,821	28,958,336	0.97	2,295,372.4
July	2,620	2,620	28,925,439	0.91	2,375,165.1
August	2,787	2,787	28,961,102	0.96	2,375,887.9
September	2,560	2,560	29,022,773	0.88	2,303,422.5
October	2,619	2,619	28,967,662	0.90	2,385,311.6
November	2,758	2,758	29,055,104	0.95	2,309,890.2
December	2,833	2,833	31,868,695	0.89	2,398,069.1
2017					
January	3,140	3,140	29,089,780	1.08	2,393,670.2
February	3,073	3,073	28,677,979	1.07	2,158,952.1
March	3,439	3,439	28,766,224	1.20	2,392,202.9
April	3,160	3,160	28,731,704	1.10	2,313,752.3
May	3,520	3,520	28,725,904	1.23	2,389,230.8
June	3,161	3,161	28,724,143	1.10	2,313,609.3

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
July	2,503	2,503	28,714,609	0.87	2,392,832.2
August	2,756	2,756	28,811,737	0.96	2,396,220.1
September	2,492	2,492	28,832,993	0.86	2,323,017.3
October	2,739	2,739	28,915,208	0.95	2,406,007.5
November	2,770	2,770	28,895,873	0.96	2,329,036.1
December	2,572	2,572	28,996,351	0.89	2,412,892.5
2018					
January	3,220	3,220	28,878,209	1.12	2,401,157.7
February	3,015	3,015	28,788,619	1.05	2,166,886.5
March	3,366	3,366	28,857,955	1.17	2,399,655.9
April	3,313	3,313	28,793,206	1.15	2,318,534.1
May	3,316	3,316	28,758,375	1.15	2,391,456.0
June	2,903	2,903	28,735,519	1.01	2,313,980.5
July	2,350	2,350	28,690,181	0.82	2,389,954.0
August	2,032	2,032	28,757,908	0.71	2,392,169.4
September	1,897	1,897	28,753,009	0.66	2,317,018.5
October	2,477	2,477	28,799,308	0.86	2,394,149.0
November	2,703	2,703	28,781,661	0.94	2,319,287.6
December	2,673	2,673	28,822,491	0.93	2,399,029.8
2019					
January	6,647	6,647	28,522,880	2.33	2,370,820.6
February	7,381	7,381	28,420,202	2.60	2,139,645.1
March	13,325	13,325	28,469,921	4.68	2,367,061.4
April	12,603	12,603	28,390,403	4.44	2,284,099.3
May	12,781	12,781	28,333,866	4.51	2,355,257.3
June	8,948	8,948	28,281,656	3.16	2,276,599.9
July	9,124	9,124	28,331,772	3.22	2,355,510.9
August	9,668	9,668	28,448,053	3.40	2,361,944.9
September	11,701	11,701	28,503,979	4.11	2,292,768.2
October	18,782	18,782	28,567,496	6.57	2,372,314.7
November	12,933	12,933	28,539,004	4.53	2,297,908.7
December	10,855	10,855	28,581,869	3.80	2,378,636.7
2020					

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
January	12,033	12,033	28,469,978	4.23	2,364,312.1
February	10,656	10,656	28,657,036	3.72	2,209,370.9
March	10,545	10,545	28,701,263	3.67	2,363,344.8
April	7,022	7,022	28,837,459	2.44	2,310,365.2
May	5,977	5,977	29,276,287	2.04	2,415,238.9
June	6,690	6,690	29,639,375	2.26	2,354,274.3
July	6,754	6,754	29,716,730	2.27	2,439,661.0
August	6,309	6,309	29,783,518	2.12	2,446,600.4
September	6,737	6,737	29,802,868	2.26	2,367,378.5
October	7,496	7,496	29,849,701	2.51	2,455,962.8
November	7,008	7,008	29,917,245	2.34	2,386,633.4
December	7,512	7,512	32,693,989	2.30	2,485,193.1
2021					
January	7,974	7,974	30,484,813	2.62	2,509,050.6
February	8,195	8,195	30,269,601	2.71	2,275,899.8
March	10,743	10,743	30,306,426	3.54	2,524,467.4
April	10,160	10,160	29,860,354	3.40	2,417,225.6
May	9,199	9,199	29,547,296	3.11	2,464,767.8
June	9,535	9,535	29,380,469	3.25	2,366,843.1
July	9,046	9,046	29,232,125	3.09	2,434,050.5
August	9,009	9,009	29,100,784	3.10	2,422,898.4
September	9,091	9,091	28,963,681	3.14	2,335,433.2
October	9,620	9,620	28,885,445	3.33	2,403,671.7
November	9,557	9,557	28,753,408	3.32	2,319,106.2
December	10,283	10,283	28,665,871	3.59	2,389,213.7
2022					
January	14,468	14,468	28,055,579	5.16	2,339,221.9
February	14,084	14,084	27,896,606	5.05	2,103,662.1
March	14,651	14,651	27,912,328	5.25	2,322,319.5
April	10,365	10,365	27,829,527	3.72	2,241,198.1
May	9,662	9,662	27,796,473	3.48	2,311,846.3
June	9,496	9,496	27,799,615	3.42	2,237,720.5
July	8,092	8,092	27,739,415	2.92	2,307,920.2

Sentinel

Table 2. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year and Month

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
August	9,009	9,009	27,810,090	3.24	2,308,525.1
September	8,128	8,128	23,440,097	3.47	1,886,307.5
October	2,030	2,030	10,651,574	1.91	889,659.2
November	674	674	3,592,262	1.88	290,865.7
December	636	636	3,611,835	1.76	302,104.2

[1]Eligible Members and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
Prevalent Use - All Censoring Options					
Any valsartan product					
2012, May					
18-44 years	2,109	2,109	8,364,508	2.52	685,791.5
45-64 years	9,761	9,761	7,525,643	12.97	618,088.7
65-74 years	9,933	9,933	4,787,090	20.75	390,798.7
75-84 years	7,596	7,596	2,975,916	25.52	243,391.1
≥ 85 years	3,300	3,300	1,478,285	22.32	121,347.1
2012, June					
18-44 years	2,009	2,009	8,439,754	2.38	664,978.5
45-64 years	9,221	9,221	7,572,017	12.18	599,028.0
65-74 years	9,116	9,116	4,812,888	18.94	378,816.8
75-84 years	6,933	6,933	2,976,439	23.29	235,451.1
≥ 85 years	2,978	2,978	1,479,239	20.13	117,446.2
2012, July					
18-44 years	2,038	2,038	8,433,567	2.42	687,065.5
45-64 years	9,309	9,309	7,512,418	12.39	618,367.3
65-74 years	9,286	9,286	4,815,120	19.29	393,489.8
75-84 years	6,765	6,765	2,972,401	22.76	243,646.9
≥ 85 years	3,055	3,055	1,479,218	20.65	121,640.5
2012, August					
18-44 years	2,029	2,029	8,458,411	2.40	688,780.3
45-64 years	9,343	9,343	7,534,562	12.40	618,951.9
65-74 years	9,201	9,201	4,842,935	19.00	394,472.6
75-84 years	6,793	6,793	2,980,930	22.79	243,764.8
≥ 85 years	3,075	3,075	1,484,666	20.71	121,820.5
2012, September					
18-44 years	1,845	1,845	8,461,860	2.18	667,463.8
45-64 years	8,458	8,458	7,546,214	11.21	599,710.0
65-74 years	8,553	8,553	4,852,539	17.63	383,018.4
75-84 years	6,353	6,353	2,978,540	21.33	235,991.0
≥ 85 years	2,775	2,775	1,485,027	18.69	118,067.0

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2012, October					
18-44 years	2,051	2,051	8,410,780	2.44	692,353.4
45-64 years	9,558	9,558	7,535,482	12.68	620,487.1
65-74 years	9,827	9,827	4,872,569	20.17	397,292.1
75-84 years	7,031	7,031	2,985,327	23.55	244,054.5
≥ 85 years	3,141	3,141	1,489,217	21.09	122,217.3
2012, November					
18-44 years	2,009	2,009	8,383,816	2.40	670,514.1
45-64 years	9,316	9,316	7,522,298	12.38	601,201.8
65-74 years	9,202	9,202	4,877,771	18.87	385,739.1
75-84 years	6,910	6,910	2,976,557	23.21	236,289.4
≥ 85 years	2,854	2,854	1,484,866	19.22	118,305.0
2012, December					
18-44 years	1,821	1,821	8,954,111	2.03	694,328.3
45-64 years	9,085	9,085	7,957,095	11.42	622,901.1
65-74 years	8,831	8,831	5,338,172	16.54	400,981.5
75-84 years	6,259	6,259	3,184,349	19.66	244,629.9
≥ 85 years	2,939	2,939	1,566,633	18.76	122,311.3
2013, January					
18-44 years	2,019	2,019	8,353,700	2.42	687,648.1
45-64 years	9,485	9,485	7,548,041	12.57	621,880.1
65-74 years	10,938	10,938	5,100,007	21.45	415,361.8
75-84 years	7,838	7,838	3,078,255	25.46	251,576.0
≥ 85 years	3,513	3,513	1,530,143	22.96	125,538.3
2013, February					
18-44 years	1,801	1,801	8,175,825	2.20	619,070.5
45-64 years	8,683	8,683	7,436,868	11.68	560,449.5
65-74 years	8,979	8,979	5,027,964	17.86	375,918.3
75-84 years	6,402	6,402	3,054,008	20.96	227,022.2
≥ 85 years	2,888	2,888	1,512,480	19.09	112,781.3
2013, March					
18-44 years	1,762	1,762	8,193,743	2.15	685,513.4

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	8,611	8,611	7,458,564	11.55	620,998.7
65-74 years	8,682	8,682	5,062,078	17.15	417,643.1
75-84 years	6,430	6,430	3,068,318	20.96	251,434.5
≥ 85 years	2,958	2,958	1,517,564	19.49	124,778.9
2013, April					
18-44 years	1,708	1,708	8,163,103	2.09	661,545.4
45-64 years	8,596	8,596	7,448,315	11.54	600,540.3
65-74 years	9,166	9,166	5,066,600	18.09	404,730.2
75-84 years	6,718	6,718	3,064,944	21.92	243,135.3
≥ 85 years	2,992	2,992	1,512,954	19.78	120,475.5
2013, May					
18-44 years	1,674	1,674	8,167,935	2.05	683,740.2
45-64 years	8,284	8,284	7,448,510	11.12	620,475.7
65-74 years	8,683	8,683	5,073,554	17.11	418,646.0
75-84 years	6,385	6,385	3,063,443	20.84	250,971.7
≥ 85 years	2,836	2,836	1,513,127	18.74	124,414.9
2013, June					
18-44 years	1,580	1,580	8,172,089	1.93	662,092.7
45-64 years	7,742	7,742	7,451,057	10.39	600,884.6
65-74 years	7,888	7,888	5,078,332	15.53	405,880.9
75-84 years	5,801	5,801	3,061,768	18.95	242,903.2
≥ 85 years	2,547	2,547	1,515,140	16.81	120,598.6
2013, July					
18-44 years	1,639	1,639	8,186,238	2.00	685,446.1
45-64 years	8,279	8,279	7,477,827	11.07	623,277.3
65-74 years	8,362	8,362	5,106,423	16.38	421,838.0
75-84 years	6,089	6,089	3,068,486	19.84	251,632.8
≥ 85 years	2,759	2,759	1,518,798	18.17	125,022.4
2013, August					
18-44 years	1,568	1,568	8,222,861	1.91	686,985.1
45-64 years	8,072	8,072	7,485,928	10.78	623,387.5
65-74 years	7,994	7,994	5,122,700	15.61	422,614.0

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	5,807	5,807	3,072,300	18.90	251,599.8
≥ 85 years	2,615	2,615	1,522,012	17.18	125,098.2
2013, September					
18-44 years	1,501	1,501	8,206,097	1.83	663,185.4
45-64 years	7,420	7,420	7,481,401	9.92	603,284.7
65-74 years	7,830	7,830	5,129,144	15.27	409,982.8
75-84 years	5,747	5,747	3,068,476	18.73	243,479.4
≥ 85 years	2,522	2,522	1,521,423	16.58	121,186.3
2013, October					
18-44 years	1,583	1,583	8,151,267	1.94	682,468.5
45-64 years	8,035	8,035	7,486,691	10.73	623,439.9
65-74 years	8,080	8,080	5,143,267	15.71	424,173.3
75-84 years	5,858	5,858	3,072,371	19.07	251,525.2
≥ 85 years	2,631	2,631	1,524,246	17.26	125,281.1
2013, November					
18-44 years	1,405	1,405	8,140,272	1.73	660,095.1
45-64 years	7,187	7,187	7,472,138	9.62	602,666.2
65-74 years	7,224	7,224	5,131,443	14.08	410,239.6
75-84 years	5,154	5,154	3,056,902	16.86	242,817.7
≥ 85 years	2,327	2,327	1,516,932	15.34	120,948.8
2013, December					
18-44 years	1,373	1,373	8,111,311	1.69	679,413.8
45-64 years	7,289	7,289	7,453,904	9.78	620,953.7
65-74 years	7,433	7,433	5,132,287	14.48	424,162.2
75-84 years	5,322	5,322	3,056,031	17.41	251,034.8
≥ 85 years	2,412	2,412	1,516,170	15.91	125,022.0
2014, January					
18-44 years	1,858	1,858	8,900,862	2.09	743,878.7
45-64 years	8,539	8,539	8,097,588	10.55	673,473.1
65-74 years	9,089	9,089	5,828,215	15.59	480,960.5
75-84 years	6,490	6,490	3,436,548	18.89	281,800.4
≥ 85 years	2,852	2,852	1,692,042	16.86	139,286.0

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2014, February					
18-44 years	1,595	1,595	8,846,077	1.80	669,432.3
45-64 years	7,857	7,857	8,045,772	9.77	606,140.0
65-74 years	8,037	8,037	5,820,892	13.81	435,355.3
75-84 years	5,694	5,694	3,424,581	16.63	254,601.6
≥ 85 years	2,494	2,494	1,684,773	14.80	125,668.1
2014, March					
18-44 years	1,635	1,635	8,829,117	1.85	738,714.1
45-64 years	8,158	8,158	8,023,113	10.17	667,865.6
65-74 years	8,446	8,446	5,847,596	14.44	482,829.3
75-84 years	6,073	6,073	3,437,822	17.67	281,924.6
≥ 85 years	2,669	2,669	1,691,245	15.78	139,172.4
2014, April					
18-44 years	1,421	1,421	8,792,157	1.62	711,953.1
45-64 years	7,494	7,494	7,984,409	9.39	643,156.4
65-74 years	7,916	7,916	5,863,303	13.50	468,166.6
75-84 years	5,705	5,705	3,445,634	16.56	273,159.9
≥ 85 years	2,555	2,555	1,693,294	15.09	134,731.3
2014, May					
18-44 years	1,388	1,388	8,775,025	1.58	733,930.6
45-64 years	7,268	7,268	7,950,385	9.14	661,633.0
65-74 years	7,763	7,763	5,858,001	13.25	483,089.2
75-84 years	5,377	5,377	3,440,683	15.63	281,659.7
≥ 85 years	2,393	2,393	1,690,431	14.16	138,907.8
2014, June					
18-44 years	1,379	1,379	8,755,301	1.58	708,949.4
45-64 years	6,861	6,861	7,924,298	8.66	638,515.2
65-74 years	7,379	7,379	5,854,865	12.60	467,718.1
75-84 years	5,229	5,229	3,431,651	15.24	272,104.9
≥ 85 years	2,330	2,330	1,686,277	13.82	134,187.3
2014, July					
18-44 years	1,413	1,413	8,833,991	1.60	738,989.7

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	7,438	7,438	7,983,593	9.32	664,707.5
65-74 years	7,578	7,578	5,874,178	12.90	484,891.1
75-84 years	5,394	5,394	3,427,276	15.74	280,728.7
≥ 85 years	2,581	2,581	1,684,119	15.33	138,431.0
2014, August					
18-44 years	1,436	1,436	8,797,059	1.63	735,222.7
45-64 years	7,240	7,240	7,935,928	9.12	660,431.2
65-74 years	7,761	7,761	5,888,903	13.18	485,876.7
75-84 years	5,496	5,496	3,428,655	16.03	280,695.3
≥ 85 years	2,567	2,567	1,684,601	15.24	138,438.1
2014, September					
18-44 years	1,396	1,396	8,769,121	1.59	710,028.2
45-64 years	7,495	7,495	7,912,260	9.47	637,550.1
65-74 years	7,841	7,841	5,894,672	13.30	470,964.9
75-84 years	5,624	5,624	3,426,341	16.41	271,705.1
≥ 85 years	2,588	2,588	1,682,352	15.38	133,959.4
2014, October					
18-44 years	1,513	1,513	8,785,078	1.72	734,914.6
45-64 years	7,676	7,676	7,910,421	9.70	658,014.1
65-74 years	8,550	8,550	5,914,239	14.46	487,351.0
75-84 years	6,128	6,128	3,435,649	17.84	280,981.9
≥ 85 years	2,817	2,817	1,685,805	16.71	138,418.0
2014, November					
18-44 years	1,319	1,319	8,754,559	1.51	709,819.2
45-64 years	6,815	6,815	7,883,454	8.64	635,697.5
65-74 years	7,034	7,034	5,900,692	11.92	471,898.8
75-84 years	4,963	4,963	3,422,502	14.50	271,908.9
≥ 85 years	2,267	2,267	1,678,279	13.51	133,802.6
2014, December					
18-44 years	1,427	1,427	8,757,751	1.63	732,068.5
45-64 years	7,289	7,289	7,881,283	9.25	654,824.6
65-74 years	7,578	7,578	5,904,938	12.83	487,099.3

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	5,478	5,478	3,421,590	16.01	280,390.3
≥ 85 years	2,386	2,386	1,674,759	14.25	137,861.6
2015, January					
18-44 years	1,569	1,569	9,123,915	1.72	762,766.6
45-64 years	7,753	7,753	8,180,925	9.48	680,368.3
65-74 years	8,285	8,285	6,127,270	13.52	505,457.1
75-84 years	5,793	5,793	3,490,024	16.60	285,957.7
≥ 85 years	2,566	2,566	1,693,775	15.15	139,302.5
2015, February					
18-44 years	1,431	1,431	9,086,841	1.57	687,415.6
45-64 years	7,077	7,077	8,160,229	8.67	614,176.1
65-74 years	7,483	7,483	6,120,863	12.23	457,054.2
75-84 years	5,196	5,196	3,474,987	14.95	257,792.2
≥ 85 years	2,259	2,259	1,677,605	13.47	124,947.6
2015, March					
18-44 years	1,596	1,596	9,100,046	1.75	761,135.6
45-64 years	7,910	7,910	8,180,125	9.67	680,528.2
65-74 years	8,259	8,259	6,143,987	13.44	506,922.6
75-84 years	5,765	5,765	3,486,096	16.54	285,560.7
≥ 85 years	2,607	2,607	1,680,197	15.52	138,115.5
2015, April					
18-44 years	1,423	1,423	9,138,675	1.56	739,977.1
45-64 years	7,497	7,497	8,211,131	9.13	661,233.4
65-74 years	7,837	7,837	6,145,884	12.75	490,587.7
75-84 years	5,425	5,425	3,483,308	15.57	275,957.6
≥ 85 years	2,416	2,416	1,675,829	14.42	133,251.0
2015, May					
18-44 years	1,335	1,335	9,175,195	1.46	767,475.7
45-64 years	7,006	7,006	8,246,239	8.50	686,093.7
65-74 years	7,288	7,288	6,153,081	11.84	507,293.6
75-84 years	5,045	5,045	3,481,086	14.49	284,736.1
≥ 85 years	2,241	2,241	1,671,940	13.40	137,323.4

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2015, June					
18-44 years	1,424	1,424	9,183,380	1.55	743,496.2
45-64 years	7,348	7,348	8,249,066	8.91	664,426.9
65-74 years	7,392	7,392	6,156,861	12.01	491,430.5
75-84 years	5,296	5,296	3,476,280	15.23	275,392.3
≥ 85 years	2,236	2,236	1,669,641	13.39	132,738.1
2015, July					
18-44 years	1,445	1,445	9,174,711	1.57	767,433.8
45-64 years	7,143	7,143	8,243,111	8.67	686,070.7
65-74 years	7,372	7,372	6,183,678	11.92	510,273.2
75-84 years	5,081	5,081	3,480,494	14.60	284,897.6
≥ 85 years	2,257	2,257	1,671,542	13.50	137,352.4
2015, August					
18-44 years	1,338	1,338	9,185,511	1.46	767,910.7
45-64 years	7,039	7,039	8,238,322	8.54	685,699.0
65-74 years	7,371	7,371	6,202,569	11.88	511,943.7
75-84 years	4,910	4,910	3,486,959	14.08	285,474.9
≥ 85 years	2,190	2,190	1,673,569	13.09	137,559.6
2015, September					
18-44 years	1,384	1,384	9,195,873	1.51	744,491.9
45-64 years	7,145	7,145	8,246,416	8.66	664,166.7
65-74 years	7,577	7,577	6,220,835	12.18	496,832.6
75-84 years	5,208	5,208	3,489,823	14.92	276,503.9
≥ 85 years	2,154	2,154	1,674,405	12.86	133,188.6
2015, October					
18-44 years	1,463	1,463	9,186,832	1.59	768,057.8
45-64 years	7,353	7,353	8,256,279	8.91	685,957.0
65-74 years	7,674	7,674	6,247,993	12.28	514,567.3
75-84 years	5,282	5,282	3,499,155	15.10	285,939.0
≥ 85 years	2,188	2,188	1,678,202	13.04	137,656.7
2015, November					
18-44 years	1,417	1,417	9,158,717	1.55	741,953.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	6,820	6,820	8,233,444	8.28	663,167.1
65-74 years	7,434	7,434	6,234,026	11.92	498,253.2
75-84 years	4,930	4,930	3,484,813	14.15	276,549.0
≥ 85 years	2,111	2,111	1,669,179	12.65	133,003.4
2015, December					
18-44 years	1,534	1,534	9,161,719	1.67	766,268.6
45-64 years	7,508	7,508	8,238,837	9.11	684,479.4
65-74 years	7,767	7,767	6,246,451	12.43	514,985.8
75-84 years	5,366	5,366	3,490,650	15.37	285,784.2
≥ 85 years	2,170	2,170	1,669,468	13.00	137,277.3
2016, January					
18-44 years	1,556	1,556	9,197,891	1.69	768,766.8
45-64 years	7,623	7,623	8,317,974	9.16	691,508.8
65-74 years	9,015	9,015	6,466,038	13.94	533,020.6
75-84 years	5,822	5,822	3,552,538	16.39	290,765.5
≥ 85 years	2,334	2,334	1,689,811	13.81	138,879.7
2016, February					
18-44 years	1,620	1,620	9,347,756	1.73	718,151.0
45-64 years	7,848	7,848	8,432,703	9.31	646,433.4
65-74 years	8,419	8,419	6,545,713	12.86	499,704.7
75-84 years	5,493	5,493	3,556,873	15.44	272,312.5
≥ 85 years	2,310	2,310	1,687,003	13.69	129,677.7
2016, March					
18-44 years	1,619	1,619	9,366,076	1.73	769,852.1
45-64 years	8,194	8,194	8,439,304	9.71	693,183.1
65-74 years	9,081	9,081	6,572,078	13.82	535,044.1
75-84 years	5,905	5,905	3,571,421	16.53	291,183.6
≥ 85 years	2,480	2,480	1,690,174	14.67	138,375.5
2016, April					
18-44 years	1,502	1,502	9,384,822	1.60	744,418.9
45-64 years	7,554	7,554	8,419,060	8.97	669,792.2
65-74 years	8,335	8,335	6,569,124	12.69	518,068.0

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	5,451	5,451	3,570,432	15.27	281,952.1
≥ 85 years	2,241	2,241	1,685,515	13.30	133,676.6
2016, May					
18-44 years	1,492	1,492	9,394,394	1.59	772,087.7
45-64 years	7,328	7,328	8,404,391	8.72	691,299.2
65-74 years	8,383	8,383	6,572,106	12.76	535,445.0
75-84 years	5,582	5,582	3,574,047	15.62	291,433.1
≥ 85 years	2,288	2,288	1,684,428	13.58	137,891.7
2016, June					
18-44 years	1,446	1,446	9,443,249	1.53	746,629.4
45-64 years	7,490	7,490	8,432,609	8.88	668,337.1
65-74 years	8,495	8,495	6,613,244	12.85	519,406.7
75-84 years	5,490	5,490	3,585,720	15.31	282,753.3
≥ 85 years	2,251	2,251	1,685,376	13.36	133,560.2
2016, July					
18-44 years	1,418	1,418	9,461,262	1.50	771,598.4
45-64 years	7,073	7,073	8,377,595	8.44	690,024.6
65-74 years	7,708	7,708	6,618,431	11.65	539,385.0
75-84 years	5,089	5,089	3,591,786	14.17	293,279.9
≥ 85 years	2,192	2,192	1,685,623	13.00	138,210.5
2016, August					
18-44 years	1,573	1,573	9,439,117	1.67	770,338.6
45-64 years	7,878	7,878	8,394,924	9.38	689,729.7
65-74 years	8,626	8,626	6,643,992	12.98	540,791.4
75-84 years	5,549	5,549	3,607,137	15.38	294,163.3
≥ 85 years	2,278	2,278	1,689,827	13.48	138,380.9
2016, September					
18-44 years	1,482	1,482	9,456,740	1.57	747,592.2
45-64 years	7,680	7,680	8,420,353	9.12	667,450.2
65-74 years	8,334	8,334	6,657,344	12.52	524,840.8
75-84 years	5,328	5,328	3,610,739	14.76	285,278.9
≥ 85 years	2,258	2,258	1,690,174	13.36	134,110.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2016, October					
18-44 years	1,592	1,592	9,401,480	1.69	774,245.1
45-64 years	7,805	7,805	8,391,271	9.30	690,619.5
65-74 years	8,498	8,498	6,674,329	12.73	544,213.4
75-84 years	5,593	5,593	3,620,317	15.45	295,502.5
≥ 85 years	2,295	2,295	1,692,643	13.56	138,700.0
2016, November					
18-44 years	1,553	1,553	9,463,510	1.64	750,054.5
45-64 years	7,688	7,688	8,428,158	9.12	668,345.6
65-74 years	8,716	8,716	6,670,099	13.07	527,483.5
75-84 years	5,555	5,555	3,616,309	15.36	286,279.8
≥ 85 years	2,197	2,197	1,686,419	13.03	134,060.8
2016, December					
18-44 years	1,514	1,514	10,721,076	1.41	781,111.1
45-64 years	7,829	7,829	9,379,592	8.35	694,190.9
65-74 years	8,861	8,861	7,114,665	12.45	546,461.2
75-84 years	5,886	5,886	3,773,569	15.60	296,434.9
≥ 85 years	2,407	2,407	1,738,486	13.85	138,471.1
2017, January					
18-44 years	1,753	1,753	9,487,856	1.85	780,593.7
45-64 years	8,337	8,337	8,370,471	9.96	688,283.0
65-74 years	9,760	9,760	6,757,194	14.44	550,680.7
75-84 years	6,007	6,007	3,618,289	16.60	295,409.8
≥ 85 years	2,473	2,473	1,668,592	14.82	136,859.5
2017, February					
18-44 years	1,553	1,553	9,319,963	1.67	704,706.1
45-64 years	7,661	7,661	8,251,261	9.28	620,296.0
65-74 years	8,869	8,869	6,661,229	13.31	497,103.7
75-84 years	5,613	5,613	3,596,912	15.61	266,670.0
≥ 85 years	2,203	2,203	1,651,950	13.34	122,924.4
2017, March					
18-44 years	1,714	1,714	9,350,278	1.83	781,603.2

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	8,466	8,466	8,270,143	10.24	686,825.6
65-74 years	9,795	9,795	6,691,510	14.64	551,117.1
75-84 years	6,422	6,422	3,615,640	17.76	295,535.4
≥ 85 years	2,590	2,590	1,654,674	15.65	135,829.5
2017, April					
18-44 years	1,460	1,460	9,349,585	1.56	756,960.8
45-64 years	7,422	7,422	8,252,018	8.99	663,883.1
65-74 years	8,746	8,746	6,682,659	13.09	533,106.3
75-84 years	5,631	5,631	3,612,985	15.59	286,004.9
≥ 85 years	2,287	2,287	1,646,563	13.89	130,920.9
2017, May					
18-44 years	1,583	1,583	9,359,246	1.69	782,545.8
45-64 years	8,093	8,093	8,242,827	9.82	685,007.1
65-74 years	9,436	9,436	6,683,727	14.12	550,617.9
75-84 years	6,197	6,197	3,615,549	17.14	295,460.0
≥ 85 years	2,390	2,390	1,644,327	14.53	134,947.3
2017, June					
18-44 years	1,638	1,638	9,368,314	1.75	758,284.8
45-64 years	7,816	7,816	8,236,072	9.49	662,790.7
65-74 years	8,969	8,969	6,685,793	13.42	533,532.9
75-84 years	5,976	5,976	3,614,209	16.53	286,199.9
≥ 85 years	2,352	2,352	1,641,664	14.33	130,526.2
2017, July					
18-44 years	1,477	1,477	9,360,900	1.58	783,019.8
45-64 years	7,346	7,346	8,212,151	8.95	683,447.3
65-74 years	8,356	8,356	6,710,909	12.45	554,364.4
75-84 years	5,517	5,517	3,622,293	15.23	296,907.7
≥ 85 years	2,208	2,208	1,641,767	13.45	135,088.0
2017, August					
18-44 years	1,646	1,646	9,399,555	1.75	785,055.2
45-64 years	7,853	7,853	8,228,369	9.54	683,721.6
65-74 years	9,135	9,135	6,738,146	13.56	555,144.4

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	5,961	5,961	3,640,885	16.37	297,460.1
≥ 85 years	2,300	2,300	1,645,959	13.97	135,098.6
2017, September					
18-44 years	1,494	1,494	9,421,945	1.59	761,989.4
45-64 years	7,431	7,431	8,220,393	9.04	661,559.6
65-74 years	8,528	8,528	6,745,048	12.64	538,528.5
75-84 years	5,608	5,608	3,647,418	15.38	288,766.8
≥ 85 years	2,162	2,162	1,644,162	13.15	130,811.6
2017, October					
18-44 years	1,654	1,654	9,454,118	1.75	790,593.0
45-64 years	8,139	8,139	8,236,320	9.88	684,557.1
65-74 years	9,297	9,297	6,763,065	13.75	557,097.3
75-84 years	6,056	6,056	3,666,424	16.52	299,459.9
≥ 85 years	2,317	2,317	1,646,493	14.07	135,210.8
2017, November					
18-44 years	1,639	1,639	9,457,099	1.73	765,967.4
45-64 years	8,008	8,008	8,226,510	9.73	662,163.3
65-74 years	9,120	9,120	6,748,161	13.51	538,762.6
75-84 years	5,974	5,974	3,669,059	16.28	290,676.9
≥ 85 years	2,380	2,380	1,641,248	14.50	130,722.6
2017, December					
18-44 years	1,633	1,633	9,512,862	1.72	795,812.9
45-64 years	7,940	7,940	8,262,799	9.61	686,174.5
65-74 years	9,103	9,103	6,750,567	13.48	556,154.5
75-84 years	5,812	5,812	3,685,019	15.77	301,394.2
≥ 85 years	2,297	2,297	1,640,972	14.00	134,987.8
2018, January					
18-44 years	1,854	1,854	9,411,393	1.97	786,490.6
45-64 years	8,786	8,786	8,122,894	10.82	674,527.7
65-74 years	10,579	10,579	6,851,321	15.44	564,139.1
75-84 years	6,954	6,954	3,707,032	18.76	302,899.5
≥ 85 years	2,706	2,706	1,641,321	16.49	134,841.7

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2018, February					
18-44 years	1,817	1,817	9,382,753	1.94	709,452.0
45-64 years	8,083	8,083	8,090,351	9.99	608,094.1
65-74 years	9,853	9,853	6,835,848	14.41	510,078.0
75-84 years	6,207	6,207	3,701,578	16.77	274,336.5
≥ 85 years	2,444	2,444	1,626,820	15.02	121,124.8
2018, March					
18-44 years	1,886	1,886	9,392,826	2.01	785,448.5
45-64 years	8,876	8,876	8,099,891	10.96	672,713.9
65-74 years	10,597	10,597	6,869,445	15.43	565,619.0
75-84 years	6,964	6,964	3,730,810	18.67	304,739.6
≥ 85 years	2,644	2,644	1,631,627	16.20	133,909.9
2018, April					
18-44 years	1,813	1,813	9,363,972	1.94	758,295.2
45-64 years	8,325	8,325	8,068,016	10.32	649,082.6
65-74 years	10,340	10,340	6,863,140	15.07	547,460.5
75-84 years	6,785	6,785	3,735,222	18.16	295,581.3
≥ 85 years	2,559	2,559	1,627,275	15.73	129,359.4
2018, May					
18-44 years	1,803	1,803	9,359,197	1.93	782,603.3
45-64 years	8,387	8,387	8,046,118	10.42	668,567.6
65-74 years	10,247	10,247	6,858,911	14.94	564,915.3
75-84 years	6,779	6,779	3,741,973	18.12	305,708.9
≥ 85 years	2,452	2,452	1,625,170	15.09	133,396.3
2018, June					
18-44 years	1,687	1,687	9,355,214	1.80	757,239.2
45-64 years	7,942	7,942	8,031,646	9.89	646,118.4
65-74 years	9,372	9,372	6,859,400	13.66	547,288.6
75-84 years	6,204	6,204	3,745,198	16.57	296,434.7
≥ 85 years	2,408	2,408	1,622,051	14.85	128,992.3
2018, July					
18-44 years	1,084	1,084	9,325,025	1.16	779,896.4

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	5,608	5,608	7,996,496	7.01	665,165.5
65-74 years	6,704	6,704	6,884,005	9.74	568,456.6
75-84 years	4,547	4,547	3,753,036	12.12	307,496.8
≥ 85 years	1,674	1,674	1,621,477	10.32	133,402.9
2018, August					
18-44 years	648	648	9,342,250	0.69	780,743.0
45-64 years	3,457	3,457	7,997,529	4.32	664,422.4
65-74 years	4,051	4,051	6,912,169	5.86	569,472.3
75-84 years	2,638	2,638	3,773,483	6.99	308,334.2
≥ 85 years	955	955	1,624,520	5.88	133,380.5
2018, September					
18-44 years	662	662	9,336,289	0.71	755,687.7
45-64 years	3,558	3,558	7,983,674	4.46	642,447.1
65-74 years	3,953	3,953	6,917,718	5.71	552,396.8
75-84 years	2,826	2,826	3,776,505	7.48	299,243.0
≥ 85 years	1,061	1,061	1,621,269	6.54	129,045.1
2018, October					
18-44 years	821	821	9,330,009	0.88	779,822.9
45-64 years	4,685	4,685	7,981,185	5.87	662,722.0
65-74 years	5,991	5,991	6,944,645	8.63	571,742.6
75-84 years	3,907	3,907	3,797,734	10.29	310,157.6
≥ 85 years	1,574	1,574	1,624,514	9.69	133,281.3
2018, November					
18-44 years	874	874	9,333,468	0.94	755,821.1
45-64 years	4,857	4,857	7,969,645	6.09	641,301.6
65-74 years	6,208	6,208	6,936,315	8.95	553,920.0
75-84 years	4,103	4,103	3,793,271	10.82	300,748.1
≥ 85 years	1,589	1,589	1,617,808	9.82	128,820.7
2018, December					
18-44 years	801	801	9,347,510	0.86	781,951.5
45-64 years	4,346	4,346	7,979,185	5.45	662,733.2
65-74 years	5,457	5,457	6,948,928	7.85	573,096.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	3,775	3,775	3,802,423	9.93	311,486.1
≥ 85 years	1,376	1,376	1,616,217	8.51	132,992.1
2019, January					
18-44 years	891	891	9,184,029	0.97	767,483.9
45-64 years	5,047	5,047	7,841,450	6.44	651,034.9
65-74 years	7,024	7,024	6,965,817	10.08	573,552.6
75-84 years	4,831	4,831	3,783,078	12.77	309,174.1
≥ 85 years	1,697	1,697	1,602,222	10.59	131,530.7
2019, February					
18-44 years	957	957	9,149,627	1.05	692,192.3
45-64 years	5,004	5,004	7,801,140	6.41	586,528.1
65-74 years	6,779	6,779	6,949,214	9.76	518,842.9
75-84 years	4,638	4,638	3,770,143	12.30	279,501.2
≥ 85 years	1,716	1,716	1,591,499	10.78	118,495.3
2019, March					
18-44 years	1,222	1,222	9,156,656	1.33	765,646.5
45-64 years	6,866	6,866	7,802,332	8.80	647,985.4
65-74 years	10,130	10,130	6,976,383	14.52	574,768.3
75-84 years	6,811	6,811	3,788,593	17.98	309,807.6
≥ 85 years	2,336	2,336	1,594,767	14.65	130,934.9
2019, April					
18-44 years	1,238	1,238	9,136,170	1.36	739,464.3
45-64 years	6,974	6,974	7,766,447	8.98	624,357.9
65-74 years	9,703	9,703	6,962,884	13.94	555,156.1
75-84 years	6,716	6,716	3,782,855	17.75	299,286.2
≥ 85 years	2,514	2,514	1,587,028	15.84	126,105.7
2019, May					
18-44 years	1,255	1,255	9,128,266	1.37	763,291.8
45-64 years	6,706	6,706	7,736,780	8.67	642,728.3
65-74 years	9,881	9,881	6,955,427	14.21	572,891.6
75-84 years	6,476	6,476	3,779,431	17.13	308,808.9
≥ 85 years	2,226	2,226	1,583,532	14.06	129,924.4

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2019, June					
18-44 years	1,030	1,030	9,112,720	1.13	737,720.0
45-64 years	5,507	5,507	7,708,750	7.14	620,098.4
65-74 years	7,534	7,534	6,950,564	10.84	554,620.6
75-84 years	5,042	5,042	3,774,062	13.36	298,746.4
≥ 85 years	1,808	1,808	1,578,446	11.45	125,459.7
2019, July					
18-44 years	1,103	1,103	9,113,385	1.21	762,082.7
45-64 years	5,957	5,957	7,690,937	7.75	639,454.9
65-74 years	7,892	7,892	6,973,807	11.32	575,412.2
75-84 years	5,301	5,301	3,777,919	14.03	309,141.0
≥ 85 years	1,865	1,865	1,577,077	11.83	129,575.5
2019, August					
18-44 years	1,180	1,180	9,121,342	1.29	762,180.0
45-64 years	5,948	5,948	7,677,929	7.75	637,781.4
65-74 years	7,757	7,757	6,994,980	11.09	576,341.6
75-84 years	5,055	5,055	3,787,381	13.35	309,444.0
≥ 85 years	1,748	1,748	1,579,248	11.07	129,539.6
2019, September					
18-44 years	1,175	1,175	9,120,128	1.29	737,804.7
45-64 years	6,253	6,253	7,665,835	8.16	616,426.0
65-74 years	8,188	8,188	7,001,801	11.69	559,027.6
75-84 years	5,318	5,318	3,783,064	14.06	299,711.7
≥ 85 years	1,809	1,809	1,576,974	11.47	125,378.1
2019, October					
18-44 years	1,528	1,528	9,118,721	1.68	762,354.7
45-64 years	8,116	8,116	7,654,719	10.60	635,537.8
65-74 years	11,644	11,644	7,023,286	16.58	578,181.3
75-84 years	7,582	7,582	3,793,403	19.99	309,705.0
≥ 85 years	2,449	2,449	1,580,557	15.49	129,543.0
2019, November					
18-44 years	1,223	1,223	9,114,258	1.34	738,130.2

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	6,270	6,270	7,640,376	8.21	614,640.2
65-74 years	8,653	8,653	7,017,732	12.33	560,236.7
75-84 years	5,407	5,407	3,785,047	14.29	299,886.6
≥ 85 years	1,897	1,897	1,573,787	12.05	125,234.1
2019, December					
18-44 years	1,169	1,169	9,132,910	1.28	764,313.3
45-64 years	5,741	5,741	7,649,969	7.50	635,552.4
65-74 years	7,928	7,928	7,028,317	11.28	579,849.7
75-84 years	5,055	5,055	3,791,023	13.33	310,631.0
≥ 85 years	1,732	1,732	1,571,719	11.02	129,332.1
2020, January					
18-44 years	1,420	1,420	9,002,386	1.58	751,526.1
45-64 years	6,880	6,880	7,526,263	9.14	624,232.5
65-74 years	8,738	8,738	7,126,350	12.26	587,012.0
75-84 years	5,703	5,703	3,818,975	14.93	312,191.6
≥ 85 years	1,991	1,991	1,578,016	12.62	129,534.9
2020, February					
18-44 years	1,223	1,223	9,087,615	1.35	701,995.6
45-64 years	6,187	6,187	7,553,927	8.19	582,148.3
65-74 years	7,688	7,688	7,201,247	10.68	549,796.8
75-84 years	4,953	4,953	3,816,966	12.98	292,007.9
≥ 85 years	1,708	1,708	1,573,517	10.85	120,837.3
2020, March					
18-44 years	1,405	1,405	9,107,758	1.54	750,642.1
45-64 years	7,096	7,096	7,551,528	9.40	621,434.4
65-74 years	8,890	8,890	7,224,111	12.31	589,273.9
75-84 years	5,571	5,571	3,829,785	14.55	312,932.6
≥ 85 years	1,944	1,944	1,575,170	12.34	129,240.4
2020, April					
18-44 years	977	977	9,092,548	1.07	727,622.6
45-64 years	5,079	5,079	7,557,750	6.72	604,936.0
65-74 years	6,506	6,506	7,306,753	8.90	581,002.3

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	4,196	4,196	3,880,306	10.81	309,336.5
≥ 85 years	1,496	1,496	1,590,630	9.41	127,144.6
2020, May					
18-44 years	847	847	9,170,191	0.92	756,234.5
45-64 years	4,311	4,311	7,646,251	5.64	630,155.7
65-74 years	5,867	5,867	7,474,756	7.85	611,553.7
75-84 years	3,778	3,778	3,977,793	9.50	326,104.4
≥ 85 years	1,406	1,406	1,615,643	8.70	132,897.6
2020, June					
18-44 years	994	994	9,272,406	1.07	735,789.3
45-64 years	4,981	4,981	7,716,117	6.46	612,640.1
65-74 years	6,650	6,650	7,597,110	8.75	598,066.6
75-84 years	4,374	4,374	4,037,109	10.83	319,044.9
≥ 85 years	1,439	1,439	1,632,270	8.82	129,541.5
2020, July					
18-44 years	1,046	1,046	9,313,626	1.12	760,948.6
45-64 years	5,299	5,299	7,682,855	6.90	632,594.1
65-74 years	7,019	7,019	7,643,009	9.18	622,497.8
75-84 years	4,478	4,478	4,062,264	11.02	331,573.7
≥ 85 years	1,621	1,621	1,642,479	9.87	134,509.5
2020, August					
18-44 years	1,015	1,015	9,291,974	1.09	761,399.5
45-64 years	4,959	4,959	7,698,572	6.44	632,887.8
65-74 years	6,713	6,713	7,688,982	8.73	626,303.2
75-84 years	4,253	4,253	4,086,608	10.41	333,539.0
≥ 85 years	1,515	1,515	1,650,675	9.18	135,208.7
2020, September					
18-44 years	1,034	1,034	9,234,357	1.12	732,524.0
45-64 years	5,098	5,098	7,694,124	6.63	610,545.8
65-74 years	6,815	6,815	7,737,220	8.81	609,932.9
75-84 years	4,417	4,417	4,112,143	10.74	324,581.7
≥ 85 years	1,583	1,583	1,659,319	9.54	131,394.3

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2020, October					
18-44 years	1,073	1,073	9,210,754	1.16	759,781.9
45-64 years	5,376	5,376	7,675,219	7.00	631,582.7
65-74 years	7,155	7,155	7,785,320	9.19	634,008.8
75-84 years	4,718	4,718	4,144,057	11.38	337,406.9
≥ 85 years	1,558	1,558	1,671,028	9.32	136,502.7
2020, November					
18-44 years	1,031	1,031	9,239,028	1.12	737,558.0
45-64 years	4,940	4,940	7,691,115	6.42	612,670.5
65-74 years	6,879	6,879	7,798,194	8.82	617,411.0
75-84 years	4,331	4,331	4,150,813	10.43	328,622.0
≥ 85 years	1,584	1,584	1,669,534	9.49	132,607.4
2020, December					
18-44 years	1,069	1,069	10,286,028	1.04	768,033.9
45-64 years	5,335	5,335	8,435,101	6.32	637,131.0
65-74 years	7,549	7,549	8,488,213	8.89	643,730.1
75-84 years	4,838	4,838	4,414,229	10.96	342,667.5
≥ 85 years	1,591	1,591	1,742,858	9.13	137,627.7
2021, January					
18-44 years	1,280	1,280	9,399,543	1.36	775,873.9
45-64 years	5,865	5,865	7,796,964	7.52	641,375.7
65-74 years	8,005	8,005	8,025,906	9.97	654,183.2
75-84 years	5,107	5,107	4,226,374	12.08	344,541.6
≥ 85 years	1,678	1,678	1,681,467	9.98	137,421.5
2021, February					
18-44 years	1,176	1,176	9,284,118	1.27	702,446.6
45-64 years	5,683	5,683	7,733,331	7.35	580,858.6
65-74 years	7,481	7,481	7,979,319	9.38	595,068.8
75-84 years	4,730	4,730	4,235,795	11.17	313,571.3
≥ 85 years	1,609	1,609	1,676,783	9.60	124,354.9
2021, March					
18-44 years	1,423	1,423	9,302,962	1.53	777,407.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	7,006	7,006	7,730,644	9.06	643,101.3
65-74 years	9,239	9,239	8,000,632	11.55	662,143.3
75-84 years	5,749	5,749	4,245,677	13.54	348,748.5
≥ 85 years	2,007	2,007	1,676,364	11.97	138,139.3
2021, April					
18-44 years	1,203	1,203	9,216,725	1.31	748,619.4
45-64 years	5,770	5,770	7,618,087	7.57	615,970.0
65-74 years	8,363	8,363	7,862,635	10.64	632,338.6
75-84 years	5,481	5,481	4,156,753	13.19	332,067.3
≥ 85 years	1,972	1,972	1,639,381	12.03	131,341.5
2021, May					
18-44 years	1,129	1,129	9,132,775	1.24	765,664.6
45-64 years	5,354	5,354	7,538,270	7.10	628,352.8
65-74 years	7,816	7,816	7,780,334	10.05	643,848.2
75-84 years	5,017	5,017	4,108,069	12.21	337,470.0
≥ 85 years	1,767	1,767	1,615,841	10.94	133,221.2
2021, June					
18-44 years	1,182	1,182	9,059,461	1.30	734,183.9
45-64 years	5,796	5,796	7,488,460	7.74	602,907.1
65-74 years	8,146	8,146	7,755,411	10.50	619,393.8
75-84 years	5,383	5,383	4,097,573	13.14	324,544.3
≥ 85 years	1,822	1,822	1,606,467	11.34	127,740.5
2021, July					
18-44 years	1,091	1,091	8,984,678	1.21	752,150.2
45-64 years	5,328	5,328	7,439,191	7.16	618,861.2
65-74 years	7,701	7,701	7,749,701	9.94	639,666.5
75-84 years	5,023	5,023	4,095,516	12.26	335,064.3
≥ 85 years	1,787	1,787	1,600,296	11.17	131,486.4
2021, August					
18-44 years	1,220	1,220	8,926,567	1.37	746,812.6
45-64 years	5,584	5,584	7,396,191	7.55	615,215.4
65-74 years	7,805	7,805	7,731,853	10.09	637,981.3

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	4,940	4,940	4,097,051	12.06	335,093.5
≥ 85 years	1,688	1,688	1,593,691	10.59	131,022.9
2021, September					
18-44 years	1,198	1,198	8,865,015	1.35	718,465.9
45-64 years	5,537	5,537	7,348,858	7.53	591,866.3
65-74 years	7,638	7,638	7,707,924	9.91	615,827.3
75-84 years	4,923	4,923	4,102,176	12.00	324,833.5
≥ 85 years	1,728	1,728	1,587,775	10.88	126,393.9
2021, October					
18-44 years	1,190	1,190	8,812,573	1.35	737,751.1
45-64 years	5,671	5,671	7,314,481	7.75	608,071.7
65-74 years	7,945	7,945	7,701,787	10.32	634,545.4
75-84 years	5,164	5,164	4,123,318	12.52	336,635.3
≥ 85 years	1,765	1,765	1,586,283	11.13	130,259.8
2021, November					
18-44 years	1,178	1,178	8,767,500	1.34	711,033.8
45-64 years	5,427	5,427	7,278,571	7.46	586,425.8
65-74 years	7,866	7,866	7,658,452	10.27	611,885.9
75-84 years	5,142	5,142	4,122,121	12.47	326,684.9
≥ 85 years	1,761	1,761	1,575,548	11.18	125,596.9
2021, December					
18-44 years	1,186	1,186	8,744,448	1.36	732,997.0
45-64 years	5,663	5,663	7,261,305	7.80	604,165.6
65-74 years	8,216	8,216	7,619,677	10.78	628,897.4
75-84 years	5,300	5,300	4,129,821	12.83	338,295.6
≥ 85 years	1,966	1,966	1,566,846	12.55	129,062.3
2022, January					
18-44 years	1,415	1,415	8,423,050	1.68	705,713.4
45-64 years	6,760	6,760	7,012,614	9.64	584,164.5
65-74 years	10,195	10,195	7,597,533	13.42	627,811.6
75-84 years	6,886	6,886	4,117,612	16.72	337,571.9
≥ 85 years	2,325	2,325	1,556,500	14.94	128,249.7

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2022, February					
18-44 years	1,366	1,366	8,372,496	1.63	634,530.3
45-64 years	6,532	6,532	6,968,915	9.37	524,973.7
65-74 years	9,360	9,360	7,552,260	12.39	564,747.3
75-84 years	6,201	6,201	4,110,983	15.08	305,241.6
≥ 85 years	2,152	2,152	1,538,838	13.98	114,755.0
2022, March					
18-44 years	1,576	1,576	8,366,128	1.88	700,322.2
45-64 years	7,183	7,183	6,967,214	10.31	579,235.7
65-74 years	9,901	9,901	7,559,461	13.10	623,092.1
75-84 years	6,651	6,651	4,145,217	16.04	338,692.3
≥ 85 years	2,254	2,254	1,542,260	14.61	126,606.1
2022, April					
18-44 years	1,202	1,202	8,337,695	1.44	675,512.0
45-64 years	5,538	5,538	6,936,428	7.98	558,303.6
65-74 years	7,976	7,976	7,531,215	10.59	601,034.8
75-84 years	5,309	5,309	4,151,163	12.79	328,601.9
≥ 85 years	1,931	1,931	1,539,861	12.54	122,376.8
2022, May					
18-44 years	1,162	1,162	8,316,499	1.40	695,918.5
45-64 years	5,542	5,542	6,915,670	8.01	574,889.5
65-74 years	7,975	7,975	7,527,345	10.59	620,217.8
75-84 years	5,480	5,480	4,171,167	13.14	340,789.5
≥ 85 years	1,854	1,854	1,542,400	12.02	126,546.1
2022, June					
18-44 years	1,188	1,188	8,319,741	1.43	673,612.7
45-64 years	5,591	5,591	6,906,949	8.09	555,700.3
65-74 years	7,884	7,884	7,520,572	10.48	599,895.7
75-84 years	5,469	5,469	4,189,099	13.06	331,327.7
≥ 85 years	1,948	1,948	1,542,944	12.63	122,551.7
2022, July					
18-44 years	1,098	1,098	8,275,977	1.33	692,162.0

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	5,298	5,298	6,867,325	7.71	570,847.9
65-74 years	7,260	7,260	7,531,837	9.64	621,198.9
75-84 years	5,090	5,090	4,208,469	12.09	344,073.0
≥ 85 years	1,952	1,952	1,547,024	12.62	126,923.9
2022, August					
18-44 years	1,273	1,273	8,312,068	1.53	691,956.6
45-64 years	5,749	5,749	6,865,498	8.37	569,648.5
65-74 years	8,137	8,137	7,547,902	10.78	621,835.5
75-84 years	5,448	5,448	4,231,109	12.88	345,580.6
≥ 85 years	1,947	1,947	1,550,080	12.56	127,096.0
2022, September					
18-44 years	899	899	5,804,982	1.55	470,027.4
45-64 years	4,446	4,446	5,109,876	8.70	410,908.6
65-74 years	7,470	7,470	7,413,293	10.08	592,049.4
75-84 years	5,256	5,256	4,220,648	12.45	334,261.5
≥ 85 years	1,861	1,861	1,542,160	12.07	122,589.2
2022, October					
18-44 years	691	691	5,134,203	1.35	429,654.8
45-64 years	2,719	2,719	3,762,103	7.23	312,905.4
65-74 years	984	984	1,183,649	8.31	97,591.1
75-84 years	555	555	552,453	10.05	45,279.3
≥ 85 years	182	182	187,020	9.73	15,351.9
2022, November					
18-44 years	173	173	1,548,848	1.12	125,997.8
45-64 years	758	758	1,031,759	7.35	83,221.7
65-74 years	396	396	659,484	6.00	52,781.0
75-84 years	223	223	318,059	7.01	25,260.5
≥ 85 years	61	61	97,766	6.24	7,771.9
2022, December					
18-44 years	152	152	1,559,288	0.97	131,024.9
45-64 years	771	771	1,036,512	7.44	86,341.2
65-74 years	393	393	661,461	5.94	54,696.3

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	192	192	319,763	6.00	26,251.4
≥ 85 years	57	57	97,917	5.82	8,057.2
Contaminated valsartan					
2012, May					
18-44 years	0	0	8,364,508	0.00	685,791.5
45-64 years	0	0	7,525,643	0.00	618,088.7
65-74 years	0	0	4,787,090	0.00	390,798.7
75-84 years	0	0	2,975,916	0.00	243,391.1
≥ 85 years	0	0	1,478,285	0.00	121,347.1
2012, June					
18-44 years	0	0	8,439,754	0.00	664,978.5
45-64 years	0	0	7,572,017	0.00	599,028.0
65-74 years	0	0	4,812,888	0.00	378,816.8
75-84 years	0	0	2,976,439	0.00	235,451.1
≥ 85 years	0	0	1,479,239	0.00	117,446.2
2012, July					
18-44 years	0	0	8,433,567	0.00	687,065.5
45-64 years	0	0	7,512,418	0.00	618,367.3
65-74 years	0	0	4,815,120	0.00	393,489.8
75-84 years	0	0	2,972,401	0.00	243,646.9
≥ 85 years	0	0	1,479,218	0.00	121,640.5
2012, August					
18-44 years	0	0	8,458,411	0.00	688,780.3
45-64 years	0	0	7,534,562	0.00	618,951.9
65-74 years	0	0	4,842,935	0.00	394,472.6
75-84 years	0	0	2,980,930	0.00	243,764.8
≥ 85 years	0	0	1,484,666	0.00	121,820.5
2012, September					
18-44 years	294	294	8,461,860	0.35	667,463.8
45-64 years	2,303	2,303	7,546,214	3.05	599,710.0
65-74 years	1,739	1,739	4,852,539	3.58	383,018.4
75-84 years	1,166	1,166	2,978,540	3.91	235,991.0

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
≥ 85 years	401	401	1,485,027	2.70	118,067.0
2012, October					
18-44 years	1,743	1,743	8,410,780	2.07	692,353.4
45-64 years	12,158	12,158	7,535,482	16.13	620,487.1
65-74 years	10,925	10,925	4,872,569	22.42	397,292.1
75-84 years	7,125	7,125	2,985,327	23.87	244,054.5
≥ 85 years	2,733	2,733	1,489,217	18.35	122,217.3
2012, November					
18-44 years	772	772	8,383,816	0.92	670,514.1
45-64 years	5,425	5,425	7,522,298	7.21	601,201.8
65-74 years	5,948	5,948	4,877,771	12.19	385,739.1
75-84 years	3,962	3,962	2,976,557	13.31	236,289.4
≥ 85 years	1,425	1,425	1,484,866	9.60	118,305.0
2012, December					
18-44 years	504	504	8,954,111	0.56	694,328.3
45-64 years	3,702	3,702	7,957,095	4.65	622,901.1
65-74 years	4,193	4,193	5,338,172	7.85	400,981.5
75-84 years	2,665	2,665	3,184,349	8.37	244,629.9
≥ 85 years	948	948	1,566,633	6.05	122,311.3
2013, January					
18-44 years	505	505	8,353,700	0.60	687,648.1
45-64 years	2,898	2,898	7,548,041	3.84	621,880.1
65-74 years	4,192	4,192	5,100,007	8.22	415,361.8
75-84 years	2,807	2,807	3,078,255	9.12	251,576.0
≥ 85 years	987	987	1,530,143	6.45	125,538.3
2013, February					
18-44 years	386	386	8,175,825	0.47	619,070.5
45-64 years	2,169	2,169	7,436,868	2.92	560,449.5
65-74 years	2,609	2,609	5,027,964	5.19	375,918.3
75-84 years	1,729	1,729	3,054,008	5.66	227,022.2
≥ 85 years	671	671	1,512,480	4.44	112,781.3
2013, March					

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
18-44 years	322	322	8,193,743	0.39	685,513.4
45-64 years	2,115	2,115	7,458,564	2.84	620,998.7
65-74 years	2,425	2,425	5,062,078	4.79	417,643.1
75-84 years	1,561	1,561	3,068,318	5.09	251,434.5
≥ 85 years	631	631	1,517,564	4.16	124,778.9
2013, April					
18-44 years	736	736	8,163,103	0.90	661,545.4
45-64 years	5,139	5,139	7,448,315	6.90	600,540.3
65-74 years	6,961	6,961	5,066,600	13.74	404,730.2
75-84 years	4,930	4,930	3,064,944	16.09	243,135.3
≥ 85 years	2,050	2,050	1,512,954	13.55	120,475.5
2013, May					
18-44 years	716	716	8,167,935	0.88	683,740.2
45-64 years	5,712	5,712	7,448,510	7.67	620,475.7
65-74 years	6,649	6,649	5,073,554	13.11	418,646.0
75-84 years	4,562	4,562	3,063,443	14.89	250,971.7
≥ 85 years	1,845	1,845	1,513,127	12.19	124,414.9
2013, June					
18-44 years	630	630	8,172,089	0.77	662,092.7
45-64 years	4,607	4,607	7,451,057	6.18	600,884.6
65-74 years	5,521	5,521	5,078,332	10.87	405,880.9
75-84 years	3,676	3,676	3,061,768	12.01	242,903.2
≥ 85 years	1,544	1,544	1,515,140	10.19	120,598.6
2013, July					
18-44 years	632	632	8,186,238	0.77	685,446.1
45-64 years	4,345	4,345	7,477,827	5.81	623,277.3
65-74 years	4,527	4,527	5,106,423	8.87	421,838.0
75-84 years	3,233	3,233	3,068,486	10.54	251,632.8
≥ 85 years	1,212	1,212	1,518,798	7.98	125,022.4
2013, August					
18-44 years	526	526	8,222,861	0.64	686,985.1
45-64 years	3,434	3,434	7,485,928	4.59	623,387.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
65-74 years	3,501	3,501	5,122,700	6.83	422,614.0
75-84 years	2,430	2,430	3,072,300	7.91	251,599.8
≥ 85 years	900	900	1,522,012	5.91	125,098.2
2013, September					
18-44 years	515	515	8,206,097	0.63	663,185.4
45-64 years	3,218	3,218	7,481,401	4.30	603,284.7
65-74 years	3,613	3,613	5,129,144	7.04	409,982.8
75-84 years	2,361	2,361	3,068,476	7.69	243,479.4
≥ 85 years	848	848	1,521,423	5.57	121,186.3
2013, October					
18-44 years	521	521	8,151,267	0.64	682,468.5
45-64 years	3,084	3,084	7,486,691	4.12	623,439.9
65-74 years	3,037	3,037	5,143,267	5.90	424,173.3
75-84 years	2,139	2,139	3,072,371	6.96	251,525.2
≥ 85 years	856	856	1,524,246	5.62	125,281.1
2013, November					
18-44 years	520	520	8,140,272	0.64	660,095.1
45-64 years	3,163	3,163	7,472,138	4.23	602,666.2
65-74 years	3,203	3,203	5,131,443	6.24	410,239.6
75-84 years	2,190	2,190	3,056,902	7.16	242,817.7
≥ 85 years	878	878	1,516,932	5.79	120,948.8
2013, December					
18-44 years	432	432	8,111,311	0.53	679,413.8
45-64 years	2,826	2,826	7,453,904	3.79	620,953.7
65-74 years	2,989	2,989	5,132,287	5.82	424,162.2
75-84 years	2,053	2,053	3,056,031	6.72	251,034.8
≥ 85 years	765	765	1,516,170	5.05	125,022.0
2014, January					
18-44 years	538	538	8,900,862	0.60	743,878.7
45-64 years	3,143	3,143	8,097,588	3.88	673,473.1
65-74 years	3,784	3,784	5,828,215	6.49	480,960.5
75-84 years	2,389	2,389	3,436,548	6.95	281,800.4

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
≥ 85 years	857	857	1,692,042	5.06	139,286.0
2014, February					
18-44 years	550	550	8,846,077	0.62	669,432.3
45-64 years	3,426	3,426	8,045,772	4.26	606,140.0
65-74 years	3,990	3,990	5,820,892	6.85	435,355.3
75-84 years	2,548	2,548	3,424,581	7.44	254,601.6
≥ 85 years	924	924	1,684,773	5.48	125,668.1
2014, March					
18-44 years	649	649	8,829,117	0.74	738,714.1
45-64 years	4,333	4,333	8,023,113	5.40	667,865.6
65-74 years	5,337	5,337	5,847,596	9.13	482,829.3
75-84 years	3,314	3,314	3,437,822	9.64	281,924.6
≥ 85 years	1,123	1,123	1,691,245	6.64	139,172.4
2014, April					
18-44 years	535	535	8,792,157	0.61	711,953.1
45-64 years	3,660	3,660	7,984,409	4.58	643,156.4
65-74 years	4,726	4,726	5,863,303	8.06	468,166.6
75-84 years	2,903	2,903	3,445,634	8.43	273,159.9
≥ 85 years	1,000	1,000	1,693,294	5.91	134,731.3
2014, May					
18-44 years	468	468	8,775,025	0.53	733,930.6
45-64 years	3,071	3,071	7,950,385	3.86	661,633.0
65-74 years	3,794	3,794	5,858,001	6.48	483,089.2
75-84 years	2,283	2,283	3,440,683	6.64	281,659.7
≥ 85 years	841	841	1,690,431	4.98	138,907.8
2014, June					
18-44 years	423	423	8,755,301	0.48	708,949.4
45-64 years	2,774	2,774	7,924,298	3.50	638,515.2
65-74 years	3,082	3,082	5,854,865	5.26	467,718.1
75-84 years	1,908	1,908	3,431,651	5.56	272,104.9
≥ 85 years	706	706	1,686,277	4.19	134,187.3
2014, July					

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
18-44 years	601	601	8,833,991	0.68	738,989.7
45-64 years	3,805	3,805	7,983,593	4.77	664,707.5
65-74 years	3,708	3,708	5,874,178	6.31	484,891.1
75-84 years	2,525	2,525	3,427,276	7.37	280,728.7
≥ 85 years	924	924	1,684,119	5.49	138,431.0
2014, August					
18-44 years	574	574	8,797,059	0.65	735,222.7
45-64 years	3,935	3,935	7,935,928	4.96	660,431.2
65-74 years	3,920	3,920	5,888,903	6.66	485,876.7
75-84 years	2,606	2,606	3,428,655	7.60	280,695.3
≥ 85 years	913	913	1,684,601	5.42	138,438.1
2014, September					
18-44 years	515	515	8,769,121	0.59	710,028.2
45-64 years	3,585	3,585	7,912,260	4.53	637,550.1
65-74 years	3,864	3,864	5,894,672	6.56	470,964.9
75-84 years	2,269	2,269	3,426,341	6.62	271,705.1
≥ 85 years	835	835	1,682,352	4.96	133,959.4
2014, October					
18-44 years	954	954	8,785,078	1.09	734,914.6
45-64 years	6,282	6,282	7,910,421	7.94	658,014.1
65-74 years	6,310	6,310	5,914,239	10.67	487,351.0
75-84 years	4,066	4,066	3,435,649	11.83	280,981.9
≥ 85 years	1,694	1,694	1,685,805	10.05	138,418.0
2014, November					
18-44 years	718	718	8,754,559	0.82	709,819.2
45-64 years	4,568	4,568	7,883,454	5.79	635,697.5
65-74 years	4,992	4,992	5,900,692	8.46	471,898.8
75-84 years	3,200	3,200	3,422,502	9.35	271,908.9
≥ 85 years	1,228	1,228	1,678,279	7.32	133,802.6
2014, December					
18-44 years	865	865	8,757,751	0.99	732,068.5
45-64 years	5,346	5,346	7,881,283	6.78	654,824.6

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
65-74 years	5,756	5,756	5,904,938	9.75	487,099.3
75-84 years	3,576	3,576	3,421,590	10.45	280,390.3
≥ 85 years	1,305	1,305	1,674,759	7.79	137,861.6
2015, January					
18-44 years	1,030	1,030	9,123,915	1.13	762,766.6
45-64 years	6,169	6,169	8,180,925	7.54	680,368.3
65-74 years	8,129	8,129	6,127,270	13.27	505,457.1
75-84 years	5,852	5,852	3,490,024	16.77	285,957.7
≥ 85 years	2,816	2,816	1,693,775	16.63	139,302.5
2015, February					
18-44 years	1,057	1,057	9,086,841	1.16	687,415.6
45-64 years	7,219	7,219	8,160,229	8.85	614,176.1
65-74 years	9,585	9,585	6,120,863	15.66	457,054.2
75-84 years	7,668	7,668	3,474,987	22.07	257,792.2
≥ 85 years	4,135	4,135	1,677,605	24.65	124,947.6
2015, March					
18-44 years	1,018	1,018	9,100,046	1.12	761,135.6
45-64 years	6,822	6,822	8,180,125	8.34	680,528.2
65-74 years	9,053	9,053	6,143,987	14.73	506,922.6
75-84 years	7,172	7,172	3,486,096	20.57	285,560.7
≥ 85 years	3,851	3,851	1,680,197	22.92	138,115.5
2015, April					
18-44 years	949	949	9,138,675	1.04	739,977.1
45-64 years	6,250	6,250	8,211,131	7.61	661,233.4
65-74 years	8,153	8,153	6,145,884	13.27	490,587.7
75-84 years	6,489	6,489	3,483,308	18.63	275,957.6
≥ 85 years	3,288	3,288	1,675,829	19.62	133,251.0
2015, May					
18-44 years	1,041	1,041	9,175,195	1.13	767,475.7
45-64 years	6,664	6,664	8,246,239	8.08	686,093.7
65-74 years	7,824	7,824	6,153,081	12.72	507,293.6
75-84 years	5,767	5,767	3,481,086	16.57	284,736.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
≥ 85 years	2,832	2,832	1,671,940	16.94	137,323.4
2015, June					
18-44 years	1,155	1,155	9,183,380	1.26	743,496.2
45-64 years	8,388	8,388	8,249,066	10.17	664,426.9
65-74 years	9,945	9,945	6,156,861	16.15	491,430.5
75-84 years	7,481	7,481	3,476,280	21.52	275,392.3
≥ 85 years	3,397	3,397	1,669,641	20.35	132,738.1
2015, July					
18-44 years	1,255	1,255	9,174,711	1.37	767,433.8
45-64 years	9,028	9,028	8,243,111	10.95	686,070.7
65-74 years	10,527	10,527	6,183,678	17.02	510,273.2
75-84 years	7,294	7,294	3,480,494	20.96	284,897.6
≥ 85 years	3,351	3,351	1,671,542	20.05	137,352.4
2015, August					
18-44 years	1,152	1,152	9,185,511	1.25	767,910.7
45-64 years	7,797	7,797	8,238,322	9.46	685,699.0
65-74 years	8,983	8,983	6,202,569	14.48	511,943.7
75-84 years	6,463	6,463	3,486,959	18.53	285,474.9
≥ 85 years	2,982	2,982	1,673,569	17.82	137,559.6
2015, September					
18-44 years	994	994	9,195,873	1.08	744,491.9
45-64 years	6,380	6,380	8,246,416	7.74	664,166.7
65-74 years	7,532	7,532	6,220,835	12.11	496,832.6
75-84 years	5,526	5,526	3,489,823	15.83	276,503.9
≥ 85 years	2,564	2,564	1,674,405	15.31	133,188.6
2015, October					
18-44 years	887	887	9,186,832	0.97	768,057.8
45-64 years	5,780	5,780	8,256,279	7.00	685,957.0
65-74 years	6,585	6,585	6,247,993	10.54	514,567.3
75-84 years	4,816	4,816	3,499,155	13.76	285,939.0
≥ 85 years	2,219	2,219	1,678,202	13.22	137,656.7
2015, November					

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
18-44 years	939	939	9,158,717	1.03	741,953.8
45-64 years	5,701	5,701	8,233,444	6.92	663,167.1
65-74 years	6,663	6,663	6,234,026	10.69	498,253.2
75-84 years	5,075	5,075	3,484,813	14.56	276,549.0
≥ 85 years	2,633	2,633	1,669,179	15.77	133,003.4
2015, December					
18-44 years	1,061	1,061	9,161,719	1.16	766,268.6
45-64 years	6,709	6,709	8,238,837	8.14	684,479.4
65-74 years	8,006	8,006	6,246,451	12.82	514,985.8
75-84 years	6,256	6,256	3,490,650	17.92	285,784.2
≥ 85 years	3,232	3,232	1,669,468	19.36	137,277.3
2016, January					
18-44 years	1,207	1,207	9,197,891	1.31	768,766.8
45-64 years	7,847	7,847	8,317,974	9.43	691,508.8
65-74 years	10,469	10,469	6,466,038	16.19	533,020.6
75-84 years	7,862	7,862	3,552,538	22.13	290,765.5
≥ 85 years	3,813	3,813	1,689,811	22.56	138,879.7
2016, February					
18-44 years	1,313	1,313	9,347,756	1.40	718,151.0
45-64 years	8,580	8,580	8,432,703	10.17	646,433.4
65-74 years	10,992	10,992	6,545,713	16.79	499,704.7
75-84 years	8,189	8,189	3,556,873	23.02	272,312.5
≥ 85 years	4,314	4,314	1,687,003	25.57	129,677.7
2016, March					
18-44 years	1,434	1,434	9,366,076	1.53	769,852.1
45-64 years	9,272	9,272	8,439,304	10.99	693,183.1
65-74 years	12,702	12,702	6,572,078	19.33	535,044.1
75-84 years	9,295	9,295	3,571,421	26.03	291,183.6
≥ 85 years	4,527	4,527	1,690,174	26.78	138,375.5
2016, April					
18-44 years	1,638	1,638	9,384,822	1.75	744,418.9
45-64 years	10,761	10,761	8,419,060	12.78	669,792.2

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
65-74 years	15,056	15,056	6,569,124	22.92	518,068.0
75-84 years	10,625	10,625	3,570,432	29.76	281,952.1
≥ 85 years	4,947	4,947	1,685,515	29.35	133,676.6
2016, May					
18-44 years	1,745	1,745	9,394,394	1.86	772,087.7
45-64 years	10,629	10,629	8,404,391	12.65	691,299.2
65-74 years	15,502	15,502	6,572,106	23.59	535,445.0
75-84 years	10,737	10,737	3,574,047	30.04	291,433.1
≥ 85 years	4,832	4,832	1,684,428	28.69	137,891.7
2016, June					
18-44 years	1,490	1,490	9,443,249	1.58	746,629.4
45-64 years	9,496	9,496	8,432,609	11.26	668,337.1
65-74 years	13,634	13,634	6,613,244	20.62	519,406.7
75-84 years	9,550	9,550	3,585,720	26.63	282,753.3
≥ 85 years	4,332	4,332	1,685,376	25.70	133,560.2
2016, July					
18-44 years	1,483	1,483	9,461,262	1.57	771,598.4
45-64 years	8,841	8,841	8,377,595	10.55	690,024.6
65-74 years	12,090	12,090	6,618,431	18.27	539,385.0
75-84 years	8,306	8,306	3,591,786	23.12	293,279.9
≥ 85 years	3,564	3,564	1,685,623	21.14	138,210.5
2016, August					
18-44 years	1,630	1,630	9,439,117	1.73	770,338.6
45-64 years	10,349	10,349	8,394,924	12.33	689,729.7
65-74 years	13,418	13,418	6,643,992	20.20	540,791.4
75-84 years	8,943	8,943	3,607,137	24.79	294,163.3
≥ 85 years	3,690	3,690	1,689,827	21.84	138,380.9
2016, September					
18-44 years	1,495	1,495	9,456,740	1.58	747,592.2
45-64 years	10,153	10,153	8,420,353	12.06	667,450.2
65-74 years	13,483	13,483	6,657,344	20.25	524,840.8
75-84 years	8,396	8,396	3,610,739	23.25	285,278.9

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
≥ 85 years	3,641	3,641	1,690,174	21.54	134,110.8
2016, October					
18-44 years	1,470	1,470	9,401,480	1.56	774,245.1
45-64 years	9,261	9,261	8,391,271	11.04	690,619.5
65-74 years	12,081	12,081	6,674,329	18.10	544,213.4
75-84 years	7,859	7,859	3,620,317	21.71	295,502.5
≥ 85 years	3,246	3,246	1,692,643	19.18	138,700.0
2016, November					
18-44 years	1,393	1,393	9,463,510	1.47	750,054.5
45-64 years	7,890	7,890	8,428,158	9.36	668,345.6
65-74 years	10,027	10,027	6,670,099	15.03	527,483.5
75-84 years	6,576	6,576	3,616,309	18.18	286,279.8
≥ 85 years	2,729	2,729	1,686,419	16.18	134,060.8
2016, December					
18-44 years	1,225	1,225	10,721,076	1.14	781,111.1
45-64 years	7,173	7,173	9,379,592	7.65	694,190.9
65-74 years	9,107	9,107	7,114,665	12.80	546,461.2
75-84 years	6,139	6,139	3,773,569	16.27	296,434.9
≥ 85 years	2,580	2,580	1,738,486	14.84	138,471.1
2017, January					
18-44 years	1,432	1,432	9,487,856	1.51	780,593.7
45-64 years	7,374	7,374	8,370,471	8.81	688,283.0
65-74 years	9,726	9,726	6,757,194	14.39	550,680.7
75-84 years	6,189	6,189	3,618,289	17.10	295,409.8
≥ 85 years	2,650	2,650	1,668,592	15.88	136,859.5
2017, February					
18-44 years	1,226	1,226	9,319,963	1.32	704,706.1
45-64 years	6,833	6,833	8,251,261	8.28	620,296.0
65-74 years	8,625	8,625	6,661,229	12.95	497,103.7
75-84 years	5,508	5,508	3,596,912	15.31	266,670.0
≥ 85 years	2,233	2,233	1,651,950	13.52	122,924.4
2017, March					

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
18-44 years	1,398	1,398	9,350,278	1.50	781,603.2
45-64 years	7,128	7,128	8,270,143	8.62	686,825.6
65-74 years	9,036	9,036	6,691,510	13.50	551,117.1
75-84 years	5,917	5,917	3,615,640	16.37	295,535.4
≥ 85 years	2,465	2,465	1,654,674	14.90	135,829.5
2017, April					
18-44 years	1,143	1,143	9,349,585	1.22	756,960.8
45-64 years	6,134	6,134	8,252,018	7.43	663,883.1
65-74 years	7,727	7,727	6,682,659	11.56	533,106.3
75-84 years	5,177	5,177	3,612,985	14.33	286,004.9
≥ 85 years	2,089	2,089	1,646,563	12.69	130,920.9
2017, May					
18-44 years	1,287	1,287	9,359,246	1.38	782,545.8
45-64 years	6,861	6,861	8,242,827	8.32	685,007.1
65-74 years	8,345	8,345	6,683,727	12.49	550,617.9
75-84 years	5,530	5,530	3,615,549	15.30	295,460.0
≥ 85 years	2,300	2,300	1,644,327	13.99	134,947.3
2017, June					
18-44 years	1,353	1,353	9,368,314	1.44	758,284.8
45-64 years	7,057	7,057	8,236,072	8.57	662,790.7
65-74 years	8,671	8,671	6,685,793	12.97	533,532.9
75-84 years	6,104	6,104	3,614,209	16.89	286,199.9
≥ 85 years	2,695	2,695	1,641,664	16.42	130,526.2
2017, July					
18-44 years	1,507	1,507	9,360,900	1.61	783,019.8
45-64 years	8,176	8,176	8,212,151	9.96	683,447.3
65-74 years	10,072	10,072	6,710,909	15.01	554,364.4
75-84 years	7,261	7,261	3,622,293	20.05	296,907.7
≥ 85 years	3,518	3,518	1,641,767	21.43	135,088.0
2017, August					
18-44 years	1,602	1,602	9,399,555	1.70	785,055.2
45-64 years	8,252	8,252	8,228,369	10.03	683,721.6

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
65-74 years	10,841	10,841	6,738,146	16.09	555,144.4
75-84 years	7,833	7,833	3,640,885	21.51	297,460.1
≥ 85 years	3,653	3,653	1,645,959	22.19	135,098.6
2017, September					
18-44 years	1,371	1,371	9,421,945	1.46	761,989.4
45-64 years	7,077	7,077	8,220,393	8.61	661,559.6
65-74 years	9,180	9,180	6,745,048	13.61	538,528.5
75-84 years	6,614	6,614	3,647,418	18.13	288,766.8
≥ 85 years	2,958	2,958	1,644,162	17.99	130,811.6
2017, October					
18-44 years	1,368	1,368	9,454,118	1.45	790,593.0
45-64 years	7,130	7,130	8,236,320	8.66	684,557.1
65-74 years	9,266	9,266	6,763,065	13.70	557,097.3
75-84 years	6,314	6,314	3,666,424	17.22	299,459.9
≥ 85 years	2,766	2,766	1,646,493	16.80	135,210.8
2017, November					
18-44 years	1,379	1,379	9,457,099	1.46	765,967.4
45-64 years	7,109	7,109	8,226,510	8.64	662,163.3
65-74 years	9,124	9,124	6,748,161	13.52	538,762.6
75-84 years	6,104	6,104	3,669,059	16.64	290,676.9
≥ 85 years	2,545	2,545	1,641,248	15.51	130,722.6
2017, December					
18-44 years	1,369	1,369	9,512,862	1.44	795,812.9
45-64 years	7,249	7,249	8,262,799	8.77	686,174.5
65-74 years	9,085	9,085	6,750,567	13.46	556,154.5
75-84 years	5,940	5,940	3,685,019	16.12	301,394.2
≥ 85 years	2,514	2,514	1,640,972	15.32	134,987.8
2018, January					
18-44 years	1,529	1,529	9,411,393	1.62	786,490.6
45-64 years	7,629	7,629	8,122,894	9.39	674,527.7
65-74 years	10,501	10,501	6,851,321	15.33	564,139.1
75-84 years	6,996	6,996	3,707,032	18.87	302,899.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
≥ 85 years	2,825	2,825	1,641,321	17.21	134,841.7
2018, February					
18-44 years	1,511	1,511	9,382,753	1.61	709,452.0
45-64 years	7,019	7,019	8,090,351	8.68	608,094.1
65-74 years	9,645	9,645	6,835,848	14.11	510,078.0
75-84 years	6,250	6,250	3,701,578	16.88	274,336.5
≥ 85 years	2,706	2,706	1,626,820	16.63	121,124.8
2018, March					
18-44 years	1,541	1,541	9,392,826	1.64	785,448.5
45-64 years	7,612	7,612	8,099,891	9.40	672,713.9
65-74 years	10,022	10,022	6,869,445	14.59	565,619.0
75-84 years	6,727	6,727	3,730,810	18.03	304,739.6
≥ 85 years	2,567	2,567	1,631,627	15.73	133,909.9
2018, April					
18-44 years	1,365	1,365	9,363,972	1.46	758,295.2
45-64 years	6,816	6,816	8,068,016	8.45	649,082.6
65-74 years	9,251	9,251	6,863,140	13.48	547,460.5
75-84 years	6,223	6,223	3,735,222	16.66	295,581.3
≥ 85 years	2,467	2,467	1,627,275	15.16	129,359.4
2018, May					
18-44 years	1,425	1,425	9,359,197	1.52	782,603.3
45-64 years	7,040	7,040	8,046,118	8.75	668,567.6
65-74 years	9,152	9,152	6,858,911	13.34	564,915.3
75-84 years	6,199	6,199	3,741,973	16.57	305,708.9
≥ 85 years	2,480	2,480	1,625,170	15.26	133,396.3
2018, June					
18-44 years	1,430	1,430	9,355,214	1.53	757,239.2
45-64 years	7,197	7,197	8,031,646	8.96	646,118.4
65-74 years	9,118	9,118	6,859,400	13.29	547,288.6
75-84 years	6,168	6,168	3,745,198	16.47	296,434.7
≥ 85 years	2,479	2,479	1,622,051	15.28	128,992.3
2018, July					

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
18-44 years	887	887	9,325,025	0.95	779,896.4
45-64 years	4,897	4,897	7,996,496	6.12	665,165.5
65-74 years	6,350	6,350	6,884,005	9.22	568,456.6
75-84 years	4,270	4,270	3,753,036	11.38	307,496.8
≥ 85 years	1,689	1,689	1,621,477	10.42	133,402.9
2018, August					
18-44 years	384	384	9,342,250	0.41	780,743.0
45-64 years	2,405	2,405	7,997,529	3.01	664,422.4
65-74 years	2,952	2,952	6,912,169	4.27	569,472.3
75-84 years	1,942	1,942	3,773,483	5.15	308,334.2
≥ 85 years	792	792	1,624,520	4.88	133,380.5
2018, September					
18-44 years	388	388	9,336,289	0.42	755,687.7
45-64 years	2,462	2,462	7,983,674	3.08	642,447.1
65-74 years	3,046	3,046	6,917,718	4.40	552,396.8
75-84 years	2,092	2,092	3,776,505	5.54	299,243.0
≥ 85 years	892	892	1,621,269	5.50	129,045.1
2018, October					
18-44 years	551	551	9,330,009	0.59	779,822.9
45-64 years	3,365	3,365	7,981,185	4.22	662,722.0
65-74 years	4,653	4,653	6,944,645	6.70	571,742.6
75-84 years	3,066	3,066	3,797,734	8.07	310,157.6
≥ 85 years	1,289	1,289	1,624,514	7.93	133,281.3
2018, November					
18-44 years	554	554	9,333,468	0.59	755,821.1
45-64 years	3,808	3,808	7,969,645	4.78	641,301.6
65-74 years	4,979	4,979	6,936,315	7.18	553,920.0
75-84 years	3,330	3,330	3,793,271	8.78	300,748.1
≥ 85 years	1,399	1,399	1,617,808	8.65	128,820.7
2018, December					
18-44 years	517	517	9,347,510	0.55	781,951.5
45-64 years	3,789	3,789	7,979,185	4.75	662,733.2

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
65-74 years	4,813	4,813	6,948,928	6.93	573,096.1
75-84 years	3,294	3,294	3,802,423	8.66	311,486.1
≥ 85 years	1,269	1,269	1,616,217	7.85	132,992.1
2019, January					
18-44 years	0	0	9,184,029	0.00	767,483.9
45-64 years	0	0	7,841,450	0.00	651,034.9
65-74 years	0	0	6,965,817	0.00	573,552.6
75-84 years	0	0	3,783,078	0.00	309,174.1
≥ 85 years	0	0	1,602,222	0.00	131,530.7
2019, February					
18-44 years	0	0	9,149,627	0.00	692,192.3
45-64 years	0	0	7,801,140	0.00	586,528.1
65-74 years	0	0	6,949,214	0.00	518,842.9
75-84 years	0	0	3,770,143	0.00	279,501.2
≥ 85 years	0	0	1,591,499	0.00	118,495.3
2019, March					
18-44 years	0	0	9,156,656	0.00	765,646.5
45-64 years	0	0	7,802,332	0.00	647,985.4
65-74 years	0	0	6,976,383	0.00	574,768.3
75-84 years	0	0	3,788,593	0.00	309,807.6
≥ 85 years	0	0	1,594,767	0.00	130,934.9
2019, April					
18-44 years	0	0	9,136,170	0.00	739,464.3
45-64 years	0	0	7,766,447	0.00	624,357.9
65-74 years	0	0	6,962,884	0.00	555,156.1
75-84 years	0	0	3,782,855	0.00	299,286.2
≥ 85 years	0	0	1,587,028	0.00	126,105.7
2019, May					
18-44 years	0	0	9,128,266	0.00	763,291.8
45-64 years	0	0	7,736,780	0.00	642,728.3
65-74 years	0	0	6,955,427	0.00	572,891.6
75-84 years	0	0	3,779,431	0.00	308,808.9

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
≥ 85 years	0	0	1,583,532	0.00	129,924.4
2019, June					
18-44 years	0	0	9,112,720	0.00	737,720.0
45-64 years	0	0	7,708,750	0.00	620,098.4
65-74 years	0	0	6,950,564	0.00	554,620.6
75-84 years	0	0	3,774,062	0.00	298,746.4
≥ 85 years	0	0	1,578,446	0.00	125,459.7
2019, July					
18-44 years	0	0	9,113,385	0.00	762,082.7
45-64 years	0	0	7,690,937	0.00	639,454.9
65-74 years	0	0	6,973,807	0.00	575,412.2
75-84 years	0	0	3,777,919	0.00	309,141.0
≥ 85 years	0	0	1,577,077	0.00	129,575.5
2019, August					
18-44 years	0	0	9,121,342	0.00	762,180.0
45-64 years	0	0	7,677,929	0.00	637,781.4
65-74 years	0	0	6,994,980	0.00	576,341.6
75-84 years	0	0	3,787,381	0.00	309,444.0
≥ 85 years	0	0	1,579,248	0.00	129,539.6
2019, September					
18-44 years	0	0	9,120,128	0.00	737,804.7
45-64 years	0	0	7,665,835	0.00	616,426.0
65-74 years	0	0	7,001,801	0.00	559,027.6
75-84 years	0	0	3,783,064	0.00	299,711.7
≥ 85 years	0	0	1,576,974	0.00	125,378.1
2019, October					
18-44 years	0	0	9,118,721	0.00	762,354.7
45-64 years	0	0	7,654,719	0.00	635,537.8
65-74 years	0	0	7,023,286	0.00	578,181.3
75-84 years	0	0	3,793,403	0.00	309,705.0
≥ 85 years	0	0	1,580,557	0.00	129,543.0
2019, November					

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
18-44 years	0	0	9,114,258	0.00	738,130.2
45-64 years	0	0	7,640,376	0.00	614,640.2
65-74 years	0	0	7,017,732	0.00	560,236.7
75-84 years	0	0	3,785,047	0.00	299,886.6
≥ 85 years	0	0	1,573,787	0.00	125,234.1
2019, December					
18-44 years	0	0	9,132,910	0.00	764,313.3
45-64 years	0	0	7,649,969	0.00	635,552.4
65-74 years	0	0	7,028,317	0.00	579,849.7
75-84 years	0	0	3,791,023	0.00	310,631.0
≥ 85 years	0	0	1,571,719	0.00	129,332.1
2020, January					
18-44 years	0	0	9,002,386	0.00	751,526.1
45-64 years	0	0	7,526,263	0.00	624,232.5
65-74 years	0	0	7,126,350	0.00	587,012.0
75-84 years	0	0	3,818,975	0.00	312,191.6
≥ 85 years	0	0	1,578,016	0.00	129,534.9
2020, February					
18-44 years	0	0	9,087,615	0.00	701,995.6
45-64 years	0	0	7,553,927	0.00	582,148.3
65-74 years	0	0	7,201,247	0.00	549,796.8
75-84 years	0	0	3,816,966	0.00	292,007.9
≥ 85 years	0	0	1,573,517	0.00	120,837.3
2020, March					
18-44 years	0	0	9,107,758	0.00	750,642.1
45-64 years	0	0	7,551,528	0.00	621,434.4
65-74 years	0	0	7,224,111	0.00	589,273.9
75-84 years	0	0	3,829,785	0.00	312,932.6
≥ 85 years	0	0	1,575,170	0.00	129,240.4
2020, April					
18-44 years	0	0	9,092,548	0.00	727,622.6
45-64 years	0	0	7,557,750	0.00	604,936.0

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
65-74 years	0	0	7,306,753	0.00	581,002.3
75-84 years	0	0	3,880,306	0.00	309,336.5
≥ 85 years	0	0	1,590,630	0.00	127,144.6
2020, May					
18-44 years	0	0	9,170,191	0.00	756,234.5
45-64 years	0	0	7,646,251	0.00	630,155.7
65-74 years	0	0	7,474,756	0.00	611,553.7
75-84 years	0	0	3,977,793	0.00	326,104.4
≥ 85 years	0	0	1,615,643	0.00	132,897.6
2020, June					
18-44 years	0	0	9,272,406	0.00	735,789.3
45-64 years	0	0	7,716,117	0.00	612,640.1
65-74 years	0	0	7,597,110	0.00	598,066.6
75-84 years	0	0	4,037,109	0.00	319,044.9
≥ 85 years	0	0	1,632,270	0.00	129,541.5
2020, July					
18-44 years	0	0	9,313,626	0.00	760,948.6
45-64 years	0	0	7,682,855	0.00	632,594.1
65-74 years	0	0	7,643,009	0.00	622,497.8
75-84 years	0	0	4,062,264	0.00	331,573.7
≥ 85 years	0	0	1,642,479	0.00	134,509.5
2020, August					
18-44 years	0	0	9,291,974	0.00	761,399.5
45-64 years	0	0	7,698,572	0.00	632,887.8
65-74 years	0	0	7,688,982	0.00	626,303.2
75-84 years	0	0	4,086,608	0.00	333,539.0
≥ 85 years	0	0	1,650,675	0.00	135,208.7
2020, September					
18-44 years	0	0	9,234,357	0.00	732,524.0
45-64 years	0	0	7,694,124	0.00	610,545.8
65-74 years	0	0	7,737,220	0.00	609,932.9
75-84 years	0	0	4,112,143	0.00	324,581.7

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
≥ 85 years	0	0	1,659,319	0.00	131,394.3
2020, October					
18-44 years	0	0	9,210,754	0.00	759,781.9
45-64 years	0	0	7,675,219	0.00	631,582.7
65-74 years	0	0	7,785,320	0.00	634,008.8
75-84 years	0	0	4,144,057	0.00	337,406.9
≥ 85 years	0	0	1,671,028	0.00	136,502.7
2020, November					
18-44 years	0	0	9,239,028	0.00	737,558.0
45-64 years	0	0	7,691,115	0.00	612,670.5
65-74 years	0	0	7,798,194	0.00	617,411.0
75-84 years	0	0	4,150,813	0.00	328,622.0
≥ 85 years	0	0	1,669,534	0.00	132,607.4
2020, December					
18-44 years	0	0	10,286,028	0.00	768,033.9
45-64 years	0	0	8,435,101	0.00	637,131.0
65-74 years	0	0	8,488,213	0.00	643,730.1
75-84 years	0	0	4,414,229	0.00	342,667.5
≥ 85 years	0	0	1,742,858	0.00	137,627.7
2021, January					
18-44 years	0	0	9,399,543	0.00	775,873.9
45-64 years	0	0	7,796,964	0.00	641,375.7
65-74 years	0	0	8,025,906	0.00	654,183.2
75-84 years	0	0	4,226,374	0.00	344,541.6
≥ 85 years	0	0	1,681,467	0.00	137,421.5
2021, February					
18-44 years	0	0	9,284,118	0.00	702,446.6
45-64 years	0	0	7,733,331	0.00	580,858.6
65-74 years	0	0	7,979,319	0.00	595,068.8
75-84 years	0	0	4,235,795	0.00	313,571.3
≥ 85 years	0	0	1,676,783	0.00	124,354.9
2021, March					

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
18-44 years	0	0	9,302,962	0.00	777,407.5
45-64 years	0	0	7,730,644	0.00	643,101.3
65-74 years	0	0	8,000,632	0.00	662,143.3
75-84 years	0	0	4,245,677	0.00	348,748.5
≥ 85 years	0	0	1,676,364	0.00	138,139.3
2021, April					
18-44 years	0	0	9,216,725	0.00	748,619.4
45-64 years	0	0	7,618,087	0.00	615,970.0
65-74 years	0	0	7,862,635	0.00	632,338.6
75-84 years	0	0	4,156,753	0.00	332,067.3
≥ 85 years	0	0	1,639,381	0.00	131,341.5
2021, May					
18-44 years	0	0	9,132,775	0.00	765,664.6
45-64 years	0	0	7,538,270	0.00	628,352.8
65-74 years	0	0	7,780,334	0.00	643,848.2
75-84 years	0	0	4,108,069	0.00	337,470.0
≥ 85 years	0	0	1,615,841	0.00	133,221.2
2021, June					
18-44 years	0	0	9,059,461	0.00	734,183.9
45-64 years	0	0	7,488,460	0.00	602,907.1
65-74 years	0	0	7,755,411	0.00	619,393.8
75-84 years	0	0	4,097,573	0.00	324,544.3
≥ 85 years	0	0	1,606,467	0.00	127,740.5
2021, July					
18-44 years	0	0	8,984,678	0.00	752,150.2
45-64 years	0	0	7,439,191	0.00	618,861.2
65-74 years	0	0	7,749,701	0.00	639,666.5
75-84 years	0	0	4,095,516	0.00	335,064.3
≥ 85 years	0	0	1,600,296	0.00	131,486.4
2021, August					
18-44 years	0	0	8,926,567	0.00	746,812.6
45-64 years	0	0	7,396,191	0.00	615,215.4

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
65-74 years	0	0	7,731,853	0.00	637,981.3
75-84 years	0	0	4,097,051	0.00	335,093.5
≥ 85 years	0	0	1,593,691	0.00	131,022.9
2021, September					
18-44 years	0	0	8,865,015	0.00	718,465.9
45-64 years	0	0	7,348,858	0.00	591,866.3
65-74 years	0	0	7,707,924	0.00	615,827.3
75-84 years	0	0	4,102,176	0.00	324,833.5
≥ 85 years	0	0	1,587,775	0.00	126,393.9
2021, October					
18-44 years	0	0	8,812,573	0.00	737,751.1
45-64 years	0	0	7,314,481	0.00	608,071.7
65-74 years	0	0	7,701,787	0.00	634,545.4
75-84 years	0	0	4,123,318	0.00	336,635.3
≥ 85 years	0	0	1,586,283	0.00	130,259.8
2021, November					
18-44 years	0	0	8,767,500	0.00	711,033.8
45-64 years	0	0	7,278,571	0.00	586,425.8
65-74 years	0	0	7,658,452	0.00	611,885.9
75-84 years	0	0	4,122,121	0.00	326,684.9
≥ 85 years	0	0	1,575,548	0.00	125,596.9
2021, December					
18-44 years	0	0	8,744,448	0.00	732,997.0
45-64 years	0	0	7,261,305	0.00	604,165.6
65-74 years	0	0	7,619,677	0.00	628,897.4
75-84 years	0	0	4,129,821	0.00	338,295.6
≥ 85 years	0	0	1,566,846	0.00	129,062.3
2022, January					
18-44 years	0	0	8,423,050	0.00	705,713.4
45-64 years	0	0	7,012,614	0.00	584,164.5
65-74 years	0	0	7,597,533	0.00	627,811.6
75-84 years	0	0	4,117,612	0.00	337,571.9

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
≥ 85 years	0	0	1,556,500	0.00	128,249.7
2022, February					
18-44 years	0	0	8,372,496	0.00	634,530.3
45-64 years	0	0	6,968,915	0.00	524,973.7
65-74 years	0	0	7,552,260	0.00	564,747.3
75-84 years	0	0	4,110,983	0.00	305,241.6
≥ 85 years	0	0	1,538,838	0.00	114,755.0
2022, March					
18-44 years	0	0	8,366,128	0.00	700,322.2
45-64 years	0	0	6,967,214	0.00	579,235.7
65-74 years	0	0	7,559,461	0.00	623,092.1
75-84 years	0	0	4,145,217	0.00	338,692.3
≥ 85 years	0	0	1,542,260	0.00	126,606.1
2022, April					
18-44 years	0	0	8,337,695	0.00	675,512.0
45-64 years	0	0	6,936,428	0.00	558,303.6
65-74 years	0	0	7,531,215	0.00	601,034.8
75-84 years	0	0	4,151,163	0.00	328,601.9
≥ 85 years	0	0	1,539,861	0.00	122,376.8
2022, May					
18-44 years	0	0	8,316,499	0.00	695,918.5
45-64 years	0	0	6,915,670	0.00	574,889.5
65-74 years	0	0	7,527,345	0.00	620,217.8
75-84 years	0	0	4,171,167	0.00	340,789.5
≥ 85 years	0	0	1,542,400	0.00	126,546.1
2022, June					
18-44 years	0	0	8,319,741	0.00	673,612.7
45-64 years	0	0	6,906,949	0.00	555,700.3
65-74 years	0	0	7,520,572	0.00	599,895.7
75-84 years	0	0	4,189,099	0.00	331,327.7
≥ 85 years	0	0	1,542,944	0.00	122,551.7
2022, July					

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
18-44 years	0	0	8,275,977	0.00	692,162.0
45-64 years	0	0	6,867,325	0.00	570,847.9
65-74 years	0	0	7,531,837	0.00	621,198.9
75-84 years	0	0	4,208,469	0.00	344,073.0
≥ 85 years	0	0	1,547,024	0.00	126,923.9
2022, August					
18-44 years	0	0	8,312,068	0.00	691,956.6
45-64 years	0	0	6,865,498	0.00	569,648.5
65-74 years	0	0	7,547,902	0.00	621,835.5
75-84 years	0	0	4,231,109	0.00	345,580.6
≥ 85 years	0	0	1,550,080	0.00	127,096.0
2022, September					
18-44 years	0	0	5,804,982	0.00	470,027.4
45-64 years	0	0	5,109,876	0.00	410,908.6
65-74 years	0	0	7,413,293	0.00	592,049.4
75-84 years	0	0	4,220,648	0.00	334,261.5
≥ 85 years	0	0	1,542,160	0.00	122,589.2
2022, October					
18-44 years	0	0	5,134,203	0.00	429,654.8
45-64 years	0	0	3,762,103	0.00	312,905.4
65-74 years	0	0	1,183,649	0.00	97,591.1
75-84 years	0	0	552,453	0.00	45,279.3
≥ 85 years	0	0	187,020	0.00	15,351.9
2022, November					
18-44 years	0	0	1,548,848	0.00	125,997.8
45-64 years	0	0	1,031,759	0.00	83,221.7
65-74 years	0	0	659,484	0.00	52,781.0
75-84 years	0	0	318,059	0.00	25,260.5
≥ 85 years	0	0	97,766	0.00	7,771.9
2022, December					
18-44 years	0	0	1,559,288	0.00	131,024.9
45-64 years	0	0	1,036,512	0.00	86,341.2

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
65-74 years	0	0	661,461	0.00	54,696.3
75-84 years	0	0	319,763	0.00	26,251.4
≥ 85 years	0	0	97,917	0.00	8,057.2
Non-contaminated valsartan					
2012, May					
18-44 years	2,109	2,109	8,364,508	2.52	685,791.5
45-64 years	9,761	9,761	7,525,643	12.97	618,088.7
65-74 years	9,933	9,933	4,787,090	20.75	390,798.7
75-84 years	7,596	7,596	2,975,916	25.52	243,391.1
≥ 85 years	3,300	3,300	1,478,285	22.32	121,347.1
2012, June					
18-44 years	2,009	2,009	8,439,754	2.38	664,978.5
45-64 years	9,221	9,221	7,572,017	12.18	599,028.0
65-74 years	9,116	9,116	4,812,888	18.94	378,816.8
75-84 years	6,933	6,933	2,976,439	23.29	235,451.1
≥ 85 years	2,978	2,978	1,479,239	20.13	117,446.2
2012, July					
18-44 years	2,038	2,038	8,433,567	2.42	687,065.5
45-64 years	9,309	9,309	7,512,418	12.39	618,367.3
65-74 years	9,286	9,286	4,815,120	19.29	393,489.8
75-84 years	6,765	6,765	2,972,401	22.76	243,646.9
≥ 85 years	3,055	3,055	1,479,218	20.65	121,640.5
2012, August					
18-44 years	2,029	2,029	8,458,411	2.40	688,780.3
45-64 years	9,343	9,343	7,534,562	12.40	618,951.9
65-74 years	9,201	9,201	4,842,935	19.00	394,472.6
75-84 years	6,793	6,793	2,980,930	22.79	243,764.8
≥ 85 years	3,075	3,075	1,484,666	20.71	121,820.5
2012, September					
18-44 years	1,805	1,805	8,461,860	2.13	667,463.8
45-64 years	8,254	8,254	7,546,214	10.94	599,710.0
65-74 years	8,434	8,434	4,852,539	17.38	383,018.4

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	6,261	6,261	2,978,540	21.02	235,991.0
≥ 85 years	2,738	2,738	1,485,027	18.44	118,067.0
2012, October					
18-44 years	1,833	1,833	8,410,780	2.18	692,353.4
45-64 years	8,487	8,487	7,535,482	11.26	620,487.1
65-74 years	8,992	8,992	4,872,569	18.45	397,292.1
75-84 years	6,499	6,499	2,985,327	21.77	244,054.5
≥ 85 years	2,961	2,961	1,489,217	19.88	122,217.3
2012, November					
18-44 years	1,835	1,835	8,383,816	2.19	670,514.1
45-64 years	8,574	8,574	7,522,298	11.40	601,201.8
65-74 years	8,551	8,551	4,877,771	17.53	385,739.1
75-84 years	6,519	6,519	2,976,557	21.90	236,289.4
≥ 85 years	2,733	2,733	1,484,866	18.41	118,305.0
2012, December					
18-44 years	1,679	1,679	8,954,111	1.88	694,328.3
45-64 years	8,442	8,442	7,957,095	10.61	622,901.1
65-74 years	8,502	8,502	5,338,172	15.93	400,981.5
75-84 years	6,117	6,117	3,184,349	19.21	244,629.9
≥ 85 years	2,860	2,860	1,566,633	18.26	122,311.3
2013, January					
18-44 years	1,830	1,830	8,353,700	2.19	687,648.1
45-64 years	8,873	8,873	7,548,041	11.76	621,880.1
65-74 years	10,623	10,623	5,100,007	20.83	415,361.8
75-84 years	7,645	7,645	3,078,255	24.84	251,576.0
≥ 85 years	3,460	3,460	1,530,143	22.61	125,538.3
2013, February					
18-44 years	1,655	1,655	8,175,825	2.02	619,070.5
45-64 years	8,172	8,172	7,436,868	10.99	560,449.5
65-74 years	8,882	8,882	5,027,964	17.67	375,918.3
75-84 years	6,404	6,404	3,054,008	20.97	227,022.2
≥ 85 years	2,875	2,875	1,512,480	19.01	112,781.3

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2013, March					
18-44 years	1,651	1,651	8,193,743	2.01	685,513.4
45-64 years	8,207	8,207	7,458,564	11.00	620,998.7
65-74 years	8,802	8,802	5,062,078	17.39	417,643.1
75-84 years	6,586	6,586	3,068,318	21.46	251,434.5
≥ 85 years	2,998	2,998	1,517,564	19.76	124,778.9
2013, April					
18-44 years	1,555	1,555	8,163,103	1.90	661,545.4
45-64 years	8,139	8,139	7,448,315	10.93	600,540.3
65-74 years	9,696	9,696	5,066,600	19.14	404,730.2
75-84 years	7,059	7,059	3,064,944	23.03	243,135.3
≥ 85 years	3,089	3,089	1,512,954	20.42	120,475.5
2013, May					
18-44 years	1,496	1,496	8,167,935	1.83	683,740.2
45-64 years	7,609	7,609	7,448,510	10.22	620,475.7
65-74 years	9,114	9,114	5,073,554	17.96	418,646.0
75-84 years	6,655	6,655	3,063,443	21.72	250,971.7
≥ 85 years	2,892	2,892	1,513,127	19.11	124,414.9
2013, June					
18-44 years	1,418	1,418	8,172,089	1.74	662,092.7
45-64 years	7,294	7,294	7,451,057	9.79	600,884.6
65-74 years	7,873	7,873	5,078,332	15.50	405,880.9
75-84 years	5,894	5,894	3,061,768	19.25	242,903.2
≥ 85 years	2,553	2,553	1,515,140	16.85	120,598.6
2013, July					
18-44 years	1,455	1,455	8,186,238	1.78	685,446.1
45-64 years	7,689	7,689	7,477,827	10.28	623,277.3
65-74 years	8,069	8,069	5,106,423	15.80	421,838.0
75-84 years	5,929	5,929	3,068,486	19.32	251,632.8
≥ 85 years	2,759	2,759	1,518,798	18.17	125,022.4
2013, August					
18-44 years	1,407	1,407	8,222,861	1.71	686,985.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	7,482	7,482	7,485,928	9.99	623,387.5
65-74 years	7,615	7,615	5,122,700	14.87	422,614.0
75-84 years	5,620	5,620	3,072,300	18.29	251,599.8
≥ 85 years	2,595	2,595	1,522,012	17.05	125,098.2
2013, September					
18-44 years	1,339	1,339	8,206,097	1.63	663,185.4
45-64 years	7,094	7,094	7,481,401	9.48	603,284.7
65-74 years	7,540	7,540	5,129,144	14.70	409,982.8
75-84 years	5,627	5,627	3,068,476	18.34	243,479.4
≥ 85 years	2,501	2,501	1,521,423	16.44	121,186.3
2013, October					
18-44 years	1,448	1,448	8,151,267	1.78	682,468.5
45-64 years	7,735	7,735	7,486,691	10.33	623,439.9
65-74 years	8,039	8,039	5,143,267	15.63	424,173.3
75-84 years	5,836	5,836	3,072,371	19.00	251,525.2
≥ 85 years	2,639	2,639	1,524,246	17.31	125,281.1
2013, November					
18-44 years	1,229	1,229	8,140,272	1.51	660,095.1
45-64 years	6,649	6,649	7,472,138	8.90	602,666.2
65-74 years	6,958	6,958	5,131,443	13.56	410,239.6
75-84 years	5,119	5,119	3,056,902	16.75	242,817.7
≥ 85 years	2,329	2,329	1,516,932	15.35	120,948.8
2013, December					
18-44 years	1,250	1,250	8,111,311	1.54	679,413.8
45-64 years	6,895	6,895	7,453,904	9.25	620,953.7
65-74 years	7,295	7,295	5,132,287	14.21	424,162.2
75-84 years	5,307	5,307	3,056,031	17.37	251,034.8
≥ 85 years	2,447	2,447	1,516,170	16.14	125,022.0
2014, January					
18-44 years	1,672	1,672	8,900,862	1.88	743,878.7
45-64 years	7,769	7,769	8,097,588	9.59	673,473.1
65-74 years	8,897	8,897	5,828,215	15.27	480,960.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	6,401	6,401	3,436,548	18.63	281,800.4
≥ 85 years	2,922	2,922	1,692,042	17.27	139,286.0
2014, February					
18-44 years	1,382	1,382	8,846,077	1.56	669,432.3
45-64 years	6,863	6,863	8,045,772	8.53	606,140.0
65-74 years	7,612	7,612	5,820,892	13.08	435,355.3
75-84 years	5,524	5,524	3,424,581	16.13	254,601.6
≥ 85 years	2,465	2,465	1,684,773	14.63	125,668.1
2014, March					
18-44 years	1,308	1,308	8,829,117	1.48	738,714.1
45-64 years	6,604	6,604	8,023,113	8.23	667,865.6
65-74 years	7,335	7,335	5,847,596	12.54	482,829.3
75-84 years	5,463	5,463	3,437,822	15.89	281,924.6
≥ 85 years	2,529	2,529	1,691,245	14.95	139,172.4
2014, April					
18-44 years	1,128	1,128	8,792,157	1.28	711,953.1
45-64 years	5,953	5,953	7,984,409	7.46	643,156.4
65-74 years	6,606	6,606	5,863,303	11.27	468,166.6
75-84 years	5,018	5,018	3,445,634	14.56	273,159.9
≥ 85 years	2,355	2,355	1,693,294	13.91	134,731.3
2014, May					
18-44 years	1,049	1,049	8,775,025	1.20	733,930.6
45-64 years	5,852	5,852	7,950,385	7.36	661,633.0
65-74 years	6,418	6,418	5,858,001	10.96	483,089.2
75-84 years	4,763	4,763	3,440,683	13.84	281,659.7
≥ 85 years	2,221	2,221	1,690,431	13.14	138,907.8
2014, June					
18-44 years	1,089	1,089	8,755,301	1.24	708,949.4
45-64 years	6,410	6,410	7,924,298	8.09	638,515.2
65-74 years	7,483	7,483	5,854,865	12.78	467,718.1
75-84 years	5,266	5,266	3,431,651	15.35	272,104.9
≥ 85 years	2,334	2,334	1,686,277	13.84	134,187.3

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2014, July					
18-44 years	1,043	1,043	8,833,991	1.18	738,989.7
45-64 years	5,495	5,495	7,983,593	6.88	664,707.5
65-74 years	6,406	6,406	5,874,178	10.91	484,891.1
75-84 years	4,815	4,815	3,427,276	14.05	280,728.7
≥ 85 years	2,407	2,407	1,684,119	14.29	138,431.0
2014, August					
18-44 years	1,005	1,005	8,797,059	1.14	735,222.7
45-64 years	5,360	5,360	7,935,928	6.75	660,431.2
65-74 years	6,431	6,431	5,888,903	10.92	485,876.7
75-84 years	4,773	4,773	3,428,655	13.92	280,695.3
≥ 85 years	2,409	2,409	1,684,601	14.30	138,438.1
2014, September					
18-44 years	990	990	8,769,121	1.13	710,028.2
45-64 years	5,410	5,410	7,912,260	6.84	637,550.1
65-74 years	6,176	6,176	5,894,672	10.48	470,964.9
75-84 years	4,778	4,778	3,426,341	13.94	271,705.1
≥ 85 years	2,304	2,304	1,682,352	13.70	133,959.4
2014, October					
18-44 years	1,091	1,091	8,785,078	1.24	734,914.6
45-64 years	6,239	6,239	7,910,421	7.89	658,014.1
65-74 years	7,771	7,771	5,914,239	13.14	487,351.0
75-84 years	5,868	5,868	3,435,649	17.08	280,981.9
≥ 85 years	2,708	2,708	1,685,805	16.06	138,418.0
2014, November					
18-44 years	916	916	8,754,559	1.05	709,819.2
45-64 years	5,869	5,869	7,883,454	7.44	635,697.5
65-74 years	6,678	6,678	5,900,692	11.32	471,898.8
75-84 years	4,892	4,892	3,422,502	14.29	271,908.9
≥ 85 years	2,302	2,302	1,678,279	13.72	133,802.6
2014, December					
18-44 years	982	982	8,757,751	1.12	732,068.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	6,155	6,155	7,881,283	7.81	654,824.6
65-74 years	7,138	7,138	5,904,938	12.09	487,099.3
75-84 years	5,405	5,405	3,421,590	15.80	280,390.3
≥ 85 years	2,392	2,392	1,674,759	14.28	137,861.6
2015, January					
18-44 years	952	952	9,123,915	1.04	762,766.6
45-64 years	5,698	5,698	8,180,925	6.96	680,368.3
65-74 years	6,961	6,961	6,127,270	11.36	505,457.1
75-84 years	5,097	5,097	3,490,024	14.60	285,957.7
≥ 85 years	2,304	2,304	1,693,775	13.60	139,302.5
2015, February					
18-44 years	850	850	9,086,841	0.94	687,415.6
45-64 years	4,685	4,685	8,160,229	5.74	614,176.1
65-74 years	5,690	5,690	6,120,863	9.30	457,054.2
75-84 years	4,082	4,082	3,474,987	11.75	257,792.2
≥ 85 years	1,855	1,855	1,677,605	11.06	124,947.6
2015, March					
18-44 years	1,034	1,034	9,100,046	1.14	761,135.6
45-64 years	6,038	6,038	8,180,125	7.38	680,528.2
65-74 years	7,184	7,184	6,143,987	11.69	506,922.6
75-84 years	5,140	5,140	3,486,096	14.74	285,560.7
≥ 85 years	2,299	2,299	1,680,197	13.68	138,115.5
2015, April					
18-44 years	1,013	1,013	9,138,675	1.11	739,977.1
45-64 years	6,588	6,588	8,211,131	8.02	661,233.4
65-74 years	8,268	8,268	6,145,884	13.45	490,587.7
75-84 years	5,469	5,469	3,483,308	15.70	275,957.6
≥ 85 years	2,301	2,301	1,675,829	13.73	133,251.0
2015, May					
18-44 years	1,172	1,172	9,175,195	1.28	767,475.7
45-64 years	7,562	7,562	8,246,239	9.17	686,093.7
65-74 years	9,455	9,455	6,153,081	15.37	507,293.6

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	6,154	6,154	3,481,086	17.68	284,736.1
≥ 85 years	2,589	2,589	1,671,940	15.49	137,323.4
2015, June					
18-44 years	1,329	1,329	9,183,380	1.45	743,496.2
45-64 years	7,858	7,858	8,249,066	9.53	664,426.9
65-74 years	9,842	9,842	6,156,861	15.99	491,430.5
75-84 years	6,713	6,713	3,476,280	19.31	275,392.3
≥ 85 years	2,701	2,701	1,669,641	16.18	132,738.1
2015, July					
18-44 years	1,134	1,134	9,174,711	1.24	767,433.8
45-64 years	6,585	6,585	8,243,111	7.99	686,070.7
65-74 years	9,124	9,124	6,183,678	14.75	510,273.2
75-84 years	6,112	6,112	3,480,494	17.56	284,897.6
≥ 85 years	2,612	2,612	1,671,542	15.63	137,352.4
2015, August					
18-44 years	976	976	9,185,511	1.06	767,910.7
45-64 years	5,823	5,823	8,238,322	7.07	685,699.0
65-74 years	7,531	7,531	6,202,569	12.14	511,943.7
75-84 years	5,065	5,065	3,486,959	14.53	285,474.9
≥ 85 years	2,283	2,283	1,673,569	13.64	137,559.6
2015, September					
18-44 years	904	904	9,195,873	0.98	744,491.9
45-64 years	5,415	5,415	8,246,416	6.57	664,166.7
65-74 years	6,983	6,983	6,220,835	11.23	496,832.6
75-84 years	4,704	4,704	3,489,823	13.48	276,503.9
≥ 85 years	2,029	2,029	1,674,405	12.12	133,188.6
2015, October					
18-44 years	1,015	1,015	9,186,832	1.10	768,057.8
45-64 years	5,734	5,734	8,256,279	6.95	685,957.0
65-74 years	7,554	7,554	6,247,993	12.09	514,567.3
75-84 years	5,331	5,331	3,499,155	15.24	285,939.0
≥ 85 years	2,270	2,270	1,678,202	13.53	137,656.7

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2015, November					
18-44 years	1,125	1,125	9,158,717	1.23	741,953.8
45-64 years	6,747	6,747	8,233,444	8.19	663,167.1
65-74 years	8,410	8,410	6,234,026	13.49	498,253.2
75-84 years	6,084	6,084	3,484,813	17.46	276,549.0
≥ 85 years	2,984	2,984	1,669,179	17.88	133,003.4
2015, December					
18-44 years	1,183	1,183	9,161,719	1.29	766,268.6
45-64 years	6,843	6,843	8,238,837	8.31	684,479.4
65-74 years	8,375	8,375	6,246,451	13.41	514,985.8
75-84 years	6,041	6,041	3,490,650	17.31	285,784.2
≥ 85 years	2,859	2,859	1,669,468	17.13	137,277.3
2016, January					
18-44 years	1,101	1,101	9,197,891	1.20	768,766.8
45-64 years	6,395	6,395	8,317,974	7.69	691,508.8
65-74 years	8,889	8,889	6,466,038	13.75	533,020.6
75-84 years	6,001	6,001	3,552,538	16.89	290,765.5
≥ 85 years	2,601	2,601	1,689,811	15.39	138,879.7
2016, February					
18-44 years	1,016	1,016	9,347,756	1.09	718,151.0
45-64 years	5,738	5,738	8,432,703	6.80	646,433.4
65-74 years	7,344	7,344	6,545,713	11.22	499,704.7
75-84 years	4,933	4,933	3,556,873	13.87	272,312.5
≥ 85 years	2,004	2,004	1,687,003	11.88	129,677.7
2016, March					
18-44 years	967	967	9,366,076	1.03	769,852.1
45-64 years	5,050	5,050	8,439,304	5.98	693,183.1
65-74 years	6,352	6,352	6,572,078	9.67	535,044.1
75-84 years	4,188	4,188	3,571,421	11.73	291,183.6
≥ 85 years	1,832	1,832	1,690,174	10.84	138,375.5
2016, April					
18-44 years	758	758	9,384,822	0.81	744,418.9

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	3,980	3,980	8,419,060	4.73	669,792.2
65-74 years	4,988	4,988	6,569,124	7.59	518,068.0
75-84 years	3,409	3,409	3,570,432	9.55	281,952.1
≥ 85 years	1,736	1,736	1,685,515	10.30	133,676.6
2016, May					
18-44 years	733	733	9,394,394	0.78	772,087.7
45-64 years	4,124	4,124	8,404,391	4.91	691,299.2
65-74 years	4,909	4,909	6,572,106	7.47	535,445.0
75-84 years	3,613	3,613	3,574,047	10.11	291,433.1
≥ 85 years	1,859	1,859	1,684,428	11.04	137,891.7
2016, June					
18-44 years	741	741	9,443,249	0.78	746,629.4
45-64 years	4,735	4,735	8,432,609	5.62	668,337.1
65-74 years	5,829	5,829	6,613,244	8.81	519,406.7
75-84 years	4,118	4,118	3,585,720	11.48	282,753.3
≥ 85 years	1,672	1,672	1,685,376	9.92	133,560.2
2016, July					
18-44 years	769	769	9,461,262	0.81	771,598.4
45-64 years	4,850	4,850	8,377,595	5.79	690,024.6
65-74 years	5,759	5,759	6,618,431	8.70	539,385.0
75-84 years	3,986	3,986	3,591,786	11.10	293,279.9
≥ 85 years	1,796	1,796	1,685,623	10.65	138,210.5
2016, August					
18-44 years	713	713	9,439,117	0.76	770,338.6
45-64 years	4,402	4,402	8,394,924	5.24	689,729.7
65-74 years	5,391	5,391	6,643,992	8.11	540,791.4
75-84 years	3,681	3,681	3,607,137	10.20	294,163.3
≥ 85 years	1,610	1,610	1,689,827	9.53	138,380.9
2016, September					
18-44 years	640	640	9,456,740	0.68	747,592.2
45-64 years	3,474	3,474	8,420,353	4.13	667,450.2
65-74 years	4,229	4,229	6,657,344	6.35	524,840.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	3,118	3,118	3,610,739	8.64	285,278.9
≥ 85 years	1,338	1,338	1,690,174	7.92	134,110.8
2016, October					
18-44 years	661	661	9,401,480	0.70	774,245.1
45-64 years	3,384	3,384	8,391,271	4.03	690,619.5
65-74 years	4,100	4,100	6,674,329	6.14	544,213.4
75-84 years	2,971	2,971	3,620,317	8.21	295,502.5
≥ 85 years	1,331	1,331	1,692,643	7.86	138,700.0
2016, November					
18-44 years	553	553	9,463,510	0.58	750,054.5
45-64 years	3,296	3,296	8,428,158	3.91	668,345.6
65-74 years	4,143	4,143	6,670,099	6.21	527,483.5
75-84 years	2,973	2,973	3,616,309	8.22	286,279.8
≥ 85 years	1,320	1,320	1,686,419	7.83	134,060.8
2016, December					
18-44 years	579	579	10,721,076	0.54	781,111.1
45-64 years	3,322	3,322	9,379,592	3.54	694,190.9
65-74 years	4,049	4,049	7,114,665	5.69	546,461.2
75-84 years	2,970	2,970	3,773,569	7.87	296,434.9
≥ 85 years	1,313	1,313	1,738,486	7.55	138,471.1
2017, January					
18-44 years	611	611	9,487,856	0.64	780,593.7
45-64 years	3,382	3,382	8,370,471	4.04	688,283.0
65-74 years	5,132	5,132	6,757,194	7.59	550,680.7
75-84 years	3,518	3,518	3,618,289	9.72	295,409.8
≥ 85 years	1,588	1,588	1,668,592	9.52	136,859.5
2017, February					
18-44 years	571	571	9,319,963	0.61	704,706.1
45-64 years	3,108	3,108	8,251,261	3.77	620,296.0
65-74 years	4,462	4,462	6,661,229	6.70	497,103.7
75-84 years	3,090	3,090	3,596,912	8.59	266,670.0
≥ 85 years	1,387	1,387	1,651,950	8.40	122,924.4

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2017, March					
18-44 years	566	566	9,350,278	0.61	781,603.2
45-64 years	3,420	3,420	8,270,143	4.14	686,825.6
65-74 years	4,640	4,640	6,691,510	6.93	551,117.1
75-84 years	3,424	3,424	3,615,640	9.47	295,535.4
≥ 85 years	1,489	1,489	1,654,674	9.00	135,829.5
2017, April					
18-44 years	525	525	9,349,585	0.56	756,960.8
45-64 years	2,952	2,952	8,252,018	3.58	663,883.1
65-74 years	3,804	3,804	6,682,659	5.69	533,106.3
75-84 years	2,690	2,690	3,612,985	7.45	286,004.9
≥ 85 years	1,261	1,261	1,646,563	7.66	130,920.9
2017, May					
18-44 years	599	599	9,359,246	0.64	782,545.8
45-64 years	3,977	3,977	8,242,827	4.82	685,007.1
65-74 years	5,515	5,515	6,683,727	8.25	550,617.9
75-84 years	3,901	3,901	3,615,549	10.79	295,460.0
≥ 85 years	1,508	1,508	1,644,327	9.17	134,947.3
2017, June					
18-44 years	668	668	9,368,314	0.71	758,284.8
45-64 years	4,269	4,269	8,236,072	5.18	662,790.7
65-74 years	5,400	5,400	6,685,793	8.08	533,532.9
75-84 years	3,595	3,595	3,614,209	9.95	286,199.9
≥ 85 years	1,436	1,436	1,641,664	8.75	130,526.2
2017, July					
18-44 years	691	691	9,360,900	0.74	783,019.8
45-64 years	5,291	5,291	8,212,151	6.44	683,447.3
65-74 years	6,196	6,196	6,710,909	9.23	554,364.4
75-84 years	3,796	3,796	3,622,293	10.48	296,907.7
≥ 85 years	1,400	1,400	1,641,767	8.53	135,088.0
2017, August					
18-44 years	766	766	9,399,555	0.81	785,055.2

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	5,773	5,773	8,228,369	7.02	683,721.6
65-74 years	6,376	6,376	6,738,146	9.46	555,144.4
75-84 years	4,126	4,126	3,640,885	11.33	297,460.1
≥ 85 years	1,512	1,512	1,645,959	9.19	135,098.6
2017, September					
18-44 years	675	675	9,421,945	0.72	761,989.4
45-64 years	4,971	4,971	8,220,393	6.05	661,559.6
65-74 years	5,957	5,957	6,745,048	8.83	538,528.5
75-84 years	3,943	3,943	3,647,418	10.81	288,766.8
≥ 85 years	1,420	1,420	1,644,162	8.64	130,811.6
2017, October					
18-44 years	677	677	9,454,118	0.72	790,593.0
45-64 years	4,656	4,656	8,236,320	5.65	684,557.1
65-74 years	5,847	5,847	6,763,065	8.65	557,097.3
75-84 years	4,015	4,015	3,666,424	10.95	299,459.9
≥ 85 years	1,462	1,462	1,646,493	8.88	135,210.8
2017, November					
18-44 years	631	631	9,457,099	0.67	765,967.4
45-64 years	4,203	4,203	8,226,510	5.11	662,163.3
65-74 years	5,368	5,368	6,748,161	7.95	538,762.6
75-84 years	3,723	3,723	3,669,059	10.15	290,676.9
≥ 85 years	1,443	1,443	1,641,248	8.79	130,722.6
2017, December					
18-44 years	598	598	9,512,862	0.63	795,812.9
45-64 years	3,736	3,736	8,262,799	4.52	686,174.5
65-74 years	5,068	5,068	6,750,567	7.51	556,154.5
75-84 years	3,489	3,489	3,685,019	9.47	301,394.2
≥ 85 years	1,307	1,307	1,640,972	7.96	134,987.8
2018, January					
18-44 years	636	636	9,411,393	0.68	786,490.6
45-64 years	4,029	4,029	8,122,894	4.96	674,527.7
65-74 years	5,843	5,843	6,851,321	8.53	564,139.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	3,848	3,848	3,707,032	10.38	302,899.5
≥ 85 years	1,372	1,372	1,641,321	8.36	134,841.7
2018, February					
18-44 years	599	599	9,382,753	0.64	709,452.0
45-64 years	3,431	3,431	8,090,351	4.24	608,094.1
65-74 years	4,687	4,687	6,835,848	6.86	510,078.0
75-84 years	3,008	3,008	3,701,578	8.13	274,336.5
≥ 85 years	1,056	1,056	1,626,820	6.49	121,124.8
2018, March					
18-44 years	654	654	9,392,826	0.70	785,448.5
45-64 years	3,839	3,839	8,099,891	4.74	672,713.9
65-74 years	5,234	5,234	6,869,445	7.62	565,619.0
75-84 years	3,468	3,468	3,730,810	9.30	304,739.6
≥ 85 years	1,313	1,313	1,631,627	8.05	133,909.9
2018, April					
18-44 years	708	708	9,363,972	0.76	758,295.2
45-64 years	3,763	3,763	8,068,016	4.66	649,082.6
65-74 years	5,448	5,448	6,863,140	7.94	547,460.5
75-84 years	3,674	3,674	3,735,222	9.84	295,581.3
≥ 85 years	1,327	1,327	1,627,275	8.15	129,359.4
2018, May					
18-44 years	644	644	9,359,197	0.69	782,603.3
45-64 years	3,640	3,640	8,046,118	4.52	668,567.6
65-74 years	5,786	5,786	6,858,911	8.44	564,915.3
75-84 years	3,750	3,750	3,741,973	10.02	305,708.9
≥ 85 years	1,312	1,312	1,625,170	8.07	133,396.3
2018, June					
18-44 years	590	590	9,355,214	0.63	757,239.2
45-64 years	3,351	3,351	8,031,646	4.17	646,118.4
65-74 years	4,860	4,860	6,859,400	7.09	547,288.6
75-84 years	3,325	3,325	3,745,198	8.88	296,434.7
≥ 85 years	1,182	1,182	1,622,051	7.29	128,992.3

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2018, July					
18-44 years	672	672	9,325,025	0.72	779,896.4
45-64 years	4,823	4,823	7,996,496	6.03	665,165.5
65-74 years	7,742	7,742	6,884,005	11.25	568,456.6
75-84 years	5,282	5,282	3,753,036	14.07	307,496.8
≥ 85 years	2,067	2,067	1,621,477	12.75	133,402.9
2018, August					
18-44 years	639	639	9,342,250	0.68	780,743.0
45-64 years	4,107	4,107	7,997,529	5.14	664,422.4
65-74 years	5,805	5,805	6,912,169	8.40	569,472.3
75-84 years	4,072	4,072	3,773,483	10.79	308,334.2
≥ 85 years	1,736	1,736	1,624,520	10.69	133,380.5
2018, September					
18-44 years	598	598	9,336,289	0.64	755,687.7
45-64 years	3,837	3,837	7,983,674	4.81	642,447.1
65-74 years	5,457	5,457	6,917,718	7.89	552,396.8
75-84 years	3,922	3,922	3,776,505	10.39	299,243.0
≥ 85 years	1,643	1,643	1,621,269	10.13	129,045.1
2018, October					
18-44 years	595	595	9,330,009	0.64	779,822.9
45-64 years	4,292	4,292	7,981,185	5.38	662,722.0
65-74 years	6,671	6,671	6,944,645	9.61	571,742.6
75-84 years	4,527	4,527	3,797,734	11.92	310,157.6
≥ 85 years	1,749	1,749	1,624,514	10.77	133,281.3
2018, November					
18-44 years	579	579	9,333,468	0.62	755,821.1
45-64 years	3,604	3,604	7,969,645	4.52	641,301.6
65-74 years	4,911	4,911	6,936,315	7.08	553,920.0
75-84 years	3,244	3,244	3,793,271	8.55	300,748.1
≥ 85 years	1,212	1,212	1,617,808	7.49	128,820.7
2018, December					
18-44 years	612	612	9,347,510	0.65	781,951.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	3,902	3,902	7,979,185	4.89	662,733.2
65-74 years	5,494	5,494	6,948,928	7.91	573,096.1
75-84 years	3,802	3,802	3,802,423	10.00	311,486.1
≥ 85 years	1,429	1,429	1,616,217	8.84	132,992.1
2019, January					
18-44 years	2,548	2,548	9,184,029	2.77	767,483.9
45-64 years	17,275	17,275	7,841,450	22.03	651,034.9
65-74 years	23,291	23,291	6,965,817	33.44	573,552.6
75-84 years	15,835	15,835	3,783,078	41.86	309,174.1
≥ 85 years	7,184	7,184	1,602,222	44.84	131,530.7
2019, February					
18-44 years	1,509	1,509	9,149,627	1.65	692,192.3
45-64 years	9,836	9,836	7,801,140	12.61	586,528.1
65-74 years	15,902	15,902	6,949,214	22.88	518,842.9
75-84 years	10,525	10,525	3,770,143	27.92	279,501.2
≥ 85 years	3,942	3,942	1,591,499	24.77	118,495.3
2019, March					
18-44 years	1,587	1,587	9,156,656	1.73	765,646.5
45-64 years	10,935	10,935	7,802,332	14.02	647,985.4
65-74 years	18,310	18,310	6,976,383	26.25	574,768.3
75-84 years	12,368	12,368	3,788,593	32.65	309,807.6
≥ 85 years	4,267	4,267	1,594,767	26.76	130,934.9
2019, April					
18-44 years	1,298	1,298	9,136,170	1.42	739,464.3
45-64 years	7,838	7,838	7,766,447	10.09	624,357.9
65-74 years	11,475	11,475	6,962,884	16.48	555,156.1
75-84 years	7,986	7,986	3,782,855	21.11	299,286.2
≥ 85 years	3,067	3,067	1,587,028	19.33	126,105.7
2019, May					
18-44 years	1,238	1,238	9,128,266	1.36	763,291.8
45-64 years	6,784	6,784	7,736,780	8.77	642,728.3
65-74 years	10,153	10,153	6,955,427	14.60	572,891.6

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	6,712	6,712	3,779,431	17.76	308,808.9
≥ 85 years	2,363	2,363	1,583,532	14.92	129,924.4
2019, June					
18-44 years	1,004	1,004	9,112,720	1.10	737,720.0
45-64 years	5,349	5,349	7,708,750	6.94	620,098.4
65-74 years	7,517	7,517	6,950,564	10.81	554,620.6
75-84 years	5,059	5,059	3,774,062	13.40	298,746.4
≥ 85 years	1,850	1,850	1,578,446	11.72	125,459.7
2019, July					
18-44 years	1,019	1,019	9,113,385	1.12	762,082.7
45-64 years	5,736	5,736	7,690,937	7.46	639,454.9
65-74 years	7,595	7,595	6,973,807	10.89	575,412.2
75-84 years	5,254	5,254	3,777,919	13.91	309,141.0
≥ 85 years	1,879	1,879	1,577,077	11.91	129,575.5
2019, August					
18-44 years	1,154	1,154	9,121,342	1.27	762,180.0
45-64 years	5,926	5,926	7,677,929	7.72	637,781.4
65-74 years	7,916	7,916	6,994,980	11.32	576,341.6
75-84 years	5,263	5,263	3,787,381	13.90	309,444.0
≥ 85 years	1,890	1,890	1,579,248	11.97	129,539.6
2019, September					
18-44 years	1,170	1,170	9,120,128	1.28	737,804.7
45-64 years	6,457	6,457	7,665,835	8.42	616,426.0
65-74 years	8,711	8,711	7,001,801	12.44	559,027.6
75-84 years	5,702	5,702	3,783,064	15.07	299,711.7
≥ 85 years	2,035	2,035	1,576,974	12.90	125,378.1
2019, October					
18-44 years	1,555	1,555	9,118,721	1.71	762,354.7
45-64 years	8,473	8,473	7,654,719	11.07	635,537.8
65-74 years	12,296	12,296	7,023,286	17.51	578,181.3
75-84 years	8,098	8,098	3,793,403	21.35	309,705.0
≥ 85 years	2,772	2,772	1,580,557	17.54	129,543.0

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2019, November					
18-44 years	1,203	1,203	9,114,258	1.32	738,130.2
45-64 years	6,441	6,441	7,640,376	8.43	614,640.2
65-74 years	9,084	9,084	7,017,732	12.94	560,236.7
75-84 years	5,774	5,774	3,785,047	15.25	299,886.6
≥ 85 years	2,109	2,109	1,573,787	13.40	125,234.1
2019, December					
18-44 years	1,304	1,304	9,132,910	1.43	764,313.3
45-64 years	6,779	6,779	7,649,969	8.86	635,552.4
65-74 years	9,762	9,762	7,028,317	13.89	579,849.7
75-84 years	6,289	6,289	3,791,023	16.59	310,631.0
≥ 85 years	2,287	2,287	1,571,719	14.55	129,332.1
2020, January					
18-44 years	1,601	1,601	9,002,386	1.78	751,526.1
45-64 years	8,300	8,300	7,526,263	11.03	624,232.5
65-74 years	11,414	11,414	7,126,350	16.02	587,012.0
75-84 years	7,375	7,375	3,818,975	19.31	312,191.6
≥ 85 years	2,634	2,634	1,578,016	16.69	129,534.9
2020, February					
18-44 years	1,353	1,353	9,087,615	1.49	701,995.6
45-64 years	7,029	7,029	7,553,927	9.31	582,148.3
65-74 years	9,434	9,434	7,201,247	13.10	549,796.8
75-84 years	6,081	6,081	3,816,966	15.93	292,007.9
≥ 85 years	2,160	2,160	1,573,517	13.73	120,837.3
2020, March					
18-44 years	1,412	1,412	9,107,758	1.55	750,642.1
45-64 years	7,233	7,233	7,551,528	9.58	621,434.4
65-74 years	9,460	9,460	7,224,111	13.10	589,273.9
75-84 years	5,973	5,973	3,829,785	15.60	312,932.6
≥ 85 years	2,108	2,108	1,575,170	13.38	129,240.4
2020, April					
18-44 years	885	885	9,092,548	0.97	727,622.6

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	4,675	4,675	7,557,750	6.19	604,936.0
65-74 years	6,054	6,054	7,306,753	8.29	581,002.3
75-84 years	3,929	3,929	3,880,306	10.13	309,336.5
≥ 85 years	1,414	1,414	1,590,630	8.89	127,144.6
2020, May					
18-44 years	811	811	9,170,191	0.88	756,234.5
45-64 years	4,115	4,115	7,646,251	5.38	630,155.7
65-74 years	5,628	5,628	7,474,756	7.53	611,553.7
75-84 years	3,625	3,625	3,977,793	9.11	326,104.4
≥ 85 years	1,335	1,335	1,615,643	8.26	132,897.6
2020, June					
18-44 years	979	979	9,272,406	1.06	735,789.3
45-64 years	5,012	5,012	7,716,117	6.50	612,640.1
65-74 years	6,829	6,829	7,597,110	8.99	598,066.6
75-84 years	4,499	4,499	4,037,109	11.14	319,044.9
≥ 85 years	1,530	1,530	1,632,270	9.37	129,541.5
2020, July					
18-44 years	1,008	1,008	9,313,626	1.08	760,948.6
45-64 years	5,206	5,206	7,682,855	6.78	632,594.1
65-74 years	7,031	7,031	7,643,009	9.20	622,497.8
75-84 years	4,557	4,557	4,062,264	11.22	331,573.7
≥ 85 years	1,686	1,686	1,642,479	10.26	134,509.5
2020, August					
18-44 years	959	959	9,291,974	1.03	761,399.5
45-64 years	4,780	4,780	7,698,572	6.21	632,887.8
65-74 years	6,529	6,529	7,688,982	8.49	626,303.2
75-84 years	4,145	4,145	4,086,608	10.14	333,539.0
≥ 85 years	1,555	1,555	1,650,675	9.42	135,208.7
2020, September					
18-44 years	1,013	1,013	9,234,357	1.10	732,524.0
45-64 years	5,021	5,021	7,694,124	6.53	610,545.8
65-74 years	6,873	6,873	7,737,220	8.88	609,932.9

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	4,509	4,509	4,112,143	10.97	324,581.7
≥ 85 years	1,617	1,617	1,659,319	9.74	131,394.3
2020, October					
18-44 years	1,167	1,167	9,210,754	1.27	759,781.9
45-64 years	5,924	5,924	7,675,219	7.72	631,582.7
65-74 years	7,915	7,915	7,785,320	10.17	634,008.8
75-84 years	5,100	5,100	4,144,057	12.31	337,406.9
≥ 85 years	1,722	1,722	1,671,028	10.31	136,502.7
2020, November					
18-44 years	1,047	1,047	9,239,028	1.13	737,558.0
45-64 years	5,295	5,295	7,691,115	6.88	612,670.5
65-74 years	7,649	7,649	7,798,194	9.81	617,411.0
75-84 years	4,853	4,853	4,150,813	11.69	328,622.0
≥ 85 years	1,751	1,751	1,669,534	10.49	132,607.4
2020, December					
18-44 years	1,074	1,074	10,286,028	1.04	768,033.9
45-64 years	5,594	5,594	8,435,101	6.63	637,131.0
65-74 years	8,199	8,199	8,488,213	9.66	643,730.1
75-84 years	5,268	5,268	4,414,229	11.93	342,667.5
≥ 85 years	1,747	1,747	1,742,858	10.02	137,627.7
2021, January					
18-44 years	1,186	1,186	9,399,543	1.26	775,873.9
45-64 years	5,729	5,729	7,796,964	7.35	641,375.7
65-74 years	8,084	8,084	8,025,906	10.07	654,183.2
75-84 years	5,195	5,195	4,226,374	12.29	344,541.6
≥ 85 years	1,742	1,742	1,681,467	10.36	137,421.5
2021, February					
18-44 years	1,115	1,115	9,284,118	1.20	702,446.6
45-64 years	5,507	5,507	7,733,331	7.12	580,858.6
65-74 years	7,415	7,415	7,979,319	9.29	595,068.8
75-84 years	4,766	4,766	4,235,795	11.25	313,571.3
≥ 85 years	1,600	1,600	1,676,783	9.54	124,354.9

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2021, March					
18-44 years	1,358	1,358	9,302,962	1.46	777,407.5
45-64 years	6,768	6,768	7,730,644	8.75	643,101.3
65-74 years	9,311	9,311	8,000,632	11.64	662,143.3
75-84 years	5,834	5,834	4,245,677	13.74	348,748.5
≥ 85 years	2,058	2,058	1,676,364	12.28	138,139.3
2021, April					
18-44 years	1,130	1,130	9,216,725	1.23	748,619.4
45-64 years	5,703	5,703	7,618,087	7.49	615,970.0
65-74 years	8,538	8,538	7,862,635	10.86	632,338.6
75-84 years	5,587	5,587	4,156,753	13.44	332,067.3
≥ 85 years	2,089	2,089	1,639,381	12.74	131,341.5
2021, May					
18-44 years	1,107	1,107	9,132,775	1.21	765,664.6
45-64 years	5,295	5,295	7,538,270	7.02	628,352.8
65-74 years	7,899	7,899	7,780,334	10.15	643,848.2
75-84 years	5,088	5,088	4,108,069	12.39	337,470.0
≥ 85 years	1,836	1,836	1,615,841	11.36	133,221.2
2021, June					
18-44 years	1,119	1,119	9,059,461	1.24	734,183.9
45-64 years	5,665	5,665	7,488,460	7.56	602,907.1
65-74 years	8,193	8,193	7,755,411	10.56	619,393.8
75-84 years	5,420	5,420	4,097,573	13.23	324,544.3
≥ 85 years	1,876	1,876	1,606,467	11.68	127,740.5
2021, July					
18-44 years	1,160	1,160	8,984,678	1.29	752,150.2
45-64 years	5,997	5,997	7,439,191	8.06	618,861.2
65-74 years	9,214	9,214	7,749,701	11.89	639,666.5
75-84 years	5,972	5,972	4,095,516	14.58	335,064.3
≥ 85 years	2,156	2,156	1,600,296	13.47	131,486.4
2021, August					
18-44 years	1,302	1,302	8,926,567	1.46	746,812.6

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	6,568	6,568	7,396,191	8.88	615,215.4
65-74 years	10,232	10,232	7,731,853	13.23	637,981.3
75-84 years	6,467	6,467	4,097,051	15.78	335,093.5
≥ 85 years	2,297	2,297	1,593,691	14.41	131,022.9
2021, September					
18-44 years	1,350	1,350	8,865,015	1.52	718,465.9
45-64 years	6,879	6,879	7,348,858	9.36	591,866.3
65-74 years	11,112	11,112	7,707,924	14.42	615,827.3
75-84 years	7,104	7,104	4,102,176	17.32	324,833.5
≥ 85 years	2,553	2,553	1,587,775	16.08	126,393.9
2021, October					
18-44 years	1,362	1,362	8,812,573	1.55	737,751.1
45-64 years	6,674	6,674	7,314,481	9.12	608,071.7
65-74 years	10,635	10,635	7,701,787	13.81	634,545.4
75-84 years	7,009	7,009	4,123,318	17.00	336,635.3
≥ 85 years	2,484	2,484	1,586,283	15.66	130,259.8
2021, November					
18-44 years	1,313	1,313	8,767,500	1.50	711,033.8
45-64 years	6,207	6,207	7,278,571	8.53	586,425.8
65-74 years	10,008	10,008	7,658,452	13.07	611,885.9
75-84 years	6,575	6,575	4,122,121	15.95	326,684.9
≥ 85 years	2,308	2,308	1,575,548	14.65	125,596.9
2021, December					
18-44 years	1,313	1,313	8,744,448	1.50	732,997.0
45-64 years	6,486	6,486	7,261,305	8.93	604,165.6
65-74 years	10,098	10,098	7,619,677	13.25	628,897.4
75-84 years	6,503	6,503	4,129,821	15.75	338,295.6
≥ 85 years	2,391	2,391	1,566,846	15.26	129,062.3
2022, January					
18-44 years	1,518	1,518	8,423,050	1.80	705,713.4
45-64 years	7,333	7,333	7,012,614	10.46	584,164.5
65-74 years	11,431	11,431	7,597,533	15.05	627,811.6

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	7,695	7,695	4,117,612	18.69	337,571.9
≥ 85 years	2,618	2,618	1,556,500	16.82	128,249.7
2022, February					
18-44 years	1,429	1,429	8,372,496	1.71	634,530.3
45-64 years	6,848	6,848	6,968,915	9.83	524,973.7
65-74 years	10,193	10,193	7,552,260	13.50	564,747.3
75-84 years	6,819	6,819	4,110,983	16.59	305,241.6
≥ 85 years	2,327	2,327	1,538,838	15.12	114,755.0
2022, March					
18-44 years	1,613	1,613	8,366,128	1.93	700,322.2
45-64 years	7,369	7,369	6,967,214	10.58	579,235.7
65-74 years	10,435	10,435	7,559,461	13.80	623,092.1
75-84 years	7,054	7,054	4,145,217	17.02	338,692.3
≥ 85 years	2,381	2,381	1,542,260	15.44	126,606.1
2022, April					
18-44 years	1,222	1,222	8,337,695	1.47	675,512.0
45-64 years	5,552	5,552	6,936,428	8.00	558,303.6
65-74 years	8,125	8,125	7,531,215	10.79	601,034.8
75-84 years	5,430	5,430	4,151,163	13.08	328,601.9
≥ 85 years	2,025	2,025	1,539,861	13.15	122,376.8
2022, May					
18-44 years	1,121	1,121	8,316,499	1.35	695,918.5
45-64 years	5,388	5,388	6,915,670	7.79	574,889.5
65-74 years	7,769	7,769	7,527,345	10.32	620,217.8
75-84 years	5,394	5,394	4,171,167	12.93	340,789.5
≥ 85 years	1,845	1,845	1,542,400	11.96	126,546.1
2022, June					
18-44 years	1,155	1,155	8,319,741	1.39	673,612.7
45-64 years	5,484	5,484	6,906,949	7.94	555,700.3
65-74 years	7,639	7,639	7,520,572	10.16	599,895.7
75-84 years	5,361	5,361	4,189,099	12.80	331,327.7
≥ 85 years	1,905	1,905	1,542,944	12.35	122,551.7

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2022, July					
18-44 years	1,068	1,068	8,275,977	1.29	692,162.0
45-64 years	5,126	5,126	6,867,325	7.46	570,847.9
65-74 years	6,917	6,917	7,531,837	9.18	621,198.9
75-84 years	4,875	4,875	4,208,469	11.58	344,073.0
≥ 85 years	1,822	1,822	1,547,024	11.78	126,923.9
2022, August					
18-44 years	1,202	1,202	8,312,068	1.45	691,956.6
45-64 years	5,481	5,481	6,865,498	7.98	569,648.5
65-74 years	7,757	7,757	7,547,902	10.28	621,835.5
75-84 years	5,190	5,190	4,231,109	12.27	345,580.6
≥ 85 years	1,868	1,868	1,550,080	12.05	127,096.0
2022, September					
18-44 years	864	864	5,804,982	1.49	470,027.4
45-64 years	4,306	4,306	5,109,876	8.43	410,908.6
65-74 years	7,241	7,241	7,413,293	9.77	592,049.4
75-84 years	5,072	5,072	4,220,648	12.02	334,261.5
≥ 85 years	1,806	1,806	1,542,160	11.71	122,589.2
2022, October					
18-44 years	670	670	5,134,203	1.30	429,654.8
45-64 years	2,723	2,723	3,762,103	7.24	312,905.4
65-74 years	979	979	1,183,649	8.27	97,591.1
75-84 years	543	543	552,453	9.83	45,279.3
≥ 85 years	172	172	187,020	9.20	15,351.9
2022, November					
18-44 years	167	167	1,548,848	1.08	125,997.8
45-64 years	771	771	1,031,759	7.47	83,221.7
65-74 years	410	410	659,484	6.22	52,781.0
75-84 years	228	228	318,059	7.17	25,260.5
≥ 85 years	61	61	97,766	6.24	7,771.9
2022, December					
18-44 years	151	151	1,559,288	0.97	131,024.9

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	777	777	1,036,512	7.50	86,341.2
65-74 years	396	396	661,461	5.99	54,696.3
75-84 years	195	195	319,763	6.10	26,251.4
≥ 85 years	60	60	97,917	6.13	8,057.2
New Use - All Censoring Options					
Any valsartan product					
2012, May					
18-44 years	582	582	8,329,327	0.70	682,864.3
45-64 years	2,255	2,255	7,305,629	3.09	599,815.7
65-74 years	2,231	2,231	4,505,222	4.95	367,569.0
75-84 years	1,628	1,628	2,750,256	5.92	224,760.7
≥ 85 years	725	725	1,364,911	5.31	111,962.3
2012, June					
18-44 years	549	549	8,404,778	0.65	662,181.5
45-64 years	2,025	2,025	7,353,202	2.75	581,548.1
65-74 years	2,009	2,009	4,532,877	4.43	356,570.9
75-84 years	1,510	1,510	2,752,791	5.49	217,613.1
≥ 85 years	607	607	1,366,577	4.44	108,428.4
2012, July					
18-44 years	505	505	8,399,342	0.60	684,215.9
45-64 years	2,004	2,004	7,297,781	2.75	600,528.4
65-74 years	2,069	2,069	4,538,048	4.56	370,644.1
75-84 years	1,422	1,422	2,750,954	5.17	225,352.6
≥ 85 years	624	624	1,367,363	4.56	112,369.0
2012, August					
18-44 years	553	553	8,424,636	0.66	685,979.8
45-64 years	2,044	2,044	7,321,558	2.79	601,295.9
65-74 years	2,078	2,078	4,567,013	4.55	371,801.6
75-84 years	1,424	1,424	2,760,687	5.16	225,626.6
≥ 85 years	595	595	1,373,224	4.33	112,602.9
2012, September					
18-44 years	479	479	8,428,571	0.57	664,792.9

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	1,794	1,794	7,335,138	2.45	582,794.4
65-74 years	1,859	1,859	4,578,884	4.06	361,244.4
75-84 years	1,302	1,302	2,760,164	4.72	218,568.0
≥ 85 years	543	543	1,374,268	3.95	109,202.4
2012, October					
18-44 years	577	577	8,378,083	0.69	689,632.5
45-64 years	2,292	2,292	7,326,786	3.13	603,154.7
65-74 years	2,461	2,461	4,600,671	5.35	374,916.0
75-84 years	1,590	1,590	2,768,302	5.74	226,170.3
≥ 85 years	677	677	1,379,022	4.91	113,098.9
2012, November					
18-44 years	579	579	8,351,641	0.69	667,913.3
45-64 years	2,334	2,334	7,315,318	3.19	584,519.1
65-74 years	2,264	2,264	4,607,793	4.91	364,211.2
75-84 years	1,600	1,600	2,761,508	5.79	219,089.6
≥ 85 years	602	602	1,375,463	4.38	109,529.3
2012, December					
18-44 years	495	495	8,920,839	0.55	691,665.1
45-64 years	2,074	2,074	7,742,079	2.68	605,753.5
65-74 years	2,154	2,154	5,047,452	4.27	378,802.5
75-84 years	1,364	1,364	2,957,179	4.61	226,938.8
≥ 85 years	612	612	1,452,652	4.21	113,275.3
2013, January					
18-44 years	616	616	8,322,726	0.74	685,061.0
45-64 years	2,347	2,347	7,345,235	3.20	604,995.7
65-74 years	2,606	2,606	4,822,366	5.40	392,524.1
75-84 years	1,753	1,753	2,858,633	6.13	233,474.1
≥ 85 years	741	741	1,418,911	5.22	116,328.4
2013, February					
18-44 years	514	514	8,145,675	0.63	616,774.1
45-64 years	2,206	2,206	7,238,454	3.05	545,378.5
65-74 years	2,292	2,292	4,756,867	4.82	355,483.0

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	1,551	1,551	2,838,125	5.46	210,827.8
≥ 85 years	630	630	1,403,197	4.49	104,567.3
2013, March					
18-44 years	534	534	8,164,170	0.65	683,020.1
45-64 years	2,222	2,222	7,261,602	3.06	604,477.0
65-74 years	2,125	2,125	4,792,235	4.43	395,218.6
75-84 years	1,456	1,456	2,853,380	5.10	233,679.5
≥ 85 years	622	622	1,408,731	4.42	115,758.9
2013, April					
18-44 years	505	505	8,134,035	0.62	659,172.4
45-64 years	2,192	2,192	7,253,578	3.02	584,725.7
65-74 years	2,285	2,285	4,799,751	4.76	383,258.9
75-84 years	1,492	1,492	2,851,892	5.23	226,106.4
≥ 85 years	600	600	1,405,028	4.27	111,822.0
2013, May					
18-44 years	439	439	8,139,231	0.54	681,322.6
45-64 years	1,994	1,994	7,255,694	2.75	604,304.7
65-74 years	2,067	2,067	4,808,827	4.30	396,660.6
75-84 years	1,375	1,375	2,851,931	4.82	233,530.2
≥ 85 years	514	514	1,405,829	3.66	115,530.8
2013, June					
18-44 years	441	441	8,143,809	0.54	659,788.5
45-64 years	1,768	1,768	7,259,898	2.44	585,389.7
65-74 years	1,721	1,721	4,815,745	3.57	384,784.1
75-84 years	1,238	1,238	2,851,729	4.34	226,138.3
≥ 85 years	476	476	1,408,140	3.38	112,031.4
2013, July					
18-44 years	469	469	8,158,469	0.57	683,101.4
45-64 years	2,065	2,065	7,288,086	2.83	607,359.2
65-74 years	1,844	1,844	4,845,395	3.81	400,148.6
75-84 years	1,301	1,301	2,859,802	4.55	234,393.2
≥ 85 years	547	547	1,412,502	3.87	116,206.4

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2013, August					
18-44 years	454	454	8,195,465	0.55	684,678.8
45-64 years	1,862	1,862	7,297,485	2.55	607,602.1
65-74 years	1,835	1,835	4,863,486	3.77	401,125.0
75-84 years	1,186	1,186	2,864,580	4.14	234,483.7
≥ 85 years	518	518	1,416,206	3.66	116,345.6
2013, September					
18-44 years	444	444	8,179,124	0.54	660,990.4
45-64 years	1,671	1,671	7,294,592	2.29	588,146.7
65-74 years	1,677	1,677	4,872,080	3.44	389,328.5
75-84 years	1,182	1,182	2,862,456	4.13	227,030.1
≥ 85 years	479	479	1,416,322	3.38	112,762.2
2013, October					
18-44 years	482	482	8,124,695	0.59	680,234.9
45-64 years	1,820	1,820	7,301,556	2.49	607,936.3
65-74 years	1,890	1,890	4,887,922	3.87	402,981.9
75-84 years	1,246	1,246	2,867,862	4.34	234,664.7
≥ 85 years	483	483	1,419,580	3.40	116,630.1
2013, November					
18-44 years	425	425	8,114,094	0.52	657,962.2
45-64 years	1,634	1,634	7,289,160	2.24	587,816.8
65-74 years	1,566	1,566	4,879,063	3.21	389,952.6
75-84 years	1,069	1,069	2,855,250	3.74	226,688.0
≥ 85 years	447	447	1,413,722	3.16	112,663.3
2013, December					
18-44 years	387	387	8,085,491	0.48	677,240.5
45-64 years	1,524	1,524	7,272,585	2.10	605,751.8
65-74 years	1,573	1,573	4,882,657	3.22	403,393.2
75-84 years	1,043	1,043	2,856,311	3.65	234,508.8
≥ 85 years	418	418	1,413,838	2.96	116,519.8
2014, January					
18-44 years	511	511	8,873,043	0.58	741,538.7

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	2,006	2,006	7,900,203	2.54	656,932.3
65-74 years	1,988	1,988	5,545,516	3.58	457,500.4
75-84 years	1,282	1,282	3,215,569	3.99	263,547.9
≥ 85 years	507	507	1,580,090	3.21	130,013.0
2014, February					
18-44 years	431	431	8,818,855	0.49	667,361.5
45-64 years	1,780	1,780	7,851,780	2.27	591,432.5
65-74 years	1,827	1,827	5,542,399	3.30	414,362.6
75-84 years	1,126	1,126	3,207,332	3.51	238,293.2
≥ 85 years	429	429	1,574,872	2.72	117,384.6
2014, March					
18-44 years	487	487	8,802,363	0.55	736,461.1
45-64 years	1,862	1,862	7,831,616	2.38	651,818.1
65-74 years	1,829	1,829	5,571,276	3.28	459,863.6
75-84 years	1,219	1,219	3,222,359	3.78	264,103.8
≥ 85 years	459	459	1,582,192	2.90	130,119.2
2014, April					
18-44 years	417	417	8,765,869	0.48	709,814.9
45-64 years	1,604	1,604	7,795,435	2.06	627,853.6
65-74 years	1,719	1,719	5,589,363	3.08	446,165.2
75-84 years	1,173	1,173	3,231,998	3.63	256,089.1
≥ 85 years	427	427	1,585,249	2.69	126,072.7
2014, May					
18-44 years	395	395	8,749,273	0.45	731,766.3
45-64 years	1,505	1,505	7,764,368	1.94	646,073.5
65-74 years	1,478	1,478	5,587,162	2.65	460,651.8
75-84 years	937	937	3,229,002	2.90	264,242.1
≥ 85 years	410	410	1,583,612	2.59	130,070.1
2014, June					
18-44 years	358	358	8,730,043	0.41	706,897.1
45-64 years	1,361	1,361	7,741,531	1.76	623,713.6
65-74 years	1,440	1,440	5,586,898	2.58	446,226.9

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	897	897	3,222,856	2.78	255,453.3
≥ 85 years	382	382	1,580,445	2.42	125,715.9
2014, July					
18-44 years	379	379	8,808,988	0.43	736,882.4
45-64 years	1,554	1,554	7,801,603	1.99	649,435.5
65-74 years	1,416	1,416	5,608,211	2.52	462,840.2
75-84 years	904	904	3,220,677	2.81	263,713.7
≥ 85 years	428	428	1,579,358	2.71	129,769.4
2014, August					
18-44 years	391	391	8,772,603	0.45	733,168.1
45-64 years	1,535	1,535	7,757,144	1.98	645,470.1
65-74 years	1,522	1,522	5,625,046	2.71	464,013.1
75-84 years	938	938	3,224,105	2.91	263,841.1
≥ 85 years	438	438	1,580,713	2.77	129,850.4
2014, September					
18-44 years	388	388	8,745,204	0.44	708,083.1
45-64 years	1,628	1,628	7,736,029	2.10	623,272.4
65-74 years	1,621	1,621	5,633,159	2.88	449,972.3
75-84 years	1,017	1,017	3,223,453	3.16	255,525.9
≥ 85 years	417	417	1,579,481	2.64	125,719.2
2014, October					
18-44 years	486	486	8,761,627	0.55	732,939.9
45-64 years	1,867	1,867	7,735,896	2.41	643,421.6
65-74 years	1,758	1,758	5,654,698	3.11	465,850.6
75-84 years	1,079	1,079	3,233,821	3.34	264,371.8
≥ 85 years	465	465	1,583,791	2.94	129,971.7
2014, November					
18-44 years	407	407	8,731,463	0.47	707,933.4
45-64 years	1,614	1,614	7,711,217	2.09	621,733.1
65-74 years	1,515	1,515	5,644,276	2.68	451,285.4
75-84 years	950	950	3,223,374	2.95	255,976.1
≥ 85 years	402	402	1,577,735	2.55	125,727.4

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2014, December					
18-44 years	431	431	8,734,837	0.49	730,143.2
45-64 years	1,743	1,743	7,710,752	2.26	640,567.1
65-74 years	1,707	1,707	5,651,163	3.02	466,025.3
75-84 years	1,131	1,131	3,224,160	3.51	264,089.6
≥ 85 years	413	413	1,575,314	2.62	129,615.4
2015, January					
18-44 years	542	542	9,100,485	0.60	760,792.1
45-64 years	2,072	2,072	8,007,202	2.59	665,831.6
65-74 years	2,142	2,142	5,868,721	3.65	483,963.7
75-84 years	1,280	1,280	3,292,199	3.89	269,596.7
≥ 85 years	474	474	1,594,791	2.97	131,082.6
2015, February					
18-44 years	502	502	9,063,819	0.55	685,659.9
45-64 years	2,054	2,054	7,989,169	2.57	601,197.9
65-74 years	2,083	2,083	5,866,920	3.55	437,898.9
75-84 years	1,261	1,261	3,281,608	3.84	243,274.0
≥ 85 years	525	525	1,581,755	3.32	117,699.3
2015, March					
18-44 years	605	605	9,077,269	0.67	759,212.7
45-64 years	2,253	2,253	8,010,566	2.81	666,302.7
65-74 years	2,347	2,347	5,892,685	3.98	485,998.5
75-84 years	1,462	1,462	3,295,268	4.44	269,743.1
≥ 85 years	573	573	1,585,806	3.61	130,257.5
2015, April					
18-44 years	499	499	9,116,083	0.55	738,134.8
45-64 years	2,130	2,130	8,042,440	2.65	647,554.4
65-74 years	2,160	2,160	5,896,978	3.66	470,567.9
75-84 years	1,396	1,396	3,294,757	4.24	260,864.5
≥ 85 years	554	554	1,582,941	3.50	125,779.5
2015, May					
18-44 years	502	502	9,152,851	0.55	765,592.9

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	2,045	2,045	8,078,376	2.53	672,035.5
65-74 years	1,948	1,948	5,905,892	3.30	486,804.4
75-84 years	1,253	1,253	3,293,919	3.80	269,309.6
≥ 85 years	467	467	1,580,037	2.96	129,709.6
2015, June					
18-44 years	482	482	9,161,169	0.53	741,683.5
45-64 years	2,091	2,091	8,082,207	2.59	650,902.1
65-74 years	2,010	2,010	5,911,711	3.40	471,756.4
75-84 years	1,321	1,321	3,290,653	4.01	260,580.3
≥ 85 years	518	518	1,578,733	3.28	125,453.2
2015, July					
18-44 years	521	521	9,152,724	0.57	765,582.3
45-64 years	2,100	2,100	8,077,598	2.60	672,209.9
65-74 years	2,044	2,044	5,939,320	3.44	490,002.6
75-84 years	1,259	1,259	3,295,958	3.82	269,681.9
≥ 85 years	502	502	1,581,088	3.18	129,871.9
2015, August					
18-44 years	489	489	9,163,735	0.53	766,075.8
45-64 years	1,958	1,958	8,073,804	2.43	671,915.1
65-74 years	2,086	2,086	5,958,804	3.50	491,718.1
75-84 years	1,175	1,175	3,303,045	3.56	270,322.9
≥ 85 years	417	417	1,583,743	2.63	130,124.1
2015, September					
18-44 years	514	514	9,174,232	0.56	742,727.8
45-64 years	2,104	2,104	8,082,378	2.60	650,886.0
65-74 years	2,168	2,168	5,977,252	3.63	477,286.2
75-84 years	1,357	1,357	3,306,502	4.10	261,888.9
≥ 85 years	495	495	1,584,965	3.12	126,032.3
2015, October					
18-44 years	587	587	9,165,264	0.64	766,244.5
45-64 years	2,149	2,149	8,092,331	2.66	672,270.2
65-74 years	2,501	2,501	6,004,392	4.17	494,397.7

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	1,422	1,422	3,316,179	4.29	270,878.6
≥ 85 years	528	528	1,589,242	3.32	130,309.4
2015, November					
18-44 years	538	538	9,137,229	0.59	740,198.0
45-64 years	2,082	2,082	8,070,264	2.58	649,941.5
65-74 years	2,396	2,396	5,992,141	4.00	478,783.1
75-84 years	1,394	1,394	3,303,891	4.22	262,051.3
≥ 85 years	525	525	1,581,676	3.32	125,959.8
2015, December					
18-44 years	599	599	9,140,219	0.66	764,457.6
45-64 years	2,363	2,363	8,076,025	2.93	670,867.3
65-74 years	2,526	2,526	6,006,218	4.21	494,992.0
75-84 years	1,643	1,643	3,311,457	4.96	270,924.6
≥ 85 years	564	564	1,583,322	3.56	130,102.7
2016, January					
18-44 years	622	622	9,176,220	0.68	766,940.8
45-64 years	2,637	2,637	8,154,456	3.23	677,817.0
65-74 years	3,400	3,400	6,221,672	5.46	512,641.8
75-84 years	1,857	1,857	3,373,232	5.51	275,891.9
≥ 85 years	675	675	1,604,515	4.21	131,756.6
2016, February					
18-44 years	693	693	9,325,950	0.74	716,442.5
45-64 years	2,743	2,743	8,268,075	3.32	633,641.7
65-74 years	3,348	3,348	6,301,064	5.31	480,773.8
75-84 years	1,977	1,977	3,379,993	5.85	258,569.1
≥ 85 years	696	696	1,603,408	4.34	123,145.8
2016, March					
18-44 years	717	717	9,344,110	0.77	768,020.0
45-64 years	2,961	2,961	8,274,584	3.58	679,504.0
65-74 years	3,574	3,574	6,327,246	5.65	514,900.1
75-84 years	2,069	2,069	3,395,108	6.09	276,652.7
≥ 85 years	757	757	1,607,208	4.71	131,501.3

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2016, April					
18-44 years	696	696	9,362,785	0.74	742,641.0
45-64 years	2,627	2,627	8,254,230	3.18	656,554.2
65-74 years	3,262	3,262	6,323,795	5.16	498,574.7
75-84 years	1,984	1,984	3,394,424	5.84	267,926.7
≥ 85 years	681	681	1,603,015	4.25	127,074.2
2016, May					
18-44 years	639	639	9,372,241	0.68	770,240.4
45-64 years	2,563	2,563	8,239,478	3.11	677,617.1
65-74 years	3,211	3,211	6,326,026	5.08	515,252.6
75-84 years	1,966	1,966	3,397,631	5.79	276,939.5
≥ 85 years	689	689	1,602,141	4.30	131,096.2
2016, June					
18-44 years	609	609	9,420,958	0.65	744,840.9
45-64 years	2,463	2,463	8,267,083	2.98	655,097.1
65-74 years	3,147	3,147	6,364,931	4.94	499,766.6
75-84 years	1,911	1,911	3,408,541	5.61	268,679.1
≥ 85 years	638	638	1,603,035	3.98	126,988.7
2016, July					
18-44 years	541	541	9,439,126	0.57	769,754.8
45-64 years	2,294	2,294	8,213,249	2.79	676,374.3
65-74 years	2,790	2,790	6,368,804	4.38	518,935.5
75-84 years	1,661	1,661	3,414,091	4.87	278,679.6
≥ 85 years	643	643	1,603,410	4.01	131,421.0
2016, August					
18-44 years	649	649	9,416,905	0.69	768,495.9
45-64 years	2,688	2,688	8,230,288	3.27	676,076.8
65-74 years	3,136	3,136	6,392,801	4.91	520,221.7
75-84 years	1,798	1,798	3,428,500	5.24	279,500.5
≥ 85 years	687	687	1,607,526	4.27	131,592.9
2016, September					
18-44 years	605	605	9,434,469	0.64	745,800.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	2,613	2,613	8,255,250	3.17	654,223.6
65-74 years	3,062	3,062	6,404,820	4.78	504,824.0
75-84 years	1,819	1,819	3,431,581	5.30	271,030.1
≥ 85 years	689	689	1,607,962	4.28	127,543.9
2016, October					
18-44 years	695	695	9,379,269	0.74	772,388.8
45-64 years	2,808	2,808	8,226,366	3.41	676,925.0
65-74 years	3,246	3,246	6,420,451	5.06	523,389.4
75-84 years	1,887	1,887	3,440,101	5.49	280,707.2
≥ 85 years	714	714	1,610,263	4.43	131,901.2
2016, November					
18-44 years	626	626	9,441,046	0.66	748,248.7
45-64 years	2,838	2,838	8,261,933	3.44	655,041.0
65-74 years	3,493	3,493	6,415,440	5.44	507,212.7
75-84 years	2,093	2,093	3,436,159	6.09	271,907.7
≥ 85 years	714	714	1,604,218	4.45	127,480.0
2016, December					
18-44 years	658	658	10,696,088	0.62	779,225.6
45-64 years	2,784	2,784	9,195,836	3.03	680,330.7
65-74 years	3,557	3,557	6,843,153	5.20	525,344.6
75-84 years	2,216	2,216	3,586,282	6.18	281,504.8
≥ 85 years	783	783	1,654,234	4.73	131,663.4
2017, January					
18-44 years	747	747	9,465,272	0.79	778,709.6
45-64 years	3,091	3,091	8,204,900	3.77	674,527.8
65-74 years	4,177	4,177	6,500,557	6.43	529,619.9
75-84 years	2,327	2,327	3,438,853	6.77	280,643.2
≥ 85 years	809	809	1,587,598	5.10	130,169.8
2017, February					
18-44 years	707	707	9,297,604	0.76	702,997.8
45-64 years	3,021	3,021	8,086,799	3.74	607,838.7
65-74 years	3,896	3,896	6,406,324	6.08	477,952.7

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	2,338	2,338	3,417,742	6.84	253,278.0
≥ 85 years	818	818	1,571,365	5.21	116,884.8
2017, March					
18-44 years	824	824	9,327,787	0.88	779,701.9
45-64 years	3,338	3,338	8,104,819	4.12	672,990.1
65-74 years	4,203	4,203	6,434,056	6.53	529,769.8
75-84 years	2,660	2,660	3,434,437	7.75	280,607.8
≥ 85 years	912	912	1,573,762	5.80	129,133.4
2017, April					
18-44 years	671	671	9,326,910	0.72	755,106.4
45-64 years	2,859	2,859	8,085,974	3.54	650,435.5
65-74 years	3,765	3,765	6,423,129	5.86	512,293.3
75-84 years	2,174	2,174	3,430,625	6.34	271,479.6
≥ 85 years	801	801	1,565,479	5.12	124,437.5
2017, May					
18-44 years	747	747	9,336,398	0.80	780,617.5
45-64 years	3,158	3,158	8,076,349	3.91	671,067.2
65-74 years	3,969	3,969	6,422,364	6.18	528,959.7
75-84 years	2,460	2,460	3,432,128	7.17	280,357.2
≥ 85 years	847	847	1,563,077	5.42	128,229.1
2017, June					
18-44 years	727	727	9,345,343	0.78	756,404.8
45-64 years	3,057	3,057	8,068,837	3.79	649,248.4
65-74 years	3,595	3,595	6,422,885	5.60	512,443.4
75-84 years	2,200	2,200	3,429,840	6.41	271,504.4
≥ 85 years	772	772	1,560,248	4.95	124,008.1
2017, July					
18-44 years	637	637	9,337,822	0.68	781,072.6
45-64 years	2,597	2,597	8,044,798	3.23	669,442.6
65-74 years	3,128	3,128	6,446,061	4.85	532,384.2
75-84 years	1,952	1,952	3,436,709	5.68	281,599.0
≥ 85 years	741	741	1,560,250	4.75	128,333.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2017, August					
18-44 years	752	752	9,376,293	0.80	783,090.6
45-64 years	2,819	2,819	8,060,365	3.50	669,667.2
65-74 years	3,627	3,627	6,471,392	5.60	533,061.2
75-84 years	2,284	2,284	3,453,887	6.61	282,074.7
≥ 85 years	781	781	1,563,923	4.99	128,326.4
2017, September					
18-44 years	644	644	9,398,518	0.69	760,080.2
45-64 years	2,644	2,644	8,051,607	3.28	647,905.5
65-74 years	3,222	3,222	6,476,558	4.97	517,010.7
75-84 years	1,951	1,951	3,459,174	5.64	273,778.4
≥ 85 years	724	724	1,562,059	4.63	124,242.4
2017, October					
18-44 years	765	765	9,430,536	0.81	788,601.3
45-64 years	3,044	3,044	8,066,894	3.77	670,379.2
65-74 years	3,696	3,696	6,493,201	5.69	534,771.5
75-84 years	2,193	2,193	3,476,501	6.31	283,848.0
≥ 85 years	734	734	1,564,101	4.69	128,407.4
2017, November					
18-44 years	746	746	9,433,265	0.79	764,020.6
45-64 years	3,095	3,095	8,056,501	3.84	648,394.3
65-74 years	3,886	3,886	6,477,550	6.00	517,049.0
75-84 years	2,253	2,253	3,478,149	6.48	275,452.3
≥ 85 years	829	829	1,558,806	5.32	124,119.9
2017, December					
18-44 years	763	763	9,488,685	0.80	793,772.1
45-64 years	3,079	3,079	8,091,437	3.81	671,845.8
65-74 years	3,713	3,713	6,478,341	5.73	533,599.4
75-84 years	2,299	2,299	3,492,434	6.58	285,540.1
≥ 85 years	838	838	1,558,251	5.38	128,135.1
2018, January					
18-44 years	882	882	9,387,361	0.94	784,459.3

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	3,574	3,574	7,953,725	4.49	660,373.1
65-74 years	4,637	4,637	6,576,139	7.05	541,336.0
75-84 years	2,769	2,769	3,513,732	7.88	286,989.0
≥ 85 years	971	971	1,558,715	6.23	128,000.2
2018, February					
18-44 years	854	854	9,358,498	0.91	707,598.9
45-64 years	3,352	3,352	7,920,293	4.23	595,218.7
65-74 years	4,531	4,531	6,559,008	6.91	489,306.8
75-84 years	2,646	2,646	3,507,213	7.54	259,830.9
≥ 85 years	970	970	1,544,201	6.28	114,931.1
2018, March					
18-44 years	959	959	9,368,243	1.02	783,364.6
45-64 years	3,702	3,702	7,928,618	4.67	658,371.8
65-74 years	4,803	4,803	6,589,258	7.29	542,389.4
75-84 years	3,033	3,033	3,533,830	8.58	288,513.7
≥ 85 years	1,000	1,000	1,548,219	6.46	127,016.3
2018, April					
18-44 years	905	905	9,339,102	0.97	756,258.4
45-64 years	3,530	3,530	7,895,979	4.47	635,129.2
65-74 years	4,517	4,517	6,580,285	6.86	524,761.3
75-84 years	2,877	2,877	3,536,432	8.14	279,729.1
≥ 85 years	987	987	1,543,453	6.39	122,656.0
2018, May					
18-44 years	886	886	9,334,074	0.95	780,477.6
45-64 years	3,558	3,558	7,873,220	4.52	654,078.4
65-74 years	4,527	4,527	6,573,697	6.89	541,278.8
75-84 years	2,895	2,895	3,541,350	8.17	289,181.6
≥ 85 years	929	929	1,540,857	6.03	126,439.6
2018, June					
18-44 years	805	805	9,329,819	0.86	755,163.3
45-64 years	3,311	3,311	7,857,567	4.21	632,018.0
65-74 years	3,991	3,991	6,571,993	6.07	524,245.7

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	2,491	2,491	3,543,087	7.03	280,326.5
≥ 85 years	906	906	1,537,477	5.89	122,226.9
2018, July					
18-44 years	400	400	9,299,490	0.43	777,751.2
45-64 years	1,825	1,825	7,822,285	2.33	650,604.9
65-74 years	2,203	2,203	6,594,504	3.34	544,465.1
75-84 years	1,477	1,477	3,549,698	4.16	290,750.7
≥ 85 years	514	514	1,536,578	3.35	126,382.2
2018, August					
18-44 years	152	152	9,316,964	0.16	778,634.6
45-64 years	752	752	7,823,740	0.96	649,989.6
65-74 years	937	937	6,621,705	1.42	545,547.4
75-84 years	636	636	3,569,323	1.78	291,613.1
≥ 85 years	232	232	1,539,475	1.51	126,384.8
2018, September					
18-44 years	166	166	9,311,506	0.18	753,685.1
45-64 years	724	724	7,811,887	0.93	628,619.7
65-74 years	835	835	6,628,459	1.26	529,311.1
75-84 years	676	676	3,573,287	1.89	283,103.7
≥ 85 years	227	227	1,536,737	1.48	122,298.9
2018, October					
18-44 years	248	248	9,305,628	0.27	777,790.0
45-64 years	1,075	1,075	7,810,671	1.38	648,558.6
65-74 years	1,353	1,353	6,655,857	2.03	547,967.1
75-84 years	915	915	3,594,196	2.55	293,494.1
≥ 85 years	357	357	1,540,093	2.32	126,339.1
2018, November					
18-44 years	316	316	9,309,494	0.34	753,878.4
45-64 years	1,358	1,358	7,800,785	1.74	627,690.9
65-74 years	1,810	1,810	6,649,127	2.72	530,961.9
75-84 years	1,161	1,161	3,590,756	3.23	284,635.0
≥ 85 years	406	406	1,534,095	2.65	122,121.3

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2018, December					
18-44 years	267	267	9,323,750	0.29	779,965.7
45-64 years	1,228	1,228	7,810,831	1.57	648,735.9
65-74 years	1,620	1,620	6,662,134	2.43	549,412.8
75-84 years	1,083	1,083	3,599,825	3.01	294,826.3
≥ 85 years	360	360	1,532,691	2.35	126,089.1
2019, January					
18-44 years	364	364	9,161,315	0.40	765,578.7
45-64 years	1,901	1,901	7,679,078	2.48	637,514.8
65-74 years	2,581	2,581	6,682,391	3.86	550,152.1
75-84 years	1,770	1,770	3,583,947	4.94	292,828.0
≥ 85 years	599	599	1,520,016	3.94	124,747.0
2019, February					
18-44 years	439	439	9,127,310	0.48	690,495.3
45-64 years	2,059	2,059	7,640,253	2.69	574,374.2
65-74 years	2,871	2,871	6,666,836	4.31	497,681.8
75-84 years	1,958	1,958	3,571,955	5.48	264,725.7
≥ 85 years	720	720	1,509,718	4.77	112,368.2
2019, March					
18-44 years	674	674	9,134,562	0.74	763,777.9
45-64 years	3,555	3,555	7,642,005	4.65	634,532.1
65-74 years	5,512	5,512	6,693,440	8.23	551,251.2
75-84 years	3,619	3,619	3,589,367	10.08	293,352.4
≥ 85 years	1,169	1,169	1,512,749	7.73	124,147.8
2019, April					
18-44 years	705	705	9,114,225	0.77	737,660.4
45-64 years	3,539	3,539	7,606,045	4.65	611,331.1
65-74 years	5,087	5,087	6,678,869	7.62	532,307.7
75-84 years	3,458	3,458	3,582,472	9.65	283,268.4
≥ 85 years	1,209	1,209	1,505,107	8.03	119,531.8
2019, May					
18-44 years	750	750	9,106,433	0.82	761,432.7

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	3,585	3,585	7,577,167	4.73	629,289.8
65-74 years	5,432	5,432	6,671,015	8.14	549,197.8
75-84 years	3,429	3,429	3,578,709	9.58	292,207.2
≥ 85 years	1,110	1,110	1,501,690	7.39	123,129.9
2019, June					
18-44 years	556	556	9,091,191	0.61	735,943.4
45-64 years	2,672	2,672	7,550,932	3.54	607,217.9
65-74 years	3,803	3,803	6,667,557	5.70	531,771.2
75-84 years	2,555	2,555	3,574,461	7.15	282,733.5
≥ 85 years	868	868	1,497,410	5.80	118,934.0
2019, July					
18-44 years	618	618	9,093,784	0.68	760,336.3
45-64 years	2,876	2,876	7,545,305	3.81	626,651.7
65-74 years	3,948	3,948	6,708,925	5.88	552,461.0
75-84 years	2,637	2,637	3,590,758	7.34	293,017.9
≥ 85 years	851	851	1,501,937	5.67	123,043.9
2019, August					
18-44 years	670	670	9,104,228	0.74	760,648.5
45-64 years	3,082	3,082	7,550,890	4.08	626,465.0
65-74 years	4,102	4,102	6,764,246	6.06	555,905.7
75-84 years	2,669	2,669	3,624,462	7.36	295,080.9
≥ 85 years	825	825	1,515,520	5.44	123,844.9
2019, September					
18-44 years	694	694	9,104,058	0.76	736,443.3
45-64 years	3,440	3,440	7,549,377	4.56	606,552.3
65-74 years	4,859	4,859	6,797,852	7.15	541,598.8
75-84 years	3,101	3,101	3,640,400	8.52	287,547.1
≥ 85 years	1,024	1,024	1,521,526	6.73	120,626.7
2019, October					
18-44 years	1,027	1,027	9,103,174	1.13	760,995.9
45-64 years	5,173	5,173	7,544,021	6.86	625,912.1
65-74 years	7,921	7,921	6,835,746	11.59	561,844.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	4,978	4,978	3,663,199	13.59	298,389.2
≥ 85 years	1,552	1,552	1,530,415	10.14	125,173.0
2019, November					
18-44 years	758	758	9,098,398	0.83	736,811.2
45-64 years	3,665	3,665	7,529,419	4.87	605,472.5
65-74 years	5,404	5,404	6,832,195	7.91	544,975.2
75-84 years	3,350	3,350	3,657,228	9.16	289,427.7
≥ 85 years	1,130	1,130	1,524,919	7.41	121,222.2
2019, December					
18-44 years	650	650	9,116,903	0.71	762,942.3
45-64 years	2,986	2,986	7,539,345	3.96	626,143.0
65-74 years	4,417	4,417	6,843,823	6.45	564,266.9
75-84 years	2,745	2,745	3,664,849	7.49	300,005.1
≥ 85 years	848	848	1,523,821	5.56	125,279.4
2020, January					
18-44 years	723	723	8,986,565	0.80	750,177.3
45-64 years	3,255	3,255	7,419,092	4.39	615,155.2
65-74 years	4,605	4,605	6,943,046	6.63	571,609.0
75-84 years	2,944	2,944	3,694,576	7.97	301,786.5
≥ 85 years	1,000	1,000	1,531,007	6.53	125,584.1
2020, February					
18-44 years	651	651	9,071,381	0.72	700,718.4
45-64 years	2,960	2,960	7,445,927	3.98	573,688.0
65-74 years	4,029	4,029	7,016,205	5.74	535,429.0
75-84 years	2,555	2,555	3,692,891	6.92	282,351.5
≥ 85 years	883	883	1,526,710	5.78	117,184.0
2020, March					
18-44 years	698	698	9,091,245	0.77	749,252.8
45-64 years	3,192	3,192	7,443,084	4.29	612,338.0
65-74 years	4,348	4,348	7,038,015	6.18	573,844.3
75-84 years	2,705	2,705	3,705,390	7.30	302,588.6
≥ 85 years	916	916	1,528,183	5.99	125,321.2

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2020, April					
18-44 years	474	474	9,075,730	0.52	726,257.5
45-64 years	2,357	2,357	7,447,973	3.16	596,019.5
65-74 years	3,274	3,274	7,116,965	4.60	565,709.8
75-84 years	1,950	1,950	3,753,814	5.19	299,100.1
≥ 85 years	687	687	1,542,992	4.45	123,278.3
2020, May					
18-44 years	420	420	9,153,112	0.46	754,807.9
45-64 years	1,892	1,892	7,534,461	2.51	620,845.8
65-74 years	2,709	2,709	7,279,402	3.72	595,417.9
75-84 years	1,719	1,719	3,847,805	4.47	315,325.6
≥ 85 years	602	602	1,566,846	3.84	128,841.7
2020, June					
18-44 years	440	440	9,255,133	0.48	734,398.8
45-64 years	2,152	2,152	7,603,031	2.83	603,554.3
65-74 years	3,127	3,127	7,398,245	4.23	582,246.5
75-84 years	2,005	2,005	3,904,985	5.13	308,490.5
≥ 85 years	622	622	1,582,906	3.93	125,584.1
2020, July					
18-44 years	482	482	9,296,333	0.52	759,505.8
45-64 years	2,144	2,144	7,569,687	2.83	623,177.2
65-74 years	2,958	2,958	7,442,197	3.97	605,983.6
75-84 years	1,962	1,962	3,929,093	4.99	320,597.1
≥ 85 years	660	660	1,592,773	4.14	130,397.3
2020, August					
18-44 years	447	447	9,274,591	0.48	759,954.0
45-64 years	1,875	1,875	7,584,827	2.47	623,450.5
65-74 years	2,649	2,649	7,486,130	3.54	609,643.9
75-84 years	1,727	1,727	3,952,317	4.37	322,487.8
≥ 85 years	576	576	1,600,407	3.60	131,064.2
2020, September					
18-44 years	487	487	9,216,988	0.53	731,132.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	2,027	2,027	7,579,894	2.67	601,394.4
65-74 years	2,767	2,767	7,532,777	3.67	593,688.2
75-84 years	1,802	1,802	3,976,933	4.53	313,814.3
≥ 85 years	609	609	1,608,651	3.79	127,349.6
2020, October					
18-44 years	532	532	9,193,389	0.58	758,328.2
45-64 years	2,236	2,236	7,560,762	2.96	622,065.4
65-74 years	3,146	3,146	7,579,235	4.15	617,078.1
75-84 years	2,030	2,030	4,007,653	5.07	326,201.6
≥ 85 years	601	601	1,619,843	3.71	132,289.5
2020, November					
18-44 years	485	485	9,221,551	0.53	736,146.4
45-64 years	2,083	2,083	7,576,294	2.75	603,408.4
65-74 years	3,054	3,054	7,591,709	4.02	600,886.9
75-84 years	1,873	1,873	4,014,004	4.67	317,684.8
≥ 85 years	679	679	1,618,484	4.20	128,506.9
2020, December					
18-44 years	519	519	10,266,951	0.51	766,557.8
45-64 years	2,181	2,181	8,310,148	2.62	627,494.4
65-74 years	3,426	3,426	8,266,284	4.14	626,506.4
75-84 years	2,196	2,196	4,270,577	5.14	331,256.6
≥ 85 years	658	658	1,690,033	3.89	133,377.8
2021, January					
18-44 years	617	617	9,381,782	0.66	774,388.3
45-64 years	2,435	2,435	7,681,319	3.17	631,759.7
65-74 years	3,597	3,597	7,813,588	4.60	636,682.1
75-84 years	2,288	2,288	4,087,162	5.60	333,054.3
≥ 85 years	673	673	1,630,032	4.13	133,166.2
2021, February					
18-44 years	582	582	9,266,325	0.63	701,085.7
45-64 years	2,444	2,444	7,618,091	3.21	572,102.6
65-74 years	3,678	3,678	7,767,637	4.74	579,119.9

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	2,274	2,274	4,095,961	5.55	303,099.6
≥ 85 years	728	728	1,625,260	4.48	120,492.0
2021, March					
18-44 years	725	725	9,285,032	0.78	775,880.4
45-64 years	3,187	3,187	7,615,217	4.19	633,341.8
65-74 years	4,783	4,783	7,788,382	6.14	644,333.6
75-84 years	3,013	3,013	4,105,542	7.34	337,071.1
≥ 85 years	980	980	1,624,887	6.03	133,840.6
2021, April					
18-44 years	635	635	9,198,813	0.69	747,142.5
45-64 years	2,811	2,811	7,503,958	3.75	606,601.7
65-74 years	4,471	4,471	7,653,776	5.84	615,297.6
75-84 years	2,966	2,966	4,019,707	7.38	320,934.3
≥ 85 years	1,018	1,018	1,589,183	6.41	127,249.5
2021, May					
18-44 years	577	577	9,115,108	0.63	764,156.7
45-64 years	2,538	2,538	7,425,492	3.42	618,811.4
65-74 years	4,113	4,113	7,574,271	5.43	626,529.8
75-84 years	2,732	2,732	3,973,145	6.88	326,183.1
≥ 85 years	901	901	1,566,545	5.75	129,086.8
2021, June					
18-44 years	605	605	9,041,948	0.67	732,740.0
45-64 years	2,671	2,671	7,376,671	3.62	593,778.0
65-74 years	4,160	4,160	7,550,472	5.51	602,799.3
75-84 years	2,841	2,841	3,963,138	7.17	313,731.2
≥ 85 years	926	926	1,557,573	5.95	123,794.7
2021, July					
18-44 years	530	530	8,967,153	0.59	750,666.3
45-64 years	2,387	2,387	7,327,814	3.26	609,483.9
65-74 years	3,860	3,860	7,544,687	5.12	622,559.1
75-84 years	2,608	2,608	3,961,147	6.58	323,919.2
≥ 85 years	894	894	1,551,474	5.76	127,422.0

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2021, August					
18-44 years	581	581	8,909,004	0.65	745,325.0
45-64 years	2,559	2,559	7,284,973	3.51	605,863.0
65-74 years	3,845	3,845	7,525,967	5.11	620,847.1
75-84 years	2,393	2,393	3,961,798	6.04	323,914.0
≥ 85 years	789	789	1,544,622	5.11	126,949.3
2021, September					
18-44 years	602	602	8,847,418	0.68	717,025.6
45-64 years	2,437	2,437	7,237,552	3.37	582,823.8
65-74 years	3,724	3,724	7,501,646	4.96	599,218.2
75-84 years	2,423	2,423	3,965,841	6.11	313,937.1
≥ 85 years	849	849	1,538,410	5.52	122,428.6
2021, October					
18-44 years	585	585	8,794,893	0.67	736,254.9
45-64 years	2,586	2,586	7,203,055	3.59	598,713.7
65-74 years	3,942	3,942	7,494,173	5.26	617,300.0
75-84 years	2,596	2,596	3,985,400	6.51	325,267.5
≥ 85 years	859	859	1,536,519	5.59	126,135.6
2021, November					
18-44 years	582	582	8,749,707	0.67	709,574.0
45-64 years	2,455	2,455	7,166,680	3.43	577,315.4
65-74 years	3,922	3,922	7,450,141	5.26	595,085.3
75-84 years	2,563	2,563	3,983,058	6.43	315,559.0
≥ 85 years	832	832	1,525,584	5.45	121,572.5
2021, December					
18-44 years	582	582	8,726,561	0.67	731,479.7
45-64 years	2,579	2,579	7,148,818	3.61	594,707.4
65-74 years	4,073	4,073	7,410,326	5.50	611,479.6
75-84 years	2,722	2,722	3,989,359	6.82	326,659.5
≥ 85 years	1,008	1,008	1,516,694	6.65	124,887.6
2022, January					
18-44 years	753	753	8,405,657	0.90	704,233.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	3,512	3,512	6,903,167	5.09	574,917.4
65-74 years	5,856	5,856	7,387,245	7.93	610,225.5
75-84 years	3,934	3,934	3,976,033	9.89	325,808.2
≥ 85 years	1,318	1,318	1,506,037	8.75	124,037.0
2022, February					
18-44 years	804	804	8,354,858	0.96	633,167.4
45-64 years	3,636	3,636	6,858,065	5.30	516,498.6
65-74 years	5,472	5,472	7,339,629	7.46	548,666.7
75-84 years	3,669	3,669	3,967,052	9.25	294,417.5
≥ 85 years	1,233	1,233	1,487,972	8.29	110,911.9
2022, March					
18-44 years	910	910	8,348,025	1.09	698,776.1
45-64 years	3,813	3,813	6,854,139	5.56	569,691.2
65-74 years	5,578	5,578	7,343,435	7.60	605,072.7
75-84 years	3,868	3,868	3,997,679	9.68	326,485.5
≥ 85 years	1,233	1,233	1,490,394	8.27	122,294.0
2022, April					
18-44 years	592	592	8,319,160	0.71	673,996.5
45-64 years	2,637	2,637	6,821,708	3.87	548,979.9
65-74 years	4,028	4,028	7,312,574	5.51	583,457.2
75-84 years	2,844	2,844	4,001,061	7.11	316,617.2
≥ 85 years	992	992	1,487,127	6.67	118,147.3
2022, May					
18-44 years	558	558	8,297,817	0.67	694,342.1
45-64 years	2,531	2,531	6,800,127	3.72	565,194.3
65-74 years	3,841	3,841	7,307,195	5.26	601,951.0
75-84 years	2,766	2,766	4,018,998	6.88	328,244.6
≥ 85 years	898	898	1,488,802	6.03	122,114.2
2022, June					
18-44 years	565	565	8,301,014	0.68	672,081.1
45-64 years	2,405	2,405	6,790,708	3.54	546,268.5
65-74 years	3,776	3,776	7,299,152	5.17	582,116.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	2,650	2,650	4,035,098	6.57	319,045.3
≥ 85 years	917	917	1,488,728	6.16	118,208.8
2022, July					
18-44 years	502	502	8,257,152	0.61	690,577.0
45-64 years	2,189	2,189	6,750,560	3.24	561,064.2
65-74 years	3,110	3,110	7,308,368	4.26	602,661.4
75-84 years	2,323	2,323	4,052,524	5.73	331,231.0
≥ 85 years	851	851	1,492,092	5.70	122,386.5
2022, August					
18-44 years	580	580	8,293,145	0.70	690,359.8
45-64 years	2,415	2,415	6,748,244	3.58	559,828.4
65-74 years	3,612	3,612	7,323,261	4.93	603,207.0
75-84 years	2,500	2,500	4,073,678	6.14	332,617.5
≥ 85 years	865	865	1,494,610	5.79	122,512.4
2022, September					
18-44 years	406	406	5,790,783	0.70	468,869.4
45-64 years	1,892	1,892	5,017,361	3.77	403,404.3
65-74 years	3,397	3,397	7,191,411	4.72	574,223.2
75-84 years	2,411	2,411	4,062,772	5.93	321,673.4
≥ 85 years	800	800	1,486,543	5.38	118,137.1
2022, October					
18-44 years	315	315	5,124,002	0.61	428,790.3
45-64 years	1,130	1,130	3,700,182	3.05	307,705.4
65-74 years	436	436	1,149,066	3.79	94,714.7
75-84 years	227	227	532,380	4.26	43,619.0
≥ 85 years	83	83	180,721	4.59	14,829.7
2022, November					
18-44 years	77	77	1,546,194	0.50	125,779.2
45-64 years	317	317	1,015,580	3.12	81,904.1
65-74 years	175	175	641,203	2.73	51,303.9
75-84 years	109	109	306,921	3.55	24,366.2
≥ 85 years	30	30	94,527	3.17	7,512.3

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2022, December					
18-44 years	67	67	1,556,653	0.43	130,800.3
45-64 years	311	311	1,020,388	3.05	84,982.0
65-74 years	182	182	643,598	2.83	53,193.5
75-84 years	85	85	308,809	2.75	25,336.3
≥ 85 years	21	21	94,754	2.22	7,792.1
Contaminated valsartan					
2012, May					
18-44 years	0	0	8,329,327	0.00	682,864.3
45-64 years	0	0	7,305,629	0.00	599,815.7
65-74 years	0	0	4,505,222	0.00	367,569.0
75-84 years	0	0	2,750,256	0.00	224,760.7
≥ 85 years	0	0	1,364,911	0.00	111,962.3
2012, June					
18-44 years	0	0	8,404,778	0.00	662,181.5
45-64 years	0	0	7,353,202	0.00	581,548.1
65-74 years	0	0	4,532,877	0.00	356,570.9
75-84 years	0	0	2,752,791	0.00	217,613.1
≥ 85 years	0	0	1,366,577	0.00	108,428.4
2012, July					
18-44 years	0	0	8,399,342	0.00	684,215.9
45-64 years	0	0	7,297,781	0.00	600,528.4
65-74 years	0	0	4,538,048	0.00	370,644.1
75-84 years	0	0	2,750,954	0.00	225,352.6
≥ 85 years	0	0	1,367,363	0.00	112,369.0
2012, August					
18-44 years	0	0	8,424,636	0.00	685,979.8
45-64 years	0	0	7,321,558	0.00	601,295.9
65-74 years	0	0	4,567,013	0.00	371,801.6
75-84 years	0	0	2,760,687	0.00	225,626.6
≥ 85 years	0	0	1,373,224	0.00	112,602.9
2012, September					

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
18-44 years	*****	*****	8,428,571	*****	664,792.9
45-64 years	28	28	7,335,138	0.04	582,794.4
65-74 years	26	26	4,578,884	0.06	361,244.4
75-84 years	11	11	2,760,164	0.04	218,568.0
≥ 85 years	*****	*****	1,374,268	*****	109,202.4
2012, October					
18-44 years	52	52	8,378,083	0.06	689,632.5
45-64 years	234	234	7,326,786	0.32	603,154.7
65-74 years	171	171	4,600,671	0.37	374,916.0
75-84 years	106	106	2,768,302	0.38	226,170.3
≥ 85 years	27	27	1,379,022	0.20	113,098.9
2012, November					
18-44 years	68	68	8,351,641	0.08	667,913.3
45-64 years	246	246	7,315,318	0.34	584,519.1
65-74 years	218	218	4,607,793	0.47	364,211.2
75-84 years	95	95	2,761,508	0.34	219,089.6
≥ 85 years	39	39	1,375,463	0.28	109,529.3
2012, December					
18-44 years	54	54	8,920,839	0.06	691,665.1
45-64 years	238	238	7,742,079	0.31	605,753.5
65-74 years	195	195	5,047,452	0.39	378,802.5
75-84 years	84	84	2,957,179	0.28	226,938.8
≥ 85 years	32	32	1,452,652	0.22	113,275.3
2013, January					
18-44 years	86	86	8,322,726	0.10	685,061.0
45-64 years	276	276	7,345,235	0.38	604,995.7
65-74 years	264	264	4,822,366	0.55	392,524.1
75-84 years	162	162	2,858,633	0.57	233,474.1
≥ 85 years	36	36	1,418,911	0.25	116,328.4
2013, February					
18-44 years	68	68	8,145,675	0.08	616,774.1
45-64 years	258	258	7,238,454	0.36	545,378.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
65-74 years	221	221	4,756,867	0.46	355,483.0
75-84 years	129	129	2,838,125	0.45	210,827.8
≥ 85 years	42	42	1,403,197	0.30	104,567.3
2013, March					
18-44 years	70	70	8,164,170	0.09	683,020.1
45-64 years	284	284	7,261,602	0.39	604,477.0
65-74 years	191	191	4,792,235	0.40	395,218.6
75-84 years	127	127	2,853,380	0.45	233,679.5
≥ 85 years	41	41	1,408,731	0.29	115,758.9
2013, April					
18-44 years	81	81	8,134,035	0.10	659,172.4
45-64 years	280	280	7,253,578	0.39	584,725.7
65-74 years	331	331	4,799,751	0.69	383,258.9
75-84 years	172	172	2,851,892	0.60	226,106.4
≥ 85 years	54	54	1,405,028	0.38	111,822.0
2013, May					
18-44 years	64	64	8,139,231	0.08	681,322.6
45-64 years	305	305	7,255,694	0.42	604,304.7
65-74 years	355	355	4,808,827	0.74	396,660.6
75-84 years	176	176	2,851,931	0.62	233,530.2
≥ 85 years	51	51	1,405,829	0.36	115,530.8
2013, June					
18-44 years	75	75	8,143,809	0.09	659,788.5
45-64 years	303	303	7,259,898	0.42	585,389.7
65-74 years	267	267	4,815,745	0.55	384,784.1
75-84 years	157	157	2,851,729	0.55	226,138.3
≥ 85 years	56	56	1,408,140	0.40	112,031.4
2013, July					
18-44 years	85	85	8,158,469	0.10	683,101.4
45-64 years	395	395	7,288,086	0.54	607,359.2
65-74 years	283	283	4,845,395	0.58	400,148.6
75-84 years	175	175	2,859,802	0.61	234,393.2

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
≥ 85 years	63	63	1,412,502	0.45	116,206.4
2013, August					
18-44 years	96	96	8,195,465	0.12	684,678.8
45-64 years	388	388	7,297,485	0.53	607,602.1
65-74 years	304	304	4,863,486	0.63	401,125.0
75-84 years	175	175	2,864,580	0.61	234,483.7
≥ 85 years	59	59	1,416,206	0.42	116,345.6
2013, September					
18-44 years	85	85	8,179,124	0.10	660,990.4
45-64 years	367	367	7,294,592	0.50	588,146.7
65-74 years	269	269	4,872,080	0.55	389,328.5
75-84 years	166	166	2,862,456	0.58	227,030.1
≥ 85 years	34	34	1,416,322	0.24	112,762.2
2013, October					
18-44 years	106	106	8,124,695	0.13	680,234.9
45-64 years	402	402	7,301,556	0.55	607,936.3
65-74 years	318	318	4,887,922	0.65	402,981.9
75-84 years	181	181	2,867,862	0.63	234,664.7
≥ 85 years	52	52	1,419,580	0.37	116,630.1
2013, November					
18-44 years	89	89	8,114,094	0.11	657,962.2
45-64 years	347	347	7,289,160	0.48	587,816.8
65-74 years	279	279	4,879,063	0.57	389,952.6
75-84 years	153	153	2,855,250	0.54	226,688.0
≥ 85 years	43	43	1,413,722	0.30	112,663.3
2013, December					
18-44 years	69	69	8,085,491	0.09	677,240.5
45-64 years	301	301	7,272,585	0.41	605,751.8
65-74 years	282	282	4,882,657	0.58	403,393.2
75-84 years	168	168	2,856,311	0.59	234,508.8
≥ 85 years	39	39	1,413,838	0.28	116,519.8
2014, January					

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
18-44 years	104	104	8,873,043	0.12	741,538.7
45-64 years	490	490	7,900,203	0.62	656,932.3
65-74 years	433	433	5,545,516	0.78	457,500.4
75-84 years	225	225	3,215,569	0.70	263,547.9
≥ 85 years	62	62	1,580,090	0.39	130,013.0
2014, February					
18-44 years	88	88	8,818,855	0.10	667,361.5
45-64 years	408	408	7,851,780	0.52	591,432.5
65-74 years	368	368	5,542,399	0.66	414,362.6
75-84 years	227	227	3,207,332	0.71	238,293.2
≥ 85 years	49	49	1,574,872	0.31	117,384.6
2014, March					
18-44 years	106	106	8,802,363	0.12	736,461.1
45-64 years	445	445	7,831,616	0.57	651,818.1
65-74 years	434	434	5,571,276	0.78	459,863.6
75-84 years	243	243	3,222,359	0.75	264,103.8
≥ 85 years	64	64	1,582,192	0.40	130,119.2
2014, April					
18-44 years	93	93	8,765,869	0.11	709,814.9
45-64 years	368	368	7,795,435	0.47	627,853.6
65-74 years	376	376	5,589,363	0.67	446,165.2
75-84 years	228	228	3,231,998	0.71	256,089.1
≥ 85 years	54	54	1,585,249	0.34	126,072.7
2014, May					
18-44 years	91	91	8,749,273	0.10	731,766.3
45-64 years	360	360	7,764,368	0.46	646,073.5
65-74 years	322	322	5,587,162	0.58	460,651.8
75-84 years	170	170	3,229,002	0.53	264,242.1
≥ 85 years	57	57	1,583,612	0.36	130,070.1
2014, June					
18-44 years	80	80	8,730,043	0.09	706,897.1
45-64 years	324	324	7,741,531	0.42	623,713.6

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
65-74 years	292	292	5,586,898	0.52	446,226.9
75-84 years	139	139	3,222,856	0.43	255,453.3
≥ 85 years	61	61	1,580,445	0.39	125,715.9
2014, July					
18-44 years	84	84	8,808,988	0.10	736,882.4
45-64 years	345	345	7,801,603	0.44	649,435.5
65-74 years	279	279	5,608,211	0.50	462,840.2
75-84 years	135	135	3,220,677	0.42	263,713.7
≥ 85 years	53	53	1,579,358	0.34	129,769.4
2014, August					
18-44 years	82	82	8,772,603	0.09	733,168.1
45-64 years	324	324	7,757,144	0.42	645,470.1
65-74 years	247	247	5,625,046	0.44	464,013.1
75-84 years	137	137	3,224,105	0.42	263,841.1
≥ 85 years	44	44	1,580,713	0.28	129,850.4
2014, September					
18-44 years	74	74	8,745,204	0.08	708,083.1
45-64 years	355	355	7,736,029	0.46	623,272.4
65-74 years	258	258	5,633,159	0.46	449,972.3
75-84 years	149	149	3,223,453	0.46	255,525.9
≥ 85 years	36	36	1,579,481	0.23	125,719.2
2014, October					
18-44 years	102	102	8,761,627	0.12	732,939.9
45-64 years	453	453	7,735,896	0.59	643,421.6
65-74 years	335	335	5,654,698	0.59	465,850.6
75-84 years	179	179	3,233,821	0.55	264,371.8
≥ 85 years	64	64	1,583,791	0.40	129,971.7
2014, November					
18-44 years	98	98	8,731,463	0.11	707,933.4
45-64 years	380	380	7,711,217	0.49	621,733.1
65-74 years	300	300	5,644,276	0.53	451,285.4
75-84 years	162	162	3,223,374	0.50	255,976.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
≥ 85 years	49	49	1,577,735	0.31	125,727.4
2014, December					
18-44 years	113	113	8,734,837	0.13	730,143.2
45-64 years	404	404	7,710,752	0.52	640,567.1
65-74 years	344	344	5,651,163	0.61	466,025.3
75-84 years	190	190	3,224,160	0.59	264,089.6
≥ 85 years	55	55	1,575,314	0.35	129,615.4
2015, January					
18-44 years	182	182	9,100,485	0.20	760,792.1
45-64 years	626	626	8,007,202	0.78	665,831.6
65-74 years	610	610	5,868,721	1.04	483,963.7
75-84 years	285	285	3,292,199	0.87	269,596.7
≥ 85 years	106	106	1,594,791	0.66	131,082.6
2015, February					
18-44 years	172	172	9,063,819	0.19	685,659.9
45-64 years	732	732	7,989,169	0.92	601,197.9
65-74 years	651	651	5,866,920	1.11	437,898.9
75-84 years	369	369	3,281,608	1.12	243,274.0
≥ 85 years	164	164	1,581,755	1.04	117,699.3
2015, March					
18-44 years	212	212	9,077,269	0.23	759,212.7
45-64 years	763	763	8,010,566	0.95	666,302.7
65-74 years	808	808	5,892,685	1.37	485,998.5
75-84 years	464	464	3,295,268	1.41	269,743.1
≥ 85 years	184	184	1,585,806	1.16	130,257.5
2015, April					
18-44 years	163	163	9,116,083	0.18	738,134.8
45-64 years	736	736	8,042,440	0.92	647,554.4
65-74 years	679	679	5,896,978	1.15	470,567.9
75-84 years	460	460	3,294,757	1.40	260,864.5
≥ 85 years	179	179	1,582,941	1.13	125,779.5
2015, May					

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
18-44 years	187	187	9,152,851	0.20	765,592.9
45-64 years	737	737	8,078,376	0.91	672,035.5
65-74 years	663	663	5,905,892	1.12	486,804.4
75-84 years	412	412	3,293,919	1.25	269,309.6
≥ 85 years	170	170	1,580,037	1.08	129,709.6
2015, June					
18-44 years	170	170	9,161,169	0.19	741,683.5
45-64 years	811	811	8,082,207	1.00	650,902.1
65-74 years	737	737	5,911,711	1.25	471,756.4
75-84 years	461	461	3,290,653	1.40	260,580.3
≥ 85 years	178	178	1,578,733	1.13	125,453.2
2015, July					
18-44 years	209	209	9,152,724	0.23	765,582.3
45-64 years	889	889	8,077,598	1.10	672,209.9
65-74 years	782	782	5,939,320	1.32	490,002.6
75-84 years	446	446	3,295,958	1.35	269,681.9
≥ 85 years	194	194	1,581,088	1.23	129,871.9
2015, August					
18-44 years	188	188	9,163,735	0.21	766,075.8
45-64 years	806	806	8,073,804	1.00	671,915.1
65-74 years	800	800	5,958,804	1.34	491,718.1
75-84 years	465	465	3,303,045	1.41	270,322.9
≥ 85 years	161	161	1,583,743	1.02	130,124.1
2015, September					
18-44 years	212	212	9,174,232	0.23	742,727.8
45-64 years	849	849	8,082,378	1.05	650,886.0
65-74 years	857	857	5,977,252	1.43	477,286.2
75-84 years	544	544	3,306,502	1.65	261,888.9
≥ 85 years	193	193	1,584,965	1.22	126,032.3
2015, October					
18-44 years	252	252	9,165,264	0.27	766,244.5
45-64 years	907	907	8,092,331	1.12	672,270.2

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
65-74 years	936	936	6,004,392	1.56	494,397.7
75-84 years	521	521	3,316,179	1.57	270,878.6
≥ 85 years	190	190	1,589,242	1.20	130,309.4
2015, November					
18-44 years	220	220	9,137,229	0.24	740,198.0
45-64 years	873	873	8,070,264	1.08	649,941.5
65-74 years	913	913	5,992,141	1.52	478,783.1
75-84 years	528	528	3,303,891	1.60	262,051.3
≥ 85 years	215	215	1,581,676	1.36	125,959.8
2015, December					
18-44 years	244	244	9,140,219	0.27	764,457.6
45-64 years	1,031	1,031	8,076,025	1.28	670,867.3
65-74 years	993	993	6,006,218	1.65	494,992.0
75-84 years	685	685	3,311,457	2.07	270,924.6
≥ 85 years	215	215	1,583,322	1.36	130,102.7
2016, January					
18-44 years	260	260	9,176,220	0.28	766,940.8
45-64 years	1,225	1,225	8,154,456	1.50	677,817.0
65-74 years	1,470	1,470	6,221,672	2.36	512,641.8
75-84 years	832	832	3,373,232	2.47	275,891.9
≥ 85 years	308	308	1,604,515	1.92	131,756.6
2016, February					
18-44 years	311	311	9,325,950	0.33	716,442.5
45-64 years	1,353	1,353	8,268,075	1.64	633,641.7
65-74 years	1,580	1,580	6,301,064	2.51	480,773.8
75-84 years	892	892	3,379,993	2.64	258,569.1
≥ 85 years	371	371	1,603,408	2.31	123,145.8
2016, March					
18-44 years	342	342	9,344,110	0.37	768,020.0
45-64 years	1,520	1,520	8,274,584	1.84	679,504.0
65-74 years	1,694	1,694	6,327,246	2.68	514,900.1
75-84 years	1,010	1,010	3,395,108	2.97	276,652.7

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
≥ 85 years	373	373	1,607,208	2.32	131,501.3
2016, April					
18-44 years	403	403	9,362,785	0.43	742,641.0
45-64 years	1,473	1,473	8,254,230	1.78	656,554.2
65-74 years	1,834	1,834	6,323,795	2.90	498,574.7
75-84 years	1,123	1,123	3,394,424	3.31	267,926.7
≥ 85 years	393	393	1,603,015	2.45	127,074.2
2016, May					
18-44 years	397	397	9,372,241	0.42	770,240.4
45-64 years	1,566	1,566	8,239,478	1.90	677,617.1
65-74 years	1,990	1,990	6,326,026	3.15	515,252.6
75-84 years	1,166	1,166	3,397,631	3.43	276,939.5
≥ 85 years	405	405	1,602,141	2.53	131,096.2
2016, June					
18-44 years	389	389	9,420,958	0.41	744,840.9
45-64 years	1,505	1,505	8,267,083	1.82	655,097.1
65-74 years	1,945	1,945	6,364,931	3.06	499,766.6
75-84 years	1,144	1,144	3,408,541	3.36	268,679.1
≥ 85 years	385	385	1,603,035	2.40	126,988.7
2016, July					
18-44 years	357	357	9,439,126	0.38	769,754.8
45-64 years	1,407	1,407	8,213,249	1.71	676,374.3
65-74 years	1,720	1,720	6,368,804	2.70	518,935.5
75-84 years	985	985	3,414,091	2.89	278,679.6
≥ 85 years	379	379	1,603,410	2.36	131,421.0
2016, August					
18-44 years	413	413	9,416,905	0.44	768,495.9
45-64 years	1,768	1,768	8,230,288	2.15	676,076.8
65-74 years	2,007	2,007	6,392,801	3.14	520,221.7
75-84 years	1,117	1,117	3,428,500	3.26	279,500.5
≥ 85 years	421	421	1,607,526	2.62	131,592.9
2016, September					

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
18-44 years	396	396	9,434,469	0.42	745,800.8
45-64 years	1,795	1,795	8,255,250	2.17	654,223.6
65-74 years	2,049	2,049	6,404,820	3.20	504,824.0
75-84 years	1,129	1,129	3,431,581	3.29	271,030.1
≥ 85 years	436	436	1,607,962	2.71	127,543.9
2016, October					
18-44 years	452	452	9,379,269	0.48	772,388.8
45-64 years	1,894	1,894	8,226,366	2.30	676,925.0
65-74 years	2,233	2,233	6,420,451	3.48	523,389.4
75-84 years	1,216	1,216	3,440,101	3.53	280,707.2
≥ 85 years	469	469	1,610,263	2.91	131,901.2
2016, November					
18-44 years	439	439	9,441,046	0.46	748,248.7
45-64 years	1,937	1,937	8,261,933	2.34	655,041.0
65-74 years	2,381	2,381	6,415,440	3.71	507,212.7
75-84 years	1,331	1,331	3,436,159	3.87	271,907.7
≥ 85 years	459	459	1,604,218	2.86	127,480.0
2016, December					
18-44 years	436	436	10,696,088	0.41	779,225.6
45-64 years	1,880	1,880	9,195,836	2.04	680,330.7
65-74 years	2,405	2,405	6,843,153	3.51	525,344.6
75-84 years	1,453	1,453	3,586,282	4.05	281,504.8
≥ 85 years	496	496	1,654,234	3.00	131,663.4
2017, January					
18-44 years	525	525	9,465,272	0.55	778,709.6
45-64 years	2,076	2,076	8,204,900	2.53	674,527.8
65-74 years	2,870	2,870	6,500,557	4.42	529,619.9
75-84 years	1,515	1,515	3,438,853	4.41	280,643.2
≥ 85 years	514	514	1,587,598	3.24	130,169.8
2017, February					
18-44 years	453	453	9,297,604	0.49	702,997.8
45-64 years	2,052	2,052	8,086,799	2.54	607,838.7

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
65-74 years	2,676	2,676	6,406,324	4.18	477,952.7
75-84 years	1,529	1,529	3,417,742	4.47	253,278.0
≥ 85 years	504	504	1,571,365	3.21	116,884.8
2017, March					
18-44 years	590	590	9,327,787	0.63	779,701.9
45-64 years	2,211	2,211	8,104,819	2.73	672,990.1
65-74 years	2,836	2,836	6,434,056	4.41	529,769.8
75-84 years	1,690	1,690	3,434,437	4.92	280,607.8
≥ 85 years	579	579	1,573,762	3.68	129,133.4
2017, April					
18-44 years	450	450	9,326,910	0.48	755,106.4
45-64 years	1,872	1,872	8,085,974	2.32	650,435.5
65-74 years	2,462	2,462	6,423,129	3.83	512,293.3
75-84 years	1,384	1,384	3,430,625	4.03	271,479.6
≥ 85 years	466	466	1,565,479	2.98	124,437.5
2017, May					
18-44 years	519	519	9,336,398	0.56	780,617.5
45-64 years	2,071	2,071	8,076,349	2.56	671,067.2
65-74 years	2,521	2,521	6,422,364	3.93	528,959.7
75-84 years	1,515	1,515	3,432,128	4.41	280,357.2
≥ 85 years	521	521	1,563,077	3.33	128,229.1
2017, June					
18-44 years	504	504	9,345,343	0.54	756,404.8
45-64 years	2,025	2,025	8,068,837	2.51	649,248.4
65-74 years	2,314	2,314	6,422,885	3.60	512,443.4
75-84 years	1,378	1,378	3,429,840	4.02	271,504.4
≥ 85 years	499	499	1,560,248	3.20	124,008.1
2017, July					
18-44 years	453	453	9,337,822	0.49	781,072.6
45-64 years	1,789	1,789	8,044,798	2.22	669,442.6
65-74 years	2,139	2,139	6,446,061	3.32	532,384.2
75-84 years	1,284	1,284	3,436,709	3.74	281,599.0

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
≥ 85 years	471	471	1,560,250	3.02	128,333.8
2017, August					
18-44 years	564	564	9,376,293	0.60	783,090.6
45-64 years	1,944	1,944	8,060,365	2.41	669,667.2
65-74 years	2,541	2,541	6,471,392	3.93	533,061.2
75-84 years	1,524	1,524	3,453,887	4.41	282,074.7
≥ 85 years	521	521	1,563,923	3.33	128,326.4
2017, September					
18-44 years	456	456	9,398,518	0.49	760,080.2
45-64 years	1,832	1,832	8,051,607	2.28	647,905.5
65-74 years	2,207	2,207	6,476,558	3.41	517,010.7
75-84 years	1,300	1,300	3,459,174	3.76	273,778.4
≥ 85 years	470	470	1,562,059	3.01	124,242.4
2017, October					
18-44 years	541	541	9,430,536	0.57	788,601.3
45-64 years	2,107	2,107	8,066,894	2.61	670,379.2
65-74 years	2,558	2,558	6,493,201	3.94	534,771.5
75-84 years	1,459	1,459	3,476,501	4.20	283,848.0
≥ 85 years	485	485	1,564,101	3.10	128,407.4
2017, November					
18-44 years	543	543	9,433,265	0.58	764,020.6
45-64 years	2,111	2,111	8,056,501	2.62	648,394.3
65-74 years	2,766	2,766	6,477,550	4.27	517,049.0
75-84 years	1,532	1,532	3,478,149	4.40	275,452.3
≥ 85 years	556	556	1,558,806	3.57	124,119.9
2017, December					
18-44 years	563	563	9,488,685	0.59	793,772.1
45-64 years	2,200	2,200	8,091,437	2.72	671,845.8
65-74 years	2,682	2,682	6,478,341	4.14	533,599.4
75-84 years	1,596	1,596	3,492,434	4.57	285,540.1
≥ 85 years	575	575	1,558,251	3.69	128,135.1
2018, January					

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
18-44 years	641	641	9,387,361	0.68	784,459.3
45-64 years	2,464	2,464	7,953,725	3.10	660,373.1
65-74 years	3,265	3,265	6,576,139	4.96	541,336.0
75-84 years	1,884	1,884	3,513,732	5.36	286,989.0
≥ 85 years	685	685	1,558,715	4.39	128,000.2
2018, February					
18-44 years	635	635	9,358,498	0.68	707,598.9
45-64 years	2,342	2,342	7,920,293	2.96	595,218.7
65-74 years	3,215	3,215	6,559,008	4.90	489,306.8
75-84 years	1,828	1,828	3,507,213	5.21	259,830.9
≥ 85 years	720	720	1,544,201	4.66	114,931.1
2018, March					
18-44 years	706	706	9,368,243	0.75	783,364.6
45-64 years	2,612	2,612	7,928,618	3.29	658,371.8
65-74 years	3,324	3,324	6,589,258	5.04	542,389.4
75-84 years	2,112	2,112	3,533,830	5.98	288,513.7
≥ 85 years	703	703	1,548,219	4.54	127,016.3
2018, April					
18-44 years	628	628	9,339,102	0.67	756,258.4
45-64 years	2,396	2,396	7,895,979	3.03	635,129.2
65-74 years	3,181	3,181	6,580,285	4.83	524,761.3
75-84 years	1,954	1,954	3,536,432	5.53	279,729.1
≥ 85 years	689	689	1,543,453	4.46	122,656.0
2018, May					
18-44 years	620	620	9,334,074	0.66	780,477.6
45-64 years	2,488	2,488	7,873,220	3.16	654,078.4
65-74 years	3,126	3,126	6,573,697	4.76	541,278.8
75-84 years	1,920	1,920	3,541,350	5.42	289,181.6
≥ 85 years	627	627	1,540,857	4.07	126,439.6
2018, June					
18-44 years	594	594	9,329,819	0.64	755,163.3
45-64 years	2,338	2,338	7,857,567	2.98	632,018.0

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
65-74 years	2,808	2,808	6,571,993	4.27	524,245.7
75-84 years	1,638	1,638	3,543,087	4.62	280,326.5
≥ 85 years	599	599	1,537,477	3.90	122,226.9
2018, July					
18-44 years	261	261	9,299,490	0.28	777,751.2
45-64 years	1,111	1,111	7,822,285	1.42	650,604.9
65-74 years	1,249	1,249	6,594,504	1.89	544,465.1
75-84 years	788	788	3,549,698	2.22	290,750.7
≥ 85 years	283	283	1,536,578	1.84	126,382.2
2018, August					
18-44 years	48	48	9,316,964	0.05	778,634.6
45-64 years	189	189	7,823,740	0.24	649,989.6
65-74 years	184	184	6,621,705	0.28	545,547.4
75-84 years	98	98	3,569,323	0.27	291,613.1
≥ 85 years	39	39	1,539,475	0.25	126,384.8
2018, September					
18-44 years	57	57	9,311,506	0.06	753,685.1
45-64 years	211	211	7,811,887	0.27	628,619.7
65-74 years	182	182	6,628,459	0.27	529,311.1
75-84 years	122	122	3,573,287	0.34	283,103.7
≥ 85 years	41	41	1,536,737	0.27	122,298.9
2018, October					
18-44 years	116	116	9,305,628	0.12	777,790.0
45-64 years	369	369	7,810,671	0.47	648,558.6
65-74 years	424	424	6,655,857	0.64	547,967.1
75-84 years	224	224	3,594,196	0.62	293,494.1
≥ 85 years	90	90	1,540,093	0.58	126,339.1
2018, November					
18-44 years	152	152	9,309,494	0.16	753,878.4
45-64 years	568	568	7,800,785	0.73	627,690.9
65-74 years	714	714	6,649,127	1.07	530,961.9
75-84 years	436	436	3,590,756	1.21	284,635.0

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
≥ 85 years	155	155	1,534,095	1.01	122,121.3
2018, December					
18-44 years	100	100	9,323,750	0.11	779,965.7
45-64 years	440	440	7,810,831	0.56	648,735.9
65-74 years	503	503	6,662,134	0.76	549,412.8
75-84 years	337	337	3,599,825	0.94	294,826.3
≥ 85 years	114	114	1,532,691	0.74	126,089.1
2019, January					
18-44 years	0	0	9,161,315	0.00	765,578.7
45-64 years	0	0	7,679,078	0.00	637,514.8
65-74 years	0	0	6,682,391	0.00	550,152.1
75-84 years	0	0	3,583,947	0.00	292,828.0
≥ 85 years	0	0	1,520,016	0.00	124,747.0
2019, February					
18-44 years	0	0	9,127,310	0.00	690,495.3
45-64 years	0	0	7,640,253	0.00	574,374.2
65-74 years	0	0	6,666,836	0.00	497,681.8
75-84 years	0	0	3,571,955	0.00	264,725.7
≥ 85 years	0	0	1,509,718	0.00	112,368.2
2019, March					
18-44 years	0	0	9,134,562	0.00	763,777.9
45-64 years	0	0	7,642,005	0.00	634,532.1
65-74 years	0	0	6,693,440	0.00	551,251.2
75-84 years	0	0	3,589,367	0.00	293,352.4
≥ 85 years	0	0	1,512,749	0.00	124,147.8
2019, April					
18-44 years	0	0	9,114,225	0.00	737,660.4
45-64 years	0	0	7,606,045	0.00	611,331.1
65-74 years	0	0	6,678,869	0.00	532,307.7
75-84 years	0	0	3,582,472	0.00	283,268.4
≥ 85 years	0	0	1,505,107	0.00	119,531.8
2019, May					

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
18-44 years	0	0	9,106,433	0.00	761,432.7
45-64 years	0	0	7,577,167	0.00	629,289.8
65-74 years	0	0	6,671,015	0.00	549,197.8
75-84 years	0	0	3,578,709	0.00	292,207.2
≥ 85 years	0	0	1,501,690	0.00	123,129.9
2019, June					
18-44 years	0	0	9,091,191	0.00	735,943.4
45-64 years	0	0	7,550,932	0.00	607,217.9
65-74 years	0	0	6,667,557	0.00	531,771.2
75-84 years	0	0	3,574,461	0.00	282,733.5
≥ 85 years	0	0	1,497,410	0.00	118,934.0
2019, July					
18-44 years	0	0	9,093,784	0.00	760,336.3
45-64 years	0	0	7,545,305	0.00	626,651.7
65-74 years	0	0	6,708,925	0.00	552,461.0
75-84 years	0	0	3,590,758	0.00	293,017.9
≥ 85 years	0	0	1,501,937	0.00	123,043.9
2019, August					
18-44 years	0	0	9,104,228	0.00	760,648.5
45-64 years	0	0	7,550,890	0.00	626,465.0
65-74 years	0	0	6,764,246	0.00	555,905.7
75-84 years	0	0	3,624,462	0.00	295,080.9
≥ 85 years	0	0	1,515,520	0.00	123,844.9
2019, September					
18-44 years	0	0	9,104,058	0.00	736,443.3
45-64 years	0	0	7,549,377	0.00	606,552.3
65-74 years	0	0	6,797,852	0.00	541,598.8
75-84 years	0	0	3,640,400	0.00	287,547.1
≥ 85 years	0	0	1,521,526	0.00	120,626.7
2019, October					
18-44 years	0	0	9,103,174	0.00	760,995.9
45-64 years	0	0	7,544,021	0.00	625,912.1

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
65-74 years	0	0	6,835,746	0.00	561,844.5
75-84 years	0	0	3,663,199	0.00	298,389.2
≥ 85 years	0	0	1,530,415	0.00	125,173.0
2019, November					
18-44 years	0	0	9,098,398	0.00	736,811.2
45-64 years	0	0	7,529,419	0.00	605,472.5
65-74 years	0	0	6,832,195	0.00	544,975.2
75-84 years	0	0	3,657,228	0.00	289,427.7
≥ 85 years	0	0	1,524,919	0.00	121,222.2
2019, December					
18-44 years	0	0	9,116,903	0.00	762,942.3
45-64 years	0	0	7,539,345	0.00	626,143.0
65-74 years	0	0	6,843,823	0.00	564,266.9
75-84 years	0	0	3,664,849	0.00	300,005.1
≥ 85 years	0	0	1,523,821	0.00	125,279.4
2020, January					
18-44 years	0	0	8,986,565	0.00	750,177.3
45-64 years	0	0	7,419,092	0.00	615,155.2
65-74 years	0	0	6,943,046	0.00	571,609.0
75-84 years	0	0	3,694,576	0.00	301,786.5
≥ 85 years	0	0	1,531,007	0.00	125,584.1
2020, February					
18-44 years	0	0	9,071,381	0.00	700,718.4
45-64 years	0	0	7,445,927	0.00	573,688.0
65-74 years	0	0	7,016,205	0.00	535,429.0
75-84 years	0	0	3,692,891	0.00	282,351.5
≥ 85 years	0	0	1,526,710	0.00	117,184.0
2020, March					
18-44 years	0	0	9,091,245	0.00	749,252.8
45-64 years	0	0	7,443,084	0.00	612,338.0
65-74 years	0	0	7,038,015	0.00	573,844.3
75-84 years	0	0	3,705,390	0.00	302,588.6

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
≥ 85 years	0	0	1,528,183	0.00	125,321.2
2020, April					
18-44 years	0	0	9,075,730	0.00	726,257.5
45-64 years	0	0	7,447,973	0.00	596,019.5
65-74 years	0	0	7,116,965	0.00	565,709.8
75-84 years	0	0	3,753,814	0.00	299,100.1
≥ 85 years	0	0	1,542,992	0.00	123,278.3
2020, May					
18-44 years	0	0	9,153,112	0.00	754,807.9
45-64 years	0	0	7,534,461	0.00	620,845.8
65-74 years	0	0	7,279,402	0.00	595,417.9
75-84 years	0	0	3,847,805	0.00	315,325.6
≥ 85 years	0	0	1,566,846	0.00	128,841.7
2020, June					
18-44 years	0	0	9,255,133	0.00	734,398.8
45-64 years	0	0	7,603,031	0.00	603,554.3
65-74 years	0	0	7,398,245	0.00	582,246.5
75-84 years	0	0	3,904,985	0.00	308,490.5
≥ 85 years	0	0	1,582,906	0.00	125,584.1
2020, July					
18-44 years	0	0	9,296,333	0.00	759,505.8
45-64 years	0	0	7,569,687	0.00	623,177.2
65-74 years	0	0	7,442,197	0.00	605,983.6
75-84 years	0	0	3,929,093	0.00	320,597.1
≥ 85 years	0	0	1,592,773	0.00	130,397.3
2020, August					
18-44 years	0	0	9,274,591	0.00	759,954.0
45-64 years	0	0	7,584,827	0.00	623,450.5
65-74 years	0	0	7,486,130	0.00	609,643.9
75-84 years	0	0	3,952,317	0.00	322,487.8
≥ 85 years	0	0	1,600,407	0.00	131,064.2
2020, September					

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
18-44 years	0	0	9,216,988	0.00	731,132.1
45-64 years	0	0	7,579,894	0.00	601,394.4
65-74 years	0	0	7,532,777	0.00	593,688.2
75-84 years	0	0	3,976,933	0.00	313,814.3
≥ 85 years	0	0	1,608,651	0.00	127,349.6
2020, October					
18-44 years	0	0	9,193,389	0.00	758,328.2
45-64 years	0	0	7,560,762	0.00	622,065.4
65-74 years	0	0	7,579,235	0.00	617,078.1
75-84 years	0	0	4,007,653	0.00	326,201.6
≥ 85 years	0	0	1,619,843	0.00	132,289.5
2020, November					
18-44 years	0	0	9,221,551	0.00	736,146.4
45-64 years	0	0	7,576,294	0.00	603,408.4
65-74 years	0	0	7,591,709	0.00	600,886.9
75-84 years	0	0	4,014,004	0.00	317,684.8
≥ 85 years	0	0	1,618,484	0.00	128,506.9
2020, December					
18-44 years	0	0	10,266,951	0.00	766,557.8
45-64 years	0	0	8,310,148	0.00	627,494.4
65-74 years	0	0	8,266,284	0.00	626,506.4
75-84 years	0	0	4,270,577	0.00	331,256.6
≥ 85 years	0	0	1,690,033	0.00	133,377.8
2021, January					
18-44 years	0	0	9,381,782	0.00	774,388.3
45-64 years	0	0	7,681,319	0.00	631,759.7
65-74 years	0	0	7,813,588	0.00	636,682.1
75-84 years	0	0	4,087,162	0.00	333,054.3
≥ 85 years	0	0	1,630,032	0.00	133,166.2
2021, February					
18-44 years	0	0	9,266,325	0.00	701,085.7
45-64 years	0	0	7,618,091	0.00	572,102.6

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
65-74 years	0	0	7,767,637	0.00	579,119.9
75-84 years	0	0	4,095,961	0.00	303,099.6
≥ 85 years	0	0	1,625,260	0.00	120,492.0
2021, March					
18-44 years	0	0	9,285,032	0.00	775,880.4
45-64 years	0	0	7,615,217	0.00	633,341.8
65-74 years	0	0	7,788,382	0.00	644,333.6
75-84 years	0	0	4,105,542	0.00	337,071.1
≥ 85 years	0	0	1,624,887	0.00	133,840.6
2021, April					
18-44 years	0	0	9,198,813	0.00	747,142.5
45-64 years	0	0	7,503,958	0.00	606,601.7
65-74 years	0	0	7,653,776	0.00	615,297.6
75-84 years	0	0	4,019,707	0.00	320,934.3
≥ 85 years	0	0	1,589,183	0.00	127,249.5
2021, May					
18-44 years	0	0	9,115,108	0.00	764,156.7
45-64 years	0	0	7,425,492	0.00	618,811.4
65-74 years	0	0	7,574,271	0.00	626,529.8
75-84 years	0	0	3,973,145	0.00	326,183.1
≥ 85 years	0	0	1,566,545	0.00	129,086.8
2021, June					
18-44 years	0	0	9,041,948	0.00	732,740.0
45-64 years	0	0	7,376,671	0.00	593,778.0
65-74 years	0	0	7,550,472	0.00	602,799.3
75-84 years	0	0	3,963,138	0.00	313,731.2
≥ 85 years	0	0	1,557,573	0.00	123,794.7
2021, July					
18-44 years	0	0	8,967,153	0.00	750,666.3
45-64 years	0	0	7,327,814	0.00	609,483.9
65-74 years	0	0	7,544,687	0.00	622,559.1
75-84 years	0	0	3,961,147	0.00	323,919.2

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
≥ 85 years	0	0	1,551,474	0.00	127,422.0
2021, August					
18-44 years	0	0	8,909,004	0.00	745,325.0
45-64 years	0	0	7,284,973	0.00	605,863.0
65-74 years	0	0	7,525,967	0.00	620,847.1
75-84 years	0	0	3,961,798	0.00	323,914.0
≥ 85 years	0	0	1,544,622	0.00	126,949.3
2021, September					
18-44 years	0	0	8,847,418	0.00	717,025.6
45-64 years	0	0	7,237,552	0.00	582,823.8
65-74 years	0	0	7,501,646	0.00	599,218.2
75-84 years	0	0	3,965,841	0.00	313,937.1
≥ 85 years	0	0	1,538,410	0.00	122,428.6
2021, October					
18-44 years	0	0	8,794,893	0.00	736,254.9
45-64 years	0	0	7,203,055	0.00	598,713.7
65-74 years	0	0	7,494,173	0.00	617,300.0
75-84 years	0	0	3,985,400	0.00	325,267.5
≥ 85 years	0	0	1,536,519	0.00	126,135.6
2021, November					
18-44 years	0	0	8,749,707	0.00	709,574.0
45-64 years	0	0	7,166,680	0.00	577,315.4
65-74 years	0	0	7,450,141	0.00	595,085.3
75-84 years	0	0	3,983,058	0.00	315,559.0
≥ 85 years	0	0	1,525,584	0.00	121,572.5
2021, December					
18-44 years	0	0	8,726,561	0.00	731,479.7
45-64 years	0	0	7,148,818	0.00	594,707.4
65-74 years	0	0	7,410,326	0.00	611,479.6
75-84 years	0	0	3,989,359	0.00	326,659.5
≥ 85 years	0	0	1,516,694	0.00	124,887.6
2022, January					

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
18-44 years	0	0	8,405,657	0.00	704,233.8
45-64 years	0	0	6,903,167	0.00	574,917.4
65-74 years	0	0	7,387,245	0.00	610,225.5
75-84 years	0	0	3,976,033	0.00	325,808.2
≥ 85 years	0	0	1,506,037	0.00	124,037.0
2022, February					
18-44 years	0	0	8,354,858	0.00	633,167.4
45-64 years	0	0	6,858,065	0.00	516,498.6
65-74 years	0	0	7,339,629	0.00	548,666.7
75-84 years	0	0	3,967,052	0.00	294,417.5
≥ 85 years	0	0	1,487,972	0.00	110,911.9
2022, March					
18-44 years	0	0	8,348,025	0.00	698,776.1
45-64 years	0	0	6,854,139	0.00	569,691.2
65-74 years	0	0	7,343,435	0.00	605,072.7
75-84 years	0	0	3,997,679	0.00	326,485.5
≥ 85 years	0	0	1,490,394	0.00	122,294.0
2022, April					
18-44 years	0	0	8,319,160	0.00	673,996.5
45-64 years	0	0	6,821,708	0.00	548,979.9
65-74 years	0	0	7,312,574	0.00	583,457.2
75-84 years	0	0	4,001,061	0.00	316,617.2
≥ 85 years	0	0	1,487,127	0.00	118,147.3
2022, May					
18-44 years	0	0	8,297,817	0.00	694,342.1
45-64 years	0	0	6,800,127	0.00	565,194.3
65-74 years	0	0	7,307,195	0.00	601,951.0
75-84 years	0	0	4,018,998	0.00	328,244.6
≥ 85 years	0	0	1,488,802	0.00	122,114.2
2022, June					
18-44 years	0	0	8,301,014	0.00	672,081.1
45-64 years	0	0	6,790,708	0.00	546,268.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
65-74 years	0	0	7,299,152	0.00	582,116.8
75-84 years	0	0	4,035,098	0.00	319,045.3
≥ 85 years	0	0	1,488,728	0.00	118,208.8
2022, July					
18-44 years	0	0	8,257,152	0.00	690,577.0
45-64 years	0	0	6,750,560	0.00	561,064.2
65-74 years	0	0	7,308,368	0.00	602,661.4
75-84 years	0	0	4,052,524	0.00	331,231.0
≥ 85 years	0	0	1,492,092	0.00	122,386.5
2022, August					
18-44 years	0	0	8,293,145	0.00	690,359.8
45-64 years	0	0	6,748,244	0.00	559,828.4
65-74 years	0	0	7,323,261	0.00	603,207.0
75-84 years	0	0	4,073,678	0.00	332,617.5
≥ 85 years	0	0	1,494,610	0.00	122,512.4
2022, September					
18-44 years	0	0	5,790,783	0.00	468,869.4
45-64 years	0	0	5,017,361	0.00	403,404.3
65-74 years	0	0	7,191,411	0.00	574,223.2
75-84 years	0	0	4,062,772	0.00	321,673.4
≥ 85 years	0	0	1,486,543	0.00	118,137.1
2022, October					
18-44 years	0	0	5,124,002	0.00	428,790.3
45-64 years	0	0	3,700,182	0.00	307,705.4
65-74 years	0	0	1,149,066	0.00	94,714.7
75-84 years	0	0	532,380	0.00	43,619.0
≥ 85 years	0	0	180,721	0.00	14,829.7
2022, November					
18-44 years	0	0	1,546,194	0.00	125,779.2
45-64 years	0	0	1,015,580	0.00	81,904.1
65-74 years	0	0	641,203	0.00	51,303.9
75-84 years	0	0	306,921	0.00	24,366.2

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
≥ 85 years	0	0	94,527	0.00	7,512.3
2022, December					
18-44 years	0	0	1,556,653	0.00	130,800.3
45-64 years	0	0	1,020,388	0.00	84,982.0
65-74 years	0	0	643,598	0.00	53,193.5
75-84 years	0	0	308,809	0.00	25,336.3
≥ 85 years	0	0	94,754	0.00	7,792.1
Non-contaminated valsartan					
2012, May					
18-44 years	582	582	8,329,327	0.70	682,864.3
45-64 years	2,255	2,255	7,305,629	3.09	599,815.7
65-74 years	2,231	2,231	4,505,222	4.95	367,569.0
75-84 years	1,628	1,628	2,750,256	5.92	224,760.7
≥ 85 years	725	725	1,364,911	5.31	111,962.3
2012, June					
18-44 years	549	549	8,404,778	0.65	662,181.5
45-64 years	2,025	2,025	7,353,202	2.75	581,548.1
65-74 years	2,009	2,009	4,532,877	4.43	356,570.9
75-84 years	1,510	1,510	2,752,791	5.49	217,613.1
≥ 85 years	607	607	1,366,577	4.44	108,428.4
2012, July					
18-44 years	505	505	8,399,342	0.60	684,215.9
45-64 years	2,004	2,004	7,297,781	2.75	600,528.4
65-74 years	2,069	2,069	4,538,048	4.56	370,644.1
75-84 years	1,422	1,422	2,750,954	5.17	225,352.6
≥ 85 years	624	624	1,367,363	4.56	112,369.0
2012, August					
18-44 years	553	553	8,424,636	0.66	685,979.8
45-64 years	2,044	2,044	7,321,558	2.79	601,295.9
65-74 years	2,078	2,078	4,567,013	4.55	371,801.6
75-84 years	1,424	1,424	2,760,687	5.16	225,626.6
≥ 85 years	595	595	1,373,224	4.33	112,602.9

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2012, September					
18-44 years	470	470	8,428,571	0.56	664,792.9
45-64 years	1,766	1,766	7,335,138	2.41	582,794.4
65-74 years	1,833	1,833	4,578,884	4.00	361,244.4
75-84 years	1,291	1,291	2,760,164	4.68	218,568.0
≥ 85 years	541	541	1,374,268	3.94	109,202.4
2012, October					
18-44 years	526	526	8,378,083	0.63	689,632.5
45-64 years	2,058	2,058	7,326,786	2.81	603,154.7
65-74 years	2,290	2,290	4,600,671	4.98	374,916.0
75-84 years	1,486	1,486	2,768,302	5.37	226,170.3
≥ 85 years	650	650	1,379,022	4.71	113,098.9
2012, November					
18-44 years	511	511	8,351,641	0.61	667,913.3
45-64 years	2,088	2,088	7,315,318	2.85	584,519.1
65-74 years	2,046	2,046	4,607,793	4.44	364,211.2
75-84 years	1,505	1,505	2,761,508	5.45	219,089.6
≥ 85 years	563	563	1,375,463	4.09	109,529.3
2012, December					
18-44 years	441	441	8,920,839	0.49	691,665.1
45-64 years	1,836	1,836	7,742,079	2.37	605,753.5
65-74 years	1,961	1,961	5,047,452	3.89	378,802.5
75-84 years	1,280	1,280	2,957,179	4.33	226,938.8
≥ 85 years	580	580	1,452,652	3.99	113,275.3
2013, January					
18-44 years	530	530	8,322,726	0.64	685,061.0
45-64 years	2,072	2,072	7,345,235	2.82	604,995.7
65-74 years	2,342	2,342	4,822,366	4.86	392,524.1
75-84 years	1,594	1,594	2,858,633	5.58	233,474.1
≥ 85 years	705	705	1,418,911	4.97	116,328.4
2013, February					
18-44 years	446	446	8,145,675	0.55	616,774.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	1,949	1,949	7,238,454	2.69	545,378.5
65-74 years	2,072	2,072	4,756,867	4.36	355,483.0
75-84 years	1,423	1,423	2,838,125	5.01	210,827.8
≥ 85 years	588	588	1,403,197	4.19	104,567.3
2013, March					
18-44 years	464	464	8,164,170	0.57	683,020.1
45-64 years	1,939	1,939	7,261,602	2.67	604,477.0
65-74 years	1,934	1,934	4,792,235	4.04	395,218.6
75-84 years	1,329	1,329	2,853,380	4.66	233,679.5
≥ 85 years	581	581	1,408,731	4.12	115,758.9
2013, April					
18-44 years	425	425	8,134,035	0.52	659,172.4
45-64 years	1,912	1,912	7,253,578	2.64	584,725.7
65-74 years	1,954	1,954	4,799,751	4.07	383,258.9
75-84 years	1,320	1,320	2,851,892	4.63	226,106.4
≥ 85 years	546	546	1,405,028	3.89	111,822.0
2013, May					
18-44 years	375	375	8,139,231	0.46	681,322.6
45-64 years	1,692	1,692	7,255,694	2.33	604,304.7
65-74 years	1,715	1,715	4,808,827	3.57	396,660.6
75-84 years	1,199	1,199	2,851,931	4.20	233,530.2
≥ 85 years	463	463	1,405,829	3.29	115,530.8
2013, June					
18-44 years	366	366	8,143,809	0.45	659,788.5
45-64 years	1,467	1,467	7,259,898	2.02	585,389.7
65-74 years	1,454	1,454	4,815,745	3.02	384,784.1
75-84 years	1,082	1,082	2,851,729	3.79	226,138.3
≥ 85 years	421	421	1,408,140	2.99	112,031.4
2013, July					
18-44 years	384	384	8,158,469	0.47	683,101.4
45-64 years	1,672	1,672	7,288,086	2.29	607,359.2
65-74 years	1,561	1,561	4,845,395	3.22	400,148.6

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	1,126	1,126	2,859,802	3.94	234,393.2
≥ 85 years	484	484	1,412,502	3.43	116,206.4
2013, August					
18-44 years	358	358	8,195,465	0.44	684,678.8
45-64 years	1,475	1,475	7,297,485	2.02	607,602.1
65-74 years	1,532	1,532	4,863,486	3.15	401,125.0
75-84 years	1,013	1,013	2,864,580	3.54	234,483.7
≥ 85 years	460	460	1,416,206	3.25	116,345.6
2013, September					
18-44 years	359	359	8,179,124	0.44	660,990.4
45-64 years	1,307	1,307	7,294,592	1.79	588,146.7
65-74 years	1,407	1,407	4,872,080	2.89	389,328.5
75-84 years	1,016	1,016	2,862,456	3.55	227,030.1
≥ 85 years	445	445	1,416,322	3.14	112,762.2
2013, October					
18-44 years	376	376	8,124,695	0.46	680,234.9
45-64 years	1,420	1,420	7,301,556	1.94	607,936.3
65-74 years	1,572	1,572	4,887,922	3.22	402,981.9
75-84 years	1,066	1,066	2,867,862	3.72	234,664.7
≥ 85 years	431	431	1,419,580	3.04	116,630.1
2013, November					
18-44 years	336	336	8,114,094	0.41	657,962.2
45-64 years	1,288	1,288	7,289,160	1.77	587,816.8
65-74 years	1,287	1,287	4,879,063	2.64	389,952.6
75-84 years	916	916	2,855,250	3.21	226,688.0
≥ 85 years	404	404	1,413,722	2.86	112,663.3
2013, December					
18-44 years	319	319	8,085,491	0.39	677,240.5
45-64 years	1,223	1,223	7,272,585	1.68	605,751.8
65-74 years	1,292	1,292	4,882,657	2.65	403,393.2
75-84 years	874	874	2,856,311	3.06	234,508.8
≥ 85 years	379	379	1,413,838	2.68	116,519.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2014, January					
18-44 years	406	406	8,873,043	0.46	741,538.7
45-64 years	1,518	1,518	7,900,203	1.92	656,932.3
65-74 years	1,553	1,553	5,545,516	2.80	457,500.4
75-84 years	1,055	1,055	3,215,569	3.28	263,547.9
≥ 85 years	445	445	1,580,090	2.82	130,013.0
2014, February					
18-44 years	339	339	8,818,855	0.38	667,361.5
45-64 years	1,369	1,369	7,851,780	1.74	591,432.5
65-74 years	1,446	1,446	5,542,399	2.61	414,362.6
75-84 years	893	893	3,207,332	2.78	238,293.2
≥ 85 years	378	378	1,574,872	2.40	117,384.6
2014, March					
18-44 years	355	355	8,802,363	0.40	736,461.1
45-64 years	1,342	1,342	7,831,616	1.71	651,818.1
65-74 years	1,341	1,341	5,571,276	2.41	459,863.6
75-84 years	948	948	3,222,359	2.94	264,103.8
≥ 85 years	391	391	1,582,192	2.47	130,119.2
2014, April					
18-44 years	283	283	8,765,869	0.32	709,814.9
45-64 years	1,120	1,120	7,795,435	1.44	627,853.6
65-74 years	1,227	1,227	5,589,363	2.20	446,165.2
75-84 years	898	898	3,231,998	2.78	256,089.1
≥ 85 years	360	360	1,585,249	2.27	126,072.7
2014, May					
18-44 years	259	259	8,749,273	0.30	731,766.3
45-64 years	1,006	1,006	7,764,368	1.30	646,073.5
65-74 years	1,020	1,020	5,587,162	1.83	460,651.8
75-84 years	706	706	3,229,002	2.19	264,242.1
≥ 85 years	342	342	1,583,612	2.16	130,070.1
2014, June					
18-44 years	224	224	8,730,043	0.26	706,897.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	890	890	7,741,531	1.15	623,713.6
65-74 years	1,004	1,004	5,586,898	1.80	446,226.9
75-84 years	689	689	3,222,856	2.14	255,453.3
≥ 85 years	306	306	1,580,445	1.94	125,715.9
2014, July					
18-44 years	250	250	8,808,988	0.28	736,882.4
45-64 years	1,042	1,042	7,801,603	1.34	649,435.5
65-74 years	998	998	5,608,211	1.78	462,840.2
75-84 years	716	716	3,220,677	2.22	263,713.7
≥ 85 years	354	354	1,579,358	2.24	129,769.4
2014, August					
18-44 years	257	257	8,772,603	0.29	733,168.1
45-64 years	1,051	1,051	7,757,144	1.35	645,470.1
65-74 years	1,141	1,141	5,625,046	2.03	464,013.1
75-84 years	733	733	3,224,105	2.27	263,841.1
≥ 85 years	381	381	1,580,713	2.41	129,850.4
2014, September					
18-44 years	261	261	8,745,204	0.30	708,083.1
45-64 years	1,074	1,074	7,736,029	1.39	623,272.4
65-74 years	1,187	1,187	5,633,159	2.11	449,972.3
75-84 years	779	779	3,223,453	2.42	255,525.9
≥ 85 years	354	354	1,579,481	2.24	125,719.2
2014, October					
18-44 years	327	327	8,761,627	0.37	732,939.9
45-64 years	1,194	1,194	7,735,896	1.54	643,421.6
65-74 years	1,232	1,232	5,654,698	2.18	465,850.6
75-84 years	809	809	3,233,821	2.50	264,371.8
≥ 85 years	373	373	1,583,791	2.36	129,971.7
2014, November					
18-44 years	250	250	8,731,463	0.29	707,933.4
45-64 years	1,064	1,064	7,711,217	1.38	621,733.1
65-74 years	1,058	1,058	5,644,276	1.87	451,285.4

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	719	719	3,223,374	2.23	255,976.1
≥ 85 years	331	331	1,577,735	2.10	125,727.4
2014, December					
18-44 years	251	251	8,734,837	0.29	730,143.2
45-64 years	1,124	1,124	7,710,752	1.46	640,567.1
65-74 years	1,173	1,173	5,651,163	2.08	466,025.3
75-84 years	857	857	3,224,160	2.66	264,089.6
≥ 85 years	339	339	1,575,314	2.15	129,615.4
2015, January					
18-44 years	282	282	9,100,485	0.31	760,792.1
45-64 years	1,170	1,170	8,007,202	1.46	665,831.6
65-74 years	1,240	1,240	5,868,721	2.11	483,963.7
75-84 years	866	866	3,292,199	2.63	269,596.7
≥ 85 years	341	341	1,594,791	2.14	131,082.6
2015, February					
18-44 years	243	243	9,063,819	0.27	685,659.9
45-64 years	1,010	1,010	7,989,169	1.26	601,197.9
65-74 years	1,073	1,073	5,866,920	1.83	437,898.9
75-84 years	701	701	3,281,608	2.14	243,274.0
≥ 85 years	314	314	1,581,755	1.99	117,699.3
2015, March					
18-44 years	285	285	9,077,269	0.31	759,212.7
45-64 years	1,119	1,119	8,010,566	1.40	666,302.7
65-74 years	1,171	1,171	5,892,685	1.99	485,998.5
75-84 years	772	772	3,295,268	2.34	269,743.1
≥ 85 years	327	327	1,585,806	2.06	130,257.5
2015, April					
18-44 years	234	234	9,116,083	0.26	738,134.8
45-64 years	1,045	1,045	8,042,440	1.30	647,554.4
65-74 years	1,143	1,143	5,896,978	1.94	470,567.9
75-84 years	727	727	3,294,757	2.21	260,864.5
≥ 85 years	301	301	1,582,941	1.90	125,779.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2015, May					
18-44 years	246	246	9,152,851	0.27	765,592.9
45-64 years	1,073	1,073	8,078,376	1.33	672,035.5
65-74 years	1,021	1,021	5,905,892	1.73	486,804.4
75-84 years	659	659	3,293,919	2.00	269,309.6
≥ 85 years	239	239	1,580,037	1.51	129,709.6
2015, June					
18-44 years	256	256	9,161,169	0.28	741,683.5
45-64 years	1,059	1,059	8,082,207	1.31	650,902.1
65-74 years	1,016	1,016	5,911,711	1.72	471,756.4
75-84 years	708	708	3,290,653	2.15	260,580.3
≥ 85 years	270	270	1,578,733	1.71	125,453.2
2015, July					
18-44 years	267	267	9,152,724	0.29	765,582.3
45-64 years	1,002	1,002	8,077,598	1.24	672,209.9
65-74 years	1,006	1,006	5,939,320	1.69	490,002.6
75-84 years	662	662	3,295,958	2.01	269,681.9
≥ 85 years	251	251	1,581,088	1.59	129,871.9
2015, August					
18-44 years	260	260	9,163,735	0.28	766,075.8
45-64 years	957	957	8,073,804	1.19	671,915.1
65-74 years	1,055	1,055	5,958,804	1.77	491,718.1
75-84 years	579	579	3,303,045	1.75	270,322.9
≥ 85 years	207	207	1,583,743	1.31	130,124.1
2015, September					
18-44 years	255	255	9,174,232	0.28	742,727.8
45-64 years	1,052	1,052	8,082,378	1.30	650,886.0
65-74 years	1,108	1,108	5,977,252	1.85	477,286.2
75-84 years	652	652	3,306,502	1.97	261,888.9
≥ 85 years	256	256	1,584,965	1.62	126,032.3
2015, October					
18-44 years	291	291	9,165,264	0.32	766,244.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	1,067	1,067	8,092,331	1.32	672,270.2
65-74 years	1,301	1,301	6,004,392	2.17	494,397.7
75-84 years	740	740	3,316,179	2.23	270,878.6
≥ 85 years	276	276	1,589,242	1.74	130,309.4
2015, November					
18-44 years	288	288	9,137,229	0.32	740,198.0
45-64 years	1,076	1,076	8,070,264	1.33	649,941.5
65-74 years	1,330	1,330	5,992,141	2.22	478,783.1
75-84 years	759	759	3,303,891	2.30	262,051.3
≥ 85 years	273	273	1,581,676	1.73	125,959.8
2015, December					
18-44 years	323	323	9,140,219	0.35	764,457.6
45-64 years	1,224	1,224	8,076,025	1.52	670,867.3
65-74 years	1,373	1,373	6,006,218	2.29	494,992.0
75-84 years	873	873	3,311,457	2.64	270,924.6
≥ 85 years	307	307	1,583,322	1.94	130,102.7
2016, January					
18-44 years	339	339	9,176,220	0.37	766,940.8
45-64 years	1,318	1,318	8,154,456	1.62	677,817.0
65-74 years	1,753	1,753	6,221,672	2.82	512,641.8
75-84 years	929	929	3,373,232	2.75	275,891.9
≥ 85 years	335	335	1,604,515	2.09	131,756.6
2016, February					
18-44 years	352	352	9,325,950	0.38	716,442.5
45-64 years	1,293	1,293	8,268,075	1.56	633,641.7
65-74 years	1,602	1,602	6,301,064	2.54	480,773.8
75-84 years	981	981	3,379,993	2.90	258,569.1
≥ 85 years	278	278	1,603,408	1.73	123,145.8
2016, March					
18-44 years	336	336	9,344,110	0.36	768,020.0
45-64 years	1,239	1,239	8,274,584	1.50	679,504.0
65-74 years	1,619	1,619	6,327,246	2.56	514,900.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	925	925	3,395,108	2.72	276,652.7
≥ 85 years	344	344	1,607,208	2.14	131,501.3
2016, April					
18-44 years	247	247	9,362,785	0.26	742,641.0
45-64 years	953	953	8,254,230	1.15	656,554.2
65-74 years	1,179	1,179	6,323,795	1.86	498,574.7
75-84 years	686	686	3,394,424	2.02	267,926.7
≥ 85 years	239	239	1,603,015	1.49	127,074.2
2016, May					
18-44 years	196	196	9,372,241	0.21	770,240.4
45-64 years	827	827	8,239,478	1.00	677,617.1
65-74 years	1,022	1,022	6,326,026	1.62	515,252.6
75-84 years	672	672	3,397,631	1.98	276,939.5
≥ 85 years	246	246	1,602,141	1.54	131,096.2
2016, June					
18-44 years	183	183	9,420,958	0.19	744,840.9
45-64 years	806	806	8,267,083	0.97	655,097.1
65-74 years	1,020	1,020	6,364,931	1.60	499,766.6
75-84 years	635	635	3,408,541	1.86	268,679.1
≥ 85 years	213	213	1,603,035	1.33	126,988.7
2016, July					
18-44 years	157	157	9,439,126	0.17	769,754.8
45-64 years	758	758	8,213,249	0.92	676,374.3
65-74 years	924	924	6,368,804	1.45	518,935.5
75-84 years	583	583	3,414,091	1.71	278,679.6
≥ 85 years	236	236	1,603,410	1.47	131,421.0
2016, August					
18-44 years	207	207	9,416,905	0.22	768,495.9
45-64 years	794	794	8,230,288	0.96	676,076.8
65-74 years	998	998	6,392,801	1.56	520,221.7
75-84 years	590	590	3,428,500	1.72	279,500.5
≥ 85 years	225	225	1,607,526	1.40	131,592.9

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2016, September					
18-44 years	186	186	9,434,469	0.20	745,800.8
45-64 years	702	702	8,255,250	0.85	654,223.6
65-74 years	890	890	6,404,820	1.39	504,824.0
75-84 years	611	611	3,431,581	1.78	271,030.1
≥ 85 years	219	219	1,607,962	1.36	127,543.9
2016, October					
18-44 years	203	203	9,379,269	0.22	772,388.8
45-64 years	792	792	8,226,366	0.96	676,925.0
65-74 years	881	881	6,420,451	1.37	523,389.4
75-84 years	580	580	3,440,101	1.69	280,707.2
≥ 85 years	207	207	1,610,263	1.29	131,901.2
2016, November					
18-44 years	156	156	9,441,046	0.17	748,248.7
45-64 years	793	793	8,261,933	0.96	655,041.0
65-74 years	958	958	6,415,440	1.49	507,212.7
75-84 years	661	661	3,436,159	1.92	271,907.7
≥ 85 years	226	226	1,604,218	1.41	127,480.0
2016, December					
18-44 years	188	188	10,696,088	0.18	779,225.6
45-64 years	778	778	9,195,836	0.85	680,330.7
65-74 years	995	995	6,843,153	1.45	525,344.6
75-84 years	667	667	3,586,282	1.86	281,504.8
≥ 85 years	245	245	1,654,234	1.48	131,663.4
2017, January					
18-44 years	187	187	9,465,272	0.20	778,709.6
45-64 years	861	861	8,204,900	1.05	674,527.8
65-74 years	1,155	1,155	6,500,557	1.78	529,619.9
75-84 years	710	710	3,438,853	2.06	280,643.2
≥ 85 years	268	268	1,587,598	1.69	130,169.8
2017, February					
18-44 years	211	211	9,297,604	0.23	702,997.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	814	814	8,086,799	1.01	607,838.7
65-74 years	1,085	1,085	6,406,324	1.69	477,952.7
75-84 years	733	733	3,417,742	2.14	253,278.0
≥ 85 years	276	276	1,571,365	1.76	116,884.8
2017, March					
18-44 years	193	193	9,327,787	0.21	779,701.9
45-64 years	957	957	8,104,819	1.18	672,990.1
65-74 years	1,186	1,186	6,434,056	1.84	529,769.8
75-84 years	862	862	3,434,437	2.51	280,607.8
≥ 85 years	288	288	1,573,762	1.83	129,133.4
2017, April					
18-44 years	186	186	9,326,910	0.20	755,106.4
45-64 years	852	852	8,085,974	1.05	650,435.5
65-74 years	1,142	1,142	6,423,129	1.78	512,293.3
75-84 years	700	700	3,430,625	2.04	271,479.6
≥ 85 years	306	306	1,565,479	1.95	124,437.5
2017, May					
18-44 years	190	190	9,336,398	0.20	780,617.5
45-64 years	948	948	8,076,349	1.17	671,067.2
65-74 years	1,278	1,278	6,422,364	1.99	528,959.7
75-84 years	842	842	3,432,128	2.45	280,357.2
≥ 85 years	303	303	1,563,077	1.94	128,229.1
2017, June					
18-44 years	193	193	9,345,343	0.21	756,404.8
45-64 years	893	893	8,068,837	1.11	649,248.4
65-74 years	1,136	1,136	6,422,885	1.77	512,443.4
75-84 years	743	743	3,429,840	2.17	271,504.4
≥ 85 years	243	243	1,560,248	1.56	124,008.1
2017, July					
18-44 years	148	148	9,337,822	0.16	781,072.6
45-64 years	715	715	8,044,798	0.89	669,442.6
65-74 years	853	853	6,446,061	1.32	532,384.2

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	584	584	3,436,709	1.70	281,599.0
≥ 85 years	233	233	1,560,250	1.49	128,333.8
2017, August					
18-44 years	168	168	9,376,293	0.18	783,090.6
45-64 years	758	758	8,060,365	0.94	669,667.2
65-74 years	943	943	6,471,392	1.46	533,061.2
75-84 years	687	687	3,453,887	1.99	282,074.7
≥ 85 years	239	239	1,563,923	1.53	128,326.4
2017, September					
18-44 years	148	148	9,398,518	0.16	760,080.2
45-64 years	681	681	8,051,607	0.85	647,905.5
65-74 years	876	876	6,476,558	1.35	517,010.7
75-84 years	587	587	3,459,174	1.70	273,778.4
≥ 85 years	222	222	1,562,059	1.42	124,242.4
2017, October					
18-44 years	168	168	9,430,536	0.18	788,601.3
45-64 years	779	779	8,066,894	0.97	670,379.2
65-74 years	977	977	6,493,201	1.50	534,771.5
75-84 years	636	636	3,476,501	1.83	283,848.0
≥ 85 years	213	213	1,564,101	1.36	128,407.4
2017, November					
18-44 years	159	159	9,433,265	0.17	764,020.6
45-64 years	813	813	8,056,501	1.01	648,394.3
65-74 years	964	964	6,477,550	1.49	517,049.0
75-84 years	626	626	3,478,149	1.80	275,452.3
≥ 85 years	236	236	1,558,806	1.51	124,119.9
2017, December					
18-44 years	157	157	9,488,685	0.17	793,772.1
45-64 years	710	710	8,091,437	0.88	671,845.8
65-74 years	875	875	6,478,341	1.35	533,599.4
75-84 years	616	616	3,492,434	1.76	285,540.1
≥ 85 years	233	233	1,558,251	1.50	128,135.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2018, January					
18-44 years	190	190	9,387,361	0.20	784,459.3
45-64 years	905	905	7,953,725	1.14	660,373.1
65-74 years	1,160	1,160	6,576,139	1.76	541,336.0
75-84 years	766	766	3,513,732	2.18	286,989.0
≥ 85 years	246	246	1,558,715	1.58	128,000.2
2018, February					
18-44 years	168	168	9,358,498	0.18	707,598.9
45-64 years	842	842	7,920,293	1.06	595,218.7
65-74 years	1,112	1,112	6,559,008	1.70	489,306.8
75-84 years	706	706	3,507,213	2.01	259,830.9
≥ 85 years	220	220	1,544,201	1.42	114,931.1
2018, March					
18-44 years	209	209	9,368,243	0.22	783,364.6
45-64 years	901	901	7,928,618	1.14	658,371.8
65-74 years	1,253	1,253	6,589,258	1.90	542,389.4
75-84 years	788	788	3,533,830	2.23	288,513.7
≥ 85 years	258	258	1,548,219	1.67	127,016.3
2018, April					
18-44 years	227	227	9,339,102	0.24	756,258.4
45-64 years	919	919	7,895,979	1.16	635,129.2
65-74 years	1,144	1,144	6,580,285	1.74	524,761.3
75-84 years	799	799	3,536,432	2.26	279,729.1
≥ 85 years	261	261	1,543,453	1.69	122,656.0
2018, May					
18-44 years	222	222	9,334,074	0.24	780,477.6
45-64 years	881	881	7,873,220	1.12	654,078.4
65-74 years	1,181	1,181	6,573,697	1.80	541,278.8
75-84 years	818	818	3,541,350	2.31	289,181.6
≥ 85 years	242	242	1,540,857	1.57	126,439.6
2018, June					
18-44 years	169	169	9,329,819	0.18	755,163.3

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	806	806	7,857,567	1.03	632,018.0
65-74 years	989	989	6,571,993	1.50	524,245.7
75-84 years	714	714	3,543,087	2.02	280,326.5
≥ 85 years	261	261	1,537,477	1.70	122,226.9
2018, July					
18-44 years	116	116	9,299,490	0.12	777,751.2
45-64 years	616	616	7,822,285	0.79	650,604.9
65-74 years	842	842	6,594,504	1.28	544,465.1
75-84 years	607	607	3,549,698	1.71	290,750.7
≥ 85 years	203	203	1,536,578	1.32	126,382.2
2018, August					
18-44 years	91	91	9,316,964	0.10	778,634.6
45-64 years	540	540	7,823,740	0.69	649,989.6
65-74 years	719	719	6,621,705	1.09	545,547.4
75-84 years	518	518	3,569,323	1.45	291,613.1
≥ 85 years	188	188	1,539,475	1.22	126,384.8
2018, September					
18-44 years	108	108	9,311,506	0.12	753,685.1
45-64 years	487	487	7,811,887	0.62	628,619.7
65-74 years	626	626	6,628,459	0.94	529,311.1
75-84 years	537	537	3,573,287	1.50	283,103.7
≥ 85 years	177	177	1,536,737	1.15	122,298.9
2018, October					
18-44 years	126	126	9,305,628	0.14	777,790.0
45-64 years	636	636	7,810,671	0.81	648,558.6
65-74 years	871	871	6,655,857	1.31	547,967.1
75-84 years	645	645	3,594,196	1.79	293,494.1
≥ 85 years	247	247	1,540,093	1.60	126,339.1
2018, November					
18-44 years	149	149	9,309,494	0.16	753,878.4
45-64 years	714	714	7,800,785	0.92	627,690.9
65-74 years	992	992	6,649,127	1.49	530,961.9

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	658	658	3,590,756	1.83	284,635.0
≥ 85 years	227	227	1,534,095	1.48	122,121.3
2018, December					
18-44 years	144	144	9,323,750	0.15	779,965.7
45-64 years	698	698	7,810,831	0.89	648,735.9
65-74 years	984	984	6,662,134	1.48	549,412.8
75-84 years	663	663	3,599,825	1.84	294,826.3
≥ 85 years	226	226	1,532,691	1.47	126,089.1
2019, January					
18-44 years	334	334	9,161,315	0.36	765,578.7
45-64 years	1,760	1,760	7,679,078	2.29	637,514.8
65-74 years	2,416	2,416	6,682,391	3.62	550,152.1
75-84 years	1,658	1,658	3,583,947	4.63	292,828.0
≥ 85 years	550	550	1,520,016	3.62	124,747.0
2019, February					
18-44 years	410	410	9,127,310	0.45	690,495.3
45-64 years	1,892	1,892	7,640,253	2.48	574,374.2
65-74 years	2,658	2,658	6,666,836	3.99	497,681.8
75-84 years	1,819	1,819	3,571,955	5.09	264,725.7
≥ 85 years	663	663	1,509,718	4.39	112,368.2
2019, March					
18-44 years	611	611	9,134,562	0.67	763,777.9
45-64 years	3,262	3,262	7,642,005	4.27	634,532.1
65-74 years	5,090	5,090	6,693,440	7.60	551,251.2
75-84 years	3,366	3,366	3,589,367	9.38	293,352.4
≥ 85 years	1,095	1,095	1,512,749	7.24	124,147.8
2019, April					
18-44 years	639	639	9,114,225	0.70	737,660.4
45-64 years	3,169	3,169	7,606,045	4.17	611,331.1
65-74 years	4,651	4,651	6,678,869	6.96	532,307.7
75-84 years	3,160	3,160	3,582,472	8.82	283,268.4
≥ 85 years	1,093	1,093	1,505,107	7.26	119,531.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2019, May					
18-44 years	673	673	9,106,433	0.74	761,432.7
45-64 years	3,196	3,196	7,577,167	4.22	629,289.8
65-74 years	4,909	4,909	6,671,015	7.36	549,197.8
75-84 years	3,119	3,119	3,578,709	8.72	292,207.2
≥ 85 years	991	991	1,501,690	6.60	123,129.9
2019, June					
18-44 years	486	486	9,091,191	0.53	735,943.4
45-64 years	2,291	2,291	7,550,932	3.03	607,217.9
65-74 years	3,301	3,301	6,667,557	4.95	531,771.2
75-84 years	2,206	2,206	3,574,461	6.17	282,733.5
≥ 85 years	753	753	1,497,410	5.03	118,934.0
2019, July					
18-44 years	527	527	9,093,784	0.58	760,336.3
45-64 years	2,443	2,443	7,545,305	3.24	626,651.7
65-74 years	3,296	3,296	6,708,925	4.91	552,461.0
75-84 years	2,223	2,223	3,590,758	6.19	293,017.9
≥ 85 years	711	711	1,501,937	4.73	123,043.9
2019, August					
18-44 years	588	588	9,104,228	0.65	760,648.5
45-64 years	2,641	2,641	7,550,890	3.50	626,465.0
65-74 years	3,534	3,534	6,764,246	5.22	555,905.7
75-84 years	2,304	2,304	3,624,462	6.36	295,080.9
≥ 85 years	705	705	1,515,520	4.65	123,844.9
2019, September					
18-44 years	622	622	9,104,058	0.68	736,443.3
45-64 years	3,065	3,065	7,549,377	4.06	606,552.3
65-74 years	4,401	4,401	6,797,852	6.47	541,598.8
75-84 years	2,814	2,814	3,640,400	7.73	287,547.1
≥ 85 years	921	921	1,521,526	6.05	120,626.7
2019, October					
18-44 years	945	945	9,103,174	1.04	760,995.9

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	4,744	4,744	7,544,021	6.29	625,912.1
65-74 years	7,247	7,247	6,835,746	10.60	561,844.5
75-84 years	4,575	4,575	3,663,199	12.49	298,389.2
≥ 85 years	1,412	1,412	1,530,415	9.23	125,173.0
2019, November					
18-44 years	677	677	9,098,398	0.74	736,811.2
45-64 years	3,322	3,322	7,529,419	4.41	605,472.5
65-74 years	4,930	4,930	6,832,195	7.22	544,975.2
75-84 years	3,084	3,084	3,657,228	8.43	289,427.7
≥ 85 years	1,043	1,043	1,524,919	6.84	121,222.2
2019, December					
18-44 years	599	599	9,116,903	0.66	762,942.3
45-64 years	2,802	2,802	7,539,345	3.72	626,143.0
65-74 years	4,154	4,154	6,843,823	6.07	564,266.9
75-84 years	2,628	2,628	3,664,849	7.17	300,005.1
≥ 85 years	803	803	1,523,821	5.27	125,279.4
2020, January					
18-44 years	686	686	8,986,565	0.76	750,177.3
45-64 years	3,146	3,146	7,419,092	4.24	615,155.2
65-74 years	4,475	4,475	6,943,046	6.45	571,609.0
75-84 years	2,852	2,852	3,694,576	7.72	301,786.5
≥ 85 years	974	974	1,531,007	6.36	125,584.1
2020, February					
18-44 years	629	629	9,071,381	0.69	700,718.4
45-64 years	2,873	2,873	7,445,927	3.86	573,688.0
65-74 years	3,920	3,920	7,016,205	5.59	535,429.0
75-84 years	2,489	2,489	3,692,891	6.74	282,351.5
≥ 85 years	863	863	1,526,710	5.65	117,184.0
2020, March					
18-44 years	626	626	9,091,245	0.69	749,252.8
45-64 years	2,840	2,840	7,443,084	3.82	612,338.0
65-74 years	3,915	3,915	7,038,015	5.56	573,844.3

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	2,465	2,465	3,705,390	6.65	302,588.6
≥ 85 years	819	819	1,528,183	5.36	125,321.2
2020, April					
18-44 years	384	384	9,075,730	0.42	726,257.5
45-64 years	1,914	1,914	7,447,973	2.57	596,019.5
65-74 years	2,668	2,668	7,116,965	3.75	565,709.8
75-84 years	1,593	1,593	3,753,814	4.24	299,100.1
≥ 85 years	554	554	1,542,992	3.59	123,278.3
2020, May					
18-44 years	351	351	9,153,112	0.38	754,807.9
45-64 years	1,538	1,538	7,534,461	2.04	620,845.8
65-74 years	2,238	2,238	7,279,402	3.07	595,417.9
75-84 years	1,443	1,443	3,847,805	3.75	315,325.6
≥ 85 years	499	499	1,566,846	3.18	128,841.7
2020, June					
18-44 years	361	361	9,255,133	0.39	734,398.8
45-64 years	1,739	1,739	7,603,031	2.29	603,554.3
65-74 years	2,554	2,554	7,398,245	3.45	582,246.5
75-84 years	1,637	1,637	3,904,985	4.19	308,490.5
≥ 85 years	493	493	1,582,906	3.11	125,584.1
2020, July					
18-44 years	418	418	9,296,333	0.45	759,505.8
45-64 years	1,789	1,789	7,569,687	2.36	623,177.2
65-74 years	2,459	2,459	7,442,197	3.30	605,983.6
75-84 years	1,657	1,657	3,929,093	4.22	320,597.1
≥ 85 years	548	548	1,592,773	3.44	130,397.3
2020, August					
18-44 years	386	386	9,274,591	0.42	759,954.0
45-64 years	1,629	1,629	7,584,827	2.15	623,450.5
65-74 years	2,360	2,360	7,486,130	3.15	609,643.9
75-84 years	1,527	1,527	3,952,317	3.86	322,487.8
≥ 85 years	523	523	1,600,407	3.27	131,064.2

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2020, September					
18-44 years	445	445	9,216,988	0.48	731,132.1
45-64 years	1,789	1,789	7,579,894	2.36	601,394.4
65-74 years	2,466	2,466	7,532,777	3.27	593,688.2
75-84 years	1,620	1,620	3,976,933	4.07	313,814.3
≥ 85 years	549	549	1,608,651	3.41	127,349.6
2020, October					
18-44 years	485	485	9,193,389	0.53	758,328.2
45-64 years	1,993	1,993	7,560,762	2.64	622,065.4
65-74 years	2,806	2,806	7,579,235	3.70	617,078.1
75-84 years	1,813	1,813	4,007,653	4.52	326,201.6
≥ 85 years	540	540	1,619,843	3.33	132,289.5
2020, November					
18-44 years	416	416	9,221,551	0.45	736,146.4
45-64 years	1,825	1,825	7,576,294	2.41	603,408.4
65-74 years	2,668	2,668	7,591,709	3.51	600,886.9
75-84 years	1,638	1,638	4,014,004	4.08	317,684.8
≥ 85 years	608	608	1,618,484	3.76	128,506.9
2020, December					
18-44 years	435	435	10,266,951	0.42	766,557.8
45-64 years	1,882	1,882	8,310,148	2.26	627,494.4
65-74 years	2,883	2,883	8,266,284	3.49	626,506.4
75-84 years	1,885	1,885	4,270,577	4.41	331,256.6
≥ 85 years	579	579	1,690,033	3.43	133,377.8
2021, January					
18-44 years	507	507	9,381,782	0.54	774,388.3
45-64 years	2,094	2,094	7,681,319	2.73	631,759.7
65-74 years	3,027	3,027	7,813,588	3.87	636,682.1
75-84 years	1,972	1,972	4,087,162	4.82	333,054.3
≥ 85 years	566	566	1,630,032	3.47	133,166.2
2021, February					
18-44 years	496	496	9,266,325	0.54	701,085.7

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	2,119	2,119	7,618,091	2.78	572,102.6
65-74 years	3,145	3,145	7,767,637	4.05	579,119.9
75-84 years	1,974	1,974	4,095,961	4.82	303,099.6
≥ 85 years	619	619	1,625,260	3.81	120,492.0
2021, March					
18-44 years	617	617	9,285,032	0.66	775,880.4
45-64 years	2,762	2,762	7,615,217	3.63	633,341.8
65-74 years	4,149	4,149	7,788,382	5.33	644,333.6
75-84 years	2,608	2,608	4,105,542	6.35	337,071.1
≥ 85 years	852	852	1,624,887	5.24	133,840.6
2021, April					
18-44 years	538	538	9,198,813	0.58	747,142.5
45-64 years	2,482	2,482	7,503,958	3.31	606,601.7
65-74 years	3,877	3,877	7,653,776	5.07	615,297.6
75-84 years	2,607	2,607	4,019,707	6.49	320,934.3
≥ 85 years	892	892	1,589,183	5.61	127,249.5
2021, May					
18-44 years	491	491	9,115,108	0.54	764,156.7
45-64 years	2,198	2,198	7,425,492	2.96	618,811.4
65-74 years	3,575	3,575	7,574,271	4.72	626,529.8
75-84 years	2,346	2,346	3,973,145	5.90	326,183.1
≥ 85 years	808	808	1,566,545	5.16	129,086.8
2021, June					
18-44 years	519	519	9,041,948	0.57	732,740.0
45-64 years	2,347	2,347	7,376,671	3.18	593,778.0
65-74 years	3,647	3,647	7,550,472	4.83	602,799.3
75-84 years	2,464	2,464	3,963,138	6.22	313,731.2
≥ 85 years	800	800	1,557,573	5.14	123,794.7
2021, July					
18-44 years	473	473	8,967,153	0.53	750,666.3
45-64 years	2,167	2,167	7,327,814	2.96	609,483.9
65-74 years	3,476	3,476	7,544,687	4.61	622,559.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	2,356	2,356	3,961,147	5.95	323,919.2
≥ 85 years	800	800	1,551,474	5.16	127,422.0
2021, August					
18-44 years	516	516	8,909,004	0.58	745,325.0
45-64 years	2,322	2,322	7,284,973	3.19	605,863.0
65-74 years	3,492	3,492	7,525,967	4.64	620,847.1
75-84 years	2,179	2,179	3,961,798	5.50	323,914.0
≥ 85 years	701	701	1,544,622	4.54	126,949.3
2021, September					
18-44 years	546	546	8,847,418	0.62	717,025.6
45-64 years	2,284	2,284	7,237,552	3.16	582,823.8
65-74 years	3,449	3,449	7,501,646	4.60	599,218.2
75-84 years	2,244	2,244	3,965,841	5.66	313,937.1
≥ 85 years	782	782	1,538,410	5.08	122,428.6
2021, October					
18-44 years	547	547	8,794,893	0.62	736,254.9
45-64 years	2,417	2,417	7,203,055	3.36	598,713.7
65-74 years	3,641	3,641	7,494,173	4.86	617,300.0
75-84 years	2,451	2,451	3,985,400	6.15	325,267.5
≥ 85 years	810	810	1,536,519	5.27	126,135.6
2021, November					
18-44 years	549	549	8,749,707	0.63	709,574.0
45-64 years	2,330	2,330	7,166,680	3.25	577,315.4
65-74 years	3,692	3,692	7,450,141	4.96	595,085.3
75-84 years	2,435	2,435	3,983,058	6.11	315,559.0
≥ 85 years	798	798	1,525,584	5.23	121,572.5
2021, December					
18-44 years	556	556	8,726,561	0.64	731,479.7
45-64 years	2,505	2,505	7,148,818	3.50	594,707.4
65-74 years	3,926	3,926	7,410,326	5.30	611,479.6
75-84 years	2,622	2,622	3,989,359	6.57	326,659.5
≥ 85 years	959	959	1,516,694	6.32	124,887.6

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2022, January					
18-44 years	720	720	8,405,657	0.86	704,233.8
45-64 years	3,395	3,395	6,903,167	4.92	574,917.4
65-74 years	5,663	5,663	7,387,245	7.67	610,225.5
75-84 years	3,785	3,785	3,976,033	9.52	325,808.2
≥ 85 years	1,260	1,260	1,506,037	8.37	124,037.0
2022, February					
18-44 years	785	785	8,354,858	0.94	633,167.4
45-64 years	3,533	3,533	6,858,065	5.15	516,498.6
65-74 years	5,322	5,322	7,339,629	7.25	548,666.7
75-84 years	3,568	3,568	3,967,052	8.99	294,417.5
≥ 85 years	1,164	1,164	1,487,972	7.82	110,911.9
2022, March					
18-44 years	882	882	8,348,025	1.06	698,776.1
45-64 years	3,691	3,691	6,854,139	5.39	569,691.2
65-74 years	5,434	5,434	7,343,435	7.40	605,072.7
75-84 years	3,758	3,758	3,997,679	9.40	326,485.5
≥ 85 years	1,202	1,202	1,490,394	8.06	122,294.0
2022, April					
18-44 years	568	568	8,319,160	0.68	673,996.5
45-64 years	2,517	2,517	6,821,708	3.69	548,979.9
65-74 years	3,844	3,844	7,312,574	5.26	583,457.2
75-84 years	2,737	2,737	4,001,061	6.84	316,617.2
≥ 85 years	958	958	1,487,127	6.44	118,147.3
2022, May					
18-44 years	517	517	8,297,817	0.62	694,342.1
45-64 years	2,359	2,359	6,800,127	3.47	565,194.3
65-74 years	3,596	3,596	7,307,195	4.92	601,951.0
75-84 years	2,598	2,598	4,018,998	6.46	328,244.6
≥ 85 years	839	839	1,488,802	5.64	122,114.2
2022, June					
18-44 years	534	534	8,301,014	0.64	672,081.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	2,282	2,282	6,790,708	3.36	546,268.5
65-74 years	3,541	3,541	7,299,152	4.85	582,116.8
75-84 years	2,499	2,499	4,035,098	6.19	319,045.3
≥ 85 years	868	868	1,488,728	5.83	118,208.8
2022, July					
18-44 years	474	474	8,257,152	0.57	690,577.0
45-64 years	2,055	2,055	6,750,560	3.04	561,064.2
65-74 years	2,859	2,859	7,308,368	3.91	602,661.4
75-84 years	2,139	2,139	4,052,524	5.28	331,231.0
≥ 85 years	775	775	1,492,092	5.19	122,386.5
2022, August					
18-44 years	540	540	8,293,145	0.65	690,359.8
45-64 years	2,249	2,249	6,748,244	3.33	559,828.4
65-74 years	3,360	3,360	7,323,261	4.59	603,207.0
75-84 years	2,303	2,303	4,073,678	5.65	332,617.5
≥ 85 years	803	803	1,494,610	5.37	122,512.4
2022, September					
18-44 years	381	381	5,790,783	0.66	468,869.4
45-64 years	1,771	1,771	5,017,361	3.53	403,404.3
65-74 years	3,187	3,187	7,191,411	4.43	574,223.2
75-84 years	2,284	2,284	4,062,772	5.62	321,673.4
≥ 85 years	741	741	1,486,543	4.98	118,137.1
2022, October					
18-44 years	292	292	5,124,002	0.57	428,790.3
45-64 years	1,087	1,087	3,700,182	2.94	307,705.4
65-74 years	413	413	1,149,066	3.59	94,714.7
75-84 years	216	216	532,380	4.06	43,619.0
≥ 85 years	79	79	180,721	4.37	14,829.7
2022, November					
18-44 years	75	75	1,546,194	0.49	125,779.2
45-64 years	310	310	1,015,580	3.05	81,904.1
65-74 years	171	171	641,203	2.67	51,303.9

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	106	106	306,921	3.45	24,366.2
≥ 85 years	28	28	94,527	2.96	7,512.3
2022, December					
18-44 years	64	64	1,556,653	0.41	130,800.3
45-64 years	302	302	1,020,388	2.96	84,982.0
65-74 years	177	177	643,598	2.75	53,193.5
75-84 years	82	82	308,809	2.66	25,336.3
≥ 85 years	21	21	94,754	2.22	7,792.1
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death					
Contaminated valsartan					
2012, May					
18-44 years	0	0	8,364,508	0.00	685,791.5
45-64 years	0	0	7,525,643	0.00	618,088.7
65-74 years	0	0	4,787,090	0.00	390,798.7
75-84 years	0	0	2,975,916	0.00	243,391.1
≥ 85 years	0	0	1,478,285	0.00	121,347.1
2012, June					
18-44 years	0	0	8,439,754	0.00	664,978.5
45-64 years	0	0	7,572,017	0.00	599,028.0
65-74 years	0	0	4,812,888	0.00	378,816.8
75-84 years	0	0	2,976,439	0.00	235,451.1
≥ 85 years	0	0	1,479,239	0.00	117,446.2
2012, July					
18-44 years	0	0	8,433,567	0.00	687,065.5
45-64 years	0	0	7,512,418	0.00	618,367.3
65-74 years	0	0	4,815,120	0.00	393,489.8
75-84 years	0	0	2,972,401	0.00	243,646.9
≥ 85 years	0	0	1,479,218	0.00	121,640.5
2012, August					
18-44 years	0	0	8,458,411	0.00	688,780.3
45-64 years	0	0	7,534,562	0.00	618,951.9
65-74 years	0	0	4,842,935	0.00	394,472.6

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	0	0	2,980,930	0.00	243,764.8
≥ 85 years	0	0	1,484,666	0.00	121,820.5
2012, September					
18-44 years	294	294	8,461,860	0.35	667,463.8
45-64 years	2,303	2,303	7,546,214	3.05	599,710.0
65-74 years	1,739	1,739	4,852,539	3.58	383,018.4
75-84 years	1,166	1,166	2,978,540	3.91	235,991.0
≥ 85 years	401	401	1,485,027	2.70	118,067.0
2012, October					
18-44 years	1,743	1,743	8,410,780	2.07	692,353.4
45-64 years	12,158	12,158	7,535,482	16.13	620,487.1
65-74 years	10,924	10,924	4,872,569	22.42	397,292.1
75-84 years	7,125	7,125	2,985,327	23.87	244,054.5
≥ 85 years	2,733	2,733	1,489,217	18.35	122,217.3
2012, November					
18-44 years	772	772	8,383,816	0.92	670,514.1
45-64 years	5,402	5,402	7,522,298	7.18	601,201.8
65-74 years	5,933	5,933	4,877,771	12.16	385,739.1
75-84 years	3,954	3,954	2,976,557	13.28	236,289.4
≥ 85 years	1,416	1,416	1,484,866	9.54	118,305.0
2012, December					
18-44 years	451	451	8,954,111	0.50	694,328.3
45-64 years	3,379	3,379	7,957,095	4.25	622,901.1
65-74 years	4,032	4,032	5,338,172	7.55	400,981.5
75-84 years	2,542	2,542	3,184,349	7.98	244,629.9
≥ 85 years	886	886	1,566,633	5.66	122,311.3
2013, January					
18-44 years	414	414	8,353,700	0.50	687,648.1
45-64 years	2,401	2,401	7,548,041	3.18	621,880.1
65-74 years	3,849	3,849	5,100,007	7.55	415,361.8
75-84 years	2,567	2,567	3,078,255	8.34	251,576.0
≥ 85 years	891	891	1,530,143	5.82	125,538.3

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2013, February					
18-44 years	276	276	8,175,825	0.34	619,070.5
45-64 years	1,569	1,569	7,436,868	2.11	560,449.5
65-74 years	2,138	2,138	5,027,964	4.25	375,918.3
75-84 years	1,433	1,433	3,054,008	4.69	227,022.2
≥ 85 years	553	553	1,512,480	3.66	112,781.3
2013, March					
18-44 years	223	223	8,193,743	0.27	685,513.4
45-64 years	1,395	1,395	7,458,564	1.87	620,998.7
65-74 years	1,793	1,793	5,062,078	3.54	417,643.1
75-84 years	1,188	1,188	3,068,318	3.87	251,434.5
≥ 85 years	481	481	1,517,564	3.17	124,778.9
2013, April					
18-44 years	578	578	8,163,103	0.71	661,545.4
45-64 years	4,226	4,226	7,448,315	5.67	600,540.3
65-74 years	6,079	6,079	5,066,600	12.00	404,730.2
75-84 years	4,312	4,312	3,064,944	14.07	243,135.3
≥ 85 years	1,788	1,788	1,512,954	11.82	120,475.5
2013, May					
18-44 years	550	550	8,167,935	0.67	683,740.2
45-64 years	4,759	4,759	7,448,510	6.39	620,475.7
65-74 years	5,836	5,836	5,073,554	11.50	418,646.0
75-84 years	4,014	4,014	3,063,443	13.10	250,971.7
≥ 85 years	1,630	1,630	1,513,127	10.77	124,414.9
2013, June					
18-44 years	488	488	8,172,089	0.60	662,092.7
45-64 years	3,688	3,688	7,451,057	4.95	600,884.6
65-74 years	4,724	4,724	5,078,332	9.30	405,880.9
75-84 years	3,154	3,154	3,061,768	10.30	242,903.2
≥ 85 years	1,354	1,354	1,515,140	8.94	120,598.6
2013, July					
18-44 years	459	459	8,186,238	0.56	685,446.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	3,258	3,258	7,477,827	4.36	623,277.3
65-74 years	3,726	3,726	5,106,423	7.30	421,838.0
75-84 years	2,633	2,633	3,068,486	8.58	251,632.8
≥ 85 years	967	967	1,518,798	6.37	125,022.4
2013, August					
18-44 years	367	367	8,222,861	0.45	686,985.1
45-64 years	2,336	2,336	7,485,928	3.12	623,387.5
65-74 years	2,595	2,595	5,122,700	5.07	422,614.0
75-84 years	1,787	1,787	3,072,300	5.82	251,599.8
≥ 85 years	650	650	1,522,012	4.27	125,098.2
2013, September					
18-44 years	346	346	8,206,097	0.42	663,185.4
45-64 years	2,140	2,140	7,481,401	2.86	603,284.7
65-74 years	2,558	2,558	5,129,144	4.99	409,982.8
75-84 years	1,667	1,667	3,068,476	5.43	243,479.4
≥ 85 years	594	594	1,521,423	3.90	121,186.3
2013, October					
18-44 years	321	321	8,151,267	0.39	682,468.5
45-64 years	1,770	1,770	7,486,691	2.36	623,439.9
65-74 years	2,008	2,008	5,143,267	3.90	424,173.3
75-84 years	1,382	1,382	3,072,371	4.50	251,525.2
≥ 85 years	540	540	1,524,246	3.54	125,281.1
2013, November					
18-44 years	295	295	8,140,272	0.36	660,095.1
45-64 years	1,866	1,866	7,472,138	2.50	602,666.2
65-74 years	2,076	2,076	5,131,443	4.05	410,239.6
75-84 years	1,404	1,404	3,056,902	4.59	242,817.7
≥ 85 years	559	559	1,516,932	3.69	120,948.8
2013, December					
18-44 years	232	232	8,111,311	0.29	679,413.8
45-64 years	1,474	1,474	7,453,904	1.98	620,953.7
65-74 years	1,831	1,831	5,132,287	3.57	424,162.2

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	1,243	1,243	3,056,031	4.07	251,034.8
≥ 85 years	440	440	1,516,170	2.90	125,022.0
2014, January					
18-44 years	336	336	8,900,862	0.38	743,878.7
45-64 years	1,961	1,961	8,097,588	2.42	673,473.1
65-74 years	2,564	2,564	5,828,215	4.40	480,960.5
75-84 years	1,541	1,541	3,436,548	4.48	281,800.4
≥ 85 years	528	528	1,692,042	3.12	139,286.0
2014, February					
18-44 years	346	346	8,846,077	0.39	669,432.3
45-64 years	2,073	2,073	8,045,772	2.58	606,140.0
65-74 years	2,743	2,743	5,820,892	4.71	435,355.3
75-84 years	1,654	1,654	3,424,581	4.83	254,601.6
≥ 85 years	607	607	1,684,773	3.60	125,668.1
2014, March					
18-44 years	409	409	8,829,117	0.46	738,714.1
45-64 years	2,600	2,600	8,023,113	3.24	667,865.6
65-74 years	3,405	3,405	5,847,596	5.82	482,829.3
75-84 years	2,004	2,004	3,437,822	5.83	281,924.6
≥ 85 years	665	665	1,691,245	3.93	139,172.4
2014, April					
18-44 years	317	317	8,792,157	0.36	711,953.1
45-64 years	2,072	2,072	7,984,409	2.60	643,156.4
65-74 years	2,866	2,866	5,863,303	4.89	468,166.6
75-84 years	1,701	1,701	3,445,634	4.94	273,159.9
≥ 85 years	525	525	1,693,294	3.10	134,731.3
2014, May					
18-44 years	275	275	8,775,025	0.31	733,930.6
45-64 years	1,654	1,654	7,950,385	2.08	661,633.0
65-74 years	2,250	2,250	5,858,001	3.84	483,089.2
75-84 years	1,234	1,234	3,440,683	3.59	281,659.7
≥ 85 years	457	457	1,690,431	2.70	138,907.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2014, June					
18-44 years	226	226	8,755,301	0.26	708,949.4
45-64 years	1,442	1,442	7,924,298	1.82	638,515.2
65-74 years	1,755	1,755	5,854,865	3.00	467,718.1
75-84 years	1,041	1,041	3,431,651	3.03	272,104.9
≥ 85 years	362	362	1,686,277	2.15	134,187.3
2014, July					
18-44 years	338	338	8,833,991	0.38	738,989.7
45-64 years	1,982	1,982	7,983,593	2.48	664,707.5
65-74 years	2,106	2,106	5,874,178	3.59	484,891.1
75-84 years	1,366	1,366	3,427,276	3.99	280,728.7
≥ 85 years	488	488	1,684,119	2.90	138,431.0
2014, August					
18-44 years	320	320	8,797,059	0.36	735,222.7
45-64 years	2,064	2,064	7,935,928	2.60	660,431.2
65-74 years	2,273	2,273	5,888,903	3.86	485,876.7
75-84 years	1,330	1,330	3,428,655	3.88	280,695.3
≥ 85 years	448	448	1,684,601	2.66	138,438.1
2014, September					
18-44 years	262	262	8,769,121	0.30	710,028.2
45-64 years	1,826	1,826	7,912,260	2.31	637,550.1
65-74 years	2,112	2,112	5,894,672	3.58	470,964.9
75-84 years	1,176	1,176	3,426,341	3.43	271,705.1
≥ 85 years	392	392	1,682,352	2.33	133,959.4
2014, October					
18-44 years	736	736	8,785,078	0.84	734,914.6
45-64 years	4,672	4,672	7,910,421	5.91	658,014.1
65-74 years	4,808	4,808	5,914,239	8.13	487,351.0
75-84 years	2,975	2,975	3,435,649	8.66	280,981.9
≥ 85 years	1,276	1,276	1,685,805	7.57	138,418.0
2014, November					
18-44 years	479	479	8,754,559	0.55	709,819.2

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	3,140	3,140	7,883,454	3.98	635,697.5
65-74 years	3,586	3,586	5,900,692	6.08	471,898.8
75-84 years	2,179	2,179	3,422,502	6.37	271,908.9
≥ 85 years	884	884	1,678,279	5.27	133,802.6
2014, December					
18-44 years	589	589	8,757,751	0.67	732,068.5
45-64 years	3,525	3,525	7,881,283	4.47	654,824.6
65-74 years	4,055	4,055	5,904,938	6.87	487,099.3
75-84 years	2,402	2,402	3,421,590	7.02	280,390.3
≥ 85 years	872	872	1,674,759	5.21	137,861.6
2015, January					
18-44 years	780	780	9,123,915	0.85	762,766.6
45-64 years	4,502	4,502	8,180,925	5.50	680,368.3
65-74 years	6,424	6,424	6,127,270	10.48	505,457.1
75-84 years	4,596	4,596	3,490,024	13.17	285,957.7
≥ 85 years	2,346	2,346	1,693,775	13.85	139,302.5
2015, February					
18-44 years	854	854	9,086,841	0.94	687,415.6
45-64 years	5,779	5,779	8,160,229	7.08	614,176.1
65-74 years	8,161	8,161	6,120,863	13.33	457,054.2
75-84 years	6,568	6,568	3,474,987	18.90	257,792.2
≥ 85 years	3,661	3,661	1,677,605	21.82	124,947.6
2015, March					
18-44 years	767	767	9,100,046	0.84	761,135.6
45-64 years	5,242	5,242	8,180,125	6.41	680,528.2
65-74 years	7,447	7,447	6,143,987	12.12	506,922.6
75-84 years	5,950	5,950	3,486,096	17.07	285,560.7
≥ 85 years	3,317	3,317	1,680,197	19.74	138,115.5
2015, April					
18-44 years	683	683	9,138,675	0.75	739,977.1
45-64 years	4,510	4,510	8,211,131	5.49	661,233.4
65-74 years	6,385	6,385	6,145,884	10.39	490,587.7

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	5,109	5,109	3,483,308	14.67	275,957.6
≥ 85 years	2,699	2,699	1,675,829	16.11	133,251.0
2015, May					
18-44 years	694	694	9,175,195	0.76	767,475.7
45-64 years	4,681	4,681	8,246,239	5.68	686,093.7
65-74 years	5,829	5,829	6,153,081	9.47	507,293.6
75-84 years	4,267	4,267	3,481,086	12.26	284,736.1
≥ 85 years	2,179	2,179	1,671,940	13.03	137,323.4
2015, June					
18-44 years	754	754	9,183,380	0.82	743,496.2
45-64 years	5,825	5,825	8,249,066	7.06	664,426.9
65-74 years	7,438	7,438	6,156,861	12.08	491,430.5
75-84 years	5,510	5,510	3,476,280	15.85	275,392.3
≥ 85 years	2,555	2,555	1,669,641	15.30	132,738.1
2015, July					
18-44 years	848	848	9,174,711	0.92	767,433.8
45-64 years	6,348	6,348	8,243,111	7.70	686,070.7
65-74 years	7,811	7,811	6,183,678	12.63	510,273.2
75-84 years	5,177	5,177	3,480,494	14.87	284,897.6
≥ 85 years	2,350	2,350	1,671,542	14.06	137,352.4
2015, August					
18-44 years	732	732	9,185,511	0.80	767,910.7
45-64 years	5,042	5,042	8,238,322	6.12	685,699.0
65-74 years	6,268	6,268	6,202,569	10.11	511,943.7
75-84 years	4,369	4,369	3,486,959	12.53	285,474.9
≥ 85 years	2,006	2,006	1,673,569	11.99	137,559.6
2015, September					
18-44 years	589	589	9,195,873	0.64	744,491.9
45-64 years	3,744	3,744	8,246,416	4.54	664,166.7
65-74 years	4,802	4,802	6,220,835	7.72	496,832.6
75-84 years	3,433	3,433	3,489,823	9.84	276,503.9
≥ 85 years	1,597	1,597	1,674,405	9.54	133,188.6

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2015, October					
18-44 years	535	535	9,186,832	0.58	768,057.8
45-64 years	3,181	3,181	8,256,279	3.85	685,957.0
65-74 years	4,034	4,034	6,247,993	6.46	514,567.3
75-84 years	2,831	2,831	3,499,155	8.09	285,939.0
≥ 85 years	1,319	1,319	1,678,202	7.86	137,656.7
2015, November					
18-44 years	575	575	9,158,717	0.63	741,953.8
45-64 years	3,426	3,426	8,233,444	4.16	663,167.1
65-74 years	4,381	4,381	6,234,026	7.03	498,253.2
75-84 years	3,129	3,129	3,484,813	8.98	276,549.0
≥ 85 years	1,727	1,727	1,669,179	10.35	133,003.4
2015, December					
18-44 years	664	664	9,161,719	0.72	766,268.6
45-64 years	3,995	3,995	8,238,837	4.85	684,479.4
65-74 years	5,218	5,218	6,246,451	8.35	514,985.8
75-84 years	3,941	3,941	3,490,650	11.29	285,784.2
≥ 85 years	2,134	2,134	1,669,468	12.78	137,277.3
2016, January					
18-44 years	761	761	9,197,891	0.83	768,766.8
45-64 years	4,716	4,716	8,317,974	5.67	691,508.8
65-74 years	6,863	6,863	6,466,038	10.61	533,020.6
75-84 years	4,813	4,813	3,552,538	13.55	290,765.5
≥ 85 years	2,351	2,351	1,689,811	13.91	138,879.7
2016, February					
18-44 years	796	796	9,347,756	0.85	718,151.0
45-64 years	5,125	5,125	8,432,703	6.08	646,433.4
65-74 years	7,150	7,150	6,545,713	10.92	499,704.7
75-84 years	5,077	5,077	3,556,873	14.27	272,312.5
≥ 85 years	2,624	2,624	1,687,003	15.55	129,677.7
2016, March					
18-44 years	943	943	9,366,076	1.01	769,852.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	5,684	5,684	8,439,304	6.74	693,183.1
65-74 years	8,622	8,622	6,572,078	13.12	535,044.1
75-84 years	5,815	5,815	3,571,421	16.28	291,183.6
≥ 85 years	2,757	2,757	1,690,174	16.31	138,375.5
2016, April					
18-44 years	1,148	1,148	9,384,822	1.22	744,418.9
45-64 years	7,126	7,126	8,419,060	8.46	669,792.2
65-74 years	10,864	10,864	6,569,124	16.54	518,068.0
75-84 years	7,282	7,282	3,570,432	20.40	281,952.1
≥ 85 years	3,232	3,232	1,685,515	19.18	133,676.6
2016, May					
18-44 years	1,225	1,225	9,394,394	1.30	772,087.7
45-64 years	6,952	6,952	8,404,391	8.27	691,299.2
65-74 years	11,060	11,060	6,572,106	16.83	535,445.0
75-84 years	7,201	7,201	3,574,047	20.15	291,433.1
≥ 85 years	3,240	3,240	1,684,428	19.24	137,891.7
2016, June					
18-44 years	961	961	9,443,249	1.02	746,629.4
45-64 years	5,855	5,855	8,432,609	6.94	668,337.1
65-74 years	9,519	9,519	6,613,244	14.39	519,406.7
75-84 years	6,120	6,120	3,585,720	17.07	282,753.3
≥ 85 years	2,714	2,714	1,685,376	16.10	133,560.2
2016, July					
18-44 years	875	875	9,461,262	0.92	771,598.4
45-64 years	5,080	5,080	8,377,595	6.06	690,024.6
65-74 years	7,875	7,875	6,618,431	11.90	539,385.0
75-84 years	4,844	4,844	3,591,786	13.49	293,279.9
≥ 85 years	2,007	2,007	1,685,623	11.91	138,210.5
2016, August					
18-44 years	974	974	9,439,117	1.03	770,338.6
45-64 years	5,617	5,617	8,394,924	6.69	689,729.7
65-74 years	8,398	8,398	6,643,992	12.64	540,791.4

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	4,963	4,963	3,607,137	13.76	294,163.3
≥ 85 years	1,961	1,961	1,689,827	11.60	138,380.9
2016, September					
18-44 years	884	884	9,456,740	0.93	747,592.2
45-64 years	5,520	5,520	8,420,353	6.56	667,450.2
65-74 years	8,218	8,218	6,657,344	12.34	524,840.8
75-84 years	4,434	4,434	3,610,739	12.28	285,278.9
≥ 85 years	1,903	1,903	1,690,174	11.26	134,110.8
2016, October					
18-44 years	861	861	9,401,480	0.92	774,245.1
45-64 years	4,923	4,923	8,391,271	5.87	690,619.5
65-74 years	7,191	7,191	6,674,329	10.77	544,213.4
75-84 years	4,028	4,028	3,620,317	11.13	295,502.5
≥ 85 years	1,605	1,605	1,692,643	9.48	138,700.0
2016, November					
18-44 years	797	797	9,463,510	0.84	750,054.5
45-64 years	4,097	4,097	8,428,158	4.86	668,345.6
65-74 years	5,899	5,899	6,670,099	8.84	527,483.5
75-84 years	3,403	3,403	3,616,309	9.41	286,279.8
≥ 85 years	1,326	1,326	1,686,419	7.86	134,060.8
2016, December					
18-44 years	681	681	10,721,076	0.64	781,111.1
45-64 years	3,609	3,609	9,379,592	3.85	694,190.9
65-74 years	5,160	5,160	7,114,665	7.25	546,461.2
75-84 years	3,103	3,103	3,773,569	8.22	296,434.9
≥ 85 years	1,222	1,222	1,738,486	7.03	138,471.1
2017, January					
18-44 years	843	843	9,487,856	0.89	780,593.7
45-64 years	3,922	3,922	8,370,471	4.69	688,283.0
65-74 years	5,939	5,939	6,757,194	8.79	550,680.7
75-84 years	3,277	3,277	3,618,289	9.06	295,409.8
≥ 85 years	1,292	1,292	1,668,592	7.74	136,859.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2017, February					
18-44 years	708	708	9,319,963	0.76	704,706.1
45-64 years	3,698	3,698	8,251,261	4.48	620,296.0
65-74 years	5,107	5,107	6,661,229	7.67	497,103.7
75-84 years	2,888	2,888	3,596,912	8.03	266,670.0
≥ 85 years	1,100	1,100	1,651,950	6.66	122,924.4
2017, March					
18-44 years	843	843	9,350,278	0.90	781,603.2
45-64 years	3,828	3,828	8,270,143	4.63	686,825.6
65-74 years	5,374	5,374	6,691,510	8.03	551,117.1
75-84 years	3,108	3,108	3,615,640	8.60	295,535.4
≥ 85 years	1,180	1,180	1,654,674	7.13	135,829.5
2017, April					
18-44 years	678	678	9,349,585	0.73	756,960.8
45-64 years	3,196	3,196	8,252,018	3.87	663,883.1
65-74 years	4,503	4,503	6,682,659	6.74	533,106.3
75-84 years	2,543	2,543	3,612,985	7.04	286,004.9
≥ 85 years	948	948	1,646,563	5.76	130,920.9
2017, May					
18-44 years	772	772	9,359,246	0.82	782,545.8
45-64 years	3,644	3,644	8,242,827	4.42	685,007.1
65-74 years	4,748	4,748	6,683,727	7.10	550,617.9
75-84 years	2,713	2,713	3,615,549	7.50	295,460.0
≥ 85 years	1,103	1,103	1,644,327	6.71	134,947.3
2017, June					
18-44 years	776	776	9,368,314	0.83	758,284.8
45-64 years	3,743	3,743	8,236,072	4.54	662,790.7
65-74 years	4,913	4,913	6,685,793	7.35	533,532.9
75-84 years	2,964	2,964	3,614,209	8.20	286,199.9
≥ 85 years	1,250	1,250	1,641,664	7.61	130,526.2
2017, July					
18-44 years	905	905	9,360,900	0.97	783,019.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	4,651	4,651	8,212,151	5.66	683,447.3
65-74 years	6,035	6,035	6,710,909	8.99	554,364.4
75-84 years	3,881	3,881	3,622,293	10.71	296,907.7
≥ 85 years	1,860	1,860	1,641,767	11.33	135,088.0
2017, August					
18-44 years	1,011	1,011	9,399,555	1.08	785,055.2
45-64 years	4,563	4,563	8,228,369	5.55	683,721.6
65-74 years	6,679	6,679	6,738,146	9.91	555,144.4
75-84 years	4,212	4,212	3,640,885	11.57	297,460.1
≥ 85 years	1,923	1,923	1,645,959	11.68	135,098.6
2017, September					
18-44 years	815	815	9,421,945	0.87	761,989.4
45-64 years	3,743	3,743	8,220,393	4.55	661,559.6
65-74 years	5,514	5,514	6,745,048	8.17	538,528.5
75-84 years	3,368	3,368	3,647,418	9.23	288,766.8
≥ 85 years	1,512	1,512	1,644,162	9.20	130,811.6
2017, October					
18-44 years	783	783	9,454,118	0.83	790,593.0
45-64 years	3,713	3,713	8,236,320	4.51	684,557.1
65-74 years	5,420	5,420	6,763,065	8.01	557,097.3
75-84 years	3,137	3,137	3,666,424	8.56	299,459.9
≥ 85 years	1,318	1,318	1,646,493	8.00	135,210.8
2017, November					
18-44 years	793	793	9,457,099	0.84	765,967.4
45-64 years	3,653	3,653	8,226,510	4.44	662,163.3
65-74 years	5,441	5,441	6,748,161	8.06	538,762.6
75-84 years	3,002	3,002	3,669,059	8.18	290,676.9
≥ 85 years	1,168	1,168	1,641,248	7.12	130,722.6
2017, December					
18-44 years	821	821	9,512,862	0.86	795,812.9
45-64 years	3,753	3,753	8,262,799	4.54	686,174.5
65-74 years	5,292	5,292	6,750,567	7.84	556,154.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	2,949	2,949	3,685,019	8.00	301,394.2
≥ 85 years	1,189	1,189	1,640,972	7.25	134,987.8
2018, January					
18-44 years	973	973	9,411,393	1.03	786,490.6
45-64 years	4,220	4,220	8,122,894	5.20	674,527.7
65-74 years	6,556	6,556	6,851,321	9.57	564,139.1
75-84 years	3,580	3,580	3,707,032	9.66	302,899.5
≥ 85 years	1,323	1,323	1,641,321	8.06	134,841.7
2018, February					
18-44 years	937	937	9,382,753	1.00	709,452.0
45-64 years	3,926	3,926	8,090,351	4.85	608,094.1
65-74 years	6,067	6,067	6,835,848	8.88	510,078.0
75-84 years	3,320	3,320	3,701,578	8.97	274,336.5
≥ 85 years	1,291	1,291	1,626,820	7.94	121,124.8
2018, March					
18-44 years	986	986	9,392,826	1.05	785,448.5
45-64 years	4,250	4,250	8,099,891	5.25	672,713.9
65-74 years	6,156	6,156	6,869,445	8.96	565,619.0
75-84 years	3,503	3,503	3,730,810	9.39	304,739.6
≥ 85 years	1,227	1,227	1,631,627	7.52	133,909.9
2018, April					
18-44 years	858	858	9,363,972	0.92	758,295.2
45-64 years	3,778	3,778	8,068,016	4.68	649,082.6
65-74 years	5,567	5,567	6,863,140	8.11	547,460.5
75-84 years	3,167	3,167	3,735,222	8.48	295,581.3
≥ 85 years	1,165	1,165	1,627,275	7.16	129,359.4
2018, May					
18-44 years	852	852	9,359,197	0.91	782,603.3
45-64 years	3,820	3,820	8,046,118	4.75	668,567.6
65-74 years	5,404	5,404	6,858,911	7.88	564,915.3
75-84 years	3,047	3,047	3,741,973	8.14	305,708.9
≥ 85 years	1,115	1,115	1,625,170	6.86	133,396.3

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2018, June					
18-44 years	817	817	9,355,214	0.87	757,239.2
45-64 years	3,908	3,908	8,031,646	4.87	646,118.4
65-74 years	5,235	5,235	6,859,400	7.63	547,288.6
75-84 years	2,793	2,793	3,745,198	7.46	296,434.7
≥ 85 years	1,085	1,085	1,622,051	6.69	128,992.3
2018, July					
18-44 years	453	453	9,325,025	0.49	779,896.4
45-64 years	2,364	2,364	7,996,496	2.96	665,165.5
65-74 years	3,288	3,288	6,884,005	4.78	568,456.6
75-84 years	1,747	1,747	3,753,036	4.65	307,496.8
≥ 85 years	626	626	1,621,477	3.86	133,402.9
2018, August					
18-44 years	154	154	9,342,250	0.16	780,743.0
45-64 years	913	913	7,997,529	1.14	664,422.4
65-74 years	1,339	1,339	6,912,169	1.94	569,472.3
75-84 years	587	587	3,773,483	1.56	308,334.2
≥ 85 years	258	258	1,624,520	1.59	133,380.5
2018, September					
18-44 years	150	150	9,336,289	0.16	755,687.7
45-64 years	968	968	7,983,674	1.21	642,447.1
65-74 years	1,360	1,360	6,917,718	1.97	552,396.8
75-84 years	652	652	3,776,505	1.73	299,243.0
≥ 85 years	254	254	1,621,269	1.57	129,045.1
2018, October					
18-44 years	255	255	9,330,009	0.27	779,822.9
45-64 years	1,317	1,317	7,981,185	1.65	662,722.0
65-74 years	2,125	2,125	6,944,645	3.06	571,742.6
75-84 years	939	939	3,797,734	2.47	310,157.6
≥ 85 years	371	371	1,624,514	2.28	133,281.3
2018, November					
18-44 years	268	268	9,333,468	0.29	755,821.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	1,626	1,626	7,969,645	2.04	641,301.6
65-74 years	2,460	2,460	6,936,315	3.55	553,920.0
75-84 years	1,221	1,221	3,793,271	3.22	300,748.1
≥ 85 years	433	433	1,617,808	2.68	128,820.7
2018, December					
18-44 years	251	251	9,347,510	0.27	781,951.5
45-64 years	1,653	1,653	7,979,185	2.07	662,733.2
65-74 years	2,351	2,351	6,948,928	3.38	573,096.1
75-84 years	1,233	1,233	3,802,423	3.24	311,486.1
≥ 85 years	423	423	1,616,217	2.62	132,992.1
2019, January					
18-44 years	0	0	9,184,029	0.00	767,483.9
45-64 years	0	0	7,841,450	0.00	651,034.9
65-74 years	0	0	6,965,817	0.00	573,552.6
75-84 years	0	0	3,783,078	0.00	309,174.1
≥ 85 years	0	0	1,602,222	0.00	131,530.7
2019, February					
18-44 years	0	0	9,149,627	0.00	692,192.3
45-64 years	0	0	7,801,140	0.00	586,528.1
65-74 years	0	0	6,949,214	0.00	518,842.9
75-84 years	0	0	3,770,143	0.00	279,501.2
≥ 85 years	0	0	1,591,499	0.00	118,495.3
2019, March					
18-44 years	0	0	9,156,656	0.00	765,646.5
45-64 years	0	0	7,802,332	0.00	647,985.4
65-74 years	0	0	6,976,383	0.00	574,768.3
75-84 years	0	0	3,788,593	0.00	309,807.6
≥ 85 years	0	0	1,594,767	0.00	130,934.9
2019, April					
18-44 years	0	0	9,136,170	0.00	739,464.3
45-64 years	0	0	7,766,447	0.00	624,357.9
65-74 years	0	0	6,962,884	0.00	555,156.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	0	0	3,782,855	0.00	299,286.2
≥ 85 years	0	0	1,587,028	0.00	126,105.7
2019, May					
18-44 years	0	0	9,128,266	0.00	763,291.8
45-64 years	0	0	7,736,780	0.00	642,728.3
65-74 years	0	0	6,955,427	0.00	572,891.6
75-84 years	0	0	3,779,431	0.00	308,808.9
≥ 85 years	0	0	1,583,532	0.00	129,924.4
2019, June					
18-44 years	0	0	9,112,720	0.00	737,720.0
45-64 years	0	0	7,708,750	0.00	620,098.4
65-74 years	0	0	6,950,564	0.00	554,620.6
75-84 years	0	0	3,774,062	0.00	298,746.4
≥ 85 years	0	0	1,578,446	0.00	125,459.7
2019, July					
18-44 years	0	0	9,113,385	0.00	762,082.7
45-64 years	0	0	7,690,937	0.00	639,454.9
65-74 years	0	0	6,973,807	0.00	575,412.2
75-84 years	0	0	3,777,919	0.00	309,141.0
≥ 85 years	0	0	1,577,077	0.00	129,575.5
2019, August					
18-44 years	0	0	9,121,342	0.00	762,180.0
45-64 years	0	0	7,677,929	0.00	637,781.4
65-74 years	0	0	6,994,980	0.00	576,341.6
75-84 years	0	0	3,787,381	0.00	309,444.0
≥ 85 years	0	0	1,579,248	0.00	129,539.6
2019, September					
18-44 years	0	0	9,120,128	0.00	737,804.7
45-64 years	0	0	7,665,835	0.00	616,426.0
65-74 years	0	0	7,001,801	0.00	559,027.6
75-84 years	0	0	3,783,064	0.00	299,711.7
≥ 85 years	0	0	1,576,974	0.00	125,378.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2019, October					
18-44 years	0	0	9,118,721	0.00	762,354.7
45-64 years	0	0	7,654,719	0.00	635,537.8
65-74 years	0	0	7,023,286	0.00	578,181.3
75-84 years	0	0	3,793,403	0.00	309,705.0
≥ 85 years	0	0	1,580,557	0.00	129,543.0
2019, November					
18-44 years	0	0	9,114,258	0.00	738,130.2
45-64 years	0	0	7,640,376	0.00	614,640.2
65-74 years	0	0	7,017,732	0.00	560,236.7
75-84 years	0	0	3,785,047	0.00	299,886.6
≥ 85 years	0	0	1,573,787	0.00	125,234.1
2019, December					
18-44 years	0	0	9,132,910	0.00	764,313.3
45-64 years	0	0	7,649,969	0.00	635,552.4
65-74 years	0	0	7,028,317	0.00	579,849.7
75-84 years	0	0	3,791,023	0.00	310,631.0
≥ 85 years	0	0	1,571,719	0.00	129,332.1
2020, January					
18-44 years	0	0	9,002,386	0.00	751,526.1
45-64 years	0	0	7,526,263	0.00	624,232.5
65-74 years	0	0	7,126,350	0.00	587,012.0
75-84 years	0	0	3,818,975	0.00	312,191.6
≥ 85 years	0	0	1,578,016	0.00	129,534.9
2020, February					
18-44 years	0	0	9,087,615	0.00	701,995.6
45-64 years	0	0	7,553,927	0.00	582,148.3
65-74 years	0	0	7,201,247	0.00	549,796.8
75-84 years	0	0	3,816,966	0.00	292,007.9
≥ 85 years	0	0	1,573,517	0.00	120,837.3
2020, March					
18-44 years	0	0	9,107,758	0.00	750,642.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	0	0	7,551,528	0.00	621,434.4
65-74 years	0	0	7,224,111	0.00	589,273.9
75-84 years	0	0	3,829,785	0.00	312,932.6
≥ 85 years	0	0	1,575,170	0.00	129,240.4
2020, April					
18-44 years	0	0	9,092,548	0.00	727,622.6
45-64 years	0	0	7,557,750	0.00	604,936.0
65-74 years	0	0	7,306,753	0.00	581,002.3
75-84 years	0	0	3,880,306	0.00	309,336.5
≥ 85 years	0	0	1,590,630	0.00	127,144.6
2020, May					
18-44 years	0	0	9,170,191	0.00	756,234.5
45-64 years	0	0	7,646,251	0.00	630,155.7
65-74 years	0	0	7,474,756	0.00	611,553.7
75-84 years	0	0	3,977,793	0.00	326,104.4
≥ 85 years	0	0	1,615,643	0.00	132,897.6
2020, June					
18-44 years	0	0	9,272,406	0.00	735,789.3
45-64 years	0	0	7,716,117	0.00	612,640.1
65-74 years	0	0	7,597,110	0.00	598,066.6
75-84 years	0	0	4,037,109	0.00	319,044.9
≥ 85 years	0	0	1,632,270	0.00	129,541.5
2020, July					
18-44 years	0	0	9,313,626	0.00	760,948.6
45-64 years	0	0	7,682,855	0.00	632,594.1
65-74 years	0	0	7,643,009	0.00	622,497.8
75-84 years	0	0	4,062,264	0.00	331,573.7
≥ 85 years	0	0	1,642,479	0.00	134,509.5
2020, August					
18-44 years	0	0	9,291,974	0.00	761,399.5
45-64 years	0	0	7,698,572	0.00	632,887.8
65-74 years	0	0	7,688,982	0.00	626,303.2

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	0	0	4,086,608	0.00	333,539.0
≥ 85 years	0	0	1,650,675	0.00	135,208.7
2020, September					
18-44 years	0	0	9,234,357	0.00	732,524.0
45-64 years	0	0	7,694,124	0.00	610,545.8
65-74 years	0	0	7,737,220	0.00	609,932.9
75-84 years	0	0	4,112,143	0.00	324,581.7
≥ 85 years	0	0	1,659,319	0.00	131,394.3
2020, October					
18-44 years	0	0	9,210,754	0.00	759,781.9
45-64 years	0	0	7,675,219	0.00	631,582.7
65-74 years	0	0	7,785,320	0.00	634,008.8
75-84 years	0	0	4,144,057	0.00	337,406.9
≥ 85 years	0	0	1,671,028	0.00	136,502.7
2020, November					
18-44 years	0	0	9,239,028	0.00	737,558.0
45-64 years	0	0	7,691,115	0.00	612,670.5
65-74 years	0	0	7,798,194	0.00	617,411.0
75-84 years	0	0	4,150,813	0.00	328,622.0
≥ 85 years	0	0	1,669,534	0.00	132,607.4
2020, December					
18-44 years	0	0	10,286,028	0.00	768,033.9
45-64 years	0	0	8,435,101	0.00	637,131.0
65-74 years	0	0	8,488,213	0.00	643,730.1
75-84 years	0	0	4,414,229	0.00	342,667.5
≥ 85 years	0	0	1,742,858	0.00	137,627.7
2021, January					
18-44 years	0	0	9,399,543	0.00	775,873.9
45-64 years	0	0	7,796,964	0.00	641,375.7
65-74 years	0	0	8,025,906	0.00	654,183.2
75-84 years	0	0	4,226,374	0.00	344,541.6
≥ 85 years	0	0	1,681,467	0.00	137,421.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2021, February					
18-44 years	0	0	9,284,118	0.00	702,446.6
45-64 years	0	0	7,733,331	0.00	580,858.6
65-74 years	0	0	7,979,319	0.00	595,068.8
75-84 years	0	0	4,235,795	0.00	313,571.3
≥ 85 years	0	0	1,676,783	0.00	124,354.9
2021, March					
18-44 years	0	0	9,302,962	0.00	777,407.5
45-64 years	0	0	7,730,644	0.00	643,101.3
65-74 years	0	0	8,000,632	0.00	662,143.3
75-84 years	0	0	4,245,677	0.00	348,748.5
≥ 85 years	0	0	1,676,364	0.00	138,139.3
2021, April					
18-44 years	0	0	9,216,725	0.00	748,619.4
45-64 years	0	0	7,618,087	0.00	615,970.0
65-74 years	0	0	7,862,635	0.00	632,338.6
75-84 years	0	0	4,156,753	0.00	332,067.3
≥ 85 years	0	0	1,639,381	0.00	131,341.5
2021, May					
18-44 years	0	0	9,132,775	0.00	765,664.6
45-64 years	0	0	7,538,270	0.00	628,352.8
65-74 years	0	0	7,780,334	0.00	643,848.2
75-84 years	0	0	4,108,069	0.00	337,470.0
≥ 85 years	0	0	1,615,841	0.00	133,221.2
2021, June					
18-44 years	0	0	9,059,461	0.00	734,183.9
45-64 years	0	0	7,488,460	0.00	602,907.1
65-74 years	0	0	7,755,411	0.00	619,393.8
75-84 years	0	0	4,097,573	0.00	324,544.3
≥ 85 years	0	0	1,606,467	0.00	127,740.5
2021, July					
18-44 years	0	0	8,984,678	0.00	752,150.2

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	0	0	7,439,191	0.00	618,861.2
65-74 years	0	0	7,749,701	0.00	639,666.5
75-84 years	0	0	4,095,516	0.00	335,064.3
≥ 85 years	0	0	1,600,296	0.00	131,486.4
2021, August					
18-44 years	0	0	8,926,567	0.00	746,812.6
45-64 years	0	0	7,396,191	0.00	615,215.4
65-74 years	0	0	7,731,853	0.00	637,981.3
75-84 years	0	0	4,097,051	0.00	335,093.5
≥ 85 years	0	0	1,593,691	0.00	131,022.9
2021, September					
18-44 years	0	0	8,865,015	0.00	718,465.9
45-64 years	0	0	7,348,858	0.00	591,866.3
65-74 years	0	0	7,707,924	0.00	615,827.3
75-84 years	0	0	4,102,176	0.00	324,833.5
≥ 85 years	0	0	1,587,775	0.00	126,393.9
2021, October					
18-44 years	0	0	8,812,573	0.00	737,751.1
45-64 years	0	0	7,314,481	0.00	608,071.7
65-74 years	0	0	7,701,787	0.00	634,545.4
75-84 years	0	0	4,123,318	0.00	336,635.3
≥ 85 years	0	0	1,586,283	0.00	130,259.8
2021, November					
18-44 years	0	0	8,767,500	0.00	711,033.8
45-64 years	0	0	7,278,571	0.00	586,425.8
65-74 years	0	0	7,658,452	0.00	611,885.9
75-84 years	0	0	4,122,121	0.00	326,684.9
≥ 85 years	0	0	1,575,548	0.00	125,596.9
2021, December					
18-44 years	0	0	8,744,448	0.00	732,997.0
45-64 years	0	0	7,261,305	0.00	604,165.6
65-74 years	0	0	7,619,677	0.00	628,897.4

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	0	0	4,129,821	0.00	338,295.6
≥ 85 years	0	0	1,566,846	0.00	129,062.3
2022, January					
18-44 years	0	0	8,423,050	0.00	705,713.4
45-64 years	0	0	7,012,614	0.00	584,164.5
65-74 years	0	0	7,597,533	0.00	627,811.6
75-84 years	0	0	4,117,612	0.00	337,571.9
≥ 85 years	0	0	1,556,500	0.00	128,249.7
2022, February					
18-44 years	0	0	8,372,496	0.00	634,530.3
45-64 years	0	0	6,968,915	0.00	524,973.7
65-74 years	0	0	7,552,260	0.00	564,747.3
75-84 years	0	0	4,110,983	0.00	305,241.6
≥ 85 years	0	0	1,538,838	0.00	114,755.0
2022, March					
18-44 years	0	0	8,366,128	0.00	700,322.2
45-64 years	0	0	6,967,214	0.00	579,235.7
65-74 years	0	0	7,559,461	0.00	623,092.1
75-84 years	0	0	4,145,217	0.00	338,692.3
≥ 85 years	0	0	1,542,260	0.00	126,606.1
2022, April					
18-44 years	0	0	8,337,695	0.00	675,512.0
45-64 years	0	0	6,936,428	0.00	558,303.6
65-74 years	0	0	7,531,215	0.00	601,034.8
75-84 years	0	0	4,151,163	0.00	328,601.9
≥ 85 years	0	0	1,539,861	0.00	122,376.8
2022, May					
18-44 years	0	0	8,316,499	0.00	695,918.5
45-64 years	0	0	6,915,670	0.00	574,889.5
65-74 years	0	0	7,527,345	0.00	620,217.8
75-84 years	0	0	4,171,167	0.00	340,789.5
≥ 85 years	0	0	1,542,400	0.00	126,546.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2022, June					
18-44 years	0	0	8,319,741	0.00	673,612.7
45-64 years	0	0	6,906,949	0.00	555,700.3
65-74 years	0	0	7,520,572	0.00	599,895.7
75-84 years	0	0	4,189,099	0.00	331,327.7
≥ 85 years	0	0	1,542,944	0.00	122,551.7
2022, July					
18-44 years	0	0	8,275,977	0.00	692,162.0
45-64 years	0	0	6,867,325	0.00	570,847.9
65-74 years	0	0	7,531,837	0.00	621,198.9
75-84 years	0	0	4,208,469	0.00	344,073.0
≥ 85 years	0	0	1,547,024	0.00	126,923.9
2022, August					
18-44 years	0	0	8,312,068	0.00	691,956.6
45-64 years	0	0	6,865,498	0.00	569,648.5
65-74 years	0	0	7,547,902	0.00	621,835.5
75-84 years	0	0	4,231,109	0.00	345,580.6
≥ 85 years	0	0	1,550,080	0.00	127,096.0
2022, September					
18-44 years	0	0	5,804,982	0.00	470,027.4
45-64 years	0	0	5,109,876	0.00	410,908.6
65-74 years	0	0	7,413,293	0.00	592,049.4
75-84 years	0	0	4,220,648	0.00	334,261.5
≥ 85 years	0	0	1,542,160	0.00	122,589.2
2022, October					
18-44 years	0	0	5,134,203	0.00	429,654.8
45-64 years	0	0	3,762,103	0.00	312,905.4
65-74 years	0	0	1,183,649	0.00	97,591.1
75-84 years	0	0	552,453	0.00	45,279.3
≥ 85 years	0	0	187,020	0.00	15,351.9
2022, November					
18-44 years	0	0	1,548,848	0.00	125,997.8

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	0	0	1,031,759	0.00	83,221.7
65-74 years	0	0	659,484	0.00	52,781.0
75-84 years	0	0	318,059	0.00	25,260.5
≥ 85 years	0	0	97,766	0.00	7,771.9
2022, December					
18-44 years	0	0	1,559,288	0.00	131,024.9
45-64 years	0	0	1,036,512	0.00	86,341.2
65-74 years	0	0	661,461	0.00	54,696.3
75-84 years	0	0	319,763	0.00	26,251.4
≥ 85 years	0	0	97,917	0.00	8,057.2
New Use - Censoring on Query/Data End Date, Disenrollment, or Death					
Contaminated valsartan					
2012, May					
18-44 years	0	0	8,329,327	0.00	682,864.3
45-64 years	0	0	7,305,629	0.00	599,815.7
65-74 years	0	0	4,505,222	0.00	367,569.0
75-84 years	0	0	2,750,256	0.00	224,760.7
≥ 85 years	0	0	1,364,911	0.00	111,962.3
2012, June					
18-44 years	0	0	8,404,778	0.00	662,181.5
45-64 years	0	0	7,353,202	0.00	581,548.1
65-74 years	0	0	4,532,877	0.00	356,570.9
75-84 years	0	0	2,752,791	0.00	217,613.1
≥ 85 years	0	0	1,366,577	0.00	108,428.4
2012, July					
18-44 years	0	0	8,399,342	0.00	684,215.9
45-64 years	0	0	7,297,781	0.00	600,528.4
65-74 years	0	0	4,538,048	0.00	370,644.1
75-84 years	0	0	2,750,954	0.00	225,352.6
≥ 85 years	0	0	1,367,363	0.00	112,369.0
2012, August					
18-44 years	0	0	8,424,636	0.00	685,979.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	0	0	7,321,558	0.00	601,295.9
65-74 years	0	0	4,567,013	0.00	371,801.6
75-84 years	0	0	2,760,687	0.00	225,626.6
≥ 85 years	0	0	1,373,224	0.00	112,602.9
2012, September					
18-44 years	*****	*****	8,428,571	*****	664,792.9
45-64 years	28	28	7,335,138	0.04	582,794.4
65-74 years	26	26	4,578,884	0.06	361,244.4
75-84 years	11	11	2,760,164	0.04	218,568.0
≥ 85 years	*****	*****	1,374,268	*****	109,202.4
2012, October					
18-44 years	52	52	8,378,083	0.06	689,632.5
45-64 years	234	234	7,326,786	0.32	603,154.7
65-74 years	171	171	4,600,671	0.37	374,916.0
75-84 years	106	106	2,768,302	0.38	226,170.3
≥ 85 years	27	27	1,379,022	0.20	113,098.9
2012, November					
18-44 years	68	68	8,351,641	0.08	667,913.3
45-64 years	246	246	7,315,318	0.34	584,519.1
65-74 years	218	218	4,607,793	0.47	364,211.2
75-84 years	95	95	2,761,508	0.34	219,089.6
≥ 85 years	39	39	1,375,463	0.28	109,529.3
2012, December					
18-44 years	54	54	8,920,839	0.06	691,665.1
45-64 years	238	238	7,742,079	0.31	605,753.5
65-74 years	195	195	5,047,452	0.39	378,802.5
75-84 years	84	84	2,957,179	0.28	226,938.8
≥ 85 years	32	32	1,452,652	0.22	113,275.3
2013, January					
18-44 years	86	86	8,322,726	0.10	685,061.0
45-64 years	276	276	7,345,235	0.38	604,995.7
65-74 years	264	264	4,822,366	0.55	392,524.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	162	162	2,858,633	0.57	233,474.1
≥ 85 years	36	36	1,418,911	0.25	116,328.4
2013, February					
18-44 years	68	68	8,145,675	0.08	616,774.1
45-64 years	258	258	7,238,454	0.36	545,378.5
65-74 years	221	221	4,756,867	0.46	355,483.0
75-84 years	129	129	2,838,125	0.45	210,827.8
≥ 85 years	42	42	1,403,197	0.30	104,567.3
2013, March					
18-44 years	70	70	8,164,170	0.09	683,020.1
45-64 years	284	284	7,261,602	0.39	604,477.0
65-74 years	191	191	4,792,235	0.40	395,218.6
75-84 years	127	127	2,853,380	0.45	233,679.5
≥ 85 years	41	41	1,408,731	0.29	115,758.9
2013, April					
18-44 years	81	81	8,134,035	0.10	659,172.4
45-64 years	280	280	7,253,578	0.39	584,725.7
65-74 years	331	331	4,799,751	0.69	383,258.9
75-84 years	172	172	2,851,892	0.60	226,106.4
≥ 85 years	54	54	1,405,028	0.38	111,822.0
2013, May					
18-44 years	64	64	8,139,231	0.08	681,322.6
45-64 years	305	305	7,255,694	0.42	604,304.7
65-74 years	355	355	4,808,827	0.74	396,660.6
75-84 years	176	176	2,851,931	0.62	233,530.2
≥ 85 years	51	51	1,405,829	0.36	115,530.8
2013, June					
18-44 years	75	75	8,143,809	0.09	659,788.5
45-64 years	303	303	7,259,898	0.42	585,389.7
65-74 years	267	267	4,815,745	0.55	384,784.1
75-84 years	157	157	2,851,729	0.55	226,138.3
≥ 85 years	56	56	1,408,140	0.40	112,031.4

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2013, July					
18-44 years	85	85	8,158,469	0.10	683,101.4
45-64 years	395	395	7,288,086	0.54	607,359.2
65-74 years	283	283	4,845,395	0.58	400,148.6
75-84 years	175	175	2,859,802	0.61	234,393.2
≥ 85 years	63	63	1,412,502	0.45	116,206.4
2013, August					
18-44 years	96	96	8,195,465	0.12	684,678.8
45-64 years	388	388	7,297,485	0.53	607,602.1
65-74 years	304	304	4,863,486	0.63	401,125.0
75-84 years	175	175	2,864,580	0.61	234,483.7
≥ 85 years	59	59	1,416,206	0.42	116,345.6
2013, September					
18-44 years	85	85	8,179,124	0.10	660,990.4
45-64 years	367	367	7,294,592	0.50	588,146.7
65-74 years	269	269	4,872,080	0.55	389,328.5
75-84 years	166	166	2,862,456	0.58	227,030.1
≥ 85 years	34	34	1,416,322	0.24	112,762.2
2013, October					
18-44 years	106	106	8,124,695	0.13	680,234.9
45-64 years	402	402	7,301,556	0.55	607,936.3
65-74 years	318	318	4,887,922	0.65	402,981.9
75-84 years	181	181	2,867,862	0.63	234,664.7
≥ 85 years	52	52	1,419,580	0.37	116,630.1
2013, November					
18-44 years	89	89	8,114,094	0.11	657,962.2
45-64 years	347	347	7,289,160	0.48	587,816.8
65-74 years	279	279	4,879,063	0.57	389,952.6
75-84 years	153	153	2,855,250	0.54	226,688.0
≥ 85 years	43	43	1,413,722	0.30	112,663.3
2013, December					
18-44 years	69	69	8,085,491	0.09	677,240.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	301	301	7,272,585	0.41	605,751.8
65-74 years	282	282	4,882,657	0.58	403,393.2
75-84 years	168	168	2,856,311	0.59	234,508.8
≥ 85 years	39	39	1,413,838	0.28	116,519.8
2014, January					
18-44 years	104	104	8,873,043	0.12	741,538.7
45-64 years	490	490	7,900,203	0.62	656,932.3
65-74 years	433	433	5,545,516	0.78	457,500.4
75-84 years	225	225	3,215,569	0.70	263,547.9
≥ 85 years	62	62	1,580,090	0.39	130,013.0
2014, February					
18-44 years	88	88	8,818,855	0.10	667,361.5
45-64 years	407	407	7,851,780	0.52	591,432.5
65-74 years	368	368	5,542,399	0.66	414,362.6
75-84 years	226	226	3,207,332	0.70	238,293.2
≥ 85 years	49	49	1,574,872	0.31	117,384.6
2014, March					
18-44 years	106	106	8,802,363	0.12	736,461.1
45-64 years	445	445	7,831,616	0.57	651,818.1
65-74 years	434	434	5,571,276	0.78	459,863.6
75-84 years	242	242	3,222,359	0.75	264,103.8
≥ 85 years	64	64	1,582,192	0.40	130,119.2
2014, April					
18-44 years	93	93	8,765,869	0.11	709,814.9
45-64 years	368	368	7,795,435	0.47	627,853.6
65-74 years	376	376	5,589,363	0.67	446,165.2
75-84 years	227	227	3,231,998	0.70	256,089.1
≥ 85 years	54	54	1,585,249	0.34	126,072.7
2014, May					
18-44 years	91	91	8,749,273	0.10	731,766.3
45-64 years	359	359	7,764,368	0.46	646,073.5
65-74 years	322	322	5,587,162	0.58	460,651.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	170	170	3,229,002	0.53	264,242.1
≥ 85 years	57	57	1,583,612	0.36	130,070.1
2014, June					
18-44 years	80	80	8,730,043	0.09	706,897.1
45-64 years	322	322	7,741,531	0.42	623,713.6
65-74 years	290	290	5,586,898	0.52	446,226.9
75-84 years	139	139	3,222,856	0.43	255,453.3
≥ 85 years	59	59	1,580,445	0.37	125,715.9
2014, July					
18-44 years	83	83	8,808,988	0.09	736,882.4
45-64 years	343	343	7,801,603	0.44	649,435.5
65-74 years	277	277	5,608,211	0.49	462,840.2
75-84 years	135	135	3,220,677	0.42	263,713.7
≥ 85 years	52	52	1,579,358	0.33	129,769.4
2014, August					
18-44 years	82	82	8,772,603	0.09	733,168.1
45-64 years	324	324	7,757,144	0.42	645,470.1
65-74 years	246	246	5,625,046	0.44	464,013.1
75-84 years	137	137	3,224,105	0.42	263,841.1
≥ 85 years	44	44	1,580,713	0.28	129,850.4
2014, September					
18-44 years	74	74	8,745,204	0.08	708,083.1
45-64 years	350	350	7,736,029	0.45	623,272.4
65-74 years	257	257	5,633,159	0.46	449,972.3
75-84 years	149	149	3,223,453	0.46	255,525.9
≥ 85 years	36	36	1,579,481	0.23	125,719.2
2014, October					
18-44 years	102	102	8,761,627	0.12	732,939.9
45-64 years	449	449	7,735,896	0.58	643,421.6
65-74 years	333	333	5,654,698	0.59	465,850.6
75-84 years	176	176	3,233,821	0.54	264,371.8
≥ 85 years	64	64	1,583,791	0.40	129,971.7

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2014, November					
18-44 years	97	97	8,731,463	0.11	707,933.4
45-64 years	377	377	7,711,217	0.49	621,733.1
65-74 years	299	299	5,644,276	0.53	451,285.4
75-84 years	162	162	3,223,374	0.50	255,976.1
≥ 85 years	48	48	1,577,735	0.30	125,727.4
2014, December					
18-44 years	113	113	8,734,837	0.13	730,143.2
45-64 years	398	398	7,710,752	0.52	640,567.1
65-74 years	342	342	5,651,163	0.61	466,025.3
75-84 years	189	189	3,224,160	0.59	264,089.6
≥ 85 years	54	54	1,575,314	0.34	129,615.4
2015, January					
18-44 years	181	181	9,100,485	0.20	760,792.1
45-64 years	622	622	8,007,202	0.78	665,831.6
65-74 years	609	609	5,868,721	1.04	483,963.7
75-84 years	285	285	3,292,199	0.87	269,596.7
≥ 85 years	106	106	1,594,791	0.66	131,082.6
2015, February					
18-44 years	171	171	9,063,819	0.19	685,659.9
45-64 years	729	729	7,989,169	0.91	601,197.9
65-74 years	648	648	5,866,920	1.10	437,898.9
75-84 years	368	368	3,281,608	1.12	243,274.0
≥ 85 years	164	164	1,581,755	1.04	117,699.3
2015, March					
18-44 years	211	211	9,077,269	0.23	759,212.7
45-64 years	757	757	8,010,566	0.95	666,302.7
65-74 years	805	805	5,892,685	1.37	485,998.5
75-84 years	461	461	3,295,268	1.40	269,743.1
≥ 85 years	183	183	1,585,806	1.15	130,257.5
2015, April					
18-44 years	163	163	9,116,083	0.18	738,134.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	730	730	8,042,440	0.91	647,554.4
65-74 years	677	677	5,896,978	1.15	470,567.9
75-84 years	458	458	3,294,757	1.39	260,864.5
≥ 85 years	178	178	1,582,941	1.12	125,779.5
2015, May					
18-44 years	185	185	9,152,851	0.20	765,592.9
45-64 years	734	734	8,078,376	0.91	672,035.5
65-74 years	659	659	5,905,892	1.12	486,804.4
75-84 years	412	412	3,293,919	1.25	269,309.6
≥ 85 years	170	170	1,580,037	1.08	129,709.6
2015, June					
18-44 years	170	170	9,161,169	0.19	741,683.5
45-64 years	806	806	8,082,207	1.00	650,902.1
65-74 years	733	733	5,911,711	1.24	471,756.4
75-84 years	459	459	3,290,653	1.39	260,580.3
≥ 85 years	178	178	1,578,733	1.13	125,453.2
2015, July					
18-44 years	209	209	9,152,724	0.23	765,582.3
45-64 years	879	879	8,077,598	1.09	672,209.9
65-74 years	780	780	5,939,320	1.31	490,002.6
75-84 years	445	445	3,295,958	1.35	269,681.9
≥ 85 years	193	193	1,581,088	1.22	129,871.9
2015, August					
18-44 years	187	187	9,163,735	0.20	766,075.8
45-64 years	804	804	8,073,804	1.00	671,915.1
65-74 years	795	795	5,958,804	1.33	491,718.1
75-84 years	465	465	3,303,045	1.41	270,322.9
≥ 85 years	161	161	1,583,743	1.02	130,124.1
2015, September					
18-44 years	210	210	9,174,232	0.23	742,727.8
45-64 years	847	847	8,082,378	1.05	650,886.0
65-74 years	852	852	5,977,252	1.43	477,286.2

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	542	542	3,306,502	1.64	261,888.9
≥ 85 years	192	192	1,584,965	1.21	126,032.3
2015, October					
18-44 years	251	251	9,165,264	0.27	766,244.5
45-64 years	900	900	8,092,331	1.11	672,270.2
65-74 years	929	929	6,004,392	1.55	494,397.7
75-84 years	518	518	3,316,179	1.56	270,878.6
≥ 85 years	188	188	1,589,242	1.18	130,309.4
2015, November					
18-44 years	218	218	9,137,229	0.24	740,198.0
45-64 years	863	863	8,070,264	1.07	649,941.5
65-74 years	904	904	5,992,141	1.51	478,783.1
75-84 years	526	526	3,303,891	1.59	262,051.3
≥ 85 years	215	215	1,581,676	1.36	125,959.8
2015, December					
18-44 years	244	244	9,140,219	0.27	764,457.6
45-64 years	1,025	1,025	8,076,025	1.27	670,867.3
65-74 years	990	990	6,006,218	1.65	494,992.0
75-84 years	682	682	3,311,457	2.06	270,924.6
≥ 85 years	213	213	1,583,322	1.35	130,102.7
2016, January					
18-44 years	258	258	9,176,220	0.28	766,940.8
45-64 years	1,223	1,223	8,154,456	1.50	677,817.0
65-74 years	1,464	1,464	6,221,672	2.35	512,641.8
75-84 years	827	827	3,373,232	2.45	275,891.9
≥ 85 years	305	305	1,604,515	1.90	131,756.6
2016, February					
18-44 years	310	310	9,325,950	0.33	716,442.5
45-64 years	1,342	1,342	8,268,075	1.62	633,641.7
65-74 years	1,572	1,572	6,301,064	2.49	480,773.8
75-84 years	885	885	3,379,993	2.62	258,569.1
≥ 85 years	367	367	1,603,408	2.29	123,145.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2016, March					
18-44 years	340	340	9,344,110	0.36	768,020.0
45-64 years	1,510	1,510	8,274,584	1.82	679,504.0
65-74 years	1,689	1,689	6,327,246	2.67	514,900.1
75-84 years	1,005	1,005	3,395,108	2.96	276,652.7
≥ 85 years	373	373	1,607,208	2.32	131,501.3
2016, April					
18-44 years	400	400	9,362,785	0.43	742,641.0
45-64 years	1,458	1,458	8,254,230	1.77	656,554.2
65-74 years	1,827	1,827	6,323,795	2.89	498,574.7
75-84 years	1,116	1,116	3,394,424	3.29	267,926.7
≥ 85 years	393	393	1,603,015	2.45	127,074.2
2016, May					
18-44 years	396	396	9,372,241	0.42	770,240.4
45-64 years	1,556	1,556	8,239,478	1.89	677,617.1
65-74 years	1,982	1,982	6,326,026	3.13	515,252.6
75-84 years	1,161	1,161	3,397,631	3.42	276,939.5
≥ 85 years	405	405	1,602,141	2.53	131,096.2
2016, June					
18-44 years	388	388	9,420,958	0.41	744,840.9
45-64 years	1,490	1,490	8,267,083	1.80	655,097.1
65-74 years	1,936	1,936	6,364,931	3.04	499,766.6
75-84 years	1,133	1,133	3,408,541	3.32	268,679.1
≥ 85 years	383	383	1,603,035	2.39	126,988.7
2016, July					
18-44 years	354	354	9,439,126	0.38	769,754.8
45-64 years	1,395	1,395	8,213,249	1.70	676,374.3
65-74 years	1,711	1,711	6,368,804	2.69	518,935.5
75-84 years	981	981	3,414,091	2.87	278,679.6
≥ 85 years	374	374	1,603,410	2.33	131,421.0
2016, August					
18-44 years	408	408	9,416,905	0.43	768,495.9

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	1,750	1,750	8,230,288	2.13	676,076.8
65-74 years	1,998	1,998	6,392,801	3.13	520,221.7
75-84 years	1,110	1,110	3,428,500	3.24	279,500.5
≥ 85 years	418	418	1,607,526	2.60	131,592.9
2016, September					
18-44 years	392	392	9,434,469	0.42	745,800.8
45-64 years	1,781	1,781	8,255,250	2.16	654,223.6
65-74 years	2,038	2,038	6,404,820	3.18	504,824.0
75-84 years	1,119	1,119	3,431,581	3.26	271,030.1
≥ 85 years	434	434	1,607,962	2.70	127,543.9
2016, October					
18-44 years	451	451	9,379,269	0.48	772,388.8
45-64 years	1,875	1,875	8,226,366	2.28	676,925.0
65-74 years	2,225	2,225	6,420,451	3.47	523,389.4
75-84 years	1,205	1,205	3,440,101	3.50	280,707.2
≥ 85 years	469	469	1,610,263	2.91	131,901.2
2016, November					
18-44 years	437	437	9,441,046	0.46	748,248.7
45-64 years	1,924	1,924	8,261,933	2.33	655,041.0
65-74 years	2,371	2,371	6,415,440	3.70	507,212.7
75-84 years	1,324	1,324	3,436,159	3.85	271,907.7
≥ 85 years	455	455	1,604,218	2.84	127,480.0
2016, December					
18-44 years	432	432	10,696,088	0.40	779,225.6
45-64 years	1,865	1,865	9,195,836	2.03	680,330.7
65-74 years	2,388	2,388	6,843,153	3.49	525,344.6
75-84 years	1,444	1,444	3,586,282	4.03	281,504.8
≥ 85 years	496	496	1,654,234	3.00	131,663.4
2017, January					
18-44 years	519	519	9,465,272	0.55	778,709.6
45-64 years	2,053	2,053	8,204,900	2.50	674,527.8
65-74 years	2,857	2,857	6,500,557	4.40	529,619.9

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	1,507	1,507	3,438,853	4.38	280,643.2
≥ 85 years	512	512	1,587,598	3.22	130,169.8
2017, February					
18-44 years	448	448	9,297,604	0.48	702,997.8
45-64 years	2,033	2,033	8,086,799	2.51	607,838.7
65-74 years	2,666	2,666	6,406,324	4.16	477,952.7
75-84 years	1,522	1,522	3,417,742	4.45	253,278.0
≥ 85 years	502	502	1,571,365	3.19	116,884.8
2017, March					
18-44 years	585	585	9,327,787	0.63	779,701.9
45-64 years	2,187	2,187	8,104,819	2.70	672,990.1
65-74 years	2,820	2,820	6,434,056	4.38	529,769.8
75-84 years	1,679	1,679	3,434,437	4.89	280,607.8
≥ 85 years	577	577	1,573,762	3.67	129,133.4
2017, April					
18-44 years	448	448	9,326,910	0.48	755,106.4
45-64 years	1,852	1,852	8,085,974	2.29	650,435.5
65-74 years	2,446	2,446	6,423,129	3.81	512,293.3
75-84 years	1,376	1,376	3,430,625	4.01	271,479.6
≥ 85 years	466	466	1,565,479	2.98	124,437.5
2017, May					
18-44 years	509	509	9,336,398	0.55	780,617.5
45-64 years	2,051	2,051	8,076,349	2.54	671,067.2
65-74 years	2,500	2,500	6,422,364	3.89	528,959.7
75-84 years	1,500	1,500	3,432,128	4.37	280,357.2
≥ 85 years	515	515	1,563,077	3.29	128,229.1
2017, June					
18-44 years	499	499	9,345,343	0.53	756,404.8
45-64 years	2,006	2,006	8,068,837	2.49	649,248.4
65-74 years	2,289	2,289	6,422,885	3.56	512,443.4
75-84 years	1,361	1,361	3,429,840	3.97	271,504.4
≥ 85 years	489	489	1,560,248	3.13	124,008.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2017, July					
18-44 years	448	448	9,337,822	0.48	781,072.6
45-64 years	1,768	1,768	8,044,798	2.20	669,442.6
65-74 years	2,119	2,119	6,446,061	3.29	532,384.2
75-84 years	1,277	1,277	3,436,709	3.72	281,599.0
≥ 85 years	465	465	1,560,250	2.98	128,333.8
2017, August					
18-44 years	558	558	9,376,293	0.60	783,090.6
45-64 years	1,922	1,922	8,060,365	2.38	669,667.2
65-74 years	2,524	2,524	6,471,392	3.90	533,061.2
75-84 years	1,499	1,499	3,453,887	4.34	282,074.7
≥ 85 years	517	517	1,563,923	3.31	128,326.4
2017, September					
18-44 years	452	452	9,398,518	0.48	760,080.2
45-64 years	1,802	1,802	8,051,607	2.24	647,905.5
65-74 years	2,186	2,186	6,476,558	3.38	517,010.7
75-84 years	1,286	1,286	3,459,174	3.72	273,778.4
≥ 85 years	468	468	1,562,059	3.00	124,242.4
2017, October					
18-44 years	540	540	9,430,536	0.57	788,601.3
45-64 years	2,078	2,078	8,066,894	2.58	670,379.2
65-74 years	2,535	2,535	6,493,201	3.90	534,771.5
75-84 years	1,445	1,445	3,476,501	4.16	283,848.0
≥ 85 years	477	477	1,564,101	3.05	128,407.4
2017, November					
18-44 years	535	535	9,433,265	0.57	764,020.6
45-64 years	2,080	2,080	8,056,501	2.58	648,394.3
65-74 years	2,748	2,748	6,477,550	4.24	517,049.0
75-84 years	1,509	1,509	3,478,149	4.34	275,452.3
≥ 85 years	547	547	1,558,806	3.51	124,119.9
2017, December					
18-44 years	555	555	9,488,685	0.58	793,772.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	2,162	2,162	8,091,437	2.67	671,845.8
65-74 years	2,659	2,659	6,478,341	4.10	533,599.4
75-84 years	1,578	1,578	3,492,434	4.52	285,540.1
≥ 85 years	566	566	1,558,251	3.63	128,135.1
2018, January					
18-44 years	635	635	9,387,361	0.68	784,459.3
45-64 years	2,433	2,433	7,953,725	3.06	660,373.1
65-74 years	3,234	3,234	6,576,139	4.92	541,336.0
75-84 years	1,858	1,858	3,513,732	5.29	286,989.0
≥ 85 years	679	679	1,558,715	4.36	128,000.2
2018, February					
18-44 years	630	630	9,358,498	0.67	707,598.9
45-64 years	2,311	2,311	7,920,293	2.92	595,218.7
65-74 years	3,188	3,188	6,559,008	4.86	489,306.8
75-84 years	1,799	1,799	3,507,213	5.13	259,830.9
≥ 85 years	713	713	1,544,201	4.62	114,931.1
2018, March					
18-44 years	697	697	9,368,243	0.74	783,364.6
45-64 years	2,570	2,570	7,928,618	3.24	658,371.8
65-74 years	3,294	3,294	6,589,258	5.00	542,389.4
75-84 years	2,087	2,087	3,533,830	5.91	288,513.7
≥ 85 years	698	698	1,548,219	4.51	127,016.3
2018, April					
18-44 years	620	620	9,339,102	0.66	756,258.4
45-64 years	2,354	2,354	7,895,979	2.98	635,129.2
65-74 years	3,151	3,151	6,580,285	4.79	524,761.3
75-84 years	1,930	1,930	3,536,432	5.46	279,729.1
≥ 85 years	684	684	1,543,453	4.43	122,656.0
2018, May					
18-44 years	616	616	9,334,074	0.66	780,477.6
45-64 years	2,452	2,452	7,873,220	3.11	654,078.4
65-74 years	3,102	3,102	6,573,697	4.72	541,278.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	1,885	1,885	3,541,350	5.32	289,181.6
≥ 85 years	617	617	1,540,857	4.00	126,439.6
2018, June					
18-44 years	586	586	9,329,819	0.63	755,163.3
45-64 years	2,303	2,303	7,857,567	2.93	632,018.0
65-74 years	2,783	2,783	6,571,993	4.23	524,245.7
75-84 years	1,616	1,616	3,543,087	4.56	280,326.5
≥ 85 years	589	589	1,537,477	3.83	122,226.9
2018, July					
18-44 years	254	254	9,299,490	0.27	777,751.2
45-64 years	1,089	1,089	7,822,285	1.39	650,604.9
65-74 years	1,232	1,232	6,594,504	1.87	544,465.1
75-84 years	767	767	3,549,698	2.16	290,750.7
≥ 85 years	275	275	1,536,578	1.79	126,382.2
2018, August					
18-44 years	46	46	9,316,964	0.05	778,634.6
45-64 years	181	181	7,823,740	0.23	649,989.6
65-74 years	180	180	6,621,705	0.27	545,547.4
75-84 years	91	91	3,569,323	0.25	291,613.1
≥ 85 years	39	39	1,539,475	0.25	126,384.8
2018, September					
18-44 years	55	55	9,311,506	0.06	753,685.1
45-64 years	201	201	7,811,887	0.26	628,619.7
65-74 years	179	179	6,628,459	0.27	529,311.1
75-84 years	117	117	3,573,287	0.33	283,103.7
≥ 85 years	41	41	1,536,737	0.27	122,298.9
2018, October					
18-44 years	113	113	9,305,628	0.12	777,790.0
45-64 years	355	355	7,810,671	0.45	648,558.6
65-74 years	409	409	6,655,857	0.61	547,967.1
75-84 years	216	216	3,594,196	0.60	293,494.1
≥ 85 years	85	85	1,540,093	0.55	126,339.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2018, November					
18-44 years	149	149	9,309,494	0.16	753,878.4
45-64 years	549	549	7,800,785	0.70	627,690.9
65-74 years	699	699	6,649,127	1.05	530,961.9
75-84 years	425	425	3,590,756	1.18	284,635.0
≥ 85 years	150	150	1,534,095	0.98	122,121.3
2018, December					
18-44 years	100	100	9,323,750	0.11	779,965.7
45-64 years	420	420	7,810,831	0.54	648,735.9
65-74 years	477	477	6,662,134	0.72	549,412.8
75-84 years	331	331	3,599,825	0.92	294,826.3
≥ 85 years	108	108	1,532,691	0.70	126,089.1
2019, January					
18-44 years	0	0	9,161,315	0.00	765,578.7
45-64 years	0	0	7,679,078	0.00	637,514.8
65-74 years	0	0	6,682,391	0.00	550,152.1
75-84 years	0	0	3,583,947	0.00	292,828.0
≥ 85 years	0	0	1,520,016	0.00	124,747.0
2019, February					
18-44 years	0	0	9,127,310	0.00	690,495.3
45-64 years	0	0	7,640,253	0.00	574,374.2
65-74 years	0	0	6,666,836	0.00	497,681.8
75-84 years	0	0	3,571,955	0.00	264,725.7
≥ 85 years	0	0	1,509,718	0.00	112,368.2
2019, March					
18-44 years	0	0	9,134,562	0.00	763,777.9
45-64 years	0	0	7,642,005	0.00	634,532.1
65-74 years	0	0	6,693,440	0.00	551,251.2
75-84 years	0	0	3,589,367	0.00	293,352.4
≥ 85 years	0	0	1,512,749	0.00	124,147.8
2019, April					
18-44 years	0	0	9,114,225	0.00	737,660.4

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	0	0	7,606,045	0.00	611,331.1
65-74 years	0	0	6,678,869	0.00	532,307.7
75-84 years	0	0	3,582,472	0.00	283,268.4
≥ 85 years	0	0	1,505,107	0.00	119,531.8
2019, May					
18-44 years	0	0	9,106,433	0.00	761,432.7
45-64 years	0	0	7,577,167	0.00	629,289.8
65-74 years	0	0	6,671,015	0.00	549,197.8
75-84 years	0	0	3,578,709	0.00	292,207.2
≥ 85 years	0	0	1,501,690	0.00	123,129.9
2019, June					
18-44 years	0	0	9,091,191	0.00	735,943.4
45-64 years	0	0	7,550,932	0.00	607,217.9
65-74 years	0	0	6,667,557	0.00	531,771.2
75-84 years	0	0	3,574,461	0.00	282,733.5
≥ 85 years	0	0	1,497,410	0.00	118,934.0
2019, July					
18-44 years	0	0	9,093,784	0.00	760,336.3
45-64 years	0	0	7,545,305	0.00	626,651.7
65-74 years	0	0	6,708,925	0.00	552,461.0
75-84 years	0	0	3,590,758	0.00	293,017.9
≥ 85 years	0	0	1,501,937	0.00	123,043.9
2019, August					
18-44 years	0	0	9,104,228	0.00	760,648.5
45-64 years	0	0	7,550,890	0.00	626,465.0
65-74 years	0	0	6,764,246	0.00	555,905.7
75-84 years	0	0	3,624,462	0.00	295,080.9
≥ 85 years	0	0	1,515,520	0.00	123,844.9
2019, September					
18-44 years	0	0	9,104,058	0.00	736,443.3
45-64 years	0	0	7,549,377	0.00	606,552.3
65-74 years	0	0	6,797,852	0.00	541,598.8

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	0	0	3,640,400	0.00	287,547.1
≥ 85 years	0	0	1,521,526	0.00	120,626.7
2019, October					
18-44 years	0	0	9,103,174	0.00	760,995.9
45-64 years	0	0	7,544,021	0.00	625,912.1
65-74 years	0	0	6,835,746	0.00	561,844.5
75-84 years	0	0	3,663,199	0.00	298,389.2
≥ 85 years	0	0	1,530,415	0.00	125,173.0
2019, November					
18-44 years	0	0	9,098,398	0.00	736,811.2
45-64 years	0	0	7,529,419	0.00	605,472.5
65-74 years	0	0	6,832,195	0.00	544,975.2
75-84 years	0	0	3,657,228	0.00	289,427.7
≥ 85 years	0	0	1,524,919	0.00	121,222.2
2019, December					
18-44 years	0	0	9,116,903	0.00	762,942.3
45-64 years	0	0	7,539,345	0.00	626,143.0
65-74 years	0	0	6,843,823	0.00	564,266.9
75-84 years	0	0	3,664,849	0.00	300,005.1
≥ 85 years	0	0	1,523,821	0.00	125,279.4
2020, January					
18-44 years	0	0	8,986,565	0.00	750,177.3
45-64 years	0	0	7,419,092	0.00	615,155.2
65-74 years	0	0	6,943,046	0.00	571,609.0
75-84 years	0	0	3,694,576	0.00	301,786.5
≥ 85 years	0	0	1,531,007	0.00	125,584.1
2020, February					
18-44 years	0	0	9,071,381	0.00	700,718.4
45-64 years	0	0	7,445,927	0.00	573,688.0
65-74 years	0	0	7,016,205	0.00	535,429.0
75-84 years	0	0	3,692,891	0.00	282,351.5
≥ 85 years	0	0	1,526,710	0.00	117,184.0

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2020, March					
18-44 years	0	0	9,091,245	0.00	749,252.8
45-64 years	0	0	7,443,084	0.00	612,338.0
65-74 years	0	0	7,038,015	0.00	573,844.3
75-84 years	0	0	3,705,390	0.00	302,588.6
≥ 85 years	0	0	1,528,183	0.00	125,321.2
2020, April					
18-44 years	0	0	9,075,730	0.00	726,257.5
45-64 years	0	0	7,447,973	0.00	596,019.5
65-74 years	0	0	7,116,965	0.00	565,709.8
75-84 years	0	0	3,753,814	0.00	299,100.1
≥ 85 years	0	0	1,542,992	0.00	123,278.3
2020, May					
18-44 years	0	0	9,153,112	0.00	754,807.9
45-64 years	0	0	7,534,461	0.00	620,845.8
65-74 years	0	0	7,279,402	0.00	595,417.9
75-84 years	0	0	3,847,805	0.00	315,325.6
≥ 85 years	0	0	1,566,846	0.00	128,841.7
2020, June					
18-44 years	0	0	9,255,133	0.00	734,398.8
45-64 years	0	0	7,603,031	0.00	603,554.3
65-74 years	0	0	7,398,245	0.00	582,246.5
75-84 years	0	0	3,904,985	0.00	308,490.5
≥ 85 years	0	0	1,582,906	0.00	125,584.1
2020, July					
18-44 years	0	0	9,296,333	0.00	759,505.8
45-64 years	0	0	7,569,687	0.00	623,177.2
65-74 years	0	0	7,442,197	0.00	605,983.6
75-84 years	0	0	3,929,093	0.00	320,597.1
≥ 85 years	0	0	1,592,773	0.00	130,397.3
2020, August					
18-44 years	0	0	9,274,591	0.00	759,954.0

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	0	0	7,584,827	0.00	623,450.5
65-74 years	0	0	7,486,130	0.00	609,643.9
75-84 years	0	0	3,952,317	0.00	322,487.8
≥ 85 years	0	0	1,600,407	0.00	131,064.2
2020, September					
18-44 years	0	0	9,216,988	0.00	731,132.1
45-64 years	0	0	7,579,894	0.00	601,394.4
65-74 years	0	0	7,532,777	0.00	593,688.2
75-84 years	0	0	3,976,933	0.00	313,814.3
≥ 85 years	0	0	1,608,651	0.00	127,349.6
2020, October					
18-44 years	0	0	9,193,389	0.00	758,328.2
45-64 years	0	0	7,560,762	0.00	622,065.4
65-74 years	0	0	7,579,235	0.00	617,078.1
75-84 years	0	0	4,007,653	0.00	326,201.6
≥ 85 years	0	0	1,619,843	0.00	132,289.5
2020, November					
18-44 years	0	0	9,221,551	0.00	736,146.4
45-64 years	0	0	7,576,294	0.00	603,408.4
65-74 years	0	0	7,591,709	0.00	600,886.9
75-84 years	0	0	4,014,004	0.00	317,684.8
≥ 85 years	0	0	1,618,484	0.00	128,506.9
2020, December					
18-44 years	0	0	10,266,951	0.00	766,557.8
45-64 years	0	0	8,310,148	0.00	627,494.4
65-74 years	0	0	8,266,284	0.00	626,506.4
75-84 years	0	0	4,270,577	0.00	331,256.6
≥ 85 years	0	0	1,690,033	0.00	133,377.8
2021, January					
18-44 years	0	0	9,381,782	0.00	774,388.3
45-64 years	0	0	7,681,319	0.00	631,759.7
65-74 years	0	0	7,813,588	0.00	636,682.1

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	0	0	4,087,162	0.00	333,054.3
≥ 85 years	0	0	1,630,032	0.00	133,166.2
2021, February					
18-44 years	0	0	9,266,325	0.00	701,085.7
45-64 years	0	0	7,618,091	0.00	572,102.6
65-74 years	0	0	7,767,637	0.00	579,119.9
75-84 years	0	0	4,095,961	0.00	303,099.6
≥ 85 years	0	0	1,625,260	0.00	120,492.0
2021, March					
18-44 years	0	0	9,285,032	0.00	775,880.4
45-64 years	0	0	7,615,217	0.00	633,341.8
65-74 years	0	0	7,788,382	0.00	644,333.6
75-84 years	0	0	4,105,542	0.00	337,071.1
≥ 85 years	0	0	1,624,887	0.00	133,840.6
2021, April					
18-44 years	0	0	9,198,813	0.00	747,142.5
45-64 years	0	0	7,503,958	0.00	606,601.7
65-74 years	0	0	7,653,776	0.00	615,297.6
75-84 years	0	0	4,019,707	0.00	320,934.3
≥ 85 years	0	0	1,589,183	0.00	127,249.5
2021, May					
18-44 years	0	0	9,115,108	0.00	764,156.7
45-64 years	0	0	7,425,492	0.00	618,811.4
65-74 years	0	0	7,574,271	0.00	626,529.8
75-84 years	0	0	3,973,145	0.00	326,183.1
≥ 85 years	0	0	1,566,545	0.00	129,086.8
2021, June					
18-44 years	0	0	9,041,948	0.00	732,740.0
45-64 years	0	0	7,376,671	0.00	593,778.0
65-74 years	0	0	7,550,472	0.00	602,799.3
75-84 years	0	0	3,963,138	0.00	313,731.2
≥ 85 years	0	0	1,557,573	0.00	123,794.7

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2021, July					
18-44 years	0	0	8,967,153	0.00	750,666.3
45-64 years	0	0	7,327,814	0.00	609,483.9
65-74 years	0	0	7,544,687	0.00	622,559.1
75-84 years	0	0	3,961,147	0.00	323,919.2
≥ 85 years	0	0	1,551,474	0.00	127,422.0
2021, August					
18-44 years	0	0	8,909,004	0.00	745,325.0
45-64 years	0	0	7,284,973	0.00	605,863.0
65-74 years	0	0	7,525,967	0.00	620,847.1
75-84 years	0	0	3,961,798	0.00	323,914.0
≥ 85 years	0	0	1,544,622	0.00	126,949.3
2021, September					
18-44 years	0	0	8,847,418	0.00	717,025.6
45-64 years	0	0	7,237,552	0.00	582,823.8
65-74 years	0	0	7,501,646	0.00	599,218.2
75-84 years	0	0	3,965,841	0.00	313,937.1
≥ 85 years	0	0	1,538,410	0.00	122,428.6
2021, October					
18-44 years	0	0	8,794,893	0.00	736,254.9
45-64 years	0	0	7,203,055	0.00	598,713.7
65-74 years	0	0	7,494,173	0.00	617,300.0
75-84 years	0	0	3,985,400	0.00	325,267.5
≥ 85 years	0	0	1,536,519	0.00	126,135.6
2021, November					
18-44 years	0	0	8,749,707	0.00	709,574.0
45-64 years	0	0	7,166,680	0.00	577,315.4
65-74 years	0	0	7,450,141	0.00	595,085.3
75-84 years	0	0	3,983,058	0.00	315,559.0
≥ 85 years	0	0	1,525,584	0.00	121,572.5
2021, December					
18-44 years	0	0	8,726,561	0.00	731,479.7

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	0	0	7,148,818	0.00	594,707.4
65-74 years	0	0	7,410,326	0.00	611,479.6
75-84 years	0	0	3,989,359	0.00	326,659.5
≥ 85 years	0	0	1,516,694	0.00	124,887.6
2022, January					
18-44 years	0	0	8,405,657	0.00	704,233.8
45-64 years	0	0	6,903,167	0.00	574,917.4
65-74 years	0	0	7,387,245	0.00	610,225.5
75-84 years	0	0	3,976,033	0.00	325,808.2
≥ 85 years	0	0	1,506,037	0.00	124,037.0
2022, February					
18-44 years	0	0	8,354,858	0.00	633,167.4
45-64 years	0	0	6,858,065	0.00	516,498.6
65-74 years	0	0	7,339,629	0.00	548,666.7
75-84 years	0	0	3,967,052	0.00	294,417.5
≥ 85 years	0	0	1,487,972	0.00	110,911.9
2022, March					
18-44 years	0	0	8,348,025	0.00	698,776.1
45-64 years	0	0	6,854,139	0.00	569,691.2
65-74 years	0	0	7,343,435	0.00	605,072.7
75-84 years	0	0	3,997,679	0.00	326,485.5
≥ 85 years	0	0	1,490,394	0.00	122,294.0
2022, April					
18-44 years	0	0	8,319,160	0.00	673,996.5
45-64 years	0	0	6,821,708	0.00	548,979.9
65-74 years	0	0	7,312,574	0.00	583,457.2
75-84 years	0	0	4,001,061	0.00	316,617.2
≥ 85 years	0	0	1,487,127	0.00	118,147.3
2022, May					
18-44 years	0	0	8,297,817	0.00	694,342.1
45-64 years	0	0	6,800,127	0.00	565,194.3
65-74 years	0	0	7,307,195	0.00	601,951.0

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	0	0	4,018,998	0.00	328,244.6
≥ 85 years	0	0	1,488,802	0.00	122,114.2
2022, June					
18-44 years	0	0	8,301,014	0.00	672,081.1
45-64 years	0	0	6,790,708	0.00	546,268.5
65-74 years	0	0	7,299,152	0.00	582,116.8
75-84 years	0	0	4,035,098	0.00	319,045.3
≥ 85 years	0	0	1,488,728	0.00	118,208.8
2022, July					
18-44 years	0	0	8,257,152	0.00	690,577.0
45-64 years	0	0	6,750,560	0.00	561,064.2
65-74 years	0	0	7,308,368	0.00	602,661.4
75-84 years	0	0	4,052,524	0.00	331,231.0
≥ 85 years	0	0	1,492,092	0.00	122,386.5
2022, August					
18-44 years	0	0	8,293,145	0.00	690,359.8
45-64 years	0	0	6,748,244	0.00	559,828.4
65-74 years	0	0	7,323,261	0.00	603,207.0
75-84 years	0	0	4,073,678	0.00	332,617.5
≥ 85 years	0	0	1,494,610	0.00	122,512.4
2022, September					
18-44 years	0	0	5,790,783	0.00	468,869.4
45-64 years	0	0	5,017,361	0.00	403,404.3
65-74 years	0	0	7,191,411	0.00	574,223.2
75-84 years	0	0	4,062,772	0.00	321,673.4
≥ 85 years	0	0	1,486,543	0.00	118,137.1
2022, October					
18-44 years	0	0	5,124,002	0.00	428,790.3
45-64 years	0	0	3,700,182	0.00	307,705.4
65-74 years	0	0	1,149,066	0.00	94,714.7
75-84 years	0	0	532,380	0.00	43,619.0
≥ 85 years	0	0	180,721	0.00	14,829.7

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2022, November					
18-44 years	0	0	1,546,194	0.00	125,779.2
45-64 years	0	0	1,015,580	0.00	81,904.1
65-74 years	0	0	641,203	0.00	51,303.9
75-84 years	0	0	306,921	0.00	24,366.2
≥ 85 years	0	0	94,527	0.00	7,512.3
2022, December					
18-44 years	0	0	1,556,653	0.00	130,800.3
45-64 years	0	0	1,020,388	0.00	84,982.0
65-74 years	0	0	643,598	0.00	53,193.5
75-84 years	0	0	308,809	0.00	25,336.3
≥ 85 years	0	0	94,754	0.00	7,792.1
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan					
Contaminated valsartan					
2012, May					
18-44 years	0	0	8,364,508	0.00	685,791.5
45-64 years	0	0	7,525,643	0.00	618,088.7
65-74 years	0	0	4,787,090	0.00	390,798.7
75-84 years	0	0	2,975,916	0.00	243,391.1
≥ 85 years	0	0	1,478,285	0.00	121,347.1
2012, June					
18-44 years	0	0	8,439,754	0.00	664,978.5
45-64 years	0	0	7,572,017	0.00	599,028.0
65-74 years	0	0	4,812,888	0.00	378,816.8
75-84 years	0	0	2,976,439	0.00	235,451.1
≥ 85 years	0	0	1,479,239	0.00	117,446.2
2012, July					
18-44 years	0	0	8,433,567	0.00	687,065.5
45-64 years	0	0	7,512,418	0.00	618,367.3
65-74 years	0	0	4,815,120	0.00	393,489.8
75-84 years	0	0	2,972,401	0.00	243,646.9
≥ 85 years	0	0	1,479,218	0.00	121,640.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2012, August					
18-44 years	0	0	8,458,411	0.00	688,780.3
45-64 years	0	0	7,534,562	0.00	618,951.9
65-74 years	0	0	4,842,935	0.00	394,472.6
75-84 years	0	0	2,980,930	0.00	243,764.8
≥ 85 years	0	0	1,484,666	0.00	121,820.5
2012, September					
18-44 years	294	294	8,461,860	0.35	667,463.8
45-64 years	2,303	2,303	7,546,214	3.05	599,710.0
65-74 years	1,739	1,739	4,852,539	3.58	383,018.4
75-84 years	1,166	1,166	2,978,540	3.91	235,991.0
≥ 85 years	401	401	1,485,027	2.70	118,067.0
2012, October					
18-44 years	1,743	1,743	8,410,780	2.07	692,353.4
45-64 years	12,158	12,158	7,535,482	16.13	620,487.1
65-74 years	10,924	10,924	4,872,569	22.42	397,292.1
75-84 years	7,125	7,125	2,985,327	23.87	244,054.5
≥ 85 years	2,733	2,733	1,489,217	18.35	122,217.3
2012, November					
18-44 years	772	772	8,383,816	0.92	670,514.1
45-64 years	5,407	5,407	7,522,298	7.19	601,201.8
65-74 years	5,937	5,937	4,877,771	12.17	385,739.1
75-84 years	3,957	3,957	2,976,557	13.29	236,289.4
≥ 85 years	1,418	1,418	1,484,866	9.55	118,305.0
2012, December					
18-44 years	462	462	8,954,111	0.52	694,328.3
45-64 years	3,454	3,454	7,957,095	4.34	622,901.1
65-74 years	4,071	4,071	5,338,172	7.63	400,981.5
75-84 years	2,567	2,567	3,184,349	8.06	244,629.9
≥ 85 years	905	905	1,566,633	5.78	122,311.3
2013, January					
18-44 years	428	428	8,353,700	0.51	687,648.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	2,508	2,508	7,548,041	3.32	621,880.1
65-74 years	3,959	3,959	5,100,007	7.76	415,361.8
75-84 years	2,642	2,642	3,078,255	8.58	251,576.0
≥ 85 years	914	914	1,530,143	5.97	125,538.3
2013, February					
18-44 years	295	295	8,175,825	0.36	619,070.5
45-64 years	1,678	1,678	7,436,868	2.26	560,449.5
65-74 years	2,244	2,244	5,027,964	4.46	375,918.3
75-84 years	1,501	1,501	3,054,008	4.91	227,022.2
≥ 85 years	580	580	1,512,480	3.83	112,781.3
2013, March					
18-44 years	239	239	8,193,743	0.29	685,513.4
45-64 years	1,525	1,525	7,458,564	2.04	620,998.7
65-74 years	1,948	1,948	5,062,078	3.85	417,643.1
75-84 years	1,280	1,280	3,068,318	4.17	251,434.5
≥ 85 years	512	512	1,517,564	3.37	124,778.9
2013, April					
18-44 years	629	629	8,163,103	0.77	661,545.4
45-64 years	4,542	4,542	7,448,315	6.10	600,540.3
65-74 years	6,468	6,468	5,066,600	12.77	404,730.2
75-84 years	4,620	4,620	3,064,944	15.07	243,135.3
≥ 85 years	1,896	1,896	1,512,954	12.53	120,475.5
2013, May					
18-44 years	601	601	8,167,935	0.74	683,740.2
45-64 years	5,103	5,103	7,448,510	6.85	620,475.7
65-74 years	6,220	6,220	5,073,554	12.26	418,646.0
75-84 years	4,278	4,278	3,063,443	13.96	250,971.7
≥ 85 years	1,740	1,740	1,513,127	11.50	124,414.9
2013, June					
18-44 years	527	527	8,172,089	0.64	662,092.7
45-64 years	4,001	4,001	7,451,057	5.37	600,884.6
65-74 years	5,070	5,070	5,078,332	9.98	405,880.9

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	3,391	3,391	3,061,768	11.08	242,903.2
≥ 85 years	1,435	1,435	1,515,140	9.47	120,598.6
2013, July					
18-44 years	512	512	8,186,238	0.63	685,446.1
45-64 years	3,613	3,613	7,477,827	4.83	623,277.3
65-74 years	4,019	4,019	5,106,423	7.87	421,838.0
75-84 years	2,877	2,877	3,068,486	9.38	251,632.8
≥ 85 years	1,068	1,068	1,518,798	7.03	125,022.4
2013, August					
18-44 years	402	402	8,222,861	0.49	686,985.1
45-64 years	2,639	2,639	7,485,928	3.53	623,387.5
65-74 years	2,868	2,868	5,122,700	5.60	422,614.0
75-84 years	2,007	2,007	3,072,300	6.53	251,599.8
≥ 85 years	726	726	1,522,012	4.77	125,098.2
2013, September					
18-44 years	377	377	8,206,097	0.46	663,185.4
45-64 years	2,446	2,446	7,481,401	3.27	603,284.7
65-74 years	2,852	2,852	5,129,144	5.56	409,982.8
75-84 years	1,905	1,905	3,068,476	6.21	243,479.4
≥ 85 years	669	669	1,521,423	4.40	121,186.3
2013, October					
18-44 years	371	371	8,151,267	0.46	682,468.5
45-64 years	2,137	2,137	7,486,691	2.85	623,439.9
65-74 years	2,327	2,327	5,143,267	4.52	424,173.3
75-84 years	1,614	1,614	3,072,371	5.25	251,525.2
≥ 85 years	643	643	1,524,246	4.22	125,281.1
2013, November					
18-44 years	375	375	8,140,272	0.46	660,095.1
45-64 years	2,276	2,276	7,472,138	3.05	602,666.2
65-74 years	2,462	2,462	5,131,443	4.80	410,239.6
75-84 years	1,713	1,713	3,056,902	5.60	242,817.7
≥ 85 years	701	701	1,516,932	4.62	120,948.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2013, December					
18-44 years	276	276	8,111,311	0.34	679,413.8
45-64 years	1,886	1,886	7,453,904	2.53	620,953.7
65-74 years	2,246	2,246	5,132,287	4.38	424,162.2
75-84 years	1,541	1,541	3,056,031	5.04	251,034.8
≥ 85 years	555	555	1,516,170	3.66	125,022.0
2014, January					
18-44 years	385	385	8,900,862	0.43	743,878.7
45-64 years	2,299	2,299	8,097,588	2.84	673,473.1
65-74 years	3,008	3,008	5,828,215	5.16	480,960.5
75-84 years	1,870	1,870	3,436,548	5.44	281,800.4
≥ 85 years	648	648	1,692,042	3.83	139,286.0
2014, February					
18-44 years	421	421	8,846,077	0.48	669,432.3
45-64 years	2,580	2,580	8,045,772	3.21	606,140.0
65-74 years	3,346	3,346	5,820,892	5.75	435,355.3
75-84 years	2,049	2,049	3,424,581	5.98	254,601.6
≥ 85 years	741	741	1,684,773	4.40	125,668.1
2014, March					
18-44 years	515	515	8,829,117	0.58	738,714.1
45-64 years	3,438	3,438	8,023,113	4.29	667,865.6
65-74 years	4,611	4,611	5,847,596	7.89	482,829.3
75-84 years	2,766	2,766	3,437,822	8.05	281,924.6
≥ 85 years	902	902	1,691,245	5.33	139,172.4
2014, April					
18-44 years	406	406	8,792,157	0.46	711,953.1
45-64 years	2,848	2,848	7,984,409	3.57	643,156.4
65-74 years	4,023	4,023	5,863,303	6.86	468,166.6
75-84 years	2,385	2,385	3,445,634	6.92	273,159.9
≥ 85 years	774	774	1,693,294	4.57	134,731.3
2014, May					
18-44 years	326	326	8,775,025	0.37	733,930.6

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	2,253	2,253	7,950,385	2.83	661,633.0
65-74 years	3,028	3,028	5,858,001	5.17	483,089.2
75-84 years	1,773	1,773	3,440,683	5.15	281,659.7
≥ 85 years	649	649	1,690,431	3.84	138,907.8
2014, June					
18-44 years	270	270	8,755,301	0.31	708,949.4
45-64 years	1,931	1,931	7,924,298	2.44	638,515.2
65-74 years	2,363	2,363	5,854,865	4.04	467,718.1
75-84 years	1,449	1,449	3,431,651	4.22	272,104.9
≥ 85 years	519	519	1,686,277	3.08	134,187.3
2014, July					
18-44 years	453	453	8,833,991	0.51	738,989.7
45-64 years	2,817	2,817	7,983,593	3.53	664,707.5
65-74 years	2,862	2,862	5,874,178	4.87	484,891.1
75-84 years	1,954	1,954	3,427,276	5.70	280,728.7
≥ 85 years	696	696	1,684,119	4.13	138,431.0
2014, August					
18-44 years	427	427	8,797,059	0.49	735,222.7
45-64 years	2,976	2,976	7,935,928	3.75	660,431.2
65-74 years	3,090	3,090	5,888,903	5.25	485,876.7
75-84 years	2,013	2,013	3,428,655	5.87	280,695.3
≥ 85 years	699	699	1,684,601	4.15	138,438.1
2014, September					
18-44 years	349	349	8,769,121	0.40	710,028.2
45-64 years	2,603	2,603	7,912,260	3.29	637,550.1
65-74 years	2,924	2,924	5,894,672	4.96	470,964.9
75-84 years	1,668	1,668	3,426,341	4.87	271,705.1
≥ 85 years	601	601	1,682,352	3.57	133,959.4
2014, October					
18-44 years	823	823	8,785,078	0.94	734,914.6
45-64 years	5,355	5,355	7,910,421	6.77	658,014.1
65-74 years	5,467	5,467	5,914,239	9.24	487,351.0

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	3,480	3,480	3,435,649	10.13	280,981.9
≥ 85 years	1,482	1,482	1,685,805	8.79	138,418.0
2014, November					
18-44 years	568	568	8,754,559	0.65	709,819.2
45-64 years	3,717	3,717	7,883,454	4.71	635,697.5
65-74 years	4,213	4,213	5,900,692	7.14	471,898.8
75-84 years	2,674	2,674	3,422,502	7.81	271,908.9
≥ 85 years	1,045	1,045	1,678,279	6.23	133,802.6
2014, December					
18-44 years	698	698	8,757,751	0.80	732,068.5
45-64 years	4,367	4,367	7,881,283	5.54	654,824.6
65-74 years	4,886	4,886	5,904,938	8.27	487,099.3
75-84 years	3,005	3,005	3,421,590	8.78	280,390.3
≥ 85 years	1,081	1,081	1,674,759	6.45	137,861.6
2015, January					
18-44 years	859	859	9,123,915	0.94	762,766.6
45-64 years	5,149	5,149	8,180,925	6.29	680,368.3
65-74 years	7,259	7,259	6,127,270	11.85	505,457.1
75-84 years	5,238	5,238	3,490,024	15.01	285,957.7
≥ 85 years	2,579	2,579	1,693,775	15.23	139,302.5
2015, February					
18-44 years	908	908	9,086,841	1.00	687,415.6
45-64 years	6,308	6,308	8,160,229	7.73	614,176.1
65-74 years	8,804	8,804	6,120,863	14.38	457,054.2
75-84 years	7,151	7,151	3,474,987	20.58	257,792.2
≥ 85 years	3,919	3,919	1,677,605	23.36	124,947.6
2015, March					
18-44 years	826	826	9,100,046	0.91	761,135.6
45-64 years	5,721	5,721	8,180,125	6.99	680,528.2
65-74 years	8,122	8,122	6,143,987	13.22	506,922.6
75-84 years	6,558	6,558	3,486,096	18.81	285,560.7
≥ 85 years	3,590	3,590	1,680,197	21.37	138,115.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2015, April					
18-44 years	769	769	9,138,675	0.84	739,977.1
45-64 years	5,148	5,148	8,211,131	6.27	661,233.4
65-74 years	7,203	7,203	6,145,884	11.72	490,587.7
75-84 years	5,793	5,793	3,483,308	16.63	275,957.6
≥ 85 years	2,987	2,987	1,675,829	17.82	133,251.0
2015, May					
18-44 years	838	838	9,175,195	0.91	767,475.7
45-64 years	5,588	5,588	8,246,239	6.78	686,093.7
65-74 years	6,792	6,792	6,153,081	11.04	507,293.6
75-84 years	5,065	5,065	3,481,086	14.55	284,736.1
≥ 85 years	2,544	2,544	1,671,940	15.22	137,323.4
2015, June					
18-44 years	909	909	9,183,380	0.99	743,496.2
45-64 years	7,019	7,019	8,249,066	8.51	664,426.9
65-74 years	8,797	8,797	6,156,861	14.29	491,430.5
75-84 years	6,662	6,662	3,476,280	19.16	275,392.3
≥ 85 years	3,058	3,058	1,669,641	18.32	132,738.1
2015, July					
18-44 years	1,005	1,005	9,174,711	1.10	767,433.8
45-64 years	7,707	7,707	8,243,111	9.35	686,070.7
65-74 years	9,288	9,288	6,183,678	15.02	510,273.2
75-84 years	6,443	6,443	3,480,494	18.51	284,897.6
≥ 85 years	2,951	2,951	1,671,542	17.65	137,352.4
2015, August					
18-44 years	904	904	9,185,511	0.98	767,910.7
45-64 years	6,413	6,413	8,238,322	7.78	685,699.0
65-74 years	7,706	7,706	6,202,569	12.42	511,943.7
75-84 years	5,557	5,557	3,486,959	15.94	285,474.9
≥ 85 years	2,588	2,588	1,673,569	15.46	137,559.6
2015, September					
18-44 years	733	733	9,195,873	0.80	744,491.9

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	4,912	4,912	8,246,416	5.96	664,166.7
65-74 years	6,170	6,170	6,220,835	9.92	496,832.6
75-84 years	4,554	4,554	3,489,823	13.05	276,503.9
≥ 85 years	2,137	2,137	1,674,405	12.76	133,188.6
2015, October					
18-44 years	640	640	9,186,832	0.70	768,057.8
45-64 years	4,171	4,171	8,256,279	5.05	685,957.0
65-74 years	5,228	5,228	6,247,993	8.37	514,567.3
75-84 years	3,804	3,804	3,499,155	10.87	285,939.0
≥ 85 years	1,818	1,818	1,678,202	10.83	137,656.7
2015, November					
18-44 years	669	669	9,158,717	0.73	741,953.8
45-64 years	4,210	4,210	8,233,444	5.11	663,167.1
65-74 years	5,362	5,362	6,234,026	8.60	498,253.2
75-84 years	4,107	4,107	3,484,813	11.79	276,549.0
≥ 85 years	2,220	2,220	1,669,179	13.30	133,003.4
2015, December					
18-44 years	770	770	9,161,719	0.84	766,268.6
45-64 years	5,039	5,039	8,238,837	6.12	684,479.4
65-74 years	6,515	6,515	6,246,451	10.43	514,985.8
75-84 years	5,226	5,226	3,490,650	14.97	285,784.2
≥ 85 years	2,792	2,792	1,669,468	16.72	137,277.3
2016, January					
18-44 years	941	941	9,197,891	1.02	768,766.8
45-64 years	6,338	6,338	8,317,974	7.62	691,508.8
65-74 years	8,988	8,988	6,466,038	13.90	533,020.6
75-84 years	6,751	6,751	3,552,538	19.00	290,765.5
≥ 85 years	3,374	3,374	1,689,811	19.97	138,879.7
2016, February					
18-44 years	1,000	1,000	9,347,756	1.07	718,151.0
45-64 years	6,974	6,974	8,432,703	8.27	646,433.4
65-74 years	9,656	9,656	6,545,713	14.75	499,704.7

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	7,187	7,187	3,556,873	20.21	272,312.5
≥ 85 years	3,843	3,843	1,687,003	22.78	129,677.7
2016, March					
18-44 years	1,140	1,140	9,366,076	1.22	769,852.1
45-64 years	7,584	7,584	8,439,304	8.99	693,183.1
65-74 years	11,132	11,132	6,572,078	16.94	535,044.1
75-84 years	8,100	8,100	3,571,421	22.68	291,183.6
≥ 85 years	3,957	3,957	1,690,174	23.41	138,375.5
2016, April					
18-44 years	1,366	1,366	9,384,822	1.46	744,418.9
45-64 years	9,038	9,038	8,419,060	10.74	669,792.2
65-74 years	13,572	13,572	6,569,124	20.66	518,068.0
75-84 years	9,542	9,542	3,570,432	26.73	281,952.1
≥ 85 years	4,417	4,417	1,685,515	26.21	133,676.6
2016, May					
18-44 years	1,425	1,425	9,394,394	1.52	772,087.7
45-64 years	8,952	8,952	8,404,391	10.65	691,299.2
65-74 years	13,800	13,800	6,572,106	21.00	535,445.0
75-84 years	9,508	9,508	3,574,047	26.60	291,433.1
≥ 85 years	4,305	4,305	1,684,428	25.56	137,891.7
2016, June					
18-44 years	1,142	1,142	9,443,249	1.21	746,629.4
45-64 years	7,554	7,554	8,432,609	8.96	668,337.1
65-74 years	11,935	11,935	6,613,244	18.05	519,406.7
75-84 years	8,246	8,246	3,585,720	23.00	282,753.3
≥ 85 years	3,732	3,732	1,685,376	22.14	133,560.2
2016, July					
18-44 years	1,097	1,097	9,461,262	1.16	771,598.4
45-64 years	6,835	6,835	8,377,595	8.16	690,024.6
65-74 years	10,270	10,270	6,618,431	15.52	539,385.0
75-84 years	6,962	6,962	3,591,786	19.38	293,279.9
≥ 85 years	2,948	2,948	1,685,623	17.49	138,210.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2016, August					
18-44 years	1,238	1,238	9,439,117	1.31	770,338.6
45-64 years	7,938	7,938	8,394,924	9.46	689,729.7
65-74 years	11,184	11,184	6,643,992	16.83	540,791.4
75-84 years	7,296	7,296	3,607,137	20.23	294,163.3
≥ 85 years	2,974	2,974	1,689,827	17.60	138,380.9
2016, September					
18-44 years	1,098	1,098	9,456,740	1.16	747,592.2
45-64 years	7,703	7,703	8,420,353	9.15	667,450.2
65-74 years	11,124	11,124	6,657,344	16.71	524,840.8
75-84 years	6,775	6,775	3,610,739	18.76	285,278.9
≥ 85 years	2,917	2,917	1,690,174	17.26	134,110.8
2016, October					
18-44 years	1,053	1,053	9,401,480	1.12	774,245.1
45-64 years	6,799	6,799	8,391,271	8.10	690,619.5
65-74 years	9,642	9,642	6,674,329	14.45	544,213.4
75-84 years	6,035	6,035	3,620,317	16.67	295,502.5
≥ 85 years	2,436	2,436	1,692,643	14.39	138,700.0
2016, November					
18-44 years	929	929	9,463,510	0.98	750,054.5
45-64 years	5,342	5,342	8,428,158	6.34	668,345.6
65-74 years	7,557	7,557	6,670,099	11.33	527,483.5
75-84 years	4,855	4,855	3,616,309	13.43	286,279.8
≥ 85 years	1,940	1,940	1,686,419	11.50	134,060.8
2016, December					
18-44 years	793	793	10,721,076	0.74	781,111.1
45-64 years	4,571	4,571	9,379,592	4.87	694,190.9
65-74 years	6,459	6,459	7,114,665	9.08	546,461.2
75-84 years	4,209	4,209	3,773,569	11.15	296,434.9
≥ 85 years	1,722	1,722	1,738,486	9.91	138,471.1
2017, January					
18-44 years	954	954	9,487,856	1.01	780,593.7

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	4,758	4,758	8,370,471	5.68	688,283.0
65-74 years	7,139	7,139	6,757,194	10.57	550,680.7
75-84 years	4,341	4,341	3,618,289	12.00	295,409.8
≥ 85 years	1,823	1,823	1,668,592	10.93	136,859.5
2017, February					
18-44 years	794	794	9,319,963	0.85	704,706.1
45-64 years	4,462	4,462	8,251,261	5.41	620,296.0
65-74 years	6,125	6,125	6,661,229	9.19	497,103.7
75-84 years	3,831	3,831	3,596,912	10.65	266,670.0
≥ 85 years	1,528	1,528	1,651,950	9.25	122,924.4
2017, March					
18-44 years	933	933	9,350,278	1.00	781,603.2
45-64 years	4,531	4,531	8,270,143	5.48	686,825.6
65-74 years	6,263	6,263	6,691,510	9.36	551,117.1
75-84 years	3,984	3,984	3,615,640	11.02	295,535.4
≥ 85 years	1,586	1,586	1,654,674	9.58	135,829.5
2017, April					
18-44 years	758	758	9,349,585	0.81	756,960.8
45-64 years	3,793	3,793	8,252,018	4.60	663,883.1
65-74 years	5,286	5,286	6,682,659	7.91	533,106.3
75-84 years	3,290	3,290	3,612,985	9.11	286,004.9
≥ 85 years	1,328	1,328	1,646,563	8.07	130,920.9
2017, May					
18-44 years	851	851	9,359,246	0.91	782,545.8
45-64 years	4,314	4,314	8,242,827	5.23	685,007.1
65-74 years	5,648	5,648	6,683,727	8.45	550,617.9
75-84 years	3,573	3,573	3,615,549	9.88	295,460.0
≥ 85 years	1,492	1,492	1,644,327	9.07	134,947.3
2017, June					
18-44 years	878	878	9,368,314	0.94	758,284.8
45-64 years	4,576	4,576	8,236,072	5.56	662,790.7
65-74 years	6,013	6,013	6,685,793	8.99	533,532.9

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	4,041	4,041	3,614,209	11.18	286,199.9
≥ 85 years	1,876	1,876	1,641,664	11.43	130,526.2
2017, July					
18-44 years	1,057	1,057	9,360,900	1.13	783,019.8
45-64 years	5,795	5,795	8,212,151	7.06	683,447.3
65-74 years	7,506	7,506	6,710,909	11.18	554,364.4
75-84 years	5,334	5,334	3,622,293	14.73	296,907.7
≥ 85 years	2,761	2,761	1,641,767	16.82	135,088.0
2017, August					
18-44 years	1,153	1,153	9,399,555	1.23	785,055.2
45-64 years	5,681	5,681	8,228,369	6.90	683,721.6
65-74 years	8,214	8,214	6,738,146	12.19	555,144.4
75-84 years	5,896	5,896	3,640,885	16.19	297,460.1
≥ 85 years	2,858	2,858	1,645,959	17.36	135,098.6
2017, September					
18-44 years	933	933	9,421,945	0.99	761,989.4
45-64 years	4,638	4,638	8,220,393	5.64	661,559.6
65-74 years	6,700	6,700	6,745,048	9.93	538,528.5
75-84 years	4,624	4,624	3,647,418	12.68	288,766.8
≥ 85 years	2,226	2,226	1,644,162	13.54	130,811.6
2017, October					
18-44 years	898	898	9,454,118	0.95	790,593.0
45-64 years	4,585	4,585	8,236,320	5.57	684,557.1
65-74 years	6,521	6,521	6,763,065	9.64	557,097.3
75-84 years	4,263	4,263	3,666,424	11.63	299,459.9
≥ 85 years	1,875	1,875	1,646,493	11.39	135,210.8
2017, November					
18-44 years	908	908	9,457,099	0.96	765,967.4
45-64 years	4,536	4,536	8,226,510	5.51	662,163.3
65-74 years	6,590	6,590	6,748,161	9.77	538,762.6
75-84 years	4,098	4,098	3,669,059	11.17	290,676.9
≥ 85 years	1,669	1,669	1,641,248	10.17	130,722.6

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2017, December					
18-44 years	944	944	9,512,862	0.99	795,812.9
45-64 years	4,649	4,649	8,262,799	5.63	686,174.5
65-74 years	6,437	6,437	6,750,567	9.54	556,154.5
75-84 years	4,065	4,065	3,685,019	11.03	301,394.2
≥ 85 years	1,696	1,696	1,640,972	10.34	134,987.8
2018, January					
18-44 years	1,066	1,066	9,411,393	1.13	786,490.6
45-64 years	5,092	5,092	8,122,894	6.27	674,527.7
65-74 years	7,858	7,858	6,851,321	11.47	564,139.1
75-84 years	4,844	4,844	3,707,032	13.07	302,899.5
≥ 85 years	1,868	1,868	1,641,321	11.38	134,841.7
2018, February					
18-44 years	1,032	1,032	9,382,753	1.10	709,452.0
45-64 years	4,682	4,682	8,090,351	5.79	608,094.1
65-74 years	7,177	7,177	6,835,848	10.50	510,078.0
75-84 years	4,387	4,387	3,701,578	11.85	274,336.5
≥ 85 years	1,856	1,856	1,626,820	11.41	121,124.8
2018, March					
18-44 years	1,083	1,083	9,392,826	1.15	785,448.5
45-64 years	5,051	5,051	8,099,891	6.24	672,713.9
65-74 years	7,306	7,306	6,869,445	10.64	565,619.0
75-84 years	4,603	4,603	3,730,810	12.34	304,739.6
≥ 85 years	1,693	1,693	1,631,627	10.38	133,909.9
2018, April					
18-44 years	932	932	9,363,972	1.00	758,295.2
45-64 years	4,462	4,462	8,068,016	5.53	649,082.6
65-74 years	6,561	6,561	6,863,140	9.56	547,460.5
75-84 years	4,156	4,156	3,735,222	11.13	295,581.3
≥ 85 years	1,597	1,597	1,627,275	9.81	129,359.4
2018, May					
18-44 years	957	957	9,359,197	1.02	782,603.3

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	4,644	4,644	8,046,118	5.77	668,567.6
65-74 years	6,459	6,459	6,858,911	9.42	564,915.3
75-84 years	4,100	4,100	3,741,973	10.96	305,708.9
≥ 85 years	1,617	1,617	1,625,170	9.95	133,396.3
2018, June					
18-44 years	988	988	9,355,214	1.06	757,239.2
45-64 years	4,955	4,955	8,031,646	6.17	646,118.4
65-74 years	6,603	6,603	6,859,400	9.63	547,288.6
75-84 years	4,169	4,169	3,745,198	11.13	296,434.7
≥ 85 years	1,660	1,660	1,622,051	10.23	128,992.3
2018, July					
18-44 years	574	574	9,325,025	0.62	779,896.4
45-64 years	3,272	3,272	7,996,496	4.09	665,165.5
65-74 years	4,466	4,466	6,884,005	6.49	568,456.6
75-84 years	2,879	2,879	3,753,036	7.67	307,496.8
≥ 85 years	1,107	1,107	1,621,477	6.83	133,402.9
2018, August					
18-44 years	219	219	9,342,250	0.23	780,743.0
45-64 years	1,493	1,493	7,997,529	1.87	664,422.4
65-74 years	2,038	2,038	6,912,169	2.95	569,472.3
75-84 years	1,266	1,266	3,773,483	3.35	308,334.2
≥ 85 years	538	538	1,624,520	3.31	133,380.5
2018, September					
18-44 years	225	225	9,336,289	0.24	755,687.7
45-64 years	1,625	1,625	7,983,674	2.04	642,447.1
65-74 years	2,203	2,203	6,917,718	3.18	552,396.8
75-84 years	1,439	1,439	3,776,505	3.81	299,243.0
≥ 85 years	616	616	1,621,269	3.80	129,045.1
2018, October					
18-44 years	366	366	9,330,009	0.39	779,822.9
45-64 years	2,229	2,229	7,981,185	2.79	662,722.0
65-74 years	3,329	3,329	6,944,645	4.79	571,742.6

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	2,025	2,025	3,797,734	5.33	310,157.6
≥ 85 years	847	847	1,624,514	5.21	133,281.3
2018, November					
18-44 years	373	373	9,333,468	0.40	755,821.1
45-64 years	2,662	2,662	7,969,645	3.34	641,301.6
65-74 years	3,690	3,690	6,936,315	5.32	553,920.0
75-84 years	2,297	2,297	3,793,271	6.06	300,748.1
≥ 85 years	954	954	1,617,808	5.90	128,820.7
2018, December					
18-44 years	364	364	9,347,510	0.39	781,951.5
45-64 years	2,880	2,880	7,979,185	3.61	662,733.2
65-74 years	3,772	3,772	6,948,928	5.43	573,096.1
75-84 years	2,498	2,498	3,802,423	6.57	311,486.1
≥ 85 years	964	964	1,616,217	5.96	132,992.1
2019, January					
18-44 years	0	0	9,184,029	0.00	767,483.9
45-64 years	0	0	7,841,450	0.00	651,034.9
65-74 years	0	0	6,965,817	0.00	573,552.6
75-84 years	0	0	3,783,078	0.00	309,174.1
≥ 85 years	0	0	1,602,222	0.00	131,530.7
2019, February					
18-44 years	0	0	9,149,627	0.00	692,192.3
45-64 years	0	0	7,801,140	0.00	586,528.1
65-74 years	0	0	6,949,214	0.00	518,842.9
75-84 years	0	0	3,770,143	0.00	279,501.2
≥ 85 years	0	0	1,591,499	0.00	118,495.3
2019, March					
18-44 years	0	0	9,156,656	0.00	765,646.5
45-64 years	0	0	7,802,332	0.00	647,985.4
65-74 years	0	0	6,976,383	0.00	574,768.3
75-84 years	0	0	3,788,593	0.00	309,807.6
≥ 85 years	0	0	1,594,767	0.00	130,934.9

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2019, April					
18-44 years	0	0	9,136,170	0.00	739,464.3
45-64 years	0	0	7,766,447	0.00	624,357.9
65-74 years	0	0	6,962,884	0.00	555,156.1
75-84 years	0	0	3,782,855	0.00	299,286.2
≥ 85 years	0	0	1,587,028	0.00	126,105.7
2019, May					
18-44 years	0	0	9,128,266	0.00	763,291.8
45-64 years	0	0	7,736,780	0.00	642,728.3
65-74 years	0	0	6,955,427	0.00	572,891.6
75-84 years	0	0	3,779,431	0.00	308,808.9
≥ 85 years	0	0	1,583,532	0.00	129,924.4
2019, June					
18-44 years	0	0	9,112,720	0.00	737,720.0
45-64 years	0	0	7,708,750	0.00	620,098.4
65-74 years	0	0	6,950,564	0.00	554,620.6
75-84 years	0	0	3,774,062	0.00	298,746.4
≥ 85 years	0	0	1,578,446	0.00	125,459.7
2019, July					
18-44 years	0	0	9,113,385	0.00	762,082.7
45-64 years	0	0	7,690,937	0.00	639,454.9
65-74 years	0	0	6,973,807	0.00	575,412.2
75-84 years	0	0	3,777,919	0.00	309,141.0
≥ 85 years	0	0	1,577,077	0.00	129,575.5
2019, August					
18-44 years	0	0	9,121,342	0.00	762,180.0
45-64 years	0	0	7,677,929	0.00	637,781.4
65-74 years	0	0	6,994,980	0.00	576,341.6
75-84 years	0	0	3,787,381	0.00	309,444.0
≥ 85 years	0	0	1,579,248	0.00	129,539.6
2019, September					
18-44 years	0	0	9,120,128	0.00	737,804.7

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	0	0	7,665,835	0.00	616,426.0
65-74 years	0	0	7,001,801	0.00	559,027.6
75-84 years	0	0	3,783,064	0.00	299,711.7
≥ 85 years	0	0	1,576,974	0.00	125,378.1
2019, October					
18-44 years	0	0	9,118,721	0.00	762,354.7
45-64 years	0	0	7,654,719	0.00	635,537.8
65-74 years	0	0	7,023,286	0.00	578,181.3
75-84 years	0	0	3,793,403	0.00	309,705.0
≥ 85 years	0	0	1,580,557	0.00	129,543.0
2019, November					
18-44 years	0	0	9,114,258	0.00	738,130.2
45-64 years	0	0	7,640,376	0.00	614,640.2
65-74 years	0	0	7,017,732	0.00	560,236.7
75-84 years	0	0	3,785,047	0.00	299,886.6
≥ 85 years	0	0	1,573,787	0.00	125,234.1
2019, December					
18-44 years	0	0	9,132,910	0.00	764,313.3
45-64 years	0	0	7,649,969	0.00	635,552.4
65-74 years	0	0	7,028,317	0.00	579,849.7
75-84 years	0	0	3,791,023	0.00	310,631.0
≥ 85 years	0	0	1,571,719	0.00	129,332.1
2020, January					
18-44 years	0	0	9,002,386	0.00	751,526.1
45-64 years	0	0	7,526,263	0.00	624,232.5
65-74 years	0	0	7,126,350	0.00	587,012.0
75-84 years	0	0	3,818,975	0.00	312,191.6
≥ 85 years	0	0	1,578,016	0.00	129,534.9
2020, February					
18-44 years	0	0	9,087,615	0.00	701,995.6
45-64 years	0	0	7,553,927	0.00	582,148.3
65-74 years	0	0	7,201,247	0.00	549,796.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	0	0	3,816,966	0.00	292,007.9
≥ 85 years	0	0	1,573,517	0.00	120,837.3
2020, March					
18-44 years	0	0	9,107,758	0.00	750,642.1
45-64 years	0	0	7,551,528	0.00	621,434.4
65-74 years	0	0	7,224,111	0.00	589,273.9
75-84 years	0	0	3,829,785	0.00	312,932.6
≥ 85 years	0	0	1,575,170	0.00	129,240.4
2020, April					
18-44 years	0	0	9,092,548	0.00	727,622.6
45-64 years	0	0	7,557,750	0.00	604,936.0
65-74 years	0	0	7,306,753	0.00	581,002.3
75-84 years	0	0	3,880,306	0.00	309,336.5
≥ 85 years	0	0	1,590,630	0.00	127,144.6
2020, May					
18-44 years	0	0	9,170,191	0.00	756,234.5
45-64 years	0	0	7,646,251	0.00	630,155.7
65-74 years	0	0	7,474,756	0.00	611,553.7
75-84 years	0	0	3,977,793	0.00	326,104.4
≥ 85 years	0	0	1,615,643	0.00	132,897.6
2020, June					
18-44 years	0	0	9,272,406	0.00	735,789.3
45-64 years	0	0	7,716,117	0.00	612,640.1
65-74 years	0	0	7,597,110	0.00	598,066.6
75-84 years	0	0	4,037,109	0.00	319,044.9
≥ 85 years	0	0	1,632,270	0.00	129,541.5
2020, July					
18-44 years	0	0	9,313,626	0.00	760,948.6
45-64 years	0	0	7,682,855	0.00	632,594.1
65-74 years	0	0	7,643,009	0.00	622,497.8
75-84 years	0	0	4,062,264	0.00	331,573.7
≥ 85 years	0	0	1,642,479	0.00	134,509.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2020, August					
18-44 years	0	0	9,291,974	0.00	761,399.5
45-64 years	0	0	7,698,572	0.00	632,887.8
65-74 years	0	0	7,688,982	0.00	626,303.2
75-84 years	0	0	4,086,608	0.00	333,539.0
≥ 85 years	0	0	1,650,675	0.00	135,208.7
2020, September					
18-44 years	0	0	9,234,357	0.00	732,524.0
45-64 years	0	0	7,694,124	0.00	610,545.8
65-74 years	0	0	7,737,220	0.00	609,932.9
75-84 years	0	0	4,112,143	0.00	324,581.7
≥ 85 years	0	0	1,659,319	0.00	131,394.3
2020, October					
18-44 years	0	0	9,210,754	0.00	759,781.9
45-64 years	0	0	7,675,219	0.00	631,582.7
65-74 years	0	0	7,785,320	0.00	634,008.8
75-84 years	0	0	4,144,057	0.00	337,406.9
≥ 85 years	0	0	1,671,028	0.00	136,502.7
2020, November					
18-44 years	0	0	9,239,028	0.00	737,558.0
45-64 years	0	0	7,691,115	0.00	612,670.5
65-74 years	0	0	7,798,194	0.00	617,411.0
75-84 years	0	0	4,150,813	0.00	328,622.0
≥ 85 years	0	0	1,669,534	0.00	132,607.4
2020, December					
18-44 years	0	0	10,286,028	0.00	768,033.9
45-64 years	0	0	8,435,101	0.00	637,131.0
65-74 years	0	0	8,488,213	0.00	643,730.1
75-84 years	0	0	4,414,229	0.00	342,667.5
≥ 85 years	0	0	1,742,858	0.00	137,627.7
2021, January					
18-44 years	0	0	9,399,543	0.00	775,873.9

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	0	0	7,796,964	0.00	641,375.7
65-74 years	0	0	8,025,906	0.00	654,183.2
75-84 years	0	0	4,226,374	0.00	344,541.6
≥ 85 years	0	0	1,681,467	0.00	137,421.5
2021, February					
18-44 years	0	0	9,284,118	0.00	702,446.6
45-64 years	0	0	7,733,331	0.00	580,858.6
65-74 years	0	0	7,979,319	0.00	595,068.8
75-84 years	0	0	4,235,795	0.00	313,571.3
≥ 85 years	0	0	1,676,783	0.00	124,354.9
2021, March					
18-44 years	0	0	9,302,962	0.00	777,407.5
45-64 years	0	0	7,730,644	0.00	643,101.3
65-74 years	0	0	8,000,632	0.00	662,143.3
75-84 years	0	0	4,245,677	0.00	348,748.5
≥ 85 years	0	0	1,676,364	0.00	138,139.3
2021, April					
18-44 years	0	0	9,216,725	0.00	748,619.4
45-64 years	0	0	7,618,087	0.00	615,970.0
65-74 years	0	0	7,862,635	0.00	632,338.6
75-84 years	0	0	4,156,753	0.00	332,067.3
≥ 85 years	0	0	1,639,381	0.00	131,341.5
2021, May					
18-44 years	0	0	9,132,775	0.00	765,664.6
45-64 years	0	0	7,538,270	0.00	628,352.8
65-74 years	0	0	7,780,334	0.00	643,848.2
75-84 years	0	0	4,108,069	0.00	337,470.0
≥ 85 years	0	0	1,615,841	0.00	133,221.2
2021, June					
18-44 years	0	0	9,059,461	0.00	734,183.9
45-64 years	0	0	7,488,460	0.00	602,907.1
65-74 years	0	0	7,755,411	0.00	619,393.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	0	0	4,097,573	0.00	324,544.3
≥ 85 years	0	0	1,606,467	0.00	127,740.5
2021, July					
18-44 years	0	0	8,984,678	0.00	752,150.2
45-64 years	0	0	7,439,191	0.00	618,861.2
65-74 years	0	0	7,749,701	0.00	639,666.5
75-84 years	0	0	4,095,516	0.00	335,064.3
≥ 85 years	0	0	1,600,296	0.00	131,486.4
2021, August					
18-44 years	0	0	8,926,567	0.00	746,812.6
45-64 years	0	0	7,396,191	0.00	615,215.4
65-74 years	0	0	7,731,853	0.00	637,981.3
75-84 years	0	0	4,097,051	0.00	335,093.5
≥ 85 years	0	0	1,593,691	0.00	131,022.9
2021, September					
18-44 years	0	0	8,865,015	0.00	718,465.9
45-64 years	0	0	7,348,858	0.00	591,866.3
65-74 years	0	0	7,707,924	0.00	615,827.3
75-84 years	0	0	4,102,176	0.00	324,833.5
≥ 85 years	0	0	1,587,775	0.00	126,393.9
2021, October					
18-44 years	0	0	8,812,573	0.00	737,751.1
45-64 years	0	0	7,314,481	0.00	608,071.7
65-74 years	0	0	7,701,787	0.00	634,545.4
75-84 years	0	0	4,123,318	0.00	336,635.3
≥ 85 years	0	0	1,586,283	0.00	130,259.8
2021, November					
18-44 years	0	0	8,767,500	0.00	711,033.8
45-64 years	0	0	7,278,571	0.00	586,425.8
65-74 years	0	0	7,658,452	0.00	611,885.9
75-84 years	0	0	4,122,121	0.00	326,684.9
≥ 85 years	0	0	1,575,548	0.00	125,596.9

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2021, December					
18-44 years	0	0	8,744,448	0.00	732,997.0
45-64 years	0	0	7,261,305	0.00	604,165.6
65-74 years	0	0	7,619,677	0.00	628,897.4
75-84 years	0	0	4,129,821	0.00	338,295.6
≥ 85 years	0	0	1,566,846	0.00	129,062.3
2022, January					
18-44 years	0	0	8,423,050	0.00	705,713.4
45-64 years	0	0	7,012,614	0.00	584,164.5
65-74 years	0	0	7,597,533	0.00	627,811.6
75-84 years	0	0	4,117,612	0.00	337,571.9
≥ 85 years	0	0	1,556,500	0.00	128,249.7
2022, February					
18-44 years	0	0	8,372,496	0.00	634,530.3
45-64 years	0	0	6,968,915	0.00	524,973.7
65-74 years	0	0	7,552,260	0.00	564,747.3
75-84 years	0	0	4,110,983	0.00	305,241.6
≥ 85 years	0	0	1,538,838	0.00	114,755.0
2022, March					
18-44 years	0	0	8,366,128	0.00	700,322.2
45-64 years	0	0	6,967,214	0.00	579,235.7
65-74 years	0	0	7,559,461	0.00	623,092.1
75-84 years	0	0	4,145,217	0.00	338,692.3
≥ 85 years	0	0	1,542,260	0.00	126,606.1
2022, April					
18-44 years	0	0	8,337,695	0.00	675,512.0
45-64 years	0	0	6,936,428	0.00	558,303.6
65-74 years	0	0	7,531,215	0.00	601,034.8
75-84 years	0	0	4,151,163	0.00	328,601.9
≥ 85 years	0	0	1,539,861	0.00	122,376.8
2022, May					
18-44 years	0	0	8,316,499	0.00	695,918.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	0	0	6,915,670	0.00	574,889.5
65-74 years	0	0	7,527,345	0.00	620,217.8
75-84 years	0	0	4,171,167	0.00	340,789.5
≥ 85 years	0	0	1,542,400	0.00	126,546.1
2022, June					
18-44 years	0	0	8,319,741	0.00	673,612.7
45-64 years	0	0	6,906,949	0.00	555,700.3
65-74 years	0	0	7,520,572	0.00	599,895.7
75-84 years	0	0	4,189,099	0.00	331,327.7
≥ 85 years	0	0	1,542,944	0.00	122,551.7
2022, July					
18-44 years	0	0	8,275,977	0.00	692,162.0
45-64 years	0	0	6,867,325	0.00	570,847.9
65-74 years	0	0	7,531,837	0.00	621,198.9
75-84 years	0	0	4,208,469	0.00	344,073.0
≥ 85 years	0	0	1,547,024	0.00	126,923.9
2022, August					
18-44 years	0	0	8,312,068	0.00	691,956.6
45-64 years	0	0	6,865,498	0.00	569,648.5
65-74 years	0	0	7,547,902	0.00	621,835.5
75-84 years	0	0	4,231,109	0.00	345,580.6
≥ 85 years	0	0	1,550,080	0.00	127,096.0
2022, September					
18-44 years	0	0	5,804,982	0.00	470,027.4
45-64 years	0	0	5,109,876	0.00	410,908.6
65-74 years	0	0	7,413,293	0.00	592,049.4
75-84 years	0	0	4,220,648	0.00	334,261.5
≥ 85 years	0	0	1,542,160	0.00	122,589.2
2022, October					
18-44 years	0	0	5,134,203	0.00	429,654.8
45-64 years	0	0	3,762,103	0.00	312,905.4
65-74 years	0	0	1,183,649	0.00	97,591.1

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	0	0	552,453	0.00	45,279.3
≥ 85 years	0	0	187,020	0.00	15,351.9
2022, November					
18-44 years	0	0	1,548,848	0.00	125,997.8
45-64 years	0	0	1,031,759	0.00	83,221.7
65-74 years	0	0	659,484	0.00	52,781.0
75-84 years	0	0	318,059	0.00	25,260.5
≥ 85 years	0	0	97,766	0.00	7,771.9
2022, December					
18-44 years	0	0	1,559,288	0.00	131,024.9
45-64 years	0	0	1,036,512	0.00	86,341.2
65-74 years	0	0	661,461	0.00	54,696.3
75-84 years	0	0	319,763	0.00	26,251.4
≥ 85 years	0	0	97,917	0.00	8,057.2
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan					
Contaminated valsartan					
2012, May					
18-44 years	0	0	8,329,327	0.00	682,864.3
45-64 years	0	0	7,305,629	0.00	599,815.7
65-74 years	0	0	4,505,222	0.00	367,569.0
75-84 years	0	0	2,750,256	0.00	224,760.7
≥ 85 years	0	0	1,364,911	0.00	111,962.3
2012, June					
18-44 years	0	0	8,404,778	0.00	662,181.5
45-64 years	0	0	7,353,202	0.00	581,548.1
65-74 years	0	0	4,532,877	0.00	356,570.9
75-84 years	0	0	2,752,791	0.00	217,613.1
≥ 85 years	0	0	1,366,577	0.00	108,428.4
2012, July					
18-44 years	0	0	8,399,342	0.00	684,215.9
45-64 years	0	0	7,297,781	0.00	600,528.4
65-74 years	0	0	4,538,048	0.00	370,644.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	0	0	2,750,954	0.00	225,352.6
≥ 85 years	0	0	1,367,363	0.00	112,369.0
2012, August					
18-44 years	0	0	8,424,636	0.00	685,979.8
45-64 years	0	0	7,321,558	0.00	601,295.9
65-74 years	0	0	4,567,013	0.00	371,801.6
75-84 years	0	0	2,760,687	0.00	225,626.6
≥ 85 years	0	0	1,373,224	0.00	112,602.9
2012, September					
18-44 years	*****	*****	8,428,571	*****	664,792.9
45-64 years	28	28	7,335,138	0.04	582,794.4
65-74 years	26	26	4,578,884	0.06	361,244.4
75-84 years	11	11	2,760,164	0.04	218,568.0
≥ 85 years	*****	*****	1,374,268	*****	109,202.4
2012, October					
18-44 years	52	52	8,378,083	0.06	689,632.5
45-64 years	234	234	7,326,786	0.32	603,154.7
65-74 years	171	171	4,600,671	0.37	374,916.0
75-84 years	106	106	2,768,302	0.38	226,170.3
≥ 85 years	27	27	1,379,022	0.20	113,098.9
2012, November					
18-44 years	68	68	8,351,641	0.08	667,913.3
45-64 years	246	246	7,315,318	0.34	584,519.1
65-74 years	218	218	4,607,793	0.47	364,211.2
75-84 years	95	95	2,761,508	0.34	219,089.6
≥ 85 years	39	39	1,375,463	0.28	109,529.3
2012, December					
18-44 years	54	54	8,920,839	0.06	691,665.1
45-64 years	238	238	7,742,079	0.31	605,753.5
65-74 years	195	195	5,047,452	0.39	378,802.5
75-84 years	84	84	2,957,179	0.28	226,938.8
≥ 85 years	32	32	1,452,652	0.22	113,275.3

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2013, January					
18-44 years	86	86	8,322,726	0.10	685,061.0
45-64 years	276	276	7,345,235	0.38	604,995.7
65-74 years	264	264	4,822,366	0.55	392,524.1
75-84 years	162	162	2,858,633	0.57	233,474.1
≥ 85 years	36	36	1,418,911	0.25	116,328.4
2013, February					
18-44 years	68	68	8,145,675	0.08	616,774.1
45-64 years	258	258	7,238,454	0.36	545,378.5
65-74 years	221	221	4,756,867	0.46	355,483.0
75-84 years	129	129	2,838,125	0.45	210,827.8
≥ 85 years	42	42	1,403,197	0.30	104,567.3
2013, March					
18-44 years	70	70	8,164,170	0.09	683,020.1
45-64 years	284	284	7,261,602	0.39	604,477.0
65-74 years	191	191	4,792,235	0.40	395,218.6
75-84 years	127	127	2,853,380	0.45	233,679.5
≥ 85 years	41	41	1,408,731	0.29	115,758.9
2013, April					
18-44 years	81	81	8,134,035	0.10	659,172.4
45-64 years	280	280	7,253,578	0.39	584,725.7
65-74 years	331	331	4,799,751	0.69	383,258.9
75-84 years	172	172	2,851,892	0.60	226,106.4
≥ 85 years	54	54	1,405,028	0.38	111,822.0
2013, May					
18-44 years	64	64	8,139,231	0.08	681,322.6
45-64 years	305	305	7,255,694	0.42	604,304.7
65-74 years	355	355	4,808,827	0.74	396,660.6
75-84 years	176	176	2,851,931	0.62	233,530.2
≥ 85 years	51	51	1,405,829	0.36	115,530.8
2013, June					
18-44 years	75	75	8,143,809	0.09	659,788.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	303	303	7,259,898	0.42	585,389.7
65-74 years	267	267	4,815,745	0.55	384,784.1
75-84 years	157	157	2,851,729	0.55	226,138.3
≥ 85 years	56	56	1,408,140	0.40	112,031.4
2013, July					
18-44 years	85	85	8,158,469	0.10	683,101.4
45-64 years	395	395	7,288,086	0.54	607,359.2
65-74 years	283	283	4,845,395	0.58	400,148.6
75-84 years	175	175	2,859,802	0.61	234,393.2
≥ 85 years	63	63	1,412,502	0.45	116,206.4
2013, August					
18-44 years	96	96	8,195,465	0.12	684,678.8
45-64 years	388	388	7,297,485	0.53	607,602.1
65-74 years	304	304	4,863,486	0.63	401,125.0
75-84 years	175	175	2,864,580	0.61	234,483.7
≥ 85 years	59	59	1,416,206	0.42	116,345.6
2013, September					
18-44 years	85	85	8,179,124	0.10	660,990.4
45-64 years	367	367	7,294,592	0.50	588,146.7
65-74 years	269	269	4,872,080	0.55	389,328.5
75-84 years	166	166	2,862,456	0.58	227,030.1
≥ 85 years	34	34	1,416,322	0.24	112,762.2
2013, October					
18-44 years	106	106	8,124,695	0.13	680,234.9
45-64 years	402	402	7,301,556	0.55	607,936.3
65-74 years	318	318	4,887,922	0.65	402,981.9
75-84 years	181	181	2,867,862	0.63	234,664.7
≥ 85 years	52	52	1,419,580	0.37	116,630.1
2013, November					
18-44 years	89	89	8,114,094	0.11	657,962.2
45-64 years	347	347	7,289,160	0.48	587,816.8
65-74 years	279	279	4,879,063	0.57	389,952.6

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	153	153	2,855,250	0.54	226,688.0
≥ 85 years	43	43	1,413,722	0.30	112,663.3
2013, December					
18-44 years	69	69	8,085,491	0.09	677,240.5
45-64 years	301	301	7,272,585	0.41	605,751.8
65-74 years	282	282	4,882,657	0.58	403,393.2
75-84 years	168	168	2,856,311	0.59	234,508.8
≥ 85 years	39	39	1,413,838	0.28	116,519.8
2014, January					
18-44 years	104	104	8,873,043	0.12	741,538.7
45-64 years	490	490	7,900,203	0.62	656,932.3
65-74 years	433	433	5,545,516	0.78	457,500.4
75-84 years	225	225	3,215,569	0.70	263,547.9
≥ 85 years	62	62	1,580,090	0.39	130,013.0
2014, February					
18-44 years	88	88	8,818,855	0.10	667,361.5
45-64 years	407	407	7,851,780	0.52	591,432.5
65-74 years	368	368	5,542,399	0.66	414,362.6
75-84 years	226	226	3,207,332	0.70	238,293.2
≥ 85 years	49	49	1,574,872	0.31	117,384.6
2014, March					
18-44 years	106	106	8,802,363	0.12	736,461.1
45-64 years	445	445	7,831,616	0.57	651,818.1
65-74 years	434	434	5,571,276	0.78	459,863.6
75-84 years	242	242	3,222,359	0.75	264,103.8
≥ 85 years	64	64	1,582,192	0.40	130,119.2
2014, April					
18-44 years	93	93	8,765,869	0.11	709,814.9
45-64 years	368	368	7,795,435	0.47	627,853.6
65-74 years	376	376	5,589,363	0.67	446,165.2
75-84 years	227	227	3,231,998	0.70	256,089.1
≥ 85 years	54	54	1,585,249	0.34	126,072.7

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2014, May					
18-44 years	91	91	8,749,273	0.10	731,766.3
45-64 years	359	359	7,764,368	0.46	646,073.5
65-74 years	322	322	5,587,162	0.58	460,651.8
75-84 years	170	170	3,229,002	0.53	264,242.1
≥ 85 years	57	57	1,583,612	0.36	130,070.1
2014, June					
18-44 years	80	80	8,730,043	0.09	706,897.1
45-64 years	323	323	7,741,531	0.42	623,713.6
65-74 years	291	291	5,586,898	0.52	446,226.9
75-84 years	139	139	3,222,856	0.43	255,453.3
≥ 85 years	59	59	1,580,445	0.37	125,715.9
2014, July					
18-44 years	83	83	8,808,988	0.09	736,882.4
45-64 years	344	344	7,801,603	0.44	649,435.5
65-74 years	277	277	5,608,211	0.49	462,840.2
75-84 years	135	135	3,220,677	0.42	263,713.7
≥ 85 years	52	52	1,579,358	0.33	129,769.4
2014, August					
18-44 years	82	82	8,772,603	0.09	733,168.1
45-64 years	324	324	7,757,144	0.42	645,470.1
65-74 years	246	246	5,625,046	0.44	464,013.1
75-84 years	137	137	3,224,105	0.42	263,841.1
≥ 85 years	44	44	1,580,713	0.28	129,850.4
2014, September					
18-44 years	74	74	8,745,204	0.08	708,083.1
45-64 years	350	350	7,736,029	0.45	623,272.4
65-74 years	257	257	5,633,159	0.46	449,972.3
75-84 years	149	149	3,223,453	0.46	255,525.9
≥ 85 years	36	36	1,579,481	0.23	125,719.2
2014, October					
18-44 years	102	102	8,761,627	0.12	732,939.9

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	449	449	7,735,896	0.58	643,421.6
65-74 years	333	333	5,654,698	0.59	465,850.6
75-84 years	176	176	3,233,821	0.54	264,371.8
≥ 85 years	64	64	1,583,791	0.40	129,971.7
2014, November					
18-44 years	97	97	8,731,463	0.11	707,933.4
45-64 years	378	378	7,711,217	0.49	621,733.1
65-74 years	299	299	5,644,276	0.53	451,285.4
75-84 years	162	162	3,223,374	0.50	255,976.1
≥ 85 years	48	48	1,577,735	0.30	125,727.4
2014, December					
18-44 years	113	113	8,734,837	0.13	730,143.2
45-64 years	399	399	7,710,752	0.52	640,567.1
65-74 years	343	343	5,651,163	0.61	466,025.3
75-84 years	189	189	3,224,160	0.59	264,089.6
≥ 85 years	54	54	1,575,314	0.34	129,615.4
2015, January					
18-44 years	181	181	9,100,485	0.20	760,792.1
45-64 years	622	622	8,007,202	0.78	665,831.6
65-74 years	609	609	5,868,721	1.04	483,963.7
75-84 years	285	285	3,292,199	0.87	269,596.7
≥ 85 years	106	106	1,594,791	0.66	131,082.6
2015, February					
18-44 years	171	171	9,063,819	0.19	685,659.9
45-64 years	729	729	7,989,169	0.91	601,197.9
65-74 years	648	648	5,866,920	1.10	437,898.9
75-84 years	368	368	3,281,608	1.12	243,274.0
≥ 85 years	164	164	1,581,755	1.04	117,699.3
2015, March					
18-44 years	211	211	9,077,269	0.23	759,212.7
45-64 years	758	758	8,010,566	0.95	666,302.7
65-74 years	805	805	5,892,685	1.37	485,998.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	462	462	3,295,268	1.40	269,743.1
≥ 85 years	183	183	1,585,806	1.15	130,257.5
2015, April					
18-44 years	163	163	9,116,083	0.18	738,134.8
45-64 years	730	730	8,042,440	0.91	647,554.4
65-74 years	677	677	5,896,978	1.15	470,567.9
75-84 years	458	458	3,294,757	1.39	260,864.5
≥ 85 years	178	178	1,582,941	1.12	125,779.5
2015, May					
18-44 years	185	185	9,152,851	0.20	765,592.9
45-64 years	735	735	8,078,376	0.91	672,035.5
65-74 years	660	660	5,905,892	1.12	486,804.4
75-84 years	412	412	3,293,919	1.25	269,309.6
≥ 85 years	170	170	1,580,037	1.08	129,709.6
2015, June					
18-44 years	170	170	9,161,169	0.19	741,683.5
45-64 years	806	806	8,082,207	1.00	650,902.1
65-74 years	734	734	5,911,711	1.24	471,756.4
75-84 years	459	459	3,290,653	1.39	260,580.3
≥ 85 years	178	178	1,578,733	1.13	125,453.2
2015, July					
18-44 years	209	209	9,152,724	0.23	765,582.3
45-64 years	879	879	8,077,598	1.09	672,209.9
65-74 years	780	780	5,939,320	1.31	490,002.6
75-84 years	445	445	3,295,958	1.35	269,681.9
≥ 85 years	193	193	1,581,088	1.22	129,871.9
2015, August					
18-44 years	187	187	9,163,735	0.20	766,075.8
45-64 years	804	804	8,073,804	1.00	671,915.1
65-74 years	796	796	5,958,804	1.34	491,718.1
75-84 years	465	465	3,303,045	1.41	270,322.9
≥ 85 years	161	161	1,583,743	1.02	130,124.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2015, September					
18-44 years	211	211	9,174,232	0.23	742,727.8
45-64 years	848	848	8,082,378	1.05	650,886.0
65-74 years	852	852	5,977,252	1.43	477,286.2
75-84 years	542	542	3,306,502	1.64	261,888.9
≥ 85 years	192	192	1,584,965	1.21	126,032.3
2015, October					
18-44 years	251	251	9,165,264	0.27	766,244.5
45-64 years	902	902	8,092,331	1.11	672,270.2
65-74 years	931	931	6,004,392	1.55	494,397.7
75-84 years	518	518	3,316,179	1.56	270,878.6
≥ 85 years	188	188	1,589,242	1.18	130,309.4
2015, November					
18-44 years	219	219	9,137,229	0.24	740,198.0
45-64 years	865	865	8,070,264	1.07	649,941.5
65-74 years	905	905	5,992,141	1.51	478,783.1
75-84 years	526	526	3,303,891	1.59	262,051.3
≥ 85 years	215	215	1,581,676	1.36	125,959.8
2015, December					
18-44 years	244	244	9,140,219	0.27	764,457.6
45-64 years	1,026	1,026	8,076,025	1.27	670,867.3
65-74 years	990	990	6,006,218	1.65	494,992.0
75-84 years	684	684	3,311,457	2.07	270,924.6
≥ 85 years	213	213	1,583,322	1.35	130,102.7
2016, January					
18-44 years	258	258	9,176,220	0.28	766,940.8
45-64 years	1,223	1,223	8,154,456	1.50	677,817.0
65-74 years	1,464	1,464	6,221,672	2.35	512,641.8
75-84 years	827	827	3,373,232	2.45	275,891.9
≥ 85 years	305	305	1,604,515	1.90	131,756.6
2016, February					
18-44 years	310	310	9,325,950	0.33	716,442.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	1,344	1,344	8,268,075	1.63	633,641.7
65-74 years	1,573	1,573	6,301,064	2.50	480,773.8
75-84 years	886	886	3,379,993	2.62	258,569.1
≥ 85 years	368	368	1,603,408	2.30	123,145.8
2016, March					
18-44 years	340	340	9,344,110	0.36	768,020.0
45-64 years	1,511	1,511	8,274,584	1.83	679,504.0
65-74 years	1,689	1,689	6,327,246	2.67	514,900.1
75-84 years	1,005	1,005	3,395,108	2.96	276,652.7
≥ 85 years	373	373	1,607,208	2.32	131,501.3
2016, April					
18-44 years	401	401	9,362,785	0.43	742,641.0
45-64 years	1,460	1,460	8,254,230	1.77	656,554.2
65-74 years	1,827	1,827	6,323,795	2.89	498,574.7
75-84 years	1,116	1,116	3,394,424	3.29	267,926.7
≥ 85 years	393	393	1,603,015	2.45	127,074.2
2016, May					
18-44 years	396	396	9,372,241	0.42	770,240.4
45-64 years	1,559	1,559	8,239,478	1.89	677,617.1
65-74 years	1,983	1,983	6,326,026	3.13	515,252.6
75-84 years	1,162	1,162	3,397,631	3.42	276,939.5
≥ 85 years	405	405	1,602,141	2.53	131,096.2
2016, June					
18-44 years	388	388	9,420,958	0.41	744,840.9
45-64 years	1,491	1,491	8,267,083	1.80	655,097.1
65-74 years	1,937	1,937	6,364,931	3.04	499,766.6
75-84 years	1,135	1,135	3,408,541	3.33	268,679.1
≥ 85 years	384	384	1,603,035	2.40	126,988.7
2016, July					
18-44 years	354	354	9,439,126	0.38	769,754.8
45-64 years	1,396	1,396	8,213,249	1.70	676,374.3
65-74 years	1,711	1,711	6,368,804	2.69	518,935.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	982	982	3,414,091	2.88	278,679.6
≥ 85 years	374	374	1,603,410	2.33	131,421.0
2016, August					
18-44 years	408	408	9,416,905	0.43	768,495.9
45-64 years	1,754	1,754	8,230,288	2.13	676,076.8
65-74 years	1,998	1,998	6,392,801	3.13	520,221.7
75-84 years	1,111	1,111	3,428,500	3.24	279,500.5
≥ 85 years	418	418	1,607,526	2.60	131,592.9
2016, September					
18-44 years	392	392	9,434,469	0.42	745,800.8
45-64 years	1,782	1,782	8,255,250	2.16	654,223.6
65-74 years	2,038	2,038	6,404,820	3.18	504,824.0
75-84 years	1,119	1,119	3,431,581	3.26	271,030.1
≥ 85 years	434	434	1,607,962	2.70	127,543.9
2016, October					
18-44 years	451	451	9,379,269	0.48	772,388.8
45-64 years	1,877	1,877	8,226,366	2.28	676,925.0
65-74 years	2,225	2,225	6,420,451	3.47	523,389.4
75-84 years	1,208	1,208	3,440,101	3.51	280,707.2
≥ 85 years	469	469	1,610,263	2.91	131,901.2
2016, November					
18-44 years	438	438	9,441,046	0.46	748,248.7
45-64 years	1,925	1,925	8,261,933	2.33	655,041.0
65-74 years	2,374	2,374	6,415,440	3.70	507,212.7
75-84 years	1,325	1,325	3,436,159	3.86	271,907.7
≥ 85 years	457	457	1,604,218	2.85	127,480.0
2016, December					
18-44 years	432	432	10,696,088	0.40	779,225.6
45-64 years	1,866	1,866	9,195,836	2.03	680,330.7
65-74 years	2,391	2,391	6,843,153	3.49	525,344.6
75-84 years	1,447	1,447	3,586,282	4.03	281,504.8
≥ 85 years	496	496	1,654,234	3.00	131,663.4

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2017, January					
18-44 years	519	519	9,465,272	0.55	778,709.6
45-64 years	2,055	2,055	8,204,900	2.50	674,527.8
65-74 years	2,859	2,859	6,500,557	4.40	529,619.9
75-84 years	1,509	1,509	3,438,853	4.39	280,643.2
≥ 85 years	513	513	1,587,598	3.23	130,169.8
2017, February					
18-44 years	448	448	9,297,604	0.48	702,997.8
45-64 years	2,037	2,037	8,086,799	2.52	607,838.7
65-74 years	2,667	2,667	6,406,324	4.16	477,952.7
75-84 years	1,523	1,523	3,417,742	4.46	253,278.0
≥ 85 years	502	502	1,571,365	3.19	116,884.8
2017, March					
18-44 years	585	585	9,327,787	0.63	779,701.9
45-64 years	2,190	2,190	8,104,819	2.70	672,990.1
65-74 years	2,824	2,824	6,434,056	4.39	529,769.8
75-84 years	1,686	1,686	3,434,437	4.91	280,607.8
≥ 85 years	577	577	1,573,762	3.67	129,133.4
2017, April					
18-44 years	448	448	9,326,910	0.48	755,106.4
45-64 years	1,854	1,854	8,085,974	2.29	650,435.5
65-74 years	2,447	2,447	6,423,129	3.81	512,293.3
75-84 years	1,378	1,378	3,430,625	4.02	271,479.6
≥ 85 years	466	466	1,565,479	2.98	124,437.5
2017, May					
18-44 years	509	509	9,336,398	0.55	780,617.5
45-64 years	2,055	2,055	8,076,349	2.54	671,067.2
65-74 years	2,501	2,501	6,422,364	3.89	528,959.7
75-84 years	1,504	1,504	3,432,128	4.38	280,357.2
≥ 85 years	517	517	1,563,077	3.31	128,229.1
2017, June					
18-44 years	500	500	9,345,343	0.54	756,404.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	2,010	2,010	8,068,837	2.49	649,248.4
65-74 years	2,293	2,293	6,422,885	3.57	512,443.4
75-84 years	1,363	1,363	3,429,840	3.97	271,504.4
≥ 85 years	489	489	1,560,248	3.13	124,008.1
2017, July					
18-44 years	448	448	9,337,822	0.48	781,072.6
45-64 years	1,769	1,769	8,044,798	2.20	669,442.6
65-74 years	2,120	2,120	6,446,061	3.29	532,384.2
75-84 years	1,279	1,279	3,436,709	3.72	281,599.0
≥ 85 years	466	466	1,560,250	2.99	128,333.8
2017, August					
18-44 years	559	559	9,376,293	0.60	783,090.6
45-64 years	1,926	1,926	8,060,365	2.39	669,667.2
65-74 years	2,527	2,527	6,471,392	3.90	533,061.2
75-84 years	1,506	1,506	3,453,887	4.36	282,074.7
≥ 85 years	517	517	1,563,923	3.31	128,326.4
2017, September					
18-44 years	453	453	9,398,518	0.48	760,080.2
45-64 years	1,807	1,807	8,051,607	2.24	647,905.5
65-74 years	2,192	2,192	6,476,558	3.38	517,010.7
75-84 years	1,286	1,286	3,459,174	3.72	273,778.4
≥ 85 years	468	468	1,562,059	3.00	124,242.4
2017, October					
18-44 years	540	540	9,430,536	0.57	788,601.3
45-64 years	2,084	2,084	8,066,894	2.58	670,379.2
65-74 years	2,539	2,539	6,493,201	3.91	534,771.5
75-84 years	1,446	1,446	3,476,501	4.16	283,848.0
≥ 85 years	478	478	1,564,101	3.06	128,407.4
2017, November					
18-44 years	535	535	9,433,265	0.57	764,020.6
45-64 years	2,085	2,085	8,056,501	2.59	648,394.3
65-74 years	2,749	2,749	6,477,550	4.24	517,049.0

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	1,514	1,514	3,478,149	4.35	275,452.3
≥ 85 years	549	549	1,558,806	3.52	124,119.9
2017, December					
18-44 years	555	555	9,488,685	0.58	793,772.1
45-64 years	2,166	2,166	8,091,437	2.68	671,845.8
65-74 years	2,661	2,661	6,478,341	4.11	533,599.4
75-84 years	1,580	1,580	3,492,434	4.52	285,540.1
≥ 85 years	566	566	1,558,251	3.63	128,135.1
2018, January					
18-44 years	636	636	9,387,361	0.68	784,459.3
45-64 years	2,436	2,436	7,953,725	3.06	660,373.1
65-74 years	3,237	3,237	6,576,139	4.92	541,336.0
75-84 years	1,861	1,861	3,513,732	5.30	286,989.0
≥ 85 years	679	679	1,558,715	4.36	128,000.2
2018, February					
18-44 years	631	631	9,358,498	0.67	707,598.9
45-64 years	2,315	2,315	7,920,293	2.92	595,218.7
65-74 years	3,193	3,193	6,559,008	4.87	489,306.8
75-84 years	1,802	1,802	3,507,213	5.14	259,830.9
≥ 85 years	713	713	1,544,201	4.62	114,931.1
2018, March					
18-44 years	698	698	9,368,243	0.75	783,364.6
45-64 years	2,575	2,575	7,928,618	3.25	658,371.8
65-74 years	3,301	3,301	6,589,258	5.01	542,389.4
75-84 years	2,091	2,091	3,533,830	5.92	288,513.7
≥ 85 years	699	699	1,548,219	4.51	127,016.3
2018, April					
18-44 years	621	621	9,339,102	0.66	756,258.4
45-64 years	2,358	2,358	7,895,979	2.99	635,129.2
65-74 years	3,154	3,154	6,580,285	4.79	524,761.3
75-84 years	1,934	1,934	3,536,432	5.47	279,729.1
≥ 85 years	684	684	1,543,453	4.43	122,656.0

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2018, May					
18-44 years	616	616	9,334,074	0.66	780,477.6
45-64 years	2,457	2,457	7,873,220	3.12	654,078.4
65-74 years	3,105	3,105	6,573,697	4.72	541,278.8
75-84 years	1,889	1,889	3,541,350	5.33	289,181.6
≥ 85 years	618	618	1,540,857	4.01	126,439.6
2018, June					
18-44 years	586	586	9,329,819	0.63	755,163.3
45-64 years	2,305	2,305	7,857,567	2.93	632,018.0
65-74 years	2,786	2,786	6,571,993	4.24	524,245.7
75-84 years	1,617	1,617	3,543,087	4.56	280,326.5
≥ 85 years	591	591	1,537,477	3.84	122,226.9
2018, July					
18-44 years	255	255	9,299,490	0.27	777,751.2
45-64 years	1,091	1,091	7,822,285	1.39	650,604.9
65-74 years	1,235	1,235	6,594,504	1.87	544,465.1
75-84 years	770	770	3,549,698	2.17	290,750.7
≥ 85 years	275	275	1,536,578	1.79	126,382.2
2018, August					
18-44 years	46	46	9,316,964	0.05	778,634.6
45-64 years	181	181	7,823,740	0.23	649,989.6
65-74 years	180	180	6,621,705	0.27	545,547.4
75-84 years	94	94	3,569,323	0.26	291,613.1
≥ 85 years	39	39	1,539,475	0.25	126,384.8
2018, September					
18-44 years	55	55	9,311,506	0.06	753,685.1
45-64 years	201	201	7,811,887	0.26	628,619.7
65-74 years	179	179	6,628,459	0.27	529,311.1
75-84 years	119	119	3,573,287	0.33	283,103.7
≥ 85 years	41	41	1,536,737	0.27	122,298.9
2018, October					
18-44 years	113	113	9,305,628	0.12	777,790.0

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	359	359	7,810,671	0.46	648,558.6
65-74 years	411	411	6,655,857	0.62	547,967.1
75-84 years	216	216	3,594,196	0.60	293,494.1
≥ 85 years	86	86	1,540,093	0.56	126,339.1
2018, November					
18-44 years	150	150	9,309,494	0.16	753,878.4
45-64 years	553	553	7,800,785	0.71	627,690.9
65-74 years	699	699	6,649,127	1.05	530,961.9
75-84 years	427	427	3,590,756	1.19	284,635.0
≥ 85 years	150	150	1,534,095	0.98	122,121.3
2018, December					
18-44 years	100	100	9,323,750	0.11	779,965.7
45-64 years	422	422	7,810,831	0.54	648,735.9
65-74 years	482	482	6,662,134	0.72	549,412.8
75-84 years	331	331	3,599,825	0.92	294,826.3
≥ 85 years	108	108	1,532,691	0.70	126,089.1
2019, January					
18-44 years	0	0	9,161,315	0.00	765,578.7
45-64 years	0	0	7,679,078	0.00	637,514.8
65-74 years	0	0	6,682,391	0.00	550,152.1
75-84 years	0	0	3,583,947	0.00	292,828.0
≥ 85 years	0	0	1,520,016	0.00	124,747.0
2019, February					
18-44 years	0	0	9,127,310	0.00	690,495.3
45-64 years	0	0	7,640,253	0.00	574,374.2
65-74 years	0	0	6,666,836	0.00	497,681.8
75-84 years	0	0	3,571,955	0.00	264,725.7
≥ 85 years	0	0	1,509,718	0.00	112,368.2
2019, March					
18-44 years	0	0	9,134,562	0.00	763,777.9
45-64 years	0	0	7,642,005	0.00	634,532.1
65-74 years	0	0	6,693,440	0.00	551,251.2

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	0	0	3,589,367	0.00	293,352.4
≥ 85 years	0	0	1,512,749	0.00	124,147.8
2019, April					
18-44 years	0	0	9,114,225	0.00	737,660.4
45-64 years	0	0	7,606,045	0.00	611,331.1
65-74 years	0	0	6,678,869	0.00	532,307.7
75-84 years	0	0	3,582,472	0.00	283,268.4
≥ 85 years	0	0	1,505,107	0.00	119,531.8
2019, May					
18-44 years	0	0	9,106,433	0.00	761,432.7
45-64 years	0	0	7,577,167	0.00	629,289.8
65-74 years	0	0	6,671,015	0.00	549,197.8
75-84 years	0	0	3,578,709	0.00	292,207.2
≥ 85 years	0	0	1,501,690	0.00	123,129.9
2019, June					
18-44 years	0	0	9,091,191	0.00	735,943.4
45-64 years	0	0	7,550,932	0.00	607,217.9
65-74 years	0	0	6,667,557	0.00	531,771.2
75-84 years	0	0	3,574,461	0.00	282,733.5
≥ 85 years	0	0	1,497,410	0.00	118,934.0
2019, July					
18-44 years	0	0	9,093,784	0.00	760,336.3
45-64 years	0	0	7,545,305	0.00	626,651.7
65-74 years	0	0	6,708,925	0.00	552,461.0
75-84 years	0	0	3,590,758	0.00	293,017.9
≥ 85 years	0	0	1,501,937	0.00	123,043.9
2019, August					
18-44 years	0	0	9,104,228	0.00	760,648.5
45-64 years	0	0	7,550,890	0.00	626,465.0
65-74 years	0	0	6,764,246	0.00	555,905.7
75-84 years	0	0	3,624,462	0.00	295,080.9
≥ 85 years	0	0	1,515,520	0.00	123,844.9

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2019, September					
18-44 years	0	0	9,104,058	0.00	736,443.3
45-64 years	0	0	7,549,377	0.00	606,552.3
65-74 years	0	0	6,797,852	0.00	541,598.8
75-84 years	0	0	3,640,400	0.00	287,547.1
≥ 85 years	0	0	1,521,526	0.00	120,626.7
2019, October					
18-44 years	0	0	9,103,174	0.00	760,995.9
45-64 years	0	0	7,544,021	0.00	625,912.1
65-74 years	0	0	6,835,746	0.00	561,844.5
75-84 years	0	0	3,663,199	0.00	298,389.2
≥ 85 years	0	0	1,530,415	0.00	125,173.0
2019, November					
18-44 years	0	0	9,098,398	0.00	736,811.2
45-64 years	0	0	7,529,419	0.00	605,472.5
65-74 years	0	0	6,832,195	0.00	544,975.2
75-84 years	0	0	3,657,228	0.00	289,427.7
≥ 85 years	0	0	1,524,919	0.00	121,222.2
2019, December					
18-44 years	0	0	9,116,903	0.00	762,942.3
45-64 years	0	0	7,539,345	0.00	626,143.0
65-74 years	0	0	6,843,823	0.00	564,266.9
75-84 years	0	0	3,664,849	0.00	300,005.1
≥ 85 years	0	0	1,523,821	0.00	125,279.4
2020, January					
18-44 years	0	0	8,986,565	0.00	750,177.3
45-64 years	0	0	7,419,092	0.00	615,155.2
65-74 years	0	0	6,943,046	0.00	571,609.0
75-84 years	0	0	3,694,576	0.00	301,786.5
≥ 85 years	0	0	1,531,007	0.00	125,584.1
2020, February					
18-44 years	0	0	9,071,381	0.00	700,718.4

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	0	0	7,445,927	0.00	573,688.0
65-74 years	0	0	7,016,205	0.00	535,429.0
75-84 years	0	0	3,692,891	0.00	282,351.5
≥ 85 years	0	0	1,526,710	0.00	117,184.0
2020, March					
18-44 years	0	0	9,091,245	0.00	749,252.8
45-64 years	0	0	7,443,084	0.00	612,338.0
65-74 years	0	0	7,038,015	0.00	573,844.3
75-84 years	0	0	3,705,390	0.00	302,588.6
≥ 85 years	0	0	1,528,183	0.00	125,321.2
2020, April					
18-44 years	0	0	9,075,730	0.00	726,257.5
45-64 years	0	0	7,447,973	0.00	596,019.5
65-74 years	0	0	7,116,965	0.00	565,709.8
75-84 years	0	0	3,753,814	0.00	299,100.1
≥ 85 years	0	0	1,542,992	0.00	123,278.3
2020, May					
18-44 years	0	0	9,153,112	0.00	754,807.9
45-64 years	0	0	7,534,461	0.00	620,845.8
65-74 years	0	0	7,279,402	0.00	595,417.9
75-84 years	0	0	3,847,805	0.00	315,325.6
≥ 85 years	0	0	1,566,846	0.00	128,841.7
2020, June					
18-44 years	0	0	9,255,133	0.00	734,398.8
45-64 years	0	0	7,603,031	0.00	603,554.3
65-74 years	0	0	7,398,245	0.00	582,246.5
75-84 years	0	0	3,904,985	0.00	308,490.5
≥ 85 years	0	0	1,582,906	0.00	125,584.1
2020, July					
18-44 years	0	0	9,296,333	0.00	759,505.8
45-64 years	0	0	7,569,687	0.00	623,177.2
65-74 years	0	0	7,442,197	0.00	605,983.6

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	0	0	3,929,093	0.00	320,597.1
≥ 85 years	0	0	1,592,773	0.00	130,397.3
2020, August					
18-44 years	0	0	9,274,591	0.00	759,954.0
45-64 years	0	0	7,584,827	0.00	623,450.5
65-74 years	0	0	7,486,130	0.00	609,643.9
75-84 years	0	0	3,952,317	0.00	322,487.8
≥ 85 years	0	0	1,600,407	0.00	131,064.2
2020, September					
18-44 years	0	0	9,216,988	0.00	731,132.1
45-64 years	0	0	7,579,894	0.00	601,394.4
65-74 years	0	0	7,532,777	0.00	593,688.2
75-84 years	0	0	3,976,933	0.00	313,814.3
≥ 85 years	0	0	1,608,651	0.00	127,349.6
2020, October					
18-44 years	0	0	9,193,389	0.00	758,328.2
45-64 years	0	0	7,560,762	0.00	622,065.4
65-74 years	0	0	7,579,235	0.00	617,078.1
75-84 years	0	0	4,007,653	0.00	326,201.6
≥ 85 years	0	0	1,619,843	0.00	132,289.5
2020, November					
18-44 years	0	0	9,221,551	0.00	736,146.4
45-64 years	0	0	7,576,294	0.00	603,408.4
65-74 years	0	0	7,591,709	0.00	600,886.9
75-84 years	0	0	4,014,004	0.00	317,684.8
≥ 85 years	0	0	1,618,484	0.00	128,506.9
2020, December					
18-44 years	0	0	10,266,951	0.00	766,557.8
45-64 years	0	0	8,310,148	0.00	627,494.4
65-74 years	0	0	8,266,284	0.00	626,506.4
75-84 years	0	0	4,270,577	0.00	331,256.6
≥ 85 years	0	0	1,690,033	0.00	133,377.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2021, January					
18-44 years	0	0	9,381,782	0.00	774,388.3
45-64 years	0	0	7,681,319	0.00	631,759.7
65-74 years	0	0	7,813,588	0.00	636,682.1
75-84 years	0	0	4,087,162	0.00	333,054.3
≥ 85 years	0	0	1,630,032	0.00	133,166.2
2021, February					
18-44 years	0	0	9,266,325	0.00	701,085.7
45-64 years	0	0	7,618,091	0.00	572,102.6
65-74 years	0	0	7,767,637	0.00	579,119.9
75-84 years	0	0	4,095,961	0.00	303,099.6
≥ 85 years	0	0	1,625,260	0.00	120,492.0
2021, March					
18-44 years	0	0	9,285,032	0.00	775,880.4
45-64 years	0	0	7,615,217	0.00	633,341.8
65-74 years	0	0	7,788,382	0.00	644,333.6
75-84 years	0	0	4,105,542	0.00	337,071.1
≥ 85 years	0	0	1,624,887	0.00	133,840.6
2021, April					
18-44 years	0	0	9,198,813	0.00	747,142.5
45-64 years	0	0	7,503,958	0.00	606,601.7
65-74 years	0	0	7,653,776	0.00	615,297.6
75-84 years	0	0	4,019,707	0.00	320,934.3
≥ 85 years	0	0	1,589,183	0.00	127,249.5
2021, May					
18-44 years	0	0	9,115,108	0.00	764,156.7
45-64 years	0	0	7,425,492	0.00	618,811.4
65-74 years	0	0	7,574,271	0.00	626,529.8
75-84 years	0	0	3,973,145	0.00	326,183.1
≥ 85 years	0	0	1,566,545	0.00	129,086.8
2021, June					
18-44 years	0	0	9,041,948	0.00	732,740.0

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	0	0	7,376,671	0.00	593,778.0
65-74 years	0	0	7,550,472	0.00	602,799.3
75-84 years	0	0	3,963,138	0.00	313,731.2
≥ 85 years	0	0	1,557,573	0.00	123,794.7
2021, July					
18-44 years	0	0	8,967,153	0.00	750,666.3
45-64 years	0	0	7,327,814	0.00	609,483.9
65-74 years	0	0	7,544,687	0.00	622,559.1
75-84 years	0	0	3,961,147	0.00	323,919.2
≥ 85 years	0	0	1,551,474	0.00	127,422.0
2021, August					
18-44 years	0	0	8,909,004	0.00	745,325.0
45-64 years	0	0	7,284,973	0.00	605,863.0
65-74 years	0	0	7,525,967	0.00	620,847.1
75-84 years	0	0	3,961,798	0.00	323,914.0
≥ 85 years	0	0	1,544,622	0.00	126,949.3
2021, September					
18-44 years	0	0	8,847,418	0.00	717,025.6
45-64 years	0	0	7,237,552	0.00	582,823.8
65-74 years	0	0	7,501,646	0.00	599,218.2
75-84 years	0	0	3,965,841	0.00	313,937.1
≥ 85 years	0	0	1,538,410	0.00	122,428.6
2021, October					
18-44 years	0	0	8,794,893	0.00	736,254.9
45-64 years	0	0	7,203,055	0.00	598,713.7
65-74 years	0	0	7,494,173	0.00	617,300.0
75-84 years	0	0	3,985,400	0.00	325,267.5
≥ 85 years	0	0	1,536,519	0.00	126,135.6
2021, November					
18-44 years	0	0	8,749,707	0.00	709,574.0
45-64 years	0	0	7,166,680	0.00	577,315.4
65-74 years	0	0	7,450,141	0.00	595,085.3

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	0	0	3,983,058	0.00	315,559.0
≥ 85 years	0	0	1,525,584	0.00	121,572.5
2021, December					
18-44 years	0	0	8,726,561	0.00	731,479.7
45-64 years	0	0	7,148,818	0.00	594,707.4
65-74 years	0	0	7,410,326	0.00	611,479.6
75-84 years	0	0	3,989,359	0.00	326,659.5
≥ 85 years	0	0	1,516,694	0.00	124,887.6
2022, January					
18-44 years	0	0	8,405,657	0.00	704,233.8
45-64 years	0	0	6,903,167	0.00	574,917.4
65-74 years	0	0	7,387,245	0.00	610,225.5
75-84 years	0	0	3,976,033	0.00	325,808.2
≥ 85 years	0	0	1,506,037	0.00	124,037.0
2022, February					
18-44 years	0	0	8,354,858	0.00	633,167.4
45-64 years	0	0	6,858,065	0.00	516,498.6
65-74 years	0	0	7,339,629	0.00	548,666.7
75-84 years	0	0	3,967,052	0.00	294,417.5
≥ 85 years	0	0	1,487,972	0.00	110,911.9
2022, March					
18-44 years	0	0	8,348,025	0.00	698,776.1
45-64 years	0	0	6,854,139	0.00	569,691.2
65-74 years	0	0	7,343,435	0.00	605,072.7
75-84 years	0	0	3,997,679	0.00	326,485.5
≥ 85 years	0	0	1,490,394	0.00	122,294.0
2022, April					
18-44 years	0	0	8,319,160	0.00	673,996.5
45-64 years	0	0	6,821,708	0.00	548,979.9
65-74 years	0	0	7,312,574	0.00	583,457.2
75-84 years	0	0	4,001,061	0.00	316,617.2
≥ 85 years	0	0	1,487,127	0.00	118,147.3

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2022, May					
18-44 years	0	0	8,297,817	0.00	694,342.1
45-64 years	0	0	6,800,127	0.00	565,194.3
65-74 years	0	0	7,307,195	0.00	601,951.0
75-84 years	0	0	4,018,998	0.00	328,244.6
≥ 85 years	0	0	1,488,802	0.00	122,114.2
2022, June					
18-44 years	0	0	8,301,014	0.00	672,081.1
45-64 years	0	0	6,790,708	0.00	546,268.5
65-74 years	0	0	7,299,152	0.00	582,116.8
75-84 years	0	0	4,035,098	0.00	319,045.3
≥ 85 years	0	0	1,488,728	0.00	118,208.8
2022, July					
18-44 years	0	0	8,257,152	0.00	690,577.0
45-64 years	0	0	6,750,560	0.00	561,064.2
65-74 years	0	0	7,308,368	0.00	602,661.4
75-84 years	0	0	4,052,524	0.00	331,231.0
≥ 85 years	0	0	1,492,092	0.00	122,386.5
2022, August					
18-44 years	0	0	8,293,145	0.00	690,359.8
45-64 years	0	0	6,748,244	0.00	559,828.4
65-74 years	0	0	7,323,261	0.00	603,207.0
75-84 years	0	0	4,073,678	0.00	332,617.5
≥ 85 years	0	0	1,494,610	0.00	122,512.4
2022, September					
18-44 years	0	0	5,790,783	0.00	468,869.4
45-64 years	0	0	5,017,361	0.00	403,404.3
65-74 years	0	0	7,191,411	0.00	574,223.2
75-84 years	0	0	4,062,772	0.00	321,673.4
≥ 85 years	0	0	1,486,543	0.00	118,137.1
2022, October					
18-44 years	0	0	5,124,002	0.00	428,790.3

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	0	0	3,700,182	0.00	307,705.4
65-74 years	0	0	1,149,066	0.00	94,714.7
75-84 years	0	0	532,380	0.00	43,619.0
≥ 85 years	0	0	180,721	0.00	14,829.7
2022, November					
18-44 years	0	0	1,546,194	0.00	125,779.2
45-64 years	0	0	1,015,580	0.00	81,904.1
65-74 years	0	0	641,203	0.00	51,303.9
75-84 years	0	0	306,921	0.00	24,366.2
≥ 85 years	0	0	94,527	0.00	7,512.3
2022, December					
18-44 years	0	0	1,556,653	0.00	130,800.3
45-64 years	0	0	1,020,388	0.00	84,982.0
65-74 years	0	0	643,598	0.00	53,193.5
75-84 years	0	0	308,809	0.00	25,336.3
≥ 85 years	0	0	94,754	0.00	7,792.1
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan					
Non-contaminated valsartan					
2012, May					
18-44 years	2,109	2,109	8,364,508	2.52	685,791.5
45-64 years	9,761	9,761	7,525,643	12.97	618,088.7
65-74 years	9,933	9,933	4,787,090	20.75	390,798.7
75-84 years	7,596	7,596	2,975,916	25.52	243,391.1
≥ 85 years	3,300	3,300	1,478,285	22.32	121,347.1
2012, June					
18-44 years	2,007	2,007	8,439,754	2.38	664,978.5
45-64 years	9,218	9,218	7,572,017	12.17	599,028.0
65-74 years	9,111	9,111	4,812,888	18.93	378,816.8
75-84 years	6,931	6,931	2,976,439	23.29	235,451.1
≥ 85 years	2,975	2,975	1,479,239	20.11	117,446.2
2012, July					
18-44 years	1,889	1,889	8,433,567	2.24	687,065.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	8,562	8,562	7,512,418	11.40	618,367.3
65-74 years	8,706	8,706	4,815,120	18.08	393,489.8
75-84 years	6,316	6,316	2,972,401	21.25	243,646.9
≥ 85 years	2,850	2,850	1,479,218	19.27	121,640.5
2012, August					
18-44 years	1,687	1,687	8,458,411	1.99	688,780.3
45-64 years	7,876	7,876	7,534,562	10.45	618,951.9
65-74 years	8,099	8,099	4,842,935	16.72	394,472.6
75-84 years	5,946	5,946	2,980,930	19.95	243,764.8
≥ 85 years	2,720	2,720	1,484,666	18.32	121,820.5
2012, September					
18-44 years	1,341	1,341	8,461,860	1.58	667,463.8
45-64 years	6,308	6,308	7,546,214	8.36	599,710.0
65-74 years	6,781	6,781	4,852,539	13.97	383,018.4
75-84 years	5,035	5,035	2,978,540	16.90	235,991.0
≥ 85 years	2,259	2,259	1,485,027	15.21	118,067.0
2012, October					
18-44 years	1,329	1,329	8,410,780	1.58	692,353.4
45-64 years	6,106	6,106	7,535,482	8.10	620,487.1
65-74 years	6,840	6,840	4,872,569	14.04	397,292.1
75-84 years	4,886	4,886	2,985,327	16.37	244,054.5
≥ 85 years	2,316	2,316	1,489,217	15.55	122,217.3
2012, November					
18-44 years	1,232	1,232	8,383,816	1.47	670,514.1
45-64 years	5,880	5,880	7,522,298	7.82	601,201.8
65-74 years	6,198	6,198	4,877,771	12.71	385,739.1
75-84 years	4,640	4,640	2,976,557	15.59	236,289.4
≥ 85 years	2,005	2,005	1,484,866	13.50	118,305.0
2012, December					
18-44 years	1,043	1,043	8,954,111	1.16	694,328.3
45-64 years	5,524	5,524	7,957,095	6.94	622,901.1
65-74 years	5,994	5,994	5,338,172	11.23	400,981.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	4,197	4,197	3,184,349	13.18	244,629.9
≥ 85 years	2,017	2,017	1,566,633	12.87	122,311.3
2013, January					
18-44 years	1,157	1,157	8,353,700	1.39	687,648.1
45-64 years	5,830	5,830	7,548,041	7.72	621,880.1
65-74 years	7,728	7,728	5,100,007	15.15	415,361.8
75-84 years	5,415	5,415	3,078,255	17.59	251,576.0
≥ 85 years	2,519	2,519	1,530,143	16.46	125,538.3
2013, February					
18-44 years	1,000	1,000	8,175,825	1.22	619,070.5
45-64 years	5,198	5,198	7,436,868	6.99	560,449.5
65-74 years	6,212	6,212	5,027,964	12.35	375,918.3
75-84 years	4,382	4,382	3,054,008	14.35	227,022.2
≥ 85 years	2,015	2,015	1,512,480	13.32	112,781.3
2013, March					
18-44 years	999	999	8,193,743	1.22	685,513.4
45-64 years	5,183	5,183	7,458,564	6.95	620,998.7
65-74 years	6,046	6,046	5,062,078	11.94	417,643.1
75-84 years	4,488	4,488	3,068,318	14.63	251,434.5
≥ 85 years	2,062	2,062	1,517,564	13.59	124,778.9
2013, April					
18-44 years	917	917	8,163,103	1.12	661,545.4
45-64 years	5,031	5,031	7,448,315	6.75	600,540.3
65-74 years	6,770	6,770	5,066,600	13.36	404,730.2
75-84 years	4,728	4,728	3,064,944	15.43	243,135.3
≥ 85 years	2,106	2,106	1,512,954	13.92	120,475.5
2013, May					
18-44 years	817	817	8,167,935	1.00	683,740.2
45-64 years	4,549	4,549	7,448,510	6.11	620,475.7
65-74 years	6,182	6,182	5,073,554	12.18	418,646.0
75-84 years	4,369	4,369	3,063,443	14.26	250,971.7
≥ 85 years	1,924	1,924	1,513,127	12.72	124,414.9

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2013, June					
18-44 years	796	796	8,172,089	0.97	662,092.7
45-64 years	4,336	4,336	7,451,057	5.82	600,884.6
65-74 years	5,208	5,208	5,078,332	10.26	405,880.9
75-84 years	3,756	3,756	3,061,768	12.27	242,903.2
≥ 85 years	1,629	1,629	1,515,140	10.75	120,598.6
2013, July					
18-44 years	783	783	8,186,238	0.96	685,446.1
45-64 years	4,617	4,617	7,477,827	6.17	623,277.3
65-74 years	5,059	5,059	5,106,423	9.91	421,838.0
75-84 years	3,657	3,657	3,068,486	11.92	251,632.8
≥ 85 years	1,713	1,713	1,518,798	11.28	125,022.4
2013, August					
18-44 years	785	785	8,222,861	0.95	686,985.1
45-64 years	4,319	4,319	7,485,928	5.77	623,387.5
65-74 years	4,596	4,596	5,122,700	8.97	422,614.0
75-84 years	3,341	3,341	3,072,300	10.87	251,599.8
≥ 85 years	1,564	1,564	1,522,012	10.28	125,098.2
2013, September					
18-44 years	729	729	8,206,097	0.89	663,185.4
45-64 years	4,063	4,063	7,481,401	5.43	603,284.7
65-74 years	4,503	4,503	5,129,144	8.78	409,982.8
75-84 years	3,271	3,271	3,068,476	10.66	243,479.4
≥ 85 years	1,550	1,550	1,521,423	10.19	121,186.3
2013, October					
18-44 years	819	819	8,151,267	1.00	682,468.5
45-64 years	4,443	4,443	7,486,691	5.93	623,439.9
65-74 years	4,921	4,921	5,143,267	9.57	424,173.3
75-84 years	3,446	3,446	3,072,371	11.22	251,525.2
≥ 85 years	1,531	1,531	1,524,246	10.04	125,281.1
2013, November					
18-44 years	674	674	8,140,272	0.83	660,095.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	3,679	3,679	7,472,138	4.92	602,666.2
65-74 years	4,121	4,121	5,131,443	8.03	410,239.6
75-84 years	2,974	2,974	3,056,902	9.73	242,817.7
≥ 85 years	1,391	1,391	1,516,932	9.17	120,948.8
2013, December					
18-44 years	653	653	8,111,311	0.81	679,413.8
45-64 years	3,736	3,736	7,453,904	5.01	620,953.7
65-74 years	4,228	4,228	5,132,287	8.24	424,162.2
75-84 years	3,043	3,043	3,056,031	9.96	251,034.8
≥ 85 years	1,418	1,418	1,516,170	9.35	125,022.0
2014, January					
18-44 years	1,032	1,032	8,900,862	1.16	743,878.7
45-64 years	4,812	4,812	8,097,588	5.94	673,473.1
65-74 years	5,909	5,909	5,828,215	10.14	480,960.5
75-84 years	4,021	4,021	3,436,548	11.70	281,800.4
≥ 85 years	1,865	1,865	1,692,042	11.02	139,286.0
2014, February					
18-44 years	810	810	8,846,077	0.92	669,432.3
45-64 years	4,076	4,076	8,045,772	5.07	606,140.0
65-74 years	4,935	4,935	5,820,892	8.48	435,355.3
75-84 years	3,435	3,435	3,424,581	10.03	254,601.6
≥ 85 years	1,512	1,512	1,684,773	8.97	125,668.1
2014, March					
18-44 years	791	791	8,829,117	0.90	738,714.1
45-64 years	3,889	3,889	8,023,113	4.85	667,865.6
65-74 years	4,688	4,688	5,847,596	8.02	482,829.3
75-84 years	3,264	3,264	3,437,822	9.49	281,924.6
≥ 85 years	1,570	1,570	1,691,245	9.28	139,172.4
2014, April					
18-44 years	653	653	8,792,157	0.74	711,953.1
45-64 years	3,390	3,390	7,984,409	4.25	643,156.4
65-74 years	4,163	4,163	5,863,303	7.10	468,166.6

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	3,021	3,021	3,445,634	8.77	273,159.9
≥ 85 years	1,406	1,406	1,693,294	8.30	134,731.3
2014, May					
18-44 years	564	564	8,775,025	0.64	733,930.6
45-64 years	3,344	3,344	7,950,385	4.21	661,633.0
65-74 years	3,902	3,902	5,858,001	6.66	483,089.2
75-84 years	2,766	2,766	3,440,683	8.04	281,659.7
≥ 85 years	1,326	1,326	1,690,431	7.84	138,907.8
2014, June					
18-44 years	620	620	8,755,301	0.71	708,949.4
45-64 years	4,009	4,009	7,924,298	5.06	638,515.2
65-74 years	5,130	5,130	5,854,865	8.76	467,718.1
75-84 years	3,364	3,364	3,431,651	9.80	272,104.9
≥ 85 years	1,482	1,482	1,686,277	8.79	134,187.3
2014, July					
18-44 years	548	548	8,833,991	0.62	738,989.7
45-64 years	3,003	3,003	7,983,593	3.76	664,707.5
65-74 years	3,870	3,870	5,874,178	6.59	484,891.1
75-84 years	2,855	2,855	3,427,276	8.33	280,728.7
≥ 85 years	1,380	1,380	1,684,119	8.19	138,431.0
2014, August					
18-44 years	526	526	8,797,059	0.60	735,222.7
45-64 years	2,959	2,959	7,935,928	3.73	660,431.2
65-74 years	3,933	3,933	5,888,903	6.68	485,876.7
75-84 years	2,769	2,769	3,428,655	8.08	280,695.3
≥ 85 years	1,469	1,469	1,684,601	8.72	138,438.1
2014, September					
18-44 years	523	523	8,769,121	0.60	710,028.2
45-64 years	2,882	2,882	7,912,260	3.64	637,550.1
65-74 years	3,659	3,659	5,894,672	6.21	470,964.9
75-84 years	2,720	2,720	3,426,341	7.94	271,705.1
≥ 85 years	1,336	1,336	1,682,352	7.94	133,959.4

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2014, October					
18-44 years	648	648	8,785,078	0.74	734,914.6
45-64 years	3,839	3,839	7,910,421	4.85	658,014.1
65-74 years	5,256	5,256	5,914,239	8.89	487,351.0
75-84 years	3,842	3,842	3,435,649	11.18	280,981.9
≥ 85 years	1,714	1,714	1,685,805	10.17	138,418.0
2014, November					
18-44 years	544	544	8,754,559	0.62	709,819.2
45-64 years	3,827	3,827	7,883,454	4.85	635,697.5
65-74 years	4,607	4,607	5,900,692	7.81	471,898.8
75-84 years	3,257	3,257	3,422,502	9.52	271,908.9
≥ 85 years	1,448	1,448	1,678,279	8.63	133,802.6
2014, December					
18-44 years	581	581	8,757,751	0.66	732,068.5
45-64 years	4,062	4,062	7,881,283	5.15	654,824.6
65-74 years	4,927	4,927	5,904,938	8.34	487,099.3
75-84 years	3,497	3,497	3,421,590	10.22	280,390.3
≥ 85 years	1,517	1,517	1,674,759	9.06	137,861.6
2015, January					
18-44 years	601	601	9,123,915	0.66	762,766.6
45-64 years	3,856	3,856	8,180,925	4.71	680,368.3
65-74 years	5,020	5,020	6,127,270	8.19	505,457.1
75-84 years	3,484	3,484	3,490,024	9.98	285,957.7
≥ 85 years	1,514	1,514	1,693,775	8.94	139,302.5
2015, February					
18-44 years	567	567	9,086,841	0.62	687,415.6
45-64 years	3,139	3,139	8,160,229	3.85	614,176.1
65-74 years	4,067	4,067	6,120,863	6.64	457,054.2
75-84 years	2,742	2,742	3,474,987	7.89	257,792.2
≥ 85 years	1,266	1,266	1,677,605	7.55	124,947.6
2015, March					
18-44 years	726	726	9,100,046	0.80	761,135.6

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	4,310	4,310	8,180,125	5.27	680,528.2
65-74 years	5,456	5,456	6,143,987	8.88	506,922.6
75-84 years	3,693	3,693	3,486,096	10.59	285,560.7
≥ 85 years	1,605	1,605	1,680,197	9.55	138,115.5
2015, April					
18-44 years	726	726	9,138,675	0.79	739,977.1
45-64 years	5,030	5,030	8,211,131	6.13	661,233.4
65-74 years	6,680	6,680	6,145,884	10.87	490,587.7
75-84 years	4,190	4,190	3,483,308	12.03	275,957.6
≥ 85 years	1,719	1,719	1,675,829	10.26	133,251.0
2015, May					
18-44 years	934	934	9,175,195	1.02	767,475.7
45-64 years	6,083	6,083	8,246,239	7.38	686,093.7
65-74 years	8,037	8,037	6,153,081	13.06	507,293.6
75-84 years	4,983	4,983	3,481,086	14.31	284,736.1
≥ 85 years	2,032	2,032	1,671,940	12.15	137,323.4
2015, June					
18-44 years	1,057	1,057	9,183,380	1.15	743,496.2
45-64 years	6,385	6,385	8,249,066	7.74	664,426.9
65-74 years	8,407	8,407	6,156,861	13.65	491,430.5
75-84 years	5,548	5,548	3,476,280	15.96	275,392.3
≥ 85 years	2,225	2,225	1,669,641	13.33	132,738.1
2015, July					
18-44 years	897	897	9,174,711	0.98	767,433.8
45-64 years	5,234	5,234	8,243,111	6.35	686,070.7
65-74 years	7,726	7,726	6,183,678	12.49	510,273.2
75-84 years	4,994	4,994	3,480,494	14.35	284,897.6
≥ 85 years	2,107	2,107	1,671,542	12.61	137,352.4
2015, August					
18-44 years	728	728	9,185,511	0.79	767,910.7
45-64 years	4,308	4,308	8,238,322	5.23	685,699.0
65-74 years	6,076	6,076	6,202,569	9.80	511,943.7

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	3,966	3,966	3,486,959	11.37	285,474.9
≥ 85 years	1,779	1,779	1,673,569	10.63	137,559.6
2015, September					
18-44 years	637	637	9,195,873	0.69	744,491.9
45-64 years	3,841	3,841	8,246,416	4.66	664,166.7
65-74 years	5,439	5,439	6,220,835	8.74	496,832.6
75-84 years	3,517	3,517	3,489,823	10.08	276,503.9
≥ 85 years	1,516	1,516	1,674,405	9.05	133,188.6
2015, October					
18-44 years	706	706	9,186,832	0.77	768,057.8
45-64 years	4,103	4,103	8,256,279	4.97	685,957.0
65-74 years	5,937	5,937	6,247,993	9.50	514,567.3
75-84 years	4,115	4,115	3,499,155	11.76	285,939.0
≥ 85 years	1,751	1,751	1,678,202	10.43	137,656.7
2015, November					
18-44 years	830	830	9,158,717	0.91	741,953.8
45-64 years	5,179	5,179	8,233,444	6.29	663,167.1
65-74 years	6,837	6,837	6,234,026	10.97	498,253.2
75-84 years	4,962	4,962	3,484,813	14.24	276,549.0
≥ 85 years	2,455	2,455	1,669,179	14.71	133,003.4
2015, December					
18-44 years	884	884	9,161,719	0.96	766,268.6
45-64 years	5,184	5,184	8,238,837	6.29	684,479.4
65-74 years	6,670	6,670	6,246,451	10.68	514,985.8
75-84 years	4,804	4,804	3,490,650	13.76	285,784.2
≥ 85 years	2,384	2,384	1,669,468	14.28	137,277.3
2016, January					
18-44 years	782	782	9,197,891	0.85	768,766.8
45-64 years	4,886	4,886	8,317,974	5.87	691,508.8
65-74 years	7,243	7,243	6,466,038	11.20	533,020.6
75-84 years	4,785	4,785	3,552,538	13.47	290,765.5
≥ 85 years	2,077	2,077	1,689,811	12.29	138,879.7

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2016, February					
18-44 years	708	708	9,347,756	0.76	718,151.0
45-64 years	4,231	4,231	8,432,703	5.02	646,433.4
65-74 years	5,837	5,837	6,545,713	8.92	499,704.7
75-84 years	3,858	3,858	3,556,873	10.85	272,312.5
≥ 85 years	1,544	1,544	1,687,003	9.15	129,677.7
2016, March					
18-44 years	685	685	9,366,076	0.73	769,852.1
45-64 years	3,577	3,577	8,439,304	4.24	693,183.1
65-74 years	4,900	4,900	6,572,078	7.46	535,044.1
75-84 years	3,153	3,153	3,571,421	8.83	291,183.6
≥ 85 years	1,387	1,387	1,690,174	8.21	138,375.5
2016, April					
18-44 years	546	546	9,384,822	0.58	744,418.9
45-64 years	2,856	2,856	8,419,060	3.39	669,792.2
65-74 years	3,768	3,768	6,569,124	5.74	518,068.0
75-84 years	2,565	2,565	3,570,432	7.18	281,952.1
≥ 85 years	1,398	1,398	1,685,515	8.29	133,676.6
2016, May					
18-44 years	524	524	9,394,394	0.56	772,087.7
45-64 years	2,998	2,998	8,404,391	3.57	691,299.2
65-74 years	3,820	3,820	6,572,106	5.81	535,445.0
75-84 years	2,791	2,791	3,574,047	7.81	291,433.1
≥ 85 years	1,502	1,502	1,684,428	8.92	137,891.7
2016, June					
18-44 years	541	541	9,443,249	0.57	746,629.4
45-64 years	3,640	3,640	8,432,609	4.32	668,337.1
65-74 years	4,719	4,719	6,613,244	7.14	519,406.7
75-84 years	3,338	3,338	3,585,720	9.31	282,753.3
≥ 85 years	1,374	1,374	1,685,376	8.15	133,560.2
2016, July					
18-44 years	571	571	9,461,262	0.60	771,598.4

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	3,868	3,868	8,377,595	4.62	690,024.6
65-74 years	4,847	4,847	6,618,431	7.32	539,385.0
75-84 years	3,273	3,273	3,591,786	9.11	293,279.9
≥ 85 years	1,475	1,475	1,685,623	8.75	138,210.5
2016, August					
18-44 years	510	510	9,439,117	0.54	770,338.6
45-64 years	3,424	3,424	8,394,924	4.08	689,729.7
65-74 years	4,368	4,368	6,643,992	6.57	540,791.4
75-84 years	2,988	2,988	3,607,137	8.28	294,163.3
≥ 85 years	1,335	1,335	1,689,827	7.90	138,380.9
2016, September					
18-44 years	466	466	9,456,740	0.49	747,592.2
45-64 years	2,628	2,628	8,420,353	3.12	667,450.2
65-74 years	3,372	3,372	6,657,344	5.07	524,840.8
75-84 years	2,483	2,483	3,610,739	6.88	285,278.9
≥ 85 years	1,061	1,061	1,690,174	6.28	134,110.8
2016, October					
18-44 years	470	470	9,401,480	0.50	774,245.1
45-64 years	2,506	2,506	8,391,271	2.99	690,619.5
65-74 years	3,224	3,224	6,674,329	4.83	544,213.4
75-84 years	2,343	2,343	3,620,317	6.47	295,502.5
≥ 85 years	1,070	1,070	1,692,643	6.32	138,700.0
2016, November					
18-44 years	372	372	9,463,510	0.39	750,054.5
45-64 years	2,442	2,442	8,428,158	2.90	668,345.6
65-74 years	3,266	3,266	6,670,099	4.90	527,483.5
75-84 years	2,331	2,331	3,616,309	6.45	286,279.8
≥ 85 years	1,078	1,078	1,686,419	6.39	134,060.8
2016, December					
18-44 years	398	398	10,721,076	0.37	781,111.1
45-64 years	2,397	2,397	9,379,592	2.56	694,190.9
65-74 years	3,227	3,227	7,114,665	4.54	546,461.2

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	2,297	2,297	3,773,569	6.09	296,434.9
≥ 85 years	1,025	1,025	1,738,486	5.90	138,471.1
2017, January					
18-44 years	448	448	9,487,856	0.47	780,593.7
45-64 years	2,533	2,533	8,370,471	3.03	688,283.0
65-74 years	4,228	4,228	6,757,194	6.26	550,680.7
75-84 years	2,840	2,840	3,618,289	7.85	295,409.8
≥ 85 years	1,298	1,298	1,668,592	7.78	136,859.5
2017, February					
18-44 years	430	430	9,319,963	0.46	704,706.1
45-64 years	2,341	2,341	8,251,261	2.84	620,296.0
65-74 years	3,681	3,681	6,661,229	5.53	497,103.7
75-84 years	2,487	2,487	3,596,912	6.91	266,670.0
≥ 85 years	1,136	1,136	1,651,950	6.88	122,924.4
2017, March					
18-44 years	417	417	9,350,278	0.45	781,603.2
45-64 years	2,483	2,483	8,270,143	3.00	686,825.6
65-74 years	3,758	3,758	6,691,510	5.62	551,117.1
75-84 years	2,712	2,712	3,615,640	7.50	295,535.4
≥ 85 years	1,178	1,178	1,654,674	7.12	135,829.5
2017, April					
18-44 years	368	368	9,349,585	0.39	756,960.8
45-64 years	2,148	2,148	8,252,018	2.60	663,883.1
65-74 years	2,974	2,974	6,682,659	4.45	533,106.3
75-84 years	2,090	2,090	3,612,985	5.78	286,004.9
≥ 85 years	974	974	1,646,563	5.92	130,920.9
2017, May					
18-44 years	457	457	9,359,246	0.49	782,545.8
45-64 years	3,118	3,118	8,242,827	3.78	685,007.1
65-74 years	4,613	4,613	6,683,727	6.90	550,617.9
75-84 years	3,166	3,166	3,615,549	8.76	295,460.0
≥ 85 years	1,226	1,226	1,644,327	7.46	134,947.3

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2017, June					
18-44 years	493	493	9,368,314	0.53	758,284.8
45-64 years	3,401	3,401	8,236,072	4.13	662,790.7
65-74 years	4,515	4,515	6,685,793	6.75	533,532.9
75-84 years	2,859	2,859	3,614,209	7.91	286,199.9
≥ 85 years	1,140	1,140	1,641,664	6.94	130,526.2
2017, July					
18-44 years	544	544	9,360,900	0.58	783,019.8
45-64 years	4,448	4,448	8,212,151	5.42	683,447.3
65-74 years	5,374	5,374	6,710,909	8.01	554,364.4
75-84 years	3,215	3,215	3,622,293	8.88	296,907.7
≥ 85 years	1,153	1,153	1,641,767	7.02	135,088.0
2017, August					
18-44 years	620	620	9,399,555	0.66	785,055.2
45-64 years	4,948	4,948	8,228,369	6.01	683,721.6
65-74 years	5,569	5,569	6,738,146	8.26	555,144.4
75-84 years	3,490	3,490	3,640,885	9.59	297,460.1
≥ 85 years	1,282	1,282	1,645,959	7.79	135,098.6
2017, September					
18-44 years	550	550	9,421,945	0.58	761,989.4
45-64 years	4,186	4,186	8,220,393	5.09	661,559.6
65-74 years	5,086	5,086	6,745,048	7.54	538,528.5
75-84 years	3,345	3,345	3,647,418	9.17	288,766.8
≥ 85 years	1,204	1,204	1,644,162	7.32	130,811.6
2017, October					
18-44 years	532	532	9,454,118	0.56	790,593.0
45-64 years	3,763	3,763	8,236,320	4.57	684,557.1
65-74 years	4,922	4,922	6,763,065	7.28	557,097.3
75-84 years	3,323	3,323	3,666,424	9.06	299,459.9
≥ 85 years	1,231	1,231	1,646,493	7.48	135,210.8
2017, November					
18-44 years	501	501	9,457,099	0.53	765,967.4

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	3,311	3,311	8,226,510	4.02	662,163.3
65-74 years	4,490	4,490	6,748,161	6.65	538,762.6
75-84 years	3,087	3,087	3,669,059	8.41	290,676.9
≥ 85 years	1,210	1,210	1,641,248	7.37	130,722.6
2017, December					
18-44 years	435	435	9,512,862	0.46	795,812.9
45-64 years	2,836	2,836	8,262,799	3.43	686,174.5
65-74 years	4,146	4,146	6,750,567	6.14	556,154.5
75-84 years	2,806	2,806	3,685,019	7.61	301,394.2
≥ 85 years	1,088	1,088	1,640,972	6.63	134,987.8
2018, January					
18-44 years	453	453	9,411,393	0.48	786,490.6
45-64 years	3,043	3,043	8,122,894	3.75	674,527.7
65-74 years	4,781	4,781	6,851,321	6.98	564,139.1
75-84 years	2,995	2,995	3,707,032	8.08	302,899.5
≥ 85 years	1,090	1,090	1,641,321	6.64	134,841.7
2018, February					
18-44 years	433	433	9,382,753	0.46	709,452.0
45-64 years	2,527	2,527	8,090,351	3.12	608,094.1
65-74 years	3,796	3,796	6,835,848	5.55	510,078.0
75-84 years	2,341	2,341	3,701,578	6.32	274,336.5
≥ 85 years	821	821	1,626,820	5.05	121,124.8
2018, March					
18-44 years	492	492	9,392,826	0.52	785,448.5
45-64 years	2,858	2,858	8,099,891	3.53	672,713.9
65-74 years	4,162	4,162	6,869,445	6.06	565,619.0
75-84 years	2,720	2,720	3,730,810	7.29	304,739.6
≥ 85 years	1,040	1,040	1,631,627	6.37	133,909.9
2018, April					
18-44 years	526	526	9,363,972	0.56	758,295.2
45-64 years	2,780	2,780	8,068,016	3.45	649,082.6
65-74 years	4,429	4,429	6,863,140	6.45	547,460.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	2,921	2,921	3,735,222	7.82	295,581.3
≥ 85 years	1,049	1,049	1,627,275	6.45	129,359.4
2018, May					
18-44 years	452	452	9,359,197	0.48	782,603.3
45-64 years	2,626	2,626	8,046,118	3.26	668,567.6
65-74 years	4,724	4,724	6,858,911	6.89	564,915.3
75-84 years	2,985	2,985	3,741,973	7.98	305,708.9
≥ 85 years	1,038	1,038	1,625,170	6.39	133,396.3
2018, June					
18-44 years	407	407	9,355,214	0.44	757,239.2
45-64 years	2,351	2,351	8,031,646	2.93	646,118.4
65-74 years	3,869	3,869	6,859,400	5.64	547,288.6
75-84 years	2,560	2,560	3,745,198	6.84	296,434.7
≥ 85 years	919	919	1,622,051	5.67	128,992.3
2018, July					
18-44 years	502	502	9,325,025	0.54	779,896.4
45-64 years	3,898	3,898	7,996,496	4.87	665,165.5
65-74 years	6,789	6,789	6,884,005	9.86	568,456.6
75-84 years	4,577	4,577	3,753,036	12.20	307,496.8
≥ 85 years	1,838	1,838	1,621,477	11.34	133,402.9
2018, August					
18-44 years	488	488	9,342,250	0.52	780,743.0
45-64 years	3,248	3,248	7,997,529	4.06	664,422.4
65-74 years	4,947	4,947	6,912,169	7.16	569,472.3
75-84 years	3,468	3,468	3,773,483	9.19	308,334.2
≥ 85 years	1,537	1,537	1,624,520	9.46	133,380.5
2018, September					
18-44 years	458	458	9,336,289	0.49	755,687.7
45-64 years	3,003	3,003	7,983,674	3.76	642,447.1
65-74 years	4,542	4,542	6,917,718	6.57	552,396.8
75-84 years	3,257	3,257	3,776,505	8.62	299,243.0
≥ 85 years	1,383	1,383	1,621,269	8.53	129,045.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2018, October					
18-44 years	452	452	9,330,009	0.48	779,822.9
45-64 years	3,356	3,356	7,981,185	4.20	662,722.0
65-74 years	5,573	5,573	6,944,645	8.02	571,742.6
75-84 years	3,759	3,759	3,797,734	9.90	310,157.6
≥ 85 years	1,465	1,465	1,624,514	9.02	133,281.3
2018, November					
18-44 years	414	414	9,333,468	0.44	755,821.1
45-64 years	2,657	2,657	7,969,645	3.33	641,301.6
65-74 years	3,886	3,886	6,936,315	5.60	553,920.0
75-84 years	2,540	2,540	3,793,271	6.70	300,748.1
≥ 85 years	925	925	1,617,808	5.72	128,820.7
2018, December					
18-44 years	462	462	9,347,510	0.49	781,951.5
45-64 years	3,013	3,013	7,979,185	3.78	662,733.2
65-74 years	4,583	4,583	6,948,928	6.60	573,096.1
75-84 years	3,054	3,054	3,802,423	8.03	311,486.1
≥ 85 years	1,178	1,178	1,616,217	7.29	132,992.1
2019, January					
18-44 years	2,370	2,370	9,184,029	2.58	767,483.9
45-64 years	16,201	16,201	7,841,450	20.66	651,034.9
65-74 years	21,784	21,784	6,965,817	31.27	573,552.6
75-84 years	14,649	14,649	3,783,078	38.72	309,174.1
≥ 85 years	6,807	6,807	1,602,222	42.48	131,530.7
2019, February					
18-44 years	1,327	1,327	9,149,627	1.45	692,192.3
45-64 years	8,863	8,863	7,801,140	11.36	586,528.1
65-74 years	14,661	14,661	6,949,214	21.10	518,842.9
75-84 years	9,560	9,560	3,770,143	25.36	279,501.2
≥ 85 years	3,646	3,646	1,591,499	22.91	118,495.3
2019, March					
18-44 years	1,373	1,373	9,156,656	1.50	765,646.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	9,731	9,731	7,802,332	12.47	647,985.4
65-74 years	16,912	16,912	6,976,383	24.24	574,768.3
75-84 years	11,287	11,287	3,788,593	29.79	309,807.6
≥ 85 years	3,910	3,910	1,594,767	24.52	130,934.9
2019, April					
18-44 years	1,069	1,069	9,136,170	1.17	739,464.3
45-64 years	6,488	6,488	7,766,447	8.35	624,357.9
65-74 years	9,979	9,979	6,962,884	14.33	555,156.1
75-84 years	6,756	6,756	3,782,855	17.86	299,286.2
≥ 85 years	2,586	2,586	1,587,028	16.29	126,105.7
2019, May					
18-44 years	980	980	9,128,266	1.07	763,291.8
45-64 years	5,360	5,360	7,736,780	6.93	642,728.3
65-74 years	8,394	8,394	6,955,427	12.07	572,891.6
75-84 years	5,372	5,372	3,779,431	14.21	308,808.9
≥ 85 years	1,834	1,834	1,583,532	11.58	129,924.4
2019, June					
18-44 years	712	712	9,112,720	0.78	737,720.0
45-64 years	3,734	3,734	7,708,750	4.84	620,098.4
65-74 years	5,661	5,661	6,950,564	8.14	554,620.6
75-84 years	3,682	3,682	3,774,062	9.76	298,746.4
≥ 85 years	1,300	1,300	1,578,446	8.24	125,459.7
2019, July					
18-44 years	701	701	9,113,385	0.77	762,082.7
45-64 years	3,842	3,842	7,690,937	5.00	639,454.9
65-74 years	5,417	5,417	6,973,807	7.77	575,412.2
75-84 years	3,606	3,606	3,777,919	9.54	309,141.0
≥ 85 years	1,306	1,306	1,577,077	8.28	129,575.5
2019, August					
18-44 years	797	797	9,121,342	0.87	762,180.0
45-64 years	3,996	3,996	7,677,929	5.20	637,781.4
65-74 years	5,701	5,701	6,994,980	8.15	576,341.6

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	3,648	3,648	3,787,381	9.63	309,444.0
≥ 85 years	1,301	1,301	1,579,248	8.24	129,539.6
2019, September					
18-44 years	838	838	9,120,128	0.92	737,804.7
45-64 years	4,449	4,449	7,665,835	5.80	616,426.0
65-74 years	6,446	6,446	7,001,801	9.21	559,027.6
75-84 years	4,064	4,064	3,783,064	10.74	299,711.7
≥ 85 years	1,443	1,443	1,576,974	9.15	125,378.1
2019, October					
18-44 years	1,200	1,200	9,118,721	1.32	762,354.7
45-64 years	6,345	6,345	7,654,719	8.29	635,537.8
65-74 years	9,768	9,768	7,023,286	13.91	578,181.3
75-84 years	6,119	6,119	3,793,403	16.13	309,705.0
≥ 85 years	2,098	2,098	1,580,557	13.27	129,543.0
2019, November					
18-44 years	874	874	9,114,258	0.96	738,130.2
45-64 years	4,509	4,509	7,640,376	5.90	614,640.2
65-74 years	6,779	6,779	7,017,732	9.66	560,236.7
75-84 years	4,169	4,169	3,785,047	11.01	299,886.6
≥ 85 years	1,518	1,518	1,573,787	9.65	125,234.1
2019, December					
18-44 years	927	927	9,132,910	1.02	764,313.3
45-64 years	4,724	4,724	7,649,969	6.18	635,552.4
65-74 years	7,267	7,267	7,028,317	10.34	579,849.7
75-84 years	4,415	4,415	3,791,023	11.65	310,631.0
≥ 85 years	1,597	1,597	1,571,719	10.16	129,332.1
2020, January					
18-44 years	1,102	1,102	9,002,386	1.22	751,526.1
45-64 years	5,719	5,719	7,526,263	7.60	624,232.5
65-74 years	8,538	8,538	7,126,350	11.98	587,012.0
75-84 years	5,265	5,265	3,818,975	13.79	312,191.6
≥ 85 years	1,885	1,885	1,578,016	11.95	129,534.9

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2020, February					
18-44 years	945	945	9,087,615	1.04	701,995.6
45-64 years	4,696	4,696	7,553,927	6.22	582,148.3
65-74 years	6,855	6,855	7,201,247	9.52	549,796.8
75-84 years	4,185	4,185	3,816,966	10.96	292,007.9
≥ 85 years	1,491	1,491	1,573,517	9.48	120,837.3
2020, March					
18-44 years	909	909	9,107,758	1.00	750,642.1
45-64 years	4,441	4,441	7,551,528	5.88	621,434.4
65-74 years	6,328	6,328	7,224,111	8.76	589,273.9
75-84 years	3,779	3,779	3,829,785	9.87	312,932.6
≥ 85 years	1,301	1,301	1,575,170	8.26	129,240.4
2020, April					
18-44 years	547	547	9,092,548	0.60	727,622.6
45-64 years	2,766	2,766	7,557,750	3.66	604,936.0
65-74 years	3,893	3,893	7,306,753	5.33	581,002.3
75-84 years	2,269	2,269	3,880,306	5.85	309,336.5
≥ 85 years	815	815	1,590,630	5.12	127,144.6
2020, May					
18-44 years	497	497	9,170,191	0.54	756,234.5
45-64 years	2,348	2,348	7,646,251	3.07	630,155.7
65-74 years	3,472	3,472	7,474,756	4.64	611,553.7
75-84 years	2,059	2,059	3,977,793	5.18	326,104.4
≥ 85 years	725	725	1,615,643	4.49	132,897.6
2020, June					
18-44 years	586	586	9,272,406	0.63	735,789.3
45-64 years	2,976	2,976	7,716,117	3.86	612,640.1
65-74 years	4,419	4,419	7,597,110	5.82	598,066.6
75-84 years	2,712	2,712	4,037,109	6.72	319,044.9
≥ 85 years	912	912	1,632,270	5.59	129,541.5
2020, July					
18-44 years	614	614	9,313,626	0.66	760,948.6

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	2,945	2,945	7,682,855	3.83	632,594.1
65-74 years	4,304	4,304	7,643,009	5.63	622,497.8
75-84 years	2,641	2,641	4,062,264	6.50	331,573.7
≥ 85 years	966	966	1,642,479	5.88	134,509.5
2020, August					
18-44 years	557	557	9,291,974	0.60	761,399.5
45-64 years	2,589	2,589	7,698,572	3.36	632,887.8
65-74 years	3,922	3,922	7,688,982	5.10	626,303.2
75-84 years	2,309	2,309	4,086,608	5.65	333,539.0
≥ 85 years	847	847	1,650,675	5.13	135,208.7
2020, September					
18-44 years	633	633	9,234,357	0.69	732,524.0
45-64 years	2,869	2,869	7,694,124	3.73	610,545.8
65-74 years	4,264	4,264	7,737,220	5.51	609,932.9
75-84 years	2,597	2,597	4,112,143	6.32	324,581.7
≥ 85 years	908	908	1,659,319	5.47	131,394.3
2020, October					
18-44 years	778	778	9,210,754	0.84	759,781.9
45-64 years	3,719	3,719	7,675,219	4.85	631,582.7
65-74 years	5,307	5,307	7,785,320	6.82	634,008.8
75-84 years	3,125	3,125	4,144,057	7.54	337,406.9
≥ 85 years	1,032	1,032	1,671,028	6.18	136,502.7
2020, November					
18-44 years	679	679	9,239,028	0.73	737,558.0
45-64 years	3,291	3,291	7,691,115	4.28	612,670.5
65-74 years	5,182	5,182	7,798,194	6.65	617,411.0
75-84 years	3,036	3,036	4,150,813	7.31	328,622.0
≥ 85 years	1,108	1,108	1,669,534	6.64	132,607.4
2020, December					
18-44 years	707	707	10,286,028	0.69	768,033.9
45-64 years	3,434	3,434	8,435,101	4.07	637,131.0
65-74 years	5,572	5,572	8,488,213	6.56	643,730.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	3,393	3,393	4,414,229	7.69	342,667.5
≥ 85 years	1,075	1,075	1,742,858	6.17	137,627.7
2021, January					
18-44 years	759	759	9,399,543	0.81	775,873.9
45-64 years	3,605	3,605	7,796,964	4.62	641,375.7
65-74 years	5,466	5,466	8,025,906	6.81	654,183.2
75-84 years	3,196	3,196	4,226,374	7.56	344,541.6
≥ 85 years	1,062	1,062	1,681,467	6.32	137,421.5
2021, February					
18-44 years	743	743	9,284,118	0.80	702,446.6
45-64 years	3,356	3,356	7,733,331	4.34	580,858.6
65-74 years	5,089	5,089	7,979,319	6.38	595,068.8
75-84 years	3,086	3,086	4,235,795	7.29	313,571.3
≥ 85 years	1,002	1,002	1,676,783	5.98	124,354.9
2021, March					
18-44 years	894	894	9,302,962	0.96	777,407.5
45-64 years	4,209	4,209	7,730,644	5.44	643,101.3
65-74 years	6,531	6,531	8,000,632	8.16	662,143.3
75-84 years	3,900	3,900	4,245,677	9.19	348,748.5
≥ 85 years	1,324	1,324	1,676,364	7.90	138,139.3
2021, April					
18-44 years	753	753	9,216,725	0.82	748,619.4
45-64 years	3,654	3,654	7,618,087	4.80	615,970.0
65-74 years	6,098	6,098	7,862,635	7.76	632,338.6
75-84 years	3,756	3,756	4,156,753	9.04	332,067.3
≥ 85 years	1,391	1,391	1,639,381	8.48	131,341.5
2021, May					
18-44 years	729	729	9,132,775	0.80	765,664.6
45-64 years	3,307	3,307	7,538,270	4.39	628,352.8
65-74 years	5,534	5,534	7,780,334	7.11	643,848.2
75-84 years	3,387	3,387	4,108,069	8.24	337,470.0
≥ 85 years	1,193	1,193	1,615,841	7.38	133,221.2

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2021, June					
18-44 years	705	705	9,059,461	0.78	734,183.9
45-64 years	3,470	3,470	7,488,460	4.63	602,907.1
65-74 years	5,638	5,638	7,755,411	7.27	619,393.8
75-84 years	3,530	3,530	4,097,573	8.61	324,544.3
≥ 85 years	1,243	1,243	1,606,467	7.74	127,740.5
2021, July					
18-44 years	769	769	8,984,678	0.86	752,150.2
45-64 years	3,909	3,909	7,439,191	5.25	618,861.2
65-74 years	6,661	6,661	7,749,701	8.60	639,666.5
75-84 years	4,115	4,115	4,095,516	10.05	335,064.3
≥ 85 years	1,462	1,462	1,600,296	9.14	131,486.4
2021, August					
18-44 years	847	847	8,926,567	0.95	746,812.6
45-64 years	4,337	4,337	7,396,191	5.86	615,215.4
65-74 years	7,607	7,607	7,731,853	9.84	637,981.3
75-84 years	4,587	4,587	4,097,051	11.20	335,093.5
≥ 85 years	1,635	1,635	1,593,691	10.26	131,022.9
2021, September					
18-44 years	916	916	8,865,015	1.03	718,465.9
45-64 years	4,622	4,622	7,348,858	6.29	591,866.3
65-74 years	8,520	8,520	7,707,924	11.05	615,827.3
75-84 years	5,159	5,159	4,102,176	12.58	324,833.5
≥ 85 years	1,871	1,871	1,587,775	11.78	126,393.9
2021, October					
18-44 years	906	906	8,812,573	1.03	737,751.1
45-64 years	4,438	4,438	7,314,481	6.07	608,071.7
65-74 years	7,917	7,917	7,701,787	10.28	634,545.4
75-84 years	4,990	4,990	4,123,318	12.10	336,635.3
≥ 85 years	1,777	1,777	1,586,283	11.20	130,259.8
2021, November					
18-44 years	885	885	8,767,500	1.01	711,033.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	4,004	4,004	7,278,571	5.50	586,425.8
65-74 years	7,316	7,316	7,658,452	9.55	611,885.9
75-84 years	4,539	4,539	4,122,121	11.01	326,684.9
≥ 85 years	1,586	1,586	1,575,548	10.07	125,596.9
2021, December					
18-44 years	863	863	8,744,448	0.99	732,997.0
45-64 years	4,145	4,145	7,261,305	5.71	604,165.6
65-74 years	7,144	7,144	7,619,677	9.38	628,897.4
75-84 years	4,401	4,401	4,129,821	10.66	338,295.6
≥ 85 years	1,595	1,595	1,566,846	10.18	129,062.3
2022, January					
18-44 years	1,059	1,059	8,423,050	1.26	705,713.4
45-64 years	5,007	5,007	7,012,614	7.14	584,164.5
65-74 years	8,484	8,484	7,597,533	11.17	627,811.6
75-84 years	5,302	5,302	4,117,612	12.88	337,571.9
≥ 85 years	1,803	1,803	1,556,500	11.58	128,249.7
2022, February					
18-44 years	1,032	1,032	8,372,496	1.23	634,530.3
45-64 years	4,728	4,728	6,968,915	6.78	524,973.7
65-74 years	7,501	7,501	7,552,260	9.93	564,747.3
75-84 years	4,791	4,791	4,110,983	11.65	305,241.6
≥ 85 years	1,571	1,571	1,538,838	10.21	114,755.0
2022, March					
18-44 years	1,126	1,126	8,366,128	1.35	700,322.2
45-64 years	4,973	4,973	6,967,214	7.14	579,235.7
65-74 years	7,484	7,484	7,559,461	9.90	623,092.1
75-84 years	4,808	4,808	4,145,217	11.60	338,692.3
≥ 85 years	1,579	1,579	1,542,260	10.24	126,606.1
2022, April					
18-44 years	789	789	8,337,695	0.95	675,512.0
45-64 years	3,472	3,472	6,936,428	5.01	558,303.6
65-74 years	5,492	5,492	7,531,215	7.29	601,034.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	3,488	3,488	4,151,163	8.40	328,601.9
≥ 85 years	1,266	1,266	1,539,861	8.22	122,376.8
2022, May					
18-44 years	694	694	8,316,499	0.83	695,918.5
45-64 years	3,250	3,250	6,915,670	4.70	574,889.5
65-74 years	5,117	5,117	7,527,345	6.80	620,217.8
75-84 years	3,274	3,274	4,171,167	7.85	340,789.5
≥ 85 years	1,112	1,112	1,542,400	7.21	126,546.1
2022, June					
18-44 years	708	708	8,319,741	0.85	673,612.7
45-64 years	3,135	3,135	6,906,949	4.54	555,700.3
65-74 years	4,977	4,977	7,520,572	6.62	599,895.7
75-84 years	3,254	3,254	4,189,099	7.77	331,327.7
≥ 85 years	1,118	1,118	1,542,944	7.25	122,551.7
2022, July					
18-44 years	644	644	8,275,977	0.78	692,162.0
45-64 years	2,900	2,900	6,867,325	4.22	570,847.9
65-74 years	4,264	4,264	7,531,837	5.66	621,198.9
75-84 years	2,812	2,812	4,208,469	6.68	344,073.0
≥ 85 years	1,030	1,030	1,547,024	6.66	126,923.9
2022, August					
18-44 years	714	714	8,312,068	0.86	691,956.6
45-64 years	3,086	3,086	6,865,498	4.49	569,648.5
65-74 years	4,814	4,814	7,547,902	6.38	621,835.5
75-84 years	3,004	3,004	4,231,109	7.10	345,580.6
≥ 85 years	1,069	1,069	1,550,080	6.90	127,096.0
2022, September					
18-44 years	493	493	5,804,982	0.85	470,027.4
45-64 years	2,421	2,421	5,109,876	4.74	410,908.6
65-74 years	4,508	4,508	7,413,293	6.08	592,049.4
75-84 years	2,941	2,941	4,220,648	6.97	334,261.5
≥ 85 years	992	992	1,542,160	6.43	122,589.2

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2022, October					
18-44 years	407	407	5,134,203	0.79	429,654.8
45-64 years	1,529	1,529	3,762,103	4.06	312,905.4
65-74 years	591	591	1,183,649	4.99	97,591.1
75-84 years	331	331	552,453	5.99	45,279.3
≥ 85 years	101	101	187,020	5.40	15,351.9
2022, November					
18-44 years	92	92	1,548,848	0.59	125,997.8
45-64 years	434	434	1,031,759	4.21	83,221.7
65-74 years	264	264	659,484	4.00	52,781.0
75-84 years	156	156	318,059	4.90	25,260.5
≥ 85 years	41	41	97,766	4.19	7,771.9
2022, December					
18-44 years	83	83	1,559,288	0.53	131,024.9
45-64 years	415	415	1,036,512	4.00	86,341.2
65-74 years	260	260	661,461	3.93	54,696.3
75-84 years	126	126	319,763	3.94	26,251.4
≥ 85 years	42	42	97,917	4.29	8,057.2
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan					
Non-contaminated valsartan					
2012, May					
18-44 years	582	582	8,329,327	0.70	682,864.3
45-64 years	2,255	2,255	7,305,629	3.09	599,815.7
65-74 years	2,231	2,231	4,505,222	4.95	367,569.0
75-84 years	1,628	1,628	2,750,256	5.92	224,760.7
≥ 85 years	725	725	1,364,911	5.31	111,962.3
2012, June					
18-44 years	549	549	8,404,778	0.65	662,181.5
45-64 years	2,025	2,025	7,353,202	2.75	581,548.1
65-74 years	2,009	2,009	4,532,877	4.43	356,570.9
75-84 years	1,510	1,510	2,752,791	5.49	217,613.1
≥ 85 years	607	607	1,366,577	4.44	108,428.4

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2012, July					
18-44 years	505	505	8,399,342	0.60	684,215.9
45-64 years	2,004	2,004	7,297,781	2.75	600,528.4
65-74 years	2,069	2,069	4,538,048	4.56	370,644.1
75-84 years	1,422	1,422	2,750,954	5.17	225,352.6
≥ 85 years	624	624	1,367,363	4.56	112,369.0
2012, August					
18-44 years	553	553	8,424,636	0.66	685,979.8
45-64 years	2,044	2,044	7,321,558	2.79	601,295.9
65-74 years	2,078	2,078	4,567,013	4.55	371,801.6
75-84 years	1,424	1,424	2,760,687	5.16	225,626.6
≥ 85 years	595	595	1,373,224	4.33	112,602.9
2012, September					
18-44 years	470	470	8,428,571	0.56	664,792.9
45-64 years	1,766	1,766	7,335,138	2.41	582,794.4
65-74 years	1,833	1,833	4,578,884	4.00	361,244.4
75-84 years	1,291	1,291	2,760,164	4.68	218,568.0
≥ 85 years	541	541	1,374,268	3.94	109,202.4
2012, October					
18-44 years	526	526	8,378,083	0.63	689,632.5
45-64 years	2,058	2,058	7,326,786	2.81	603,154.7
65-74 years	2,290	2,290	4,600,671	4.98	374,916.0
75-84 years	1,486	1,486	2,768,302	5.37	226,170.3
≥ 85 years	650	650	1,379,022	4.71	113,098.9
2012, November					
18-44 years	511	511	8,351,641	0.61	667,913.3
45-64 years	2,088	2,088	7,315,318	2.85	584,519.1
65-74 years	2,046	2,046	4,607,793	4.44	364,211.2
75-84 years	1,505	1,505	2,761,508	5.45	219,089.6
≥ 85 years	563	563	1,375,463	4.09	109,529.3
2012, December					
18-44 years	441	441	8,920,839	0.49	691,665.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	1,836	1,836	7,742,079	2.37	605,753.5
65-74 years	1,961	1,961	5,047,452	3.89	378,802.5
75-84 years	1,280	1,280	2,957,179	4.33	226,938.8
≥ 85 years	580	580	1,452,652	3.99	113,275.3
2013, January					
18-44 years	530	530	8,322,726	0.64	685,061.0
45-64 years	2,072	2,072	7,345,235	2.82	604,995.7
65-74 years	2,342	2,342	4,822,366	4.86	392,524.1
75-84 years	1,594	1,594	2,858,633	5.58	233,474.1
≥ 85 years	705	705	1,418,911	4.97	116,328.4
2013, February					
18-44 years	446	446	8,145,675	0.55	616,774.1
45-64 years	1,949	1,949	7,238,454	2.69	545,378.5
65-74 years	2,072	2,072	4,756,867	4.36	355,483.0
75-84 years	1,423	1,423	2,838,125	5.01	210,827.8
≥ 85 years	588	588	1,403,197	4.19	104,567.3
2013, March					
18-44 years	464	464	8,164,170	0.57	683,020.1
45-64 years	1,939	1,939	7,261,602	2.67	604,477.0
65-74 years	1,934	1,934	4,792,235	4.04	395,218.6
75-84 years	1,329	1,329	2,853,380	4.66	233,679.5
≥ 85 years	581	581	1,408,731	4.12	115,758.9
2013, April					
18-44 years	425	425	8,134,035	0.52	659,172.4
45-64 years	1,912	1,912	7,253,578	2.64	584,725.7
65-74 years	1,954	1,954	4,799,751	4.07	383,258.9
75-84 years	1,320	1,320	2,851,892	4.63	226,106.4
≥ 85 years	546	546	1,405,028	3.89	111,822.0
2013, May					
18-44 years	375	375	8,139,231	0.46	681,322.6
45-64 years	1,692	1,692	7,255,694	2.33	604,304.7
65-74 years	1,715	1,715	4,808,827	3.57	396,660.6

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	1,199	1,199	2,851,931	4.20	233,530.2
≥ 85 years	463	463	1,405,829	3.29	115,530.8
2013, June					
18-44 years	366	366	8,143,809	0.45	659,788.5
45-64 years	1,467	1,467	7,259,898	2.02	585,389.7
65-74 years	1,454	1,454	4,815,745	3.02	384,784.1
75-84 years	1,082	1,082	2,851,729	3.79	226,138.3
≥ 85 years	420	420	1,408,140	2.98	112,031.4
2013, July					
18-44 years	384	384	8,158,469	0.47	683,101.4
45-64 years	1,668	1,668	7,288,086	2.29	607,359.2
65-74 years	1,556	1,556	4,845,395	3.21	400,148.6
75-84 years	1,125	1,125	2,859,802	3.93	234,393.2
≥ 85 years	484	484	1,412,502	3.43	116,206.4
2013, August					
18-44 years	357	357	8,195,465	0.44	684,678.8
45-64 years	1,467	1,467	7,297,485	2.01	607,602.1
65-74 years	1,529	1,529	4,863,486	3.14	401,125.0
75-84 years	1,012	1,012	2,864,580	3.53	234,483.7
≥ 85 years	457	457	1,416,206	3.23	116,345.6
2013, September					
18-44 years	356	356	8,179,124	0.44	660,990.4
45-64 years	1,302	1,302	7,294,592	1.78	588,146.7
65-74 years	1,400	1,400	4,872,080	2.87	389,328.5
75-84 years	1,011	1,011	2,862,456	3.53	227,030.1
≥ 85 years	445	445	1,416,322	3.14	112,762.2
2013, October					
18-44 years	373	373	8,124,695	0.46	680,234.9
45-64 years	1,408	1,408	7,301,556	1.93	607,936.3
65-74 years	1,565	1,565	4,887,922	3.20	402,981.9
75-84 years	1,059	1,059	2,867,862	3.69	234,664.7
≥ 85 years	428	428	1,419,580	3.01	116,630.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2013, November					
18-44 years	330	330	8,114,094	0.41	657,962.2
45-64 years	1,275	1,275	7,289,160	1.75	587,816.8
65-74 years	1,281	1,281	4,879,063	2.63	389,952.6
75-84 years	908	908	2,855,250	3.18	226,688.0
≥ 85 years	401	401	1,413,722	2.84	112,663.3
2013, December					
18-44 years	314	314	8,085,491	0.39	677,240.5
45-64 years	1,212	1,212	7,272,585	1.67	605,751.8
65-74 years	1,280	1,280	4,882,657	2.62	403,393.2
75-84 years	868	868	2,856,311	3.04	234,508.8
≥ 85 years	372	372	1,413,838	2.63	116,519.8
2014, January					
18-44 years	400	400	8,873,043	0.45	741,538.7
45-64 years	1,504	1,504	7,900,203	1.90	656,932.3
65-74 years	1,543	1,543	5,545,516	2.78	457,500.4
75-84 years	1,043	1,043	3,215,569	3.24	263,547.9
≥ 85 years	441	441	1,580,090	2.79	130,013.0
2014, February					
18-44 years	336	336	8,818,855	0.38	667,361.5
45-64 years	1,354	1,354	7,851,780	1.72	591,432.5
65-74 years	1,429	1,429	5,542,399	2.58	414,362.6
75-84 years	887	887	3,207,332	2.77	238,293.2
≥ 85 years	375	375	1,574,872	2.38	117,384.6
2014, March					
18-44 years	351	351	8,802,363	0.40	736,461.1
45-64 years	1,322	1,322	7,831,616	1.69	651,818.1
65-74 years	1,325	1,325	5,571,276	2.38	459,863.6
75-84 years	929	929	3,222,359	2.88	264,103.8
≥ 85 years	387	387	1,582,192	2.45	130,119.2
2014, April					
18-44 years	281	281	8,765,869	0.32	709,814.9

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	1,101	1,101	7,795,435	1.41	627,853.6
65-74 years	1,214	1,214	5,589,363	2.17	446,165.2
75-84 years	888	888	3,231,998	2.75	256,089.1
≥ 85 years	351	351	1,585,249	2.21	126,072.7
2014, May					
18-44 years	251	251	8,749,273	0.29	731,766.3
45-64 years	993	993	7,764,368	1.28	646,073.5
65-74 years	1,002	1,002	5,587,162	1.79	460,651.8
75-84 years	696	696	3,229,002	2.16	264,242.1
≥ 85 years	338	338	1,583,612	2.13	130,070.1
2014, June					
18-44 years	221	221	8,730,043	0.25	706,897.1
45-64 years	872	872	7,741,531	1.13	623,713.6
65-74 years	988	988	5,586,898	1.77	446,226.9
75-84 years	673	673	3,222,856	2.09	255,453.3
≥ 85 years	298	298	1,580,445	1.89	125,715.9
2014, July					
18-44 years	247	247	8,808,988	0.28	736,882.4
45-64 years	1,012	1,012	7,801,603	1.30	649,435.5
65-74 years	985	985	5,608,211	1.76	462,840.2
75-84 years	702	702	3,220,677	2.18	263,713.7
≥ 85 years	347	347	1,579,358	2.20	129,769.4
2014, August					
18-44 years	252	252	8,772,603	0.29	733,168.1
45-64 years	1,028	1,028	7,757,144	1.33	645,470.1
65-74 years	1,119	1,119	5,625,046	1.99	464,013.1
75-84 years	712	712	3,224,105	2.21	263,841.1
≥ 85 years	372	372	1,580,713	2.35	129,850.4
2014, September					
18-44 years	257	257	8,745,204	0.29	708,083.1
45-64 years	1,039	1,039	7,736,029	1.34	623,272.4
65-74 years	1,166	1,166	5,633,159	2.07	449,972.3

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	756	756	3,223,453	2.35	255,525.9
≥ 85 years	344	344	1,579,481	2.18	125,719.2
2014, October					
18-44 years	317	317	8,761,627	0.36	732,939.9
45-64 years	1,174	1,174	7,735,896	1.52	643,421.6
65-74 years	1,218	1,218	5,654,698	2.15	465,850.6
75-84 years	797	797	3,233,821	2.46	264,371.8
≥ 85 years	366	366	1,583,791	2.31	129,971.7
2014, November					
18-44 years	245	245	8,731,463	0.28	707,933.4
45-64 years	1,040	1,040	7,711,217	1.35	621,733.1
65-74 years	1,036	1,036	5,644,276	1.84	451,285.4
75-84 years	706	706	3,223,374	2.19	255,976.1
≥ 85 years	327	327	1,577,735	2.07	125,727.4
2014, December					
18-44 years	242	242	8,734,837	0.28	730,143.2
45-64 years	1,102	1,102	7,710,752	1.43	640,567.1
65-74 years	1,149	1,149	5,651,163	2.03	466,025.3
75-84 years	830	830	3,224,160	2.57	264,089.6
≥ 85 years	333	333	1,575,314	2.11	129,615.4
2015, January					
18-44 years	277	277	9,100,485	0.30	760,792.1
45-64 years	1,149	1,149	8,007,202	1.43	665,831.6
65-74 years	1,215	1,215	5,868,721	2.07	483,963.7
75-84 years	842	842	3,292,199	2.56	269,596.7
≥ 85 years	332	332	1,594,791	2.08	131,082.6
2015, February					
18-44 years	239	239	9,063,819	0.26	685,659.9
45-64 years	988	988	7,989,169	1.24	601,197.9
65-74 years	1,058	1,058	5,866,920	1.80	437,898.9
75-84 years	690	690	3,281,608	2.10	243,274.0
≥ 85 years	310	310	1,581,755	1.96	117,699.3

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2015, March					
18-44 years	279	279	9,077,269	0.31	759,212.7
45-64 years	1,095	1,095	8,010,566	1.37	666,302.7
65-74 years	1,146	1,146	5,892,685	1.94	485,998.5
75-84 years	753	753	3,295,268	2.29	269,743.1
≥ 85 years	320	320	1,585,806	2.02	130,257.5
2015, April					
18-44 years	231	231	9,116,083	0.25	738,134.8
45-64 years	1,023	1,023	8,042,440	1.27	647,554.4
65-74 years	1,119	1,119	5,896,978	1.90	470,567.9
75-84 years	702	702	3,294,757	2.13	260,864.5
≥ 85 years	293	293	1,582,941	1.85	125,779.5
2015, May					
18-44 years	240	240	9,152,851	0.26	765,592.9
45-64 years	1,053	1,053	8,078,376	1.30	672,035.5
65-74 years	1,003	1,003	5,905,892	1.70	486,804.4
75-84 years	643	643	3,293,919	1.95	269,309.6
≥ 85 years	234	234	1,580,037	1.48	129,709.6
2015, June					
18-44 years	252	252	9,161,169	0.28	741,683.5
45-64 years	1,043	1,043	8,082,207	1.29	650,902.1
65-74 years	1,001	1,001	5,911,711	1.69	471,756.4
75-84 years	689	689	3,290,653	2.09	260,580.3
≥ 85 years	265	265	1,578,733	1.68	125,453.2
2015, July					
18-44 years	264	264	9,152,724	0.29	765,582.3
45-64 years	986	986	8,077,598	1.22	672,209.9
65-74 years	990	990	5,939,320	1.67	490,002.6
75-84 years	642	642	3,295,958	1.95	269,681.9
≥ 85 years	251	251	1,581,088	1.59	129,871.9
2015, August					
18-44 years	253	253	9,163,735	0.28	766,075.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	933	933	8,073,804	1.16	671,915.1
65-74 years	1,042	1,042	5,958,804	1.75	491,718.1
75-84 years	567	567	3,303,045	1.72	270,322.9
≥ 85 years	199	199	1,583,743	1.26	130,124.1
2015, September					
18-44 years	248	248	9,174,232	0.27	742,727.8
45-64 years	1,026	1,026	8,082,378	1.27	650,886.0
65-74 years	1,084	1,084	5,977,252	1.81	477,286.2
75-84 years	634	634	3,306,502	1.92	261,888.9
≥ 85 years	251	251	1,584,965	1.58	126,032.3
2015, October					
18-44 years	281	281	9,165,264	0.31	766,244.5
45-64 years	1,046	1,046	8,092,331	1.29	672,270.2
65-74 years	1,280	1,280	6,004,392	2.13	494,397.7
75-84 years	727	727	3,316,179	2.19	270,878.6
≥ 85 years	268	268	1,589,242	1.69	130,309.4
2015, November					
18-44 years	279	279	9,137,229	0.31	740,198.0
45-64 years	1,051	1,051	8,070,264	1.30	649,941.5
65-74 years	1,306	1,306	5,992,141	2.18	478,783.1
75-84 years	736	736	3,303,891	2.23	262,051.3
≥ 85 years	264	264	1,581,676	1.67	125,959.8
2015, December					
18-44 years	315	315	9,140,219	0.34	764,457.6
45-64 years	1,194	1,194	8,076,025	1.48	670,867.3
65-74 years	1,348	1,348	6,006,218	2.24	494,992.0
75-84 years	850	850	3,311,457	2.57	270,924.6
≥ 85 years	297	297	1,583,322	1.88	130,102.7
2016, January					
18-44 years	334	334	9,176,220	0.36	766,940.8
45-64 years	1,300	1,300	8,154,456	1.59	677,817.0
65-74 years	1,722	1,722	6,221,672	2.77	512,641.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	908	908	3,373,232	2.69	275,891.9
≥ 85 years	328	328	1,604,515	2.04	131,756.6
2016, February					
18-44 years	346	346	9,325,950	0.37	716,442.5
45-64 years	1,266	1,266	8,268,075	1.53	633,641.7
65-74 years	1,581	1,581	6,301,064	2.51	480,773.8
75-84 years	951	951	3,379,993	2.81	258,569.1
≥ 85 years	275	275	1,603,408	1.72	123,145.8
2016, March					
18-44 years	329	329	9,344,110	0.35	768,020.0
45-64 years	1,225	1,225	8,274,584	1.48	679,504.0
65-74 years	1,588	1,588	6,327,246	2.51	514,900.1
75-84 years	902	902	3,395,108	2.66	276,652.7
≥ 85 years	337	337	1,607,208	2.10	131,501.3
2016, April					
18-44 years	244	244	9,362,785	0.26	742,641.0
45-64 years	941	941	8,254,230	1.14	656,554.2
65-74 years	1,159	1,159	6,323,795	1.83	498,574.7
75-84 years	662	662	3,394,424	1.95	267,926.7
≥ 85 years	235	235	1,603,015	1.47	127,074.2
2016, May					
18-44 years	187	187	9,372,241	0.20	770,240.4
45-64 years	808	808	8,239,478	0.98	677,617.1
65-74 years	1,009	1,009	6,326,026	1.59	515,252.6
75-84 years	660	660	3,397,631	1.94	276,939.5
≥ 85 years	242	242	1,602,141	1.51	131,096.2
2016, June					
18-44 years	180	180	9,420,958	0.19	744,840.9
45-64 years	794	794	8,267,083	0.96	655,097.1
65-74 years	1,007	1,007	6,364,931	1.58	499,766.6
75-84 years	629	629	3,408,541	1.85	268,679.1
≥ 85 years	211	211	1,603,035	1.32	126,988.7

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2016, July					
18-44 years	153	153	9,439,126	0.16	769,754.8
45-64 years	746	746	8,213,249	0.91	676,374.3
65-74 years	913	913	6,368,804	1.43	518,935.5
75-84 years	574	574	3,414,091	1.68	278,679.6
≥ 85 years	234	234	1,603,410	1.46	131,421.0
2016, August					
18-44 years	205	205	9,416,905	0.22	768,495.9
45-64 years	783	783	8,230,288	0.95	676,076.8
65-74 years	990	990	6,392,801	1.55	520,221.7
75-84 years	586	586	3,428,500	1.71	279,500.5
≥ 85 years	223	223	1,607,526	1.39	131,592.9
2016, September					
18-44 years	183	183	9,434,469	0.19	745,800.8
45-64 years	692	692	8,255,250	0.84	654,223.6
65-74 years	872	872	6,404,820	1.36	504,824.0
75-84 years	597	597	3,431,581	1.74	271,030.1
≥ 85 years	216	216	1,607,962	1.34	127,543.9
2016, October					
18-44 years	196	196	9,379,269	0.21	772,388.8
45-64 years	779	779	8,226,366	0.95	676,925.0
65-74 years	867	867	6,420,451	1.35	523,389.4
75-84 years	572	572	3,440,101	1.66	280,707.2
≥ 85 years	205	205	1,610,263	1.27	131,901.2
2016, November					
18-44 years	154	154	9,441,046	0.16	748,248.7
45-64 years	780	780	8,261,933	0.94	655,041.0
65-74 years	953	953	6,415,440	1.49	507,212.7
75-84 years	646	646	3,436,159	1.88	271,907.7
≥ 85 years	225	225	1,604,218	1.40	127,480.0
2016, December					
18-44 years	182	182	10,696,088	0.17	779,225.6

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	768	768	9,195,836	0.84	680,330.7
65-74 years	982	982	6,843,153	1.44	525,344.6
75-84 years	660	660	3,586,282	1.84	281,504.8
≥ 85 years	241	241	1,654,234	1.46	131,663.4
2017, January					
18-44 years	185	185	9,465,272	0.20	778,709.6
45-64 years	852	852	8,204,900	1.04	674,527.8
65-74 years	1,141	1,141	6,500,557	1.76	529,619.9
75-84 years	697	697	3,438,853	2.03	280,643.2
≥ 85 years	265	265	1,587,598	1.67	130,169.8
2017, February					
18-44 years	205	205	9,297,604	0.22	702,997.8
45-64 years	799	799	8,086,799	0.99	607,838.7
65-74 years	1,075	1,075	6,406,324	1.68	477,952.7
75-84 years	721	721	3,417,742	2.11	253,278.0
≥ 85 years	273	273	1,571,365	1.74	116,884.8
2017, March					
18-44 years	191	191	9,327,787	0.20	779,701.9
45-64 years	947	947	8,104,819	1.17	672,990.1
65-74 years	1,175	1,175	6,434,056	1.83	529,769.8
75-84 years	843	843	3,434,437	2.45	280,607.8
≥ 85 years	283	283	1,573,762	1.80	129,133.4
2017, April					
18-44 years	184	184	9,326,910	0.20	755,106.4
45-64 years	845	845	8,085,974	1.05	650,435.5
65-74 years	1,133	1,133	6,423,129	1.76	512,293.3
75-84 years	695	695	3,430,625	2.03	271,479.6
≥ 85 years	303	303	1,565,479	1.94	124,437.5
2017, May					
18-44 years	190	190	9,336,398	0.20	780,617.5
45-64 years	931	931	8,076,349	1.15	671,067.2
65-74 years	1,268	1,268	6,422,364	1.97	528,959.7

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	833	833	3,432,128	2.43	280,357.2
≥ 85 years	298	298	1,563,077	1.91	128,229.1
2017, June					
18-44 years	192	192	9,345,343	0.21	756,404.8
45-64 years	875	875	8,068,837	1.08	649,248.4
65-74 years	1,126	1,126	6,422,885	1.75	512,443.4
75-84 years	728	728	3,429,840	2.12	271,504.4
≥ 85 years	240	240	1,560,248	1.54	124,008.1
2017, July					
18-44 years	146	146	9,337,822	0.16	781,072.6
45-64 years	702	702	8,044,798	0.87	669,442.6
65-74 years	844	844	6,446,061	1.31	532,384.2
75-84 years	578	578	3,436,709	1.68	281,599.0
≥ 85 years	233	233	1,560,250	1.49	128,333.8
2017, August					
18-44 years	165	165	9,376,293	0.18	783,090.6
45-64 years	748	748	8,060,365	0.93	669,667.2
65-74 years	930	930	6,471,392	1.44	533,061.2
75-84 years	675	675	3,453,887	1.95	282,074.7
≥ 85 years	238	238	1,563,923	1.52	128,326.4
2017, September					
18-44 years	148	148	9,398,518	0.16	760,080.2
45-64 years	676	676	8,051,607	0.84	647,905.5
65-74 years	867	867	6,476,558	1.34	517,010.7
75-84 years	581	581	3,459,174	1.68	273,778.4
≥ 85 years	220	220	1,562,059	1.41	124,242.4
2017, October					
18-44 years	166	166	9,430,536	0.18	788,601.3
45-64 years	771	771	8,066,894	0.96	670,379.2
65-74 years	970	970	6,493,201	1.49	534,771.5
75-84 years	622	622	3,476,501	1.79	283,848.0
≥ 85 years	210	210	1,564,101	1.34	128,407.4

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2017, November					
18-44 years	159	159	9,433,265	0.17	764,020.6
45-64 years	806	806	8,056,501	1.00	648,394.3
65-74 years	956	956	6,477,550	1.48	517,049.0
75-84 years	614	614	3,478,149	1.77	275,452.3
≥ 85 years	235	235	1,558,806	1.51	124,119.9
2017, December					
18-44 years	156	156	9,488,685	0.16	793,772.1
45-64 years	703	703	8,091,437	0.87	671,845.8
65-74 years	872	872	6,478,341	1.35	533,599.4
75-84 years	608	608	3,492,434	1.74	285,540.1
≥ 85 years	233	233	1,558,251	1.50	128,135.1
2018, January					
18-44 years	188	188	9,387,361	0.20	784,459.3
45-64 years	891	891	7,953,725	1.12	660,373.1
65-74 years	1,151	1,151	6,576,139	1.75	541,336.0
75-84 years	750	750	3,513,732	2.13	286,989.0
≥ 85 years	240	240	1,558,715	1.54	128,000.2
2018, February					
18-44 years	168	168	9,358,498	0.18	707,598.9
45-64 years	829	829	7,920,293	1.05	595,218.7
65-74 years	1,107	1,107	6,559,008	1.69	489,306.8
75-84 years	697	697	3,507,213	1.99	259,830.9
≥ 85 years	214	214	1,544,201	1.39	114,931.1
2018, March					
18-44 years	206	206	9,368,243	0.22	783,364.6
45-64 years	893	893	7,928,618	1.13	658,371.8
65-74 years	1,235	1,235	6,589,258	1.87	542,389.4
75-84 years	779	779	3,533,830	2.20	288,513.7
≥ 85 years	253	253	1,548,219	1.63	127,016.3
2018, April					
18-44 years	225	225	9,339,102	0.24	756,258.4

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	909	909	7,895,979	1.15	635,129.2
65-74 years	1,136	1,136	6,580,285	1.73	524,761.3
75-84 years	787	787	3,536,432	2.23	279,729.1
≥ 85 years	256	256	1,543,453	1.66	122,656.0
2018, May					
18-44 years	218	218	9,334,074	0.23	780,477.6
45-64 years	876	876	7,873,220	1.11	654,078.4
65-74 years	1,172	1,172	6,573,697	1.78	541,278.8
75-84 years	812	812	3,541,350	2.29	289,181.6
≥ 85 years	238	238	1,540,857	1.54	126,439.6
2018, June					
18-44 years	166	166	9,329,819	0.18	755,163.3
45-64 years	803	803	7,857,567	1.02	632,018.0
65-74 years	977	977	6,571,993	1.49	524,245.7
75-84 years	702	702	3,543,087	1.98	280,326.5
≥ 85 years	255	255	1,537,477	1.66	122,226.9
2018, July					
18-44 years	115	115	9,299,490	0.12	777,751.2
45-64 years	604	604	7,822,285	0.77	650,604.9
65-74 years	836	836	6,594,504	1.27	544,465.1
75-84 years	596	596	3,549,698	1.68	290,750.7
≥ 85 years	199	199	1,536,578	1.30	126,382.2
2018, August					
18-44 years	90	90	9,316,964	0.10	778,634.6
45-64 years	536	536	7,823,740	0.69	649,989.6
65-74 years	709	709	6,621,705	1.07	545,547.4
75-84 years	513	513	3,569,323	1.44	291,613.1
≥ 85 years	184	184	1,539,475	1.20	126,384.8
2018, September					
18-44 years	100	100	9,311,506	0.11	753,685.1
45-64 years	479	479	7,811,887	0.61	628,619.7
65-74 years	617	617	6,628,459	0.93	529,311.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	525	525	3,573,287	1.47	283,103.7
≥ 85 years	176	176	1,536,737	1.15	122,298.9
2018, October					
18-44 years	125	125	9,305,628	0.13	777,790.0
45-64 years	628	628	7,810,671	0.80	648,558.6
65-74 years	850	850	6,655,857	1.28	547,967.1
75-84 years	633	633	3,594,196	1.76	293,494.1
≥ 85 years	241	241	1,540,093	1.56	126,339.1
2018, November					
18-44 years	146	146	9,309,494	0.16	753,878.4
45-64 years	702	702	7,800,785	0.90	627,690.9
65-74 years	984	984	6,649,127	1.48	530,961.9
75-84 years	645	645	3,590,756	1.80	284,635.0
≥ 85 years	226	226	1,534,095	1.47	122,121.3
2018, December					
18-44 years	144	144	9,323,750	0.15	779,965.7
45-64 years	691	691	7,810,831	0.88	648,735.9
65-74 years	966	966	6,662,134	1.45	549,412.8
75-84 years	652	652	3,599,825	1.81	294,826.3
≥ 85 years	220	220	1,532,691	1.44	126,089.1
2019, January					
18-44 years	329	329	9,161,315	0.36	765,578.7
45-64 years	1,739	1,739	7,679,078	2.26	637,514.8
65-74 years	2,401	2,401	6,682,391	3.59	550,152.1
75-84 years	1,631	1,631	3,583,947	4.55	292,828.0
≥ 85 years	547	547	1,520,016	3.60	124,747.0
2019, February					
18-44 years	407	407	9,127,310	0.45	690,495.3
45-64 years	1,871	1,871	7,640,253	2.45	574,374.2
65-74 years	2,643	2,643	6,666,836	3.96	497,681.8
75-84 years	1,802	1,802	3,571,955	5.04	264,725.7
≥ 85 years	658	658	1,509,718	4.36	112,368.2

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2019, March					
18-44 years	607	607	9,134,562	0.66	763,777.9
45-64 years	3,235	3,235	7,642,005	4.23	634,532.1
65-74 years	5,064	5,064	6,693,440	7.57	551,251.2
75-84 years	3,331	3,331	3,589,367	9.28	293,352.4
≥ 85 years	1,088	1,088	1,512,749	7.19	124,147.8
2019, April					
18-44 years	635	635	9,114,225	0.70	737,660.4
45-64 years	3,146	3,146	7,606,045	4.14	611,331.1
65-74 years	4,628	4,628	6,678,869	6.93	532,307.7
75-84 years	3,115	3,115	3,582,472	8.70	283,268.4
≥ 85 years	1,079	1,079	1,505,107	7.17	119,531.8
2019, May					
18-44 years	668	668	9,106,433	0.73	761,432.7
45-64 years	3,173	3,173	7,577,167	4.19	629,289.8
65-74 years	4,878	4,878	6,671,015	7.31	549,197.8
75-84 years	3,084	3,084	3,578,709	8.62	292,207.2
≥ 85 years	978	978	1,501,690	6.51	123,129.9
2019, June					
18-44 years	483	483	9,091,191	0.53	735,943.4
45-64 years	2,275	2,275	7,550,932	3.01	607,217.9
65-74 years	3,277	3,277	6,667,557	4.91	531,771.2
75-84 years	2,178	2,178	3,574,461	6.09	282,733.5
≥ 85 years	735	735	1,497,410	4.91	118,934.0
2019, July					
18-44 years	525	525	9,093,784	0.58	760,336.3
45-64 years	2,421	2,421	7,545,305	3.21	626,651.7
65-74 years	3,274	3,274	6,708,925	4.88	552,461.0
75-84 years	2,199	2,199	3,590,758	6.12	293,017.9
≥ 85 years	705	705	1,501,937	4.69	123,043.9
2019, August					
18-44 years	584	584	9,104,228	0.64	760,648.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	2,612	2,612	7,550,890	3.46	626,465.0
65-74 years	3,512	3,512	6,764,246	5.19	555,905.7
75-84 years	2,265	2,265	3,624,462	6.25	295,080.9
≥ 85 years	695	695	1,515,520	4.59	123,844.9
2019, September					
18-44 years	619	619	9,104,058	0.68	736,443.3
45-64 years	3,026	3,026	7,549,377	4.01	606,552.3
65-74 years	4,372	4,372	6,797,852	6.43	541,598.8
75-84 years	2,775	2,775	3,640,400	7.62	287,547.1
≥ 85 years	909	909	1,521,526	5.97	120,626.7
2019, October					
18-44 years	936	936	9,103,174	1.03	760,995.9
45-64 years	4,712	4,712	7,544,021	6.25	625,912.1
65-74 years	7,211	7,211	6,835,746	10.55	561,844.5
75-84 years	4,530	4,530	3,663,199	12.37	298,389.2
≥ 85 years	1,393	1,393	1,530,415	9.10	125,173.0
2019, November					
18-44 years	672	672	9,098,398	0.74	736,811.2
45-64 years	3,290	3,290	7,529,419	4.37	605,472.5
65-74 years	4,890	4,890	6,832,195	7.16	544,975.2
75-84 years	3,051	3,051	3,657,228	8.34	289,427.7
≥ 85 years	1,030	1,030	1,524,919	6.75	121,222.2
2019, December					
18-44 years	590	590	9,116,903	0.65	762,942.3
45-64 years	2,778	2,778	7,539,345	3.68	626,143.0
65-74 years	4,114	4,114	6,843,823	6.01	564,266.9
75-84 years	2,585	2,585	3,664,849	7.05	300,005.1
≥ 85 years	788	788	1,523,821	5.17	125,279.4
2020, January					
18-44 years	683	683	8,986,565	0.76	750,177.3
45-64 years	3,116	3,116	7,419,092	4.20	615,155.2
65-74 years	4,447	4,447	6,943,046	6.40	571,609.0

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	2,821	2,821	3,694,576	7.64	301,786.5
≥ 85 years	966	966	1,531,007	6.31	125,584.1
2020, February					
18-44 years	621	621	9,071,381	0.68	700,718.4
45-64 years	2,844	2,844	7,445,927	3.82	573,688.0
65-74 years	3,891	3,891	7,016,205	5.55	535,429.0
75-84 years	2,450	2,450	3,692,891	6.63	282,351.5
≥ 85 years	850	850	1,526,710	5.57	117,184.0
2020, March					
18-44 years	618	618	9,091,245	0.68	749,252.8
45-64 years	2,818	2,818	7,443,084	3.79	612,338.0
65-74 years	3,884	3,884	7,038,015	5.52	573,844.3
75-84 years	2,424	2,424	3,705,390	6.54	302,588.6
≥ 85 years	801	801	1,528,183	5.24	125,321.2
2020, April					
18-44 years	379	379	9,075,730	0.42	726,257.5
45-64 years	1,886	1,886	7,447,973	2.53	596,019.5
65-74 years	2,646	2,646	7,116,965	3.72	565,709.8
75-84 years	1,567	1,567	3,753,814	4.17	299,100.1
≥ 85 years	544	544	1,542,992	3.53	123,278.3
2020, May					
18-44 years	346	346	9,153,112	0.38	754,807.9
45-64 years	1,517	1,517	7,534,461	2.01	620,845.8
65-74 years	2,209	2,209	7,279,402	3.03	595,417.9
75-84 years	1,412	1,412	3,847,805	3.67	315,325.6
≥ 85 years	493	493	1,566,846	3.15	128,841.7
2020, June					
18-44 years	358	358	9,255,133	0.39	734,398.8
45-64 years	1,717	1,717	7,603,031	2.26	603,554.3
65-74 years	2,526	2,526	7,398,245	3.41	582,246.5
75-84 years	1,608	1,608	3,904,985	4.12	308,490.5
≥ 85 years	481	481	1,582,906	3.04	125,584.1

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2020, July					
18-44 years	412	412	9,296,333	0.44	759,505.8
45-64 years	1,756	1,756	7,569,687	2.32	623,177.2
65-74 years	2,431	2,431	7,442,197	3.27	605,983.6
75-84 years	1,617	1,617	3,929,093	4.12	320,597.1
≥ 85 years	538	538	1,592,773	3.38	130,397.3
2020, August					
18-44 years	380	380	9,274,591	0.41	759,954.0
45-64 years	1,598	1,598	7,584,827	2.11	623,450.5
65-74 years	2,326	2,326	7,486,130	3.11	609,643.9
75-84 years	1,492	1,492	3,952,317	3.78	322,487.8
≥ 85 years	513	513	1,600,407	3.21	131,064.2
2020, September					
18-44 years	434	434	9,216,988	0.47	731,132.1
45-64 years	1,752	1,752	7,579,894	2.31	601,394.4
65-74 years	2,435	2,435	7,532,777	3.23	593,688.2
75-84 years	1,584	1,584	3,976,933	3.98	313,814.3
≥ 85 years	532	532	1,608,651	3.31	127,349.6
2020, October					
18-44 years	480	480	9,193,389	0.52	758,328.2
45-64 years	1,961	1,961	7,560,762	2.59	622,065.4
65-74 years	2,764	2,764	7,579,235	3.65	617,078.1
75-84 years	1,767	1,767	4,007,653	4.41	326,201.6
≥ 85 years	524	524	1,619,843	3.23	132,289.5
2020, November					
18-44 years	409	409	9,221,551	0.44	736,146.4
45-64 years	1,780	1,780	7,576,294	2.35	603,408.4
65-74 years	2,630	2,630	7,591,709	3.46	600,886.9
75-84 years	1,595	1,595	4,014,004	3.97	317,684.8
≥ 85 years	594	594	1,618,484	3.67	128,506.9
2020, December					
18-44 years	429	429	10,266,951	0.42	766,557.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	1,837	1,837	8,310,148	2.21	627,494.4
65-74 years	2,839	2,839	8,266,284	3.43	626,506.4
75-84 years	1,841	1,841	4,270,577	4.31	331,256.6
≥ 85 years	566	566	1,690,033	3.35	133,377.8
2021, January					
18-44 years	498	498	9,381,782	0.53	774,388.3
45-64 years	2,049	2,049	7,681,319	2.67	631,759.7
65-74 years	2,975	2,975	7,813,588	3.81	636,682.1
75-84 years	1,899	1,899	4,087,162	4.65	333,054.3
≥ 85 years	553	553	1,630,032	3.39	133,166.2
2021, February					
18-44 years	487	487	9,266,325	0.53	701,085.7
45-64 years	2,072	2,072	7,618,091	2.72	572,102.6
65-74 years	3,092	3,092	7,767,637	3.98	579,119.9
75-84 years	1,937	1,937	4,095,961	4.73	303,099.6
≥ 85 years	607	607	1,625,260	3.73	120,492.0
2021, March					
18-44 years	605	605	9,285,032	0.65	775,880.4
45-64 years	2,697	2,697	7,615,217	3.54	633,341.8
65-74 years	4,067	4,067	7,788,382	5.22	644,333.6
75-84 years	2,548	2,548	4,105,542	6.21	337,071.1
≥ 85 years	826	826	1,624,887	5.08	133,840.6
2021, April					
18-44 years	526	526	9,198,813	0.57	747,142.5
45-64 years	2,414	2,414	7,503,958	3.22	606,601.7
65-74 years	3,812	3,812	7,653,776	4.98	615,297.6
75-84 years	2,532	2,532	4,019,707	6.30	320,934.3
≥ 85 years	876	876	1,589,183	5.51	127,249.5
2021, May					
18-44 years	483	483	9,115,108	0.53	764,156.7
45-64 years	2,138	2,138	7,425,492	2.88	618,811.4
65-74 years	3,513	3,513	7,574,271	4.64	626,529.8

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	2,285	2,285	3,973,145	5.75	326,183.1
≥ 85 years	780	780	1,566,545	4.98	129,086.8
2021, June					
18-44 years	506	506	9,041,948	0.56	732,740.0
45-64 years	2,271	2,271	7,376,671	3.08	593,778.0
65-74 years	3,571	3,571	7,550,472	4.73	602,799.3
75-84 years	2,402	2,402	3,963,138	6.06	313,731.2
≥ 85 years	785	785	1,557,573	5.04	123,794.7
2021, July					
18-44 years	467	467	8,967,153	0.52	750,666.3
45-64 years	2,120	2,120	7,327,814	2.89	609,483.9
65-74 years	3,392	3,392	7,544,687	4.50	622,559.1
75-84 years	2,294	2,294	3,961,147	5.79	323,919.2
≥ 85 years	773	773	1,551,474	4.98	127,422.0
2021, August					
18-44 years	504	504	8,909,004	0.57	745,325.0
45-64 years	2,257	2,257	7,284,973	3.10	605,863.0
65-74 years	3,438	3,438	7,525,967	4.57	620,847.1
75-84 years	2,124	2,124	3,961,798	5.36	323,914.0
≥ 85 years	686	686	1,544,622	4.44	126,949.3
2021, September					
18-44 years	530	530	8,847,418	0.60	717,025.6
45-64 years	2,233	2,233	7,237,552	3.09	582,823.8
65-74 years	3,389	3,389	7,501,646	4.52	599,218.2
75-84 years	2,182	2,182	3,965,841	5.50	313,937.1
≥ 85 years	757	757	1,538,410	4.92	122,428.6
2021, October					
18-44 years	536	536	8,794,893	0.61	736,254.9
45-64 years	2,355	2,355	7,203,055	3.27	598,713.7
65-74 years	3,573	3,573	7,494,173	4.77	617,300.0
75-84 years	2,369	2,369	3,985,400	5.94	325,267.5
≥ 85 years	787	787	1,536,519	5.12	126,135.6

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
2021, November					
18-44 years	537	537	8,749,707	0.61	709,574.0
45-64 years	2,260	2,260	7,166,680	3.15	577,315.4
65-74 years	3,618	3,618	7,450,141	4.86	595,085.3
75-84 years	2,364	2,364	3,983,058	5.94	315,559.0
≥ 85 years	778	778	1,525,584	5.10	121,572.5
2021, December					
18-44 years	544	544	8,726,561	0.62	731,479.7
45-64 years	2,438	2,438	7,148,818	3.41	594,707.4
65-74 years	3,837	3,837	7,410,326	5.18	611,479.6
75-84 years	2,534	2,534	3,989,359	6.35	326,659.5
≥ 85 years	930	930	1,516,694	6.13	124,887.6
2022, January					
18-44 years	713	713	8,405,657	0.85	704,233.8
45-64 years	3,316	3,316	6,903,167	4.80	574,917.4
65-74 years	5,554	5,554	7,387,245	7.52	610,225.5
75-84 years	3,663	3,663	3,976,033	9.21	325,808.2
≥ 85 years	1,222	1,222	1,506,037	8.11	124,037.0
2022, February					
18-44 years	773	773	8,354,858	0.93	633,167.4
45-64 years	3,462	3,462	6,858,065	5.05	516,498.6
65-74 years	5,237	5,237	7,339,629	7.14	548,666.7
75-84 years	3,478	3,478	3,967,052	8.77	294,417.5
≥ 85 years	1,134	1,134	1,487,972	7.62	110,911.9
2022, March					
18-44 years	868	868	8,348,025	1.04	698,776.1
45-64 years	3,619	3,619	6,854,139	5.28	569,691.2
65-74 years	5,337	5,337	7,343,435	7.27	605,072.7
75-84 years	3,657	3,657	3,997,679	9.15	326,485.5
≥ 85 years	1,170	1,170	1,490,394	7.85	122,294.0
2022, April					
18-44 years	557	557	8,319,160	0.67	673,996.5

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
45-64 years	2,447	2,447	6,821,708	3.59	548,979.9
65-74 years	3,773	3,773	7,312,574	5.16	583,457.2
75-84 years	2,659	2,659	4,001,061	6.65	316,617.2
≥ 85 years	929	929	1,487,127	6.25	118,147.3
2022, May					
18-44 years	508	508	8,297,817	0.61	694,342.1
45-64 years	2,298	2,298	6,800,127	3.38	565,194.3
65-74 years	3,529	3,529	7,307,195	4.83	601,951.0
75-84 years	2,518	2,518	4,018,998	6.27	328,244.6
≥ 85 years	809	809	1,488,802	5.43	122,114.2
2022, June					
18-44 years	524	524	8,301,014	0.63	672,081.1
45-64 years	2,212	2,212	6,790,708	3.26	546,268.5
65-74 years	3,481	3,481	7,299,152	4.77	582,116.8
75-84 years	2,433	2,433	4,035,098	6.03	319,045.3
≥ 85 years	846	846	1,488,728	5.68	118,208.8
2022, July					
18-44 years	461	461	8,257,152	0.56	690,577.0
45-64 years	2,001	2,001	6,750,560	2.96	561,064.2
65-74 years	2,803	2,803	7,308,368	3.84	602,661.4
75-84 years	2,078	2,078	4,052,524	5.13	331,231.0
≥ 85 years	749	749	1,492,092	5.02	122,386.5
2022, August					
18-44 years	530	530	8,293,145	0.64	690,359.8
45-64 years	2,177	2,177	6,748,244	3.23	559,828.4
65-74 years	3,294	3,294	7,323,261	4.50	603,207.0
75-84 years	2,225	2,225	4,073,678	5.46	332,617.5
≥ 85 years	783	783	1,494,610	5.24	122,512.4
2022, September					
18-44 years	366	366	5,790,783	0.63	468,869.4
45-64 years	1,712	1,712	5,017,361	3.41	403,404.3
65-74 years	3,106	3,106	7,191,411	4.32	574,223.2

Sentinel

Table 3. Summary of Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Year, Month, and Age Group

	Number of Patients	Number of Exposure Episodes	Number of Eligible Members[1]	Number of Patients per 10,000 Eligible Members[1]	Total Eligible Member-Years[1]
75-84 years	2,226	2,226	4,062,772	5.48	321,673.4
≥ 85 years	718	718	1,486,543	4.83	118,137.1
2022, October					
18-44 years	290	290	5,124,002	0.57	428,790.3
45-64 years	1,059	1,059	3,700,182	2.86	307,705.4
65-74 years	397	397	1,149,066	3.45	94,714.7
75-84 years	206	206	532,380	3.87	43,619.0
≥ 85 years	78	78	180,721	4.32	14,829.7
2022, November					
18-44 years	74	74	1,546,194	0.48	125,779.2
45-64 years	298	298	1,015,580	2.93	81,904.1
65-74 years	168	168	641,203	2.62	51,303.9
75-84 years	106	106	306,921	3.45	24,366.2
≥ 85 years	28	28	94,527	2.96	7,512.3
2022, December					
18-44 years	64	64	1,556,653	0.41	130,800.3
45-64 years	295	295	1,020,388	2.89	84,982.0
65-74 years	175	175	643,598	2.72	53,193.5
75-84 years	81	81	308,809	2.62	25,336.3
≥ 85 years	21	21	94,754	2.22	7,792.1

[1]Eligible Members and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Table 4. Summary of Time to End of At-Risk Period for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

	Number of Episodes by Episode Length						
		0-364 days		365-729 days		730-1,094 days	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Prevalent Use - All Censoring Options							
Any valsartan product	3,060,902	2,455,108	80.2%	331,952	10.8%	139,318	4.6%
Contaminated valsartan	1,663,906	1,294,872	77.8%	219,740	13.2%	106,516	6.4%
Non-contaminated valsartan	2,817,719	2,347,562	83.3%	299,953	10.6%	95,921	3.4%
New Use - All Censoring Options							
Any valsartan product	1,107,774	884,242	79.8%	119,445	10.8%	56,255	5.1%
Contaminated valsartan	267,426	225,030	84.1%	31,048	11.6%	8,767	3.3%
Non-contaminated valsartan	764,735	654,568	85.6%	69,484	9.1%	27,181	3.6%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death							
Contaminated valsartan	1,056,944	140,862	13.3%	119,475	11.3%	99,423	9.4%
New Use - Censoring on Query/Data End Date, Disenrollment, or Death							
Contaminated valsartan	265,115	39,937	15.1%	30,832	11.6%	25,298	9.5%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan							
Contaminated valsartan	1,314,531	578,113	44.0%	210,405	16.0%	140,668	10.7%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan							
Contaminated valsartan	265,415	85,429	32.2%	47,183	17.8%	28,862	10.9%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan							
Non-contaminated valsartan	2,050,473	934,551	45.6%	423,001	20.6%	243,337	11.9%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan							
Non-contaminated valsartan	753,576	309,984	41.1%	171,548	22.8%	114,484	15.2%

Sentinel

Table 4. Summary of Time to End of At-Risk Period for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

	Number of Episodes by Episode Length					
	1,095-1,459 days		1,460-1,824 days		1,825+ days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Prevalent Use - All Censoring Options						
Any valsartan product	69,421	2.3%	30,779	1.0%	34,324	1.1%
Contaminated valsartan	27,852	1.7%	9,392	0.6%	5,534	0.3%
Non-contaminated valsartan	54,498	1.9%	11,218	0.4%	8,567	0.3%
New Use - All Censoring Options						
Any valsartan product	26,010	2.3%	10,082	0.9%	11,740	1.1%
Contaminated valsartan	1,856	0.7%	532	0.2%	193	0.1%
Non-contaminated valsartan	10,604	1.4%	1,803	0.2%	1,095	0.1%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death						
Contaminated valsartan	95,019	9.0%	145,105	13.7%	457,060	43.2%
New Use - Censoring on Query/Data End Date, Disenrollment, or Death						
Contaminated valsartan	24,081	9.1%	55,951	21.1%	89,016	33.6%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan						
Contaminated valsartan	84,924	6.5%	101,547	7.7%	198,874	15.1%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan						
Contaminated valsartan	19,318	7.3%	36,882	13.9%	47,741	18.0%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan						
Non-contaminated valsartan	218,889	10.7%	81,699	4.0%	148,996	7.3%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan						
Non-contaminated valsartan	77,727	10.3%	24,748	3.3%	55,085	7.3%

Table 4. Summary of Time to End of At-Risk Period for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

Number of Episodes by Episode Length							
	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Prevalent Use - All Censoring Options							
Any valsartan product	1	60	120	283	3,896	254.0	376.5
Contaminated valsartan	1	60	120	317	2,417	248.2	308.4
Non-contaminated valsartan	1	56	114	244	3,819	210.9	289.1
New Use - All Censoring Options							
Any valsartan product	1	39	91	279	3,896	245.4	377.4
Contaminated valsartan	1	41	92	235	2,348	185.7	236.5
Non-contaminated valsartan	1	32	78	210	3,819	180.6	261.6
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death							
Contaminated valsartan	1	745	1,662	2,327	3,756	1,603.9	962.2
New Use - Censoring on Query/Data End Date, Disenrollment, or Death							
Contaminated valsartan	1	675	1,584	2,001	3,748	1,411.2	815.0
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan							
Contaminated valsartan	1	128	481	1,331	3,756	802.4	813.3
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan							
Contaminated valsartan	1	266	731	1,659	3,748	965.8	788.5
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan							
Non-contaminated valsartan	1	155	424	1,000	3,897	680.9	729.0
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan							
Non-contaminated valsartan	1	202	487	1,010	3,897	708.2	716.3

Sentinel

Table 5. Summary of Reasons for End of At-Risk Period for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022[1]

		Censoring Reason					
		End of Exposure Episode[2]		Evidence of Death[3]		Disenrollment[4]	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Prevalent Use - All Censoring Options							
Any valsartan product	3,060,902	1,538,304	50.3%	46,026	1.5%	454,143	14.8%
Contaminated valsartan	1,663,906	553,183	33.2%	18,426	1.1%	124,288	7.5%
Non-contaminated valsartan	2,817,719	1,072,677	38.1%	36,153	1.3%	400,586	14.2%
New Use - All Censoring Options							
Any valsartan product	1,107,774	384,774	34.7%	16,312	1.5%	185,205	16.7%
Contaminated valsartan	267,426	82,351	30.8%	1,990	0.7%	18,168	6.8%
Non-contaminated valsartan	764,735	234,061	30.6%	10,793	1.4%	120,275	15.7%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death							
Contaminated valsartan	1,056,944	0	0.0%	173,691	16.4%	871,585	82.5%
New Use - Censoring on Query/Data End Date, Disenrollment, or Death							
Contaminated valsartan	265,115	0	0.0%	33,710	12.7%	227,113	85.7%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan							
Contaminated valsartan	1,314,531	0	0.0%	103,963	7.9%	490,677	37.3%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan							
Contaminated valsartan	265,415	0	0.0%	22,868	8.6%	143,630	54.1%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan							
Non-contaminated valsartan	2,050,473	0	0.0%	169,862	8.3%	1,043,968	50.9%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan							
Non-contaminated valsartan	753,576	0	0.0%	74,994	10.0%	499,964	66.3%

Table 5. Summary of Reasons for End of At-Risk Period for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022[1]

		Censoring Reason					
		End of Exposure Episode[2]		Evidence of Death[3]		Disenrollment[4]	
	Total Number of Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes

[1]An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

[2]Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

[3]Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

[4]Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

[5]Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

[6]Represents episodes censored due to user-specified study end date.

Sentinel

Table 5. Summary of Reasons for End of At-Risk Period for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022[1]

	Censoring Reason							
	End of Data[5]		End of Study Period[6]		Switch to Other Antihypertensive		Switch to Contaminated Product	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Prevalent Use - All Censoring Options								
Any valsartan product	*219,066*	7.2%	15,226	0.5%	1,014,727	33.2%	N/A	N/A
Contaminated valsartan	*0*	0.0%	0	0.0%	490,736	29.5%	N/A	N/A
Non-contaminated valsartan	*234,252*	8.3%	16,191	0.6%	762,820	27.1%	394,595	14.0%
New Use - All Censoring Options								
Any valsartan product	*101,899*	9.2%	7,278	0.7%	517,302	46.7%	N/A	N/A
Contaminated valsartan	*0*	0.0%	0	0.0%	125,188	46.8%	N/A	N/A
Non-contaminated valsartan	*79,644*	10.4%	6,005	0.8%	321,226	42.0%	48,131	6.3%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death								
Contaminated valsartan	*427,913*	40.5%	19,684	1.9%	0	0.0%	N/A	N/A
New Use - Censoring on Query/Data End Date, Disenrollment, or Death								
Contaminated valsartan	*116,725*	44.0%	5,995	2.3%	0	0.0%	N/A	N/A
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan								
Contaminated valsartan	*199,602*	15.2%	8,988	0.7%	0	0.0%	N/A	N/A
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan								
Contaminated valsartan	*65,274*	24.6%	3,111	1.2%	0	0.0%	N/A	N/A
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan								
Non-contaminated valsartan	*673,450*	32.8%	49,583	2.4%	0	0.0%	581,200	28.3%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan								
Non-contaminated valsartan	*353,111*	46.9%	26,007	3.5%	0	0.0%	102,508	13.6%

Table 5. Summary of Reasons for End of At-Risk Period for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022[1]

	Censoring Reason							
	End of Data[5]		End of Study Period[6]		Switch to Other Antihypertensive		Switch to Contaminated Product	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes

[1]An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

[2]Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

[3]Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

[4]Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

[5]Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

[6]Represents episodes censored due to user-specified study end date.

Sentinel

Table 5. Summary of Reasons for End of At-Risk Period for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022[1]

	Censoring Reason			
	Switch to Non-Contaminated Product		Switch to Unclassified Product	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Prevalent Use - All Censoring Options				
Any valsartan product	*N/A*	N/A	N/A	N/A
Contaminated valsartan	*404,403*	24.3%	79,608	4.8%
Non-contaminated valsartan	*N/A*	N/A	145,583	5.2%
New Use - All Censoring Options				
Any valsartan product	*N/A*	N/A	N/A	N/A
Contaminated valsartan	*34,653*	13.0%	5,943	2.2%
Non-contaminated valsartan	*N/A*	N/A	27,007	3.5%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death				
Contaminated valsartan	*N/A*	N/A	N/A	N/A
New Use - Censoring on Query/Data End Date, Disenrollment, or Death				
Contaminated valsartan	*N/A*	N/A	N/A	N/A
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan				
Contaminated valsartan	*N/A*	N/A	N/A	N/A
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan				
Contaminated valsartan	*N/A*	N/A	N/A	N/A
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan				
Non-contaminated valsartan	*N/A*	N/A	N/A	N/A
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan				
Non-contaminated valsartan	*N/A*	N/A	N/A	N/A

Table 5. Summary of Reasons for End of At-Risk Period for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022[1]

Censoring Reason				
	Switch to Non-Contaminated Product		Switch to Unclassified Product	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes

[1]An episode may be censored due to more than one reason if they occur on the same date. Therefore, the sum of the reasons for censoring may be greater than the total number of episodes.

[2]Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

[3]Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

[4]Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

[5]Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

[6]Represents episodes censored due to user-specified study end date.

Sentinel

Table 6a. Summary of Time to End of At-Risk Period due to End of Exposure Episode for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

			Number of Episodes Censored due to End of Exposure Episode by Episode Length							
			0-364 days		365-729 days		730-1,094 days		1,095-1,459 days	
	Total Number of Episodes	Total Number of Episodes Censored due to End of Exposure Episode[1]	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Prevalent Use - All Censoring Options										
Any valsartan product	3,060,902	1,538,304	1,274,053	82.8%	168,420	10.9%	55,443	*3.6%*	22,590	1.5%
Contaminated valsartan	1,663,906	553,183	460,431	83.2%	66,586	12.0%	19,474	*3.5%*	4,819	0.9%
Non-contaminated valsartan	2,817,719	1,072,677	920,964	85.9%	106,192	9.9%	30,358	*2.8%*	11,712	1.1%
New Use - All Censoring Options										
Any valsartan product	1,107,774	384,774	303,924	79.0%	49,616	12.9%	18,911	*4.9%*	7,034	1.8%
Contaminated valsartan	267,426	82,351	72,378	87.9%	8,003	9.7%	1,607	*2.0%*	282	0.3%
Non-contaminated valsartan	764,735	234,061	198,118	84.6%	25,036	10.7%	8,233	*3.5%*	2,192	0.9%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death										
Contaminated valsartan	1,056,944	0	0	NaN	0	NaN	0	*NaN*	0	NaN
New Use - Censoring on Query/Data End Date, Disenrollment, or Death										
Contaminated valsartan	265,115	0	0	NaN	0	NaN	0	*NaN*	0	NaN
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan										
Contaminated valsartan	1,314,531	0	0	NaN	0	NaN	0	*NaN*	0	NaN
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan										
Contaminated valsartan	265,415	0	0	NaN	0	NaN	0	*NaN*	0	NaN
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan										
Non-contaminated valsartan	2,050,473	0	0	NaN	0	NaN	0	*NaN*	0	NaN
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan										
Non-contaminated valsartan	753,576	0	0	NaN	0	NaN	0	*NaN*	0	NaN

[1]Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder_mpl1r_wp066

Sentinel

Table 6a. Summary of Time to End of At-Risk Period due to End of Exposure Episode for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

	Number of Episodes Censored due to End of Exposure Episode by Episode Length										
	1,460-1,824 days		1,825+ days		Distribution of At-Risk Time in Days, by Episode						
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Prevalent Use - All Censoring Options											
Any valsartan product	9,507	0.6%	8,291	0.5%	31	*74*	120	256	3,817	238.6	296.5
Contaminated valsartan	1,302	0.2%	571	0.1%	31	*90*	120	258	2,394	223.0	231.1
Non-contaminated valsartan	2,265	0.2%	1,186	0.1%	31	*60*	120	226	3,620	207.2	228.0
New Use - All Censoring Options											
Any valsartan product	2,831	0.7%	2,458	0.6%	31	*60*	120	303	3,817	263.3	323.0
Contaminated valsartan	62	0.1%	19	0.0%	31	*60*	120	212	2,234	183.1	182.9
Non-contaminated valsartan	337	0.1%	145	0.1%	31	*60*	120	238	3,598	208.3	227.2
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death											
Contaminated valsartan	0	NaN	0	NaN	NaN	*NaN*	NaN	NaN	NaN	NaN	NaN
New Use - Censoring on Query/Data End Date, Disenrollment, or Death											
Contaminated valsartan	0	NaN	0	NaN	NaN	*NaN*	NaN	NaN	NaN	NaN	NaN
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan											
Contaminated valsartan	0	NaN	0	NaN	NaN	*NaN*	NaN	NaN	NaN	NaN	NaN
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan											
Contaminated valsartan	0	NaN	0	NaN	NaN	*NaN*	NaN	NaN	NaN	NaN	NaN
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan											
Non-contaminated valsartan	0	NaN	0	NaN	NaN	*NaN*	NaN	NaN	NaN	NaN	NaN
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan											
Non-contaminated valsartan	0	NaN	0	NaN	NaN	*NaN*	NaN	NaN	NaN	NaN	NaN

[1]Represents episodes censored due to end of the exposure episode. In as-treated analyses, exposure episodes are defined using days supplied as recorded in outpatient pharmacy dispensing records, and episodes end after days supplied are exhausted or a pre-determined maximum episode duration is met. In point exposure analyses, exposure episodes end when a pre-determined maximum episode duration is met.

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

cder_mpl1r_wp066

Sentinel

Table 6b. Summary of Time to End of At-Risk Period due to Evidence of Death for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

	Number of Episodes Censored due to Evidence of Death by Episode Length							
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Episodes	Total Number of Episodes Censored due to Evidence of Death[1]	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Prevalent Use - All Censoring Options								
Any valsartan product	3,060,902	46,026	29,804	64.8%	8,139	17.7%	3,984	*8.7%*
Contaminated valsartan	1,663,906	18,426	12,356	67.1%	4,015	21.8%	1,489	*8.1%*
Non-contaminated valsartan	2,817,719	36,153	26,422	73.1%	5,986	16.6%	2,369	*6.6%*
New Use - All Censoring Options								
Any valsartan product	1,107,774	16,312	11,027	67.6%	2,708	16.6%	1,337	*8.2%*
Contaminated valsartan	267,426	1,990	1,597	80.3%	299	15.0%	70	*3.5%*
Non-contaminated valsartan	764,735	10,793	8,268	76.6%	1,556	14.4%	640	*5.9%*
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death								
Contaminated valsartan	1,056,944	173,691	22,996	13.2%	25,723	14.8%	26,577	*15.3%*
New Use - Censoring on Query/Data End Date, Disenrollment, or Death								
Contaminated valsartan	265,115	33,710	5,681	16.9%	5,685	16.9%	5,978	*17.7%*
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan								
Contaminated valsartan	1,314,531	103,963	22,327	21.5%	19,222	18.5%	17,339	*16.7%*
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan								
Contaminated valsartan	265,415	22,868	5,066	22.2%	4,293	18.8%	4,094	*17.9%*
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan								
Non-contaminated valsartan	2,050,473	169,862	51,982	30.6%	36,809	21.7%	26,844	*15.8%*
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan								
Non-contaminated valsartan	753,576	74,994	26,150	34.9%	16,656	22.2%	11,419	*15.2%*

[1]Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Sentinel

Table 6b. Summary of Time to End of At-Risk Period due to Evidence of Death for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

	Number of Episodes Censored due to Evidence of Death by Episode Length					
	1,095-1,459 days		1,460-1,824 days		1,825+ days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Prevalent Use - All Censoring Options						
Any valsartan product	1,999	4.3%	*1,116*	2.4%	984	2.1%
Contaminated valsartan	366	2.0%	*155*	0.8%	45	0.2%
Non-contaminated valsartan	937	2.6%	*273*	0.8%	166	0.5%
New Use - All Censoring Options						
Any valsartan product	612	3.8%	*361*	2.2%	267	1.6%
Contaminated valsartan	*****	*****	*****	*****	0	0.0%
Non-contaminated valsartan	215	2.0%	*81*	0.8%	33	0.3%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death						
Contaminated valsartan	26,706	15.4%	*24,584*	14.2%	47,105	27.1%
New Use - Censoring on Query/Data End Date, Disenrollment, or Death						
Contaminated valsartan	6,153	18.3%	*5,069*	15.0%	5,144	15.3%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan						
Contaminated valsartan	15,382	14.8%	*13,041*	12.5%	16,652	16.0%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan						
Contaminated valsartan	3,872	16.9%	*3,022*	13.2%	2,521	11.0%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan						
Non-contaminated valsartan	17,801	10.5%	*11,151*	6.6%	25,275	14.9%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan						
Non-contaminated valsartan	6,919	9.2%	*4,424*	5.9%	9,426	12.6%

[1]Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Sentinel

Table 6b. Summary of Time to End of At-Risk Period due to Evidence of Death for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

Number of Episodes Censored due to Evidence of Death by Episode Length							
	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Prevalent Use - All Censoring Options							
Any valsartan product	1	65	202	541	*3,762*	392.2	480.8
Contaminated valsartan	1	78	209	464	*2,330*	319.0	321.6
Non-contaminated valsartan	1	55	153	392	*3,210*	285.8	340.6
New Use - All Censoring Options							
Any valsartan product	1	50	172	493	*3,731*	356.1	452.7
Contaminated valsartan	2	44	118	302	*1,780*	213.6	247.5
Non-contaminated valsartan	1	39	115	342	*3,210*	251.0	322.5
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death							
Contaminated valsartan	1	658	1,252	1,885	*3,740*	1,318.0	807.9
New Use - Censoring on Query/Data End Date, Disenrollment, or Death							
Contaminated valsartan	2	544	1,066	1,572	*3,611*	1,104.0	686.1
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan							
Contaminated valsartan	1	430	946	1,554	*3,740*	1,044.9	723.7
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan							
Contaminated valsartan	2	416	917	1,445	*3,608*	975.4	653.6
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan							
Non-contaminated valsartan	1	286	686	1,309	*3,780*	925.3	819.5
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan							
Non-contaminated valsartan	1	240	597	1,182	*3,770*	840.0	784.7

[1]Represents episodes censored due to evidence of death. Death data source and completeness varies by Data Partner.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Sentinel

Table 6c. Summary of Time to End of At-Risk Period due to Disenrollment for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

			Number of Episodes Censored due to Disenrollment by Episode Length					
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Episodes	Total Number of Episodes Censored due to Disenrollment[1]	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Prevalent Use - All Censoring Options								
Any valsartan product	3,060,902	454,143	283,939	62.5%	79,759	17.6%	42,841	*9.4%*
Contaminated valsartan	1,663,906	124,288	89,949	72.4%	24,062	19.4%	7,374	*5.9%*
Non-contaminated valsartan	2,817,719	400,586	257,143	64.2%	70,634	17.6%	29,540	*7.4%*
New Use - All Censoring Options								
Any valsartan product	1,107,774	185,205	110,510	59.7%	34,594	18.7%	20,087	*10.8%*
Contaminated valsartan	267,426	18,168	14,706	80.9%	2,704	14.9%	583	*3.2%*
Non-contaminated valsartan	764,735	120,275	81,255	67.6%	20,384	16.9%	10,986	*9.1%*
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death								
Contaminated valsartan	1,056,944	871,585	118,796	13.6%	94,775	10.9%	73,813	*8.5%*
New Use - Censoring on Query/Data End Date, Disenrollment, or Death								
Contaminated valsartan	265,115	227,113	34,501	15.2%	25,369	11.2%	19,526	*8.6%*
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan								
Contaminated valsartan	1,314,531	490,677	113,154	23.1%	67,497	13.8%	44,920	*9.2%*
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan								
Contaminated valsartan	265,415	143,630	30,684	21.4%	18,589	12.9%	12,486	*8.7%*
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan								
Non-contaminated valsartan	2,050,473	1,043,968	346,633	33.2%	216,864	20.8%	139,749	*13.4%*
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan								
Non-contaminated valsartan	753,576	499,964	185,650	37.1%	111,391	22.3%	81,830	*16.4%*

[1]Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Sentinel

Table 6c. Summary of Time to End of At-Risk Period due to Disenrollment for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

	Number of Episodes Censored due to Disenrollment by Episode Length					
	1,095-1,459 days		1,460-1,824 days		1,825+ days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Prevalent Use - All Censoring Options						
Any valsartan product	24,699	5.4%	*9,067*	2.0%	13,838	3.0%
Contaminated valsartan	1,957	1.6%	*672*	0.5%	274	0.2%
Non-contaminated valsartan	30,565	7.6%	*6,513*	1.6%	6,191	1.5%
New Use - All Censoring Options						
Any valsartan product	11,010	5.9%	*3,562*	1.9%	5,442	2.9%
Contaminated valsartan	125	0.7%	*****	*****	*****	*****
Non-contaminated valsartan	5,947	4.9%	*962*	0.8%	741	0.6%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death						
Contaminated valsartan	69,343	8.0%	*117,651*	13.5%	397,207	45.6%
New Use - Censoring on Query/Data End Date, Disenrollment, or Death						
Contaminated valsartan	18,150	8.0%	*49,395*	21.7%	80,172	35.3%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan						
Contaminated valsartan	33,350	6.8%	*67,688*	13.8%	164,068	33.4%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan						
Contaminated valsartan	9,735	6.8%	*30,378*	21.2%	41,758	29.1%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan						
Non-contaminated valsartan	163,767	15.7%	*60,311*	5.8%	116,644	11.2%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan						
Non-contaminated valsartan	59,894	12.0%	*17,687*	3.5%	43,512	8.7%

[1]Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Sentinel

Table 6c. Summary of Time to End of At-Risk Period due to Disenrollment for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

Number of Episodes Censored due to Disenrollment by Episode Length							
	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Prevalent Use - All Censoring Options							
Any valsartan product	1	79	231	596	*3,828*	436.5	538.1
Contaminated valsartan	1	67	179	403	*2,288*	281.2	297.9
Non-contaminated valsartan	1	79	230	544	*3,819*	404.7	462.4
New Use - All Censoring Options							
Any valsartan product	1	90	260	641	*3,828*	456.3	525.0
Contaminated valsartan	1	50	137	310	*2,105*	218.3	238.3
Non-contaminated valsartan	1	72	210	491	*3,819*	350.8	386.3
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death							
Contaminated valsartan	1	752	1,713	2,361	*3,751*	1,640.0	977.3
New Use - Censoring on Query/Data End Date, Disenrollment, or Death							
Contaminated valsartan	1	684	1,618	2,027	*3,720*	1,436.2	820.9
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan							
Contaminated valsartan	1	413	1,321	2,068	*3,749*	1,295.8	911.8
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan							
Contaminated valsartan	1	454	1,474	1,908	*3,694*	1,267.6	816.4
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan							
Non-contaminated valsartan	1	267	647	1,295	*3,897*	889.2	817.1
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan							
Non-contaminated valsartan	1	235	555	1,083	*3,888*	780.5	759.3

[1]Represents episodes censored due to disenrollment from health plan. Data Partners often artificially assign a "disenrollment" date equal to data end date for members still enrolled on that date. Therefore, a patient may have dual reasons for censoring as "disenrollment" and "end of data" on the same day - this can be interpreted as right-censoring in most cases.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Sentinel

Table 6d. Summary of Time to End of At-Risk Period due to End of Data for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

			Number of Episodes Censored due to End of Data by Episode Length									
			0-364 days		365-729 days		730-1,094 days		1,095-1,459 days		1,460-1,824 days	
	Total Number of Episodes	Total Number of Episodes Censored due to End of Data[1]	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	of Total Episodes
Prevalent Use - All Censoring Options												
Any valsartan product	3,060,902	219,066	120,160	54.9%	39,359	18.0%	25,567	11.7%	17,526	8.0%	5,373	2.5%
Contaminated valsartan	1,663,906	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Non-contaminated valsartan	2,817,719	234,252	125,957	53.8%	46,688	19.9%	20,825	8.9%	29,069	12.4%	5,873	2.5%
New Use - All Censoring Options												
Any valsartan product	1,107,774	101,899	53,428	52.4%	19,169	18.8%	13,671	13.4%	8,791	8.6%	2,296	2.3%
Contaminated valsartan	267,426	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Non-contaminated valsartan	764,735	79,644	48,837	61.3%	14,334	18.0%	9,013	11.3%	5,885	7.4%	857	1.1%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death												
Contaminated valsartan	1,056,944	427,913	0	0.0%	0	0.0%	0	0.0%	8,682	2.0%	76,107	17.8%
New Use - Censoring on Query/Data End Date, Disenrollment, or Death												
Contaminated valsartan	265,115	116,725	0	0.0%	0	0.0%	0	0.0%	2,243	1.9%	39,985	34.3%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan												
Contaminated valsartan	1,314,531	199,602	0	0.0%	0	0.0%	0	0.0%	2,112	1.1%	48,778	24.4%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan												
Contaminated valsartan	265,415	65,274	0	0.0%	0	0.0%	0	0.0%	549	0.8%	25,248	38.7%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan												
Non-contaminated valsartan	2,050,473	673,450	169,215	25.1%	131,257	19.5%	88,113	13.1%	144,640	21.5%	47,445	7.0%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan												
Non-contaminated valsartan	753,576	353,111	114,233	32.4%	76,324	21.6%	62,406	17.7%	53,928	15.3%	12,306	3.5%

[1]Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Sentinel

Table 6d. Summary of Time to End of At-Risk Period due to End of Data for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

Number of Episodes Censored due to End of Data by Episode Length									
	1,825+ days		Distribution of At-Risk Time in Days, by Episode						
	Number of Episodes	Percent of Total Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Prevalent Use - All Censoring Options									
Any valsartan product	11,081	5.1%	1	103	297	799	3,896	546.4	633.4
Contaminated valsartan	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Non-contaminated valsartan	5,840	2.5%	1	118	326	778	3,819	521.4	527.1
New Use - All Censoring Options									
Any valsartan product	4,544	4.5%	1	125	331	857	3,896	553.9	593.4
Contaminated valsartan	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Non-contaminated valsartan	718	0.9%	1	99	251	611	3,819	417.6	426.1
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death									
Contaminated valsartan	343,124	80.2%	1,340	1,909	2,329	2,762	3,756	2,391.9	588.9
New Use - Censoring on Query/Data End Date, Disenrollment, or Death									
Contaminated valsartan	74,497	63.8%	1,342	1,720	1,984	2,291	3,748	2,064.1	440.1
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan									
Contaminated valsartan	148,712	74.5%	1,342	1,817	2,178	2,412	3,756	2,187.3	463.7
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan									
Contaminated valsartan	39,477	60.5%	1,343	1,705	1,934	2,199	3,748	2,002.1	379.2
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan									
Non-contaminated valsartan	92,780	13.8%	1	362	920	1,363	3,897	1,046.2	865.9
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan									
Non-contaminated valsartan	33,914	9.6%	1	269	642	1,152	3,897	858.9	794.6

[1]Represents episodes censored due to Data Partner data end date. This end date represents the last day of the most recent year-month in which all of a Data Partner's data tables in the Sentinel Common Data Model have at least 80% of the record count relative to the prior month.

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Sentinel

Table 6e. Summary of Time to End of At-Risk Period due to End of Study Period for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

			Number of Episodes Censored due to End of Study Period by Episode Length									
			0-364 days		365-729 days		730-1,094 days		1,095-1,459 days		1,460-1,824 days	
	Total Number of Episodes	Total Number of Episodes Censored due to End of Study Period[1]	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Prevalent Use - All Censoring Options												
Any valsartan product	3,060,902	15,226	9,387	61.7%	2,877	18.9%	1,320	8.7%	958	6.3%	224	1.5%
Contaminated valsartan	1,663,906	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Non-contaminated valsartan	2,817,719	16,191	9,355	57.8%	3,873	23.9%	1,140	7.0%	1,421	8.8%	257	1.6%
New Use - All Censoring Options												
Any valsartan product	1,107,774	7,278	4,195	57.6%	1,502	20.6%	683	9.4%	578	7.9%	90	1.2%
Contaminated valsartan	267,426	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Non-contaminated valsartan	764,735	6,005	3,927	65.4%	1,181	19.7%	416	6.9%	423	7.0%	28	0.5%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death												
Contaminated valsartan	1,056,944	19,684	0	0.0%	0	0.0%	0	0.0%	0	0.0%	4,106	20.9%
New Use - Censoring on Query/Data End Date, Disenrollment, or Death												
Contaminated valsartan	265,115	5,995	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1,817	30.3%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan												
Contaminated valsartan	1,314,531	8,988	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2,285	25.4%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan												
Contaminated valsartan	265,415	3,111	0	0.0%	0	0.0%	0	0.0%	0	0.0%	1,029	33.1%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan												
Non-contaminated valsartan	2,050,473	49,583	11,674	23.5%	14,791	29.8%	6,536	13.2%	10,000	20.2%	2,648	5.3%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan												
Non-contaminated valsartan	753,576	26,007	8,170	31.4%	7,548	29.0%	3,943	15.2%	4,309	16.6%	594	2.3%

[1]Represents episodes censored due to user-specified study end date.

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6e. Summary of Time to End of At-Risk Period due to End of Study Period for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

Number of Episodes Censored due to End of Study Period by Episode Length									
	1,825+ days		Distribution of At-Risk Time in Days, by Episode						
	Number of Episodes	Percent of Total Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Prevalent Use - All Censoring Options									
Any valsartan product	460	3.0%	1	91	269	608	3,896	449.3	537.2
Contaminated valsartan	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Non-contaminated valsartan	145	0.9%	1	98	298	558	3,599	430.3	440.0
New Use - All Censoring Options									
Any valsartan product	230	3.2%	1	114	310	662	3,896	485.5	529.1
Contaminated valsartan	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Non-contaminated valsartan	30	0.5%	1	93	271	514	3,086	376.2	379.7
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death									
Contaminated valsartan	15,578	79.1%	1,462	1,902	2,376	2,937	3,756	2,481.8	665.8
New Use - Censoring on Query/Data End Date, Disenrollment, or Death									
Contaminated valsartan	4,178	69.7%	1,462	1,788	2,050	2,421	3,748	2,173.1	496.7
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan									
Contaminated valsartan	6,703	74.6%	1,462	1,821	2,203	2,456	3,756	2,241.6	503.7
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan									
Contaminated valsartan	2,082	66.9%	1,465	1,777	1,984	2,308	3,748	2,100.1	431.9
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan									
Non-contaminated valsartan	3,934	7.9%	1	384	675	1,332	3,897	904.2	759.8
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan									
Non-contaminated valsartan	1,443	5.5%	1	311	591	1,084	3,897	765.3	680.3

[1]Represents episodes censored due to user-specified study end date.

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Sentinel

Table 6f. Summary of Time to End of At-Risk Period due to Switch to Other Antihypertensive for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

			Number of Episodes Censored due to End of Study Period by Episode Length									
			0-364 days		365-729 days		730-1,094 days		1,095-1,459 days		1,460-1,824 days	
	Total Number of Episodes	Total Number of Episodes Censored due to Switch to Other Antihypertensive	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
All Censoring Options												
Any valsartan product	3,060,902	1,014,727	863,673	85.1%	73,716	7.3%	36,142	3.6%	19,400	1.9%	10,950	1.1%
Contaminated valsartan	1,663,906	490,736	369,511	75.3%	60,111	12.2%	47,021	9.6%	10,164	2.1%	1,809	0.4%
Non-contaminated valsartan	2,817,719	762,820	711,432	93.3%	35,944	4.7%	10,103	1.3%	3,900	0.5%	924	0.1%
New Use - All Censoring Options												
Any valsartan product	1,107,774	517,302	456,988	88.3%	31,406	6.1%	15,402	3.0%	6,861	1.3%	3,264	0.6%
Contaminated valsartan	267,426	125,188	107,646	86.0%	12,760	10.2%	3,958	3.2%	583	0.5%	176	0.1%
Non-contaminated valsartan	764,735	321,226	309,592	96.4%	8,539	2.7%	2,382	0.7%	482	0.2%	153	0.0%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death												
Contaminated valsartan	1,056,944	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
New Use - Censoring on Query/Data End Date, Disenrollment, or Death												
Contaminated valsartan	265,115	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan												
Contaminated valsartan	1,314,531	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan												
Contaminated valsartan	265,415	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan												
Non-contaminated valsartan	2,050,473	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan												
Non-contaminated valsartan	753,576	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Sentinel

Table 6f. Summary of Time to End of At-Risk Period due to Switch to Other Antihypertensive for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

Number of Episodes Censored due to End of Study Period by Episode Length									
	1,825+ days		Distribution of At-Risk Time in Days, by Episode						
	Number of Episodes	Percent of Total Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Prevalent Use - All Censoring Options									
Any valsartan product	10,846	1.1%	1	16	47	148	3,771	186.7	360.4
Contaminated valsartan	2,120	0.4%	1	21	73	359	2,383	245.3	343.0
Non-contaminated valsartan	517	0.1%	1	13	35	83	3,422	96.4	185.9
New Use - All Censoring Options									
Any valsartan product	3,381	0.7%	1	16	42	99	3,529	150.0	304.6
Contaminated valsartan	65	0.1%	1	19	52	174	2,233	150.6	229.4
Non-contaminated valsartan	78	0.0%	1	13	32	69	3,125	70.2	134.0
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death									
Contaminated valsartan	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
New Use - Censoring on Query/Data End Date, Disenrollment, or Death									
Contaminated valsartan	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan									
Contaminated valsartan	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan									
Contaminated valsartan	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan									
Non-contaminated valsartan	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan									
Non-contaminated valsartan	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Table 6g. Summary of Time to End of At-Risk Period due to Switch to Contaminated Product for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

	Number of Episodes Censored due to Switch to Contaminated Product by Episode Length							
			0-364 days		365-729 days		730-1,094 days	
	Total Number of Episodes	Total Number of Episodes Censored due to Switch to Contaminated Product	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Prevalent Use - All Censoring Options								
Any valsartan product	3,060,902	0	0	NaN	0	NaN	0	NaN
Contaminated valsartan	1,663,906	0	0	NaN	0	NaN	0	NaN
Non-contaminated valsartan	2,817,719	394,595	314,818	79.8%	57,357	14.5%	16,714	4.2%
New Use - All Censoring Options								
Any valsartan product	1,107,774	0	0	NaN	0	NaN	0	NaN
Contaminated valsartan	267,426	0	0	NaN	0	NaN	0	NaN
Non-contaminated valsartan	764,735	48,131	35,578	73.9%	7,895	16.4%	3,270	6.8%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death								
Contaminated valsartan	1,056,944	0	0	NaN	0	NaN	0	NaN
New Use - Censoring on Query/Data End Date, Disenrollment, or Death								
Contaminated valsartan	265,115	0	0	NaN	0	NaN	0	NaN
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan								
Contaminated valsartan	1,314,531	0	0	NaN	0	NaN	0	NaN
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan								
Contaminated valsartan	265,415	0	0	NaN	0	NaN	0	NaN
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan								
Non-contaminated valsartan	2,050,473	581,200	385,463	66.3%	111,690	19.2%	52,034	9.0%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan								
Non-contaminated valsartan	753,576	102,508	58,677	57.2%	22,616	22.1%	12,774	12.5%

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Sentinel

Table 6g. Summary of Time to End of At-Risk Period due to Switch to Contaminated Product for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

Number of Episodes Censored due to Switch to Contaminated Product by Episode Length						
	1,095-1,459 days		1,460-1,824 days		1,825+ days	
	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Prevalent Use - All Censoring Options						
Any valsartan product	0	NaN	0	NaN	0	NaN
Contaminated valsartan	0	NaN	0	NaN	0	NaN
Non-contaminated valsartan	4,729	1.2%	815	0.2%	162	0.0%
New Use - All Censoring Options						
Any valsartan product	0	NaN	0	NaN	0	NaN
Contaminated valsartan	0	NaN	0	NaN	0	NaN
Non-contaminated valsartan	1,127	2.3%	211	0.4%	50	0.1%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death						
Contaminated valsartan	0	NaN	0	NaN	0	NaN
New Use - Censoring on Query/Data End Date, Disenrollment, or Death						
Contaminated valsartan	0	NaN	0	NaN	0	NaN
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan						
Contaminated valsartan	0	NaN	0	NaN	0	NaN
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan						
Contaminated valsartan	0	NaN	0	NaN	0	NaN
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan						
Non-contaminated valsartan	22,686	3.9%	6,944	1.2%	2,383	0.4%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan						
Non-contaminated valsartan	5,845	5.7%	1,953	1.9%	643	0.6%

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Sentinel

Table 6g. Summary of Time to End of At-Risk Period due to Switch to Contaminated Product for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

Number of Episodes Censored due to Switch to Contaminated Product by Episode Length							
	Distribution of At-Risk Time in Days, by Episode						
	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Prevalent Use - All Censoring Options							
Any valsartan product	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Contaminated valsartan	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Non-contaminated valsartan	1	58	115	303	2,233	224.3	255.3
New Use - All Censoring Options							
Any valsartan product	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Contaminated valsartan	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Non-contaminated valsartan	1	64	165	377	2,154	277.3	304.3
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death							
Contaminated valsartan	NaN	NaN	NaN	NaN	NaN	NaN	NaN
New Use - Censoring on Query/Data End Date, Disenrollment, or Death							
Contaminated valsartan	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan							
Contaminated valsartan	NaN	NaN	NaN	NaN	NaN	NaN	NaN
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan							
Contaminated valsartan	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan							
Non-contaminated valsartan	1	84	205	483	2,402	344.5	366.4
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan							
Non-contaminated valsartan	1	113	290	636	2,402	428.0	404.2

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Sentinel

Table 6h. Summary of Time to End of At-Risk Period due to Switch to Non-Contaminated Product for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

			Number of Episodes Censored due to Switch to Non-Contaminated Product by Episode Length									
			0-364 days		365-729 days		730-1,094 days		1,095-1,459 days		1,460-1,824 days	
	Total Number of Episodes	Total Number of Episodes Censored due to Switch to Non-Contaminated Product	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Prevalent Use - All Censoring Options												
Any valsartan product	3,060,902	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Contaminated valsartan	1,663,906	404,403	304,299	75.2%	55,051	13.6%	27,314	6.8%	9,903	2.4%	5,372	1.3%
Non-contaminated valsartan	2,817,719	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
New Use - All Censoring Options												
Any valsartan product	1,107,774	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Contaminated valsartan	267,426	34,653	24,880	71.8%	6,308	18.2%	2,310	6.7%	813	2.3%	243	0.7%
Non-contaminated valsartan	764,735	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death												
Contaminated valsartan	1,056,944	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
New Use - Censoring on Query/Data End Date, Disenrollment, or Death												
Contaminated valsartan	265,115	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan												
Contaminated valsartan	1,314,531	604,510	365,925	60.5%	105,380	17.4%	69,223	11.5%	33,836	5.6%	18,280	3.0%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan												
Contaminated valsartan	265,415	84,707	42,573	50.3%	21,464	25.3%	11,220	13.2%	5,452	6.4%	2,473	2.9%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan												
Non-contaminated valsartan	2,050,473	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan												
Non-contaminated valsartan	753,576	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Sentinel

Table 6h. Summary of Time to End of At-Risk Period due to Switch to Non-Contaminated Product for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

Number of Episodes Censored due to Switch to Non-Contaminated Product by Episode Length									
	1,825+ days		Distribution of At-Risk Time in Days, by Episode						
	Number of Episodes	Percent of Total Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Prevalent Use - All Censoring Options									
Any valsartan product	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Contaminated valsartan	2,464	0.6%	1	51	118	362	2,417	277.7	359.4
Non-contaminated valsartan	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
New Use - All Censoring Options									
Any valsartan product	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Contaminated valsartan	99	0.3%	1	62	178	405	2,348	291.4	321.7
Non-contaminated valsartan	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death									
Contaminated valsartan	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
New Use - Censoring on Query/Data End Date, Disenrollment, or Death									
Contaminated valsartan	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan									
Contaminated valsartan	11,866	2.0%	1	83	239	645	3,670	431.1	482.1
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan									
Contaminated valsartan	1,525	1.8%	1	137	362	718	3,587	496.5	461.3
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan									
Non-contaminated valsartan	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan									
Non-contaminated valsartan	0	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Sentinel

Table 6i. Summary of Time to End of At-Risk Period due to Switch to Unclassified Product for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

			Number of Episodes Censored due to Switch to Unclassified Product by Episode Length									
			0-364 days		365-729 days		730-1,094 days		1,095-1,459 days		1,460-1,824 days	
	Total Number of Episodes	Total Number of Episodes Censored due to Switch to Unclassified Product	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes	Number of Episodes	Percent of Total Episodes
Prevalent Use - All Censoring Options												
Any valsartan product	3,060,902	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Contaminated valsartan	1,663,906	79,608	63,867	80.2%	10,645	13.4%	4,178	5.2%	728	0.9%	112	0.1%
Non-contaminated valsartan	2,817,719	145,583	116,518	80.0%	21,147	14.5%	6,043	4.2%	1,443	1.0%	206	0.1%
New Use - All Censoring Options												
Any valsartan product	1,107,774	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Contaminated valsartan	267,426	5,943	4,566	76.8%	1,065	17.9%	268	4.5%	*****	*****	*****	*****
Non-contaminated valsartan	764,735	27,007	20,143	74.6%	5,192	19.2%	1,344	5.0%	266	1.0%	37	0.1%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death												
Contaminated valsartan	1,056,944	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
New Use - Censoring on Query/Data End Date, Disenrollment, or Death												
Contaminated valsartan	265,115	0	0	NaN	0	NaN	0	NaN	0	NaN	0	NaN
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan												
Contaminated valsartan	1,314,531	111,267	77,795	69.9%	19,082	17.1%	9,841	8.8%	2,914	2.6%	932	0.8%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan												
Contaminated valsartan	265,415	12,257	7,348	59.9%	3,020	24.6%	1,201	9.8%	400	3.3%	178	1.5%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan												
Non-contaminated valsartan	2,050,473	217,153	142,125	65.4%	45,739	21.1%	19,789	9.1%	6,260	2.9%	1,280	0.6%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan												
Non-contaminated valsartan	753,576	55,389	33,124	59.8%	14,706	26.6%	5,316	9.6%	1,395	2.5%	328	0.6%

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Sentinel

Table 6i. Summary of Time to End of At-Risk Period due to Switch to Unclassified Product for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

Number of Episodes Censored due to Switch to Unclassified Product by Episode Length									
	1,825+ days		Distribution of At-Risk Time in Days, by Episode						
	Number of Episodes	Percent of Total Episodes	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Prevalent Use - All Censoring Options									
Any valsartan product	*0*	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Contaminated valsartan	*78*	0.1%	1	61	102	282	2,342	221.8	259.1
Non-contaminated valsartan	*226*	0.2%	1	69	115	295	3,415	225.7	254.7
New Use - All Censoring Options									
Any valsartan product	*0*	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Contaminated valsartan	*****	*****	1	58	147	341	1,961	235.1	241.2
Non-contaminated valsartan	*25*	0.1%	1	69	153	368	2,960	251.9	262.6
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death									
Contaminated valsartan	*0*	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
New Use - Censoring on Query/Data End Date, Disenrollment, or Death									
Contaminated valsartan	*0*	NaN	NaN	NaN	NaN	NaN	NaN	NaN	NaN
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan									
Contaminated valsartan	*703*	0.6%	1	80	168	448	3,550	316.2	359.0
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan									
Contaminated valsartan	*110*	0.9%	1	99	272	542	3,174	385.7	381.3
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan									
Non-contaminated valsartan	*1,960*	0.9%	1	89	204	501	3,735	347.4	377.3
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan									
Non-contaminated valsartan	*520*	0.9%	1	96	269	540	3,545	375.6	377.1

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

*Data presented by a dash, asterisk, or period represents missing information. Data represented by NaN (Not a Number) is due to their inability to be calculated. This table may not use all data representations.

Sentinel

Table 7a. Categorical Summary of Patients' Cumulative Treatment Episode Durations[1] for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

	Number of Patients by Cumulative Treatment Episode Duration						
		0-90 Days		91-182 Days		183-364 Days	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Prevalent Use - All Censoring Options							
Any valsartan product	1,771,282	580,648	32.8%	253,239	14.3%	277,019	15.6%
Contaminated valsartan	1,054,228	304,673	28.9%	156,947	14.9%	176,161	16.7%
Non-contaminated valsartan	1,698,545	579,704	34.1%	272,892	16.1%	298,888	17.6%
New Use - All Censoring Options							
Any valsartan product	1,071,474	522,734	48.8%	176,013	16.4%	147,287	13.7%
Contaminated valsartan	265,082	130,652	49.3%	51,092	19.3%	40,772	15.4%
Non-contaminated valsartan	749,276	406,148	54.2%	130,137	17.4%	101,812	13.6%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, or Episode End Date							
Contaminated valsartan	1,054,228	115,744	11.0%	175,845	16.7%	209,339	19.9%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, or Episode End Date							
Contaminated valsartan	265,082	65,157	24.6%	69,034	26.0%	60,160	22.7%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, Switch to Unclassified Valsartan, or Episode End Date							
Contaminated valsartan	1,054,228	173,382	16.4%	167,966	15.9%	204,744	19.4%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, Switch to Unclassified Valsartan, or Episode End Date							
Contaminated valsartan	265,082	72,839	27.5%	67,096	25.3%	59,039	22.3%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, Switch to Unclassified Valsartan, or Episode End Date							
Non-contaminated valsartan	1,698,545	303,295	17.9%	309,665	18.2%	364,877	21.5%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, Switch to Unclassified Valsartan, or Episode End Date							
Non-contaminated valsartan	749,276	210,281	28.1%	186,072	24.8%	159,008	21.2%

Sentinel

Table 7a. Categorical Summary of Patients' Cumulative Treatment Episode Durations1 for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

	Number of Patients by Cumulative Treatment Episode Duration					
	365-547 Days		548-729 Days		730+ Days	
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Prevalent Use - All Censoring Options						
Any valsartan product	169,927	9.6%	121,351	6.9%	369,098	20.8%
Contaminated valsartan	118,001	11.2%	91,381	8.7%	207,065	19.6%
Non-contaminated valsartan	179,294	10.6%	112,848	6.6%	254,919	15.0%
New Use - All Censoring Options						
Any valsartan product	73,998	6.9%	45,983	4.3%	105,459	9.8%
Contaminated valsartan	19,961	7.5%	11,214	4.2%	11,391	4.3%
Non-contaminated valsartan	45,379	6.1%	24,707	3.3%	41,093	5.5%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, or Episode End Date						
Contaminated valsartan	143,425	13.6%	112,269	10.6%	297,606	28.2%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, or Episode End Date						
Contaminated valsartan	30,449	11.5%	18,800	7.1%	21,482	8.1%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, Switch						
Contaminated valsartan	139,962	13.3%	105,928	10.0%	262,246	24.9%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, Switch to U						
Contaminated valsartan	29,140	11.0%	17,843	6.7%	19,125	7.2%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, S						
Non-contaminated valsartan	227,248	13.4%	147,785	8.7%	345,675	20.4%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, Switch						
Non-contaminated valsartan	75,676	10.1%	42,444	5.7%	75,795	10.1%

[1]Treatment episode duration was calculated based on time-on-treatment for each episode; episodes were censored at the end of the treatment episode.

Sentinel

Table 7b. Continuous Summary of Patients' Cumulative Treatment Episode Durations[1] for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

		Distribution of Cumulative Treatment Episode Duration, days						
	Total Number of Patients	Minimum	Q1	Median	Q3	Maximum	Mean	Standard Deviation
Prevalent Use - All Censoring Options								
Any valsartan product	1,771,282	1	60	210	611	3,896	438.9	555.2
Contaminated valsartan	1,054,228	1	74	240	613	2,417	391.8	408.6
Non-contaminated valsartan	1,698,545	1	60	181	480	3,855	349.9	427.0
New Use - All Censoring Options								
Any valsartan product	1,071,474	1	40	96	299	3,896	253.8	384.7
Contaminated valsartan	265,082	1	41	92	240	2,348	187.3	237.6
Non-contaminated valsartan	749,276	1	33	80	211	3,819	184.3	264.9
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, or Episode End Date								
Contaminated valsartan	1,054,228	1	155	394	787	3,180	523.4	441.3
New Use - Censoring on Query/Data End Date, Disenrollment, Death, or Episode End Date								
Contaminated valsartan	265,082	1	92	180	390	2,550	284.3	278.0
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, Switch to Unclassified Valsartan, or Episode End Date								
Contaminated valsartan	1,054,228	1	120	344	727	2,715	473.7	422.4
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, Switch to Unclassified Valsartan, or Episode End Date								
Contaminated valsartan	265,082	1	90	165	364	2,520	268.7	267.6
Date								
Non-contaminated valsartan	1,698,545	1	120	294	624	3,855	449.4	455.7
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, Switch to Unclassified Valsartan, or Episode End Date								
Non-contaminated valsartan	749,276	1	87	164	380	3,819	293.2	325.5

[1]Treatment episode duration was calculated based on time-on-treatment for each episode; episodes were censored at the end of the treatment episode.

Sentinel

Table 8a. Summary of Cumulative Dose in All Treatment Episodes for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

		Number of Patients by Cumulative Filled Dose[1]									
		<=7300 mg		7301-14600 mg		14601-29200 mg		29201-43800 mg		43801-58400 mg	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Prevalent Use - All Censoring Options											
Any valsartan product	1,771,282	490,758	27.7%	230,350	13.0%	237,570	13.4%	130,727	7.4%	105,477	6.0%
Contaminated valsartan	1,054,228	211,824	20.1%	137,348	13.0%	156,098	14.8%	84,013	8.0%	76,056	7.2%
Non-contaminated valsartan	1,698,545	466,608	27.5%	238,689	14.1%	254,653	15.0%	138,534	8.2%	110,290	6.5%
New Use - All Censoring Options											
Any valsartan product	1,071,474	457,953	42.7%	173,170	16.2%	140,985	13.2%	62,852	5.9%	47,272	4.4%
Contaminated valsartan	265,082	104,079	39.3%	50,931	19.2%	41,089	15.5%	17,300	6.5%	13,546	5.1%
Non-contaminated valsartan	749,276	361,635	48.3%	127,471	17.0%	99,551	13.3%	40,954	5.5%	29,770	4.0%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, or Episode End Date											
Contaminated valsartan	1,054,228	102,775	9.7%	117,188	11.1%	153,484	14.6%	88,359	8.4%	87,674	8.3%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, or Episode End Date											
Contaminated valsartan	265,082	61,931	23.4%	49,932	18.8%	47,586	18.0%	22,563	8.5%	19,530	7.4%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, Switch to Unclassified Valsartan, or Episode End Date											
Contaminated valsartan	1,054,228	130,978	12.4%	122,641	11.6%	155,244	14.7%	87,098	8.3%	86,513	8.2%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, Switch to Unclassified Valsartan, or Episode End Date											
Contaminated valsartan	265,082	64,985	24.5%	50,118	18.9%	47,533	17.9%	22,374	8.4%	19,305	7.3%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, Switch to Unclassified Valsartan, or Episode End Da											
Non-contaminated valsartan	1,698,545	275,647	16.2%	225,227	13.3%	272,341	16.0%	159,745	9.4%	133,103	7.8%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, Switch to Unclassified Valsartan, or Episode End Date											
Non-contaminated valsartan	749,276	220,540	29.4%	137,035	18.3%	127,957	17.1%	61,414	8.2%	46,641	6.2%

Sentinel

Table 8a. Summary of Cumulative Dose in All Treatment Episodes for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

	Number of Patients by Cumulative Filled Dose[1]											
	58401-116800 mg		116801- 175200 mg		175201-233600 mg		233601+ mg		Distribution of Cumulative Filled Dose			
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Minimum	Maximum	Mean	Standard Deviation
Prevalent Use - All Censoring Options												
Any valsartan product	235,277	13.3%	122,533	6.9%	72,963	4.1%	145,627	8.2%	0.4	57,686,400.0	73,083.5	140,702.2
Contaminated valsartan	170,523	16.2%	92,558	8.8%	50,858	4.8%	74,950	7.1%	0.4	1,083,520.0	72,293.9	93,449.7
Non-contaminated valsartan	229,228	13.5%	107,717	6.3%	61,395	3.6%	91,431	5.4%	8.7	57,600,000.0	59,965.3	120,451.7
New Use - All Censoring Options												
Any valsartan product	91,201	8.5%	40,897	3.8%	21,805	2.0%	35,339	3.3%	8.7	57,657,600.0	39,806.4	108,210.6
Contaminated valsartan	22,884	8.6%	8,322	3.1%	3,725	1.4%	3,206	1.2%	17.1	734,400.0	30,499.8	50,472.2
Non-contaminated valsartan	51,569	6.9%	19,764	2.6%	9,125	1.2%	9,437	1.3%	8.7	57,600,000.0	26,726.4	99,764.7
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, or Episode End Date												
Contaminated valsartan	203,630	19.3%	117,586	11.2%	69,399	6.6%	114,133	10.8%	40.0	1,286,400.0	96,247.8	106,641.9
New Use - Censoring on Query/Data End Date, Disenrollment, Death, or Episode End Date												
Contaminated valsartan	35,257	13.3%	14,565	5.5%	6,990	2.6%	6,728	2.5%	40.0	816,000.0	47,402.0	64,804.7
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, Switch to Unclassified Valsartan, or Episode End Date												
Contaminated valsartan	196,673	18.7%	111,552	10.6%	63,352	6.0%	100,177	9.5%	2.2	1,083,520.0	88,597.7	101,633.1
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, Switch to Unclassified Valsartan, or Episode End Date												
Contaminated valsartan	34,453	13.0%	13,767	5.2%	6,599	2.5%	5,948	2.2%	40.0	734,400.0	45,271.2	62,147.0
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, Switch to Unclassified Valsartan, or Episode End Date												
Non-contaminated valsartan	285,093	16.8%	139,739	8.2%	81,244	4.8%	126,406	7.4%	20.0	57,600,000.0	76,805.8	132,027.5
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, Switch to Unclassified Valsartan, or Episode End Date												
Non-contaminated valsartan	84,772	11.3%	34,782	4.6%	17,022	2.3%	19,113	2.6%	13.0	57,600,000.0	42,839.5	116,603.7

*Cumulative dose is calculated after dispensings are stockpiled by multiplying the drug strength by the amount dispensed in each dispensing and summing over all dispensings identified by the relevant drug code(s).

[1]Cumulative dose categories determined by using 80mg as a maximum daily dose for diuretic combination products and 320 mg as a maximum daily dose for single valsartan products, and assuming <6, 6-12, 13-18, 19-24 and 25+ exposure months.

Table 8b. Summary of Cumulative Dose in All Treatment Episodes for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Cumulative Episode Duration[1]

	Number of Patients by Cumulative Filled Dose[2]										
		<=7300 mg		7301-14600 mg		14601-29200 mg		29201-43800 mg		43801-58400 mg	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Prevalent Use - All Censoring Options											
Any valsartan product	*1,771,282*	*490,758*	*100.0%*	*230,350*	*100.0%*	*237,570*	*100.0%*	*130,727*	*100.0%*	*105,477*	*100.0%*
0-90 days	580,648	426,819	87.0%	109,564	47.6%	43,914	18.5%	285	0.2%	*****	*****
91-182 days	253,239	57,482	11.7%	78,934	34.3%	80,560	33.9%	25,087	19.2%	10,916	10.3%
183-364 days	277,019	6,298	1.3%	37,669	16.4%	80,160	33.7%	58,343	44.6%	42,668	40.5%
365-547 days	169,927	*****	*****	3,654	1.6%	23,656	10.0%	27,470	21.0%	23,948	22.7%
548-729 days	121,351	*****	*****	457	0.2%	7,087	3.0%	10,999	8.4%	15,643	14.8%
730+ days	369,098	*****	*****	*****	*****	2,193	0.9%	8,543	6.5%	12,245	11.6%
Contaminated valsartan	*1,054,228*	*211,824*	*100.0%*	*137,348*	*100.0%*	*156,098*	*100.0%*	*84,013*	*100.0%*	*76,056*	*100.0%*
0-90 days	304,673	189,225	89.3%	76,820	55.9%	38,493	24.7%	110	0.1%	25	0.0%
91-182 days	156,947	20,417	9.6%	45,129	32.9%	59,463	38.1%	19,818	23.6%	11,989	15.8%
183-364 days	176,161	2,132	1.0%	13,819	10.1%	44,762	28.7%	38,623	46.0%	32,541	42.8%
365-547 days	118,001	*****	*****	1,419	1.0%	9,744	6.2%	16,802	20.0%	14,949	19.7%
548-729 days	91,381	*****	*****	135	0.1%	2,765	1.8%	5,178	6.2%	11,266	14.8%
730+ days	207,065	*****	*****	*****	*****	871	0.6%	3,482	4.1%	5,286	7.0%
Non-contaminated valsartan	*1,698,545*	*466,608*	*100.0%*	*238,689*	*100.0%*	*254,653*	*100.0%*	*138,534*	*100.0%*	*110,290*	*100.0%*
0-90 days	579,704	406,756	87.2%	118,925	49.8%	53,014	20.8%	812	0.6%	*****	*****
91-182 days	272,892	53,999	11.6%	80,327	33.7%	91,135	35.8%	31,370	22.6%	15,522	14.1%
183-364 days	298,888	5,707	1.2%	35,729	15.0%	80,934	31.8%	63,058	45.5%	49,055	44.5%
365-547 days	179,294	*****	*****	3,274	1.4%	21,987	8.6%	27,714	20.0%	22,370	20.3%
548-729 days	112,848	*****	*****	383	0.2%	5,975	2.3%	9,271	6.7%	14,229	12.9%
730+ days	254,919	*****	*****	*****	*****	1,608	0.6%	6,309	4.6%	8,927	8.1%
New Use - All Censoring Options											
Any valsartan product	*1,071,474*	*457,953*	*100.0%*	*173,170*	*100.0%*	*140,985*	*100.0%*	*62,852*	*100.0%*	*47,272*	*100.0%*
0-90 days	522,734	406,107	88.7%	87,276	50.4%	29,118	20.7%	190	0.3%	*****	*****
91-182 days	176,013	48,110	10.5%	60,986	35.2%	50,306	35.7%	11,410	18.2%	5,075	10.7%
183-364 days	147,287	3,687	0.8%	23,232	13.4%	46,380	32.9%	30,511	48.5%	20,921	44.3%
365-547 days	73,998	*****	*****	1,544	0.9%	11,530	8.2%	13,099	20.8%	9,705	20.5%

Sentinel

Table 8b. Summary of Cumulative Dose in All Treatment Episodes for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Cumulative Episode Duration[1]

	Number of Patients by Cumulative Filled Dose[2]										
		<=7300 mg		7301-14600 mg		14601-29200 mg		29201-43800 mg		43801-58400 mg	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
548-729 days	45,983	*****	*****	108	0.1%	3,040	2.2%	4,124	6.6%	7,446	15.8%
730+ days	105,459	*****	*****	*****	*****	611	0.4%	3,518	5.6%	4,087	8.6%
Contaminated valsartan	*265,082*	*104,079*	*100.0%*	*50,931*	*100.0%*	*41,089*	*100.0%*	*17,300*	*100.0%*	*13,546*	*100.0%*
0-90 days	130,652	93,060	89.4%	28,162	55.3%	9,391	22.9%	*****	*****	*****	*****
91-182 days	51,092	10,287	9.9%	18,104	35.5%	16,890	41.1%	3,758	21.7%	2,026	15.0%
183-364 days	40,772	*****	*****	4,343	8.5%	12,190	29.7%	9,273	53.6%	6,878	50.8%
365-547 days	19,961	*****	*****	299	0.6%	2,037	5.0%	3,369	19.5%	2,528	18.7%
548-729 days	11,214	0	0.0%	*****	*****	524	1.3%	595	3.4%	1,760	13.0%
730+ days	11,391	0	0.0%	*****	*****	57	0.1%	271	1.6%	*****	*****
Non-contaminated valsartan	*749,276*	*361,635*	*100.0%*	*127,471*	*100.0%*	*99,551*	*100.0%*	*40,954*	*100.0%*	*29,770*	*100.0%*
0-90 days	406,148	321,520	88.9%	63,930	50.2%	20,564	20.7%	107	0.3%	*****	*****
91-182 days	130,137	37,448	10.4%	44,802	35.1%	36,406	36.6%	7,587	18.5%	3,828	12.9%
183-364 days	101,812	2,629	0.7%	17,656	13.9%	32,309	32.5%	20,552	50.2%	13,900	46.7%
365-547 days	45,379	*****	*****	1,006	0.8%	8,129	8.2%	8,108	19.8%	5,833	19.6%
548-729 days	24,707	*****	*****	62	0.0%	1,823	1.8%	2,626	6.4%	3,967	13.3%
730+ days	41,093	0	0.0%	15	0.0%	320	0.3%	1,974	4.8%	2,219	7.5%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, or Episode End Date											
Contaminated valsartan	*1,054,228*	*102,775*	*100.0%*	*117,188*	*100.0%*	*153,484*	*100.0%*	*88,359*	*100.0%*	*87,674*	*100.0%*
0-90 days	115,744	69,305	67.4%	36,164	30.9%	10,246	6.7%	*****	*****	*****	*****
91-182 days	175,845	29,925	29.1%	58,962	50.3%	67,319	43.9%	15,074	17.1%	*****	*****
183-364 days	209,339	3,441	3.3%	19,515	16.7%	57,209	37.3%	43,124	48.8%	40,495	46.2%
365-547 days	143,425	*****	*****	2,323	2.0%	13,643	8.9%	17,385	19.7%	22,877	26.1%
548-729 days	112,269	*****	*****	171	0.1%	3,514	2.3%	8,108	9.2%	11,056	12.6%
730+ days	297,606	*****	*****	*****	*****	1,553	1.0%	4,645	5.3%	8,736	10.0%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, or Episode End Date											
Contaminated valsartan	*265,082*	*61,931*	*100.0%*	*49,932*	*100.0%*	*47,586*	*100.0%*	*22,563*	*100.0%*	*19,530*	*100.0%*
0-90 days	65,157	44,891	72.5%	17,083	34.2%	*****	*****	*****	*****	*****	*****
91-182 days	69,034	15,576	25.2%	25,373	50.8%	22,375	47.0%	4,416	19.6%	1,266	6.5%

Sentinel

Table 8b. Summary of Cumulative Dose in All Treatment Episodes for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Cumulative Episode Duration[1]

	Number of Patients by Cumulative Filled Dose[2]										
		<=7300 mg		7301-14600 mg		14601-29200 mg		29201-43800 mg		43801-58400 mg	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
183-364 days	60,160	1,444	2.3%	6,842	13.7%	17,688	37.2%	12,328	54.6%	10,746	55.0%
365-547 days	30,449	*****	*****	591	1.2%	3,322	7.0%	4,002	17.7%	4,668	23.9%
548-729 days	18,800	*****	*****	*****	*****	857	1.8%	1,328	5.9%	2,105	10.8%
730+ days	21,482	0	0.0%	*****	*****	170	0.4%	*****	*****	*****	*****
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, Switch to Unclassified Valsartan, or Episode End Date											
Contaminated valsartan	*1,054,228*	*130,978*	*100.0%*	*122,641*	*100.0%*	*155,244*	*100.0%*	*87,098*	*100.0%*	*86,513*	*100.0%*
0-90 days	173,382	101,575	77.6%	50,238	41.0%	21,513	13.9%	44	0.1%	12	0.0%
91-182 days	167,966	26,204	20.0%	52,651	42.9%	63,993	41.2%	15,424	17.7%	9,597	11.1%
183-364 days	204,744	3,108	2.4%	17,480	14.3%	52,937	34.1%	42,795	49.1%	39,027	45.1%
365-547 days	139,962	*****	*****	2,064	1.7%	12,214	7.9%	17,829	20.5%	19,494	22.5%
548-729 days	105,928	*****	*****	163	0.1%	3,272	2.1%	6,795	7.8%	11,215	13.0%
730+ days	262,246	*****	*****	*****	*****	1,315	0.8%	4,211	4.8%	7,168	8.3%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, Switch to Unclassified Valsartan, or Episode End Date											
Contaminated valsartan	*265,082*	*64,985*	*100.0%*	*50,118*	*100.0%*	*47,533*	*100.0%*	*22,374*	*100.0%*	*19,305*	*100.0%*
0-90 days	72,839	49,181	75.7%	19,114	38.1%	4,533	9.5%	*****	*****	*****	*****
91-182 days	67,096	14,479	22.3%	24,013	47.9%	22,165	46.6%	4,418	19.7%	1,985	10.3%
183-364 days	59,039	1,307	2.0%	6,411	12.8%	16,824	35.4%	12,381	55.3%	10,454	54.2%
365-547 days	29,140	18	0.0%	539	1.1%	3,054	6.4%	3,974	17.8%	4,158	21.5%
548-729 days	17,843	0	0.0%	*****	*****	808	1.7%	1,157	5.2%	2,058	10.7%
730+ days	19,125	0	0.0%	*****	*****	149	0.3%	*****	*****	*****	*****
Date											
Non-contaminated valsartan	*1,698,545*	*275,647*	*100.0%*	*225,227*	*100.0%*	*272,341*	*100.0%*	*159,745*	*100.0%*	*133,103*	*100.0%*
0-90 days	303,295	198,612	72.1%	75,450	33.5%	28,537	10.5%	543	0.3%	*****	*****
91-182 days	309,665	69,100	25.1%	95,515	42.4%	101,746	37.4%	28,978	18.1%	13,831	10.4%
183-364 days	364,877	7,717	2.8%	49,182	21.8%	99,481	36.5%	73,285	45.9%	59,267	44.5%
365-547 days	227,248	207	0.1%	4,482	2.0%	31,593	11.6%	33,640	21.1%	28,640	21.5%
548-729 days	147,785	*****	*****	529	0.2%	8,651	3.2%	13,557	8.5%	17,672	13.3%
730+ days	345,675	*****	*****	*****	*****	2,333	0.9%	9,742	6.1%	13,543	10.2%

Sentinel

Table 8b. Summary of Cumulative Dose in All Treatment Episodes for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Cumulative Episode Duration[1]

	Number of Patients by Cumulative Filled Dose[2]										
		<=7300 mg		7301-14600 mg		14601-29200 mg		29201-43800 mg		43801-58400 mg	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, Switch to Unclassified Valsartan, or Episode End Date											
Non-contaminated valsartan	*749,276*	*220,540*	*100.0%*	*137,035*	*100.0%*	*127,957*	*100.0%*	*61,414*	*100.0%*	*46,641*	*100.0%*
0-90 days	210,281	159,072	72.1%	41,342	30.2%	9,829	7.7%	*****	*****	*****	*****
91-182 days	186,072	57,176	25.9%	63,466	46.3%	50,504	39.5%	9,991	16.3%	4,835	10.4%
183-364 days	159,008	4,227	1.9%	30,422	22.2%	48,782	38.1%	29,944	48.8%	21,647	46.4%
365-547 days	75,676	*****	*****	1,667	1.2%	15,087	11.8%	12,422	20.2%	9,537	20.4%
548-729 days	42,444	*****	*****	117	0.1%	3,211	2.5%	5,265	8.6%	6,062	13.0%
730+ days	75,795	0	0.0%	21	0.0%	544	0.4%	3,762	6.1%	*****	*****

Sentinel

Table 8b. Summary of Cumulative Dose in All Treatment Episodes for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Cumulative Episode Duration[1]

	58401-116800 mg		116801-175200 mg		175201-233600 mg		233601+ mg		Distribution of Cumulative Filled Dose			
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Minimum	Maximum	Mean	Standard Deviation
Prevalent Use - All Censoring Options												
Any valsartan product	*235,277*	*100.0%*	*122,533*	*100.0%*	*72,963*	*100.0%*	*145,627*	*100.0%*	*0.4*	*57,686,400.0*	*73,083.5*	*140,702.2*
0-90 days	*****	*****	0	0.0%	0	0.0%	*****	*****	0.4	9,610,560.0	5,564.6	16,708.6
91-182 days	*****	*****	0	0.0%	0	0.0%	*****	*****	360.0	28,800,000.0	18,201.1	63,362.0
183-364 days	51,641	21.9%	227	0.2%	*****	*****	*****	*****	510.0	28,857,600.0	39,674.4	88,747.6
365-547 days	64,608	27.5%	26,214	21.4%	*****	*****	15	0.0%	2,880.0	57,686,400.0	70,554.5	165,424.8
548-729 days	49,398	21.0%	20,424	16.7%	17,128	23.5%	*****	*****	2,520.0	28,980,800.0	103,068.0	177,312.9
730+ days	69,371	29.5%	75,668	61.8%	55,621	76.2%	145,384	99.8%	4,640.0	1,302,720.0	233,336.9	164,604.6
Contaminated valsartan	*170,523*	*100.0%*	*92,558*	*100.0%*	*50,858*	*100.0%*	*74,950*	*100.0%*	*0.4*	*1,083,520.0*	*72,293.9*	*93,449.7*
0-90 days	0	0.0%	0	0.0%	0	0.0%	0	0.0%	0.4	57,600.0	7,223.8	6,708.6
91-182 days	131	0.1%	0	0.0%	0	0.0%	0	0.0%	320.0	108,480.0	21,950.8	12,777.9
183-364 days	44,175	25.9%	*****	*****	*****	*****	*****	*****	1,500.0	672,000.0	45,860.6	25,603.0
365-547 days	48,600	28.5%	26,309	28.4%	*****	*****	*****	*****	3,573.3	305,920.0	79,868.4	41,394.9
548-729 days	37,607	22.1%	13,923	15.0%	20,351	40.0%	*****	*****	5,970.0	454,400.0	116,195.5	57,991.0
730+ days	40,010	23.5%	52,223	56.4%	30,381	59.7%	74,785	99.8%	6,520.0	1,083,520.0	204,992.5	118,973.4
Non-contaminated valsartan	*229,228*	*100.0%*	*107,717*	*100.0%*	*61,395*	*100.0%*	*91,431*	*100.0%*	*8.7*	*57,600,000.0*	*59,965.3*	*120,451.7*
0-90 days	*****	*****	0	0.0%	0	0.0%	*****	*****	8.7	9,610,560.0	6,114.7	16,547.2
91-182 days	*****	*****	*****	*****	0	0.0%	*****	*****	360.0	28,800,000.0	19,534.4	61,256.9
183-364 days	64,032	27.9%	*****	*****	*****	*****	*****	*****	510.0	57,600,000.0	42,245.0	125,628.0
365-547 days	68,596	29.9%	34,902	32.4%	*****	*****	22	0.0%	1,800.0	28,915,200.0	74,447.0	88,434.8
548-729 days	45,719	19.9%	17,618	16.4%	19,414	31.6%	*****	*****	4,568.6	28,980,800.0	107,381.2	181,176.9
730+ days	50,343	22.0%	54,836	50.9%	41,688	67.9%	91,156	99.7%	7,210.7	1,287,040.0	215,308.0	140,133.2
New Use - All Censoring Options												
Any valsartan product	*91,201*	*100.0%*	*40,897*	*100.0%*	*21,805*	*100.0%*	*35,339*	*100.0%*	*8.7*	*57,657,600.0*	*39,806.4*	*108,210.6*
0-90 days	0	0.0%	0	0.0%	0	0.0%	*****	*****	8.7	3,323,320.0	4,940.1	7,842.8
91-182 days	*****	*****	0	0.0%	0	0.0%	*****	*****	548.0	28,800,000.0	16,459.3	75,439.2
183-364 days	22,444	24.6%	*****	*****	*****	*****	*****	*****	160.0	14,414,400.0	37,024.8	52,509.8
365-547 days	27,106	29.7%	10,870	26.6%	*****	*****	*****	*****	3,360.0	57,657,600.0	68,417.0	215,387.0

Sentinel

Table 8b. Summary of Cumulative Dose in All Treatment Episodes for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Cumulative Episode Duration[1]

	58401-116800 mg		116801-175200 mg		175201-233600 mg		233601+ mg		Distribution of Cumulative Filled Dose			
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Minimum	Maximum	Mean	Standard Deviation
548-729 days	18,581	20.4%	5,579	13.6%	7,007	32.1%	*****	*****	5,520.0	28,980,800.0	101,312.2	171,119.4
730+ days	22,946	25.2%	24,342	59.5%	14,699	67.4%	35,230	99.7%	4,160.0	1,302,720.0	208,587.3	149,698.2
Contaminated valsartan	*22,884*	*100.0%*	*8,322*	*100.0%*	*3,725*	*100.0%*	*3,206*	*100.0%*	*17.1*	*734,400.0*	*30,499.8*	*50,472.2*
0-90 days	0	0.0%	0	0.0%	0	0.0%	0	0.0%	17.1	54,400.0	5,847.3	5,556.9
91-182 days	27	0.1%	0	0.0%	0	0.0%	0	0.0%	1,200.0	96,000.0	18,158.8	11,402.6
183-364 days	7,343	32.1%	18	0.2%	*****	*****	0	0.0%	1,920.0	186,240.0	40,635.5	23,928.4
365-547 days	8,094	35.4%	3,610	43.4%	*****	*****	*****	*****	3,573.3	239,040.0	73,657.8	40,186.6
548-729 days	4,860	21.2%	1,344	16.1%	2,102	56.4%	*****	*****	10,800.0	311,680.0	108,067.9	56,363.9
730+ days	2,560	11.2%	3,350	40.3%	1,605	43.1%	3,195	99.7%	14,400.0	734,400.0	180,340.4	103,500.5
Non-contaminated valsartan	*51,569*	*100.0%*	*19,764*	*100.0%*	*9,125*	*100.0%*	*9,437*	*100.0%*	*8.7*	*57,600,000.0*	*26,726.4*	*99,764.7*
0-90 days	0	0.0%	0	0.0%	0	0.0%	*****	*****	8.7	1,761,760.0	4,728.4	6,563.5
91-182 days	*****	*****	0	0.0%	0	0.0%	*****	*****	720.0	28,800,000.0	16,282.4	87,489.2
183-364 days	14,706	28.5%	*****	*****	0	0.0%	*****	*****	160.0	57,600,000.0	36,738.3	186,446.0
365-547 days	16,045	31.1%	6,178	31.3%	44	0.5%	*****	*****	3,360.0	250,240.0	65,456.5	39,404.6
548-729 days	10,023	19.4%	2,664	13.5%	3,499	38.3%	*****	*****	5,520.0	28,980,800.0	98,389.4	217,604.9
730+ days	10,731	20.8%	10,867	55.0%	5,582	61.2%	9,385	99.4%	9,360.0	1,096,640.0	166,559.0	104,139.2
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, or Episode End Date												
Contaminated valsartan	*203,630*	*100.0%*	*117,586*	*100.0%*	*69,399*	*100.0%*	*114,133*	*100.0%*	*40.0*	*1,286,400.0*	*96,247.8*	*106,641.9*
0-90 days	0	0.0%	0	0.0%	0	0.0%	0	0.0%	40.0	57,600.0	7,107.7	5,311.0
91-182 days	61	0.0%	0	0.0%	0	0.0%	0	0.0%	40.0	99,840.0	19,351.3	10,857.0
183-364 days	45,473	22.3%	*****	*****	*****	*****	*****	*****	1,680.0	672,000.0	44,035.8	24,301.2
365-547 days	58,960	29.0%	28,001	23.8%	*****	*****	*****	*****	3,360.0	345,600.0	78,670.4	40,182.2
548-729 days	44,447	21.8%	23,530	20.0%	21,316	30.7%	*****	*****	3,800.0	417,600.0	115,019.4	56,224.4
730+ days	54,689	26.9%	65,977	56.1%	47,962	69.1%	113,990	99.9%	6,960.0	1,286,400.0	214,467.5	123,817.0
New Use - Censoring on Query/Data End Date, Disenrollment, Death, or Episode End Date												
Contaminated valsartan	*35,257*	*100.0%*	*14,565*	*100.0%*	*6,990*	*100.0%*	*6,728*	*100.0%*	*40.0*	*816,000.0*	*47,402.0*	*64,804.7*
0-90 days	0	0.0%	0	0.0%	0	0.0%	0	0.0%	40.0	51,840.0	6,035.8	4,441.9
91-182 days	28	0.1%	0	0.0%	0	0.0%	0	0.0%	920.0	99,840.0	17,273.7	10,398.8

Sentinel

Table 8b. Summary of Cumulative Dose in All Treatment Episodes for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Cumulative Episode Duration[1]

	58401-116800 mg		116801-175200 mg		175201-233600 mg		233601+ mg		Distribution of Cumulative Filled Dose			
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Minimum	Maximum	Mean	Standard Deviation
183-364 days	11,084	31.4%	*****	*****	*****	*****	0	0.0%	1,920.0	211,200.0	41,186.4	23,938.9
365-547 days	12,076	34.3%	5,738	39.4%	*****	*****	*****	*****	6,000.0	263,040.0	75,938.4	40,406.8
548-729 days	7,573	21.5%	3,375	23.2%	3,507	50.2%	*****	*****	3,800.0	336,000.0	112,294.7	56,710.5
730+ days	4,496	12.8%	5,426	37.3%	3,450	49.4%	6,707	99.7%	14,400.0	816,000.0	189,857.1	107,328.3
Episode End Date												
Contaminated valsartan	*196,673*	*100.0%*	*111,552*	*100.0%*	*63,352*	*100.0%*	*100,177*	*100.0%*	*2.2*	*1,083,520.0*	*88,597.7*	*101,633.1*
0-90 days	0	0.0%	0	0.0%	0	0.0%	0	0.0%	2.2	57,600.0	7,701.8	6,562.1
91-182 days	97	0.0%	0	0.0%	0	0.0%	0	0.0%	320.0	99,840.0	20,705.9	12,150.5
183-364 days	49,279	25.1%	*****	*****	*****	*****	*****	*****	1,620.0	672,000.0	45,587.2	25,381.0
365-547 days	57,279	29.1%	30,829	27.6%	*****	*****	*****	*****	3,360.0	345,600.0	80,693.5	41,430.0
548-729 days	41,812	21.3%	19,962	17.9%	22,557	35.6%	*****	*****	5,840.0	417,600.0	117,198.1	57,466.3
730+ days	48,206	24.5%	60,648	54.4%	40,647	64.2%	100,005	99.8%	6,960.0	1,083,520.0	211,811.3	121,020.1
End Date												
Contaminated valsartan	*34,453*	*100.0%*	*13,767*	*100.0%*	*6,599*	*100.0%*	*5,948*	*100.0%*	*40.0*	*734,400.0*	*45,271.2*	*62,147.0*
0-90 days	0	0.0%	0	0.0%	0	0.0%	0	0.0%	40.0	54,400.0	6,314.9	5,026.1
91-182 days	36	0.1%	0	0.0%	0	0.0%	0	0.0%	920.0	99,840.0	17,873.2	10,994.8
183-364 days	11,629	33.8%	*****	*****	*****	*****	0	0.0%	1,920.0	211,200.0	42,062.7	24,587.5
365-547 days	11,617	33.7%	5,744	41.7%	*****	*****	*****	*****	3,573.3	263,040.0	76,726.1	41,014.1
548-729 days	7,194	20.9%	3,002	21.8%	3,572	54.1%	*****	*****	10,200.0	311,680.0	113,606.3	57,323.3
730+ days	3,977	11.5%	4,991	36.3%	2,990	45.3%	5,927	99.6%	14,400.0	734,400.0	187,983.6	105,148.0
Episode End Date												
Non-contaminated valsartan	*285,093*	*100.0%*	*139,739*	*100.0%*	*81,244*	*100.0%*	*126,406*	*100.0%*	*20.0*	*57,600,000.0*	*76,805.8*	*132,027.5*
0-90 days	0	0.0%	0	0.0%	0	0.0%	*****	*****	20.0	5,285,280.0	6,832.1	12,667.9
91-182 days	*****	*****	*****	*****	0	0.0%	*****	*****	360.0	28,800,000.0	18,587.7	57,565.4
183-364 days	75,492	26.5%	*****	*****	*****	*****	*****	*****	510.0	57,600,000.0	41,451.8	114,232.8
365-547 days	84,572	29.7%	43,681	31.3%	*****	*****	39	0.0%	1,800.0	28,915,200.0	74,112.4	102,337.1
548-729 days	56,720	19.9%	24,886	17.8%	25,419	31.3%	*****	*****	4,568.6	28,980,800.0	107,373.7	176,165.9
730+ days	67,817	23.8%	70,734	50.6%	55,423	68.2%	126,013	99.7%	7,210.7	1,288,000.0	216,373.9	142,348.2

Sentinel

Table 8b. Summary of Cumulative Dose in All Treatment Episodes for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Cumulative Episode Duration[1]

	58401-116800 mg		116801-175200 mg		175201-233600 mg		233601+ mg		Distribution of Cumulative Filled Dose			
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Minimum	Maximum	Mean	Standard Deviation
Episode End Date												
Non-contaminated valsartan	*84,772*	*100.0%*	*34,782*	*100.0%*	*17,022*	*100.0%*	*19,113*	*100.0%*	*13.0*	*57,600,000.0*	*42,839.5*	*116,603.7*
0-90 days	0	0.0%	0	0.0%	0	0.0%	0	0.0%	13.0	57,600.0	5,299.4	4,828.4
91-182 days	*****	*****	0	0.0%	0	0.0%	*****	*****	720.0	28,800,000.0	15,903.9	73,408.7
183-364 days	23,878	28.2%	*****	*****	*****	*****	*****	*****	160.0	57,600,000.0	36,393.3	149,945.7
365-547 days	25,737	30.4%	11,040	31.7%	*****	*****	*****	*****	3,360.0	28,905,600.0	66,569.5	112,665.6
548-729 days	15,870	18.7%	5,343	15.4%	6,467	38.0%	*****	*****	5,520.0	28,980,800.0	99,975.8	211,365.1
730+ days	19,189	22.6%	18,298	52.6%	10,437	61.3%	18,992	99.4%	9,360.0	1,172,800.0	170,949.0	108,053.7

[*]Cumulative dose is calculated after dispensings are stockpiled by multiplying the drug strength by the amount dispensed in each dispensing and summing over all dispensings identified by the relevant drug code(s).

[1]Treatment episode duration was calculated based on time-on-treatment for each episode; episodes were censored at the end of the treatment episode.

[2]Cumulative dose categories determined by using 80mg as a maximum daily dose for diuretic combination products and 320 mg as a maximum daily dose for single valsartan products, and assuming <6, 6-12, 13-18, 19-24 and 25+ exposure months.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Sentinel

Table 9a. Summary of Cumulative Dose in Each Patient's First Treatment Episode for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

	Number of Patients by Cumulative Filled Dose[1] in First Treatment Episode								
		<=7300 mg		7301-14600 mg		14601-29200 mg		29201-43800 mg	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Prevalent Use - All Censoring Options									
Any valsartan product	1,771,282	644,212	36.4%	306,056	17.3%	261,234	14.7%	106,295	6.0%
Contaminated valsartan	1,054,228	297,064	28.2%	194,751	18.5%	183,101	17.4%	67,426	6.4%
Non-contaminated valsartan	1,698,545	621,125	36.6%	312,277	18.4%	275,883	16.2%	112,943	6.6%
New Use - All Censoring Options									
Any valsartan product	1,071,474	467,721	43.7%	174,755	16.3%	139,146	13.0%	60,531	5.6%
Contaminated valsartan	265,082	104,814	39.5%	51,091	19.3%	40,864	15.4%	17,081	6.4%
Non-contaminated valsartan	749,276	366,040	48.9%	127,854	17.1%	98,433	13.1%	39,855	5.3%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, or Episode End Date									
Contaminated valsartan	1,054,228	164,184	15.6%	188,269	17.9%	200,764	19.0%	80,339	7.6%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, or Episode End Date									
Contaminated valsartan	265,082	62,600	23.6%	50,249	19.0%	47,426	17.9%	22,322	8.4%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, Switch to Unclassified Valsartan, or Episode End Date									
Contaminated valsartan	1,054,228	203,757	19.3%	189,752	18.0%	196,054	18.6%	76,061	7.2%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, Switch to Unclassified Valsartan, or Episode End Date									
Contaminated valsartan	265,082	65,667	24.8%	50,425	19.0%	47,352	17.9%	22,132	8.3%
Date									
Non-contaminated valsartan	1,698,545	405,238	23.9%	320,037	18.8%	317,833	18.7%	143,616	8.5%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, Switch to Unclassified Valsartan, or Episode End Date									
Non-contaminated valsartan	749,276	224,767	30.0%	138,295	18.5%	127,419	17.0%	60,252	8.0%

Sentinel

Table 9a. Summary of Cumulative Dose in Each Patient's First Treatment Episode for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

	Number of Patients by Cumulative Filled Dose[1] in First Treatment Episode									
	43801-58400 mg		58401-116800 mg		116801-175200 mg		175201-233600 mg		233601+ mg	
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Prevalent Use - All Censoring Options										
Any valsartan product	90,004	5.1%	167,215	9.4%	76,486	4.3%	42,580	2.4%	77,200	4.4%
Contaminated valsartan	66,484	6.3%	119,485	11.3%	55,942	5.3%	29,103	2.8%	40,872	3.9%
Non-contaminated valsartan	90,321	5.3%	154,338	9.1%	61,498	3.6%	31,729	1.9%	38,431	2.3%
New Use - All Censoring Options										
Any valsartan product	46,002	4.3%	88,339	8.2%	39,635	3.7%	21,076	2.0%	34,269	3.2%
Contaminated valsartan	13,410	5.1%	22,674	8.6%	8,252	3.1%	3,707	1.4%	3,189	1.2%
Non-contaminated valsartan	29,200	3.9%	50,391	6.7%	19,384	2.6%	8,895	1.2%	9,224	1.2%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, or Episode End Date										
Contaminated valsartan	84,139	8.0%	154,354	14.6%	75,917	7.2%	41,972	4.0%	64,290	6.1%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, or Episode End Date										
Contaminated valsartan	19,390	7.3%	34,995	13.2%	14,447	5.5%	6,957	2.6%	6,696	2.5%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, Switch to Unclassified Valsartan, or Episode End Date										
Contaminated valsartan	80,208	7.6%	144,941	13.7%	70,340	6.7%	37,389	3.5%	55,726	5.3%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, Switch to Unclassified Valsartan, or Episode End Date										
Contaminated valsartan	19,165	7.2%	34,199	12.9%	13,656	5.2%	6,568	2.5%	5,918	2.2%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, Switch to Unclassified Valsartan, or Episode End Date										
Non-contaminated valsartan	116,796	6.9%	206,678	12.2%	85,866	5.1%	45,135	2.7%	57,346	3.4%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, Switch to Unclassified Valsartan, or Episode End Date										
Non-contaminated valsartan	46,024	6.1%	83,087	11.1%	34,109	4.6%	16,642	2.2%	18,681	2.5%

Sentinel

Table 9a. Summary of Cumulative Dose in Each Patient's First Treatment Episode for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

Number of Patients by Cumulative Filled Dose[1] in First Treatment Episode				
	Distribution of Cumulative Filled Dose			
	Minimum	Maximum	Mean	Standard Deviation
Prevalent Use - All Censoring Options				
Any valsartan product	0.4	57,657,600.0	47,641.3	119,687.4
Contaminated valsartan	0.4	948,480.0	48,898.4	75,824.6
Non-contaminated valsartan	8.7	57,600,000.0	37,208.0	101,011.7
New Use - All Censoring Options				
Any valsartan product	8.7	57,657,600.0	38,801.7	107,556.6
Contaminated valsartan	17.1	734,400.0	30,307.5	50,358.1
Non-contaminated valsartan	8.7	57,600,000.0	26,279.0	99,545.7
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, or Episode End Date				
Contaminated valsartan	40.0	1,003,200.0	66,842.5	88,966.1
New Use - Censoring on Query/Data End Date, Disenrollment, Death, or Episode End Date				
Contaminated valsartan	40.0	816,000.0	47,145.1	64,701.9
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, Switch to Unclassified Valsartan, or Episode End Date				
Contaminated valsartan	2.2	948,480.0	60,875.8	84,229.5
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, Switch to Unclassified Valsartan, or Episode End Date				
Contaminated valsartan	40.0	734,400.0	45,023.2	62,041.0
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, Switch to Unclassified Valsartan, or Episode End Date				
Non-contaminated valsartan	20.0	57,600,000.0	49,458.7	111,630.4
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, Switch to Unclassified Valsartan, or Episode End Date				
Non-contaminated valsartan	13.0	57,600,000.0	42,169.2	116,313.2

*Cumulative dose is calculated after dispensings are stockpiled by multiplying the drug strength by the amount dispensed in each dispensing and summing over all dispensings identified by the relevant drug code(s).

[1]Cumulative dose categories determined by using 80mg as a maximum daily dose for diuretic combination products and 320 mg as a maximum daily dose for single valsartan products, and assuming <6, 6-12, 13-18, 19-24 and 25+ exposure months.

Sentinel

Table 9b. Summary of Cumulative Dose in Each Patient's First Treatment Episode for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Episode Duration[1]

	Number of Patients by Cumulative Filled Dose[2] in First Treatment Episode										
		<=7300 mg		7301-14600 mg		14601-29200 mg		29201-43800 mg		43801-58400 mg	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
Prevalent Use - All Censoring Options											
Any valsartan product	1,771,282	644,212	100.0%	306,056	100.0%	261,234	100.0%	106,295	100.0%	90,004	100.0%
0-90 days	757,837	560,943	87.1%	148,384	48.5%	48,130	18.4%	304	0.3%	*****	*****
91-182 days	340,451	77,619	12.0%	119,730	39.1%	111,409	42.6%	21,514	20.2%	9,938	11.0%
183-364 days	264,942	5,551	0.9%	35,417	11.6%	79,692	30.5%	53,290	50.1%	44,021	48.9%
365-547 days	130,408	*****	*****	2,278	0.7%	16,908	6.5%	20,105	18.9%	18,305	20.3%
548-729 days	80,625	*****	*****	209	0.1%	4,159	1.6%	6,471	6.1%	11,476	12.8%
730+ days	197,019	*****	*****	*****	*****	936	0.4%	4,611	4.3%	6,197	6.9%
Contaminated valsartan	1,054,228	297,064	100.0%	194,751	100.0%	183,101	100.0%	67,426	100.0%	66,484	100.0%
0-90 days	416,399	262,580	88.4%	107,862	55.4%	45,812	25.0%	113	0.2%	32	0.0%
91-182 days	213,463	32,326	10.9%	71,437	36.7%	81,750	44.6%	15,326	22.7%	12,529	18.8%
183-364 days	170,119	2,133	0.7%	14,425	7.4%	46,348	25.3%	35,438	52.6%	32,657	49.1%
365-547 days	85,825	*****	*****	935	0.5%	7,054	3.9%	11,767	17.5%	10,984	16.5%
548-729 days	57,922	*****	*****	77	0.0%	1,697	0.9%	2,765	4.1%	7,726	11.6%
730+ days	110,500	0	0.0%	15	0.0%	440	0.2%	2,017	3.0%	2,556	3.8%
Non-contaminated valsartan	1,698,545	621,125	100.0%	312,277	100.0%	275,883	100.0%	112,943	100.0%	90,321	100.0%
0-90 days	775,633	546,196	87.9%	164,852	52.8%	63,413	23.0%	921	0.8%	237	0.3%
91-182 days	347,498	70,140	11.3%	113,767	36.4%	118,769	43.1%	29,256	25.9%	15,126	16.7%
183-364 days	270,868	4,701	0.8%	31,594	10.1%	75,351	27.3%	56,128	49.7%	46,775	51.8%
365-547 days	126,006	*****	*****	1,870	0.6%	14,623	5.3%	18,813	16.7%	15,182	16.8%
548-729 days	64,815	*****	*****	172	0.1%	3,132	1.1%	4,849	4.3%	9,075	10.0%
730+ days	113,725	0	0.0%	22	0.0%	595	0.2%	2,976	2.6%	3,926	4.3%
New Use - All Censoring Options											
Any valsartan product	1,071,474	467,721	100.0%	174,755	100.0%	139,146	100.0%	60,531	100.0%	46,002	100.0%
0-90 days	534,450	415,767	88.9%	89,168	51.0%	29,279	21.0%	191	0.3%	*****	*****
91-182 days	175,435	48,327	10.3%	61,249	35.0%	49,911	35.9%	10,770	17.8%	5,055	11.0%
183-364 days	143,307	3,581	0.8%	22,718	13.0%	45,203	32.5%	29,477	48.7%	20,441	44.4%
365-547 days	71,686	*****	*****	1,492	0.9%	11,184	8.0%	12,660	20.9%	9,260	20.1%

Sentinel

Table 9b. Summary of Cumulative Dose in Each Patient's First Treatment Episode for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Episode Duration[1]

	Number of Patients by Cumulative Filled Dose[2] in First Treatment Episode										
		<=7300 mg		7301-14600 mg		14601-29200 mg		29201-43800 mg		43801-58400 mg	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
548-729 days	44,450	*****	*****	104	0.1%	2,984	2.1%	3,988	6.6%	7,251	15.8%
730+ days	102,146	*****	*****	*****	*****	585	0.4%	3,445	5.7%	3,955	8.6%
Contaminated valsartan	265,082	104,814	100.0%	51,091	100.0%	40,864	100.0%	17,081	100.0%	13,410	100.0%
0-90 days	131,614	93,802	89.5%	28,376	55.5%	9,397	23.0%	*****	*****	*****	*****
91-182 days	50,968	10,289	9.8%	18,103	35.4%	16,829	41.2%	3,696	21.6%	2,024	15.1%
183-364 days	40,269	*****	*****	4,294	8.4%	12,032	29.4%	9,152	53.6%	6,799	50.7%
365-547 days	19,777	*****	*****	295	0.6%	2,026	5.0%	3,343	19.6%	2,486	18.5%
548-729 days	11,134	0	0.0%	*****	*****	523	1.3%	586	3.4%	1,751	13.1%
730+ days	11,320	0	0.0%	*****	*****	57	0.1%	270	1.6%	*****	*****
Non-contaminated valsartan	749,276	366,040	100.0%	127,854	100.0%	98,433	100.0%	39,855	100.0%	29,200	100.0%
0-90 days	411,654	326,175	89.1%	64,720	50.6%	20,625	21.0%	107	0.3%	*****	*****
91-182 days	129,246	37,273	10.2%	44,769	35.0%	36,073	36.6%	7,250	18.2%	3,816	13.1%
183-364 days	99,759	2,555	0.7%	17,309	13.5%	31,711	32.2%	20,081	50.4%	13,647	46.7%
365-547 days	44,273	*****	*****	979	0.8%	7,917	8.0%	7,916	19.9%	5,620	19.2%
548-729 days	24,095	*****	*****	62	0.0%	1,795	1.8%	2,558	6.4%	3,907	13.4%
730+ days	40,249	0	0.0%	15	0.0%	312	0.3%	1,943	4.9%	2,187	7.5%
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, or Episode End Date											
Contaminated valsartan	1,054,228	164,184	100.0%	188,269	100.0%	200,764	100.0%	80,339	100.0%	84,139	100.0%
0-90 days	193,986	112,869	68.7%	66,351	35.2%	14,721	7.3%	*****	*****	*****	*****
91-182 days	275,056	47,608	29.0%	97,950	52.0%	106,691	53.1%	17,403	21.7%	5,323	6.3%
183-364 days	228,246	3,636	2.2%	22,117	11.7%	65,268	32.5%	42,725	53.2%	47,592	56.6%
365-547 days	115,678	*****	*****	1,708	0.9%	10,949	5.5%	12,695	15.8%	18,568	22.1%
548-729 days	76,098	*****	*****	110	0.1%	2,307	1.1%	4,722	5.9%	7,991	9.5%
730+ days	165,164	0	0.0%	33	0.0%	828	0.4%	2,758	3.4%	*****	*****
New Use - Censoring on Query/Data End Date, Disenrollment, Death, or Episode End Date											
Contaminated valsartan	265,082	62,600	100.0%	50,249	100.0%	47,426	100.0%	22,322	100.0%	19,390	100.0%
0-90 days	66,137	45,542	72.8%	17,390	34.6%	*****	*****	*****	*****	*****	*****
91-182 days	69,167	15,607	24.9%	25,451	50.6%	22,423	47.3%	4,381	19.6%	1,276	6.6%
183-364 days	59,545	1,431	2.3%	6,780	13.5%	17,481	36.9%	12,174	54.5%	10,658	55.0%

Sentinel

Table 9b. Summary of Cumulative Dose in Each Patient's First Treatment Episode for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Episode Duration[1]

		Number of Patients by Cumulative Filled Dose[2] in First Treatment Episode									
		<=7300 mg		7301-14600 mg		14601-29200 mg		29201-43800 mg		43801-58400 mg	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
365-547 days	30,198	*****	*****	585	1.2%	3,300	7.0%	3,963	17.8%	4,617	23.8%
548-729 days	18,665	*****	*****	*****	*****	856	1.8%	1,315	5.9%	2,097	10.8%
730+ days	21,370	0	0.0%	*****	*****	170	0.4%	*****	*****	*****	*****
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, Switch to Unclassified Valsartan, or Episode End Date											
Contaminated valsartan	1,054,228	203,757	100.0%	189,752	100.0%	196,054	100.0%	76,061	100.0%	80,208	100.0%
0-90 days	279,396	160,743	78.9%	86,334	45.5%	32,235	16.4%	62	0.1%	22	0.0%
91-182 days	248,554	39,881	19.6%	83,649	44.1%	96,393	49.2%	15,986	21.0%	12,546	15.6%
183-364 days	207,244	3,074	1.5%	18,174	9.6%	55,474	28.3%	40,938	53.8%	41,334	51.5%
365-547 days	106,354	*****	*****	1,466	0.8%	9,154	4.7%	12,718	16.7%	14,797	18.4%
548-729 days	68,995	*****	*****	*****	*****	2,081	1.1%	3,884	5.1%	7,713	9.6%
730+ days	143,685	0	0.0%	28	0.0%	717	0.4%	2,473	3.3%	3,796	4.7%
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, Switch to Unclassified Valsartan, or Episode End Date											
Contaminated valsartan	265,082	65,667	100.0%	50,425	100.0%	47,352	100.0%	22,132	100.0%	19,165	100.0%
0-90 days	73,844	49,853	75.9%	19,418	38.5%	4,562	9.6%	*****	*****	*****	*****
91-182 days	67,181	14,502	22.1%	24,083	47.8%	22,184	46.8%	4,380	19.8%	1,996	10.4%
183-364 days	58,421	1,294	2.0%	6,349	12.6%	16,617	35.1%	12,225	55.2%	10,367	54.1%
365-547 days	28,895	18	0.0%	534	1.1%	3,033	6.4%	3,938	17.8%	4,110	21.4%
548-729 days	17,715	0	0.0%	*****	*****	807	1.7%	1,145	5.2%	2,047	10.7%
730+ days	19,026	0	0.0%	*****	*****	149	0.3%	*****	*****	*****	*****
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, Switch to Unclassified Valsartan, or Episode End Date											
Non-contaminated valsartan	1,698,545	405,238	100.0%	320,037	100.0%	317,833	100.0%	143,616	100.0%	116,796	100.0%
0-90 days	472,503	301,674	74.4%	127,194	39.7%	42,699	13.4%	723	0.5%	*****	*****
91-182 days	440,010	96,600	23.8%	142,567	44.5%	148,094	46.6%	35,657	24.8%	16,590	14.2%
183-364 days	357,122	6,833	1.7%	47,281	14.8%	98,320	30.9%	69,856	48.6%	60,764	52.0%
365-547 days	171,567	*****	*****	2,715	0.8%	23,011	7.2%	24,310	16.9%	20,759	17.8%
548-729 days	91,484	*****	*****	*****	*****	4,803	1.5%	8,073	5.6%	11,765	10.1%
730+ days	165,859	0	0.0%	30	0.0%	906	0.3%	4,997	3.5%	6,713	5.7%

Sentinel

Table 9b. Summary of Cumulative Dose in Each Patient's First Treatment Episode for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Episode Duration[1]

	Number of Patients by Cumulative Filled Dose[2] in First Treatment Episode										
		<=7300 mg		7301-14600 mg		14601-29200 mg		29201-43800 mg		43801-58400 mg	
	Total Number of Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, Switch to Unclassified Valsartan, or Episode End Date											
Non-contaminated valsartan	749,276	224,767	100.0%	138,295	100.0%	127,419	100.0%	60,252	100.0%	46,024	100.0%
0-90 days	215,570	163,013	72.5%	42,517	30.7%	10,000	7.8%	*****	*****	*****	*****
91-182 days	187,312	57,559	25.6%	64,034	46.3%	50,892	39.9%	9,842	16.3%	4,885	10.6%
183-364 days	156,727	4,128	1.8%	29,976	21.7%	48,098	37.7%	29,404	48.8%	21,422	46.5%
365-547 days	74,077	*****	*****	1,632	1.2%	14,772	11.6%	12,151	20.2%	9,245	20.1%
548-729 days	41,383	*****	*****	115	0.1%	3,135	2.5%	5,127	8.5%	5,976	13.0%
730+ days	74,207	0	0.0%	21	0.0%	522	0.4%	3,696	6.1%	*****	*****

[*]Cumulative dose is calculated after dispensings are stockpiled by multiplying the drug strength by the amount dispensed in each dispensing and summing over all dispensings identified by the relevant drug code(s).

[1]Treatment episode duration was calculated based on time-on-treatment for each episode; episodes were censored at the end of the treatment episode.

[2]Cumulative dose categories determined by using 80mg as a maximum daily dose for diuretic combination products and 320 mg as a maximum daily dose for single valsartan products, and assuming <6, 6-12, 13-18, 19-24 and 25+ exposure months.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Sentinel

Table 9b. Summary of Cumulative Dose in Each Patient's First Treatment Episode for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Episode Duration[1]

	58401-116800 mg		116801-175200 mg		175201-233600 mg		233601+ mg		Distribution of Cumulative Filled Dose			
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Minimum	Maximum	Mean	Standard Deviation
Prevalent Use - All Censoring Options												
Any valsartan product	167,215	100.0%	76,486	100.0%	42,580	100.0%	77,200	100.0%	0.4	57,657,600.0	47,641.3	119,687.4
0-90 days	*****	*****	0	0.0%	0	0.0%	*****	*****	N/A	N/A	N/A	N/A
91-182 days	*****	*****	0	0.0%	0	0.0%	*****	*****	N/A	N/A	N/A	N/A
183-364 days	46,754	28.0%	203	0.3%	*****	*****	*****	*****	N/A	N/A	N/A	N/A
365-547 days	49,932	29.9%	22,597	29.5%	*****	*****	*****	*****	N/A	N/A	N/A	N/A
548-729 days	32,918	19.7%	10,982	14.4%	14,221	33.4%	*****	*****	N/A	N/A	N/A	N/A
730+ days	37,373	22.4%	42,704	55.8%	28,173	66.2%	76,986	99.7%	N/A	N/A	N/A	N/A
Contaminated valsartan	119,485	100.0%	55,942	100.0%	29,103	100.0%	40,872	100.0%	0.4	948,480.0	48,898.4	75,824.6
0-90 days	0	0.0%	0	0.0%	0	0.0%	0	0.0%	N/A	N/A	N/A	N/A
91-182 days	95	0.1%	0	0.0%	0	0.0%	0	0.0%	N/A	N/A	N/A	N/A
183-364 days	39,028	32.7%	*****	*****	*****	*****	*****	*****	N/A	N/A	N/A	N/A
365-547 days	35,164	29.4%	19,804	35.4%	*****	*****	*****	*****	N/A	N/A	N/A	N/A
548-729 days	24,024	20.1%	6,979	12.5%	14,549	50.0%	*****	*****	N/A	N/A	N/A	N/A
730+ days	21,174	17.7%	29,073	52.0%	14,465	49.7%	40,760	99.7%	N/A	N/A	N/A	N/A
valsartan	154,338	100.0%	61,498	100.0%	31,729	100.0%	38,431	100.0%	8.7	57,600,000.0	37,208.0	101,011.7
0-90 days	*****	*****	0	0.0%	0	0.0%	*****	*****	N/A	N/A	N/A	N/A
91-182 days	*****	*****	*****	*****	0	0.0%	*****	*****	N/A	N/A	N/A	N/A
183-364 days	56,023	36.3%	*****	*****	*****	*****	*****	*****	N/A	N/A	N/A	N/A
365-547 days	48,155	31.2%	27,050	44.0%	*****	*****	14	0.0%	N/A	N/A	N/A	N/A
548-729 days	26,451	17.1%	7,912	12.9%	13,063	41.2%	*****	*****	N/A	N/A	N/A	N/A
730+ days	23,269	15.1%	26,254	42.7%	18,445	58.1%	38,238	99.5%	N/A	N/A	N/A	N/A
New Use - All Censoring Options												
Any valsartan product	88,339	100.0%	39,635	100.0%	21,076	100.0%	34,269	100.0%	8.7	57,657,600.0	38,801.7	107,556.6
0-90 days	0	0.0%	0	0.0%	0	0.0%	*****	*****	N/A	N/A	N/A	N/A
91-182 days	*****	*****	0	0.0%	0	0.0%	*****	*****	N/A	N/A	N/A	N/A
183-364 days	21,777	24.7%	*****	*****	*****	*****	*****	*****	N/A	N/A	N/A	N/A
365-547 days	26,270	29.7%	10,683	27.0%	*****	*****	*****	*****	N/A	N/A	N/A	N/A

Sentinel

Table 9b. Summary of Cumulative Dose in Each Patient's First Treatment Episode for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Episode Duration[1]

	58401-116800 mg		116801-175200 mg		175201-233600 mg		233601+ mg		Distribution of Cumulative Filled Dose			
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Minimum	Maximum	Mean	Standard Deviation
548-729 days	17,956	20.3%	5,218	13.2%	6,851	32.5%	*****	*****	N/A	N/A	N/A	N/A
730+ days	22,215	25.1%	23,630	59.6%	14,129	67.0%	34,161	99.7%	N/A	N/A	N/A	N/A
Contaminated valsartan	22,674	100.0%	8,252	100.0%	3,707	100.0%	3,189	100.0%	17.1	734,400.0	30,307.5	50,358.1
0-90 days	0	0.0%	0	0.0%	0	0.0%	0	0.0%	N/A	N/A	N/A	N/A
91-182 days	27	0.1%	0	0.0%	0	0.0%	0	0.0%	N/A	N/A	N/A	N/A
183-364 days	7,256	32.0%	18	0.2%	*****	*****	0	0.0%	N/A	N/A	N/A	N/A
365-547 days	8,030	35.4%	3,573	43.3%	*****	*****	*****	*****	N/A	N/A	N/A	N/A
548-729 days	4,822	21.3%	1,333	16.2%	2,090	56.4%	*****	*****	N/A	N/A	N/A	N/A
730+ days	2,539	11.2%	3,328	40.3%	1,599	43.1%	3,178	99.7%	N/A	N/A	N/A	N/A
valsartan	50,391	100.0%	19,384	100.0%	8,895	100.0%	9,224	100.0%	8.7	57,600,000.0	26,279.0	99,545.7
0-90 days	0	0.0%	0	0.0%	0	0.0%	*****	*****	N/A	N/A	N/A	N/A
91-182 days	*****	*****	0	0.0%	0	0.0%	*****	*****	N/A	N/A	N/A	N/A
183-364 days	14,397	28.6%	*****	*****	0	0.0%	*****	*****	N/A	N/A	N/A	N/A
365-547 days	15,671	31.1%	6,095	31.4%	40	0.4%	*****	*****	N/A	N/A	N/A	N/A
548-729 days	9,751	19.4%	2,559	13.2%	3,421	38.5%	*****	*****	N/A	N/A	N/A	N/A
730+ days	10,509	20.9%	10,676	55.1%	5,434	61.1%	9,173	99.4%	N/A	N/A	N/A	N/A
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, or Episode End Date												
Contaminated valsartan	154,354	100.0%	75,917	100.0%	41,972	100.0%	64,290	100.0%	40.0	1,003,200.0	66,842.5	88,966.1
0-90 days	0	0.0%	0	0.0%	0	0.0%	0	0.0%	N/A	N/A	N/A	N/A
91-182 days	81	0.1%	0	0.0%	0	0.0%	0	0.0%	N/A	N/A	N/A	N/A
183-364 days	46,822	30.3%	*****	*****	*****	*****	*****	*****	N/A	N/A	N/A	N/A
365-547 days	46,982	30.4%	24,582	32.4%	*****	*****	*****	*****	N/A	N/A	N/A	N/A
548-729 days	30,114	19.5%	13,364	17.6%	17,389	41.4%	*****	*****	N/A	N/A	N/A	N/A
730+ days	30,355	19.7%	37,892	49.9%	24,465	58.3%	64,177	99.8%	N/A	N/A	N/A	N/A
New Use - Censoring on Query/Data End Date, Disenrollment, Death, or Episode End Date												
Contaminated valsartan	34,995	100.0%	14,447	100.0%	6,957	100.0%	6,696	100.0%	40.0	816,000.0	47,145.1	64,701.9
0-90 days	0	0.0%	0	0.0%	0	0.0%	0	0.0%	N/A	N/A	N/A	N/A
91-182 days	29	0.1%	0	0.0%	0	0.0%	0	0.0%	N/A	N/A	N/A	N/A
183-364 days	10,993	31.4%	*****	*****	*****	*****	0	0.0%	N/A	N/A	N/A	N/A

Sentinel

Table 9b. Summary of Cumulative Dose in Each Patient's First Treatment Episode for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Episode Duration[1]

	58401-116800 mg		116801-175200 mg		175201-233600 mg		233601+ mg		Distribution of Cumulative Filled Dose			
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Minimum	Maximum	Mean	Standard Deviation
365-547 days	11,996	34.3%	5,685	39.4%	*****	*****	*****	*****	N/A	N/A	N/A	N/A
548-729 days	7,514	21.5%	3,340	23.1%	3,488	50.1%	*****	*****	N/A	N/A	N/A	N/A
730+ days	4,463	12.8%	5,396	37.4%	3,436	49.4%	6,675	99.7%	N/A	N/A	N/A	N/A
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, Switch to Unclassified Valsartan, or Episode End												
Contaminated valsartan	144,941	100.0%	70,340	100.0%	37,389	100.0%	55,726	100.0%	2.2	948,480.0	60,875.8	84,229.5
0-90 days	0	0.0%	0	0.0%	0	0.0%	0	0.0%	N/A	N/A	N/A	N/A
91-182 days	99	0.1%	0	0.0%	0	0.0%	0	0.0%	N/A	N/A	N/A	N/A
183-364 days	48,138	33.2%	*****	*****	*****	*****	*****	*****	N/A	N/A	N/A	N/A
365-547 days	43,109	29.7%	24,927	35.4%	*****	*****	*****	*****	N/A	N/A	N/A	N/A
548-729 days	27,319	18.8%	10,855	15.4%	16,936	45.3%	104	0.2%	N/A	N/A	N/A	N/A
730+ days	26,276	18.1%	34,454	49.0%	20,332	54.4%	55,609	99.8%	N/A	N/A	N/A	N/A
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, Switch to Unclassified Valsartan, or Episode End Date												
Contaminated valsartan	34,199	100.0%	13,656	100.0%	6,568	100.0%	5,918	100.0%	40.0	734,400.0	45,023.2	62,041.0
0-90 days	0	0.0%	0	0.0%	0	0.0%	0	0.0%	N/A	N/A	N/A	N/A
91-182 days	36	0.1%	0	0.0%	0	0.0%	0	0.0%	N/A	N/A	N/A	N/A
183-364 days	11,536	33.7%	*****	*****	*****	*****	0	0.0%	N/A	N/A	N/A	N/A
365-547 days	11,537	33.7%	5,689	41.7%	*****	*****	*****	*****	N/A	N/A	N/A	N/A
548-729 days	7,140	20.9%	2,970	21.7%	3,554	54.1%	*****	*****	N/A	N/A	N/A	N/A
730+ days	3,950	11.6%	4,967	36.4%	2,977	45.3%	5,897	99.6%	N/A	N/A	N/A	N/A
Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, Switch to Unclassified Valsartan, or Episode End Date												
Non-contaminated valsartan	206,678	100.0%	85,866	100.0%	45,135	100.0%	57,346	100.0%	20.0	57,600,000.0	49,458.7	111,630.4
0-90 days	*****	*****	0	0.0%	0	0.0%	*****	*****	N/A	N/A	N/A	N/A
91-182 days	*****	*****	*****	*****	0	0.0%	*****	*****	N/A	N/A	N/A	N/A
183-364 days	73,671	35.6%	*****	*****	*****	*****	*****	*****	N/A	N/A	N/A	N/A
365-547 days	63,596	30.8%	36,696	42.7%	*****	*****	35	0.1%	N/A	N/A	N/A	N/A
548-729 days	34,949	16.9%	12,707	14.8%	18,657	41.3%	273	0.5%	N/A	N/A	N/A	N/A
730+ days	33,961	16.4%	36,084	42.0%	26,148	57.9%	57,020	99.4%	N/A	N/A	N/A	N/A

Table 9b. Summary of Cumulative Dose in Each Patient's First Treatment Episode for Valsartan Use by Contamination Category in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022, by Episode Duration[1]

	58401-116800 mg		116801-175200 mg		175201-233600 mg		233601+ mg		Distribution of Cumulative Filled Dose			
	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Number of Patients	Percent of Total Patients	Minimum	Maximum	Mean	Standard Deviation
New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, Switch to Unclassified Valsartan, or Episode End Date												
Non-contaminated valsartan	83,087	100.0%	34,109	100.0%	16,642	100.0%	18,681	100.0%	13.0	57,600,000.0	42,169.2	116,313.2
0-90 days	0	0.0%	0	0.0%	0	0.0%	0	0.0%	N/A	N/A	N/A	N/A
91-182 days	*****	*****	0	0.0%	0	0.0%	*****	*****	N/A	N/A	N/A	N/A
183-364 days	23,590	28.4%	*****	*****	*****	*****	*****	*****	N/A	N/A	N/A	N/A
365-547 days	25,161	30.3%	10,931	32.0%	*****	*****	*****	*****	N/A	N/A	N/A	N/A
548-729 days	15,433	18.6%	5,127	15.0%	6,362	38.2%	*****	*****	N/A	N/A	N/A	N/A
730+ days	18,805	22.6%	17,949	52.6%	10,165	61.1%	18,561	99.4%	N/A	N/A	N/A	N/A

[*]Cumulative dose is calculated after dispensings are stockpiled by multiplying the drug strength by the amount dispensed in each dispensing and summing over all dispensings identified by the relevant drug code(s).

[1]Treatment episode duration was calculated based on time-on-treatment for each episode; episodes were censored at the end of the treatment episode.

[2]Cumulative dose categories determined by using 80mg as a maximum daily dose for diuretic combination products and 320 mg as a maximum daily dose for single valsartan products, and assuming <6, 6-12, 13-18, 19-24 and 25+ exposure months.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Sentinel

Table 10. Summary of Episode Level Cohort Attrition in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

	Prevalent Use - All Censoring Options					
	Any valsartan product		Contaminated valsartan		Non-contaminated	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	301,381,694	N/A	301,381,694	N/A	301,381,694	N/A
Had required coverage type (medical and/or drug coverage)	192,137,946	109,243,748	192,137,946	109,243,748	192,137,946	109,243,748
Enrolled during specified age range	171,877,110	20,260,836	171,877,110	20,260,836	171,877,110	20,260,836
Had requestable medical charts	171,877,110	0	171,877,110	0	171,877,110	0
Met demographic requirements (sex, race, and Hispanic origin)	171,727,133	149,977	171,727,133	149,977	171,727,133	149,977
Members with a valid index event						
Had any cohort-defining claim during the query period	5,017,768	166,709,365	2,226,311	169,500,822	4,336,684	167,390,449
Cohort episodes with a valid index date						
Total number of claims with cohort-identifying codes during the query period	73,253,957	N/A	21,682,292	N/A	48,230,436	N/A
Claim recorded during specified age range	73,251,720	2,237	21,681,689	603	48,228,907	1,529
Episode defining index claim recorded during the query period	7,993,737	65,257,983	3,868,170	17,813,519	6,873,941	41,354,966
Cohort episodes with required pre-index history						
Had sufficient pre-index continuous enrollment	5,484,916	2,508,821	2,925,864	942,306	5,066,057	1,807,884
Met inclusion and exclusion criteria[1]	3,060,902	2,424,014	1,663,906	1,261,958	2,817,719	2,248,338
Evidence of cancer	N/A	971,142	N/A	495,499	N/A	910,486
Evidence of chemo	N/A	1,759,044	N/A	908,666	N/A	1,616,487

Table 10. Summary of Episode Level Cohort Attrition in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

	Prevalent Use - All Censoring Options					
	Any valsartan product		Contaminated valsartan		Non-contaminated	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Evidence of radiation	N/A	47,833	N/A	23,912	N/A	44,343
Evidence of surgery	N/A	446,047	N/A	236,243	N/A	422,723
Evidence of washout	N/A	N/A	N/A	N/A	N/A	N/A
Met event incidence criteria	3,060,902	0	1,663,906	0	2,817,719	0
Cohort episodes with required post-index follow-up						
Had sufficient post-index continuous enrollment	3,060,574	328	1,663,906	0	2,817,381	338
Met minimum days' supply criteria	3,060,574	0	1,663,906	0	2,817,381	0
Met minimum episode duration criteria	3,060,574	0	1,663,906	0	2,817,381	0
Episode duration was longer than blackout period	3,060,574	0	1,663,906	0	2,817,381	0
Did not have an event during blackout period	3,060,574	0	1,663,906	0	2,817,381	0
Episode overlapped with prior cohort episode	N/A	N/A	N/A	N/A	N/A	N/A

Table 10. Summary of Episode Level Cohort Attrition in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

	Prevalent Use - All Censoring Options					
	Any valsartan product		Contaminated valsartan		Non-contaminated	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Final cohort						
Number of members	1,771,050	N/A	1,054,228	N/A	1,698,310	N/A
Number of episodes	3,060,574	N/A	1,663,906	N/A	2,817,381	N/A

Sentinel

Table 10. Summary of Episode Level Cohort Attrition in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

	New Use - All Censoring Options						Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death	
	Any valsartan product		Contaminated valsartan		Non-contaminated		Contaminated valsartan	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements								
Enrolled at any point during the query period	301,381,694	N/A	301,381,694	N/A	301,381,694	N/A	301,381,694	N/A
Had required coverage type (medical and/or drug coverage)	192,137,946	109,243,748	192,137,946	109,243,748	192,137,946	109,243,748	192,137,946	109,243,748
Enrolled during specified age range	171,877,110	20,260,836	171,877,110	20,260,836	171,877,110	20,260,836	171,877,110	20,260,836
Had requestable medical charts	171,877,110	0	171,877,110	0	171,877,110	0	171,877,110	0
Met demographic requirements (sex, race, and Hispanic origin)	171,727,133	149,977	171,727,133	149,977	171,727,133	149,977	171,727,133	149,977
Members with a valid index event								
Had any cohort-defining claim during the query period	5,017,768	166,709,365	2,226,311	169,500,822	4,336,684	167,390,449	2,226,311	169,500,822
Cohort episodes with a valid index date								
Total number of claims with cohort-identifying codes during the query period	73,253,957	N/A	21,682,292	N/A	48,230,436	N/A	21,682,292	N/A
Claim recorded during specified age range	73,251,720	2,237	21,681,689	603	48,228,907	1,529	21,681,689	603
Episode defining index claim recorded during the query period	7,993,737	65,257,983	3,868,170	17,813,519	6,873,941	41,354,966	3,868,170	17,813,519
Cohort episodes with required pre-index history								
Had sufficient pre-index continuous enrollment	5,484,916	2,508,821	2,925,864	942,306	5,066,057	1,807,884	2,925,864	942,306
Met inclusion and exclusion criteria[1]	1,107,774	4,377,142	267,426	2,658,438	764,735	4,301,322	1,663,906	1,261,958
Evidence of cancer	N/A	971,142	N/A	495,499	N/A	910,486	N/A	495,499
Evidence of chemo	N/A	1,759,044	N/A	908,666	N/A	1,616,487	N/A	908,666

Sentinel

Table 10. Summary of Episode Level Cohort Attrition in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

	New Use - All Censoring Options						Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death	
	Any valsartan product		Contaminated valsartan		Non-contaminated		Contaminated valsartan	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Evidence of radiation	N/A	47,833	N/A	23,912	N/A	44,343	N/A	23,912
Evidence of surgery	N/A	446,047	N/A	236,243	N/A	422,723	N/A	236,243
Evidence of washout	N/A	3,436,673	N/A	2,442,919	N/A	3,635,927	N/A	N/A
Met event incidence criteria	1,107,774	0	267,426	0	764,735	0	1,663,906	0
Cohort episodes with required post-index follow-up								
Had sufficient post-index continuous enrollment	1,107,570	204	267,426	0	764,534	201	1,663,906	0
Met minimum days' supply criteria	1,107,570	0	267,426	0	764,534	0	1,663,906	0
Met minimum episode duration criteria	1,107,570	0	267,426	0	764,534	0	1,663,906	0
Episode duration was longer than blackout period	1,107,570	0	267,426	0	764,534	0	1,663,906	0
Did not have an event during blackout period	1,107,570	0	267,426	0	764,534	0	1,663,906	0
Episode overlapped with prior cohort episode	N/A	N/A	N/A	N/A	N/A	N/A	1,056,944	606,962

Sentinel

Table 10. Summary of Episode Level Cohort Attrition in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

	New Use - All Censoring Options						Prevalent Use - Censoring on Query/Data End Date, Disenrollment, or Death	
	Any valsartan product		Contaminated valsartan		Non-contaminated		Contaminated valsartan	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Final cohort								
Number of members	1,071,272	N/A	265,082	N/A	749,077	N/A	1,054,228	N/A
Number of episodes	1,107,570	N/A	267,426	N/A	764,534	N/A	1,056,944	N/A

Sentinel

Table 10. Summary of Episode Level Cohort Attrition in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

	New Use - Censoring on Query/Data End Date, Disenrollment, or Death		Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan		New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan	
	Contaminated valsartan		Contaminated valsartan		Contaminated valsartan	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements						
Enrolled at any point during the query period	301,381,694	N/A	301,381,694	N/A	301,381,694	N/A
Had required coverage type (medical and/or drug coverage)	192,137,946	109,243,748	192,137,946	109,243,748	192,137,946	109,243,748
Enrolled during specified age range	171,877,110	20,260,836	171,877,110	20,260,836	171,877,110	20,260,836
Had requestable medical charts	171,877,110	0	171,877,110	0	171,877,110	0
Met demographic requirements (sex, race, and Hispanic origin)	171,727,133	149,977	171,727,133	149,977	171,727,133	149,977
Members with a valid index event						
Had any cohort-defining claim during the query period	2,226,311	169,500,822	2,226,311	169,500,822	2,226,311	169,500,822
Cohort episodes with a valid index date						
Total number of claims with cohort-identifying codes during the query period	21,682,292	N/A	21,682,292	N/A	21,682,292	N/A
Claim recorded during specified age range	21,681,689	603	21,681,689	603	21,681,689	603
Episode defining index claim recorded during the query period	3,868,170	17,813,519	3,868,170	17,813,519	3,868,170	17,813,519
Cohort episodes with required pre-index history						
Had sufficient pre-index continuous enrollment	2,925,864	942,306	2,925,864	942,306	2,925,864	942,306
Met inclusion and exclusion criteria[1]	267,426	2,658,438	1,663,906	1,261,958	267,426	2,658,438
Evidence of cancer	N/A	495,499	N/A	495,499	N/A	495,499
Evidence of chemo	N/A	908,666	N/A	908,666	N/A	908,666

Table 10. Summary of Episode Level Cohort Attrition in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

	New Use - Censoring on Query/Data End Date, Disenrollment, or Death		Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan		New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan	
	Contaminated valsartan		Contaminated valsartan		Contaminated valsartan	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Evidence of radiation	N/A	23,912	N/A	23,912	N/A	23,912
Evidence of surgery	N/A	236,243	N/A	236,243	N/A	236,243
Evidence of washout	N/A	2,442,919	N/A	N/A	N/A	2,442,919
Met event incidence criteria	267,426	0	1,663,906	0	267,426	0
Cohort episodes with required post-index follow-up						
Had sufficient post-index continuous enrollment	267,426	0	1,663,900	*****	267,423	*****
Met minimum days' supply criteria	267,426	0	1,663,900	0	267,423	0
Met minimum episode duration criteria	267,426	0	1,663,900	0	267,423	0
Episode duration was longer than blackout period	267,426	0	1,663,900	0	267,423	0
Did not have an event during blackout period	267,426	0	1,663,900	0	267,423	0
Episode overlapped with prior cohort episode	265,115	2,311	1,314,526	349,374	265,412	2,011

Table 10. Summary of Episode Level Cohort Attrition in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

	New Use - Censoring on Query/Data End Date, Disenrollment, or Death		Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan		New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Non-Contaminated Valsartan, or Switch to Unclassified Valsartan	
	Contaminated valsartan		Contaminated valsartan		Contaminated valsartan	
	Remaining	Excluded	Remaining	Excluded	Remaining	Excluded
Final cohort						
Number of members	265,082	N/A	1,054,224	N/A	265,079	N/A
Number of episodes	265,115	N/A	1,314,526	N/A	265,412	N/A

Sentinel

Table 10. Summary of Episode Level Cohort Attrition in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

	Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan		New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan	
	Non-contaminated valsartan		Non-contaminated valsartan	
	Remaining	Excluded	Remaining	Excluded
Members meeting enrollment and demographic requirements				
Enrolled at any point during the query period	301,381,694	N/A	301,381,694	N/A
Had required coverage type (medical and/or drug coverage)	192,137,946	109,243,748	192,137,946	109,243,748
Enrolled during specified age range	171,877,110	20,260,836	171,877,110	20,260,836
Had requestable medical charts	171,877,110	0	171,877,110	0
Met demographic requirements (sex, race, and Hispanic origin)	171,727,133	149,977	171,727,133	149,977
Members with a valid index event				
Had any cohort-defining claim during the query period	4,336,684	167,390,449	4,336,684	167,390,449
Cohort episodes with a valid index date				
Total number of claims with cohort-identifying codes during the query period	48,230,436	N/A	48,230,436	N/A
Claim recorded during specified age range	48,228,907	1,529	48,228,907	1,529
Episode defining index claim recorded during the query period	6,873,941	41,354,966	6,873,941	41,354,966
Cohort episodes with required pre-index history				
Had sufficient pre-index continuous enrollment	5,066,057	1,807,884	5,066,057	1,807,884
Met inclusion and exclusion criteria[1]	2,817,719	2,248,338	764,735	4,301,322
Evidence of cancer	N/A	910,486	N/A	910,486
Evidence of chemo	N/A	1,616,487	N/A	1,616,487

Table 10. Summary of Episode Level Cohort Attrition in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

	Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan		New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan	
	Non-contaminated valsartan		Non-contaminated valsartan	
	Remaining	Excluded	Remaining	Excluded
Evidence of radiation	N/A	44,343	N/A	44,343
Evidence of surgery	N/A	422,723	N/A	422,723
Evidence of washout	N/A	N/A	N/A	3,635,927
Met event incidence criteria	2,817,719	0	764,735	0
Cohort episodes with required post-index follow-up				
Had sufficient post-index continuous enrollment	2,817,692	27	764,727	*****
Met minimum days' supply criteria	2,817,692	0	764,727	0
Met minimum episode duration criteria	2,817,692	0	764,727	0
Episode duration was longer than blackout period	2,817,692	0	764,727	0
Did not have an event during blackout period	2,817,692	0	764,727	0
Episode overlapped with prior cohort episode	2,050,452	767,240	753,568	11,159

Table 10. Summary of Episode Level Cohort Attrition in the Sentinel Distributed Database from May 1, 2012 to December 31, 2022

	Prevalent Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan		New Use - Censoring on Query/Data End Date, Disenrollment, Death, Switch to Contaminated Valsartan Category, or Switch to Unclassified Valsartan	
	Non-contaminated valsartan		Non-contaminated valsartan	
	Remaining	Excluded	Remaining	Excluded
Final cohort				
Number of members	1,698,530	N/A	749,268	N/A
Number of episodes	2,050,452	N/A	753,568	N/A

[1]Episodes can meet multiple inclusion and/or exclusion criteria; therefore, the total number of episodes excluded overall may not equal the sum of all episodes in each criterion.

*****Data are not presented in these cells due to a small sample size or to assure a small cell cannot be recalculated through the cells presented.

Appendix A. Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (June 23, 2023)

Masked DP ID	DP Start Date	DP End Date[1]
DP01	01/01/2007	09/30/2022
DP02	01/01/2008	08/31/2022
DP03	01/01/2008	12/31/2022
DP04	01/01/2010	09/30/2022
DP05	01/01/2006	10/31/2022

1End Date represents the earliest of: (1) query end date, or (2) last day of the most recent month for which all of a Data Partner's data tables (enrollment, dispensing, etc.) have at least 80% of the record count relative to the prior month.

Appendix B. List of Generic and Brand Names of Medical Products Used to Define Exposures in this Request

Generic Name	Brand Name
Any Valsartan Products	
Valsartan	Valsartan
aliskiren/valsartan	Valturna
amlodipine besylate/valsartan	Exforge
amlodipine besylate/valsartan	amlodipine-valsartan
amlodipine besylate/valsartan/hydrochlorothiazide	Exforge HCT
amlodipine besylate/valsartan/hydrochlorothiazide	amlodipine-valsartan-hcthiazid
amlodipine/valsartan	amlodipine/valsartan
amlodipine/valsartan/hydrochlorothiazide	amlodipine/valsartan/hydrochlorothiazide
nebivolol HCl/valsartan	Byvalson
sacubitril/valsartan	Entresto
valsartan	Diovan
valsartan	valsartan
valsartan/hydrochlorothiazide	Diovan HCT
valsartan/hydrochlorothiazide	valsartan-hydrochlorothiazide
valsartan/hydrochlorothiazide	valsartan/hydrochlorothiazide
Contaminated Valsartan Products	
amlodipine besylate/valsartan	amlodipine-valsartan
amlodipine besylate/valsartan/hydrochlorothiazide	amlodipine-valsartan-hcthiazid
amlodipine/valsartan	amlodipine/valsartan
valsartan	valsartan
valsartan/hydrochlorothiazide	valsartan-hydrochlorothiazide
valsartan/hydrochlorothiazide	valsartan/hydrochlorothiazide
Non-Contaminated Valsartan Products	
Valsartan	Valsartan
aliskiren/valsartan	Valturna
amlodipine besylate/valsartan	Exforge
amlodipine besylate/valsartan	amlodipine-valsartan
amlodipine besylate/valsartan/hydrochlorothiazide	Exforge HCT
amlodipine besylate/valsartan/hydrochlorothiazide	amlodipine-valsartan-hcthiazid
amlodipine/valsartan	amlodipine/valsartan
amlodipine/valsartan/hydrochlorothiazide	amlodipine/valsartan/hydrochlorothiazide
sacubitril/valsartan	Entresto
valsartan	Diovan
valsartan	valsartan
valsartan/hydrochlorothiazide	Diovan HCT
valsartan/hydrochlorothiazide	valsartan-hydrochlorothiazide
valsartan/hydrochlorothiazide	valsartan/hydrochlorothiazide

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
	Cancer		
140	Malignant neoplasm of lip	Diagnosis	ICD-9-CM
140.0	Malignant neoplasm of upper lip, vermilion border	Diagnosis	ICD-9-CM
140.1	Malignant neoplasm of lower lip, vermilion border	Diagnosis	ICD-9-CM
140.3	Malignant neoplasm of upper lip, inner aspect	Diagnosis	ICD-9-CM
140.4	Malignant neoplasm of lower lip, inner aspect	Diagnosis	ICD-9-CM
140.5	Malignant neoplasm of lip, inner aspect, unspecified as to upper or lower	Diagnosis	ICD-9-CM
140.6	Malignant neoplasm of commissure of lip	Diagnosis	ICD-9-CM
140.8	Malignant neoplasm of other sites of lip	Diagnosis	ICD-9-CM
140.9	Malignant neoplasm of lip, vermilion border, unspecified as to upper or lower	Diagnosis	ICD-9-CM
141	Malignant neoplasm of tongue	Diagnosis	ICD-9-CM
141.0	Malignant neoplasm of base of tongue	Diagnosis	ICD-9-CM
141.1	Malignant neoplasm of dorsal surface of tongue	Diagnosis	ICD-9-CM
141.2	Malignant neoplasm of tip and lateral border of tongue	Diagnosis	ICD-9-CM
141.3	Malignant neoplasm of ventral surface of tongue	Diagnosis	ICD-9-CM
141.4	Malignant neoplasm of anterior two-thirds of tongue, part unspecified	Diagnosis	ICD-9-CM
141.5	Malignant neoplasm of junctional zone of tongue	Diagnosis	ICD-9-CM
141.6	Malignant neoplasm of lingual tonsil	Diagnosis	ICD-9-CM
141.8	Malignant neoplasm of other sites of tongue	Diagnosis	ICD-9-CM
141.9	Malignant neoplasm of tongue, unspecified site	Diagnosis	ICD-9-CM
142	Malignant neoplasm of major salivary glands	Diagnosis	ICD-9-CM
142.0	Malignant neoplasm of parotid gland	Diagnosis	ICD-9-CM
142.1	Malignant neoplasm of submandibular gland	Diagnosis	ICD-9-CM
142.2	Malignant neoplasm of sublingual gland	Diagnosis	ICD-9-CM
142.8	Malignant neoplasm of other major salivary glands	Diagnosis	ICD-9-CM
142.9	Malignant neoplasm of salivary gland, unspecified	Diagnosis	ICD-9-CM
143	Malignant neoplasm of gum	Diagnosis	ICD-9-CM
143.0	Malignant neoplasm of upper gum	Diagnosis	ICD-9-CM
143.1	Malignant neoplasm of lower gum	Diagnosis	ICD-9-CM
143.8	Malignant neoplasm of other sites of gum	Diagnosis	ICD-9-CM
143.9	Malignant neoplasm of gum, unspecified site	Diagnosis	ICD-9-CM
144	Malignant neoplasm of floor of mouth	Diagnosis	ICD-9-CM
144.0	Malignant neoplasm of anterior portion of floor of mouth	Diagnosis	ICD-9-CM
144.1	Malignant neoplasm of lateral portion of floor of mouth	Diagnosis	ICD-9-CM
144.8	Malignant neoplasm of other sites of floor of mouth	Diagnosis	ICD-9-CM
144.9	Malignant neoplasm of floor of mouth, part unspecified	Diagnosis	ICD-9-CM
145	Malignant neoplasm of other and unspecified parts of mouth	Diagnosis	ICD-9-CM
145.0	Malignant neoplasm of cheek mucosa	Diagnosis	ICD-9-CM
145.1	Malignant neoplasm of vestibule of mouth	Diagnosis	ICD-9-CM
145.2	Malignant neoplasm of hard palate	Diagnosis	ICD-9-CM
145.3	Malignant neoplasm of soft palate	Diagnosis	ICD-9-CM
145.4	Malignant neoplasm of uvula	Diagnosis	ICD-9-CM
145.5	Malignant neoplasm of palate, unspecified	Diagnosis	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
145.6	Malignant neoplasm of retromolar area	Diagnosis	ICD-9-CM
145.8	Malignant neoplasm of other specified parts of mouth	Diagnosis	ICD-9-CM
145.9	Malignant neoplasm of mouth, unspecified site	Diagnosis	ICD-9-CM
146	Malignant neoplasm of oropharynx	Diagnosis	ICD-9-CM
146.0	Malignant neoplasm of tonsil	Diagnosis	ICD-9-CM
146.1	Malignant neoplasm of tonsillar fossa	Diagnosis	ICD-9-CM
146.2	Malignant neoplasm of tonsillar pillars (anterior) (posterior)	Diagnosis	ICD-9-CM
146.3	Malignant neoplasm of vallecula	Diagnosis	ICD-9-CM
146.4	Malignant neoplasm of anterior aspect of epiglottis	Diagnosis	ICD-9-CM
146.5	Malignant neoplasm of junctional region of oropharynx	Diagnosis	ICD-9-CM
146.6	Malignant neoplasm of lateral wall of oropharynx	Diagnosis	ICD-9-CM
146.7	Malignant neoplasm of posterior wall of oropharynx	Diagnosis	ICD-9-CM
146.8	Malignant neoplasm of other specified sites of oropharynx	Diagnosis	ICD-9-CM
146.9	Malignant neoplasm of oropharynx, unspecified site	Diagnosis	ICD-9-CM
147	Malignant neoplasm of nasopharynx	Diagnosis	ICD-9-CM
147.0	Malignant neoplasm of superior wall of nasopharynx	Diagnosis	ICD-9-CM
147.1	Malignant neoplasm of posterior wall of nasopharynx	Diagnosis	ICD-9-CM
147.2	Malignant neoplasm of lateral wall of nasopharynx	Diagnosis	ICD-9-CM
147.3	Malignant neoplasm of anterior wall of nasopharynx	Diagnosis	ICD-9-CM
147.8	Malignant neoplasm of other specified sites of nasopharynx	Diagnosis	ICD-9-CM
147.9	Malignant neoplasm of nasopharynx, unspecified site	Diagnosis	ICD-9-CM
148	Malignant neoplasm of hypopharynx	Diagnosis	ICD-9-CM
148.0	Malignant neoplasm of postcricoid region of hypopharynx	Diagnosis	ICD-9-CM
148.1	Malignant neoplasm of pyriform sinus	Diagnosis	ICD-9-CM
148.2	Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect	Diagnosis	ICD-9-CM
148.3	Malignant neoplasm of posterior hypopharyngeal wall	Diagnosis	ICD-9-CM
148.8	Malignant neoplasm of other specified sites of hypopharynx	Diagnosis	ICD-9-CM
148.9	Malignant neoplasm of hypopharynx, unspecified site	Diagnosis	ICD-9-CM
149	Malignant neoplasm of other and ill-defined sites within the lip, oral cavity, and pharynx	Diagnosis	ICD-9-CM
149.0	Malignant neoplasm of pharynx, unspecified	Diagnosis	ICD-9-CM
149.1	Malignant neoplasm of Waldeyer's ring	Diagnosis	ICD-9-CM
149.8	Malignant neoplasm of other sites within the lip and oral cavity	Diagnosis	ICD-9-CM
149.9	Malignant neoplasm of ill-defined sites of lip and oral cavity	Diagnosis	ICD-9-CM
150	Malignant neoplasm of esophagus	Diagnosis	ICD-9-CM
150.0	Malignant neoplasm of cervical esophagus	Diagnosis	ICD-9-CM
150.1	Malignant neoplasm of thoracic esophagus	Diagnosis	ICD-9-CM
150.2	Malignant neoplasm of abdominal esophagus	Diagnosis	ICD-9-CM
150.3	Malignant neoplasm of upper third of esophagus	Diagnosis	ICD-9-CM
150.4	Malignant neoplasm of middle third of esophagus	Diagnosis	ICD-9-CM
150.5	Malignant neoplasm of lower third of esophagus	Diagnosis	ICD-9-CM
150.8	Malignant neoplasm of other specified part of esophagus	Diagnosis	ICD-9-CM
150.9	Malignant neoplasm of esophagus, unspecified site	Diagnosis	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
151	Malignant neoplasm of stomach	Diagnosis	ICD-9-CM
151.0	Malignant neoplasm of cardia	Diagnosis	ICD-9-CM
151.1	Malignant neoplasm of pylorus	Diagnosis	ICD-9-CM
151.2	Malignant neoplasm of pyloric antrum	Diagnosis	ICD-9-CM
151.3	Malignant neoplasm of fundus of stomach	Diagnosis	ICD-9-CM
151.4	Malignant neoplasm of body of stomach	Diagnosis	ICD-9-CM
151.5	Malignant neoplasm of lesser curvature of stomach, unspecified	Diagnosis	ICD-9-CM
151.6	Malignant neoplasm of greater curvature of stomach, unspecified	Diagnosis	ICD-9-CM
151.8	Malignant neoplasm of other specified sites of stomach	Diagnosis	ICD-9-CM
151.9	Malignant neoplasm of stomach, unspecified site	Diagnosis	ICD-9-CM
152	Malignant neoplasm of small intestine, including duodenum	Diagnosis	ICD-9-CM
152.0	Malignant neoplasm of duodenum	Diagnosis	ICD-9-CM
152.1	Malignant neoplasm of jejunum	Diagnosis	ICD-9-CM
152.2	Malignant neoplasm of ileum	Diagnosis	ICD-9-CM
152.3	Malignant neoplasm of Meckel's diverticulum	Diagnosis	ICD-9-CM
152.8	Malignant neoplasm of other specified sites of small intestine	Diagnosis	ICD-9-CM
152.9	Malignant neoplasm of small intestine, unspecified site	Diagnosis	ICD-9-CM
153	Malignant neoplasm of colon	Diagnosis	ICD-9-CM
153.0	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-9-CM
153.1	Malignant neoplasm of transverse colon	Diagnosis	ICD-9-CM
153.2	Malignant neoplasm of descending colon	Diagnosis	ICD-9-CM
153.3	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-9-CM
153.4	Malignant neoplasm of cecum	Diagnosis	ICD-9-CM
153.5	Malignant neoplasm of appendix	Diagnosis	ICD-9-CM
153.6	Malignant neoplasm of ascending colon	Diagnosis	ICD-9-CM
153.7	Malignant neoplasm of splenic flexure	Diagnosis	ICD-9-CM
153.8	Malignant neoplasm of other specified sites of large intestine	Diagnosis	ICD-9-CM
153.9	Malignant neoplasm of colon, unspecified site	Diagnosis	ICD-9-CM
154	Malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-9-CM
154.0	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-9-CM
154.1	Malignant neoplasm of rectum	Diagnosis	ICD-9-CM
154.2	Malignant neoplasm of anal canal	Diagnosis	ICD-9-CM
154.3	Malignant neoplasm of anus, unspecified site	Diagnosis	ICD-9-CM
154.8	Malignant neoplasm of other sites of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-9-CM
155	Malignant neoplasm of liver and intrahepatic bile ducts	Diagnosis	ICD-9-CM
155.0	Malignant neoplasm of liver, primary	Diagnosis	ICD-9-CM
155.1	Malignant neoplasm of intrahepatic bile ducts	Diagnosis	ICD-9-CM
155.2	Malignant neoplasm of liver, not specified as primary or secondary	Diagnosis	ICD-9-CM
156	Malignant neoplasm of gallbladder and extrahepatic bile ducts	Diagnosis	ICD-9-CM
156.0	Malignant neoplasm of gallbladder	Diagnosis	ICD-9-CM
156.1	Malignant neoplasm of extrahepatic bile ducts	Diagnosis	ICD-9-CM
156.2	Malignant neoplasm of ampulla of Vater	Diagnosis	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
156.8	Malignant neoplasm of other specified sites of gallbladder and extrahepatic bile ducts	Diagnosis	ICD-9-CM
156.9	Malignant neoplasm of biliary tract, part unspecified site	Diagnosis	ICD-9-CM
157	Malignant neoplasm of pancreas	Diagnosis	ICD-9-CM
157.0	Malignant neoplasm of head of pancreas	Diagnosis	ICD-9-CM
157.1	Malignant neoplasm of body of pancreas	Diagnosis	ICD-9-CM
157.2	Malignant neoplasm of tail of pancreas	Diagnosis	ICD-9-CM
157.3	Malignant neoplasm of pancreatic duct	Diagnosis	ICD-9-CM
157.4	Malignant neoplasm of islets of Langerhans	Diagnosis	ICD-9-CM
157.8	Malignant neoplasm of other specified sites of pancreas	Diagnosis	ICD-9-CM
157.9	Malignant neoplasm of pancreas, part unspecified	Diagnosis	ICD-9-CM
158	Malignant neoplasm of retroperitoneum and peritoneum	Diagnosis	ICD-9-CM
158.0	Malignant neoplasm of retroperitoneum	Diagnosis	ICD-9-CM
158.8	Malignant neoplasm of specified parts of peritoneum	Diagnosis	ICD-9-CM
158.9	Malignant neoplasm of peritoneum, unspecified	Diagnosis	ICD-9-CM
159	Malignant neoplasm of other and ill-defined sites within the digestive organs and peritoneum	Diagnosis	ICD-9-CM
159.0	Malignant neoplasm of intestinal tract, part unspecified	Diagnosis	ICD-9-CM
159.1	Malignant neoplasm of spleen, not elsewhere classified	Diagnosis	ICD-9-CM
159.8	Malignant neoplasm of other sites of digestive system and intra-abdominal organs	Diagnosis	ICD-9-CM
159.9	Malignant neoplasm of ill-defined sites of digestive organs and peritoneum	Diagnosis	ICD-9-CM
160	Malignant neoplasm of nasal cavities, middle ear, and accessory sinuses	Diagnosis	ICD-9-CM
160.0	Malignant neoplasm of nasal cavities	Diagnosis	ICD-9-CM
160.1	Malignant neoplasm of auditory tube, middle ear, and mastoid air cells	Diagnosis	ICD-9-CM
160.2	Malignant neoplasm of maxillary sinus	Diagnosis	ICD-9-CM
160.3	Malignant neoplasm of ethmoidal sinus	Diagnosis	ICD-9-CM
160.4	Malignant neoplasm of frontal sinus	Diagnosis	ICD-9-CM
160.5	Malignant neoplasm of sphenoidal sinus	Diagnosis	ICD-9-CM
160.8	Malignant neoplasm of other sites of nasal cavities, middle ear, and accessory sinuses	Diagnosis	ICD-9-CM
160.9	Malignant neoplasm of site of nasal cavities, middle ear, and accessory sinus, unspecified site	Diagnosis	ICD-9-CM
161	Malignant neoplasm of larynx	Diagnosis	ICD-9-CM
161.0	Malignant neoplasm of glottis	Diagnosis	ICD-9-CM
161.1	Malignant neoplasm of supraglottis	Diagnosis	ICD-9-CM
161.2	Malignant neoplasm of subglottis	Diagnosis	ICD-9-CM
161.3	Malignant neoplasm of laryngeal cartilages	Diagnosis	ICD-9-CM
161.8	Malignant neoplasm of other specified sites of larynx	Diagnosis	ICD-9-CM
161.9	Malignant neoplasm of larynx, unspecified site	Diagnosis	ICD-9-CM
162	Malignant neoplasm of trachea, bronchus, and lung	Diagnosis	ICD-9-CM
162.0	Malignant neoplasm of trachea	Diagnosis	ICD-9-CM
162.2	Malignant neoplasm of main bronchus	Diagnosis	ICD-9-CM
162.3	Malignant neoplasm of upper lobe, bronchus, or lung	Diagnosis	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
162.4	Malignant neoplasm of middle lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.5	Malignant neoplasm of lower lobe, bronchus, or lung	Diagnosis	ICD-9-CM
162.8	Malignant neoplasm of other parts of bronchus or lung	Diagnosis	ICD-9-CM
162.9	Malignant neoplasm of bronchus and lung, unspecified site	Diagnosis	ICD-9-CM
163	Malignant neoplasm of pleura	Diagnosis	ICD-9-CM
163.0	Malignant neoplasm of parietal pleura	Diagnosis	ICD-9-CM
163.1	Malignant neoplasm of visceral pleura	Diagnosis	ICD-9-CM
163.8	Malignant neoplasm of other specified sites of pleura	Diagnosis	ICD-9-CM
163.9	Malignant neoplasm of pleura, unspecified site	Diagnosis	ICD-9-CM
164	Malignant neoplasm of thymus, heart, and mediastinum	Diagnosis	ICD-9-CM
164.0	Malignant neoplasm of thymus	Diagnosis	ICD-9-CM
164.1	Malignant neoplasm of heart	Diagnosis	ICD-9-CM
164.2	Malignant neoplasm of anterior mediastinum	Diagnosis	ICD-9-CM
164.3	Malignant neoplasm of posterior mediastinum	Diagnosis	ICD-9-CM
164.8	Malignant neoplasm of other parts of mediastinum	Diagnosis	ICD-9-CM
164.9	Malignant neoplasm of mediastinum, part unspecified	Diagnosis	ICD-9-CM
165	Malignant neoplasm of other and ill-defined sites within the respiratory system and intrathoracic organs	Diagnosis	ICD-9-CM
165.0	Malignant neoplasm of upper respiratory tract, part unspecified	Diagnosis	ICD-9-CM
165.8	Malignant neoplasm of other sites within the respiratory system and intrathoracic organs	Diagnosis	ICD-9-CM
165.9	Malignant neoplasm of ill-defined sites within the respiratory system	Diagnosis	ICD-9-CM
170	Malignant neoplasm of bone and articular cartilage	Diagnosis	ICD-9-CM
170.0	Malignant neoplasm of bones of skull and face, except mandible	Diagnosis	ICD-9-CM
170.1	Malignant neoplasm of mandible	Diagnosis	ICD-9-CM
170.2	Malignant neoplasm of vertebral column, excluding sacrum and coccyx	Diagnosis	ICD-9-CM
170.3	Malignant neoplasm of ribs, sternum, and clavicle	Diagnosis	ICD-9-CM
170.4	Malignant neoplasm of scapula and long bones of upper limb	Diagnosis	ICD-9-CM
170.5	Malignant neoplasm of short bones of upper limb	Diagnosis	ICD-9-CM
170.6	Malignant neoplasm of pelvic bones, sacrum, and coccyx	Diagnosis	ICD-9-CM
170.7	Malignant neoplasm of long bones of lower limb	Diagnosis	ICD-9-CM
170.8	Malignant neoplasm of short bones of lower limb	Diagnosis	ICD-9-CM
170.9	Malignant neoplasm of bone and articular cartilage, site unspecified	Diagnosis	ICD-9-CM
171	Malignant neoplasm of connective and other soft tissue	Diagnosis	ICD-9-CM
171.0	Malignant neoplasm of connective and other soft tissue of head, face, and neck	Diagnosis	ICD-9-CM
171.2	Malignant neoplasm of connective and other soft tissue of upper limb, including shoulder	Diagnosis	ICD-9-CM
171.3	Malignant neoplasm of connective and other soft tissue of lower limb, including hip	Diagnosis	ICD-9-CM
171.4	Malignant neoplasm of connective and other soft tissue of thorax	Diagnosis	ICD-9-CM
171.5	Malignant neoplasm of connective and other soft tissue of abdomen	Diagnosis	ICD-9-CM
171.6	Malignant neoplasm of connective and other soft tissue of pelvis	Diagnosis	ICD-9-CM
171.7	Malignant neoplasm of connective and other soft tissue of trunk, unspecified site	Diagnosis	ICD-9-CM
171.8	Malignant neoplasm of other specified sites of connective and other soft tissue	Diagnosis	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
171.9	Malignant neoplasm of connective and other soft tissue, site unspecified	Diagnosis	ICD-9-CM
173.1	Other and unspecified malignant neoplasm of eyelid, including canthus	Diagnosis	ICD-9-CM
173.10	Unspecified malignant neoplasm of eyelid, including canthus	Diagnosis	ICD-9-CM
173.11	Basal cell carcinoma of eyelid, including canthus	Diagnosis	ICD-9-CM
173.12	Squamous cell carcinoma of eyelid, including canthus	Diagnosis	ICD-9-CM
173.19	Other specified malignant neoplasm of eyelid, including canthus	Diagnosis	ICD-9-CM
174	Malignant neoplasm of female breast	Diagnosis	ICD-9-CM
174.0	Malignant neoplasm of nipple and areola of female breast	Diagnosis	ICD-9-CM
174.1	Malignant neoplasm of central portion of female breast	Diagnosis	ICD-9-CM
174.2	Malignant neoplasm of upper-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.3	Malignant neoplasm of lower-inner quadrant of female breast	Diagnosis	ICD-9-CM
174.4	Malignant neoplasm of upper-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.5	Malignant neoplasm of lower-outer quadrant of female breast	Diagnosis	ICD-9-CM
174.6	Malignant neoplasm of axillary tail of female breast	Diagnosis	ICD-9-CM
174.8	Malignant neoplasm of other specified sites of female breast	Diagnosis	ICD-9-CM
174.9	Malignant neoplasm of breast (female), unspecified site	Diagnosis	ICD-9-CM
175	Malignant neoplasm of male breast	Diagnosis	ICD-9-CM
175.0	Malignant neoplasm of nipple and areola of male breast	Diagnosis	ICD-9-CM
175.9	Malignant neoplasm of other and unspecified sites of male breast	Diagnosis	ICD-9-CM
176	Kaposi's sarcoma	Diagnosis	ICD-9-CM
176.1	Kaposi's sarcoma of soft tissue	Diagnosis	ICD-9-CM
176.2	Kaposi's sarcoma of palate	Diagnosis	ICD-9-CM
176.3	Kaposi's sarcoma of gastrointestinal sites	Diagnosis	ICD-9-CM
176.4	Kaposi's sarcoma of lung	Diagnosis	ICD-9-CM
176.5	Kaposi's sarcoma of lymph nodes	Diagnosis	ICD-9-CM
176.8	Kaposi's sarcoma of other specified sites	Diagnosis	ICD-9-CM
176.9	Kaposi's sarcoma of unspecified site	Diagnosis	ICD-9-CM
179	Malignant neoplasm of uterus, part unspecified	Diagnosis	ICD-9-CM
180	Malignant neoplasm of cervix uteri	Diagnosis	ICD-9-CM
180.0	Malignant neoplasm of endocervix	Diagnosis	ICD-9-CM
180.1	Malignant neoplasm of exocervix	Diagnosis	ICD-9-CM
180.8	Malignant neoplasm of other specified sites of cervix	Diagnosis	ICD-9-CM
180.9	Malignant neoplasm of cervix uteri, unspecified site	Diagnosis	ICD-9-CM
181	Malignant neoplasm of placenta	Diagnosis	ICD-9-CM
182	Malignant neoplasm of body of uterus	Diagnosis	ICD-9-CM
182.0	Malignant neoplasm of corpus uteri, except isthmus	Diagnosis	ICD-9-CM
182.1	Malignant neoplasm of isthmus	Diagnosis	ICD-9-CM
182.8	Malignant neoplasm of other specified sites of body of uterus	Diagnosis	ICD-9-CM
183	Malignant neoplasm of ovary and other uterine adnexa	Diagnosis	ICD-9-CM
183.0	Malignant neoplasm of ovary	Diagnosis	ICD-9-CM
183.2	Malignant neoplasm of fallopian tube	Diagnosis	ICD-9-CM
183.3	Malignant neoplasm of broad ligament of uterus	Diagnosis	ICD-9-CM
183.4	Malignant neoplasm of parametrium of uterus	Diagnosis	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
183.5	Malignant neoplasm of round ligament of uterus	Diagnosis	ICD-9-CM
183.8	Malignant neoplasm of other specified sites of uterine adnexa	Diagnosis	ICD-9-CM
183.9	Malignant neoplasm of uterine adnexa, unspecified site	Diagnosis	ICD-9-CM
184	Malignant neoplasm of other and unspecified female genital organs	Diagnosis	ICD-9-CM
184.0	Malignant neoplasm of vagina	Diagnosis	ICD-9-CM
184.1	Malignant neoplasm of labia majora	Diagnosis	ICD-9-CM
184.2	Malignant neoplasm of labia minora	Diagnosis	ICD-9-CM
184.3	Malignant neoplasm of clitoris	Diagnosis	ICD-9-CM
184.4	Malignant neoplasm of vulva, unspecified site	Diagnosis	ICD-9-CM
184.8	Malignant neoplasm of other specified sites of female genital organs	Diagnosis	ICD-9-CM
184.9	Malignant neoplasm of female genital organ, site unspecified	Diagnosis	ICD-9-CM
185	Malignant neoplasm of prostate	Diagnosis	ICD-9-CM
186	Malignant neoplasm of testis	Diagnosis	ICD-9-CM
186.0	Malignant neoplasm of undescended testis	Diagnosis	ICD-9-CM
186.9	Malignant neoplasm of other and unspecified testis	Diagnosis	ICD-9-CM
187	Malignant neoplasm of penis and other male genital organs	Diagnosis	ICD-9-CM
187.1	Malignant neoplasm of prepuce	Diagnosis	ICD-9-CM
187.2	Malignant neoplasm of glans penis	Diagnosis	ICD-9-CM
187.3	Malignant neoplasm of body of penis	Diagnosis	ICD-9-CM
187.4	Malignant neoplasm of penis, part unspecified	Diagnosis	ICD-9-CM
187.5	Malignant neoplasm of epididymis	Diagnosis	ICD-9-CM
187.6	Malignant neoplasm of spermatic cord	Diagnosis	ICD-9-CM
187.7	Malignant neoplasm of scrotum	Diagnosis	ICD-9-CM
187.8	Malignant neoplasm of other specified sites of male genital organs	Diagnosis	ICD-9-CM
187.9	Malignant neoplasm of male genital organ, site unspecified	Diagnosis	ICD-9-CM
188	Malignant neoplasm of bladder	Diagnosis	ICD-9-CM
188.0	Malignant neoplasm of trigone of urinary bladder	Diagnosis	ICD-9-CM
188.1	Malignant neoplasm of dome of urinary bladder	Diagnosis	ICD-9-CM
188.2	Malignant neoplasm of lateral wall of urinary bladder	Diagnosis	ICD-9-CM
188.3	Malignant neoplasm of anterior wall of urinary bladder	Diagnosis	ICD-9-CM
188.4	Malignant neoplasm of posterior wall of urinary bladder	Diagnosis	ICD-9-CM
188.5	Malignant neoplasm of bladder neck	Diagnosis	ICD-9-CM
188.6	Malignant neoplasm of ureteric orifice	Diagnosis	ICD-9-CM
188.7	Malignant neoplasm of urachus	Diagnosis	ICD-9-CM
188.8	Malignant neoplasm of other specified sites of bladder	Diagnosis	ICD-9-CM
188.9	Malignant neoplasm of bladder, part unspecified	Diagnosis	ICD-9-CM
189	Malignant neoplasm of kidney and other and unspecified urinary organs	Diagnosis	ICD-9-CM
189.0	Malignant neoplasm of kidney, except pelvis	Diagnosis	ICD-9-CM
189.1	Malignant neoplasm of renal pelvis	Diagnosis	ICD-9-CM
189.2	Malignant neoplasm of ureter	Diagnosis	ICD-9-CM
189.3	Malignant neoplasm of urethra	Diagnosis	ICD-9-CM
189.4	Malignant neoplasm of paraurethral glands	Diagnosis	ICD-9-CM
189.8	Malignant neoplasm of other specified sites of urinary organs	Diagnosis	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
189.9	Malignant neoplasm of urinary organ, site unspecified	Diagnosis	ICD-9-CM
190	Malignant neoplasm of eye	Diagnosis	ICD-9-CM
190.0	Malignant neoplasm of eyeball, except conjunctiva, cornea, retina, and choroid	Diagnosis	ICD-9-CM
190.1	Malignant neoplasm of orbit	Diagnosis	ICD-9-CM
190.2	Malignant neoplasm of lacrimal gland	Diagnosis	ICD-9-CM
190.3	Malignant neoplasm of conjunctiva	Diagnosis	ICD-9-CM
190.4	Malignant neoplasm of cornea	Diagnosis	ICD-9-CM
190.5	Malignant neoplasm of retina	Diagnosis	ICD-9-CM
190.6	Malignant neoplasm of choroid	Diagnosis	ICD-9-CM
190.7	Malignant neoplasm of lacrimal duct	Diagnosis	ICD-9-CM
190.8	Malignant neoplasm of other specified sites of eye	Diagnosis	ICD-9-CM
190.9	Malignant neoplasm of eye, part unspecified	Diagnosis	ICD-9-CM
191	Malignant neoplasm of brain	Diagnosis	ICD-9-CM
191.0	Malignant neoplasm of cerebrum, except lobes and ventricles	Diagnosis	ICD-9-CM
191.1	Malignant neoplasm of frontal lobe of brain	Diagnosis	ICD-9-CM
191.2	Malignant neoplasm of temporal lobe of brain	Diagnosis	ICD-9-CM
191.3	Malignant neoplasm of parietal lobe of brain	Diagnosis	ICD-9-CM
191.4	Malignant neoplasm of occipital lobe of brain	Diagnosis	ICD-9-CM
191.5	Malignant neoplasm of ventricles of brain	Diagnosis	ICD-9-CM
191.6	Malignant neoplasm of cerebellum NOS	Diagnosis	ICD-9-CM
191.7	Malignant neoplasm of brain stem	Diagnosis	ICD-9-CM
191.8	Malignant neoplasm of other parts of brain	Diagnosis	ICD-9-CM
191.9	Malignant neoplasm of brain, unspecified site	Diagnosis	ICD-9-CM
192	Malignant neoplasm of other and unspecified parts of nervous system	Diagnosis	ICD-9-CM
192.0	Malignant neoplasm of cranial nerves	Diagnosis	ICD-9-CM
192.1	Malignant neoplasm of cerebral meninges	Diagnosis	ICD-9-CM
192.2	Malignant neoplasm of spinal cord	Diagnosis	ICD-9-CM
192.3	Malignant neoplasm of spinal meninges	Diagnosis	ICD-9-CM
192.8	Malignant neoplasm of other specified sites of nervous system	Diagnosis	ICD-9-CM
192.9	Malignant neoplasm of nervous system, part unspecified	Diagnosis	ICD-9-CM
193	Malignant neoplasm of thyroid gland	Diagnosis	ICD-9-CM
194	Malignant neoplasm of other endocrine glands and related structures	Diagnosis	ICD-9-CM
194.0	Malignant neoplasm of adrenal gland	Diagnosis	ICD-9-CM
194.1	Malignant neoplasm of parathyroid gland	Diagnosis	ICD-9-CM
194.3	Malignant neoplasm of pituitary gland and craniopharyngeal duct	Diagnosis	ICD-9-CM
194.4	Malignant neoplasm of pineal gland	Diagnosis	ICD-9-CM
194.5	Malignant neoplasm of carotid body	Diagnosis	ICD-9-CM
194.6	Malignant neoplasm of aortic body and other paraganglia	Diagnosis	ICD-9-CM
194.8	Malignant neoplasm of other endocrine glands and related structures	Diagnosis	ICD-9-CM
194.9	Malignant neoplasm of endocrine gland, site unspecified	Diagnosis	ICD-9-CM
195	Malignant neoplasm of other and ill-defined sites	Diagnosis	ICD-9-CM
195.0	Malignant neoplasm of head, face, and neck	Diagnosis	ICD-9-CM
195.1	Malignant neoplasm of thorax	Diagnosis	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
195.2	Malignant neoplasm of abdomen	Diagnosis	ICD-9-CM
195.3	Malignant neoplasm of pelvis	Diagnosis	ICD-9-CM
195.4	Malignant neoplasm of upper limb	Diagnosis	ICD-9-CM
195.5	Malignant neoplasm of lower limb	Diagnosis	ICD-9-CM
195.8	Malignant neoplasm of other specified sites	Diagnosis	ICD-9-CM
196	Secondary and unspecified malignant neoplasm of lymph nodes	Diagnosis	ICD-9-CM
196.0	Secondary and unspecified malignant neoplasm of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
196.1	Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
196.2	Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
196.3	Secondary and unspecified malignant neoplasm of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
196.5	Secondary and unspecified malignant neoplasm of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
196.6	Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
196.8	Secondary and unspecified malignant neoplasm of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
196.9	Secondary and unspecified malignant neoplasm of lymph nodes, site unspecified	Diagnosis	ICD-9-CM
197	Secondary malignant neoplasm of respiratory and digestive systems	Diagnosis	ICD-9-CM
197.0	Secondary malignant neoplasm of lung	Diagnosis	ICD-9-CM
197.1	Secondary malignant neoplasm of mediastinum	Diagnosis	ICD-9-CM
197.2	Secondary malignant neoplasm of pleura	Diagnosis	ICD-9-CM
197.3	Secondary malignant neoplasm of other respiratory organs	Diagnosis	ICD-9-CM
197.4	Secondary malignant neoplasm of small intestine including duodenum	Diagnosis	ICD-9-CM
197.5	Secondary malignant neoplasm of large intestine and rectum	Diagnosis	ICD-9-CM
197.6	Secondary malignant neoplasm of retroperitoneum and peritoneum	Diagnosis	ICD-9-CM
197.7	Secondary malignant neoplasm of liver	Diagnosis	ICD-9-CM
197.8	Secondary malignant neoplasm of other digestive organs and spleen	Diagnosis	ICD-9-CM
198	Secondary malignant neoplasm of other specified sites	Diagnosis	ICD-9-CM
198.0	Secondary malignant neoplasm of kidney	Diagnosis	ICD-9-CM
198.1	Secondary malignant neoplasm of other urinary organs	Diagnosis	ICD-9-CM
198.3	Secondary malignant neoplasm of brain and spinal cord	Diagnosis	ICD-9-CM
198.4	Secondary malignant neoplasm of other parts of nervous system	Diagnosis	ICD-9-CM
198.5	Secondary malignant neoplasm of bone and bone marrow	Diagnosis	ICD-9-CM
198.6	Secondary malignant neoplasm of ovary	Diagnosis	ICD-9-CM
198.7	Secondary malignant neoplasm of adrenal gland	Diagnosis	ICD-9-CM
198.8	Secondary malignant neoplasm of other specified sites	Diagnosis	ICD-9-CM
198.81	Secondary malignant neoplasm of breast	Diagnosis	ICD-9-CM
198.82	Secondary malignant neoplasm of genital organs	Diagnosis	ICD-9-CM
198.89	Secondary malignant neoplasm of other specified sites	Diagnosis	ICD-9-CM
199	Malignant neoplasm without specification of site	Diagnosis	ICD-9-CM
199.0	Disseminated malignant neoplasm	Diagnosis	ICD-9-CM
199.1	Other malignant neoplasm of unspecified site	Diagnosis	ICD-9-CM
199.2	Malignant neoplasm associated with transplanted organ	Diagnosis	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
200	Lymphosarcoma and reticulosarcoma and other specified malignant tumors of lymphatic tissue	Diagnosis	ICD-9-CM
200.0	Reticulosarcoma	Diagnosis	ICD-9-CM
200.00	Reticulosarcoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.01	Reticulosarcoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.02	Reticulosarcoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.03	Reticulosarcoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.04	Reticulosarcoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.05	Reticulosarcoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.06	Reticulosarcoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.07	Reticulosarcoma of spleen	Diagnosis	ICD-9-CM
200.08	Reticulosarcoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.1	Lymphosarcoma	Diagnosis	ICD-9-CM
200.10	Lymphosarcoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.11	Lymphosarcoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.12	Lymphosarcoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.13	Lymphosarcoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.14	Lymphosarcoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.15	Lymphosarcoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.16	Lymphosarcoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.17	Lymphosarcoma of spleen	Diagnosis	ICD-9-CM
200.18	Lymphosarcoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.2	Burkitt's tumor or lymphoma	Diagnosis	ICD-9-CM
200.20	Burkitt's tumor or lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.21	Burkitt's tumor or lymphoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.22	Burkitt's tumor or lymphoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.23	Burkitt's tumor or lymphoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.24	Burkitt's tumor or lymphoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.25	Burkitt's tumor or lymphoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.26	Burkitt's tumor or lymphoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.27	Burkitt's tumor or lymphoma of spleen	Diagnosis	ICD-9-CM
200.28	Burkitt's tumor or lymphoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.3	Marginal zone lymphoma	Diagnosis	ICD-9-CM
200.30	Marginal zone lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.31	Marginal zone lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.32	Marginal zone lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.33	Marginal zone lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.34	Marginal zone lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.35	Marginal zone lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.36	Marginal zone lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.37	Marginal zone lymphoma, spleen	Diagnosis	ICD-9-CM
200.38	Marginal zone lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.4	Mantle cell lymphoma	Diagnosis	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
200.40	Mantle cell lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.41	Mantle cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.42	Mantle cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.43	Mantle cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.44	Mantle cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.45	Mantle cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.46	Mantle cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.47	Mantle cell lymphoma, spleen	Diagnosis	ICD-9-CM
200.48	Mantle cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.5	Primary central nervous system lymphoma	Diagnosis	ICD-9-CM
200.50	Primary central nervous system lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.51	Primary central nervous system lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.52	Primary central nervous system lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.53	Primary central nervous system lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.54	Primary central nervous system lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.55	Primary central nervous system lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.56	Primary central nervous system lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.57	Primary central nervous system lymphoma, spleen	Diagnosis	ICD-9-CM
200.58	Primary central nervous system lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.6	Anaplastic large cell lymphoma	Diagnosis	ICD-9-CM
200.60	Anaplastic large cell lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.61	Anaplastic large cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.62	Anaplastic large cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.63	Anaplastic large cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.64	Anaplastic large cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.65	Anaplastic large cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.66	Anaplastic large cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.67	Anaplastic large cell lymphoma, spleen	Diagnosis	ICD-9-CM
200.68	Anaplastic large cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.7	Large cell lymphoma	Diagnosis	ICD-9-CM
200.70	Large cell lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
200.71	Large cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.72	Large cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.73	Large cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.74	Large cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.75	Large cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.76	Large cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.77	Large cell lymphoma, spleen	Diagnosis	ICD-9-CM
200.78	Large cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
200.8	Other named variants of lymphosarcoma and reticulosarcoma	Diagnosis	ICD-9-CM
200.80	Other named variants, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
200.81	Other named variants of lymphosarcoma and reticulosarcoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
200.82	Other named variants of lymphosarcoma and reticulosarcoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
200.83	Other named variants of lymphosarcoma and reticulosarcoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
200.84	Other named variants of lymphosarcoma and reticulosarcoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
200.85	Other named variants of lymphosarcoma and reticulosarcoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
200.86	Other named variants of lymphosarcoma and reticulosarcoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
200.87	Other named variants of lymphosarcoma and reticulosarcoma of spleen	Diagnosis	ICD-9-CM
200.88	Other named variants of lymphosarcoma and reticulosarcoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201	Hodgkin's disease	Diagnosis	ICD-9-CM
201.0	Hodgkin's paragranuloma	Diagnosis	ICD-9-CM
201.00	Hodgkin's paragranuloma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.01	Hodgkin's paragranuloma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.02	Hodgkin's paragranuloma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.03	Hodgkin's paragranuloma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.04	Hodgkin's paragranuloma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.05	Hodgkin's paragranuloma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.06	Hodgkin's paragranuloma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.07	Hodgkin's paragranuloma of spleen	Diagnosis	ICD-9-CM
201.08	Hodgkin's paragranuloma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.1	Hodgkin's granuloma	Diagnosis	ICD-9-CM
201.10	Hodgkin's granuloma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.11	Hodgkin's granuloma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.12	Hodgkin's granuloma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.13	Hodgkin's granuloma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.14	Hodgkin's granuloma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.15	Hodgkin's granuloma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.16	Hodgkin's granuloma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.17	Hodgkin's granuloma of spleen	Diagnosis	ICD-9-CM
201.18	Hodgkin's granuloma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.2	Hodgkin's sarcoma	Diagnosis	ICD-9-CM
201.20	Hodgkin's sarcoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.21	Hodgkin's sarcoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.22	Hodgkin's sarcoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.23	Hodgkin's sarcoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.24	Hodgkin's sarcoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.25	Hodgkin's sarcoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
201.26	Hodgkin's sarcoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.27	Hodgkin's sarcoma of spleen	Diagnosis	ICD-9-CM
201.28	Hodgkin's sarcoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.4	Hodgkin's disease, lymphocytic-histiocytic predominance	Diagnosis	ICD-9-CM
201.40	Hodgkin's disease, lymphocytic-histiocytic predominance, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.41	Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.42	Hodgkin's disease, lymphocytic-histiocytic predominance of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.43	Hodgkin's disease, lymphocytic-histiocytic predominance of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.44	Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.45	Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.46	Hodgkin's disease, lymphocytic-histiocytic predominance of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.47	Hodgkin's disease, lymphocytic-histiocytic predominance of spleen	Diagnosis	ICD-9-CM
201.48	Hodgkin's disease, lymphocytic-histiocytic predominance of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.5	Hodgkin's disease, nodular sclerosis	Diagnosis	ICD-9-CM
201.50	Hodgkin's disease, nodular sclerosis, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.51	Hodgkin's disease, nodular sclerosis, of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.52	Hodgkin's disease, nodular sclerosis, of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.53	Hodgkin's disease, nodular sclerosis, of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.54	Hodgkin's disease, nodular sclerosis, of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.55	Hodgkin's disease, nodular sclerosis, of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.56	Hodgkin's disease, nodular sclerosis, of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.57	Hodgkin's disease, nodular sclerosis, of spleen	Diagnosis	ICD-9-CM
201.58	Hodgkin's disease, nodular sclerosis, of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.6	Hodgkin's disease, mixed cellularity	Diagnosis	ICD-9-CM
201.60	Hodgkin's disease, mixed cellularity, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.61	Hodgkin's disease, mixed cellularity, involving lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.62	Hodgkin's disease, mixed cellularity, of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.63	Hodgkin's disease, mixed cellularity, of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.64	Hodgkin's disease, mixed cellularity, of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.65	Hodgkin's disease, mixed cellularity, of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.66	Hodgkin's disease, mixed cellularity, of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.67	Hodgkin's disease, mixed cellularity, of spleen	Diagnosis	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
201.68	Hodgkin's disease, mixed cellularity, of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.7	Hodgkin's disease, lymphocytic depletion	Diagnosis	ICD-9-CM
201.70	Hodgkin's disease, lymphocytic depletion, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.71	Hodgkin's disease, lymphocytic depletion, of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.72	Hodgkin's disease, lymphocytic depletion, of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.73	Hodgkin's disease, lymphocytic depletion, of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.74	Hodgkin's disease, lymphocytic depletion, of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.75	Hodgkin's disease, lymphocytic depletion, of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.76	Hodgkin's disease, lymphocytic depletion, of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.77	Hodgkin's disease, lymphocytic depletion, of spleen	Diagnosis	ICD-9-CM
201.78	Hodgkin's disease, lymphocytic depletion, of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
201.9	Hodgkin's disease, unspecified type	Diagnosis	ICD-9-CM
201.90	Hodgkin's disease, unspecified type, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
201.91	Hodgkin's disease, unspecified type, of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
201.92	Hodgkin's disease, unspecified type, of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
201.93	Hodgkin's disease, unspecified type, of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
201.94	Hodgkin's disease, unspecified type, of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
201.95	Hodgkin's disease, unspecified type, of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
201.96	Hodgkin's disease, unspecified type, of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
201.97	Hodgkin's disease, unspecified type, of spleen	Diagnosis	ICD-9-CM
201.98	Hodgkin's disease, unspecified type, of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202	Other malignant neoplasms of lymphoid and histiocytic tissue	Diagnosis	ICD-9-CM
202.0	Nodular lymphoma	Diagnosis	ICD-9-CM
202.00	Nodular lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.01	Nodular lymphoma of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.02	Nodular lymphoma of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.03	Nodular lymphoma of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.04	Nodular lymphoma of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.05	Nodular lymphoma of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.06	Nodular lymphoma of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.07	Nodular lymphoma of spleen	Diagnosis	ICD-9-CM
202.08	Nodular lymphoma of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.1	Mycosis fungoides	Diagnosis	ICD-9-CM
202.10	Mycosis fungoides, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.11	Mycosis fungoides of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.12	Mycosis fungoides of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.13	Mycosis fungoides of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.14	Mycosis fungoides of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.15	Mycosis fungoides of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
202.16	Mycosis fungoides of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.17	Mycosis fungoides of spleen	Diagnosis	ICD-9-CM
202.18	Mycosis fungoides of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.2	Sezary's disease	Diagnosis	ICD-9-CM
202.20	Sezary's disease, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.21	Sezary's disease of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.22	Sezary's disease of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.23	Sezary's disease of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.24	Sezary's disease of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.25	Sezary's disease of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.26	Sezary's disease of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.27	Sezary's disease of spleen	Diagnosis	ICD-9-CM
202.28	Sezary's disease of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.3	Malignant histiocytosis	Diagnosis	ICD-9-CM
202.30	Malignant histiocytosis, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.31	Malignant histiocytosis of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.32	Malignant histiocytosis of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.33	Malignant histiocytosis of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.34	Malignant histiocytosis of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.35	Malignant histiocytosis of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.36	Malignant histiocytosis of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.37	Malignant histiocytosis of spleen	Diagnosis	ICD-9-CM
202.38	Malignant histiocytosis of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.4	Leukemic reticuloendotheliosis	Diagnosis	ICD-9-CM
202.40	Leukemic reticuloendotheliosis, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.41	Leukemic reticuloendotheliosis of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.42	Leukemic reticuloendotheliosis of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.43	Leukemic reticuloendotheliosis of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.44	Leukemic reticuloendotheliosis of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.45	Leukemic reticuloendotheliosis of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.46	Leukemic reticuloendotheliosis of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.47	Leukemic reticuloendotheliosis of spleen	Diagnosis	ICD-9-CM
202.48	Leukemic reticuloendotheliosis of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.5	Letterer-Siwe disease	Diagnosis	ICD-9-CM
202.50	Letterer-Siwe disease, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.51	Letterer-Siwe disease of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.52	Letterer-Siwe disease of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.53	Letterer-Siwe disease of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.54	Letterer-Siwe disease of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.55	Letterer-Siwe disease of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.56	Letterer-Siwe disease of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.57	Letterer-Siwe disease of spleen	Diagnosis	ICD-9-CM
202.58	Letterer-Siwe disease of lymph nodes of multiple sites	Diagnosis	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
202.6	Malignant mast cell tumors	Diagnosis	ICD-9-CM
202.60	Malignant mast cell tumors, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.61	Malignant mast cell tumors of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.62	Malignant mast cell tumors of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.63	Malignant mast cell tumors of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.64	Malignant mast cell tumors of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.65	Malignant mast cell tumors of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.66	Malignant mast cell tumors of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.67	Malignant mast cell tumors of spleen	Diagnosis	ICD-9-CM
202.68	Malignant mast cell tumors of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.7	Peripheral T-cell lymphoma	Diagnosis	ICD-9-CM
202.70	Peripheral T-cell lymphoma, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.71	Peripheral T-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.72	Peripheral T-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.73	Peripheral T-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.74	Peripheral T-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.75	Peripheral T-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.76	Peripheral T-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.77	Peripheral T-cell lymphoma, spleen	Diagnosis	ICD-9-CM
202.78	Peripheral T-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.8	Other malignant lymphomas	Diagnosis	ICD-9-CM
202.80	Other malignant lymphomas, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.81	Other malignant lymphomas of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.82	Other malignant lymphomas of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.83	Other malignant lymphomas of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.84	Other malignant lymphomas of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.85	Other malignant lymphomas of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM
202.86	Other malignant lymphomas of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.87	Other malignant lymphomas of spleen	Diagnosis	ICD-9-CM
202.88	Other malignant lymphomas of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
202.9	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue	Diagnosis	ICD-9-CM
202.90	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue, unspecified site, extranodal and solid organ sites	Diagnosis	ICD-9-CM
202.91	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of lymph nodes of head, face, and neck	Diagnosis	ICD-9-CM
202.92	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of intrathoracic lymph nodes	Diagnosis	ICD-9-CM
202.93	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of intra-abdominal lymph nodes	Diagnosis	ICD-9-CM
202.94	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of lymph nodes of axilla and upper limb	Diagnosis	ICD-9-CM
202.95	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of lymph nodes of inguinal region and lower limb	Diagnosis	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
202.96	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of intrapelvic lymph nodes	Diagnosis	ICD-9-CM
202.97	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of spleen	Diagnosis	ICD-9-CM
202.98	Other and unspecified malignant neoplasms of lymphoid and histiocytic tissue of lymph nodes of multiple sites	Diagnosis	ICD-9-CM
203	Multiple myeloma and immunoproliferative neoplasms	Diagnosis	ICD-9-CM
203.0	Multiple myeloma	Diagnosis	ICD-9-CM
203.00	Multiple myeloma, without mention of having achieved remission	Diagnosis	ICD-9-CM
203.01	Multiple myeloma in remission	Diagnosis	ICD-9-CM
203.02	Multiple myeloma, in relapse	Diagnosis	ICD-9-CM
203.1	Plasma cell leukemia	Diagnosis	ICD-9-CM
203.10	Plasma cell leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
203.11	Plasma cell leukemia in remission	Diagnosis	ICD-9-CM
203.12	Plasma cell leukemia, in relapse	Diagnosis	ICD-9-CM
203.8	Other immunoproliferative neoplasms	Diagnosis	ICD-9-CM
203.80	Other immunoproliferative neoplasms, without mention of having achieved remission	Diagnosis	ICD-9-CM
203.81	Other immunoproliferative neoplasms in remission	Diagnosis	ICD-9-CM
203.82	Other immunoproliferative neoplasms, in relapse	Diagnosis	ICD-9-CM
204	Lymphoid leukemia	Diagnosis	ICD-9-CM
204.0	Acute lymphoid leukemia	Diagnosis	ICD-9-CM
204.00	Acute lymphoid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
204.01	Acute lymphoid leukemia in remission	Diagnosis	ICD-9-CM
204.02	Acute lymphoid leukemia, in relapse	Diagnosis	ICD-9-CM
204.1	Chronic lymphoid leukemia	Diagnosis	ICD-9-CM
204.10	Chronic lymphoid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
204.11	Chronic lymphoid leukemia in remission	Diagnosis	ICD-9-CM
204.12	Chronic lymphoid leukemia, in relapse	Diagnosis	ICD-9-CM
204.2	Subacute lymphoid leukemia	Diagnosis	ICD-9-CM
204.20	Subacute lymphoid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
204.21	Subacute lymphoid leukemia in remission	Diagnosis	ICD-9-CM
204.22	Subacute lymphoid leukemia, in relapse	Diagnosis	ICD-9-CM
204.8	Other lymphoid leukemia	Diagnosis	ICD-9-CM
204.80	Other lymphoid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
204.81	Other lymphoid leukemia in remission	Diagnosis	ICD-9-CM
204.82	Other lymphoid leukemia, in relapse	Diagnosis	ICD-9-CM
204.9	Unspecified lymphoid leukemia	Diagnosis	ICD-9-CM
204.90	Unspecified lymphoid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
204.91	Unspecified lymphoid leukemia in remission	Diagnosis	ICD-9-CM
204.92	Unspecified lymphoid leukemia, in relapse	Diagnosis	ICD-9-CM
205	Myeloid leukemia	Diagnosis	ICD-9-CM
205.0	Acute myeloid leukemia	Diagnosis	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
205.00	Acute myeloid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.01	Acute myeloid leukemia in remission	Diagnosis	ICD-9-CM
205.02	Acute myeloid leukemia, in relapse	Diagnosis	ICD-9-CM
205.1	Chronic myeloid leukemia	Diagnosis	ICD-9-CM
205.10	Chronic myeloid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.11	Chronic myeloid leukemia in remission	Diagnosis	ICD-9-CM
205.12	Chronic myeloid leukemia, in relapse	Diagnosis	ICD-9-CM
205.2	Subacute myeloid leukemia	Diagnosis	ICD-9-CM
205.20	Subacute myeloid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.21	Subacute myeloid leukemia in remission	Diagnosis	ICD-9-CM
205.22	Subacute myeloid leukemia, in relapse	Diagnosis	ICD-9-CM
205.3	Myeloid sarcoma	Diagnosis	ICD-9-CM
205.30	Myeloid sarcoma, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.31	Myeloid sarcoma in remission	Diagnosis	ICD-9-CM
205.32	Myeloid sarcoma, in relapse	Diagnosis	ICD-9-CM
205.8	Other myeloid leukemia	Diagnosis	ICD-9-CM
205.80	Other myeloid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.81	Other myeloid leukemia in remission	Diagnosis	ICD-9-CM
205.82	Other myeloid leukemia, in relapse	Diagnosis	ICD-9-CM
205.9	Unspecified myeloid leukemia	Diagnosis	ICD-9-CM
205.90	Unspecified myeloid leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
205.91	Unspecified myeloid leukemia in remission	Diagnosis	ICD-9-CM
205.92	Unspecified myeloid leukemia, in relapse	Diagnosis	ICD-9-CM
206	Monocytic leukemia	Diagnosis	ICD-9-CM
206.0	Acute monocytic leukemia	Diagnosis	ICD-9-CM
206.00	Acute monocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
206.01	Acute monocytic leukemia in remission	Diagnosis	ICD-9-CM
206.02	Acute monocytic leukemia, in relapse	Diagnosis	ICD-9-CM
206.1	Chronic monocytic leukemia	Diagnosis	ICD-9-CM
206.10	Chronic monocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
206.11	Chronic monocytic leukemia in remission	Diagnosis	ICD-9-CM
206.12	Chronic monocytic leukemia, in relapse	Diagnosis	ICD-9-CM
206.2	Subacute monocytic leukemia	Diagnosis	ICD-9-CM
206.20	Subacute monocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
206.21	Subacute monocytic leukemia in remission	Diagnosis	ICD-9-CM
206.22	Subacute monocytic leukemia, in relapse	Diagnosis	ICD-9-CM
206.8	Other monocytic leukemia	Diagnosis	ICD-9-CM
206.80	Other monocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
206.81	Other monocytic leukemia in remission	Diagnosis	ICD-9-CM
206.82	Other monocytic leukemia, in relapse	Diagnosis	ICD-9-CM
206.9	Unspecified monocytic leukemia	Diagnosis	ICD-9-CM
206.90	Unspecified monocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
206.91	Unspecified monocytic leukemia in remission	Diagnosis	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
206.92	Unspecified monocytic leukemia, in relapse	Diagnosis	ICD-9-CM
207	Other specified leukemia	Diagnosis	ICD-9-CM
207.0	Acute erythremia and erythroleukemia	Diagnosis	ICD-9-CM
207.00	Acute erythremia and erythroleukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
207.01	Acute erythremia and erythroleukemia in remission	Diagnosis	ICD-9-CM
207.02	Acute erythremia and erythroleukemia, in relapse	Diagnosis	ICD-9-CM
207.1	Chronic erythremia	Diagnosis	ICD-9-CM
207.10	Chronic erythremia, without mention of having achieved remission	Diagnosis	ICD-9-CM
207.11	Chronic erythremia in remission	Diagnosis	ICD-9-CM
207.12	Chronic erythremia, in relapse	Diagnosis	ICD-9-CM
207.2	Megakaryocytic leukemia	Diagnosis	ICD-9-CM
207.20	Megakaryocytic leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
207.21	Megakaryocytic leukemia in remission	Diagnosis	ICD-9-CM
207.22	Megakaryocytic leukemia, in relapse	Diagnosis	ICD-9-CM
207.8	Other specified leukemia	Diagnosis	ICD-9-CM
207.80	Other specified leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
207.81	Other specified leukemia in remission	Diagnosis	ICD-9-CM
207.82	Other specified leukemia, in relapse	Diagnosis	ICD-9-CM
208	Leukemia of unspecified cell type	Diagnosis	ICD-9-CM
208.0	Acute leukemia of unspecified cell type	Diagnosis	ICD-9-CM
208.00	Acute leukemia of unspecified cell type, without mention of having achieved remission	Diagnosis	ICD-9-CM
208.01	Acute leukemia of unspecified cell type in remission	Diagnosis	ICD-9-CM
208.02	Acute leukemia of unspecified cell type, in relapse	Diagnosis	ICD-9-CM
208.1	Chronic leukemia of unspecified cell type	Diagnosis	ICD-9-CM
208.10	Chronic leukemia of unspecified cell type, without mention of having achieved remission	Diagnosis	ICD-9-CM
208.11	Chronic leukemia of unspecified cell type in remission	Diagnosis	ICD-9-CM
208.12	Chronic leukemia of unspecified cell type, in relapse	Diagnosis	ICD-9-CM
208.2	Subacute leukemia of unspecified cell type	Diagnosis	ICD-9-CM
208.20	Subacute leukemia of unspecified cell type, without mention of having achieved remission	Diagnosis	ICD-9-CM
208.21	Subactue leukemia of unspecified cell type in remission	Diagnosis	ICD-9-CM
208.22	Subacute leukemia of unspecified cell type, in relapse	Diagnosis	ICD-9-CM
208.8	Other leukemia of unspecified cell type	Diagnosis	ICD-9-CM
208.80	Other leukemia of unspecified cell type, without mention of having achieved remission	Diagnosis	ICD-9-CM
208.81	Other leukemia of unspecified cell type in remission	Diagnosis	ICD-9-CM
208.82	Other leukemia of unspecified cell type, in relapse	Diagnosis	ICD-9-CM
208.9	Unspecified leukemia	Diagnosis	ICD-9-CM
208.90	Unspecified leukemia, without mention of having achieved remission	Diagnosis	ICD-9-CM
208.91	Unspecified leukemia in remission	Diagnosis	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
208.92	Unspecified leukemia, in relapse	Diagnosis	ICD-9-CM
209	Neuroendocrine tumors	Diagnosis	ICD-9-CM
209.0	Malignant carcinoid tumors of the small intestine	Diagnosis	ICD-9-CM
209.00	Malignant carcinoid tumor of the small intestine, unspecified portion	Diagnosis	ICD-9-CM
209.01	Malignant carcinoid tumor of the duodenum	Diagnosis	ICD-9-CM
209.02	Malignant carcinoid tumor of the jejunum	Diagnosis	ICD-9-CM
209.03	Malignant carcinoid tumor of the ileum	Diagnosis	ICD-9-CM
209.1	Malignant carcinoid tumors of the appendix, large intestine, and rectum	Diagnosis	ICD-9-CM
209.10	Malignant carcinoid tumor of the large intestine, unspecified portion	Diagnosis	ICD-9-CM
209.11	Malignant carcinoid tumor of the appendix	Diagnosis	ICD-9-CM
209.12	Malignant carcinoid tumor of the cecum	Diagnosis	ICD-9-CM
209.13	Malignant carcinoid tumor of the ascending colon	Diagnosis	ICD-9-CM
209.14	Malignant carcinoid tumor of the transverse colon	Diagnosis	ICD-9-CM
209.15	Malignant carcinoid tumor of the descending colon	Diagnosis	ICD-9-CM
209.16	Malignant carcinoid tumor of the sigmoid colon	Diagnosis	ICD-9-CM
209.17	Malignant carcinoid tumor of the rectum	Diagnosis	ICD-9-CM
209.2	Malignant carcinoid tumors of other and unspecified sites	Diagnosis	ICD-9-CM
209.20	Malignant carcinoid tumor of unknown primary site	Diagnosis	ICD-9-CM
209.21	Malignant carcinoid tumor of the bronchus and lung	Diagnosis	ICD-9-CM
209.22	Malignant carcinoid tumor of the thymus	Diagnosis	ICD-9-CM
209.23	Malignant carcinoid tumor of the stomach	Diagnosis	ICD-9-CM
209.24	Malignant carcinoid tumor of the kidney	Diagnosis	ICD-9-CM
209.25	Malignant carcinoid tumor of foregut, not otherwise specified	Diagnosis	ICD-9-CM
209.26	Malignant carcinoid tumor of midgut, not otherwise specified	Diagnosis	ICD-9-CM
209.27	Malignant carcinoid tumor of hindgut, not otherwise specified	Diagnosis	ICD-9-CM
209.29	Malignant carcinoid tumor of other sites	Diagnosis	ICD-9-CM
209.3	Malignant poorly differentiated neuroendocrine tumors	Diagnosis	ICD-9-CM
209.30	Malignant poorly differentiated neuroendocrine carcinoma, any site	Diagnosis	ICD-9-CM
209.31	Merkel cell carcinoma of the face	Diagnosis	ICD-9-CM
209.32	Merkel cell carcinoma of the scalp and neck	Diagnosis	ICD-9-CM
209.33	Merkel cell carcinoma of the upper limb	Diagnosis	ICD-9-CM
209.34	Merkel cell carcinoma of the lower limb	Diagnosis	ICD-9-CM
209.35	Merkel cell carcinoma of the trunk	Diagnosis	ICD-9-CM
209.36	Merkel cell carcinoma of other sites	Diagnosis	ICD-9-CM
209.7	Secondary neuroendocrine tumors	Diagnosis	ICD-9-CM
209.70	Secondary neuroendocrine tumor, unspecified site	Diagnosis	ICD-9-CM
209.71	Secondary neuroendocrine tumor of distant lymph nodes	Diagnosis	ICD-9-CM
209.72	Secondary neuroendocrine tumor of liver	Diagnosis	ICD-9-CM
209.73	Secondary neuroendocrine tumor of bone	Diagnosis	ICD-9-CM
209.74	Secondary neuroendocrine tumor of peritoneum	Diagnosis	ICD-9-CM
209.75	Secondary Merkel cell carcinoma	Diagnosis	ICD-9-CM
209.79	Secondary neuroendocrine tumor of other sites	Diagnosis	ICD-9-CM
235	Neoplasm of uncertain behavior of digestive and respiratory systems	Diagnosis	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
235.0	Neoplasm of uncertain behavior of major salivary glands	Diagnosis	ICD-9-CM
235.1	Neoplasm of uncertain behavior of lip, oral cavity, and pharynx	Diagnosis	ICD-9-CM
235.2	Neoplasm of uncertain behavior of stomach, intestines, and rectum	Diagnosis	ICD-9-CM
235.3	Neoplasm of uncertain behavior of liver and biliary passages	Diagnosis	ICD-9-CM
235.4	Neoplasm of uncertain behavior of retroperitoneum and peritoneum	Diagnosis	ICD-9-CM
235.5	Neoplasm of uncertain behavior of other and unspecified digestive organs	Diagnosis	ICD-9-CM
235.6	Neoplasm of uncertain behavior of larynx	Diagnosis	ICD-9-CM
235.7	Neoplasm of uncertain behavior of trachea, bronchus, and lung	Diagnosis	ICD-9-CM
235.8	Neoplasm of uncertain behavior of pleura, thymus, and mediastinum	Diagnosis	ICD-9-CM
235.9	Neoplasm of uncertain behavior of other and unspecified respiratory organs	Diagnosis	ICD-9-CM
236	Neoplasm of uncertain behavior of genitourinary organs	Diagnosis	ICD-9-CM
236.0	Neoplasm of uncertain behavior of uterus	Diagnosis	ICD-9-CM
236.1	Neoplasm of uncertain behavior of placenta	Diagnosis	ICD-9-CM
236.2	Neoplasm of uncertain behavior of ovary	Diagnosis	ICD-9-CM
236.3	Neoplasm of uncertain behavior of other and unspecified female genital organs	Diagnosis	ICD-9-CM
236.4	Neoplasm of uncertain behavior of testis	Diagnosis	ICD-9-CM
236.5	Neoplasm of uncertain behavior of prostate	Diagnosis	ICD-9-CM
236.6	Neoplasm of uncertain behavior of other and unspecified male genital organs	Diagnosis	ICD-9-CM
236.7	Neoplasm of uncertain behavior of bladder	Diagnosis	ICD-9-CM
236.9	Neoplasm of uncertain behavior of other and unspecified urinary organs	Diagnosis	ICD-9-CM
236.90	Neoplasm of uncertain behavior of urinary organ, unspecified	Diagnosis	ICD-9-CM
236.91	Neoplasm of uncertain behavior of kidney and ureter	Diagnosis	ICD-9-CM
236.99	Neoplasm of uncertain behavior of other and unspecified urinary organs	Diagnosis	ICD-9-CM
237	Neoplasm of uncertain behavior of endocrine glands and nervous system	Diagnosis	ICD-9-CM
237.0	Neoplasm of uncertain behavior of pituitary gland and craniopharyngeal duct	Diagnosis	ICD-9-CM
237.1	Neoplasm of uncertain behavior of pineal gland	Diagnosis	ICD-9-CM
237.2	Neoplasm of uncertain behavior of adrenal gland	Diagnosis	ICD-9-CM
237.3	Neoplasm of uncertain behavior of paraganglia	Diagnosis	ICD-9-CM
237.4	Neoplasm of uncertain behavior of other and unspecified endocrine glands	Diagnosis	ICD-9-CM
237.5	Neoplasm of uncertain behavior of brain and spinal cord	Diagnosis	ICD-9-CM
237.6	Neoplasm of uncertain behavior of meninges	Diagnosis	ICD-9-CM
237.7	Neurofibromatosis	Diagnosis	ICD-9-CM
237.70	Neurofibromatosis, unspecified	Diagnosis	ICD-9-CM
237.71	Neurofibromatosis, Type 1 (von Recklinghausen's disease)	Diagnosis	ICD-9-CM
237.72	Neurofibromatosis, Type 2 (acoustic neurofibromatosis)	Diagnosis	ICD-9-CM
237.73	Schwannomatosis	Diagnosis	ICD-9-CM
237.79	Other neurofibromatosis	Diagnosis	ICD-9-CM
237.9	Neoplasm of uncertain behavior of other and unspecified parts of nervous system	Diagnosis	ICD-9-CM
238	Neoplasm of uncertain behavior of other and unspecified sites and tissues	Diagnosis	ICD-9-CM
238.0	Neoplasm of uncertain behavior of bone and articular cartilage	Diagnosis	ICD-9-CM
238.1	Neoplasm of uncertain behavior of connective and other soft tissue	Diagnosis	ICD-9-CM
238.3	Neoplasm of uncertain behavior of breast	Diagnosis	ICD-9-CM
238.4	Neoplasm of uncertain behavior of polycythemia vera	Diagnosis	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
238.5	Neoplasm of uncertain behavior of histiocytic and mast cells	Diagnosis	ICD-9-CM
238.6	Neoplasm of uncertain behavior of plasma cells	Diagnosis	ICD-9-CM
238.7	Other lymphatic and hematopoietic tissues	Diagnosis	ICD-9-CM
238.71	Essential thrombocythemia	Diagnosis	ICD-9-CM
238.72	Low grade myelodysplastic syndrome lesions	Diagnosis	ICD-9-CM
238.73	High grade myelodysplastic syndrome lesions	Diagnosis	ICD-9-CM
238.74	Myelodysplastic syndrome with 5q deletion	Diagnosis	ICD-9-CM
238.75	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-9-CM
238.76	Myelofibrosis with myeloid metaplasia	Diagnosis	ICD-9-CM
238.77	Post-transplant lymphoproliferative disorder [PTLD]	Diagnosis	ICD-9-CM
238.79	Other lymphatic and hematopoietic tissues	Diagnosis	ICD-9-CM
238.8	Neoplasm of uncertain behavior of other specified sites	Diagnosis	ICD-9-CM
238.9	Neoplasm of uncertain behavior, site unspecified	Diagnosis	ICD-9-CM
239	Neoplasms of unspecified nature	Diagnosis	ICD-9-CM
239.0	Neoplasm of unspecified nature of digestive system	Diagnosis	ICD-9-CM
239.1	Neoplasm of unspecified nature of respiratory system	Diagnosis	ICD-9-CM
239.3	Neoplasm of unspecified nature of breast	Diagnosis	ICD-9-CM
239.4	Neoplasm of unspecified nature of bladder	Diagnosis	ICD-9-CM
239.5	Neoplasm of unspecified nature of other genitourinary organs	Diagnosis	ICD-9-CM
239.6	Neoplasm of unspecified nature of brain	Diagnosis	ICD-9-CM
239.7	Neoplasm of unspecified nature of endocrine glands and other parts of nervous system	Diagnosis	ICD-9-CM
239.8	Neoplasm of unspecified nature of other specified sites	Diagnosis	ICD-9-CM
239.81	Neoplasms of unspecified nature, retina and choroid	Diagnosis	ICD-9-CM
239.89	Neoplasms of unspecified nature, other specified sites	Diagnosis	ICD-9-CM
239.9	Neoplasm of unspecified nature, site unspecified	Diagnosis	ICD-9-CM
273.3	Macroglobulinemia	Diagnosis	ICD-9-CM
C00	Malignant neoplasm of lip	Diagnosis	ICD-10-CM
C00.0	Malignant neoplasm of external upper lip	Diagnosis	ICD-10-CM
C00.1	Malignant neoplasm of external lower lip	Diagnosis	ICD-10-CM
C00.2	Malignant neoplasm of external lip, unspecified	Diagnosis	ICD-10-CM
C00.3	Malignant neoplasm of upper lip, inner aspect	Diagnosis	ICD-10-CM
C00.4	Malignant neoplasm of lower lip, inner aspect	Diagnosis	ICD-10-CM
C00.5	Malignant neoplasm of lip, unspecified, inner aspect	Diagnosis	ICD-10-CM
C00.6	Malignant neoplasm of commissure of lip, unspecified	Diagnosis	ICD-10-CM
C00.8	Malignant neoplasm of overlapping sites of lip	Diagnosis	ICD-10-CM
C00.9	Malignant neoplasm of lip, unspecified	Diagnosis	ICD-10-CM
C01	Malignant neoplasm of base of tongue	Diagnosis	ICD-10-CM
C02	Malignant neoplasm of other and unspecified parts of tongue	Diagnosis	ICD-10-CM
C02.0	Malignant neoplasm of dorsal surface of tongue	Diagnosis	ICD-10-CM
C02.1	Malignant neoplasm of border of tongue	Diagnosis	ICD-10-CM
C02.2	Malignant neoplasm of ventral surface of tongue	Diagnosis	ICD-10-CM
C02.3	Malignant neoplasm of anterior two-thirds of tongue, part unspecified	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C02.4	Malignant neoplasm of lingual tonsil	Diagnosis	ICD-10-CM
C02.8	Malignant neoplasm of overlapping sites of tongue	Diagnosis	ICD-10-CM
C02.9	Malignant neoplasm of tongue, unspecified	Diagnosis	ICD-10-CM
C03	Malignant neoplasm of gum	Diagnosis	ICD-10-CM
C03.0	Malignant neoplasm of upper gum	Diagnosis	ICD-10-CM
C03.1	Malignant neoplasm of lower gum	Diagnosis	ICD-10-CM
C03.9	Malignant neoplasm of gum, unspecified	Diagnosis	ICD-10-CM
C04	Malignant neoplasm of floor of mouth	Diagnosis	ICD-10-CM
C04.0	Malignant neoplasm of anterior floor of mouth	Diagnosis	ICD-10-CM
C04.1	Malignant neoplasm of lateral floor of mouth	Diagnosis	ICD-10-CM
C04.8	Malignant neoplasm of overlapping sites of floor of mouth	Diagnosis	ICD-10-CM
C04.9	Malignant neoplasm of floor of mouth, unspecified	Diagnosis	ICD-10-CM
C05	Malignant neoplasm of palate	Diagnosis	ICD-10-CM
C05.0	Malignant neoplasm of hard palate	Diagnosis	ICD-10-CM
C05.1	Malignant neoplasm of soft palate	Diagnosis	ICD-10-CM
C05.2	Malignant neoplasm of uvula	Diagnosis	ICD-10-CM
C05.8	Malignant neoplasm of overlapping sites of palate	Diagnosis	ICD-10-CM
C05.9	Malignant neoplasm of palate, unspecified	Diagnosis	ICD-10-CM
C06	Malignant neoplasm of other and unspecified parts of mouth	Diagnosis	ICD-10-CM
C06.0	Malignant neoplasm of cheek mucosa	Diagnosis	ICD-10-CM
C06.1	Malignant neoplasm of vestibule of mouth	Diagnosis	ICD-10-CM
C06.2	Malignant neoplasm of retromolar area	Diagnosis	ICD-10-CM
C06.8	Malignant neoplasm of overlapping sites of other and unspecified parts of mouth	Diagnosis	ICD-10-CM
C06.80	Malignant neoplasm of overlapping sites of unspecified parts of mouth	Diagnosis	ICD-10-CM
C06.89	Malignant neoplasm of overlapping sites of other parts of mouth	Diagnosis	ICD-10-CM
C06.9	Malignant neoplasm of mouth, unspecified	Diagnosis	ICD-10-CM
C07	Malignant neoplasm of parotid gland	Diagnosis	ICD-10-CM
C08	Malignant neoplasm of other and unspecified major salivary glands	Diagnosis	ICD-10-CM
C08.0	Malignant neoplasm of submandibular gland	Diagnosis	ICD-10-CM
C08.1	Malignant neoplasm of sublingual gland	Diagnosis	ICD-10-CM
C08.9	Malignant neoplasm of major salivary gland, unspecified	Diagnosis	ICD-10-CM
C09	Malignant neoplasm of tonsil	Diagnosis	ICD-10-CM
C09.0	Malignant neoplasm of tonsillar fossa	Diagnosis	ICD-10-CM
C09.1	Malignant neoplasm of tonsillar pillar (anterior) (posterior)	Diagnosis	ICD-10-CM
C09.8	Malignant neoplasm of overlapping sites of tonsil	Diagnosis	ICD-10-CM
C09.9	Malignant neoplasm of tonsil, unspecified	Diagnosis	ICD-10-CM
C10	Malignant neoplasm of oropharynx	Diagnosis	ICD-10-CM
C10.0	Malignant neoplasm of vallecula	Diagnosis	ICD-10-CM
C10.1	Malignant neoplasm of anterior surface of epiglottis	Diagnosis	ICD-10-CM
C10.2	Malignant neoplasm of lateral wall of oropharynx	Diagnosis	ICD-10-CM
C10.3	Malignant neoplasm of posterior wall of oropharynx	Diagnosis	ICD-10-CM
C10.4	Malignant neoplasm of branchial cleft	Diagnosis	ICD-10-CM
C10.8	Malignant neoplasm of overlapping sites of oropharynx	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C10.9	Malignant neoplasm of oropharynx, unspecified	Diagnosis	ICD-10-CM
C11	Malignant neoplasm of nasopharynx	Diagnosis	ICD-10-CM
C11.0	Malignant neoplasm of superior wall of nasopharynx	Diagnosis	ICD-10-CM
C11.1	Malignant neoplasm of posterior wall of nasopharynx	Diagnosis	ICD-10-CM
C11.2	Malignant neoplasm of lateral wall of nasopharynx	Diagnosis	ICD-10-CM
C11.3	Malignant neoplasm of anterior wall of nasopharynx	Diagnosis	ICD-10-CM
C11.8	Malignant neoplasm of overlapping sites of nasopharynx	Diagnosis	ICD-10-CM
C11.9	Malignant neoplasm of nasopharynx, unspecified	Diagnosis	ICD-10-CM
C12	Malignant neoplasm of pyriform sinus	Diagnosis	ICD-10-CM
C13	Malignant neoplasm of hypopharynx	Diagnosis	ICD-10-CM
C13.0	Malignant neoplasm of postcricoid region	Diagnosis	ICD-10-CM
C13.1	Malignant neoplasm of aryepiglottic fold, hypopharyngeal aspect	Diagnosis	ICD-10-CM
C13.2	Malignant neoplasm of posterior wall of hypopharynx	Diagnosis	ICD-10-CM
C13.8	Malignant neoplasm of overlapping sites of hypopharynx	Diagnosis	ICD-10-CM
C13.9	Malignant neoplasm of hypopharynx, unspecified	Diagnosis	ICD-10-CM
C14	Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx	Diagnosis	ICD-10-CM
C14.0	Malignant neoplasm of pharynx, unspecified	Diagnosis	ICD-10-CM
C14.2	Malignant neoplasm of Waldeyer's ring	Diagnosis	ICD-10-CM
C14.8	Malignant neoplasm of overlapping sites of lip, oral cavity and pharynx	Diagnosis	ICD-10-CM
C15	Malignant neoplasm of esophagus	Diagnosis	ICD-10-CM
C15.3	Malignant neoplasm of upper third of esophagus	Diagnosis	ICD-10-CM
C15.4	Malignant neoplasm of middle third of esophagus	Diagnosis	ICD-10-CM
C15.5	Malignant neoplasm of lower third of esophagus	Diagnosis	ICD-10-CM
C15.8	Malignant neoplasm of overlapping sites of esophagus	Diagnosis	ICD-10-CM
C15.9	Malignant neoplasm of esophagus, unspecified	Diagnosis	ICD-10-CM
C16	Malignant neoplasm of stomach	Diagnosis	ICD-10-CM
C16.0	Malignant neoplasm of cardia	Diagnosis	ICD-10-CM
C16.1	Malignant neoplasm of fundus of stomach	Diagnosis	ICD-10-CM
C16.2	Malignant neoplasm of body of stomach	Diagnosis	ICD-10-CM
C16.3	Malignant neoplasm of pyloric antrum	Diagnosis	ICD-10-CM
C16.4	Malignant neoplasm of pylorus	Diagnosis	ICD-10-CM
C16.5	Malignant neoplasm of lesser curvature of stomach, unspecified	Diagnosis	ICD-10-CM
C16.6	Malignant neoplasm of greater curvature of stomach, unspecified	Diagnosis	ICD-10-CM
C16.8	Malignant neoplasm of overlapping sites of stomach	Diagnosis	ICD-10-CM
C16.9	Malignant neoplasm of stomach, unspecified	Diagnosis	ICD-10-CM
C17	Malignant neoplasm of small intestine	Diagnosis	ICD-10-CM
C17.0	Malignant neoplasm of duodenum	Diagnosis	ICD-10-CM
C17.1	Malignant neoplasm of jejunum	Diagnosis	ICD-10-CM
C17.2	Malignant neoplasm of ileum	Diagnosis	ICD-10-CM
C17.3	Meckel's diverticulum, malignant	Diagnosis	ICD-10-CM
C17.8	Malignant neoplasm of overlapping sites of small intestine	Diagnosis	ICD-10-CM
C17.9	Malignant neoplasm of small intestine, unspecified	Diagnosis	ICD-10-CM
C18	Malignant neoplasm of colon	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C18.0	Malignant neoplasm of cecum	Diagnosis	ICD-10-CM
C18.1	Malignant neoplasm of appendix	Diagnosis	ICD-10-CM
C18.2	Malignant neoplasm of ascending colon	Diagnosis	ICD-10-CM
C18.3	Malignant neoplasm of hepatic flexure	Diagnosis	ICD-10-CM
C18.4	Malignant neoplasm of transverse colon	Diagnosis	ICD-10-CM
C18.5	Malignant neoplasm of splenic flexure	Diagnosis	ICD-10-CM
C18.6	Malignant neoplasm of descending colon	Diagnosis	ICD-10-CM
C18.7	Malignant neoplasm of sigmoid colon	Diagnosis	ICD-10-CM
C18.8	Malignant neoplasm of overlapping sites of colon	Diagnosis	ICD-10-CM
C18.9	Malignant neoplasm of colon, unspecified	Diagnosis	ICD-10-CM
C19	Malignant neoplasm of rectosigmoid junction	Diagnosis	ICD-10-CM
C20	Malignant neoplasm of rectum	Diagnosis	ICD-10-CM
C21	Malignant neoplasm of anus and anal canal	Diagnosis	ICD-10-CM
C21.0	Malignant neoplasm of anus, unspecified	Diagnosis	ICD-10-CM
C21.1	Malignant neoplasm of anal canal	Diagnosis	ICD-10-CM
C21.2	Malignant neoplasm of cloacogenic zone	Diagnosis	ICD-10-CM
C21.8	Malignant neoplasm of overlapping sites of rectum, anus and anal canal	Diagnosis	ICD-10-CM
C22	Malignant neoplasm of liver and intrahepatic bile ducts	Diagnosis	ICD-10-CM
C22.0	Liver cell carcinoma	Diagnosis	ICD-10-CM
C22.1	Intrahepatic bile duct carcinoma	Diagnosis	ICD-10-CM
C22.2	Hepatoblastoma	Diagnosis	ICD-10-CM
C22.3	Angiosarcoma of liver	Diagnosis	ICD-10-CM
C22.4	Other sarcomas of liver	Diagnosis	ICD-10-CM
C22.7	Other specified carcinomas of liver	Diagnosis	ICD-10-CM
C22.8	Malignant neoplasm of liver, primary, unspecified as to type	Diagnosis	ICD-10-CM
C22.9	Malignant neoplasm of liver, not specified as primary or secondary	Diagnosis	ICD-10-CM
C23	Malignant neoplasm of gallbladder	Diagnosis	ICD-10-CM
C24	Malignant neoplasm of other and unspecified parts of biliary tract	Diagnosis	ICD-10-CM
C24.0	Malignant neoplasm of extrahepatic bile duct	Diagnosis	ICD-10-CM
C24.1	Malignant neoplasm of ampulla of Vater	Diagnosis	ICD-10-CM
C24.8	Malignant neoplasm of overlapping sites of biliary tract	Diagnosis	ICD-10-CM
C24.9	Malignant neoplasm of biliary tract, unspecified	Diagnosis	ICD-10-CM
C25	Malignant neoplasm of pancreas	Diagnosis	ICD-10-CM
C25.0	Malignant neoplasm of head of pancreas	Diagnosis	ICD-10-CM
C25.1	Malignant neoplasm of body of pancreas	Diagnosis	ICD-10-CM
C25.2	Malignant neoplasm of tail of pancreas	Diagnosis	ICD-10-CM
C25.3	Malignant neoplasm of pancreatic duct	Diagnosis	ICD-10-CM
C25.4	Malignant neoplasm of endocrine pancreas	Diagnosis	ICD-10-CM
C25.7	Malignant neoplasm of other parts of pancreas	Diagnosis	ICD-10-CM
C25.8	Malignant neoplasm of overlapping sites of pancreas	Diagnosis	ICD-10-CM
C25.9	Malignant neoplasm of pancreas, unspecified	Diagnosis	ICD-10-CM
C26	Malignant neoplasm of other and ill-defined digestive organs	Diagnosis	ICD-10-CM
C26.0	Malignant neoplasm of intestinal tract, part unspecified	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C26.1	Malignant neoplasm of spleen	Diagnosis	ICD-10-CM
C26.9	Malignant neoplasm of ill-defined sites within the digestive system	Diagnosis	ICD-10-CM
C30	Malignant neoplasm of nasal cavity and middle ear	Diagnosis	ICD-10-CM
C30.0	Malignant neoplasm of nasal cavity	Diagnosis	ICD-10-CM
C30.1	Malignant neoplasm of middle ear	Diagnosis	ICD-10-CM
C31	Malignant neoplasm of accessory sinuses	Diagnosis	ICD-10-CM
C31.0	Malignant neoplasm of maxillary sinus	Diagnosis	ICD-10-CM
C31.1	Malignant neoplasm of ethmoidal sinus	Diagnosis	ICD-10-CM
C31.2	Malignant neoplasm of frontal sinus	Diagnosis	ICD-10-CM
C31.3	Malignant neoplasm of sphenoid sinus	Diagnosis	ICD-10-CM
C31.8	Malignant neoplasm of overlapping sites of accessory sinuses	Diagnosis	ICD-10-CM
C31.9	Malignant neoplasm of accessory sinus, unspecified	Diagnosis	ICD-10-CM
C32	Malignant neoplasm of larynx	Diagnosis	ICD-10-CM
C32.0	Malignant neoplasm of glottis	Diagnosis	ICD-10-CM
C32.1	Malignant neoplasm of supraglottis	Diagnosis	ICD-10-CM
C32.2	Malignant neoplasm of subglottis	Diagnosis	ICD-10-CM
C32.3	Malignant neoplasm of laryngeal cartilage	Diagnosis	ICD-10-CM
C32.8	Malignant neoplasm of overlapping sites of larynx	Diagnosis	ICD-10-CM
C32.9	Malignant neoplasm of larynx, unspecified	Diagnosis	ICD-10-CM
C33	Malignant neoplasm of trachea	Diagnosis	ICD-10-CM
C34	Malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM
C34.0	Malignant neoplasm of main bronchus	Diagnosis	ICD-10-CM
C34.00	Malignant neoplasm of unspecified main bronchus	Diagnosis	ICD-10-CM
C34.01	Malignant neoplasm of right main bronchus	Diagnosis	ICD-10-CM
C34.02	Malignant neoplasm of left main bronchus	Diagnosis	ICD-10-CM
C34.1	Malignant neoplasm of upper lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.10	Malignant neoplasm of upper lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.11	Malignant neoplasm of upper lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.12	Malignant neoplasm of upper lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.2	Malignant neoplasm of middle lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.3	Malignant neoplasm of lower lobe, bronchus or lung	Diagnosis	ICD-10-CM
C34.30	Malignant neoplasm of lower lobe, unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.31	Malignant neoplasm of lower lobe, right bronchus or lung	Diagnosis	ICD-10-CM
C34.32	Malignant neoplasm of lower lobe, left bronchus or lung	Diagnosis	ICD-10-CM
C34.8	Malignant neoplasm of overlapping sites of bronchus and lung	Diagnosis	ICD-10-CM
C34.80	Malignant neoplasm of overlapping sites of unspecified bronchus and lung	Diagnosis	ICD-10-CM
C34.81	Malignant neoplasm of overlapping sites of right bronchus and lung	Diagnosis	ICD-10-CM
C34.82	Malignant neoplasm of overlapping sites of left bronchus and lung	Diagnosis	ICD-10-CM
C34.9	Malignant neoplasm of unspecified part of bronchus or lung	Diagnosis	ICD-10-CM
C34.90	Malignant neoplasm of unspecified part of unspecified bronchus or lung	Diagnosis	ICD-10-CM
C34.91	Malignant neoplasm of unspecified part of right bronchus or lung	Diagnosis	ICD-10-CM
C34.92	Malignant neoplasm of unspecified part of left bronchus or lung	Diagnosis	ICD-10-CM
C37	Malignant neoplasm of thymus	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C38	Malignant neoplasm of heart, mediastinum and pleura	Diagnosis	ICD-10-CM
C38.0	Malignant neoplasm of heart	Diagnosis	ICD-10-CM
C38.1	Malignant neoplasm of anterior mediastinum	Diagnosis	ICD-10-CM
C38.2	Malignant neoplasm of posterior mediastinum	Diagnosis	ICD-10-CM
C38.3	Malignant neoplasm of mediastinum, part unspecified	Diagnosis	ICD-10-CM
C38.4	Malignant neoplasm of pleura	Diagnosis	ICD-10-CM
C38.8	Malignant neoplasm of overlapping sites of heart, mediastinum and pleura	Diagnosis	ICD-10-CM
C39	Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs	Diagnosis	ICD-10-CM
C39.0	Malignant neoplasm of upper respiratory tract, part unspecified	Diagnosis	ICD-10-CM
C39.9	Malignant neoplasm of lower respiratory tract, part unspecified	Diagnosis	ICD-10-CM
C40	Malignant neoplasm of bone and articular cartilage of limbs	Diagnosis	ICD-10-CM
C40.0	Malignant neoplasm of scapula and long bones of upper limb	Diagnosis	ICD-10-CM
C40.00	Malignant neoplasm of scapula and long bones of unspecified upper limb	Diagnosis	ICD-10-CM
C40.01	Malignant neoplasm of scapula and long bones of right upper limb	Diagnosis	ICD-10-CM
C40.02	Malignant neoplasm of scapula and long bones of left upper limb	Diagnosis	ICD-10-CM
C40.1	Malignant neoplasm of short bones of upper limb	Diagnosis	ICD-10-CM
C40.10	Malignant neoplasm of short bones of unspecified upper limb	Diagnosis	ICD-10-CM
C40.11	Malignant neoplasm of short bones of right upper limb	Diagnosis	ICD-10-CM
C40.12	Malignant neoplasm of short bones of left upper limb	Diagnosis	ICD-10-CM
C40.2	Malignant neoplasm of long bones of lower limb	Diagnosis	ICD-10-CM
C40.20	Malignant neoplasm of long bones of unspecified lower limb	Diagnosis	ICD-10-CM
C40.21	Malignant neoplasm of long bones of right lower limb	Diagnosis	ICD-10-CM
C40.22	Malignant neoplasm of long bones of left lower limb	Diagnosis	ICD-10-CM
C40.3	Malignant neoplasm of short bones of lower limb	Diagnosis	ICD-10-CM
C40.30	Malignant neoplasm of short bones of unspecified lower limb	Diagnosis	ICD-10-CM
C40.31	Malignant neoplasm of short bones of right lower limb	Diagnosis	ICD-10-CM
C40.32	Malignant neoplasm of short bones of left lower limb	Diagnosis	ICD-10-CM
C40.8	Malignant neoplasm of overlapping sites of bone and articular cartilage of limb	Diagnosis	ICD-10-CM
C40.80	Malignant neoplasm of overlapping sites of bone and articular cartilage of unspecified limb	Diagnosis	ICD-10-CM
C40.81	Malignant neoplasm of overlapping sites of bone and articular cartilage of right limb	Diagnosis	ICD-10-CM
C40.82	Malignant neoplasm of overlapping sites of bone and articular cartilage of left limb	Diagnosis	ICD-10-CM
C40.9	Malignant neoplasm of unspecified bones and articular cartilage of limb	Diagnosis	ICD-10-CM
C40.90	Malignant neoplasm of unspecified bones and articular cartilage of unspecified limb	Diagnosis	ICD-10-CM
C40.91	Malignant neoplasm of unspecified bones and articular cartilage of right limb	Diagnosis	ICD-10-CM
C40.92	Malignant neoplasm of unspecified bones and articular cartilage of left limb	Diagnosis	ICD-10-CM
C41	Malignant neoplasm of bone and articular cartilage of other and unspecified sites	Diagnosis	ICD-10-CM
C41.0	Malignant neoplasm of bones of skull and face	Diagnosis	ICD-10-CM
C41.1	Malignant neoplasm of mandible	Diagnosis	ICD-10-CM
C41.2	Malignant neoplasm of vertebral column	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C41.3	Malignant neoplasm of ribs, sternum and clavicle	Diagnosis	ICD-10-CM
C41.4	Malignant neoplasm of pelvic bones, sacrum and coccyx	Diagnosis	ICD-10-CM
C41.9	Malignant neoplasm of bone and articular cartilage, unspecified	Diagnosis	ICD-10-CM
C43.0	Malignant melanoma of lip	Diagnosis	ICD-10-CM
C43.1	Malignant melanoma of eyelid, including canthus	Diagnosis	ICD-10-CM
C43.10	Malignant melanoma of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
C43.11	Malignant melanoma of right eyelid, including canthus	Diagnosis	ICD-10-CM
C43.111	Malignant melanoma of right upper eyelid, including canthus	Diagnosis	ICD-10-CM
C43.112	Malignant melanoma of right lower eyelid, including canthus	Diagnosis	ICD-10-CM
C43.12	Malignant melanoma of left eyelid, including canthus	Diagnosis	ICD-10-CM
C43.121	Malignant melanoma of left upper eyelid, including canthus	Diagnosis	ICD-10-CM
C43.122	Malignant melanoma of left lower eyelid, including canthus	Diagnosis	ICD-10-CM
C43.2	Malignant melanoma of ear and external auricular canal	Diagnosis	ICD-10-CM
C43.20	Malignant melanoma of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
C43.21	Malignant melanoma of right ear and external auricular canal	Diagnosis	ICD-10-CM
C43.22	Malignant melanoma of left ear and external auricular canal	Diagnosis	ICD-10-CM
C43.3	Malignant melanoma of other and unspecified parts of face	Diagnosis	ICD-10-CM
C43.30	Malignant melanoma of unspecified part of face	Diagnosis	ICD-10-CM
C43.31	Malignant melanoma of nose	Diagnosis	ICD-10-CM
C43.39	Malignant melanoma of other parts of face	Diagnosis	ICD-10-CM
C43.4	Malignant melanoma of scalp and neck	Diagnosis	ICD-10-CM
C43.5	Malignant melanoma of trunk	Diagnosis	ICD-10-CM
C43.59	Malignant melanoma of other part of trunk	Diagnosis	ICD-10-CM
C43.6	Malignant melanoma of upper limb, including shoulder	Diagnosis	ICD-10-CM
C43.60	Malignant melanoma of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C43.61	Malignant melanoma of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C43.62	Malignant melanoma of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C43.7	Malignant melanoma of lower limb, including hip	Diagnosis	ICD-10-CM
C43.70	Malignant melanoma of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C43.71	Malignant melanoma of right lower limb, including hip	Diagnosis	ICD-10-CM
C43.72	Malignant melanoma of left lower limb, including hip	Diagnosis	ICD-10-CM
C45	Mesothelioma	Diagnosis	ICD-10-CM
C45.0	Mesothelioma of pleura	Diagnosis	ICD-10-CM
C45.1	Mesothelioma of peritoneum	Diagnosis	ICD-10-CM
C45.2	Mesothelioma of pericardium	Diagnosis	ICD-10-CM
C45.7	Mesothelioma of other sites	Diagnosis	ICD-10-CM
C45.9	Mesothelioma, unspecified	Diagnosis	ICD-10-CM
C46	Kaposi's sarcoma	Diagnosis	ICD-10-CM
C46.1	Kaposi's sarcoma of soft tissue	Diagnosis	ICD-10-CM
C46.2	Kaposi's sarcoma of palate	Diagnosis	ICD-10-CM
C46.3	Kaposi's sarcoma of lymph nodes	Diagnosis	ICD-10-CM
C46.4	Kaposi's sarcoma of gastrointestinal sites	Diagnosis	ICD-10-CM
C46.5	Kaposi's sarcoma of lung	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C46.50	Kaposi's sarcoma of unspecified lung	Diagnosis	ICD-10-CM
C46.51	Kaposi's sarcoma of right lung	Diagnosis	ICD-10-CM
C46.52	Kaposi's sarcoma of left lung	Diagnosis	ICD-10-CM
C46.7	Kaposi's sarcoma of other sites	Diagnosis	ICD-10-CM
C46.9	Kaposi's sarcoma, unspecified	Diagnosis	ICD-10-CM
C47	Malignant neoplasm of peripheral nerves and autonomic nervous system	Diagnosis	ICD-10-CM
C47.0	Malignant neoplasm of peripheral nerves of head, face and neck	Diagnosis	ICD-10-CM
C47.1	Malignant neoplasm of peripheral nerves of upper limb, including shoulder	Diagnosis	ICD-10-CM
C47.10	Malignant neoplasm of peripheral nerves of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C47.11	Malignant neoplasm of peripheral nerves of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C47.12	Malignant neoplasm of peripheral nerves of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C47.2	Malignant neoplasm of peripheral nerves of lower limb, including hip	Diagnosis	ICD-10-CM
C47.20	Malignant neoplasm of peripheral nerves of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C47.21	Malignant neoplasm of peripheral nerves of right lower limb, including hip	Diagnosis	ICD-10-CM
C47.22	Malignant neoplasm of peripheral nerves of left lower limb, including hip	Diagnosis	ICD-10-CM
C47.3	Malignant neoplasm of peripheral nerves of thorax	Diagnosis	ICD-10-CM
C47.4	Malignant neoplasm of peripheral nerves of abdomen	Diagnosis	ICD-10-CM
C47.5	Malignant neoplasm of peripheral nerves of pelvis	Diagnosis	ICD-10-CM
C47.6	Malignant neoplasm of peripheral nerves of trunk, unspecified	Diagnosis	ICD-10-CM
C47.8	Malignant neoplasm of overlapping sites of peripheral nerves and autonomic nervous system	Diagnosis	ICD-10-CM
C47.9	Malignant neoplasm of peripheral nerves and autonomic nervous system, unspecified	Diagnosis	ICD-10-CM
C48	Malignant neoplasm of retroperitoneum and peritoneum	Diagnosis	ICD-10-CM
C48.0	Malignant neoplasm of retroperitoneum	Diagnosis	ICD-10-CM
C48.1	Malignant neoplasm of specified parts of peritoneum	Diagnosis	ICD-10-CM
C48.2	Malignant neoplasm of peritoneum, unspecified	Diagnosis	ICD-10-CM
C48.8	Malignant neoplasm of overlapping sites of retroperitoneum and peritoneum	Diagnosis	ICD-10-CM
C49	Malignant neoplasm of other connective and soft tissue	Diagnosis	ICD-10-CM
C49.0	Malignant neoplasm of connective and soft tissue of head, face and neck	Diagnosis	ICD-10-CM
C49.1	Malignant neoplasm of connective and soft tissue of upper limb, including shoulder	Diagnosis	ICD-10-CM
C49.10	Malignant neoplasm of connective and soft tissue of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C49.11	Malignant neoplasm of connective and soft tissue of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C49.12	Malignant neoplasm of connective and soft tissue of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C49.2	Malignant neoplasm of connective and soft tissue of lower limb, including hip	Diagnosis	ICD-10-CM
C49.20	Malignant neoplasm of connective and soft tissue of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C49.21	Malignant neoplasm of connective and soft tissue of right lower limb, including hip	Diagnosis	ICD-10-CM
C49.22	Malignant neoplasm of connective and soft tissue of left lower limb, including hip	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C49.3	Malignant neoplasm of connective and soft tissue of thorax	Diagnosis	ICD-10-CM
C49.4	Malignant neoplasm of connective and soft tissue of abdomen	Diagnosis	ICD-10-CM
C49.5	Malignant neoplasm of connective and soft tissue of pelvis	Diagnosis	ICD-10-CM
C49.6	Malignant neoplasm of connective and soft tissue of trunk, unspecified	Diagnosis	ICD-10-CM
C49.8	Malignant neoplasm of overlapping sites of connective and soft tissue	Diagnosis	ICD-10-CM
C49.9	Malignant neoplasm of connective and soft tissue, unspecified	Diagnosis	ICD-10-CM
C49.A	Gastrointestinal stromal tumor	Diagnosis	ICD-10-CM
C49.A0	Gastrointestinal stromal tumor, unspecified site	Diagnosis	ICD-10-CM
C49.A1	Gastrointestinal stromal tumor of esophagus	Diagnosis	ICD-10-CM
C49.A2	Gastrointestinal stromal tumor of stomach	Diagnosis	ICD-10-CM
C49.A3	Gastrointestinal stromal tumor of small intestine	Diagnosis	ICD-10-CM
C49.A4	Gastrointestinal stromal tumor of large intestine	Diagnosis	ICD-10-CM
C49.A5	Gastrointestinal stromal tumor of rectum	Diagnosis	ICD-10-CM
C49.A9	Gastrointestinal stromal tumor of other sites	Diagnosis	ICD-10-CM
C4A	Merkel cell carcinoma	Diagnosis	ICD-10-CM
C4A.0	Merkel cell carcinoma of lip	Diagnosis	ICD-10-CM
C4A.1	Merkel cell carcinoma of eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.10	Merkel cell carcinoma of unspecified eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.11	Merkel cell carcinoma of right eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.111	Merkel cell carcinoma of right upper eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.112	Merkel cell carcinoma of right lower eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.12	Merkel cell carcinoma of left eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.121	Merkel cell carcinoma of left upper eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.122	Merkel cell carcinoma of left lower eyelid, including canthus	Diagnosis	ICD-10-CM
C4A.2	Merkel cell carcinoma of ear and external auricular canal	Diagnosis	ICD-10-CM
C4A.20	Merkel cell carcinoma of unspecified ear and external auricular canal	Diagnosis	ICD-10-CM
C4A.21	Merkel cell carcinoma of right ear and external auricular canal	Diagnosis	ICD-10-CM
C4A.22	Merkel cell carcinoma of left ear and external auricular canal	Diagnosis	ICD-10-CM
C4A.3	Merkel cell carcinoma of other and unspecified parts of face	Diagnosis	ICD-10-CM
C4A.30	Merkel cell carcinoma of unspecified part of face	Diagnosis	ICD-10-CM
C4A.31	Merkel cell carcinoma of nose	Diagnosis	ICD-10-CM
C4A.39	Merkel cell carcinoma of other parts of face	Diagnosis	ICD-10-CM
C4A.4	Merkel cell carcinoma of scalp and neck	Diagnosis	ICD-10-CM
C4A.5	Merkel cell carcinoma of trunk	Diagnosis	ICD-10-CM
C4A.59	Merkel cell carcinoma of other part of trunk	Diagnosis	ICD-10-CM
C4A.6	Merkel cell carcinoma of upper limb, including shoulder	Diagnosis	ICD-10-CM
C4A.60	Merkel cell carcinoma of unspecified upper limb, including shoulder	Diagnosis	ICD-10-CM
C4A.61	Merkel cell carcinoma of right upper limb, including shoulder	Diagnosis	ICD-10-CM
C4A.62	Merkel cell carcinoma of left upper limb, including shoulder	Diagnosis	ICD-10-CM
C4A.7	Merkel cell carcinoma of lower limb, including hip	Diagnosis	ICD-10-CM
C4A.70	Merkel cell carcinoma of unspecified lower limb, including hip	Diagnosis	ICD-10-CM
C4A.71	Merkel cell carcinoma of right lower limb, including hip	Diagnosis	ICD-10-CM
C4A.72	Merkel cell carcinoma of left lower limb, including hip	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C4A.8	Merkel cell carcinoma of overlapping sites	Diagnosis	ICD-10-CM
C4A.9	Merkel cell carcinoma, unspecified	Diagnosis	ICD-10-CM
C50	Malignant neoplasm of breast	Diagnosis	ICD-10-CM
C50.0	Malignant neoplasm of nipple and areola	Diagnosis	ICD-10-CM
C50.01	Malignant neoplasm of nipple and areola, female	Diagnosis	ICD-10-CM
C50.011	Malignant neoplasm of nipple and areola, right female breast	Diagnosis	ICD-10-CM
C50.012	Malignant neoplasm of nipple and areola, left female breast	Diagnosis	ICD-10-CM
C50.019	Malignant neoplasm of nipple and areola, unspecified female breast	Diagnosis	ICD-10-CM
C50.02	Malignant neoplasm of nipple and areola, male	Diagnosis	ICD-10-CM
C50.021	Malignant neoplasm of nipple and areola, right male breast	Diagnosis	ICD-10-CM
C50.022	Malignant neoplasm of nipple and areola, left male breast	Diagnosis	ICD-10-CM
C50.029	Malignant neoplasm of nipple and areola, unspecified male breast	Diagnosis	ICD-10-CM
C50.1	Malignant neoplasm of central portion of breast	Diagnosis	ICD-10-CM
C50.11	Malignant neoplasm of central portion of breast, female	Diagnosis	ICD-10-CM
C50.111	Malignant neoplasm of central portion of right female breast	Diagnosis	ICD-10-CM
C50.112	Malignant neoplasm of central portion of left female breast	Diagnosis	ICD-10-CM
C50.119	Malignant neoplasm of central portion of unspecified female breast	Diagnosis	ICD-10-CM
C50.12	Malignant neoplasm of central portion of breast, male	Diagnosis	ICD-10-CM
C50.121	Malignant neoplasm of central portion of right male breast	Diagnosis	ICD-10-CM
C50.122	Malignant neoplasm of central portion of left male breast	Diagnosis	ICD-10-CM
C50.129	Malignant neoplasm of central portion of unspecified male breast	Diagnosis	ICD-10-CM
C50.2	Malignant neoplasm of upper-inner quadrant of breast	Diagnosis	ICD-10-CM
C50.21	Malignant neoplasm of upper-inner quadrant of breast, female	Diagnosis	ICD-10-CM
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.219	Malignant neoplasm of upper-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.22	Malignant neoplasm of upper-inner quadrant of breast, male	Diagnosis	ICD-10-CM
C50.221	Malignant neoplasm of upper-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.222	Malignant neoplasm of upper-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.229	Malignant neoplasm of upper-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.3	Malignant neoplasm of lower-inner quadrant of breast	Diagnosis	ICD-10-CM
C50.31	Malignant neoplasm of lower-inner quadrant of breast, female	Diagnosis	ICD-10-CM
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast	Diagnosis	ICD-10-CM
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast	Diagnosis	ICD-10-CM
C50.319	Malignant neoplasm of lower-inner quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.32	Malignant neoplasm of lower-inner quadrant of breast, male	Diagnosis	ICD-10-CM
C50.321	Malignant neoplasm of lower-inner quadrant of right male breast	Diagnosis	ICD-10-CM
C50.322	Malignant neoplasm of lower-inner quadrant of left male breast	Diagnosis	ICD-10-CM
C50.329	Malignant neoplasm of lower-inner quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.4	Malignant neoplasm of upper-outer quadrant of breast	Diagnosis	ICD-10-CM
C50.41	Malignant neoplasm of upper-outer quadrant of breast, female	Diagnosis	ICD-10-CM
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C50.419	Malignant neoplasm of upper-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.42	Malignant neoplasm of upper-outer quadrant of breast, male	Diagnosis	ICD-10-CM
C50.421	Malignant neoplasm of upper-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.422	Malignant neoplasm of upper-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.429	Malignant neoplasm of upper-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.5	Malignant neoplasm of lower-outer quadrant of breast	Diagnosis	ICD-10-CM
C50.51	Malignant neoplasm of lower-outer quadrant of breast, female	Diagnosis	ICD-10-CM
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast	Diagnosis	ICD-10-CM
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast	Diagnosis	ICD-10-CM
C50.519	Malignant neoplasm of lower-outer quadrant of unspecified female breast	Diagnosis	ICD-10-CM
C50.52	Malignant neoplasm of lower-outer quadrant of breast, male	Diagnosis	ICD-10-CM
C50.521	Malignant neoplasm of lower-outer quadrant of right male breast	Diagnosis	ICD-10-CM
C50.522	Malignant neoplasm of lower-outer quadrant of left male breast	Diagnosis	ICD-10-CM
C50.529	Malignant neoplasm of lower-outer quadrant of unspecified male breast	Diagnosis	ICD-10-CM
C50.6	Malignant neoplasm of axillary tail of breast	Diagnosis	ICD-10-CM
C50.61	Malignant neoplasm of axillary tail of breast, female	Diagnosis	ICD-10-CM
C50.611	Malignant neoplasm of axillary tail of right female breast	Diagnosis	ICD-10-CM
C50.612	Malignant neoplasm of axillary tail of left female breast	Diagnosis	ICD-10-CM
C50.619	Malignant neoplasm of axillary tail of unspecified female breast	Diagnosis	ICD-10-CM
C50.62	Malignant neoplasm of axillary tail of breast, male	Diagnosis	ICD-10-CM
C50.621	Malignant neoplasm of axillary tail of right male breast	Diagnosis	ICD-10-CM
C50.622	Malignant neoplasm of axillary tail of left male breast	Diagnosis	ICD-10-CM
C50.629	Malignant neoplasm of axillary tail of unspecified male breast	Diagnosis	ICD-10-CM
C50.8	Malignant neoplasm of overlapping sites of breast	Diagnosis	ICD-10-CM
C50.81	Malignant neoplasm of overlapping sites of breast, female	Diagnosis	ICD-10-CM
C50.811	Malignant neoplasm of overlapping sites of right female breast	Diagnosis	ICD-10-CM
C50.812	Malignant neoplasm of overlapping sites of left female breast	Diagnosis	ICD-10-CM
C50.819	Malignant neoplasm of overlapping sites of unspecified female breast	Diagnosis	ICD-10-CM
C50.82	Malignant neoplasm of overlapping sites of breast, male	Diagnosis	ICD-10-CM
C50.821	Malignant neoplasm of overlapping sites of right male breast	Diagnosis	ICD-10-CM
C50.822	Malignant neoplasm of overlapping sites of left male breast	Diagnosis	ICD-10-CM
C50.829	Malignant neoplasm of overlapping sites of unspecified male breast	Diagnosis	ICD-10-CM
C50.9	Malignant neoplasm of breast of unspecified site	Diagnosis	ICD-10-CM
C50.91	Malignant neoplasm of breast of unspecified site, female	Diagnosis	ICD-10-CM
C50.911	Malignant neoplasm of unspecified site of right female breast	Diagnosis	ICD-10-CM
C50.912	Malignant neoplasm of unspecified site of left female breast	Diagnosis	ICD-10-CM
C50.919	Malignant neoplasm of unspecified site of unspecified female breast	Diagnosis	ICD-10-CM
C50.92	Malignant neoplasm of breast of unspecified site, male	Diagnosis	ICD-10-CM
C50.921	Malignant neoplasm of unspecified site of right male breast	Diagnosis	ICD-10-CM
C50.922	Malignant neoplasm of unspecified site of left male breast	Diagnosis	ICD-10-CM
C50.929	Malignant neoplasm of unspecified site of unspecified male breast	Diagnosis	ICD-10-CM
C51	Malignant neoplasm of vulva	Diagnosis	ICD-10-CM
C51.0	Malignant neoplasm of labium majus	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C51.1	Malignant neoplasm of labium minus	Diagnosis	ICD-10-CM
C51.2	Malignant neoplasm of clitoris	Diagnosis	ICD-10-CM
C51.8	Malignant neoplasm of overlapping sites of vulva	Diagnosis	ICD-10-CM
C51.9	Malignant neoplasm of vulva, unspecified	Diagnosis	ICD-10-CM
C52	Malignant neoplasm of vagina	Diagnosis	ICD-10-CM
C53	Malignant neoplasm of cervix uteri	Diagnosis	ICD-10-CM
C53.0	Malignant neoplasm of endocervix	Diagnosis	ICD-10-CM
C53.1	Malignant neoplasm of exocervix	Diagnosis	ICD-10-CM
C53.8	Malignant neoplasm of overlapping sites of cervix uteri	Diagnosis	ICD-10-CM
C53.9	Malignant neoplasm of cervix uteri, unspecified	Diagnosis	ICD-10-CM
C54	Malignant neoplasm of corpus uteri	Diagnosis	ICD-10-CM
C54.0	Malignant neoplasm of isthmus uteri	Diagnosis	ICD-10-CM
C54.1	Malignant neoplasm of endometrium	Diagnosis	ICD-10-CM
C54.2	Malignant neoplasm of myometrium	Diagnosis	ICD-10-CM
C54.3	Malignant neoplasm of fundus uteri	Diagnosis	ICD-10-CM
C54.8	Malignant neoplasm of overlapping sites of corpus uteri	Diagnosis	ICD-10-CM
C54.9	Malignant neoplasm of corpus uteri, unspecified	Diagnosis	ICD-10-CM
C55	Malignant neoplasm of uterus, part unspecified	Diagnosis	ICD-10-CM
C56	Malignant neoplasm of ovary	Diagnosis	ICD-10-CM
C56.1	Malignant neoplasm of right ovary	Diagnosis	ICD-10-CM
C56.2	Malignant neoplasm of left ovary	Diagnosis	ICD-10-CM
C56.9	Malignant neoplasm of unspecified ovary	Diagnosis	ICD-10-CM
C57	Malignant neoplasm of other and unspecified female genital organs	Diagnosis	ICD-10-CM
C57.0	Malignant neoplasm of fallopian tube	Diagnosis	ICD-10-CM
C57.00	Malignant neoplasm of unspecified fallopian tube	Diagnosis	ICD-10-CM
C57.01	Malignant neoplasm of right fallopian tube	Diagnosis	ICD-10-CM
C57.02	Malignant neoplasm of left fallopian tube	Diagnosis	ICD-10-CM
C57.1	Malignant neoplasm of broad ligament	Diagnosis	ICD-10-CM
C57.10	Malignant neoplasm of unspecified broad ligament	Diagnosis	ICD-10-CM
C57.11	Malignant neoplasm of right broad ligament	Diagnosis	ICD-10-CM
C57.12	Malignant neoplasm of left broad ligament	Diagnosis	ICD-10-CM
C57.2	Malignant neoplasm of round ligament	Diagnosis	ICD-10-CM
C57.20	Malignant neoplasm of unspecified round ligament	Diagnosis	ICD-10-CM
C57.21	Malignant neoplasm of right round ligament	Diagnosis	ICD-10-CM
C57.22	Malignant neoplasm of left round ligament	Diagnosis	ICD-10-CM
C57.3	Malignant neoplasm of parametrium	Diagnosis	ICD-10-CM
C57.4	Malignant neoplasm of uterine adnexa, unspecified	Diagnosis	ICD-10-CM
C57.7	Malignant neoplasm of other specified female genital organs	Diagnosis	ICD-10-CM
C57.8	Malignant neoplasm of overlapping sites of female genital organs	Diagnosis	ICD-10-CM
C57.9	Malignant neoplasm of female genital organ, unspecified	Diagnosis	ICD-10-CM
C58	Malignant neoplasm of placenta	Diagnosis	ICD-10-CM
C60	Malignant neoplasm of penis	Diagnosis	ICD-10-CM
C60.0	Malignant neoplasm of prepuce	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C60.1	Malignant neoplasm of glans penis	Diagnosis	ICD-10-CM
C60.2	Malignant neoplasm of body of penis	Diagnosis	ICD-10-CM
C60.8	Malignant neoplasm of overlapping sites of penis	Diagnosis	ICD-10-CM
C60.9	Malignant neoplasm of penis, unspecified	Diagnosis	ICD-10-CM
C61	Malignant neoplasm of prostate	Diagnosis	ICD-10-CM
C62	Malignant neoplasm of testis	Diagnosis	ICD-10-CM
C62.0	Malignant neoplasm of undescended testis	Diagnosis	ICD-10-CM
C62.00	Malignant neoplasm of unspecified undescended testis	Diagnosis	ICD-10-CM
C62.01	Malignant neoplasm of undescended right testis	Diagnosis	ICD-10-CM
C62.02	Malignant neoplasm of undescended left testis	Diagnosis	ICD-10-CM
C62.1	Malignant neoplasm of descended testis	Diagnosis	ICD-10-CM
C62.10	Malignant neoplasm of unspecified descended testis	Diagnosis	ICD-10-CM
C62.11	Malignant neoplasm of descended right testis	Diagnosis	ICD-10-CM
C62.12	Malignant neoplasm of descended left testis	Diagnosis	ICD-10-CM
C62.9	Malignant neoplasm of testis, unspecified whether descended or undescended	Diagnosis	ICD-10-CM
C62.90	Malignant neoplasm of unspecified testis, unspecified whether descended or undescended	Diagnosis	ICD-10-CM
C62.91	Malignant neoplasm of right testis, unspecified whether descended or undescended	Diagnosis	ICD-10-CM
C62.92	Malignant neoplasm of left testis, unspecified whether descended or undescended	Diagnosis	ICD-10-CM
C63	Malignant neoplasm of other and unspecified male genital organs	Diagnosis	ICD-10-CM
C63.0	Malignant neoplasm of epididymis	Diagnosis	ICD-10-CM
C63.00	Malignant neoplasm of unspecified epididymis	Diagnosis	ICD-10-CM
C63.01	Malignant neoplasm of right epididymis	Diagnosis	ICD-10-CM
C63.02	Malignant neoplasm of left epididymis	Diagnosis	ICD-10-CM
C63.1	Malignant neoplasm of spermatic cord	Diagnosis	ICD-10-CM
C63.10	Malignant neoplasm of unspecified spermatic cord	Diagnosis	ICD-10-CM
C63.11	Malignant neoplasm of right spermatic cord	Diagnosis	ICD-10-CM
C63.12	Malignant neoplasm of left spermatic cord	Diagnosis	ICD-10-CM
C63.2	Malignant neoplasm of scrotum	Diagnosis	ICD-10-CM
C63.7	Malignant neoplasm of other specified male genital organs	Diagnosis	ICD-10-CM
C63.8	Malignant neoplasm of overlapping sites of male genital organs	Diagnosis	ICD-10-CM
C63.9	Malignant neoplasm of male genital organ, unspecified	Diagnosis	ICD-10-CM
C64	Malignant neoplasm of kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.1	Malignant neoplasm of right kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.2	Malignant neoplasm of left kidney, except renal pelvis	Diagnosis	ICD-10-CM
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis	Diagnosis	ICD-10-CM
C65	Malignant neoplasm of renal pelvis	Diagnosis	ICD-10-CM
C65.1	Malignant neoplasm of right renal pelvis	Diagnosis	ICD-10-CM
C65.2	Malignant neoplasm of left renal pelvis	Diagnosis	ICD-10-CM
C65.9	Malignant neoplasm of unspecified renal pelvis	Diagnosis	ICD-10-CM
C66	Malignant neoplasm of ureter	Diagnosis	ICD-10-CM
C66.1	Malignant neoplasm of right ureter	Diagnosis	ICD-10-CM
C66.2	Malignant neoplasm of left ureter	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C66.9	Malignant neoplasm of unspecified ureter	Diagnosis	ICD-10-CM
C67	Malignant neoplasm of bladder	Diagnosis	ICD-10-CM
C67.0	Malignant neoplasm of trigone of bladder	Diagnosis	ICD-10-CM
C67.1	Malignant neoplasm of dome of bladder	Diagnosis	ICD-10-CM
C67.2	Malignant neoplasm of lateral wall of bladder	Diagnosis	ICD-10-CM
C67.3	Malignant neoplasm of anterior wall of bladder	Diagnosis	ICD-10-CM
C67.4	Malignant neoplasm of posterior wall of bladder	Diagnosis	ICD-10-CM
C67.5	Malignant neoplasm of bladder neck	Diagnosis	ICD-10-CM
C67.6	Malignant neoplasm of ureteric orifice	Diagnosis	ICD-10-CM
C67.7	Malignant neoplasm of urachus	Diagnosis	ICD-10-CM
C67.8	Malignant neoplasm of overlapping sites of bladder	Diagnosis	ICD-10-CM
C67.9	Malignant neoplasm of bladder, unspecified	Diagnosis	ICD-10-CM
C68	Malignant neoplasm of other and unspecified urinary organs	Diagnosis	ICD-10-CM
C68.0	Malignant neoplasm of urethra	Diagnosis	ICD-10-CM
C68.1	Malignant neoplasm of paraurethral glands	Diagnosis	ICD-10-CM
C68.8	Malignant neoplasm of overlapping sites of urinary organs	Diagnosis	ICD-10-CM
C68.9	Malignant neoplasm of urinary organ, unspecified	Diagnosis	ICD-10-CM
C69	Malignant neoplasm of eye and adnexa	Diagnosis	ICD-10-CM
C69.0	Malignant neoplasm of conjunctiva	Diagnosis	ICD-10-CM
C69.00	Malignant neoplasm of unspecified conjunctiva	Diagnosis	ICD-10-CM
C69.01	Malignant neoplasm of right conjunctiva	Diagnosis	ICD-10-CM
C69.02	Malignant neoplasm of left conjunctiva	Diagnosis	ICD-10-CM
C69.1	Malignant neoplasm of cornea	Diagnosis	ICD-10-CM
C69.10	Malignant neoplasm of unspecified cornea	Diagnosis	ICD-10-CM
C69.11	Malignant neoplasm of right cornea	Diagnosis	ICD-10-CM
C69.12	Malignant neoplasm of left cornea	Diagnosis	ICD-10-CM
C69.2	Malignant neoplasm of retina	Diagnosis	ICD-10-CM
C69.20	Malignant neoplasm of unspecified retina	Diagnosis	ICD-10-CM
C69.21	Malignant neoplasm of right retina	Diagnosis	ICD-10-CM
C69.22	Malignant neoplasm of left retina	Diagnosis	ICD-10-CM
C69.3	Malignant neoplasm of choroid	Diagnosis	ICD-10-CM
C69.30	Malignant neoplasm of unspecified choroid	Diagnosis	ICD-10-CM
C69.31	Malignant neoplasm of right choroid	Diagnosis	ICD-10-CM
C69.32	Malignant neoplasm of left choroid	Diagnosis	ICD-10-CM
C69.4	Malignant neoplasm of ciliary body	Diagnosis	ICD-10-CM
C69.40	Malignant neoplasm of unspecified ciliary body	Diagnosis	ICD-10-CM
C69.41	Malignant neoplasm of right ciliary body	Diagnosis	ICD-10-CM
C69.42	Malignant neoplasm of left ciliary body	Diagnosis	ICD-10-CM
C69.5	Malignant neoplasm of lacrimal gland and duct	Diagnosis	ICD-10-CM
C69.50	Malignant neoplasm of unspecified lacrimal gland and duct	Diagnosis	ICD-10-CM
C69.51	Malignant neoplasm of right lacrimal gland and duct	Diagnosis	ICD-10-CM
C69.52	Malignant neoplasm of left lacrimal gland and duct	Diagnosis	ICD-10-CM
C69.6	Malignant neoplasm of orbit	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C69.60	Malignant neoplasm of unspecified orbit	Diagnosis	ICD-10-CM
C69.61	Malignant neoplasm of right orbit	Diagnosis	ICD-10-CM
C69.62	Malignant neoplasm of left orbit	Diagnosis	ICD-10-CM
C69.8	Malignant neoplasm of overlapping sites of eye and adnexa	Diagnosis	ICD-10-CM
C69.80	Malignant neoplasm of overlapping sites of unspecified eye and adnexa	Diagnosis	ICD-10-CM
C69.81	Malignant neoplasm of overlapping sites of right eye and adnexa	Diagnosis	ICD-10-CM
C69.82	Malignant neoplasm of overlapping sites of left eye and adnexa	Diagnosis	ICD-10-CM
C69.9	Malignant neoplasm of unspecified site of eye	Diagnosis	ICD-10-CM
C69.90	Malignant neoplasm of unspecified site of unspecified eye	Diagnosis	ICD-10-CM
C69.91	Malignant neoplasm of unspecified site of right eye	Diagnosis	ICD-10-CM
C69.92	Malignant neoplasm of unspecified site of left eye	Diagnosis	ICD-10-CM
C70	Malignant neoplasm of meninges	Diagnosis	ICD-10-CM
C70.0	Malignant neoplasm of cerebral meninges	Diagnosis	ICD-10-CM
C70.1	Malignant neoplasm of spinal meninges	Diagnosis	ICD-10-CM
C70.9	Malignant neoplasm of meninges, unspecified	Diagnosis	ICD-10-CM
C71	Malignant neoplasm of brain	Diagnosis	ICD-10-CM
C71.0	Malignant neoplasm of cerebrum, except lobes and ventricles	Diagnosis	ICD-10-CM
C71.1	Malignant neoplasm of frontal lobe	Diagnosis	ICD-10-CM
C71.2	Malignant neoplasm of temporal lobe	Diagnosis	ICD-10-CM
C71.3	Malignant neoplasm of parietal lobe	Diagnosis	ICD-10-CM
C71.4	Malignant neoplasm of occipital lobe	Diagnosis	ICD-10-CM
C71.5	Malignant neoplasm of cerebral ventricle	Diagnosis	ICD-10-CM
C71.6	Malignant neoplasm of cerebellum	Diagnosis	ICD-10-CM
C71.7	Malignant neoplasm of brain stem	Diagnosis	ICD-10-CM
C71.8	Malignant neoplasm of overlapping sites of brain	Diagnosis	ICD-10-CM
C71.9	Malignant neoplasm of brain, unspecified	Diagnosis	ICD-10-CM
C72	Malignant neoplasm of spinal cord, cranial nerves and other parts of central nervous system	Diagnosis	ICD-10-CM
C72.0	Malignant neoplasm of spinal cord	Diagnosis	ICD-10-CM
C72.1	Malignant neoplasm of cauda equina	Diagnosis	ICD-10-CM
C72.2	Malignant neoplasm of olfactory nerve	Diagnosis	ICD-10-CM
C72.20	Malignant neoplasm of unspecified olfactory nerve	Diagnosis	ICD-10-CM
C72.21	Malignant neoplasm of right olfactory nerve	Diagnosis	ICD-10-CM
C72.22	Malignant neoplasm of left olfactory nerve	Diagnosis	ICD-10-CM
C72.3	Malignant neoplasm of optic nerve	Diagnosis	ICD-10-CM
C72.30	Malignant neoplasm of unspecified optic nerve	Diagnosis	ICD-10-CM
C72.31	Malignant neoplasm of right optic nerve	Diagnosis	ICD-10-CM
C72.32	Malignant neoplasm of left optic nerve	Diagnosis	ICD-10-CM
C72.4	Malignant neoplasm of acoustic nerve	Diagnosis	ICD-10-CM
C72.40	Malignant neoplasm of unspecified acoustic nerve	Diagnosis	ICD-10-CM
C72.41	Malignant neoplasm of right acoustic nerve	Diagnosis	ICD-10-CM
C72.42	Malignant neoplasm of left acoustic nerve	Diagnosis	ICD-10-CM
C72.5	Malignant neoplasm of other and unspecified cranial nerves	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C72.50	Malignant neoplasm of unspecified cranial nerve	Diagnosis	ICD-10-CM
C72.59	Malignant neoplasm of other cranial nerves	Diagnosis	ICD-10-CM
C72.9	Malignant neoplasm of central nervous system, unspecified	Diagnosis	ICD-10-CM
C73	Malignant neoplasm of thyroid gland	Diagnosis	ICD-10-CM
C74	Malignant neoplasm of adrenal gland	Diagnosis	ICD-10-CM
C74.0	Malignant neoplasm of cortex of adrenal gland	Diagnosis	ICD-10-CM
C74.00	Malignant neoplasm of cortex of unspecified adrenal gland	Diagnosis	ICD-10-CM
C74.01	Malignant neoplasm of cortex of right adrenal gland	Diagnosis	ICD-10-CM
C74.02	Malignant neoplasm of cortex of left adrenal gland	Diagnosis	ICD-10-CM
C74.1	Malignant neoplasm of medulla of adrenal gland	Diagnosis	ICD-10-CM
C74.10	Malignant neoplasm of medulla of unspecified adrenal gland	Diagnosis	ICD-10-CM
C74.11	Malignant neoplasm of medulla of right adrenal gland	Diagnosis	ICD-10-CM
C74.12	Malignant neoplasm of medulla of left adrenal gland	Diagnosis	ICD-10-CM
C74.9	Malignant neoplasm of unspecified part of adrenal gland	Diagnosis	ICD-10-CM
C74.90	Malignant neoplasm of unspecified part of unspecified adrenal gland	Diagnosis	ICD-10-CM
C74.91	Malignant neoplasm of unspecified part of right adrenal gland	Diagnosis	ICD-10-CM
C74.92	Malignant neoplasm of unspecified part of left adrenal gland	Diagnosis	ICD-10-CM
C75	Malignant neoplasm of other endocrine glands and related structures	Diagnosis	ICD-10-CM
C75.0	Malignant neoplasm of parathyroid gland	Diagnosis	ICD-10-CM
C75.1	Malignant neoplasm of pituitary gland	Diagnosis	ICD-10-CM
C75.2	Malignant neoplasm of craniopharyngeal duct	Diagnosis	ICD-10-CM
C75.3	Malignant neoplasm of pineal gland	Diagnosis	ICD-10-CM
C75.4	Malignant neoplasm of carotid body	Diagnosis	ICD-10-CM
C75.5	Malignant neoplasm of aortic body and other paraganglia	Diagnosis	ICD-10-CM
C75.8	Malignant neoplasm with pluriglandular involvement, unspecified	Diagnosis	ICD-10-CM
C75.9	Malignant neoplasm of endocrine gland, unspecified	Diagnosis	ICD-10-CM
C76	Malignant neoplasm of other and ill-defined sites	Diagnosis	ICD-10-CM
C76.0	Malignant neoplasm of head, face and neck	Diagnosis	ICD-10-CM
C76.1	Malignant neoplasm of thorax	Diagnosis	ICD-10-CM
C76.2	Malignant neoplasm of abdomen	Diagnosis	ICD-10-CM
C76.3	Malignant neoplasm of pelvis	Diagnosis	ICD-10-CM
C76.4	Malignant neoplasm of upper limb	Diagnosis	ICD-10-CM
C76.40	Malignant neoplasm of unspecified upper limb	Diagnosis	ICD-10-CM
C76.41	Malignant neoplasm of right upper limb	Diagnosis	ICD-10-CM
C76.42	Malignant neoplasm of left upper limb	Diagnosis	ICD-10-CM
C76.5	Malignant neoplasm of lower limb	Diagnosis	ICD-10-CM
C76.50	Malignant neoplasm of unspecified lower limb	Diagnosis	ICD-10-CM
C76.51	Malignant neoplasm of right lower limb	Diagnosis	ICD-10-CM
C76.52	Malignant neoplasm of left lower limb	Diagnosis	ICD-10-CM
C76.8	Malignant neoplasm of other specified ill-defined sites	Diagnosis	ICD-10-CM
C77	Secondary and unspecified malignant neoplasm of lymph nodes	Diagnosis	ICD-10-CM
C77.0	Secondary and unspecified malignant neoplasm of lymph nodes of head, face and neck	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C77.1	Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C77.2	Secondary and unspecified malignant neoplasm of intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C77.3	Secondary and unspecified malignant neoplasm of axilla and upper limb lymph nodes	Diagnosis	ICD-10-CM
C77.4	Secondary and unspecified malignant neoplasm of inguinal and lower limb lymph nodes	Diagnosis	ICD-10-CM
C77.5	Secondary and unspecified malignant neoplasm of intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C77.8	Secondary and unspecified malignant neoplasm of lymph nodes of multiple regions	Diagnosis	ICD-10-CM
C77.9	Secondary and unspecified malignant neoplasm of lymph node, unspecified	Diagnosis	ICD-10-CM
C78	Secondary malignant neoplasm of respiratory and digestive organs	Diagnosis	ICD-10-CM
C78.0	Secondary malignant neoplasm of lung	Diagnosis	ICD-10-CM
C78.00	Secondary malignant neoplasm of unspecified lung	Diagnosis	ICD-10-CM
C78.01	Secondary malignant neoplasm of right lung	Diagnosis	ICD-10-CM
C78.02	Secondary malignant neoplasm of left lung	Diagnosis	ICD-10-CM
C78.1	Secondary malignant neoplasm of mediastinum	Diagnosis	ICD-10-CM
C78.2	Secondary malignant neoplasm of pleura	Diagnosis	ICD-10-CM
C78.3	Secondary malignant neoplasm of other and unspecified respiratory organs	Diagnosis	ICD-10-CM
C78.30	Secondary malignant neoplasm of unspecified respiratory organ	Diagnosis	ICD-10-CM
C78.39	Secondary malignant neoplasm of other respiratory organs	Diagnosis	ICD-10-CM
C78.4	Secondary malignant neoplasm of small intestine	Diagnosis	ICD-10-CM
C78.5	Secondary malignant neoplasm of large intestine and rectum	Diagnosis	ICD-10-CM
C78.6	Secondary malignant neoplasm of retroperitoneum and peritoneum	Diagnosis	ICD-10-CM
C78.7	Secondary malignant neoplasm of liver and intrahepatic bile duct	Diagnosis	ICD-10-CM
C78.8	Secondary malignant neoplasm of other and unspecified digestive organs	Diagnosis	ICD-10-CM
C78.80	Secondary malignant neoplasm of unspecified digestive organ	Diagnosis	ICD-10-CM
C78.89	Secondary malignant neoplasm of other digestive organs	Diagnosis	ICD-10-CM
C79	Secondary malignant neoplasm of other and unspecified sites	Diagnosis	ICD-10-CM
C79.0	Secondary malignant neoplasm of kidney and renal pelvis	Diagnosis	ICD-10-CM
C79.00	Secondary malignant neoplasm of unspecified kidney and renal pelvis	Diagnosis	ICD-10-CM
C79.01	Secondary malignant neoplasm of right kidney and renal pelvis	Diagnosis	ICD-10-CM
C79.02	Secondary malignant neoplasm of left kidney and renal pelvis	Diagnosis	ICD-10-CM
C79.1	Secondary malignant neoplasm of bladder and other and unspecified urinary organs	Diagnosis	ICD-10-CM
C79.10	Secondary malignant neoplasm of unspecified urinary organs	Diagnosis	ICD-10-CM
C79.11	Secondary malignant neoplasm of bladder	Diagnosis	ICD-10-CM
C79.19	Secondary malignant neoplasm of other urinary organs	Diagnosis	ICD-10-CM
C79.3	Secondary malignant neoplasm of brain and cerebral meninges	Diagnosis	ICD-10-CM
C79.31	Secondary malignant neoplasm of brain	Diagnosis	ICD-10-CM
C79.32	Secondary malignant neoplasm of cerebral meninges	Diagnosis	ICD-10-CM
C79.4	Secondary malignant neoplasm of other and unspecified parts of nervous system	Diagnosis	ICD-10-CM
C79.40	Secondary malignant neoplasm of unspecified part of nervous system	Diagnosis	ICD-10-CM
C79.49	Secondary malignant neoplasm of other parts of nervous system	Diagnosis	ICD-10-CM
C79.5	Secondary malignant neoplasm of bone and bone marrow	Diagnosis	ICD-10-CM
C79.51	Secondary malignant neoplasm of bone	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C79.52	Secondary malignant neoplasm of bone marrow	Diagnosis	ICD-10-CM
C79.6	Secondary malignant neoplasm of ovary	Diagnosis	ICD-10-CM
C79.60	Secondary malignant neoplasm of unspecified ovary	Diagnosis	ICD-10-CM
C79.61	Secondary malignant neoplasm of right ovary	Diagnosis	ICD-10-CM
C79.62	Secondary malignant neoplasm of left ovary	Diagnosis	ICD-10-CM
C79.7	Secondary malignant neoplasm of adrenal gland	Diagnosis	ICD-10-CM
C79.70	Secondary malignant neoplasm of unspecified adrenal gland	Diagnosis	ICD-10-CM
C79.71	Secondary malignant neoplasm of right adrenal gland	Diagnosis	ICD-10-CM
C79.72	Secondary malignant neoplasm of left adrenal gland	Diagnosis	ICD-10-CM
C79.8	Secondary malignant neoplasm of other specified sites	Diagnosis	ICD-10-CM
C79.81	Secondary malignant neoplasm of breast	Diagnosis	ICD-10-CM
C79.82	Secondary malignant neoplasm of genital organs	Diagnosis	ICD-10-CM
C79.89	Secondary malignant neoplasm of other specified sites	Diagnosis	ICD-10-CM
C79.9	Secondary malignant neoplasm of unspecified site	Diagnosis	ICD-10-CM
C7A	Malignant neuroendocrine tumors	Diagnosis	ICD-10-CM
C7A.0	Malignant carcinoid tumors	Diagnosis	ICD-10-CM
C7A.00	Malignant carcinoid tumor of unspecified site	Diagnosis	ICD-10-CM
C7A.01	Malignant carcinoid tumors of the small intestine	Diagnosis	ICD-10-CM
C7A.010	Malignant carcinoid tumor of the duodenum	Diagnosis	ICD-10-CM
C7A.011	Malignant carcinoid tumor of the jejunum	Diagnosis	ICD-10-CM
C7A.012	Malignant carcinoid tumor of the ileum	Diagnosis	ICD-10-CM
C7A.019	Malignant carcinoid tumor of the small intestine, unspecified portion	Diagnosis	ICD-10-CM
C7A.02	Malignant carcinoid tumors of the appendix, large intestine, and rectum	Diagnosis	ICD-10-CM
C7A.020	Malignant carcinoid tumor of the appendix	Diagnosis	ICD-10-CM
C7A.021	Malignant carcinoid tumor of the cecum	Diagnosis	ICD-10-CM
C7A.022	Malignant carcinoid tumor of the ascending colon	Diagnosis	ICD-10-CM
C7A.023	Malignant carcinoid tumor of the transverse colon	Diagnosis	ICD-10-CM
C7A.024	Malignant carcinoid tumor of the descending colon	Diagnosis	ICD-10-CM
C7A.025	Malignant carcinoid tumor of the sigmoid colon	Diagnosis	ICD-10-CM
C7A.026	Malignant carcinoid tumor of the rectum	Diagnosis	ICD-10-CM
C7A.029	Malignant carcinoid tumor of the large intestine, unspecified portion	Diagnosis	ICD-10-CM
C7A.09	Malignant carcinoid tumors of other sites	Diagnosis	ICD-10-CM
C7A.090	Malignant carcinoid tumor of the bronchus and lung	Diagnosis	ICD-10-CM
C7A.091	Malignant carcinoid tumor of the thymus	Diagnosis	ICD-10-CM
C7A.092	Malignant carcinoid tumor of the stomach	Diagnosis	ICD-10-CM
C7A.093	Malignant carcinoid tumor of the kidney	Diagnosis	ICD-10-CM
C7A.094	Malignant carcinoid tumor of the foregut, unspecified	Diagnosis	ICD-10-CM
C7A.095	Malignant carcinoid tumor of the midgut, unspecified	Diagnosis	ICD-10-CM
C7A.096	Malignant carcinoid tumor of the hindgut, unspecified	Diagnosis	ICD-10-CM
C7A.098	Malignant carcinoid tumors of other sites	Diagnosis	ICD-10-CM
C7A.1	Malignant poorly differentiated neuroendocrine tumors	Diagnosis	ICD-10-CM
C7A.8	Other malignant neuroendocrine tumors	Diagnosis	ICD-10-CM
C7B	Secondary neuroendocrine tumors	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C7B.0	Secondary carcinoid tumors	Diagnosis	ICD-10-CM
C7B.00	Secondary carcinoid tumors, unspecified site	Diagnosis	ICD-10-CM
C7B.01	Secondary carcinoid tumors of distant lymph nodes	Diagnosis	ICD-10-CM
C7B.02	Secondary carcinoid tumors of liver	Diagnosis	ICD-10-CM
C7B.03	Secondary carcinoid tumors of bone	Diagnosis	ICD-10-CM
C7B.04	Secondary carcinoid tumors of peritoneum	Diagnosis	ICD-10-CM
C7B.09	Secondary carcinoid tumors of other sites	Diagnosis	ICD-10-CM
C7B.1	Secondary Merkel cell carcinoma	Diagnosis	ICD-10-CM
C7B.8	Other secondary neuroendocrine tumors	Diagnosis	ICD-10-CM
C80	Malignant neoplasm without specification of site	Diagnosis	ICD-10-CM
C80.0	Disseminated malignant neoplasm, unspecified	Diagnosis	ICD-10-CM
C80.1	Malignant (primary) neoplasm, unspecified	Diagnosis	ICD-10-CM
C80.2	Malignant neoplasm associated with transplanted organ	Diagnosis	ICD-10-CM
C81	Hodgkin lymphoma	Diagnosis	ICD-10-CM
C81.0	Nodular lymphocyte predominant Hodgkin lymphoma	Diagnosis	ICD-10-CM
C81.00	Nodular lymphocyte predominant Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.01	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.02	Nodular lymphocyte predominant Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.03	Nodular lymphocyte predominant Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.04	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.05	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.06	Nodular lymphocyte predominant Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.07	Nodular lymphocyte predominant Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.08	Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.09	Nodular lymphocyte predominant Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.1	Nodular sclerosis Hodgkin lymphoma	Diagnosis	ICD-10-CM
C81.10	Nodular sclerosis Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.11	Nodular sclerosis Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.12	Nodular sclerosis Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.13	Nodular sclerosis Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.14	Nodular sclerosis Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.15	Nodular sclerosis Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.16	Nodular sclerosis Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.17	Nodular sclerosis Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.18	Nodular sclerosis Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.19	Nodular sclerosis Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.2	Mixed cellularity Hodgkin lymphoma	Diagnosis	ICD-10-CM
C81.20	Mixed cellularity Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C81.21	Mixed cellularity Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.22	Mixed cellularity Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.23	Mixed cellularity Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.24	Mixed cellularity Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.25	Mixed cellularity Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.26	Mixed cellularity Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.27	Mixed cellularity Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.28	Mixed cellularity Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.29	Mixed cellularity Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.3	Lymphocyte depleted Hodgkin lymphoma	Diagnosis	ICD-10-CM
C81.30	Lymphocyte depleted Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.31	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.32	Lymphocyte depleted Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.33	Lymphocyte depleted Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.34	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.35	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.36	Lymphocyte depleted Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.37	Lymphocyte depleted Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.38	Lymphocyte depleted Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.39	Lymphocyte depleted Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.4	Lymphocyte-rich Hodgkin lymphoma	Diagnosis	ICD-10-CM
C81.40	Lymphocyte-rich Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.41	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.42	Lymphocyte-rich Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.43	Lymphocyte-rich Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.44	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.45	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.46	Lymphocyte-rich Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.47	Lymphocyte-rich Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.48	Lymphocyte-rich Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.49	Lymphocyte-rich Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C81.7	Other Hodgkin lymphoma	Diagnosis	ICD-10-CM
C81.70	Other Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C81.71	Other Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.72	Other Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.73	Other Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.74	Other Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.75	Other Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.76	Other Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.77	Other Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C81.78	Other Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.79	Other Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C81.9	Hodgkin lymphoma, unspecified	Diagnosis	ICD-10-CM
C81.90	Hodgkin lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C81.91	Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C81.92	Hodgkin lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C81.93	Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C81.94	Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C81.95	Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C81.96	Hodgkin lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C81.97	Hodgkin lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C81.98	Hodgkin lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C81.99	Hodgkin lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82	Follicular lymphoma	Diagnosis	ICD-10-CM
C82.0	Follicular lymphoma grade I	Diagnosis	ICD-10-CM
C82.00	Follicular lymphoma grade I, unspecified site	Diagnosis	ICD-10-CM
C82.01	Follicular lymphoma grade I, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.02	Follicular lymphoma grade I, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.03	Follicular lymphoma grade I, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.04	Follicular lymphoma grade I, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.05	Follicular lymphoma grade I, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.06	Follicular lymphoma grade I, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.07	Follicular lymphoma grade I, spleen	Diagnosis	ICD-10-CM
C82.08	Follicular lymphoma grade I, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.09	Follicular lymphoma grade I, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.1	Follicular lymphoma grade II	Diagnosis	ICD-10-CM
C82.10	Follicular lymphoma grade II, unspecified site	Diagnosis	ICD-10-CM
C82.11	Follicular lymphoma grade II, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.12	Follicular lymphoma grade II, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.13	Follicular lymphoma grade II, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.14	Follicular lymphoma grade II, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.15	Follicular lymphoma grade II, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.16	Follicular lymphoma grade II, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.17	Follicular lymphoma grade II, spleen	Diagnosis	ICD-10-CM
C82.18	Follicular lymphoma grade II, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.19	Follicular lymphoma grade II, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.2	Follicular lymphoma grade III, unspecified	Diagnosis	ICD-10-CM
C82.20	Follicular lymphoma grade III, unspecified, unspecified site	Diagnosis	ICD-10-CM
C82.21	Follicular lymphoma grade III, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.22	Follicular lymphoma grade III, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.23	Follicular lymphoma grade III, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.24	Follicular lymphoma grade III, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.25	Follicular lymphoma grade III, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.26	Follicular lymphoma grade III, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C82.27	Follicular lymphoma grade III, unspecified, spleen	Diagnosis	ICD-10-CM
C82.28	Follicular lymphoma grade III, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.29	Follicular lymphoma grade III, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.3	Follicular lymphoma grade IIIa	Diagnosis	ICD-10-CM
C82.30	Follicular lymphoma grade IIIa, unspecified site	Diagnosis	ICD-10-CM
C82.31	Follicular lymphoma grade IIIa, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.32	Follicular lymphoma grade IIIa, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.33	Follicular lymphoma grade IIIa, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.34	Follicular lymphoma grade IIIa, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.35	Follicular lymphoma grade IIIa, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.36	Follicular lymphoma grade IIIa, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.37	Follicular lymphoma grade IIIa, spleen	Diagnosis	ICD-10-CM
C82.38	Follicular lymphoma grade IIIa, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.39	Follicular lymphoma grade IIIa, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.4	Follicular lymphoma grade IIIb	Diagnosis	ICD-10-CM
C82.40	Follicular lymphoma grade IIIb, unspecified site	Diagnosis	ICD-10-CM
C82.41	Follicular lymphoma grade IIIb, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.42	Follicular lymphoma grade IIIb, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.43	Follicular lymphoma grade IIIb, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.44	Follicular lymphoma grade IIIb, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.45	Follicular lymphoma grade IIIb, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.46	Follicular lymphoma grade IIIb, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.47	Follicular lymphoma grade IIIb, spleen	Diagnosis	ICD-10-CM
C82.48	Follicular lymphoma grade IIIb, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.49	Follicular lymphoma grade IIIb, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.5	Diffuse follicle center lymphoma	Diagnosis	ICD-10-CM
C82.50	Diffuse follicle center lymphoma, unspecified site	Diagnosis	ICD-10-CM
C82.51	Diffuse follicle center lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.52	Diffuse follicle center lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.53	Diffuse follicle center lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.54	Diffuse follicle center lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.55	Diffuse follicle center lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.56	Diffuse follicle center lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.57	Diffuse follicle center lymphoma, spleen	Diagnosis	ICD-10-CM
C82.58	Diffuse follicle center lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.59	Diffuse follicle center lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.6	Cutaneous follicle center lymphoma	Diagnosis	ICD-10-CM
C82.60	Cutaneous follicle center lymphoma, unspecified site	Diagnosis	ICD-10-CM
C82.61	Cutaneous follicle center lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.62	Cutaneous follicle center lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.63	Cutaneous follicle center lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.64	Cutaneous follicle center lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.65	Cutaneous follicle center lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C82.66	Cutaneous follicle center lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.67	Cutaneous follicle center lymphoma, spleen	Diagnosis	ICD-10-CM
C82.68	Cutaneous follicle center lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.69	Cutaneous follicle center lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.8	Other types of follicular lymphoma	Diagnosis	ICD-10-CM
C82.80	Other types of follicular lymphoma, unspecified site	Diagnosis	ICD-10-CM
C82.81	Other types of follicular lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.82	Other types of follicular lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.83	Other types of follicular lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.84	Other types of follicular lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.85	Other types of follicular lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.86	Other types of follicular lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.87	Other types of follicular lymphoma, spleen	Diagnosis	ICD-10-CM
C82.88	Other types of follicular lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.89	Other types of follicular lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C82.9	Follicular lymphoma, unspecified	Diagnosis	ICD-10-CM
C82.90	Follicular lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C82.91	Follicular lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C82.92	Follicular lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C82.93	Follicular lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C82.94	Follicular lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C82.95	Follicular lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C82.96	Follicular lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C82.97	Follicular lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C82.98	Follicular lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C82.99	Follicular lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83	Non-follicular lymphoma	Diagnosis	ICD-10-CM
C83.0	Small cell B-cell lymphoma	Diagnosis	ICD-10-CM
C83.00	Small cell B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.01	Small cell B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.02	Small cell B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.03	Small cell B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.04	Small cell B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.05	Small cell B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.06	Small cell B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.07	Small cell B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C83.08	Small cell B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.09	Small cell B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.1	Mantle cell lymphoma	Diagnosis	ICD-10-CM
C83.10	Mantle cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.11	Mantle cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.12	Mantle cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.13	Mantle cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C83.14	Mantle cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.15	Mantle cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.16	Mantle cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.17	Mantle cell lymphoma, spleen	Diagnosis	ICD-10-CM
C83.18	Mantle cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.19	Mantle cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.3	Diffuse large B-cell lymphoma	Diagnosis	ICD-10-CM
C83.30	Diffuse large B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.31	Diffuse large B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.32	Diffuse large B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.33	Diffuse large B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.34	Diffuse large B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.35	Diffuse large B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.36	Diffuse large B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.37	Diffuse large B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C83.38	Diffuse large B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.39	Diffuse large B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.5	Lymphoblastic (diffuse) lymphoma	Diagnosis	ICD-10-CM
C83.50	Lymphoblastic (diffuse) lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.51	Lymphoblastic (diffuse) lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.52	Lymphoblastic (diffuse) lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.53	Lymphoblastic (diffuse) lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.54	Lymphoblastic (diffuse) lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.55	Lymphoblastic (diffuse) lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.56	Lymphoblastic (diffuse) lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.57	Lymphoblastic (diffuse) lymphoma, spleen	Diagnosis	ICD-10-CM
C83.58	Lymphoblastic (diffuse) lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.59	Lymphoblastic (diffuse) lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.7	Burkitt lymphoma	Diagnosis	ICD-10-CM
C83.70	Burkitt lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.71	Burkitt lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.72	Burkitt lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.73	Burkitt lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.74	Burkitt lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.75	Burkitt lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.76	Burkitt lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.77	Burkitt lymphoma, spleen	Diagnosis	ICD-10-CM
C83.78	Burkitt lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.79	Burkitt lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.8	Other non-follicular lymphoma	Diagnosis	ICD-10-CM
C83.80	Other non-follicular lymphoma, unspecified site	Diagnosis	ICD-10-CM
C83.81	Other non-follicular lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.82	Other non-follicular lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C83.83	Other non-follicular lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.84	Other non-follicular lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.85	Other non-follicular lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.86	Other non-follicular lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.87	Other non-follicular lymphoma, spleen	Diagnosis	ICD-10-CM
C83.88	Other non-follicular lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.89	Other non-follicular lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C83.9	Non-follicular (diffuse) lymphoma, unspecified	Diagnosis	ICD-10-CM
C83.90	Non-follicular (diffuse) lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C83.91	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C83.92	Non-follicular (diffuse) lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C83.93	Non-follicular (diffuse) lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C83.94	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C83.95	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C83.96	Non-follicular (diffuse) lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C83.97	Non-follicular (diffuse) lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C83.98	Non-follicular (diffuse) lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C83.99	Non-follicular (diffuse) lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84	Mature T/NK-cell lymphomas	Diagnosis	ICD-10-CM
C84.0	Mycosis fungoides	Diagnosis	ICD-10-CM
C84.00	Mycosis fungoides, unspecified site	Diagnosis	ICD-10-CM
C84.01	Mycosis fungoides, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.02	Mycosis fungoides, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.03	Mycosis fungoides, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.04	Mycosis fungoides, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.05	Mycosis fungoides, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.06	Mycosis fungoides, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.07	Mycosis fungoides, spleen	Diagnosis	ICD-10-CM
C84.08	Mycosis fungoides, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.09	Mycosis fungoides, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.1	Sezary disease	Diagnosis	ICD-10-CM
C84.10	Sezary disease, unspecified site	Diagnosis	ICD-10-CM
C84.11	Sezary disease, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.12	Sezary disease, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.13	Sezary disease, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.14	Sezary disease, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.15	Sezary disease, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.16	Sezary disease, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.17	Sezary disease, spleen	Diagnosis	ICD-10-CM
C84.18	Sezary disease, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.19	Sezary disease, extranodal and solid organ sites	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C84.4	Peripheral T-cell lymphoma, not classified	Diagnosis	ICD-10-CM
C84.40	Peripheral T-cell lymphoma, not classified, unspecified site	Diagnosis	ICD-10-CM
C84.41	Peripheral T-cell lymphoma, not classified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.42	Peripheral T-cell lymphoma, not classified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.43	Peripheral T-cell lymphoma, not classified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.44	Peripheral T-cell lymphoma, not classified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.45	Peripheral T-cell lymphoma, not classified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.46	Peripheral T-cell lymphoma, not classified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.47	Peripheral T-cell lymphoma, not classified, spleen	Diagnosis	ICD-10-CM
C84.48	Peripheral T-cell lymphoma, not classified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.49	Peripheral T-cell lymphoma, not classified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.6	Anaplastic large cell lymphoma, ALK-positive	Diagnosis	ICD-10-CM
C84.60	Anaplastic large cell lymphoma, ALK-positive, unspecified site	Diagnosis	ICD-10-CM
C84.61	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.62	Anaplastic large cell lymphoma, ALK-positive, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.63	Anaplastic large cell lymphoma, ALK-positive, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.64	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.65	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.66	Anaplastic large cell lymphoma, ALK-positive, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.67	Anaplastic large cell lymphoma, ALK-positive, spleen	Diagnosis	ICD-10-CM
C84.68	Anaplastic large cell lymphoma, ALK-positive, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.69	Anaplastic large cell lymphoma, ALK-positive, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.7	Anaplastic large cell lymphoma, ALK-negative	Diagnosis	ICD-10-CM
C84.70	Anaplastic large cell lymphoma, ALK-negative, unspecified site	Diagnosis	ICD-10-CM
C84.71	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.72	Anaplastic large cell lymphoma, ALK-negative, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.73	Anaplastic large cell lymphoma, ALK-negative, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.74	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.75	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.76	Anaplastic large cell lymphoma, ALK-negative, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.77	Anaplastic large cell lymphoma, ALK-negative, spleen	Diagnosis	ICD-10-CM
C84.78	Anaplastic large cell lymphoma, ALK-negative, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.79	Anaplastic large cell lymphoma, ALK-negative, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.9	Mature T/NK-cell lymphomas, unspecified	Diagnosis	ICD-10-CM
C84.90	Mature T/NK-cell lymphomas, unspecified, unspecified site	Diagnosis	ICD-10-CM
C84.91	Mature T/NK-cell lymphomas, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.92	Mature T/NK-cell lymphomas, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.93	Mature T/NK-cell lymphomas, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.94	Mature T/NK-cell lymphomas, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C84.95	Mature T/NK-cell lymphomas, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.96	Mature T/NK-cell lymphomas, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.97	Mature T/NK-cell lymphomas, unspecified, spleen	Diagnosis	ICD-10-CM
C84.98	Mature T/NK-cell lymphomas, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.99	Mature T/NK-cell lymphomas, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.A	Cutaneous T-cell lymphoma, unspecified	Diagnosis	ICD-10-CM
C84.A0	Cutaneous T-cell lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C84.A1	Cutaneous T-cell lymphoma, unspecified lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.A2	Cutaneous T-cell lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.A3	Cutaneous T-cell lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.A4	Cutaneous T-cell lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.A5	Cutaneous T-cell lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.A6	Cutaneous T-cell lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.A7	Cutaneous T-cell lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C84.A8	Cutaneous T-cell lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.A9	Cutaneous T-cell lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C84.Z	Other mature T/NK-cell lymphomas	Diagnosis	ICD-10-CM
C84.Z0	Other mature T/NK-cell lymphomas, unspecified site	Diagnosis	ICD-10-CM
C84.Z1	Other mature T/NK-cell lymphomas, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C84.Z2	Other mature T/NK-cell lymphomas, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C84.Z3	Other mature T/NK-cell lymphomas, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C84.Z4	Other mature T/NK-cell lymphomas, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C84.Z5	Other mature T/NK-cell lymphomas, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C84.Z6	Other mature T/NK-cell lymphomas, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C84.Z7	Other mature T/NK-cell lymphomas, spleen	Diagnosis	ICD-10-CM
C84.Z8	Other mature T/NK-cell lymphomas, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C84.Z9	Other mature T/NK-cell lymphomas, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85	Other specified and unspecified types of non-Hodgkin lymphoma	Diagnosis	ICD-10-CM
C85.1	Unspecified B-cell lymphoma	Diagnosis	ICD-10-CM
C85.10	Unspecified B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM
C85.11	Unspecified B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.12	Unspecified B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C85.13	Unspecified B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.14	Unspecified B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C85.15	Unspecified B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.16	Unspecified B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.17	Unspecified B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C85.18	Unspecified B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C85.19	Unspecified B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85.2	Mediastinal (thymic) large B-cell lymphoma	Diagnosis	ICD-10-CM
C85.20	Mediastinal (thymic) large B-cell lymphoma, unspecified site	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C85.21	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.22	Mediastinal (thymic) large B-cell lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C85.23	Mediastinal (thymic) large B-cell lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.24	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C85.25	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.26	Mediastinal (thymic) large B-cell lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.27	Mediastinal (thymic) large B-cell lymphoma, spleen	Diagnosis	ICD-10-CM
C85.28	Mediastinal (thymic) large B-cell lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C85.29	Mediastinal (thymic) large B-cell lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85.8	Other specified types of non-Hodgkin lymphoma	Diagnosis	ICD-10-CM
C85.80	Other specified types of non-Hodgkin lymphoma, unspecified site	Diagnosis	ICD-10-CM
C85.81	Other specified types of non-Hodgkin lymphoma, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.82	Other specified types of non-Hodgkin lymphoma, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C85.83	Other specified types of non-Hodgkin lymphoma, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.84	Other specified types of non-Hodgkin lymphoma, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C85.85	Other specified types of non-Hodgkin lymphoma, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.86	Other specified types of non-Hodgkin lymphoma, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.87	Other specified types of non-Hodgkin lymphoma, spleen	Diagnosis	ICD-10-CM
C85.88	Other specified types of non-Hodgkin lymphoma, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C85.89	Other specified types of non-Hodgkin lymphoma, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C85.9	Non-Hodgkin lymphoma, unspecified	Diagnosis	ICD-10-CM
C85.90	Non-Hodgkin lymphoma, unspecified, unspecified site	Diagnosis	ICD-10-CM
C85.91	Non-Hodgkin lymphoma, unspecified, lymph nodes of head, face, and neck	Diagnosis	ICD-10-CM
C85.92	Non-Hodgkin lymphoma, unspecified, intrathoracic lymph nodes	Diagnosis	ICD-10-CM
C85.93	Non-Hodgkin lymphoma, unspecified, intra-abdominal lymph nodes	Diagnosis	ICD-10-CM
C85.94	Non-Hodgkin lymphoma, unspecified, lymph nodes of axilla and upper limb	Diagnosis	ICD-10-CM
C85.95	Non-Hodgkin lymphoma, unspecified, lymph nodes of inguinal region and lower limb	Diagnosis	ICD-10-CM
C85.96	Non-Hodgkin lymphoma, unspecified, intrapelvic lymph nodes	Diagnosis	ICD-10-CM
C85.97	Non-Hodgkin lymphoma, unspecified, spleen	Diagnosis	ICD-10-CM
C85.98	Non-Hodgkin lymphoma, unspecified, lymph nodes of multiple sites	Diagnosis	ICD-10-CM
C85.99	Non-Hodgkin lymphoma, unspecified, extranodal and solid organ sites	Diagnosis	ICD-10-CM
C86	Other specified types of T/NK-cell lymphoma	Diagnosis	ICD-10-CM
C86.0	Extranodal NK/T-cell lymphoma, nasal type	Diagnosis	ICD-10-CM
C86.1	Hepatosplenic T-cell lymphoma	Diagnosis	ICD-10-CM
C86.2	Enteropathy-type (intestinal) T-cell lymphoma	Diagnosis	ICD-10-CM
C86.3	Subcutaneous panniculitis-like T-cell lymphoma	Diagnosis	ICD-10-CM
C86.4	Blastic NK-cell lymphoma	Diagnosis	ICD-10-CM
C86.5	Angioimmunoblastic T-cell lymphoma	Diagnosis	ICD-10-CM
C86.6	Primary cutaneous CD30-positive T-cell proliferations	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C88	Malignant immunoproliferative diseases and certain other B-cell lymphomas	Diagnosis	ICD-10-CM
C88.0	Waldenstrom macroglobulinemia	Diagnosis	ICD-10-CM
C88.2	Heavy chain disease	Diagnosis	ICD-10-CM
C88.3	Immunoproliferative small intestinal disease	Diagnosis	ICD-10-CM
C88.4	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue [MALT-lymphoma]	Diagnosis	ICD-10-CM
C88.8	Other malignant immunoproliferative diseases	Diagnosis	ICD-10-CM
C88.9	Malignant immunoproliferative disease, unspecified	Diagnosis	ICD-10-CM
C90	Multiple myeloma and malignant plasma cell neoplasms	Diagnosis	ICD-10-CM
C90.0	Multiple myeloma	Diagnosis	ICD-10-CM
C90.00	Multiple myeloma not having achieved remission	Diagnosis	ICD-10-CM
C90.01	Multiple myeloma in remission	Diagnosis	ICD-10-CM
C90.02	Multiple myeloma in relapse	Diagnosis	ICD-10-CM
C90.1	Plasma cell leukemia	Diagnosis	ICD-10-CM
C90.10	Plasma cell leukemia not having achieved remission	Diagnosis	ICD-10-CM
C90.11	Plasma cell leukemia in remission	Diagnosis	ICD-10-CM
C90.12	Plasma cell leukemia in relapse	Diagnosis	ICD-10-CM
C90.2	Extramedullary plasmacytoma	Diagnosis	ICD-10-CM
C90.20	Extramedullary plasmacytoma not having achieved remission	Diagnosis	ICD-10-CM
C90.21	Extramedullary plasmacytoma in remission	Diagnosis	ICD-10-CM
C90.22	Extramedullary plasmacytoma in relapse	Diagnosis	ICD-10-CM
C90.3	Solitary plasmacytoma	Diagnosis	ICD-10-CM
C90.30	Solitary plasmacytoma not having achieved remission	Diagnosis	ICD-10-CM
C90.31	Solitary plasmacytoma in remission	Diagnosis	ICD-10-CM
C90.32	Solitary plasmacytoma in relapse	Diagnosis	ICD-10-CM
C91	Lymphoid leukemia	Diagnosis	ICD-10-CM
C91.0	Acute lymphoblastic leukemia [ALL]	Diagnosis	ICD-10-CM
C91.00	Acute lymphoblastic leukemia not having achieved remission	Diagnosis	ICD-10-CM
C91.01	Acute lymphoblastic leukemia, in remission	Diagnosis	ICD-10-CM
C91.02	Acute lymphoblastic leukemia, in relapse	Diagnosis	ICD-10-CM
C91.1	Chronic lymphocytic leukemia of B-cell type	Diagnosis	ICD-10-CM
C91.10	Chronic lymphocytic leukemia of B-cell type not having achieved remission	Diagnosis	ICD-10-CM
C91.11	Chronic lymphocytic leukemia of B-cell type in remission	Diagnosis	ICD-10-CM
C91.12	Chronic lymphocytic leukemia of B-cell type in relapse	Diagnosis	ICD-10-CM
C91.3	Prolymphocytic leukemia of B-cell type	Diagnosis	ICD-10-CM
C91.30	Prolymphocytic leukemia of B-cell type not having achieved remission	Diagnosis	ICD-10-CM
C91.31	Prolymphocytic leukemia of B-cell type, in remission	Diagnosis	ICD-10-CM
C91.32	Prolymphocytic leukemia of B-cell type, in relapse	Diagnosis	ICD-10-CM
C91.4	Hairy cell leukemia	Diagnosis	ICD-10-CM
C91.40	Hairy cell leukemia not having achieved remission	Diagnosis	ICD-10-CM
C91.41	Hairy cell leukemia, in remission	Diagnosis	ICD-10-CM
C91.42	Hairy cell leukemia, in relapse	Diagnosis	ICD-10-CM
C91.5	Adult T-cell lymphoma/leukemia (HTLV-1-associated)	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C91.50	Adult T-cell lymphoma/leukemia (HTLV-1-associated) not having achieved remission	Diagnosis	ICD-10-CM
C91.51	Adult T-cell lymphoma/leukemia (HTLV-1-associated), in remission	Diagnosis	ICD-10-CM
C91.52	Adult T-cell lymphoma/leukemia (HTLV-1-associated), in relapse	Diagnosis	ICD-10-CM
C91.6	Prolymphocytic leukemia of T-cell type	Diagnosis	ICD-10-CM
C91.60	Prolymphocytic leukemia of T-cell type not having achieved remission	Diagnosis	ICD-10-CM
C91.61	Prolymphocytic leukemia of T-cell type, in remission	Diagnosis	ICD-10-CM
C91.62	Prolymphocytic leukemia of T-cell type, in relapse	Diagnosis	ICD-10-CM
C91.9	Lymphoid leukemia, unspecified	Diagnosis	ICD-10-CM
C91.90	Lymphoid leukemia, unspecified not having achieved remission	Diagnosis	ICD-10-CM
C91.91	Lymphoid leukemia, unspecified, in remission	Diagnosis	ICD-10-CM
C91.92	Lymphoid leukemia, unspecified, in relapse	Diagnosis	ICD-10-CM
C91.A	Mature B-cell leukemia Burkitt-type	Diagnosis	ICD-10-CM
C91.A0	Mature B-cell leukemia Burkitt-type not having achieved remission	Diagnosis	ICD-10-CM
C91.A1	Mature B-cell leukemia Burkitt-type, in remission	Diagnosis	ICD-10-CM
C91.A2	Mature B-cell leukemia Burkitt-type, in relapse	Diagnosis	ICD-10-CM
C91.Z	Other lymphoid leukemia	Diagnosis	ICD-10-CM
C91.Z0	Other lymphoid leukemia not having achieved remission	Diagnosis	ICD-10-CM
C91.Z1	Other lymphoid leukemia, in remission	Diagnosis	ICD-10-CM
C91.Z2	Other lymphoid leukemia, in relapse	Diagnosis	ICD-10-CM
C92	Myeloid leukemia	Diagnosis	ICD-10-CM
C92.0	Acute myeloblastic leukemia	Diagnosis	ICD-10-CM
C92.00	Acute myeloblastic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C92.01	Acute myeloblastic leukemia, in remission	Diagnosis	ICD-10-CM
C92.02	Acute myeloblastic leukemia, in relapse	Diagnosis	ICD-10-CM
C92.1	Chronic myeloid leukemia, BCR/ABL-positive	Diagnosis	ICD-10-CM
C92.10	Chronic myeloid leukemia, BCR/ABL-positive, not having achieved remission	Diagnosis	ICD-10-CM
C92.11	Chronic myeloid leukemia, BCR/ABL-positive, in remission	Diagnosis	ICD-10-CM
C92.12	Chronic myeloid leukemia, BCR/ABL-positive, in relapse	Diagnosis	ICD-10-CM
C92.2	Atypical chronic myeloid leukemia, BCR/ABL-negative	Diagnosis	ICD-10-CM
C92.20	Atypical chronic myeloid leukemia, BCR/ABL-negative, not having achieved remission	Diagnosis	ICD-10-CM
C92.21	Atypical chronic myeloid leukemia, BCR/ABL-negative, in remission	Diagnosis	ICD-10-CM
C92.22	Atypical chronic myeloid leukemia, BCR/ABL-negative, in relapse	Diagnosis	ICD-10-CM
C92.3	Myeloid sarcoma	Diagnosis	ICD-10-CM
C92.30	Myeloid sarcoma, not having achieved remission	Diagnosis	ICD-10-CM
C92.31	Myeloid sarcoma, in remission	Diagnosis	ICD-10-CM
C92.32	Myeloid sarcoma, in relapse	Diagnosis	ICD-10-CM
C92.4	Acute promyelocytic leukemia	Diagnosis	ICD-10-CM
C92.40	Acute promyelocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C92.41	Acute promyelocytic leukemia, in remission	Diagnosis	ICD-10-CM
C92.42	Acute promyelocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C92.5	Acute myelomonocytic leukemia	Diagnosis	ICD-10-CM
C92.50	Acute myelomonocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C92.51	Acute myelomonocytic leukemia, in remission	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C92.52	Acute myelomonocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C92.6	Acute myeloid leukemia with 11q23-abnormality	Diagnosis	ICD-10-CM
C92.60	Acute myeloid leukemia with 11q23-abnormality not having achieved remission	Diagnosis	ICD-10-CM
C92.61	Acute myeloid leukemia with 11q23-abnormality in remission	Diagnosis	ICD-10-CM
C92.62	Acute myeloid leukemia with 11q23-abnormality in relapse	Diagnosis	ICD-10-CM
C92.9	Myeloid leukemia, unspecified	Diagnosis	ICD-10-CM
C92.90	Myeloid leukemia, unspecified, not having achieved remission	Diagnosis	ICD-10-CM
C92.91	Myeloid leukemia, unspecified in remission	Diagnosis	ICD-10-CM
C92.92	Myeloid leukemia, unspecified in relapse	Diagnosis	ICD-10-CM
C92.A	Acute myeloid leukemia with multilineage dysplasia	Diagnosis	ICD-10-CM
C92.A0	Acute myeloid leukemia with multilineage dysplasia, not having achieved remission	Diagnosis	ICD-10-CM
C92.A1	Acute myeloid leukemia with multilineage dysplasia, in remission	Diagnosis	ICD-10-CM
C92.A2	Acute myeloid leukemia with multilineage dysplasia, in relapse	Diagnosis	ICD-10-CM
C92.Z	Other myeloid leukemia	Diagnosis	ICD-10-CM
C92.Z0	Other myeloid leukemia not having achieved remission	Diagnosis	ICD-10-CM
C92.Z1	Other myeloid leukemia, in remission	Diagnosis	ICD-10-CM
C92.Z2	Other myeloid leukemia, in relapse	Diagnosis	ICD-10-CM
C93	Monocytic leukemia	Diagnosis	ICD-10-CM
C93.0	Acute monoblastic/monocytic leukemia	Diagnosis	ICD-10-CM
C93.00	Acute monoblastic/monocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C93.01	Acute monoblastic/monocytic leukemia, in remission	Diagnosis	ICD-10-CM
C93.02	Acute monoblastic/monocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C93.1	Chronic myelomonocytic leukemia	Diagnosis	ICD-10-CM
C93.10	Chronic myelomonocytic leukemia not having achieved remission	Diagnosis	ICD-10-CM
C93.11	Chronic myelomonocytic leukemia, in remission	Diagnosis	ICD-10-CM
C93.12	Chronic myelomonocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C93.3	Juvenile myelomonocytic leukemia	Diagnosis	ICD-10-CM
C93.30	Juvenile myelomonocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C93.31	Juvenile myelomonocytic leukemia, in remission	Diagnosis	ICD-10-CM
C93.32	Juvenile myelomonocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C93.9	Monocytic leukemia, unspecified	Diagnosis	ICD-10-CM
C93.90	Monocytic leukemia, unspecified, not having achieved remission	Diagnosis	ICD-10-CM
C93.91	Monocytic leukemia, unspecified in remission	Diagnosis	ICD-10-CM
C93.92	Monocytic leukemia, unspecified in relapse	Diagnosis	ICD-10-CM
C93.Z	Other monocytic leukemia	Diagnosis	ICD-10-CM
C93.Z0	Other monocytic leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C93.Z1	Other monocytic leukemia, in remission	Diagnosis	ICD-10-CM
C93.Z2	Other monocytic leukemia, in relapse	Diagnosis	ICD-10-CM
C94	Other leukemias of specified cell type	Diagnosis	ICD-10-CM
C94.0	Acute erythroid leukemia	Diagnosis	ICD-10-CM
C94.00	Acute erythroid leukemia, not having achieved remission	Diagnosis	ICD-10-CM
C94.01	Acute erythroid leukemia, in remission	Diagnosis	ICD-10-CM
C94.02	Acute erythroid leukemia, in relapse	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C94.2	Acute megakaryoblastic leukemia	Diagnosis	ICD-10-CM
C94.20	Acute megakaryoblastic leukemia not having achieved remission	Diagnosis	ICD-10-CM
C94.21	Acute megakaryoblastic leukemia, in remission	Diagnosis	ICD-10-CM
C94.22	Acute megakaryoblastic leukemia, in relapse	Diagnosis	ICD-10-CM
C94.3	Mast cell leukemia	Diagnosis	ICD-10-CM
C94.30	Mast cell leukemia not having achieved remission	Diagnosis	ICD-10-CM
C94.31	Mast cell leukemia, in remission	Diagnosis	ICD-10-CM
C94.32	Mast cell leukemia, in relapse	Diagnosis	ICD-10-CM
C94.4	Acute panmyelosis with myelofibrosis	Diagnosis	ICD-10-CM
C94.40	Acute panmyelosis with myelofibrosis not having achieved remission	Diagnosis	ICD-10-CM
C94.41	Acute panmyelosis with myelofibrosis, in remission	Diagnosis	ICD-10-CM
C94.42	Acute panmyelosis with myelofibrosis, in relapse	Diagnosis	ICD-10-CM
C94.6	Myelodysplastic disease, not classified	Diagnosis	ICD-10-CM
C94.8	Other specified leukemias	Diagnosis	ICD-10-CM
C94.80	Other specified leukemias not having achieved remission	Diagnosis	ICD-10-CM
C94.81	Other specified leukemias, in remission	Diagnosis	ICD-10-CM
C94.82	Other specified leukemias, in relapse	Diagnosis	ICD-10-CM
C95	Leukemia of unspecified cell type	Diagnosis	ICD-10-CM
C95.0	Acute leukemia of unspecified cell type	Diagnosis	ICD-10-CM
C95.00	Acute leukemia of unspecified cell type not having achieved remission	Diagnosis	ICD-10-CM
C95.01	Acute leukemia of unspecified cell type, in remission	Diagnosis	ICD-10-CM
C95.02	Acute leukemia of unspecified cell type, in relapse	Diagnosis	ICD-10-CM
C95.1	Chronic leukemia of unspecified cell type	Diagnosis	ICD-10-CM
C95.10	Chronic leukemia of unspecified cell type not having achieved remission	Diagnosis	ICD-10-CM
C95.11	Chronic leukemia of unspecified cell type, in remission	Diagnosis	ICD-10-CM
C95.12	Chronic leukemia of unspecified cell type, in relapse	Diagnosis	ICD-10-CM
C95.9	Leukemia, unspecified	Diagnosis	ICD-10-CM
C95.90	Leukemia, unspecified not having achieved remission	Diagnosis	ICD-10-CM
C95.91	Leukemia, unspecified, in remission	Diagnosis	ICD-10-CM
C95.92	Leukemia, unspecified, in relapse	Diagnosis	ICD-10-CM
C96	Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue	Diagnosis	ICD-10-CM
C96.0	Multifocal and multisystemic (disseminated) Langerhans-cell histiocytosis	Diagnosis	ICD-10-CM
C96.2	Malignant mast cell neoplasm	Diagnosis	ICD-10-CM
C96.20	Malignant mast cell neoplasm, unspecified	Diagnosis	ICD-10-CM
C96.21	Aggressive systemic mastocytosis	Diagnosis	ICD-10-CM
C96.22	Mast cell sarcoma	Diagnosis	ICD-10-CM
C96.29	Other malignant mast cell neoplasm	Diagnosis	ICD-10-CM
C96.4	Sarcoma of dendritic cells (accessory cells)	Diagnosis	ICD-10-CM
C96.5	Multifocal and unisystemic Langerhans-cell histiocytosis	Diagnosis	ICD-10-CM
C96.6	Unifocal Langerhans-cell histiocytosis	Diagnosis	ICD-10-CM
C96.9	Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified	Diagnosis	ICD-10-CM
C96.A	Histiocytic sarcoma	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C96.Z	Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue	Diagnosis	ICD-10-CM
D25.0	Submucous leiomyoma of uterus	Diagnosis	ICD-10-CM
D25.1	Intramural leiomyoma of uterus	Diagnosis	ICD-10-CM
D25.2	Subserosal leiomyoma of uterus	Diagnosis	ICD-10-CM
D25.9	Leiomyoma of uterus, unspecified	Diagnosis	ICD-10-CM
D37.01	Neoplasm of uncertain behavior of lip	Diagnosis	ICD-10-CM
D37.02	Neoplasm of uncertain behavior of tongue	Diagnosis	ICD-10-CM
D37.030	Neoplasm of uncertain behavior of the parotid salivary glands	Diagnosis	ICD-10-CM
D37.031	Neoplasm of uncertain behavior of the sublingual salivary glands	Diagnosis	ICD-10-CM
D37.032	Neoplasm of uncertain behavior of the submandibular salivary glands	Diagnosis	ICD-10-CM
D37.039	Neoplasm of uncertain behavior of the major salivary glands, unspecified	Diagnosis	ICD-10-CM
D37.04	Neoplasm of uncertain behavior of the minor salivary glands	Diagnosis	ICD-10-CM
D37.05	Neoplasm of uncertain behavior of pharynx	Diagnosis	ICD-10-CM
D37.09	Neoplasm of uncertain behavior of other specified sites of the oral cavity	Diagnosis	ICD-10-CM
D37.1	Neoplasm of uncertain behavior of stomach	Diagnosis	ICD-10-CM
D37.2	Neoplasm of uncertain behavior of small intestine	Diagnosis	ICD-10-CM
D37.3	Neoplasm of uncertain behavior of appendix	Diagnosis	ICD-10-CM
D37.4	Neoplasm of uncertain behavior of colon	Diagnosis	ICD-10-CM
D37.5	Neoplasm of uncertain behavior of rectum	Diagnosis	ICD-10-CM
D37.6	Neoplasm of uncertain behavior of liver, gallbladder and bile ducts	Diagnosis	ICD-10-CM
D37.8	Neoplasm of uncertain behavior of other specified digestive organs	Diagnosis	ICD-10-CM
D37.9	Neoplasm of uncertain behavior of digestive organ, unspecified	Diagnosis	ICD-10-CM
D38.0	Neoplasm of uncertain behavior of larynx	Diagnosis	ICD-10-CM
D38.1	Neoplasm of uncertain behavior of trachea, bronchus and lung	Diagnosis	ICD-10-CM
D38.2	Neoplasm of uncertain behavior of pleura	Diagnosis	ICD-10-CM
D38.3	Neoplasm of uncertain behavior of mediastinum	Diagnosis	ICD-10-CM
D38.4	Neoplasm of uncertain behavior of thymus	Diagnosis	ICD-10-CM
D38.5	Neoplasm of uncertain behavior of other respiratory organs	Diagnosis	ICD-10-CM
D38.6	Neoplasm of uncertain behavior of respiratory organ, unspecified	Diagnosis	ICD-10-CM
D39.0	Neoplasm of uncertain behavior of uterus	Diagnosis	ICD-10-CM
D39.10	Neoplasm of uncertain behavior of unspecified ovary	Diagnosis	ICD-10-CM
D39.11	Neoplasm of uncertain behavior of right ovary	Diagnosis	ICD-10-CM
D39.12	Neoplasm of uncertain behavior of left ovary	Diagnosis	ICD-10-CM
D39.2	Neoplasm of uncertain behavior of placenta	Diagnosis	ICD-10-CM
D39.8	Neoplasm of uncertain behavior of other specified female genital organs	Diagnosis	ICD-10-CM
D39.9	Neoplasm of uncertain behavior of female genital organ, unspecified	Diagnosis	ICD-10-CM
D40.0	Neoplasm of uncertain behavior of prostate	Diagnosis	ICD-10-CM
D40.10	Neoplasm of uncertain behavior of unspecified testis	Diagnosis	ICD-10-CM
D40.11	Neoplasm of uncertain behavior of right testis	Diagnosis	ICD-10-CM
D40.12	Neoplasm of uncertain behavior of left testis	Diagnosis	ICD-10-CM
D40.8	Neoplasm of uncertain behavior of other specified male genital organs	Diagnosis	ICD-10-CM
D40.9	Neoplasm of uncertain behavior of male genital organ, unspecified	Diagnosis	ICD-10-CM
D41.00	Neoplasm of uncertain behavior of unspecified kidney	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
D41.01	Neoplasm of uncertain behavior of right kidney	Diagnosis	ICD-10-CM
D41.02	Neoplasm of uncertain behavior of left kidney	Diagnosis	ICD-10-CM
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis	Diagnosis	ICD-10-CM
D41.11	Neoplasm of uncertain behavior of right renal pelvis	Diagnosis	ICD-10-CM
D41.12	Neoplasm of uncertain behavior of left renal pelvis	Diagnosis	ICD-10-CM
D41.20	Neoplasm of uncertain behavior of unspecified ureter	Diagnosis	ICD-10-CM
D41.21	Neoplasm of uncertain behavior of right ureter	Diagnosis	ICD-10-CM
D41.22	Neoplasm of uncertain behavior of left ureter	Diagnosis	ICD-10-CM
D41.3	Neoplasm of uncertain behavior of urethra	Diagnosis	ICD-10-CM
D41.4	Neoplasm of uncertain behavior of bladder	Diagnosis	ICD-10-CM
D41.8	Neoplasm of uncertain behavior of other specified urinary organs	Diagnosis	ICD-10-CM
D41.9	Neoplasm of uncertain behavior of unspecified urinary organ	Diagnosis	ICD-10-CM
D42.0	Neoplasm of uncertain behavior of cerebral meninges	Diagnosis	ICD-10-CM
D42.1	Neoplasm of uncertain behavior of spinal meninges	Diagnosis	ICD-10-CM
D42.9	Neoplasm of uncertain behavior of meninges, unspecified	Diagnosis	ICD-10-CM
D43.0	Neoplasm of uncertain behavior of brain, supratentorial	Diagnosis	ICD-10-CM
D43.1	Neoplasm of uncertain behavior of brain, infratentorial	Diagnosis	ICD-10-CM
D43.2	Neoplasm of uncertain behavior of brain, unspecified	Diagnosis	ICD-10-CM
D43.3	Neoplasm of uncertain behavior of cranial nerves	Diagnosis	ICD-10-CM
D43.4	Neoplasm of uncertain behavior of spinal cord	Diagnosis	ICD-10-CM
D43.8	Neoplasm of uncertain behavior of other specified parts of central nervous system	Diagnosis	ICD-10-CM
D43.9	Neoplasm of uncertain behavior of central nervous system, unspecified	Diagnosis	ICD-10-CM
D44.0	Neoplasm of uncertain behavior of thyroid gland	Diagnosis	ICD-10-CM
D44.10	Neoplasm of uncertain behavior of unspecified adrenal gland	Diagnosis	ICD-10-CM
D44.11	Neoplasm of uncertain behavior of right adrenal gland	Diagnosis	ICD-10-CM
D44.12	Neoplasm of uncertain behavior of left adrenal gland	Diagnosis	ICD-10-CM
D44.2	Neoplasm of uncertain behavior of parathyroid gland	Diagnosis	ICD-10-CM
D44.3	Neoplasm of uncertain behavior of pituitary gland	Diagnosis	ICD-10-CM
D44.4	Neoplasm of uncertain behavior of craniopharyngeal duct	Diagnosis	ICD-10-CM
D44.5	Neoplasm of uncertain behavior of pineal gland	Diagnosis	ICD-10-CM
D44.6	Neoplasm of uncertain behavior of carotid body	Diagnosis	ICD-10-CM
D44.7	Neoplasm of uncertain behavior of aortic body and other paraganglia	Diagnosis	ICD-10-CM
D44.9	Neoplasm of uncertain behavior of unspecified endocrine gland	Diagnosis	ICD-10-CM
D45	Polycythemia vera	Diagnosis	ICD-10-CM
D46.0	Refractory anemia without ring sideroblasts, so stated	Diagnosis	ICD-10-CM
D46.1	Refractory anemia with ring sideroblasts	Diagnosis	ICD-10-CM
D46.20	Refractory anemia with excess of blasts, unspecified	Diagnosis	ICD-10-CM
D46.21	Refractory anemia with excess of blasts 1	Diagnosis	ICD-10-CM
D46.22	Refractory anemia with excess of blasts 2	Diagnosis	ICD-10-CM
D46.4	Refractory anemia, unspecified	Diagnosis	ICD-10-CM
D46.9	Myelodysplastic syndrome, unspecified	Diagnosis	ICD-10-CM
D46.A	Refractory cytopenia with multilineage dysplasia	Diagnosis	ICD-10-CM
D46.B	Refractory cytopenia with multilineage dysplasia and ring sideroblasts	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
D46.C	Myelodysplastic syndrome with isolated del(5q) chromosomal abnormality	Diagnosis	ICD-10-CM
D46.Z	Other myelodysplastic syndromes	Diagnosis	ICD-10-CM
D47.01	Cutaneous mastocytosis	Diagnosis	ICD-10-CM
D47.02	Systemic mastocytosis	Diagnosis	ICD-10-CM
D47.09	Other mast cell neoplasms of uncertain behavior	Diagnosis	ICD-10-CM
D47.1	Chronic myeloproliferative disease	Diagnosis	ICD-10-CM
D47.3	Essential (hemorrhagic) thrombocythemia	Diagnosis	ICD-10-CM
D47.9	Neoplasm of uncertain behavior of lymphoid, hematopoietic and related tissue, unspecified	Diagnosis	ICD-10-CM
D47.Z1	Post-transplant lymphoproliferative disorder (PTLD)	Diagnosis	ICD-10-CM
D47.Z2	Castleman disease	Diagnosis	ICD-10-CM
D47.Z9	Other specified neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue	Diagnosis	ICD-10-CM
D48.0	Neoplasm of uncertain behavior of bone and articular cartilage	Diagnosis	ICD-10-CM
D48.1	Neoplasm of uncertain behavior of connective and other soft tissue	Diagnosis	ICD-10-CM
D48.2	Neoplasm of uncertain behavior of peripheral nerves and autonomic nervous system	Diagnosis	ICD-10-CM
D48.3	Neoplasm of uncertain behavior of retroperitoneum	Diagnosis	ICD-10-CM
D48.4	Neoplasm of uncertain behavior of peritoneum	Diagnosis	ICD-10-CM
D48.60	Neoplasm of uncertain behavior of unspecified breast	Diagnosis	ICD-10-CM
D48.61	Neoplasm of uncertain behavior of right breast	Diagnosis	ICD-10-CM
D48.62	Neoplasm of uncertain behavior of left breast	Diagnosis	ICD-10-CM
D48.7	Neoplasm of uncertain behavior of other specified sites	Diagnosis	ICD-10-CM
D48.9	Neoplasm of uncertain behavior, unspecified	Diagnosis	ICD-10-CM
D49.0	Neoplasm of unspecified behavior of digestive system	Diagnosis	ICD-10-CM
D49.1	Neoplasm of unspecified behavior of respiratory system	Diagnosis	ICD-10-CM
D49.3	Neoplasm of unspecified behavior of breast	Diagnosis	ICD-10-CM
D49.4	Neoplasm of unspecified behavior of bladder	Diagnosis	ICD-10-CM
D49.511	Neoplasm of unspecified behavior of right kidney	Diagnosis	ICD-10-CM
D49.512	Neoplasm of unspecified behavior of left kidney	Diagnosis	ICD-10-CM
D49.519	Neoplasm of unspecified behavior of unspecified kidney	Diagnosis	ICD-10-CM
D49.59	Neoplasm of unspecified behavior of other genitourinary organ	Diagnosis	ICD-10-CM
D49.6	Neoplasm of unspecified behavior of brain	Diagnosis	ICD-10-CM
D49.7	Neoplasm of unspecified behavior of endocrine glands and other parts of nervous system	Diagnosis	ICD-10-CM
D49.81	Neoplasm of unspecified behavior of retina and choroid	Diagnosis	ICD-10-CM
D49.89	Neoplasm of unspecified behavior of other specified sites	Diagnosis	ICD-10-CM
D49.9	Neoplasm of unspecified behavior of unspecified site	Diagnosis	ICD-10-CM
O9A.1	Malignant neoplasm complicating pregnancy, childbirth and the puerperium	Diagnosis	ICD-10-CM
O9A.11	Malignant neoplasm complicating pregnancy	Diagnosis	ICD-10-CM
O9A.111	Malignant neoplasm complicating pregnancy, first trimester	Diagnosis	ICD-10-CM
O9A.112	Malignant neoplasm complicating pregnancy, second trimester	Diagnosis	ICD-10-CM
O9A.113	Malignant neoplasm complicating pregnancy, third trimester	Diagnosis	ICD-10-CM
O9A.119	Malignant neoplasm complicating pregnancy, unspecified trimester	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
O9A.12	Malignant neoplasm complicating childbirth	Diagnosis	ICD-10-CM
O9A.13	Malignant neoplasm complicating the puerperium	Diagnosis	ICD-10-CM
Q85.00	Neurofibromatosis, unspecified	Diagnosis	ICD-10-CM
Q85.01	Neurofibromatosis, type 1	Diagnosis	ICD-10-CM
Q85.02	Neurofibromatosis, type 2	Diagnosis	ICD-10-CM
Q85.03	Schwannomatosis	Diagnosis	ICD-10-CM
Q85.09	Other neurofibromatosis	Diagnosis	ICD-10-CM
R97.21	Rising PSA following treatment for malignant neoplasm of prostate	Diagnosis	ICD-10-CM
V10	Personal history of malignant neoplasm	Diagnosis	ICD-9-CM
V10.0	Personal history of malignant neoplasm of gastrointestinal tract	Diagnosis	ICD-9-CM
V10.00	Personal history of malignant neoplasm of unspecified site in gastrointestinal tract	Diagnosis	ICD-9-CM
V10.01	Personal history of malignant neoplasm of tongue	Diagnosis	ICD-9-CM
V10.02	Personal history of malignant neoplasm of other and unspecified parts of oral cavity and pharynx	Diagnosis	ICD-9-CM
V10.03	Personal history of malignant neoplasm of esophagus	Diagnosis	ICD-9-CM
V10.04	Personal history of malignant neoplasm of stomach	Diagnosis	ICD-9-CM
V10.05	Personal history of malignant neoplasm of large intestine	Diagnosis	ICD-9-CM
V10.06	Personal history of malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-9-CM
V10.07	Personal history of malignant neoplasm of liver	Diagnosis	ICD-9-CM
V10.09	Personal history of malignant neoplasm of other site in gastrointestinal tract	Diagnosis	ICD-9-CM
V10.1	Personal history of malignant neoplasm of trachea, bronchus, and lung	Diagnosis	ICD-9-CM
V10.11	Personal history of malignant neoplasm of bronchus and lung	Diagnosis	ICD-9-CM
V10.12	Personal history of malignant neoplasm of trachea	Diagnosis	ICD-9-CM
V10.2	Personal history of malignant neoplasm of other respiratory and intrathoracic organs	Diagnosis	ICD-9-CM
V10.20	Personal history of malignant neoplasm of unspecified respiratory organ	Diagnosis	ICD-9-CM
V10.21	Personal history of malignant neoplasm of larynx	Diagnosis	ICD-9-CM
V10.22	Personal history of malignant neoplasm of nasal cavities, middle ear, and accessory sinuses	Diagnosis	ICD-9-CM
V10.29	Personal history of malignant neoplasm of other respiratory and intrathoracic organs	Diagnosis	ICD-9-CM
V10.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-9-CM
V10.4	Personal history of malignant neoplasm of genital organs	Diagnosis	ICD-9-CM
V10.40	Personal history of malignant neoplasm of unspecified female genital organ	Diagnosis	ICD-9-CM
V10.41	Personal history of malignant neoplasm of cervix uteri	Diagnosis	ICD-9-CM
V10.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-9-CM
V10.43	Personal history of malignant neoplasm of ovary	Diagnosis	ICD-9-CM
V10.44	Personal history of malignant neoplasm of other female genital organs	Diagnosis	ICD-9-CM
V10.45	Personal history of malignant neoplasm of unspecified male genital organ	Diagnosis	ICD-9-CM
V10.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-9-CM
V10.47	Personal history of malignant neoplasm of testis	Diagnosis	ICD-9-CM
V10.48	Personal history of malignant neoplasm of epididymis	Diagnosis	ICD-9-CM
V10.49	Personal history of malignant neoplasm of other male genital organs	Diagnosis	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
V10.5	Personal history of malignant neoplasm of urinary organs	Diagnosis	ICD-9-CM
V10.50	Personal history of malignant neoplasm of unspecified urinary organ	Diagnosis	ICD-9-CM
V10.51	Personal history of malignant neoplasm of bladder	Diagnosis	ICD-9-CM
V10.52	Personal history of malignant neoplasm of kidney	Diagnosis	ICD-9-CM
V10.53	Personal history of malignant neoplasm, renal pelvis	Diagnosis	ICD-9-CM
V10.59	Personal history of malignant neoplasm of other urinary organ	Diagnosis	ICD-9-CM
V10.6	Personal history of leukemia	Diagnosis	ICD-9-CM
V10.60	Personal history of unspecified leukemia	Diagnosis	ICD-9-CM
V10.61	Personal history of lymphoid leukemia	Diagnosis	ICD-9-CM
V10.62	Personal history of myeloid leukemia	Diagnosis	ICD-9-CM
V10.63	Personal history of monocytic leukemia	Diagnosis	ICD-9-CM
V10.69	Personal history of other leukemia	Diagnosis	ICD-9-CM
V10.7	Personal history of other lymphatic and hematopoietic neoplasms	Diagnosis	ICD-9-CM
V10.71	Personal history of lymphosarcoma and reticulosarcoma	Diagnosis	ICD-9-CM
V10.72	Personal history of Hodgkin's disease	Diagnosis	ICD-9-CM
V10.79	Personal history of other lymphatic and hematopoietic neoplasm	Diagnosis	ICD-9-CM
V10.8	Personal history of malignant neoplasm of other sites	Diagnosis	ICD-9-CM
V10.81	Personal history of malignant neoplasm of bone	Diagnosis	ICD-9-CM
V10.84	Personal history of malignant neoplasm of eye	Diagnosis	ICD-9-CM
V10.85	Personal history of malignant neoplasm of brain	Diagnosis	ICD-9-CM
V10.86	Personal history of malignant neoplasm of other parts of nervous system	Diagnosis	ICD-9-CM
V10.87	Personal history of malignant neoplasm of thyroid	Diagnosis	ICD-9-CM
V10.88	Personal history of malignant neoplasm of other endocrine glands and related structures	Diagnosis	ICD-9-CM
V10.89	Personal history of malignant neoplasm of other site	Diagnosis	ICD-9-CM
V10.9	Other and unspecified personal history of malignant neoplasm	Diagnosis	ICD-9-CM
V10.90	Personal history of unspecified malignant neoplasm	Diagnosis	ICD-9-CM
V10.91	Personal history of malignant neuroendocrine tumor	Diagnosis	ICD-9-CM
Z85	Personal history of malignant neoplasm	Diagnosis	ICD-10-CM
Z85.0	Personal history of malignant neoplasm of digestive organs	Diagnosis	ICD-10-CM
Z85.00	Personal history of malignant neoplasm of unspecified digestive organ	Diagnosis	ICD-10-CM
Z85.01	Personal history of malignant neoplasm of esophagus	Diagnosis	ICD-10-CM
Z85.02	Personal history of malignant neoplasm of stomach	Diagnosis	ICD-10-CM
Z85.020	Personal history of malignant carcinoid tumor of stomach	Diagnosis	ICD-10-CM
Z85.028	Personal history of other malignant neoplasm of stomach	Diagnosis	ICD-10-CM
Z85.03	Personal history of malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.030	Personal history of malignant carcinoid tumor of large intestine	Diagnosis	ICD-10-CM
Z85.038	Personal history of other malignant neoplasm of large intestine	Diagnosis	ICD-10-CM
Z85.04	Personal history of malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
Z85.040	Personal history of malignant carcinoid tumor of rectum	Diagnosis	ICD-10-CM
Z85.048	Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus	Diagnosis	ICD-10-CM
Z85.05	Personal history of malignant neoplasm of liver	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
Z85.06	Personal history of malignant neoplasm of small intestine	Diagnosis	ICD-10-CM
Z85.060	Personal history of malignant carcinoid tumor of small intestine	Diagnosis	ICD-10-CM
Z85.068	Personal history of other malignant neoplasm of small intestine	Diagnosis	ICD-10-CM
Z85.07	Personal history of malignant neoplasm of pancreas	Diagnosis	ICD-10-CM
Z85.09	Personal history of malignant neoplasm of other digestive organs	Diagnosis	ICD-10-CM
Z85.1	Personal history of malignant neoplasm of trachea, bronchus and lung	Diagnosis	ICD-10-CM
Z85.11	Personal history of malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM
Z85.110	Personal history of malignant carcinoid tumor of bronchus and lung	Diagnosis	ICD-10-CM
Z85.118	Personal history of other malignant neoplasm of bronchus and lung	Diagnosis	ICD-10-CM
Z85.12	Personal history of malignant neoplasm of trachea	Diagnosis	ICD-10-CM
Z85.2	Personal history of malignant neoplasm of other respiratory and intrathoracic organs	Diagnosis	ICD-10-CM
Z85.20	Personal history of malignant neoplasm of unspecified respiratory organ	Diagnosis	ICD-10-CM
Z85.21	Personal history of malignant neoplasm of larynx	Diagnosis	ICD-10-CM
Z85.22	Personal history of malignant neoplasm of nasal cavities, middle ear, and accessory sinuses	Diagnosis	ICD-10-CM
Z85.23	Personal history of malignant neoplasm of thymus	Diagnosis	ICD-10-CM
Z85.230	Personal history of malignant carcinoid tumor of thymus	Diagnosis	ICD-10-CM
Z85.238	Personal history of other malignant neoplasm of thymus	Diagnosis	ICD-10-CM
Z85.29	Personal history of malignant neoplasm of other respiratory and intrathoracic organs	Diagnosis	ICD-10-CM
Z85.3	Personal history of malignant neoplasm of breast	Diagnosis	ICD-10-CM
Z85.4	Personal history of malignant neoplasm of genital organs	Diagnosis	ICD-10-CM
Z85.40	Personal history of malignant neoplasm of unspecified female genital organ	Diagnosis	ICD-10-CM
Z85.41	Personal history of malignant neoplasm of cervix uteri	Diagnosis	ICD-10-CM
Z85.42	Personal history of malignant neoplasm of other parts of uterus	Diagnosis	ICD-10-CM
Z85.43	Personal history of malignant neoplasm of ovary	Diagnosis	ICD-10-CM
Z85.44	Personal history of malignant neoplasm of other female genital organs	Diagnosis	ICD-10-CM
Z85.45	Personal history of malignant neoplasm of unspecified male genital organ	Diagnosis	ICD-10-CM
Z85.46	Personal history of malignant neoplasm of prostate	Diagnosis	ICD-10-CM
Z85.47	Personal history of malignant neoplasm of testis	Diagnosis	ICD-10-CM
Z85.48	Personal history of malignant neoplasm of epididymis	Diagnosis	ICD-10-CM
Z85.49	Personal history of malignant neoplasm of other male genital organs	Diagnosis	ICD-10-CM
Z85.5	Personal history of malignant neoplasm of urinary tract	Diagnosis	ICD-10-CM
Z85.50	Personal history of malignant neoplasm of unspecified urinary tract organ	Diagnosis	ICD-10-CM
Z85.51	Personal history of malignant neoplasm of bladder	Diagnosis	ICD-10-CM
Z85.52	Personal history of malignant neoplasm of kidney	Diagnosis	ICD-10-CM
Z85.520	Personal history of malignant carcinoid tumor of kidney	Diagnosis	ICD-10-CM
Z85.528	Personal history of other malignant neoplasm of kidney	Diagnosis	ICD-10-CM
Z85.53	Personal history of malignant neoplasm of renal pelvis	Diagnosis	ICD-10-CM
Z85.54	Personal history of malignant neoplasm of ureter	Diagnosis	ICD-10-CM
Z85.59	Personal history of malignant neoplasm of other urinary tract organ	Diagnosis	ICD-10-CM
Z85.6	Personal history of leukemia	Diagnosis	ICD-10-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
Z85.7	Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues	Diagnosis	ICD-10-CM
Z85.71	Personal history of Hodgkin lymphoma	Diagnosis	ICD-10-CM
Z85.72	Personal history of non-Hodgkin lymphomas	Diagnosis	ICD-10-CM
Z85.79	Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues	Diagnosis	ICD-10-CM
Z85.8	Personal history of malignant neoplasms of other organs and systems	Diagnosis	ICD-10-CM
Z85.81	Personal history of malignant neoplasm of lip, oral cavity, and pharynx	Diagnosis	ICD-10-CM
Z85.810	Personal history of malignant neoplasm of tongue	Diagnosis	ICD-10-CM
Z85.818	Personal history of malignant neoplasm of other sites of lip, oral cavity, and pharynx	Diagnosis	ICD-10-CM
Z85.819	Personal history of malignant neoplasm of unspecified site of lip, oral cavity, and pharynx	Diagnosis	ICD-10-CM
Z85.821	Personal history of Merkel cell carcinoma	Diagnosis	ICD-10-CM
Z85.83	Personal history of malignant neoplasm of bone and soft tissue	Diagnosis	ICD-10-CM
Z85.830	Personal history of malignant neoplasm of bone	Diagnosis	ICD-10-CM
Z85.831	Personal history of malignant neoplasm of soft tissue	Diagnosis	ICD-10-CM
Z85.84	Personal history of malignant neoplasm of eye and nervous tissue	Diagnosis	ICD-10-CM
Z85.840	Personal history of malignant neoplasm of eye	Diagnosis	ICD-10-CM
Z85.841	Personal history of malignant neoplasm of brain	Diagnosis	ICD-10-CM
Z85.848	Personal history of malignant neoplasm of other parts of nervous tissue	Diagnosis	ICD-10-CM
Z85.85	Personal history of malignant neoplasm of endocrine glands	Diagnosis	ICD-10-CM
Z85.850	Personal history of malignant neoplasm of thyroid	Diagnosis	ICD-10-CM
Z85.858	Personal history of malignant neoplasm of other endocrine glands	Diagnosis	ICD-10-CM
Z85.89	Personal history of malignant neoplasm of other organs and systems	Diagnosis	ICD-10-CM
Z85.9	Personal history of malignant neoplasm, unspecified	Diagnosis	ICD-10-CM
	Radiation		
0082T	Stereotactic body radiation therapy, treatment delivery, one or more treatment areas, per day	Procedure	CPT-3
0083T	Stereotactic body radiation therapy, treatment management, per day	Procedure	CPT-3
0182T	High dose rate electronic brachytherapy, per fraction	Procedure	CPT-3
0190T	Placement of intraocular radiation source applicator (List separately in addition to primary procedure)	Procedure	CPT-3
0285U	Oncology, response to radiation, cell-free DNA, quantitative branched chain DNA amplification, plasma, reported as a radiation toxicity score	Procedure	CPT-4
0394T	High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed	Procedure	CPT-3
0520F	Radiation dose limits to normal tissues established prior to the initiation of a course of 3D conformal radiation for a minimum of 2 tissue/organ (ONC)	Procedure	CPT-2
19294	Preparation of tumor cavity, with placement of a radiation therapy applicator for intraoperative radiation therapy (IORT) concurrent with partial mastectomy (List separately in addition to code for primary procedure)	Procedure	CPT-4

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
32553	Placement of interstitial device(s) for radiation therapy guidance (eg, fiducial markers, dosimeter), percutaneous, intra-thoracic, single or multiple	Procedure	CPT-4
32701	Thoracic target(s) delineation for stereotactic body radiation therapy (SRS/SBRT), (photon or particle beam), entire course of treatment	Procedure	CPT-4
3318F	Pathology report confirming malignancy documented in the medical record and reviewed prior to the initiation of radiation therapy (ONC)	Procedure	CPT-2
4165F	3-dimensional conformal radiotherapy (3D-CRT) or intensity modulated radiation therapy (IMRT) received (PRCA)	Procedure	CPT-2
4181F	Conformal radiation therapy received (NMA-No Measure Associated)	Procedure	CPT-2
4200F	External beam radiotherapy as primary therapy to prostate with or without nodal irradiation (PRCA)	Procedure	CPT-2
4201F	External beam radiotherapy with or without nodal irradiation as adjuvant or salvage therapy for prostate cancer patient (PRCA)	Procedure	CPT-2
49327	Laparoscopy, surgical; with placement of interstitial device(s) for radiation therapy guidance (eg, fiducial markers, dosimeter), intra-abdominal, intrapelvic, and/or retroperitoneum, including imaging guidance, if performed, single or multiple (List separately in addition to code for primary procedure)	Procedure	CPT-4
49411	Placement of interstitial device(s) for radiation therapy guidance (eg, fiducial markers, dosimeter), percutaneous, intra-abdominal, intra-pelvic (except prostate), and/or retroperitoneum, single or multiple	Procedure	CPT-4
49412	Placement of interstitial device(s) for radiation therapy guidance (eg, fiducial markers, dosimeter), open, intra-abdominal, intrapelvic, and/or retroperitoneum, including image guidance, if performed, single or multiple (List separately in addition to code for primary procedure)	Procedure	CPT-4
55859	Transperineal placement of needles or catheters into prostate for interstitial radioelement application, with or without cystoscopy	Procedure	CPT-4
55860	Exposure of prostate, any approach, for insertion of radioactive substance;	Procedure	CPT-4
55862	Exposure of prostate, any approach, for insertion of radioactive substance; with lymph node biopsy(s) (limited pelvic lymphadenectomy)	Procedure	CPT-4
55865	Exposure of prostate, any approach, for insertion of radioactive substance; with bilateral pelvic lymphadenectomy, including external iliac, hypogastric and obturator nodes	Procedure	CPT-4
55875	Transperineal placement of needles or catheters into prostate for interstitial radioelement application, with or without cystoscopy	Procedure	CPT-4
55876	Placement of interstitial device(s) for radiation therapy guidance (eg, fiducial markers, dosimeter), prostate (via needle, any approach), single or multiple	Procedure	CPT-4
61770	Stereotactic localization, including burr hole(s), with insertion of catheter(s) or probe(s) for placement of radiation source	Procedure	CPT-4
61793	Stereotactic radiosurgery (particle beam, gamma ray or linear accelerator), one or more sessions	Procedure	CPT-4
67218	Destruction of localized lesion of retina (eg, macular edema, tumors), 1 or more sessions; radiation by implantation of source (includes removal of source)	Procedure	CPT-4

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
77371	Radiation treatment delivery, stereotactic radiosurgery (SRS), complete course of treatment of cranial lesion(s) consisting of 1 session; multi-source Cobalt 60 based	Procedure	CPT-4
77372	Radiation treatment delivery, stereotactic radiosurgery (SRS), complete course of treatment of cranial lesion(s) consisting of 1 session; linear accelerator based	Procedure	CPT-4
77373	Stereotactic body radiation therapy, treatment delivery, per fraction to 1 or more lesions, including image guidance, entire course not to exceed 5 fractions	Procedure	CPT-4
77385	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple	Procedure	CPT-4
77386	Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex	Procedure	CPT-4
77401	Radiation treatment delivery, superficial and/or ortho voltage, per day	Procedure	CPT-4
77402	Radiation treatment delivery,=>1 MeV; simple	Procedure	CPT-4
77403	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks; 6-10 MeV	Procedure	CPT-4
77404	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks; 11-19 MeV	Procedure	CPT-4
77406	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks; 20 MeV or greater	Procedure	CPT-4
77407	Radiation treatment delivery, =>1 MeV; intermediate	Procedure	CPT-4
77408	Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks; 6-10 MeV	Procedure	CPT-4
77409	Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks; 11-19 MeV	Procedure	CPT-4
77411	Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks; 20 MeV or greater	Procedure	CPT-4
77412	Radiation treatment delivery, =>1 MeV; complex	Procedure	CPT-4
77413	Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 MeV	Procedure	CPT-4
77414	Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 MeV	Procedure	CPT-4
77416	Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 20 MeV or greater	Procedure	CPT-4
77418	Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session	Procedure	CPT-4
77421	Stereoscopic X-ray guidance for localization of target volume for the delivery of radiation therapy	Procedure	CPT-4
77422	High energy neutron radiation treatment delivery; single treatment area using a single port or parallel-opposed ports with no blocks or simple blocking	Procedure	CPT-4
77423	High energy neutron radiation treatment delivery, 1 or more isocenter(s) with coplanar or non-coplanar geometry with blocking and/or wedge, and/or compensator(s)	Procedure	CPT-4

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
77424	Intraoperative radiation treatment delivery, x-ray, single treatment session	Procedure	CPT-4
77425	Intraoperative radiation treatment delivery, electrons, single treatment session	Procedure	CPT-4
77427	Radiation treatment management, 5 treatments	Procedure	CPT-4
77432	Stereotactic radiation treatment management of cranial lesion(s) (complete course of treatment consisting of 1 session)	Procedure	CPT-4
77435	Stereotactic body radiation therapy, treatment management, per treatment course, to 1 or more lesions, including image guidance, entire course not to exceed 5	Procedure	CPT-4
77469	Intraoperative radiation treatment management	Procedure	CPT-4
77470	Special treatment procedure (eg, total body irradiation, hemibody radiation, per oral or endocavitary irradiation)	Procedure	CPT-4
77499	Unlisted procedure, therapeutic radiology treatment management	Procedure	CPT-4
77520	Proton treatment delivery; simple, without compensation	Procedure	CPT-4
77522	Proton treatment delivery; simple, with compensation	Procedure	CPT-4
77523	Proton treatment delivery; intermediate	Procedure	CPT-4
77525	Proton treatment delivery; complex	Procedure	CPT-4
77750	Infusion or instillation of radioelement solution (includes 3-month follow-up care)	Procedure	CPT-4
77761	Intracavitary radiation source application; simple	Procedure	CPT-4
77762	Intracavitary radiation source application; intermediate	Procedure	CPT-4
77763	Intracavitary radiation source application; complex	Procedure	CPT-4
77776	Interstitial radiation source application; simple	Procedure	CPT-4
77777	Interstitial radiation source application; intermediate	Procedure	CPT-4
77778	Interstitial radiation source application; complex	Procedure	CPT-4
77781	Remote afterloading high intensity brachytherapy; 1-4 source positions or catheters	Procedure	CPT-4
77782	Remote afterloading high intensity brachytherapy; 5-8 source positions or catheters	Procedure	CPT-4
77783	Remote afterloading high intensity brachytherapy; 9-12 source positions or catheters	Procedure	CPT-4
77784	Remote afterloading high intensity brachytherapy; over 12 source positions or catheters	Procedure	CPT-4
77785	Remote afterloading high dose rate radionuclide brachytherapy; 1 channel	Procedure	CPT-4
77786	Remote afterloading high dose rate radionuclide brachytherapy; 2-12 channels	Procedure	CPT-4
77787	Remote afterloading high dose rate radionuclide brachytherapy; over 12 channels	Procedure	CPT-4
77789	Surface application of low dose rate radionuclide source	Procedure	CPT-4
77799	Unlisted procedure, clinical brachytherapy	Procedure	CPT-4
79005	Radiopharmaceutical therapy, by oral administration	Procedure	CPT-4
79101	Radiopharmaceutical therapy, by intravenous administration	Procedure	CPT-4
79200	Radiopharmaceutical therapy, by intracavitary administration	Procedure	CPT-4
79300	Radiopharmaceutical therapy, by interstitial radioactive colloid administration	Procedure	CPT-4
79400	Radiopharmaceutical therapy, nonthyroid, nonhematologic by intervenous injection	Procedure	CPT-4
79403	Radiopharmaceutical therapy, radiolabeled monoclonal antibody by intravenous infusion	Procedure	CPT-4
79420	Intravascular radiopharmaceutical therapy, particulate	Procedure	CPT-4
79440	Radiopharmaceutical therapy, by intra-articular administration	Procedure	CPT-4
79900	Provision of therapeutic radiopharmaceutical(s)	Procedure	CPT-4
79999	Radiopharmaceutical therapy, unlisted procedure	Procedure	CPT-4

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
92.21	Superficial radiation	Procedure	ICD-9-CM
92.22	Orthovoltage radiation	Procedure	ICD-9-CM
92.24	Teleradiotherapy using photons	Procedure	ICD-9-CM
92.25	Teleradiotherapy using electrons	Procedure	ICD-9-CM
92.26	Teleradiotherapy of other particulate radiation	Procedure	ICD-9-CM
92.29	Other radiotherapeutic procedure	Procedure	ICD-9-CM
92.41	Intra-operative electron radiation therapy	Procedure	ICD-9-CM
92974	Transcatheter placement of radiation delivery device for subsequent coronary intravascular brachytherapy (List separately in addition to code for primary procedure)	Procedure	CPT-4
A4650	Implantable radiation dosimeter, each	Procedure	HCPCS
C9714	Placement of balloon catheter into the breast for interstitial radiation therapy following a partial mastectomy; concurrent/immediate (add-on)	Procedure	HCPCS
C9715	Placement of balloon catheter into the breast for interstitial radiation therapy following a partial mastectomy; delayed	Procedure	HCPCS
C9726	Placement and removal (if performed) of applicator into breast for intraoperative radiation therapy, add-on to primary breast procedure	Procedure	HCPCS
C9728	Placement of interstitial device(s) for radiation therapy/surgery guidance (e.g., fiducial markers, dosimeter), for other than the following sites (any approach): abdomen, pelvis, prostate, retroperitoneum, thorax, single or multiple	Procedure	HCPCS
D00	Radiation Therapy, Central and Peripheral Nervous System, Beam Radiation	Procedure	ICD-10-PCS
D000	Beam Radiation / Brain	Procedure	ICD-10-PCS
D0000ZZ	Beam Radiation of Brain using Photons <1 MeV	Procedure	ICD-10-PCS
D0001ZZ	Beam Radiation of Brain using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
D0002ZZ	Beam Radiation of Brain using Photons >10 MeV	Procedure	ICD-10-PCS
D0003Z0	Beam Radiation of Brain using Electrons, Intraoperative	Procedure	ICD-10-PCS
D0003ZZ	Beam Radiation of Brain using Electrons	Procedure	ICD-10-PCS
D0004ZZ	Beam Radiation of Brain using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
D0005ZZ	Beam Radiation of Brain using Neutrons	Procedure	ICD-10-PCS
D0006ZZ	Beam Radiation of Brain using Neutron Capture	Procedure	ICD-10-PCS
D001	Beam Radiation / Brain Stem	Procedure	ICD-10-PCS
D0010ZZ	Beam Radiation of Brain Stem using Photons <1 MeV	Procedure	ICD-10-PCS
D0011ZZ	Beam Radiation of Brain Stem using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
D0012ZZ	Beam Radiation of Brain Stem using Photons >10 MeV	Procedure	ICD-10-PCS
D0013Z0	Beam Radiation of Brain Stem using Electrons, Intraoperative	Procedure	ICD-10-PCS
D0013ZZ	Beam Radiation of Brain Stem using Electrons	Procedure	ICD-10-PCS
D0014ZZ	Beam Radiation of Brain Stem using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
D0015ZZ	Beam Radiation of Brain Stem using Neutrons	Procedure	ICD-10-PCS
D0016ZZ	Beam Radiation of Brain Stem using Neutron Capture	Procedure	ICD-10-PCS
D006	Beam Radiation / Spinal Cord	Procedure	ICD-10-PCS
D0060ZZ	Beam Radiation of Spinal Cord using Photons <1 MeV	Procedure	ICD-10-PCS
D0061ZZ	Beam Radiation of Spinal Cord using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
D0062ZZ	Beam Radiation of Spinal Cord using Photons >10 MeV	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
D0063Z0	Beam Radiation of Spinal Cord using Electrons, Intraoperative	Procedure	ICD-10-PCS
D0063ZZ	Beam Radiation of Spinal Cord using Electrons	Procedure	ICD-10-PCS
D0064ZZ	Beam Radiation of Spinal Cord using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
D0065ZZ	Beam Radiation of Spinal Cord using Neutrons	Procedure	ICD-10-PCS
D0066ZZ	Beam Radiation of Spinal Cord using Neutron Capture	Procedure	ICD-10-PCS
D007	Beam Radiation / Peripheral Nerve	Procedure	ICD-10-PCS
D0070ZZ	Beam Radiation of Peripheral Nerve using Photons <1 MeV	Procedure	ICD-10-PCS
D0071ZZ	Beam Radiation of Peripheral Nerve using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
D0072ZZ	Beam Radiation of Peripheral Nerve using Photons >10 MeV	Procedure	ICD-10-PCS
D0073Z0	Beam Radiation of Peripheral Nerve using Electrons, Intraoperative	Procedure	ICD-10-PCS
D0073ZZ	Beam Radiation of Peripheral Nerve using Electrons	Procedure	ICD-10-PCS
D0074ZZ	Beam Radiation of Peripheral Nerve using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
D0075ZZ	Beam Radiation of Peripheral Nerve using Neutrons	Procedure	ICD-10-PCS
D0076ZZ	Beam Radiation of Peripheral Nerve using Neutron Capture	Procedure	ICD-10-PCS
D01	Radiation Therapy, Central and Peripheral Nervous System, Brachytherapy	Procedure	ICD-10-PCS
D02	Radiation Therapy, Central and Peripheral Nervous System, Stereotactic Radiosurgery	Procedure	ICD-10-PCS
D0Y	Radiation Therapy, Central and Peripheral Nervous System, Other Radiation	Procedure	ICD-10-PCS
D0Y0	Other Radiation / Brain	Procedure	ICD-10-PCS
D0Y07ZZ	Contact Radiation of Brain	Procedure	ICD-10-PCS
D0Y0CZZ	Intraoperative Radiation Therapy (IORT) of Brain	Procedure	ICD-10-PCS
D0Y0FZZ	Plaque Radiation of Brain	Procedure	ICD-10-PCS
D0Y1	Other Radiation / Brain Stem	Procedure	ICD-10-PCS
D0Y17ZZ	Contact Radiation of Brain Stem	Procedure	ICD-10-PCS
D0Y1CZZ	Intraoperative Radiation Therapy (IORT) of Brain Stem	Procedure	ICD-10-PCS
D0Y1FZZ	Plaque Radiation of Brain Stem	Procedure	ICD-10-PCS
D0Y6	Other Radiation / Spinal Cord	Procedure	ICD-10-PCS
D0Y67ZZ	Contact Radiation of Spinal Cord	Procedure	ICD-10-PCS
D0Y6CZZ	Intraoperative Radiation Therapy (IORT) of Spinal Cord	Procedure	ICD-10-PCS
D0Y6FZZ	Plaque Radiation of Spinal Cord	Procedure	ICD-10-PCS
D0Y7	Other Radiation / Peripheral Nerve	Procedure	ICD-10-PCS
D0Y77ZZ	Contact Radiation of Peripheral Nerve	Procedure	ICD-10-PCS
D0Y7CZZ	Intraoperative Radiation Therapy (IORT) of Peripheral Nerve	Procedure	ICD-10-PCS
D0Y7FZZ	Plaque Radiation of Peripheral Nerve	Procedure	ICD-10-PCS
D70	Radiation Therapy, Lymphatic and Hematologic System, Beam Radiation	Procedure	ICD-10-PCS
D700	Beam Radiation / Bone Marrow	Procedure	ICD-10-PCS
D7000ZZ	Beam Radiation of Bone Marrow using Photons <1 MeV	Procedure	ICD-10-PCS
D7001ZZ	Beam Radiation of Bone Marrow using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
D7002ZZ	Beam Radiation of Bone Marrow using Photons >10 MeV	Procedure	ICD-10-PCS
D7003Z0	Beam Radiation of Bone Marrow using Electrons, Intraoperative	Procedure	ICD-10-PCS
D7003ZZ	Beam Radiation of Bone Marrow using Electrons	Procedure	ICD-10-PCS
D7004ZZ	Beam Radiation of Bone Marrow using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
D7005ZZ	Beam Radiation of Bone Marrow using Neutrons	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
D7006ZZ	Beam Radiation of Bone Marrow using Neutron Capture	Procedure	ICD-10-PCS
D701	Beam Radiation / Thymus	Procedure	ICD-10-PCS
D7010ZZ	Beam Radiation of Thymus using Photons <1 MeV	Procedure	ICD-10-PCS
D7011ZZ	Beam Radiation of Thymus using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
D7012ZZ	Beam Radiation of Thymus using Photons >10 MeV	Procedure	ICD-10-PCS
D7013Z0	Beam Radiation of Thymus using Electrons, Intraoperative	Procedure	ICD-10-PCS
D7013ZZ	Beam Radiation of Thymus using Electrons	Procedure	ICD-10-PCS
D7014ZZ	Beam Radiation of Thymus using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
D7015ZZ	Beam Radiation of Thymus using Neutrons	Procedure	ICD-10-PCS
D7016ZZ	Beam Radiation of Thymus using Neutron Capture	Procedure	ICD-10-PCS
D702	Beam Radiation / Spleen	Procedure	ICD-10-PCS
D7020ZZ	Beam Radiation of Spleen using Photons <1 MeV	Procedure	ICD-10-PCS
D7021ZZ	Beam Radiation of Spleen using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
D7022ZZ	Beam Radiation of Spleen using Photons >10 MeV	Procedure	ICD-10-PCS
D7023Z0	Beam Radiation of Spleen using Electrons, Intraoperative	Procedure	ICD-10-PCS
D7023ZZ	Beam Radiation of Spleen using Electrons	Procedure	ICD-10-PCS
D7024ZZ	Beam Radiation of Spleen using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
D7025ZZ	Beam Radiation of Spleen using Neutrons	Procedure	ICD-10-PCS
D7026ZZ	Beam Radiation of Spleen using Neutron Capture	Procedure	ICD-10-PCS
D703	Beam Radiation / Lymphatics, Neck	Procedure	ICD-10-PCS
D7030ZZ	Beam Radiation of Neck Lymphatics using Photons <1 MeV	Procedure	ICD-10-PCS
D7031ZZ	Beam Radiation of Neck Lymphatics using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
D7032ZZ	Beam Radiation of Neck Lymphatics using Photons >10 MeV	Procedure	ICD-10-PCS
D7033Z0	Beam Radiation of Neck Lymphatics using Electrons, Intraoperative	Procedure	ICD-10-PCS
D7033ZZ	Beam Radiation of Neck Lymphatics using Electrons	Procedure	ICD-10-PCS
D7034ZZ	Beam Radiation of Neck Lymphatics using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
D7035ZZ	Beam Radiation of Neck Lymphatics using Neutrons	Procedure	ICD-10-PCS
D7036ZZ	Beam Radiation of Neck Lymphatics using Neutron Capture	Procedure	ICD-10-PCS
D704	Beam Radiation / Lymphatics, Axillary	Procedure	ICD-10-PCS
D7040ZZ	Beam Radiation of Axillary Lymphatics using Photons <1 MeV	Procedure	ICD-10-PCS
D7041ZZ	Beam Radiation of Axillary Lymphatics using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
D7042ZZ	Beam Radiation of Axillary Lymphatics using Photons >10 MeV	Procedure	ICD-10-PCS
D7043Z0	Beam Radiation of Axillary Lymphatics using Electrons, Intraoperative	Procedure	ICD-10-PCS
D7043ZZ	Beam Radiation of Axillary Lymphatics using Electrons	Procedure	ICD-10-PCS
D7044ZZ	Beam Radiation of Axillary Lymphatics using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
D7045ZZ	Beam Radiation of Axillary Lymphatics using Neutrons	Procedure	ICD-10-PCS
D7046ZZ	Beam Radiation of Axillary Lymphatics using Neutron Capture	Procedure	ICD-10-PCS
D705	Beam Radiation / Lymphatics, Thorax	Procedure	ICD-10-PCS
D7050ZZ	Beam Radiation of Thorax Lymphatics using Photons <1 MeV	Procedure	ICD-10-PCS
D7051ZZ	Beam Radiation of Thorax Lymphatics using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
D7052ZZ	Beam Radiation of Thorax Lymphatics using Photons >10 MeV	Procedure	ICD-10-PCS
D7053Z0	Beam Radiation of Thorax Lymphatics using Electrons, Intraoperative	Procedure	ICD-10-PCS
D7053ZZ	Beam Radiation of Thorax Lymphatics using Electrons	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
D7054ZZ	Beam Radiation of Thorax Lymphatics using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
D7055ZZ	Beam Radiation of Thorax Lymphatics using Neutrons	Procedure	ICD-10-PCS
D7056ZZ	Beam Radiation of Thorax Lymphatics using Neutron Capture	Procedure	ICD-10-PCS
D706	Beam Radiation / Lymphatics, Abdomen	Procedure	ICD-10-PCS
D7060ZZ	Beam Radiation of Abdomen Lymphatics using Photons <1 MeV	Procedure	ICD-10-PCS
D7061ZZ	Beam Radiation of Abdomen Lymphatics using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
D7062ZZ	Beam Radiation of Abdomen Lymphatics using Photons >10 MeV	Procedure	ICD-10-PCS
D7063Z0	Beam Radiation of Abdomen Lymphatics using Electrons, Intraoperative	Procedure	ICD-10-PCS
D7063ZZ	Beam Radiation of Abdomen Lymphatics using Electrons	Procedure	ICD-10-PCS
D7064ZZ	Beam Radiation of Abdomen Lymphatics using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
D7065ZZ	Beam Radiation of Abdomen Lymphatics using Neutrons	Procedure	ICD-10-PCS
D7066ZZ	Beam Radiation of Abdomen Lymphatics using Neutron Capture	Procedure	ICD-10-PCS
D707	Beam Radiation / Lymphatics, Pelvis	Procedure	ICD-10-PCS
D7070ZZ	Beam Radiation of Pelvis Lymphatics using Photons <1 MeV	Procedure	ICD-10-PCS
D7071ZZ	Beam Radiation of Pelvis Lymphatics using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
D7072ZZ	Beam Radiation of Pelvis Lymphatics using Photons >10 MeV	Procedure	ICD-10-PCS
D7073Z0	Beam Radiation of Pelvis Lymphatics using Electrons, Intraoperative	Procedure	ICD-10-PCS
D7073ZZ	Beam Radiation of Pelvis Lymphatics using Electrons	Procedure	ICD-10-PCS
D7074ZZ	Beam Radiation of Pelvis Lymphatics using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
D7075ZZ	Beam Radiation of Pelvis Lymphatics using Neutrons	Procedure	ICD-10-PCS
D7076ZZ	Beam Radiation of Pelvis Lymphatics using Neutron Capture	Procedure	ICD-10-PCS
D708	Beam Radiation / Lymphatics, Inguinal	Procedure	ICD-10-PCS
D7080ZZ	Beam Radiation of Inguinal Lymphatics using Photons <1 MeV	Procedure	ICD-10-PCS
D7081ZZ	Beam Radiation of Inguinal Lymphatics using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
D7082ZZ	Beam Radiation of Inguinal Lymphatics using Photons >10 MeV	Procedure	ICD-10-PCS
D7083Z0	Beam Radiation of Inguinal Lymphatics using Electrons, Intraoperative	Procedure	ICD-10-PCS
D7083ZZ	Beam Radiation of Inguinal Lymphatics using Electrons	Procedure	ICD-10-PCS
D7084ZZ	Beam Radiation of Inguinal Lymphatics using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
D7085ZZ	Beam Radiation of Inguinal Lymphatics using Neutrons	Procedure	ICD-10-PCS
D7086ZZ	Beam Radiation of Inguinal Lymphatics using Neutron Capture	Procedure	ICD-10-PCS
D71	Radiation Therapy, Lymphatic and Hematologic System, Brachytherapy	Procedure	ICD-10-PCS
D72	Radiation Therapy, Lymphatic and Hematologic System, Stereotactic Radiosurgery	Procedure	ICD-10-PCS
D7Y	Radiation Therapy, Lymphatic and Hematologic System, Other Radiation	Procedure	ICD-10-PCS
D7Y0	Other Radiation / Bone Marrow	Procedure	ICD-10-PCS
D7Y0FZZ	Plaque Radiation of Bone Marrow	Procedure	ICD-10-PCS
D7Y1	Other Radiation / Thymus	Procedure	ICD-10-PCS
D7Y1FZZ	Plaque Radiation of Thymus	Procedure	ICD-10-PCS
D7Y2	Other Radiation / Spleen	Procedure	ICD-10-PCS
D7Y2FZZ	Plaque Radiation of Spleen	Procedure	ICD-10-PCS
D7Y3	Other Radiation / Lymphatics, Neck	Procedure	ICD-10-PCS
D7Y3FZZ	Plaque Radiation of Neck Lymphatics	Procedure	ICD-10-PCS
D7Y4	Other Radiation / Lymphatics, Axillary	Procedure	ICD-10-PCS
D7Y4FZZ	Plaque Radiation of Axillary Lymphatics	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
D7Y5	Other Radiation / Lymphatics, Thorax	Procedure	ICD-10-PCS
D7Y5FZZ	Plaque Radiation of Thorax Lymphatics	Procedure	ICD-10-PCS
D7Y6	Other Radiation / Lymphatics, Abdomen	Procedure	ICD-10-PCS
D7Y6FZZ	Plaque Radiation of Abdomen Lymphatics	Procedure	ICD-10-PCS
D7Y7	Other Radiation / Lymphatics, Pelvis	Procedure	ICD-10-PCS
D7Y7FZZ	Plaque Radiation of Pelvis Lymphatics	Procedure	ICD-10-PCS
D7Y8	Other Radiation / Lymphatics, Inguinal	Procedure	ICD-10-PCS
D7Y8FZZ	Plaque Radiation of Inguinal Lymphatics	Procedure	ICD-10-PCS
D80	Radiation Therapy, Eye, Beam Radiation	Procedure	ICD-10-PCS
D800	Beam Radiation / Eye	Procedure	ICD-10-PCS
D8000ZZ	Beam Radiation of Eye using Photons <1 MeV	Procedure	ICD-10-PCS
D8001ZZ	Beam Radiation of Eye using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
D8002ZZ	Beam Radiation of Eye using Photons >10 MeV	Procedure	ICD-10-PCS
D8003Z0	Beam Radiation of Eye using Electrons, Intraoperative	Procedure	ICD-10-PCS
D8003ZZ	Beam Radiation of Eye using Electrons	Procedure	ICD-10-PCS
D8004ZZ	Beam Radiation of Eye using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
D8005ZZ	Beam Radiation of Eye using Neutrons	Procedure	ICD-10-PCS
D8006ZZ	Beam Radiation of Eye using Neutron Capture	Procedure	ICD-10-PCS
D81	Radiation Therapy, Eye, Brachytherapy	Procedure	ICD-10-PCS
D82	Radiation Therapy, Eye, Stereotactic Radiosurgery	Procedure	ICD-10-PCS
D8Y	Radiation Therapy, Eye, Other Radiation	Procedure	ICD-10-PCS
D8Y0	Other Radiation / Eye	Procedure	ICD-10-PCS
D8Y07ZZ	Contact Radiation of Eye	Procedure	ICD-10-PCS
D8Y0FZZ	Plaque Radiation of Eye	Procedure	ICD-10-PCS
D90	Radiation Therapy, Ear, Nose, Mouth and Throat, Beam Radiation	Procedure	ICD-10-PCS
D900	Beam Radiation / Ear	Procedure	ICD-10-PCS
D9000ZZ	Beam Radiation of Ear using Photons <1 MeV	Procedure	ICD-10-PCS
D9001ZZ	Beam Radiation of Ear using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
D9002ZZ	Beam Radiation of Ear using Photons >10 MeV	Procedure	ICD-10-PCS
D9003Z0	Beam Radiation of Ear using Electrons, Intraoperative	Procedure	ICD-10-PCS
D9003ZZ	Beam Radiation of Ear using Electrons	Procedure	ICD-10-PCS
D9004ZZ	Beam Radiation of Ear using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
D9005ZZ	Beam Radiation of Ear using Neutrons	Procedure	ICD-10-PCS
D9006ZZ	Beam Radiation of Ear using Neutron Capture	Procedure	ICD-10-PCS
D901	Beam Radiation / Nose	Procedure	ICD-10-PCS
D9010ZZ	Beam Radiation of Nose using Photons <1 MeV	Procedure	ICD-10-PCS
D9011ZZ	Beam Radiation of Nose using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
D9012ZZ	Beam Radiation of Nose using Photons >10 MeV	Procedure	ICD-10-PCS
D9013Z0	Beam Radiation of Nose using Electrons, Intraoperative	Procedure	ICD-10-PCS
D9013ZZ	Beam Radiation of Nose using Electrons	Procedure	ICD-10-PCS
D9014ZZ	Beam Radiation of Nose using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
D9015ZZ	Beam Radiation of Nose using Neutrons	Procedure	ICD-10-PCS
D9016ZZ	Beam Radiation of Nose using Neutron Capture	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
D903	Beam Radiation / Hypopharynx	Procedure	ICD-10-PCS
D9030ZZ	Beam Radiation of Hypopharynx using Photons <1 MeV	Procedure	ICD-10-PCS
D9031ZZ	Beam Radiation of Hypopharynx using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
D9032ZZ	Beam Radiation of Hypopharynx using Photons >10 MeV	Procedure	ICD-10-PCS
D9033Z0	Beam Radiation of Hypopharynx using Electrons, Intraoperative	Procedure	ICD-10-PCS
D9033ZZ	Beam Radiation of Hypopharynx using Electrons	Procedure	ICD-10-PCS
D9034ZZ	Beam Radiation of Hypopharynx using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
D9035ZZ	Beam Radiation of Hypopharynx using Neutrons	Procedure	ICD-10-PCS
D9036ZZ	Beam Radiation of Hypopharynx using Neutron Capture	Procedure	ICD-10-PCS
D904	Beam Radiation / Mouth	Procedure	ICD-10-PCS
D9040ZZ	Beam Radiation of Mouth using Photons <1 MeV	Procedure	ICD-10-PCS
D9041ZZ	Beam Radiation of Mouth using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
D9042ZZ	Beam Radiation of Mouth using Photons >10 MeV	Procedure	ICD-10-PCS
D9043Z0	Beam Radiation of Mouth using Electrons, Intraoperative	Procedure	ICD-10-PCS
D9043ZZ	Beam Radiation of Mouth using Electrons	Procedure	ICD-10-PCS
D9044ZZ	Beam Radiation of Mouth using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
D9045ZZ	Beam Radiation of Mouth using Neutrons	Procedure	ICD-10-PCS
D9046ZZ	Beam Radiation of Mouth using Neutron Capture	Procedure	ICD-10-PCS
D905	Beam Radiation / Tongue	Procedure	ICD-10-PCS
D9050ZZ	Beam Radiation of Tongue using Photons <1 MeV	Procedure	ICD-10-PCS
D9051ZZ	Beam Radiation of Tongue using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
D9052ZZ	Beam Radiation of Tongue using Photons >10 MeV	Procedure	ICD-10-PCS
D9053Z0	Beam Radiation of Tongue using Electrons, Intraoperative	Procedure	ICD-10-PCS
D9053ZZ	Beam Radiation of Tongue using Electrons	Procedure	ICD-10-PCS
D9054ZZ	Beam Radiation of Tongue using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
D9055ZZ	Beam Radiation of Tongue using Neutrons	Procedure	ICD-10-PCS
D9056ZZ	Beam Radiation of Tongue using Neutron Capture	Procedure	ICD-10-PCS
D906	Beam Radiation / Salivary Glands	Procedure	ICD-10-PCS
D9060ZZ	Beam Radiation of Salivary Glands using Photons <1 MeV	Procedure	ICD-10-PCS
D9061ZZ	Beam Radiation of Salivary Glands using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
D9062ZZ	Beam Radiation of Salivary Glands using Photons >10 MeV	Procedure	ICD-10-PCS
D9063Z0	Beam Radiation of Salivary Glands using Electrons, Intraoperative	Procedure	ICD-10-PCS
D9063ZZ	Beam Radiation of Salivary Glands using Electrons	Procedure	ICD-10-PCS
D9064ZZ	Beam Radiation of Salivary Glands using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
D9065ZZ	Beam Radiation of Salivary Glands using Neutrons	Procedure	ICD-10-PCS
D9066ZZ	Beam Radiation of Salivary Glands using Neutron Capture	Procedure	ICD-10-PCS
D907	Beam Radiation / Sinuses	Procedure	ICD-10-PCS
D9070ZZ	Beam Radiation of Sinuses using Photons <1 MeV	Procedure	ICD-10-PCS
D9071ZZ	Beam Radiation of Sinuses using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
D9072ZZ	Beam Radiation of Sinuses using Photons >10 MeV	Procedure	ICD-10-PCS
D9073Z0	Beam Radiation of Sinuses using Electrons, Intraoperative	Procedure	ICD-10-PCS
D9073ZZ	Beam Radiation of Sinuses using Electrons	Procedure	ICD-10-PCS
D9074ZZ	Beam Radiation of Sinuses using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
D9075ZZ	Beam Radiation of Sinuses using Neutrons	Procedure	ICD-10-PCS
D9076ZZ	Beam Radiation of Sinuses using Neutron Capture	Procedure	ICD-10-PCS
D908	Beam Radiation / Hard Palate	Procedure	ICD-10-PCS
D9080ZZ	Beam Radiation of Hard Palate using Photons <1 MeV	Procedure	ICD-10-PCS
D9081ZZ	Beam Radiation of Hard Palate using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
D9082ZZ	Beam Radiation of Hard Palate using Photons >10 MeV	Procedure	ICD-10-PCS
D9083Z0	Beam Radiation of Hard Palate using Electrons, Intraoperative	Procedure	ICD-10-PCS
D9083ZZ	Beam Radiation of Hard Palate using Electrons	Procedure	ICD-10-PCS
D9084ZZ	Beam Radiation of Hard Palate using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
D9085ZZ	Beam Radiation of Hard Palate using Neutrons	Procedure	ICD-10-PCS
D9086ZZ	Beam Radiation of Hard Palate using Neutron Capture	Procedure	ICD-10-PCS
D909	Beam Radiation / Soft Palate	Procedure	ICD-10-PCS
D9090ZZ	Beam Radiation of Soft Palate using Photons <1 MeV	Procedure	ICD-10-PCS
D9091ZZ	Beam Radiation of Soft Palate using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
D9092ZZ	Beam Radiation of Soft Palate using Photons >10 MeV	Procedure	ICD-10-PCS
D9093Z0	Beam Radiation of Soft Palate using Electrons, Intraoperative	Procedure	ICD-10-PCS
D9093ZZ	Beam Radiation of Soft Palate using Electrons	Procedure	ICD-10-PCS
D9094ZZ	Beam Radiation of Soft Palate using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
D9095ZZ	Beam Radiation of Soft Palate using Neutrons	Procedure	ICD-10-PCS
D9096ZZ	Beam Radiation of Soft Palate using Neutron Capture	Procedure	ICD-10-PCS
D90B	Beam Radiation / Larynx	Procedure	ICD-10-PCS
D90B0ZZ	Beam Radiation of Larynx using Photons <1 MeV	Procedure	ICD-10-PCS
D90B1ZZ	Beam Radiation of Larynx using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
D90B2ZZ	Beam Radiation of Larynx using Photons >10 MeV	Procedure	ICD-10-PCS
D90B3Z0	Beam Radiation of Larynx using Electrons, Intraoperative	Procedure	ICD-10-PCS
D90B3ZZ	Beam Radiation of Larynx using Electrons	Procedure	ICD-10-PCS
D90B4ZZ	Beam Radiation of Larynx using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
D90B5ZZ	Beam Radiation of Larynx using Neutrons	Procedure	ICD-10-PCS
D90B6ZZ	Beam Radiation of Larynx using Neutron Capture	Procedure	ICD-10-PCS
D90D	Beam Radiation / Nasopharynx	Procedure	ICD-10-PCS
D90D0ZZ	Beam Radiation of Nasopharynx using Photons <1 MeV	Procedure	ICD-10-PCS
D90D1ZZ	Beam Radiation of Nasopharynx using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
D90D2ZZ	Beam Radiation of Nasopharynx using Photons >10 MeV	Procedure	ICD-10-PCS
D90D3Z0	Beam Radiation of Nasopharynx using Electrons, Intraoperative	Procedure	ICD-10-PCS
D90D3ZZ	Beam Radiation of Nasopharynx using Electrons	Procedure	ICD-10-PCS
D90D4ZZ	Beam Radiation of Nasopharynx using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
D90D5ZZ	Beam Radiation of Nasopharynx using Neutrons	Procedure	ICD-10-PCS
D90D6ZZ	Beam Radiation of Nasopharynx using Neutron Capture	Procedure	ICD-10-PCS
D90F	Beam Radiation / Oropharynx	Procedure	ICD-10-PCS
D90F0ZZ	Beam Radiation of Oropharynx using Photons <1 MeV	Procedure	ICD-10-PCS
D90F1ZZ	Beam Radiation of Oropharynx using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
D90F2ZZ	Beam Radiation of Oropharynx using Photons >10 MeV	Procedure	ICD-10-PCS
D90F3Z0	Beam Radiation of Oropharynx using Electrons, Intraoperative	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
D90F3ZZ	Beam Radiation of Oropharynx using Electrons	Procedure	ICD-10-PCS
D90F4ZZ	Beam Radiation of Oropharynx using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
D90F5ZZ	Beam Radiation of Oropharynx using Neutrons	Procedure	ICD-10-PCS
D90F6ZZ	Beam Radiation of Oropharynx using Neutron Capture	Procedure	ICD-10-PCS
D91	Radiation Therapy, Ear, Nose, Mouth and Throat, Brachytherapy	Procedure	ICD-10-PCS
D92	Radiation Therapy, Ear, Nose, Mouth and Throat, Stereotactic Radiosurgery	Procedure	ICD-10-PCS
D9Y	Radiation Therapy, Ear, Nose, Mouth and Throat, Other Radiation	Procedure	ICD-10-PCS
D9Y0	Other Radiation / Ear	Procedure	ICD-10-PCS
D9Y07ZZ	Contact Radiation of Ear	Procedure	ICD-10-PCS
D9Y0FZZ	Plaque Radiation of Ear	Procedure	ICD-10-PCS
D9Y1	Other Radiation / Nose	Procedure	ICD-10-PCS
D9Y17ZZ	Contact Radiation of Nose	Procedure	ICD-10-PCS
D9Y1FZZ	Plaque Radiation of Nose	Procedure	ICD-10-PCS
D9Y3	Other Radiation / Hypopharynx	Procedure	ICD-10-PCS
D9Y37ZZ	Contact Radiation of Hypopharynx	Procedure	ICD-10-PCS
D9Y4	Other Radiation / Mouth	Procedure	ICD-10-PCS
D9Y47ZZ	Contact Radiation of Mouth	Procedure	ICD-10-PCS
D9Y4CZZ	Intraoperative Radiation Therapy (IORT) of Mouth	Procedure	ICD-10-PCS
D9Y4FZZ	Plaque Radiation of Mouth	Procedure	ICD-10-PCS
D9Y5	Other Radiation / Tongue	Procedure	ICD-10-PCS
D9Y57ZZ	Contact Radiation of Tongue	Procedure	ICD-10-PCS
D9Y5FZZ	Plaque Radiation of Tongue	Procedure	ICD-10-PCS
D9Y6	Other Radiation / Salivary Glands	Procedure	ICD-10-PCS
D9Y67ZZ	Contact Radiation of Salivary Glands	Procedure	ICD-10-PCS
D9Y6FZZ	Plaque Radiation of Salivary Glands	Procedure	ICD-10-PCS
D9Y7	Other Radiation / Sinuses	Procedure	ICD-10-PCS
D9Y77ZZ	Contact Radiation of Sinuses	Procedure	ICD-10-PCS
D9Y7FZZ	Plaque Radiation of Sinuses	Procedure	ICD-10-PCS
D9Y8	Other Radiation / Hard Palate	Procedure	ICD-10-PCS
D9Y87ZZ	Contact Radiation of Hard Palate	Procedure	ICD-10-PCS
D9Y8FZZ	Plaque Radiation of Hard Palate	Procedure	ICD-10-PCS
D9Y9	Other Radiation / Soft Palate	Procedure	ICD-10-PCS
D9Y97ZZ	Contact Radiation of Soft Palate	Procedure	ICD-10-PCS
D9Y9FZZ	Plaque Radiation of Soft Palate	Procedure	ICD-10-PCS
D9YB	Other Radiation / Larynx	Procedure	ICD-10-PCS
D9YB7ZZ	Contact Radiation of Larynx	Procedure	ICD-10-PCS
D9YBCZZ	Intraoperative Radiation Therapy (IORT) of Larynx	Procedure	ICD-10-PCS
D9YBFZZ	Plaque Radiation of Larynx	Procedure	ICD-10-PCS
D9YC	Other Radiation / Pharynx	Procedure	ICD-10-PCS
D9YCCZZ	Intraoperative Radiation Therapy (IORT) of Pharynx	Procedure	ICD-10-PCS
D9YCFZZ	Plaque Radiation of Pharynx	Procedure	ICD-10-PCS
D9YD	Other Radiation / Nasopharynx	Procedure	ICD-10-PCS
D9YD7ZZ	Contact Radiation of Nasopharynx	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
D9YDCZZ	Intraoperative Radiation Therapy (IORT) of Nasopharynx	Procedure	ICD-10-PCS
D9YDFZZ	Plaque Radiation of Nasopharynx	Procedure	ICD-10-PCS
D9YF	Other Radiation / Oropharynx	Procedure	ICD-10-PCS
D9YF7ZZ	Contact Radiation of Oropharynx	Procedure	ICD-10-PCS
DB0	Radiation Therapy, Respiratory System, Beam Radiation	Procedure	ICD-10-PCS
DB00	Beam Radiation / Trachea	Procedure	ICD-10-PCS
DB000ZZ	Beam Radiation of Trachea using Photons <1 MeV	Procedure	ICD-10-PCS
DB001ZZ	Beam Radiation of Trachea using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DB002ZZ	Beam Radiation of Trachea using Photons >10 MeV	Procedure	ICD-10-PCS
DB003Z0	Beam Radiation of Trachea using Electrons, Intraoperative	Procedure	ICD-10-PCS
DB003ZZ	Beam Radiation of Trachea using Electrons	Procedure	ICD-10-PCS
DB004ZZ	Beam Radiation of Trachea using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DB005ZZ	Beam Radiation of Trachea using Neutrons	Procedure	ICD-10-PCS
DB006ZZ	Beam Radiation of Trachea using Neutron Capture	Procedure	ICD-10-PCS
DB01	Beam Radiation / Bronchus	Procedure	ICD-10-PCS
DB010ZZ	Beam Radiation of Bronchus using Photons <1 MeV	Procedure	ICD-10-PCS
DB011ZZ	Beam Radiation of Bronchus using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DB012ZZ	Beam Radiation of Bronchus using Photons >10 MeV	Procedure	ICD-10-PCS
DB013Z0	Beam Radiation of Bronchus using Electrons, Intraoperative	Procedure	ICD-10-PCS
DB013ZZ	Beam Radiation of Bronchus using Electrons	Procedure	ICD-10-PCS
DB014ZZ	Beam Radiation of Bronchus using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DB015ZZ	Beam Radiation of Bronchus using Neutrons	Procedure	ICD-10-PCS
DB016ZZ	Beam Radiation of Bronchus using Neutron Capture	Procedure	ICD-10-PCS
DB02	Beam Radiation / Lung	Procedure	ICD-10-PCS
DB020ZZ	Beam Radiation of Lung using Photons <1 MeV	Procedure	ICD-10-PCS
DB021ZZ	Beam Radiation of Lung using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DB022ZZ	Beam Radiation of Lung using Photons >10 MeV	Procedure	ICD-10-PCS
DB023Z0	Beam Radiation of Lung using Electrons, Intraoperative	Procedure	ICD-10-PCS
DB023ZZ	Beam Radiation of Lung using Electrons	Procedure	ICD-10-PCS
DB024ZZ	Beam Radiation of Lung using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DB025ZZ	Beam Radiation of Lung using Neutrons	Procedure	ICD-10-PCS
DB026ZZ	Beam Radiation of Lung using Neutron Capture	Procedure	ICD-10-PCS
DB05	Beam Radiation / Pleura	Procedure	ICD-10-PCS
DB050ZZ	Beam Radiation of Pleura using Photons <1 MeV	Procedure	ICD-10-PCS
DB051ZZ	Beam Radiation of Pleura using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DB052ZZ	Beam Radiation of Pleura using Photons >10 MeV	Procedure	ICD-10-PCS
DB053Z0	Beam Radiation of Pleura using Electrons, Intraoperative	Procedure	ICD-10-PCS
DB053ZZ	Beam Radiation of Pleura using Electrons	Procedure	ICD-10-PCS
DB054ZZ	Beam Radiation of Pleura using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DB055ZZ	Beam Radiation of Pleura using Neutrons	Procedure	ICD-10-PCS
DB056ZZ	Beam Radiation of Pleura using Neutron Capture	Procedure	ICD-10-PCS
DB06	Beam Radiation / Mediastinum	Procedure	ICD-10-PCS
DB060ZZ	Beam Radiation of Mediastinum using Photons <1 MeV	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
DB061ZZ	Beam Radiation of Mediastinum using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DB062ZZ	Beam Radiation of Mediastinum using Photons >10 MeV	Procedure	ICD-10-PCS
DB063Z0	Beam Radiation of Mediastinum using Electrons, Intraoperative	Procedure	ICD-10-PCS
DB063ZZ	Beam Radiation of Mediastinum using Electrons	Procedure	ICD-10-PCS
DB064ZZ	Beam Radiation of Mediastinum using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DB065ZZ	Beam Radiation of Mediastinum using Neutrons	Procedure	ICD-10-PCS
DB066ZZ	Beam Radiation of Mediastinum using Neutron Capture	Procedure	ICD-10-PCS
DB07	Beam Radiation / Chest Wall	Procedure	ICD-10-PCS
DB070ZZ	Beam Radiation of Chest Wall using Photons <1 MeV	Procedure	ICD-10-PCS
DB071ZZ	Beam Radiation of Chest Wall using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DB072ZZ	Beam Radiation of Chest Wall using Photons >10 MeV	Procedure	ICD-10-PCS
DB073Z0	Beam Radiation of Chest Wall using Electrons, Intraoperative	Procedure	ICD-10-PCS
DB073ZZ	Beam Radiation of Chest Wall using Electrons	Procedure	ICD-10-PCS
DB074ZZ	Beam Radiation of Chest Wall using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DB075ZZ	Beam Radiation of Chest Wall using Neutrons	Procedure	ICD-10-PCS
DB076ZZ	Beam Radiation of Chest Wall using Neutron Capture	Procedure	ICD-10-PCS
DB08	Beam Radiation / Diaphragm	Procedure	ICD-10-PCS
DB080ZZ	Beam Radiation of Diaphragm using Photons <1 MeV	Procedure	ICD-10-PCS
DB081ZZ	Beam Radiation of Diaphragm using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DB082ZZ	Beam Radiation of Diaphragm using Photons >10 MeV	Procedure	ICD-10-PCS
DB083Z0	Beam Radiation of Diaphragm using Electrons, Intraoperative	Procedure	ICD-10-PCS
DB083ZZ	Beam Radiation of Diaphragm using Electrons	Procedure	ICD-10-PCS
DB084ZZ	Beam Radiation of Diaphragm using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DB085ZZ	Beam Radiation of Diaphragm using Neutrons	Procedure	ICD-10-PCS
DB086ZZ	Beam Radiation of Diaphragm using Neutron Capture	Procedure	ICD-10-PCS
DB1	Radiation Therapy, Respiratory System, Brachytherapy	Procedure	ICD-10-PCS
DB2	Radiation Therapy, Respiratory System, Stereotactic Radiosurgery	Procedure	ICD-10-PCS
DBY	Radiation Therapy, Respiratory System, Other Radiation	Procedure	ICD-10-PCS
DBY0	Other Radiation / Trachea	Procedure	ICD-10-PCS
DBY07ZZ	Contact Radiation of Trachea	Procedure	ICD-10-PCS
DBY0FZZ	Plaque Radiation of Trachea	Procedure	ICD-10-PCS
DBY1	Other Radiation / Bronchus	Procedure	ICD-10-PCS
DBY17ZZ	Contact Radiation of Bronchus	Procedure	ICD-10-PCS
DBY1FZZ	Plaque Radiation of Bronchus	Procedure	ICD-10-PCS
DBY2	Other Radiation / Lung	Procedure	ICD-10-PCS
DBY27ZZ	Contact Radiation of Lung	Procedure	ICD-10-PCS
DBY2FZZ	Plaque Radiation of Lung	Procedure	ICD-10-PCS
DBY5	Other Radiation / Pleura	Procedure	ICD-10-PCS
DBY57ZZ	Contact Radiation of Pleura	Procedure	ICD-10-PCS
DBY5FZZ	Plaque Radiation of Pleura	Procedure	ICD-10-PCS
DBY6	Other Radiation / Mediastinum	Procedure	ICD-10-PCS
DBY67ZZ	Contact Radiation of Mediastinum	Procedure	ICD-10-PCS
DBY6FZZ	Plaque Radiation of Mediastinum	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
DBY7	Other Radiation / Chest Wall	Procedure	ICD-10-PCS
DBY77ZZ	Contact Radiation of Chest Wall	Procedure	ICD-10-PCS
DBY7FZZ	Plaque Radiation of Chest Wall	Procedure	ICD-10-PCS
DBY8	Other Radiation / Diaphragm	Procedure	ICD-10-PCS
DBY87ZZ	Contact Radiation of Diaphragm	Procedure	ICD-10-PCS
DBY8FZZ	Plaque Radiation of Diaphragm	Procedure	ICD-10-PCS
DD0	Radiation Therapy, Gastrointestinal System, Beam Radiation	Procedure	ICD-10-PCS
DD00	Beam Radiation / Esophagus	Procedure	ICD-10-PCS
DD000ZZ	Beam Radiation of Esophagus using Photons <1 MeV	Procedure	ICD-10-PCS
DD001ZZ	Beam Radiation of Esophagus using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DD002ZZ	Beam Radiation of Esophagus using Photons >10 MeV	Procedure	ICD-10-PCS
DD003Z0	Beam Radiation of Esophagus using Electrons, Intraoperative	Procedure	ICD-10-PCS
DD003ZZ	Beam Radiation of Esophagus using Electrons	Procedure	ICD-10-PCS
DD004ZZ	Beam Radiation of Esophagus using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DD005ZZ	Beam Radiation of Esophagus using Neutrons	Procedure	ICD-10-PCS
DD006ZZ	Beam Radiation of Esophagus using Neutron Capture	Procedure	ICD-10-PCS
DD01	Beam Radiation / Stomach	Procedure	ICD-10-PCS
DD010ZZ	Beam Radiation of Stomach using Photons <1 MeV	Procedure	ICD-10-PCS
DD011ZZ	Beam Radiation of Stomach using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DD012ZZ	Beam Radiation of Stomach using Photons >10 MeV	Procedure	ICD-10-PCS
DD013Z0	Beam Radiation of Stomach using Electrons, Intraoperative	Procedure	ICD-10-PCS
DD013ZZ	Beam Radiation of Stomach using Electrons	Procedure	ICD-10-PCS
DD014ZZ	Beam Radiation of Stomach using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DD015ZZ	Beam Radiation of Stomach using Neutrons	Procedure	ICD-10-PCS
DD016ZZ	Beam Radiation of Stomach using Neutron Capture	Procedure	ICD-10-PCS
DD02	Beam Radiation / Duodenum	Procedure	ICD-10-PCS
DD020ZZ	Beam Radiation of Duodenum using Photons <1 MeV	Procedure	ICD-10-PCS
DD021ZZ	Beam Radiation of Duodenum using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DD022ZZ	Beam Radiation of Duodenum using Photons >10 MeV	Procedure	ICD-10-PCS
DD023Z0	Beam Radiation of Duodenum using Electrons, Intraoperative	Procedure	ICD-10-PCS
DD023ZZ	Beam Radiation of Duodenum using Electrons	Procedure	ICD-10-PCS
DD024ZZ	Beam Radiation of Duodenum using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DD025ZZ	Beam Radiation of Duodenum using Neutrons	Procedure	ICD-10-PCS
DD026ZZ	Beam Radiation of Duodenum using Neutron Capture	Procedure	ICD-10-PCS
DD03	Beam Radiation / Jejunum	Procedure	ICD-10-PCS
DD030ZZ	Beam Radiation of Jejunum using Photons <1 MeV	Procedure	ICD-10-PCS
DD031ZZ	Beam Radiation of Jejunum using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DD032ZZ	Beam Radiation of Jejunum using Photons >10 MeV	Procedure	ICD-10-PCS
DD033Z0	Beam Radiation of Jejunum using Electrons, Intraoperative	Procedure	ICD-10-PCS
DD033ZZ	Beam Radiation of Jejunum using Electrons	Procedure	ICD-10-PCS
DD034ZZ	Beam Radiation of Jejunum using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DD035ZZ	Beam Radiation of Jejunum using Neutrons	Procedure	ICD-10-PCS
DD036ZZ	Beam Radiation of Jejunum using Neutron Capture	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
DD04	Beam Radiation / Ileum	Procedure	ICD-10-PCS
DD040ZZ	Beam Radiation of Ileum using Photons <1 MeV	Procedure	ICD-10-PCS
DD041ZZ	Beam Radiation of Ileum using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DD042ZZ	Beam Radiation of Ileum using Photons >10 MeV	Procedure	ICD-10-PCS
DD043Z0	Beam Radiation of Ileum using Electrons, Intraoperative	Procedure	ICD-10-PCS
DD043ZZ	Beam Radiation of Ileum using Electrons	Procedure	ICD-10-PCS
DD044ZZ	Beam Radiation of Ileum using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DD045ZZ	Beam Radiation of Ileum using Neutrons	Procedure	ICD-10-PCS
DD046ZZ	Beam Radiation of Ileum using Neutron Capture	Procedure	ICD-10-PCS
DD05	Beam Radiation / Colon	Procedure	ICD-10-PCS
DD050ZZ	Beam Radiation of Colon using Photons <1 MeV	Procedure	ICD-10-PCS
DD051ZZ	Beam Radiation of Colon using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DD052ZZ	Beam Radiation of Colon using Photons >10 MeV	Procedure	ICD-10-PCS
DD053Z0	Beam Radiation of Colon using Electrons, Intraoperative	Procedure	ICD-10-PCS
DD053ZZ	Beam Radiation of Colon using Electrons	Procedure	ICD-10-PCS
DD054ZZ	Beam Radiation of Colon using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DD055ZZ	Beam Radiation of Colon using Neutrons	Procedure	ICD-10-PCS
DD056ZZ	Beam Radiation of Colon using Neutron Capture	Procedure	ICD-10-PCS
DD07	Beam Radiation / Rectum	Procedure	ICD-10-PCS
DD070ZZ	Beam Radiation of Rectum using Photons <1 MeV	Procedure	ICD-10-PCS
DD071ZZ	Beam Radiation of Rectum using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DD072ZZ	Beam Radiation of Rectum using Photons >10 MeV	Procedure	ICD-10-PCS
DD073Z0	Beam Radiation of Rectum using Electrons, Intraoperative	Procedure	ICD-10-PCS
DD073ZZ	Beam Radiation of Rectum using Electrons	Procedure	ICD-10-PCS
DD074ZZ	Beam Radiation of Rectum using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DD075ZZ	Beam Radiation of Rectum using Neutrons	Procedure	ICD-10-PCS
DD076ZZ	Beam Radiation of Rectum using Neutron Capture	Procedure	ICD-10-PCS
DD1	Radiation Therapy, Gastrointestinal System, Brachytherapy	Procedure	ICD-10-PCS
DD2	Radiation Therapy, Gastrointestinal System, Stereotactic Radiosurgery	Procedure	ICD-10-PCS
DDY	Radiation Therapy, Gastrointestinal System, Other Radiation	Procedure	ICD-10-PCS
DDY0	Other Radiation / Esophagus	Procedure	ICD-10-PCS
DDY07ZZ	Contact Radiation of Esophagus	Procedure	ICD-10-PCS
DDY0FZZ	Plaque Radiation of Esophagus	Procedure	ICD-10-PCS
DDY1	Other Radiation / Stomach	Procedure	ICD-10-PCS
DDY17ZZ	Contact Radiation of Stomach	Procedure	ICD-10-PCS
DDY1CZZ	Intraoperative Radiation Therapy (IORT) of Stomach	Procedure	ICD-10-PCS
DDY1FZZ	Plaque Radiation of Stomach	Procedure	ICD-10-PCS
DDY2	Other Radiation / Duodenum	Procedure	ICD-10-PCS
DDY27ZZ	Contact Radiation of Duodenum	Procedure	ICD-10-PCS
DDY2CZZ	Intraoperative Radiation Therapy (IORT) of Duodenum	Procedure	ICD-10-PCS
DDY2FZZ	Plaque Radiation of Duodenum	Procedure	ICD-10-PCS
DDY3	Other Radiation / Jejunum	Procedure	ICD-10-PCS
DDY37ZZ	Contact Radiation of Jejunum	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
DDY3CZZ	Intraoperative Radiation Therapy (IORT) of Jejunum	Procedure	ICD-10-PCS
DDY3FZZ	Plaque Radiation of Jejunum	Procedure	ICD-10-PCS
DDY4	Other Radiation / Ileum	Procedure	ICD-10-PCS
DDY47ZZ	Contact Radiation of Ileum	Procedure	ICD-10-PCS
DDY4CZZ	Intraoperative Radiation Therapy (IORT) of Ileum	Procedure	ICD-10-PCS
DDY4FZZ	Plaque Radiation of Ileum	Procedure	ICD-10-PCS
DDY5	Other Radiation / Colon	Procedure	ICD-10-PCS
DDY57ZZ	Contact Radiation of Colon	Procedure	ICD-10-PCS
DDY5CZZ	Intraoperative Radiation Therapy (IORT) of Colon	Procedure	ICD-10-PCS
DDY5FZZ	Plaque Radiation of Colon	Procedure	ICD-10-PCS
DDY7	Other Radiation / Rectum	Procedure	ICD-10-PCS
DDY77ZZ	Contact Radiation of Rectum	Procedure	ICD-10-PCS
DDY7CZZ	Intraoperative Radiation Therapy (IORT) of Rectum	Procedure	ICD-10-PCS
DDY7FZZ	Plaque Radiation of Rectum	Procedure	ICD-10-PCS
DDY8	Other Radiation / Anus	Procedure	ICD-10-PCS
DDY8CZZ	Intraoperative Radiation Therapy (IORT) of Anus	Procedure	ICD-10-PCS
DDY8FZZ	Plaque Radiation of Anus	Procedure	ICD-10-PCS
DF0	Radiation Therapy, Hepatobiliary System and Pancreas, Beam Radiation	Procedure	ICD-10-PCS
DF00	Beam Radiation / Liver	Procedure	ICD-10-PCS
DF000ZZ	Beam Radiation of Liver using Photons <1 MeV	Procedure	ICD-10-PCS
DF001ZZ	Beam Radiation of Liver using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DF002ZZ	Beam Radiation of Liver using Photons >10 MeV	Procedure	ICD-10-PCS
DF003Z0	Beam Radiation of Liver using Electrons, Intraoperative	Procedure	ICD-10-PCS
DF003ZZ	Beam Radiation of Liver using Electrons	Procedure	ICD-10-PCS
DF004ZZ	Beam Radiation of Liver using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DF005ZZ	Beam Radiation of Liver using Neutrons	Procedure	ICD-10-PCS
DF006ZZ	Beam Radiation of Liver using Neutron Capture	Procedure	ICD-10-PCS
DF01	Beam Radiation / Gallbladder	Procedure	ICD-10-PCS
DF010ZZ	Beam Radiation of Gallbladder using Photons <1 MeV	Procedure	ICD-10-PCS
DF011ZZ	Beam Radiation of Gallbladder using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DF012ZZ	Beam Radiation of Gallbladder using Photons >10 MeV	Procedure	ICD-10-PCS
DF013Z0	Beam Radiation of Gallbladder using Electrons, Intraoperative	Procedure	ICD-10-PCS
DF013ZZ	Beam Radiation of Gallbladder using Electrons	Procedure	ICD-10-PCS
DF014ZZ	Beam Radiation of Gallbladder using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DF015ZZ	Beam Radiation of Gallbladder using Neutrons	Procedure	ICD-10-PCS
DF016ZZ	Beam Radiation of Gallbladder using Neutron Capture	Procedure	ICD-10-PCS
DF02	Beam Radiation / Bile Ducts	Procedure	ICD-10-PCS
DF020ZZ	Beam Radiation of Bile Ducts using Photons <1 MeV	Procedure	ICD-10-PCS
DF021ZZ	Beam Radiation of Bile Ducts using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DF022ZZ	Beam Radiation of Bile Ducts using Photons >10 MeV	Procedure	ICD-10-PCS
DF023Z0	Beam Radiation of Bile Ducts using Electrons, Intraoperative	Procedure	ICD-10-PCS
DF023ZZ	Beam Radiation of Bile Ducts using Electrons	Procedure	ICD-10-PCS
DF024ZZ	Beam Radiation of Bile Ducts using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
DF025ZZ	Beam Radiation of Bile Ducts using Neutrons	Procedure	ICD-10-PCS
DF026ZZ	Beam Radiation of Bile Ducts using Neutron Capture	Procedure	ICD-10-PCS
DF03	Beam Radiation / Pancreas	Procedure	ICD-10-PCS
DF030ZZ	Beam Radiation of Pancreas using Photons <1 MeV	Procedure	ICD-10-PCS
DF031ZZ	Beam Radiation of Pancreas using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DF032ZZ	Beam Radiation of Pancreas using Photons >10 MeV	Procedure	ICD-10-PCS
DF033Z0	Beam Radiation of Pancreas using Electrons, Intraoperative	Procedure	ICD-10-PCS
DF033ZZ	Beam Radiation of Pancreas using Electrons	Procedure	ICD-10-PCS
DF034ZZ	Beam Radiation of Pancreas using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DF035ZZ	Beam Radiation of Pancreas using Neutrons	Procedure	ICD-10-PCS
DF036ZZ	Beam Radiation of Pancreas using Neutron Capture	Procedure	ICD-10-PCS
DF1	Radiation Therapy, Hepatobiliary System and Pancreas, Brachytherapy	Procedure	ICD-10-PCS
DF2	Radiation Therapy, Hepatobiliary System and Pancreas, Stereotactic Radiosurgery	Procedure	ICD-10-PCS
DFY	Radiation Therapy, Hepatobiliary System and Pancreas, Other Radiation	Procedure	ICD-10-PCS
DFY0	Other Radiation / Liver	Procedure	ICD-10-PCS
DFY07ZZ	Contact Radiation of Liver	Procedure	ICD-10-PCS
DFY0CZZ	Intraoperative Radiation Therapy (IORT) of Liver	Procedure	ICD-10-PCS
DFY0FZZ	Plaque Radiation of Liver	Procedure	ICD-10-PCS
DFY1	Other Radiation / Gallbladder	Procedure	ICD-10-PCS
DFY17ZZ	Contact Radiation of Gallbladder	Procedure	ICD-10-PCS
DFY1CZZ	Intraoperative Radiation Therapy (IORT) of Gallbladder	Procedure	ICD-10-PCS
DFY1FZZ	Plaque Radiation of Gallbladder	Procedure	ICD-10-PCS
DFY2	Other Radiation / Bile Ducts	Procedure	ICD-10-PCS
DFY27ZZ	Contact Radiation of Bile Ducts	Procedure	ICD-10-PCS
DFY2CZZ	Intraoperative Radiation Therapy (IORT) of Bile Ducts	Procedure	ICD-10-PCS
DFY2FZZ	Plaque Radiation of Bile Ducts	Procedure	ICD-10-PCS
DFY3	Other Radiation / Pancreas	Procedure	ICD-10-PCS
DFY37ZZ	Contact Radiation of Pancreas	Procedure	ICD-10-PCS
DFY3CZZ	Intraoperative Radiation Therapy (IORT) of Pancreas	Procedure	ICD-10-PCS
DFY3FZZ	Plaque Radiation of Pancreas	Procedure	ICD-10-PCS
DG0	Radiation Therapy, Endocrine System, Beam Radiation	Procedure	ICD-10-PCS
DG00	Beam Radiation / Pituitary Gland	Procedure	ICD-10-PCS
DG000ZZ	Beam Radiation of Pituitary Gland using Photons <1 MeV	Procedure	ICD-10-PCS
DG001ZZ	Beam Radiation of Pituitary Gland using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DG002ZZ	Beam Radiation of Pituitary Gland using Photons >10 MeV	Procedure	ICD-10-PCS
DG003Z0	Beam Radiation of Pituitary Gland using Electrons, Intraoperative	Procedure	ICD-10-PCS
DG003ZZ	Beam Radiation of Pituitary Gland using Electrons	Procedure	ICD-10-PCS
DG005ZZ	Beam Radiation of Pituitary Gland using Neutrons	Procedure	ICD-10-PCS
DG006ZZ	Beam Radiation of Pituitary Gland using Neutron Capture	Procedure	ICD-10-PCS
DG01	Beam Radiation / Pineal Body	Procedure	ICD-10-PCS
DG010ZZ	Beam Radiation of Pineal Body using Photons <1 MeV	Procedure	ICD-10-PCS
DG011ZZ	Beam Radiation of Pineal Body using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DG012ZZ	Beam Radiation of Pineal Body using Photons >10 MeV	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
DG013Z0	Beam Radiation of Pineal Body using Electrons, Intraoperative	Procedure	ICD-10-PCS
DG013ZZ	Beam Radiation of Pineal Body using Electrons	Procedure	ICD-10-PCS
DG015ZZ	Beam Radiation of Pineal Body using Neutrons	Procedure	ICD-10-PCS
DG016ZZ	Beam Radiation of Pineal Body using Neutron Capture	Procedure	ICD-10-PCS
DG02	Beam Radiation / Adrenal Glands	Procedure	ICD-10-PCS
DG020ZZ	Beam Radiation of Adrenal Glands using Photons <1 MeV	Procedure	ICD-10-PCS
DG021ZZ	Beam Radiation of Adrenal Glands using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DG022ZZ	Beam Radiation of Adrenal Glands using Photons >10 MeV	Procedure	ICD-10-PCS
DG023Z0	Beam Radiation of Adrenal Glands using Electrons, Intraoperative	Procedure	ICD-10-PCS
DG023ZZ	Beam Radiation of Adrenal Glands using Electrons	Procedure	ICD-10-PCS
DG025ZZ	Beam Radiation of Adrenal Glands using Neutrons	Procedure	ICD-10-PCS
DG026ZZ	Beam Radiation of Adrenal Glands using Neutron Capture	Procedure	ICD-10-PCS
DG04	Beam Radiation / Parathyroid Glands	Procedure	ICD-10-PCS
DG040ZZ	Beam Radiation of Parathyroid Glands using Photons <1 MeV	Procedure	ICD-10-PCS
DG041ZZ	Beam Radiation of Parathyroid Glands using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DG042ZZ	Beam Radiation of Parathyroid Glands using Photons >10 MeV	Procedure	ICD-10-PCS
DG043Z0	Beam Radiation of Parathyroid Glands using Electrons, Intraoperative	Procedure	ICD-10-PCS
DG043ZZ	Beam Radiation of Parathyroid Glands using Electrons	Procedure	ICD-10-PCS
DG045ZZ	Beam Radiation of Parathyroid Glands using Neutrons	Procedure	ICD-10-PCS
DG046ZZ	Beam Radiation of Parathyroid Glands using Neutron Capture	Procedure	ICD-10-PCS
DG05	Beam Radiation / Thyroid	Procedure	ICD-10-PCS
DG050ZZ	Beam Radiation of Thyroid using Photons <1 MeV	Procedure	ICD-10-PCS
DG051ZZ	Beam Radiation of Thyroid using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DG052ZZ	Beam Radiation of Thyroid using Photons >10 MeV	Procedure	ICD-10-PCS
DG053Z0	Beam Radiation of Thyroid using Electrons, Intraoperative	Procedure	ICD-10-PCS
DG053ZZ	Beam Radiation of Thyroid using Electrons	Procedure	ICD-10-PCS
DG055ZZ	Beam Radiation of Thyroid using Neutrons	Procedure	ICD-10-PCS
DG056ZZ	Beam Radiation of Thyroid using Neutron Capture	Procedure	ICD-10-PCS
DG1	Radiation Therapy, Endocrine System, Brachytherapy	Procedure	ICD-10-PCS
DG2	Radiation Therapy, Endocrine System, Stereotactic Radiosurgery	Procedure	ICD-10-PCS
DGY	Radiation Therapy, Endocrine System, Other Radiation	Procedure	ICD-10-PCS
DGY0	Other Radiation / Pituitary Gland	Procedure	ICD-10-PCS
DGY07ZZ	Contact Radiation of Pituitary Gland	Procedure	ICD-10-PCS
DGY0FZZ	Plaque Radiation of Pituitary Gland	Procedure	ICD-10-PCS
DGY1	Other Radiation / Pineal Body	Procedure	ICD-10-PCS
DGY17ZZ	Contact Radiation of Pineal Body	Procedure	ICD-10-PCS
DGY1FZZ	Plaque Radiation of Pineal Body	Procedure	ICD-10-PCS
DGY2	Other Radiation / Adrenal Glands	Procedure	ICD-10-PCS
DGY27ZZ	Contact Radiation of Adrenal Glands	Procedure	ICD-10-PCS
DGY2FZZ	Plaque Radiation of Adrenal Glands	Procedure	ICD-10-PCS
DGY4	Other Radiation / Parathyroid Glands	Procedure	ICD-10-PCS
DGY47ZZ	Contact Radiation of Parathyroid Glands	Procedure	ICD-10-PCS
DGY4FZZ	Plaque Radiation of Parathyroid Glands	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
DGY5	Other Radiation / Thyroid	Procedure	ICD-10-PCS
DGY57ZZ	Contact Radiation of Thyroid	Procedure	ICD-10-PCS
DGY5FZZ	Plaque Radiation of Thyroid	Procedure	ICD-10-PCS
DH0	Radiation Therapy, Skin, Beam Radiation	Procedure	ICD-10-PCS
DH02	Beam Radiation / Skin, Face	Procedure	ICD-10-PCS
DH020ZZ	Beam Radiation of Face Skin using Photons <1 MeV	Procedure	ICD-10-PCS
DH021ZZ	Beam Radiation of Face Skin using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DH022ZZ	Beam Radiation of Face Skin using Photons >10 MeV	Procedure	ICD-10-PCS
DH023Z0	Beam Radiation of Face Skin using Electrons, Intraoperative	Procedure	ICD-10-PCS
DH023ZZ	Beam Radiation of Face Skin using Electrons	Procedure	ICD-10-PCS
DH024ZZ	Beam Radiation of Face Skin using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DH025ZZ	Beam Radiation of Face Skin using Neutrons	Procedure	ICD-10-PCS
DH026ZZ	Beam Radiation of Face Skin using Neutron Capture	Procedure	ICD-10-PCS
DH03	Beam Radiation / Skin, Neck	Procedure	ICD-10-PCS
DH030ZZ	Beam Radiation of Neck Skin using Photons <1 MeV	Procedure	ICD-10-PCS
DH031ZZ	Beam Radiation of Neck Skin using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DH032ZZ	Beam Radiation of Neck Skin using Photons >10 MeV	Procedure	ICD-10-PCS
DH033Z0	Beam Radiation of Neck Skin using Electrons, Intraoperative	Procedure	ICD-10-PCS
DH033ZZ	Beam Radiation of Neck Skin using Electrons	Procedure	ICD-10-PCS
DH034ZZ	Beam Radiation of Neck Skin using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DH035ZZ	Beam Radiation of Neck Skin using Neutrons	Procedure	ICD-10-PCS
DH036ZZ	Beam Radiation of Neck Skin using Neutron Capture	Procedure	ICD-10-PCS
DH04	Beam Radiation / Skin, Arm	Procedure	ICD-10-PCS
DH040ZZ	Beam Radiation of Arm Skin using Photons <1 MeV	Procedure	ICD-10-PCS
DH041ZZ	Beam Radiation of Arm Skin using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DH042ZZ	Beam Radiation of Arm Skin using Photons >10 MeV	Procedure	ICD-10-PCS
DH043Z0	Beam Radiation of Arm Skin using Electrons, Intraoperative	Procedure	ICD-10-PCS
DH043ZZ	Beam Radiation of Arm Skin using Electrons	Procedure	ICD-10-PCS
DH044ZZ	Beam Radiation of Arm Skin using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DH045ZZ	Beam Radiation of Arm Skin using Neutrons	Procedure	ICD-10-PCS
DH046ZZ	Beam Radiation of Arm Skin using Neutron Capture	Procedure	ICD-10-PCS
DH06	Beam Radiation / Skin, Chest	Procedure	ICD-10-PCS
DH060ZZ	Beam Radiation of Chest Skin using Photons <1 MeV	Procedure	ICD-10-PCS
DH061ZZ	Beam Radiation of Chest Skin using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DH062ZZ	Beam Radiation of Chest Skin using Photons >10 MeV	Procedure	ICD-10-PCS
DH063Z0	Beam Radiation of Chest Skin using Electrons, Intraoperative	Procedure	ICD-10-PCS
DH063ZZ	Beam Radiation of Chest Skin using Electrons	Procedure	ICD-10-PCS
DH064ZZ	Beam Radiation of Chest Skin using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DH065ZZ	Beam Radiation of Chest Skin using Neutrons	Procedure	ICD-10-PCS
DH066ZZ	Beam Radiation of Chest Skin using Neutron Capture	Procedure	ICD-10-PCS
DH07	Beam Radiation / Skin, Back	Procedure	ICD-10-PCS
DH070ZZ	Beam Radiation of Back Skin using Photons <1 MeV	Procedure	ICD-10-PCS
DH071ZZ	Beam Radiation of Back Skin using Photons 1 - 10 MeV	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
DH072ZZ	Beam Radiation of Back Skin using Photons >10 MeV	Procedure	ICD-10-PCS
DH073Z0	Beam Radiation of Back Skin using Electrons, Intraoperative	Procedure	ICD-10-PCS
DH073ZZ	Beam Radiation of Back Skin using Electrons	Procedure	ICD-10-PCS
DH074ZZ	Beam Radiation of Back Skin using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DH075ZZ	Beam Radiation of Back Skin using Neutrons	Procedure	ICD-10-PCS
DH076ZZ	Beam Radiation of Back Skin using Neutron Capture	Procedure	ICD-10-PCS
DH08	Beam Radiation / Skin, Abdomen	Procedure	ICD-10-PCS
DH080ZZ	Beam Radiation of Abdomen Skin using Photons <1 MeV	Procedure	ICD-10-PCS
DH081ZZ	Beam Radiation of Abdomen Skin using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DH082ZZ	Beam Radiation of Abdomen Skin using Photons >10 MeV	Procedure	ICD-10-PCS
DH083Z0	Beam Radiation of Abdomen Skin using Electrons, Intraoperative	Procedure	ICD-10-PCS
DH083ZZ	Beam Radiation of Abdomen Skin using Electrons	Procedure	ICD-10-PCS
DH084ZZ	Beam Radiation of Abdomen Skin using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DH085ZZ	Beam Radiation of Abdomen Skin using Neutrons	Procedure	ICD-10-PCS
DH086ZZ	Beam Radiation of Abdomen Skin using Neutron Capture	Procedure	ICD-10-PCS
DH09	Beam Radiation / Skin, Buttock	Procedure	ICD-10-PCS
DH090ZZ	Beam Radiation of Buttock Skin using Photons <1 MeV	Procedure	ICD-10-PCS
DH091ZZ	Beam Radiation of Buttock Skin using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DH092ZZ	Beam Radiation of Buttock Skin using Photons >10 MeV	Procedure	ICD-10-PCS
DH093Z0	Beam Radiation of Buttock Skin using Electrons, Intraoperative	Procedure	ICD-10-PCS
DH093ZZ	Beam Radiation of Buttock Skin using Electrons	Procedure	ICD-10-PCS
DH094ZZ	Beam Radiation of Buttock Skin using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DH095ZZ	Beam Radiation of Buttock Skin using Neutrons	Procedure	ICD-10-PCS
DH096ZZ	Beam Radiation of Buttock Skin using Neutron Capture	Procedure	ICD-10-PCS
DH0B	Beam Radiation / Skin, Leg	Procedure	ICD-10-PCS
DH0B0ZZ	Beam Radiation of Leg Skin using Photons <1 MeV	Procedure	ICD-10-PCS
DH0B1ZZ	Beam Radiation of Leg Skin using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DH0B2ZZ	Beam Radiation of Leg Skin using Photons >10 MeV	Procedure	ICD-10-PCS
DH0B3Z0	Beam Radiation of Leg Skin using Electrons, Intraoperative	Procedure	ICD-10-PCS
DH0B3ZZ	Beam Radiation of Leg Skin using Electrons	Procedure	ICD-10-PCS
DH0B4ZZ	Beam Radiation of Leg Skin using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DH0B5ZZ	Beam Radiation of Leg Skin using Neutrons	Procedure	ICD-10-PCS
DH0B6ZZ	Beam Radiation of Leg Skin using Neutron Capture	Procedure	ICD-10-PCS
DHY	Radiation Therapy, Skin, Other Radiation	Procedure	ICD-10-PCS
DHY2	Other Radiation / Skin, Face	Procedure	ICD-10-PCS
DHY27ZZ	Contact Radiation of Face Skin	Procedure	ICD-10-PCS
DHY2FZZ	Plaque Radiation of Face Skin	Procedure	ICD-10-PCS
DHY3	Other Radiation / Skin, Neck	Procedure	ICD-10-PCS
DHY37ZZ	Contact Radiation of Neck Skin	Procedure	ICD-10-PCS
DHY3FZZ	Plaque Radiation of Neck Skin	Procedure	ICD-10-PCS
DHY4	Other Radiation / Skin, Arm	Procedure	ICD-10-PCS
DHY47ZZ	Contact Radiation of Arm Skin	Procedure	ICD-10-PCS
DHY4FZZ	Plaque Radiation of Arm Skin	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
DHY5	Other Radiation / Skin, Hand	Procedure	ICD-10-PCS
DHY5FZZ	Plaque Radiation of Hand Skin	Procedure	ICD-10-PCS
DHY6	Other Radiation / Skin, Chest	Procedure	ICD-10-PCS
DHY67ZZ	Contact Radiation of Chest Skin	Procedure	ICD-10-PCS
DHY6FZZ	Plaque Radiation of Chest Skin	Procedure	ICD-10-PCS
DHY7	Other Radiation / Skin, Back	Procedure	ICD-10-PCS
DHY77ZZ	Contact Radiation of Back Skin	Procedure	ICD-10-PCS
DHY7FZZ	Plaque Radiation of Back Skin	Procedure	ICD-10-PCS
DHY8	Other Radiation / Skin, Abdomen	Procedure	ICD-10-PCS
DHY87ZZ	Contact Radiation of Abdomen Skin	Procedure	ICD-10-PCS
DHY8FZZ	Plaque Radiation of Abdomen Skin	Procedure	ICD-10-PCS
DHY9	Other Radiation / Skin, Buttock	Procedure	ICD-10-PCS
DHY97ZZ	Contact Radiation of Buttock Skin	Procedure	ICD-10-PCS
DHY9FZZ	Plaque Radiation of Buttock Skin	Procedure	ICD-10-PCS
DHYB	Other Radiation / Skin, Leg	Procedure	ICD-10-PCS
DHYB7ZZ	Contact Radiation of Leg Skin	Procedure	ICD-10-PCS
DHYBFZZ	Plaque Radiation of Leg Skin	Procedure	ICD-10-PCS
DHYC	Other Radiation / Skin, Foot	Procedure	ICD-10-PCS
DHYCFZZ	Plaque Radiation of Foot Skin	Procedure	ICD-10-PCS
DM0	Radiation Therapy, Breast, Beam Radiation	Procedure	ICD-10-PCS
DM00	Beam Radiation / Breast, Left	Procedure	ICD-10-PCS
DM000ZZ	Beam Radiation of Left Breast using Photons <1 MeV	Procedure	ICD-10-PCS
DM001ZZ	Beam Radiation of Left Breast using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DM002ZZ	Beam Radiation of Left Breast using Photons >10 MeV	Procedure	ICD-10-PCS
DM003Z0	Beam Radiation of Left Breast using Electrons, Intraoperative	Procedure	ICD-10-PCS
DM003ZZ	Beam Radiation of Left Breast using Electrons	Procedure	ICD-10-PCS
DM004ZZ	Beam Radiation of Left Breast using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DM005ZZ	Beam Radiation of Left Breast using Neutrons	Procedure	ICD-10-PCS
DM006ZZ	Beam Radiation of Left Breast using Neutron Capture	Procedure	ICD-10-PCS
DM01	Beam Radiation / Breast, Right	Procedure	ICD-10-PCS
DM010ZZ	Beam Radiation of Right Breast using Photons <1 MeV	Procedure	ICD-10-PCS
DM011ZZ	Beam Radiation of Right Breast using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DM012ZZ	Beam Radiation of Right Breast using Photons >10 MeV	Procedure	ICD-10-PCS
DM013Z0	Beam Radiation of Right Breast using Electrons, Intraoperative	Procedure	ICD-10-PCS
DM013ZZ	Beam Radiation of Right Breast using Electrons	Procedure	ICD-10-PCS
DM014ZZ	Beam Radiation of Right Breast using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DM015ZZ	Beam Radiation of Right Breast using Neutrons	Procedure	ICD-10-PCS
DM016ZZ	Beam Radiation of Right Breast using Neutron Capture	Procedure	ICD-10-PCS
DM1	Radiation Therapy, Breast, Brachytherapy	Procedure	ICD-10-PCS
DM2	Radiation Therapy, Breast, Stereotactic Radiosurgery	Procedure	ICD-10-PCS
DMY	Radiation Therapy, Breast, Other Radiation	Procedure	ICD-10-PCS
DMY0	Other Radiation / Breast, Left	Procedure	ICD-10-PCS
DMY07ZZ	Contact Radiation of Left Breast	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
DMY0FZZ	Plaque Radiation of Left Breast	Procedure	ICD-10-PCS
DMY1	Other Radiation / Breast, Right	Procedure	ICD-10-PCS
DMY17ZZ	Contact Radiation of Right Breast	Procedure	ICD-10-PCS
DMY1FZZ	Plaque Radiation of Right Breast	Procedure	ICD-10-PCS
DP0	Radiation Therapy, Musculoskeletal System, Beam Radiation	Procedure	ICD-10-PCS
DP00	Beam Radiation / Skull	Procedure	ICD-10-PCS
DP000ZZ	Beam Radiation of Skull using Photons <1 MeV	Procedure	ICD-10-PCS
DP001ZZ	Beam Radiation of Skull using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DP002ZZ	Beam Radiation of Skull using Photons >10 MeV	Procedure	ICD-10-PCS
DP003Z0	Beam Radiation of Skull using Electrons, Intraoperative	Procedure	ICD-10-PCS
DP003ZZ	Beam Radiation of Skull using Electrons	Procedure	ICD-10-PCS
DP004ZZ	Beam Radiation of Skull using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DP005ZZ	Beam Radiation of Skull using Neutrons	Procedure	ICD-10-PCS
DP006ZZ	Beam Radiation of Skull using Neutron Capture	Procedure	ICD-10-PCS
DP02	Beam Radiation / Maxilla	Procedure	ICD-10-PCS
DP020ZZ	Beam Radiation of Maxilla using Photons <1 MeV	Procedure	ICD-10-PCS
DP021ZZ	Beam Radiation of Maxilla using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DP022ZZ	Beam Radiation of Maxilla using Photons >10 MeV	Procedure	ICD-10-PCS
DP023Z0	Beam Radiation of Maxilla using Electrons, Intraoperative	Procedure	ICD-10-PCS
DP023ZZ	Beam Radiation of Maxilla using Electrons	Procedure	ICD-10-PCS
DP024ZZ	Beam Radiation of Maxilla using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DP025ZZ	Beam Radiation of Maxilla using Neutrons	Procedure	ICD-10-PCS
DP026ZZ	Beam Radiation of Maxilla using Neutron Capture	Procedure	ICD-10-PCS
DP03	Beam Radiation / Mandible	Procedure	ICD-10-PCS
DP030ZZ	Beam Radiation of Mandible using Photons <1 MeV	Procedure	ICD-10-PCS
DP031ZZ	Beam Radiation of Mandible using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DP032ZZ	Beam Radiation of Mandible using Photons >10 MeV	Procedure	ICD-10-PCS
DP033Z0	Beam Radiation of Mandible using Electrons, Intraoperative	Procedure	ICD-10-PCS
DP033ZZ	Beam Radiation of Mandible using Electrons	Procedure	ICD-10-PCS
DP034ZZ	Beam Radiation of Mandible using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DP035ZZ	Beam Radiation of Mandible using Neutrons	Procedure	ICD-10-PCS
DP036ZZ	Beam Radiation of Mandible using Neutron Capture	Procedure	ICD-10-PCS
DP04	Beam Radiation / Sternum	Procedure	ICD-10-PCS
DP040ZZ	Beam Radiation of Sternum using Photons <1 MeV	Procedure	ICD-10-PCS
DP041ZZ	Beam Radiation of Sternum using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DP042ZZ	Beam Radiation of Sternum using Photons >10 MeV	Procedure	ICD-10-PCS
DP043Z0	Beam Radiation of Sternum using Electrons, Intraoperative	Procedure	ICD-10-PCS
DP043ZZ	Beam Radiation of Sternum using Electrons	Procedure	ICD-10-PCS
DP044ZZ	Beam Radiation of Sternum using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DP045ZZ	Beam Radiation of Sternum using Neutrons	Procedure	ICD-10-PCS
DP046ZZ	Beam Radiation of Sternum using Neutron Capture	Procedure	ICD-10-PCS
DP05	Beam Radiation / Rib(s)	Procedure	ICD-10-PCS
DP050ZZ	Beam Radiation of Rib(s) using Photons <1 MeV	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
DP051ZZ	Beam Radiation of Rib(s) using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DP052ZZ	Beam Radiation of Rib(s) using Photons >10 MeV	Procedure	ICD-10-PCS
DP053Z0	Beam Radiation of Rib(s) using Electrons, Intraoperative	Procedure	ICD-10-PCS
DP053ZZ	Beam Radiation of Rib(s) using Electrons	Procedure	ICD-10-PCS
DP054ZZ	Beam Radiation of Rib(s) using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DP055ZZ	Beam Radiation of Rib(s) using Neutrons	Procedure	ICD-10-PCS
DP056ZZ	Beam Radiation of Rib(s) using Neutron Capture	Procedure	ICD-10-PCS
DP06	Beam Radiation / Humerus	Procedure	ICD-10-PCS
DP060ZZ	Beam Radiation of Humerus using Photons <1 MeV	Procedure	ICD-10-PCS
DP061ZZ	Beam Radiation of Humerus using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DP062ZZ	Beam Radiation of Humerus using Photons >10 MeV	Procedure	ICD-10-PCS
DP063Z0	Beam Radiation of Humerus using Electrons, Intraoperative	Procedure	ICD-10-PCS
DP063ZZ	Beam Radiation of Humerus using Electrons	Procedure	ICD-10-PCS
DP064ZZ	Beam Radiation of Humerus using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DP065ZZ	Beam Radiation of Humerus using Neutrons	Procedure	ICD-10-PCS
DP066ZZ	Beam Radiation of Humerus using Neutron Capture	Procedure	ICD-10-PCS
DP07	Beam Radiation / Radius/Ulna	Procedure	ICD-10-PCS
DP070ZZ	Beam Radiation of Radius/Ulna using Photons <1 MeV	Procedure	ICD-10-PCS
DP071ZZ	Beam Radiation of Radius/Ulna using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DP072ZZ	Beam Radiation of Radius/Ulna using Photons >10 MeV	Procedure	ICD-10-PCS
DP073Z0	Beam Radiation of Radius/Ulna using Electrons, Intraoperative	Procedure	ICD-10-PCS
DP073ZZ	Beam Radiation of Radius/Ulna using Electrons	Procedure	ICD-10-PCS
DP074ZZ	Beam Radiation of Radius/Ulna using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DP075ZZ	Beam Radiation of Radius/Ulna using Neutrons	Procedure	ICD-10-PCS
DP076ZZ	Beam Radiation of Radius/Ulna using Neutron Capture	Procedure	ICD-10-PCS
DP08	Beam Radiation / Pelvic Bones	Procedure	ICD-10-PCS
DP080ZZ	Beam Radiation of Pelvic Bones using Photons <1 MeV	Procedure	ICD-10-PCS
DP081ZZ	Beam Radiation of Pelvic Bones using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DP082ZZ	Beam Radiation of Pelvic Bones using Photons >10 MeV	Procedure	ICD-10-PCS
DP083Z0	Beam Radiation of Pelvic Bones using Electrons, Intraoperative	Procedure	ICD-10-PCS
DP083ZZ	Beam Radiation of Pelvic Bones using Electrons	Procedure	ICD-10-PCS
DP084ZZ	Beam Radiation of Pelvic Bones using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DP085ZZ	Beam Radiation of Pelvic Bones using Neutrons	Procedure	ICD-10-PCS
DP086ZZ	Beam Radiation of Pelvic Bones using Neutron Capture	Procedure	ICD-10-PCS
DP09	Beam Radiation / Femur	Procedure	ICD-10-PCS
DP090ZZ	Beam Radiation of Femur using Photons <1 MeV	Procedure	ICD-10-PCS
DP091ZZ	Beam Radiation of Femur using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DP092ZZ	Beam Radiation of Femur using Photons >10 MeV	Procedure	ICD-10-PCS
DP093Z0	Beam Radiation of Femur using Electrons, Intraoperative	Procedure	ICD-10-PCS
DP093ZZ	Beam Radiation of Femur using Electrons	Procedure	ICD-10-PCS
DP094ZZ	Beam Radiation of Femur using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DP095ZZ	Beam Radiation of Femur using Neutrons	Procedure	ICD-10-PCS
DP096ZZ	Beam Radiation of Femur using Neutron Capture	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
DP0B	Beam Radiation / Tibia/Fibula	Procedure	ICD-10-PCS
DP0B0ZZ	Beam Radiation of Tibia/Fibula using Photons <1 MeV	Procedure	ICD-10-PCS
DP0B1ZZ	Beam Radiation of Tibia/Fibula using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DP0B2ZZ	Beam Radiation of Tibia/Fibula using Photons >10 MeV	Procedure	ICD-10-PCS
DP0B3Z0	Beam Radiation of Tibia/Fibula using Electrons, Intraoperative	Procedure	ICD-10-PCS
DP0B3ZZ	Beam Radiation of Tibia/Fibula using Electrons	Procedure	ICD-10-PCS
DP0B4ZZ	Beam Radiation of Tibia/Fibula using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DP0B5ZZ	Beam Radiation of Tibia/Fibula using Neutrons	Procedure	ICD-10-PCS
DP0B6ZZ	Beam Radiation of Tibia/Fibula using Neutron Capture	Procedure	ICD-10-PCS
DP0C	Beam Radiation / Other Bone	Procedure	ICD-10-PCS
DP0C0ZZ	Beam Radiation of Other Bone using Photons <1 MeV	Procedure	ICD-10-PCS
DP0C1ZZ	Beam Radiation of Other Bone using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DP0C2ZZ	Beam Radiation of Other Bone using Photons >10 MeV	Procedure	ICD-10-PCS
DP0C3Z0	Beam Radiation of Other Bone using Electrons, Intraoperative	Procedure	ICD-10-PCS
DP0C3ZZ	Beam Radiation of Other Bone using Electrons	Procedure	ICD-10-PCS
DP0C4ZZ	Beam Radiation of Other Bone using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DP0C5ZZ	Beam Radiation of Other Bone using Neutrons	Procedure	ICD-10-PCS
DP0C6ZZ	Beam Radiation of Other Bone using Neutron Capture	Procedure	ICD-10-PCS
DPY	Radiation Therapy, Musculoskeletal System, Other Radiation	Procedure	ICD-10-PCS
DPY0	Other Radiation / Skull	Procedure	ICD-10-PCS
DPY07ZZ	Contact Radiation of Skull	Procedure	ICD-10-PCS
DPY0FZZ	Plaque Radiation of Skull	Procedure	ICD-10-PCS
DPY2	Other Radiation / Maxilla	Procedure	ICD-10-PCS
DPY27ZZ	Contact Radiation of Maxilla	Procedure	ICD-10-PCS
DPY2FZZ	Plaque Radiation of Maxilla	Procedure	ICD-10-PCS
DPY3	Other Radiation / Mandible	Procedure	ICD-10-PCS
DPY37ZZ	Contact Radiation of Mandible	Procedure	ICD-10-PCS
DPY3FZZ	Plaque Radiation of Mandible	Procedure	ICD-10-PCS
DPY4	Other Radiation / Sternum	Procedure	ICD-10-PCS
DPY47ZZ	Contact Radiation of Sternum	Procedure	ICD-10-PCS
DPY4FZZ	Plaque Radiation of Sternum	Procedure	ICD-10-PCS
DPY5	Other Radiation / Rib(s)	Procedure	ICD-10-PCS
DPY57ZZ	Contact Radiation of Rib(s)	Procedure	ICD-10-PCS
DPY5FZZ	Plaque Radiation of Rib(s)	Procedure	ICD-10-PCS
DPY6	Other Radiation / Humerus	Procedure	ICD-10-PCS
DPY67ZZ	Contact Radiation of Humerus	Procedure	ICD-10-PCS
DPY6FZZ	Plaque Radiation of Humerus	Procedure	ICD-10-PCS
DPY7	Other Radiation / Radius/Ulna	Procedure	ICD-10-PCS
DPY77ZZ	Contact Radiation of Radius/Ulna	Procedure	ICD-10-PCS
DPY7FZZ	Plaque Radiation of Radius/Ulna	Procedure	ICD-10-PCS
DPY8	Other Radiation / Pelvic Bones	Procedure	ICD-10-PCS
DPY87ZZ	Contact Radiation of Pelvic Bones	Procedure	ICD-10-PCS
DPY8FZZ	Plaque Radiation of Pelvic Bones	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
DPY9	Other Radiation / Femur	Procedure	ICD-10-PCS
DPY97ZZ	Contact Radiation of Femur	Procedure	ICD-10-PCS
DPY9FZZ	Plaque Radiation of Femur	Procedure	ICD-10-PCS
DPYB	Other Radiation / Tibia/Fibula	Procedure	ICD-10-PCS
DPYB7ZZ	Contact Radiation of Tibia/Fibula	Procedure	ICD-10-PCS
DPYBFZZ	Plaque Radiation of Tibia/Fibula	Procedure	ICD-10-PCS
DPYC	Other Radiation / Other Bone	Procedure	ICD-10-PCS
DPYC7ZZ	Contact Radiation of Other Bone	Procedure	ICD-10-PCS
DPYCFZZ	Plaque Radiation of Other Bone	Procedure	ICD-10-PCS
DT0	Radiation Therapy, Urinary System, Beam Radiation	Procedure	ICD-10-PCS
DT00	Beam Radiation / Kidney	Procedure	ICD-10-PCS
DT000ZZ	Beam Radiation of Kidney using Photons <1 MeV	Procedure	ICD-10-PCS
DT001ZZ	Beam Radiation of Kidney using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DT002ZZ	Beam Radiation of Kidney using Photons >10 MeV	Procedure	ICD-10-PCS
DT003Z0	Beam Radiation of Kidney using Electrons, Intraoperative	Procedure	ICD-10-PCS
DT003ZZ	Beam Radiation of Kidney using Electrons	Procedure	ICD-10-PCS
DT004ZZ	Beam Radiation of Kidney using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DT005ZZ	Beam Radiation of Kidney using Neutrons	Procedure	ICD-10-PCS
DT006ZZ	Beam Radiation of Kidney using Neutron Capture	Procedure	ICD-10-PCS
DT01	Beam Radiation / Ureter	Procedure	ICD-10-PCS
DT010ZZ	Beam Radiation of Ureter using Photons <1 MeV	Procedure	ICD-10-PCS
DT011ZZ	Beam Radiation of Ureter using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DT012ZZ	Beam Radiation of Ureter using Photons >10 MeV	Procedure	ICD-10-PCS
DT013Z0	Beam Radiation of Ureter using Electrons, Intraoperative	Procedure	ICD-10-PCS
DT013ZZ	Beam Radiation of Ureter using Electrons	Procedure	ICD-10-PCS
DT014ZZ	Beam Radiation of Ureter using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DT015ZZ	Beam Radiation of Ureter using Neutrons	Procedure	ICD-10-PCS
DT016ZZ	Beam Radiation of Ureter using Neutron Capture	Procedure	ICD-10-PCS
DT02	Beam Radiation / Bladder	Procedure	ICD-10-PCS
DT020ZZ	Beam Radiation of Bladder using Photons <1 MeV	Procedure	ICD-10-PCS
DT021ZZ	Beam Radiation of Bladder using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DT022ZZ	Beam Radiation of Bladder using Photons >10 MeV	Procedure	ICD-10-PCS
DT023Z0	Beam Radiation of Bladder using Electrons, Intraoperative	Procedure	ICD-10-PCS
DT023ZZ	Beam Radiation of Bladder using Electrons	Procedure	ICD-10-PCS
DT024ZZ	Beam Radiation of Bladder using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DT025ZZ	Beam Radiation of Bladder using Neutrons	Procedure	ICD-10-PCS
DT026ZZ	Beam Radiation of Bladder using Neutron Capture	Procedure	ICD-10-PCS
DT03	Beam Radiation / Urethra	Procedure	ICD-10-PCS
DT030ZZ	Beam Radiation of Urethra using Photons <1 MeV	Procedure	ICD-10-PCS
DT031ZZ	Beam Radiation of Urethra using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DT032ZZ	Beam Radiation of Urethra using Photons >10 MeV	Procedure	ICD-10-PCS
DT033Z0	Beam Radiation of Urethra using Electrons, Intraoperative	Procedure	ICD-10-PCS
DT033ZZ	Beam Radiation of Urethra using Electrons	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
DT034ZZ	Beam Radiation of Urethra using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DT035ZZ	Beam Radiation of Urethra using Neutrons	Procedure	ICD-10-PCS
DT036ZZ	Beam Radiation of Urethra using Neutron Capture	Procedure	ICD-10-PCS
DT1	Radiation Therapy, Urinary System, Brachytherapy	Procedure	ICD-10-PCS
DT2	Radiation Therapy, Urinary System, Stereotactic Radiosurgery	Procedure	ICD-10-PCS
DTY	Radiation Therapy, Urinary System, Other Radiation	Procedure	ICD-10-PCS
DTY0	Other Radiation / Kidney	Procedure	ICD-10-PCS
DTY07ZZ	Contact Radiation of Kidney	Procedure	ICD-10-PCS
DTY0CZZ	Intraoperative Radiation Therapy (IORT) of Kidney	Procedure	ICD-10-PCS
DTY0FZZ	Plaque Radiation of Kidney	Procedure	ICD-10-PCS
DTY1	Other Radiation / Ureter	Procedure	ICD-10-PCS
DTY17ZZ	Contact Radiation of Ureter	Procedure	ICD-10-PCS
DTY1CZZ	Intraoperative Radiation Therapy (IORT) of Ureter	Procedure	ICD-10-PCS
DTY1FZZ	Plaque Radiation of Ureter	Procedure	ICD-10-PCS
DTY2	Other Radiation / Bladder	Procedure	ICD-10-PCS
DTY27ZZ	Contact Radiation of Bladder	Procedure	ICD-10-PCS
DTY2CZZ	Intraoperative Radiation Therapy (IORT) of Bladder	Procedure	ICD-10-PCS
DTY2FZZ	Plaque Radiation of Bladder	Procedure	ICD-10-PCS
DTY3	Other Radiation / Urethra	Procedure	ICD-10-PCS
DTY37ZZ	Contact Radiation of Urethra	Procedure	ICD-10-PCS
DTY3CZZ	Intraoperative Radiation Therapy (IORT) of Urethra	Procedure	ICD-10-PCS
DTY3FZZ	Plaque Radiation of Urethra	Procedure	ICD-10-PCS
DU0	Radiation Therapy, Female Reproductive System, Beam Radiation	Procedure	ICD-10-PCS
DU00	Beam Radiation / Ovary	Procedure	ICD-10-PCS
DU000ZZ	Beam Radiation of Ovary using Photons <1 MeV	Procedure	ICD-10-PCS
DU001ZZ	Beam Radiation of Ovary using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DU002ZZ	Beam Radiation of Ovary using Photons >10 MeV	Procedure	ICD-10-PCS
DU003Z0	Beam Radiation of Ovary using Electrons, Intraoperative	Procedure	ICD-10-PCS
DU003ZZ	Beam Radiation of Ovary using Electrons	Procedure	ICD-10-PCS
DU004ZZ	Beam Radiation of Ovary using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DU005ZZ	Beam Radiation of Ovary using Neutrons	Procedure	ICD-10-PCS
DU006ZZ	Beam Radiation of Ovary using Neutron Capture	Procedure	ICD-10-PCS
DU01	Beam Radiation / Cervix	Procedure	ICD-10-PCS
DU010ZZ	Beam Radiation of Cervix using Photons <1 MeV	Procedure	ICD-10-PCS
DU011ZZ	Beam Radiation of Cervix using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DU012ZZ	Beam Radiation of Cervix using Photons >10 MeV	Procedure	ICD-10-PCS
DU013Z0	Beam Radiation of Cervix using Electrons, Intraoperative	Procedure	ICD-10-PCS
DU013ZZ	Beam Radiation of Cervix using Electrons	Procedure	ICD-10-PCS
DU014ZZ	Beam Radiation of Cervix using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DU015ZZ	Beam Radiation of Cervix using Neutrons	Procedure	ICD-10-PCS
DU016ZZ	Beam Radiation of Cervix using Neutron Capture	Procedure	ICD-10-PCS
DU02	Beam Radiation / Uterus	Procedure	ICD-10-PCS
DU020ZZ	Beam Radiation of Uterus using Photons <1 MeV	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
DU021ZZ	Beam Radiation of Uterus using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DU022ZZ	Beam Radiation of Uterus using Photons >10 MeV	Procedure	ICD-10-PCS
DU023Z0	Beam Radiation of Uterus using Electrons, Intraoperative	Procedure	ICD-10-PCS
DU023ZZ	Beam Radiation of Uterus using Electrons	Procedure	ICD-10-PCS
DU024ZZ	Beam Radiation of Uterus using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DU025ZZ	Beam Radiation of Uterus using Neutrons	Procedure	ICD-10-PCS
DU026ZZ	Beam Radiation of Uterus using Neutron Capture	Procedure	ICD-10-PCS
DU1	Radiation Therapy, Female Reproductive System, Brachytherapy	Procedure	ICD-10-PCS
DU2	Radiation Therapy, Female Reproductive System, Stereotactic Radiosurgery	Procedure	ICD-10-PCS
DUY	Radiation Therapy, Female Reproductive System, Other Radiation	Procedure	ICD-10-PCS
DUY0	Other Radiation / Ovary	Procedure	ICD-10-PCS
DUY07ZZ	Contact Radiation of Ovary	Procedure	ICD-10-PCS
DUY0CZZ	Intraoperative Radiation Therapy (IORT) of Ovary	Procedure	ICD-10-PCS
DUY0FZZ	Plaque Radiation of Ovary	Procedure	ICD-10-PCS
DUY1	Other Radiation / Cervix	Procedure	ICD-10-PCS
DUY17ZZ	Contact Radiation of Cervix	Procedure	ICD-10-PCS
DUY1CZZ	Intraoperative Radiation Therapy (IORT) of Cervix	Procedure	ICD-10-PCS
DUY1FZZ	Plaque Radiation of Cervix	Procedure	ICD-10-PCS
DUY2	Other Radiation / Uterus	Procedure	ICD-10-PCS
DUY27ZZ	Contact Radiation of Uterus	Procedure	ICD-10-PCS
DUY2CZZ	Intraoperative Radiation Therapy (IORT) of Uterus	Procedure	ICD-10-PCS
DUY2FZZ	Plaque Radiation of Uterus	Procedure	ICD-10-PCS
DV0	Radiation Therapy, Male Reproductive System, Beam Radiation	Procedure	ICD-10-PCS
DV00	Beam Radiation / Prostate	Procedure	ICD-10-PCS
DV000ZZ	Beam Radiation of Prostate using Photons <1 MeV	Procedure	ICD-10-PCS
DV001ZZ	Beam Radiation of Prostate using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DV002ZZ	Beam Radiation of Prostate using Photons >10 MeV	Procedure	ICD-10-PCS
DV003Z0	Beam Radiation of Prostate using Electrons, Intraoperative	Procedure	ICD-10-PCS
DV003ZZ	Beam Radiation of Prostate using Electrons	Procedure	ICD-10-PCS
DV004ZZ	Beam Radiation of Prostate using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DV005ZZ	Beam Radiation of Prostate using Neutrons	Procedure	ICD-10-PCS
DV006ZZ	Beam Radiation of Prostate using Neutron Capture	Procedure	ICD-10-PCS
DV01	Beam Radiation / Testis	Procedure	ICD-10-PCS
DV010ZZ	Beam Radiation of Testis using Photons <1 MeV	Procedure	ICD-10-PCS
DV011ZZ	Beam Radiation of Testis using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DV012ZZ	Beam Radiation of Testis using Photons >10 MeV	Procedure	ICD-10-PCS
DV013Z0	Beam Radiation of Testis using Electrons, Intraoperative	Procedure	ICD-10-PCS
DV013ZZ	Beam Radiation of Testis using Electrons	Procedure	ICD-10-PCS
DV014ZZ	Beam Radiation of Testis using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DV015ZZ	Beam Radiation of Testis using Neutrons	Procedure	ICD-10-PCS
DV016ZZ	Beam Radiation of Testis using Neutron Capture	Procedure	ICD-10-PCS
DV1	Radiation Therapy, Male Reproductive System, Brachytherapy	Procedure	ICD-10-PCS
DV2	Radiation Therapy, Male Reproductive System, Stereotactic Radiosurgery	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
DVY	Radiation Therapy, Male Reproductive System, Other Radiation	Procedure	ICD-10-PCS
DVY0	Other Radiation / Prostate	Procedure	ICD-10-PCS
DVY07ZZ	Contact Radiation of Prostate	Procedure	ICD-10-PCS
DVY0CZZ	Intraoperative Radiation Therapy (IORT) of Prostate	Procedure	ICD-10-PCS
DVY0FZZ	Plaque Radiation of Prostate	Procedure	ICD-10-PCS
DVY1	Other Radiation / Testis	Procedure	ICD-10-PCS
DVY17ZZ	Contact Radiation of Testis	Procedure	ICD-10-PCS
DVY1FZZ	Plaque Radiation of Testis	Procedure	ICD-10-PCS
DW0	Radiation Therapy, Anatomical Regions, Beam Radiation	Procedure	ICD-10-PCS
DW01	Beam Radiation / Head and Neck	Procedure	ICD-10-PCS
DW010ZZ	Beam Radiation of Head and Neck using Photons <1 MeV	Procedure	ICD-10-PCS
DW011ZZ	Beam Radiation of Head and Neck using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DW012ZZ	Beam Radiation of Head and Neck using Photons >10 MeV	Procedure	ICD-10-PCS
DW013Z0	Beam Radiation of Head and Neck using Electrons, Intraoperative	Procedure	ICD-10-PCS
DW013ZZ	Beam Radiation of Head and Neck using Electrons	Procedure	ICD-10-PCS
DW014ZZ	Beam Radiation of Head and Neck using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DW015ZZ	Beam Radiation of Head and Neck using Neutrons	Procedure	ICD-10-PCS
DW016ZZ	Beam Radiation of Head and Neck using Neutron Capture	Procedure	ICD-10-PCS
DW02	Beam Radiation / Chest	Procedure	ICD-10-PCS
DW020ZZ	Beam Radiation of Chest using Photons <1 MeV	Procedure	ICD-10-PCS
DW021ZZ	Beam Radiation of Chest using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DW022ZZ	Beam Radiation of Chest using Photons >10 MeV	Procedure	ICD-10-PCS
DW023Z0	Beam Radiation of Chest using Electrons, Intraoperative	Procedure	ICD-10-PCS
DW023ZZ	Beam Radiation of Chest using Electrons	Procedure	ICD-10-PCS
DW024ZZ	Beam Radiation of Chest using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DW025ZZ	Beam Radiation of Chest using Neutrons	Procedure	ICD-10-PCS
DW026ZZ	Beam Radiation of Chest using Neutron Capture	Procedure	ICD-10-PCS
DW03	Beam Radiation / Abdomen	Procedure	ICD-10-PCS
DW030ZZ	Beam Radiation of Abdomen using Photons <1 MeV	Procedure	ICD-10-PCS
DW031ZZ	Beam Radiation of Abdomen using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DW032ZZ	Beam Radiation of Abdomen using Photons >10 MeV	Procedure	ICD-10-PCS
DW033Z0	Beam Radiation of Abdomen using Electrons, Intraoperative	Procedure	ICD-10-PCS
DW033ZZ	Beam Radiation of Abdomen using Electrons	Procedure	ICD-10-PCS
DW034ZZ	Beam Radiation of Abdomen using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DW035ZZ	Beam Radiation of Abdomen using Neutrons	Procedure	ICD-10-PCS
DW036ZZ	Beam Radiation of Abdomen using Neutron Capture	Procedure	ICD-10-PCS
DW04	Beam Radiation / Hemibody	Procedure	ICD-10-PCS
DW040ZZ	Beam Radiation of Hemibody using Photons <1 MeV	Procedure	ICD-10-PCS
DW041ZZ	Beam Radiation of Hemibody using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DW042ZZ	Beam Radiation of Hemibody using Photons >10 MeV	Procedure	ICD-10-PCS
DW043Z0	Beam Radiation of Hemibody using Electrons, Intraoperative	Procedure	ICD-10-PCS
DW043ZZ	Beam Radiation of Hemibody using Electrons	Procedure	ICD-10-PCS
DW044ZZ	Beam Radiation of Hemibody using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
DW045ZZ	Beam Radiation of Hemibody using Neutrons	Procedure	ICD-10-PCS
DW046ZZ	Beam Radiation of Hemibody using Neutron Capture	Procedure	ICD-10-PCS
DW05	Beam Radiation / Whole Body	Procedure	ICD-10-PCS
DW050ZZ	Beam Radiation of Whole Body using Photons <1 MeV	Procedure	ICD-10-PCS
DW051ZZ	Beam Radiation of Whole Body using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DW052ZZ	Beam Radiation of Whole Body using Photons >10 MeV	Procedure	ICD-10-PCS
DW053Z0	Beam Radiation of Whole Body using Electrons, Intraoperative	Procedure	ICD-10-PCS
DW053ZZ	Beam Radiation of Whole Body using Electrons	Procedure	ICD-10-PCS
DW054ZZ	Beam Radiation of Whole Body using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DW055ZZ	Beam Radiation of Whole Body using Neutrons	Procedure	ICD-10-PCS
DW056ZZ	Beam Radiation of Whole Body using Neutron Capture	Procedure	ICD-10-PCS
DW06	Beam Radiation / Pelvic Region	Procedure	ICD-10-PCS
DW060ZZ	Beam Radiation of Pelvic Region using Photons <1 MeV	Procedure	ICD-10-PCS
DW061ZZ	Beam Radiation of Pelvic Region using Photons 1 - 10 MeV	Procedure	ICD-10-PCS
DW062ZZ	Beam Radiation of Pelvic Region using Photons >10 MeV	Procedure	ICD-10-PCS
DW063Z0	Beam Radiation of Pelvic Region using Electrons, Intraoperative	Procedure	ICD-10-PCS
DW063ZZ	Beam Radiation of Pelvic Region using Electrons	Procedure	ICD-10-PCS
DW064ZZ	Beam Radiation of Pelvic Region using Heavy Particles (Protons,Ions)	Procedure	ICD-10-PCS
DW065ZZ	Beam Radiation of Pelvic Region using Neutrons	Procedure	ICD-10-PCS
DW066ZZ	Beam Radiation of Pelvic Region using Neutron Capture	Procedure	ICD-10-PCS
DW1	Radiation Therapy, Anatomical Regions, Brachytherapy	Procedure	ICD-10-PCS
DW2	Radiation Therapy, Anatomical Regions, Stereotactic Radiosurgery	Procedure	ICD-10-PCS
DWY	Radiation Therapy, Anatomical Regions, Other Radiation	Procedure	ICD-10-PCS
DWY1	Other Radiation / Head and Neck	Procedure	ICD-10-PCS
DWY17ZZ	Contact Radiation of Head and Neck	Procedure	ICD-10-PCS
DWY1FZZ	Plaque Radiation of Head and Neck	Procedure	ICD-10-PCS
DWY2	Other Radiation / Chest	Procedure	ICD-10-PCS
DWY27ZZ	Contact Radiation of Chest	Procedure	ICD-10-PCS
DWY2FZZ	Plaque Radiation of Chest	Procedure	ICD-10-PCS
DWY3	Other Radiation / Abdomen	Procedure	ICD-10-PCS
DWY37ZZ	Contact Radiation of Abdomen	Procedure	ICD-10-PCS
DWY3FZZ	Plaque Radiation of Abdomen	Procedure	ICD-10-PCS
DWY4	Other Radiation / Hemibody	Procedure	ICD-10-PCS
DWY47ZZ	Contact Radiation of Hemibody	Procedure	ICD-10-PCS
DWY4FZZ	Plaque Radiation of Hemibody	Procedure	ICD-10-PCS
DWY5	Other Radiation / Whole Body	Procedure	ICD-10-PCS
DWY57ZZ	Contact Radiation of Whole Body	Procedure	ICD-10-PCS
DWY5FZZ	Plaque Radiation of Whole Body	Procedure	ICD-10-PCS
DWY6	Other Radiation / Pelvic Region	Procedure	ICD-10-PCS
DWY67ZZ	Contact Radiation of Pelvic Region	Procedure	ICD-10-PCS
DWY6FZZ	Plaque Radiation of Pelvic Region	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
G0174	Intensity modulated radiation therapy (imrt) delivery to one or more treatment areas, multiple couch angles/fields/arc, custom collimated pencil-beams with treatment setup and verification images, complete course of therapy requiring more than one session, per session	Procedure	HCPCS
G0178	Intensity modulated radiation therapy (imrt) plan, including dose volume histograms for target and critical structure partial tolerances, inverse plan optimization performed for highly conformal distributions, plan positional accuracy and dose verification, per course of treatment	Procedure	HCPCS
G0256	Prostate brachytherapy using permanently implanted palladium seeds, including transperitoneal placement of needles or catheters into the prostate, cystoscopy and application of permanent interstitial radiation source	Procedure	HCPCS
G0261	Prostate brachytherapy using permanently implanted iodine seeds, including transperineal placement of needles or catheters into the prostate, cystoscopy and application of permanent interstitial radiation source	Procedure	HCPCS
G6003	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: up to 5 mev	Procedure	HCPCS
G6004	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: 6-10 mev	Procedure	HCPCS
G6005	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: 11-19 mev	Procedure	HCPCS
G6006	Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: 20 mev or greater	Procedure	HCPCS
G6007	Radiation treatment delivery, two separate treatment areas, three or more ports on a single treatment area, use of multiple blocks: up to 5 mev	Procedure	HCPCS
G6008	Radiation treatment delivery, two separate treatment areas, three or more ports on a single treatment area, use of multiple blocks: 6-10 mev	Procedure	HCPCS
G6009	Radiation treatment delivery, two separate treatment areas, three or more ports on a single treatment area, use of multiple blocks: 11-19 mev	Procedure	HCPCS
G6010	Radiation treatment delivery, two separate treatment areas, three or more ports on a single treatment area, use of multiple blocks: 20 mev or greater	Procedure	HCPCS
G6011	Radiation treatment delivery, three or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; up to 5 mev	Procedure	HCPCS
G6012	Radiation treatment delivery, three or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev	Procedure	HCPCS
G6013	Radiation treatment delivery, three or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev	Procedure	HCPCS
G6014	Radiation treatment delivery, three or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 20 mev or greater	Procedure	HCPCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
G6015	Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session	Procedure	HCPCS
G6016	Compensator-based beam modulation treatment delivery of inverse planned treatment using three or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session	Procedure	HCPCS
G6017	Intra-fraction localization and tracking of target or patient motion during delivery of radiation therapy (e.g., 3D positional tracking, gating, 3D surface tracking), each fraction of treatment	Procedure	HCPCS
M1072	Radiation therapy for anal cancer under the Radiation Oncology model, 90-day episode, professional component	Procedure	HCPCS
M1073	Radiation therapy for anal cancer under the Radiation Oncology model, 90-day episode, technical component	Procedure	HCPCS
M1074	Radiation therapy for bladder cancer under the Radiation Oncology model, 90-day episode, professional component	Procedure	HCPCS
M1075	Radiation therapy for bladder cancer under the Radiation Oncology model, 90-day episode, technical component	Procedure	HCPCS
M1076	Radiation therapy for bone metastases under the Radiation Oncology model, 90-day episode, professional component	Procedure	HCPCS
M1077	Radiation therapy for bone metastases under the Radiation Oncology model, 90-day episode, technical component	Procedure	HCPCS
M1078	Radiation therapy for brain metastases under the Radiation Oncology model, 90-day episode, professional component	Procedure	HCPCS
M1079	Radiation therapy for brain metastases under the Radiation Oncology model, 90-day episode, technical component	Procedure	HCPCS
M1080	Radiation therapy for breast cancer under the Radiation Oncology model, 90-day episode, professional component	Procedure	HCPCS
M1081	Radiation therapy for breast cancer under the Radiation Oncology model, 90-day episode, technical component	Procedure	HCPCS
M1082	Radiation therapy for cervical cancer under the Radiation Oncology model, 90-day episode, professional component	Procedure	HCPCS
M1083	Radiation therapy for cervical cancer under the Radiation Oncology model, 90-day episode, technical component	Procedure	HCPCS
M1084	Radiation therapy for CNS tumors under the Radiation Oncology model, 90-day episode, professional component	Procedure	HCPCS
M1085	Radiation therapy for CNS tumors under the Radiation Oncology model, 90-day episode, technical component	Procedure	HCPCS
M1086	Radiation therapy for colorectal cancer under the Radiation Oncology model, 90-day episode, professional component	Procedure	HCPCS
M1087	Radiation therapy for colorectal cancer under the Radiation Oncology model, 90-day episode, technical component	Procedure	HCPCS
M1088	Radiation therapy for head and neck cancer under the Radiation Oncology model, 90-day episode, professional component	Procedure	HCPCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
M1089	Radiation therapy for head and neck cancer under the Radiation Oncology model, 90-day episode, technical component	Procedure	HCPCS
M1094	Radiation therapy for lung cancer under the Radiation Oncology model, 90-day episode, professional component	Procedure	HCPCS
M1095	Radiation therapy for lung cancer under the Radiation Oncology model, 90-day episode, technical component	Procedure	HCPCS
M1096	Radiation therapy for lymphoma under the Radiation Oncology model, 90-day episode, professional component	Procedure	HCPCS
M1097	Radiation therapy for lymphoma under the Radiation Oncology model, 90-day episode, technical component	Procedure	HCPCS
M1098	Radiation therapy for pancreatic cancer under the Radiation Oncology model, 90-day episode, professional component	Procedure	HCPCS
M1099	Radiation therapy for pancreatic cancer under the Radiation Oncology model, 90-day episode, technical component	Procedure	HCPCS
M1100	Radiation therapy for prostate cancer under the Radiation Oncology model, 90-day episode, professional component	Procedure	HCPCS
M1101	Radiation therapy for prostate cancer under the Radiation Oncology model, 90-day episode, technical component	Procedure	HCPCS
M1102	Radiation therapy for upper GI cancer under the Radiation Oncology model, 90-day episode, professional component	Procedure	HCPCS
M1103	Radiation therapy for upper GI cancer under the Radiation Oncology model, 90-day episode, technical component	Procedure	HCPCS
M1104	Radiation therapy for uterine cancer under the Radiation Oncology model, 90-day episode, professional component	Procedure	HCPCS
M1105	Radiation therapy for uterine cancer under the Radiation Oncology model, 90-day episode, technical component	Procedure	HCPCS
S2270	Insertion of vaginal cylinder for application of radiation source or clinical brachytherapy (report separately in addition to radiation source delivery)	Procedure	HCPCS
S8030	Scleral application of tantalum ring(s) for localization of lesions for proton beam therapy	Procedure	HCPCS
S8049	Intraoperative radiation therapy (single administration)	Procedure	HCPCS
V58.0	Radiotherapy	Diagnosis	ICD-9-CM
Z51.0	Encounter for antineoplastic radiation therapy	Diagnosis	ICD-10-CM
	Chemotherapy		
00.10	Implantation of chemotherapeutic agent	Procedure	ICD-9-CM
00.15	High-dose infusion interleukin-2 [IL-2]	Procedure	ICD-9-CM
17.70	Intravenous infusion of clofarabine	Procedure	ICD-9-CM
284.11	Antineoplastic chemotherapy induced pancytopenia	Diagnosis	ICD-9-CM
285.3	Antineoplastic chemotherapy induced anemia	Diagnosis	ICD-9-CM
3E00X05	Introduction of Other Antineoplastic into Skin and Mucous Membranes, External Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
3E01305	Introduction of Other Antineoplastic into Subcutaneous Tissue, Percutaneous Approach	Procedure	ICD-10-PCS
3E02305	Introduction of Other Antineoplastic into Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
3E03002	Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
3E03003	Introduction of Low-dose Interleukin-2 into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
3E03005	Introduction of Other Antineoplastic into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
3E0300P	Introduction of Clofarabine into Peripheral Vein, Open Approach	Procedure	ICD-10-PCS
3E03302	Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E03303	Introduction of Low-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E03305	Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E0330P	Introduction of Clofarabine into Peripheral Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E04002	Introduction of High-dose Interleukin-2 into Central Vein, Open Approach	Procedure	ICD-10-PCS
3E04003	Introduction of Low-dose Interleukin-2 into Central Vein, Open Approach	Procedure	ICD-10-PCS
3E04005	Introduction of Other Antineoplastic into Central Vein, Open Approach	Procedure	ICD-10-PCS
3E0400P	Introduction of Clofarabine into Central Vein, Open Approach	Procedure	ICD-10-PCS
3E04302	Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E04303	Introduction of Low-dose Interleukin-2 into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E04305	Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E0430P	Introduction of Clofarabine into Central Vein, Percutaneous Approach	Procedure	ICD-10-PCS
3E05002	Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
3E05003	Introduction of Low-dose Interleukin-2 into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
3E05005	Introduction of Other Antineoplastic into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
3E0500P	Introduction of Clofarabine into Peripheral Artery, Open Approach	Procedure	ICD-10-PCS
3E05302	Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E05303	Introduction of Low-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E05305	Introduction of Other Antineoplastic into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E0530P	Introduction of Clofarabine into Peripheral Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E06002	Introduction of High-dose Interleukin-2 into Central Artery, Open Approach	Procedure	ICD-10-PCS
3E06003	Introduction of Low-dose Interleukin-2 into Central Artery, Open Approach	Procedure	ICD-10-PCS
3E06005	Introduction of Other Antineoplastic into Central Artery, Open Approach	Procedure	ICD-10-PCS
3E0600P	Introduction of Clofarabine into Central Artery, Open Approach	Procedure	ICD-10-PCS
3E06302	Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E06303	Introduction of Low-dose Interleukin-2 into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E06305	Introduction of Other Antineoplastic into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E0630P	Introduction of Clofarabine into Central Artery, Percutaneous Approach	Procedure	ICD-10-PCS
3E09305	Introduction of Other Antineoplastic into Nose, Percutaneous Approach	Procedure	ICD-10-PCS
3E09705	Introduction of Other Antineoplastic into Nose, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E09X05	Introduction of Other Antineoplastic into Nose, External Approach	Procedure	ICD-10-PCS
3E0A305	Introduction of Other Antineoplastic into Bone Marrow, Percutaneous Approach	Procedure	ICD-10-PCS
3E0B305	Introduction of Other Antineoplastic into Ear, Percutaneous Approach	Procedure	ICD-10-PCS
3E0B705	Introduction of Other Antineoplastic into Ear, Via Natural or Artificial Opening	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
3E0BX05	Introduction of Other Antineoplastic into Ear, External Approach	Procedure	ICD-10-PCS
3E0C305	Introduction of Other Antineoplastic into Eye, Percutaneous Approach	Procedure	ICD-10-PCS
3E0C705	Introduction of Other Antineoplastic into Eye, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0CX05	Introduction of Other Antineoplastic into Eye, External Approach	Procedure	ICD-10-PCS
3E0D305	Introduction of Other Antineoplastic into Mouth and Pharynx, Percutaneous Approach	Procedure	ICD-10-PCS
3E0D705	Introduction of Other Antineoplastic into Mouth and Pharynx, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0DX05	Introduction of Other Antineoplastic into Mouth and Pharynx, External Approach	Procedure	ICD-10-PCS
3E0E305	Introduction of Other Antineoplastic into Products of Conception, Percutaneous Approach	Procedure	ICD-10-PCS
3E0E705	Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0E805	Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0F305	Introduction of Other Antineoplastic into Respiratory Tract, Percutaneous Approach	Procedure	ICD-10-PCS
3E0F705	Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0F805	Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0G305	Introduction of Other Antineoplastic into Upper GI, Percutaneous Approach	Procedure	ICD-10-PCS
3E0G705	Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0G805	Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0H305	Introduction of Other Antineoplastic into Lower GI, Percutaneous Approach	Procedure	ICD-10-PCS
3E0H705	Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0H805	Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0J305	Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Percutaneous Approach	Procedure	ICD-10-PCS
3E0J705	Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0J805	Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0K305	Introduction of Other Antineoplastic into Genitourinary Tract, Percutaneous Approach	Procedure	ICD-10-PCS
3E0K705	Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0K805	Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0L305	Introduction of Other Antineoplastic into Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
3E0L705	Introduction of Other Antineoplastic into Pleural Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
3E0M305	Introduction of Other Antineoplastic into Peritoneal Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
3E0M705	Introduction of Other Antineoplastic into Peritoneal Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0N305	Introduction of Other Antineoplastic into Male Reproductive, Percutaneous Approach	Procedure	ICD-10-PCS
3E0N705	Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0N805	Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0P305	Introduction of Other Antineoplastic into Female Reproductive, Percutaneous Approach	Procedure	ICD-10-PCS
3E0P705	Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0P805	Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
3E0Q005	Introduction of Other Antineoplastic into Cranial Cavity and Brain, Open Approach	Procedure	ICD-10-PCS
3E0Q305	Introduction of Other Antineoplastic into Cranial Cavity and Brain, Percutaneous Approach	Procedure	ICD-10-PCS
3E0Q705	Introduction of Other Antineoplastic into Cranial Cavity and Brain, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
3E0R302	Introduction of High-dose Interleukin-2 into Spinal Canal, Percutaneous Approach	Procedure	ICD-10-PCS
3E0R303	Introduction of Low-dose Interleukin-2 into Spinal Canal, Percutaneous Approach	Procedure	ICD-10-PCS
3E0R305	Introduction of Other Antineoplastic into Spinal Canal, Percutaneous Approach	Procedure	ICD-10-PCS
3E0S302	Introduction of High-dose Interleukin-2 into Epidural Space, Percutaneous Approach	Procedure	ICD-10-PCS
3E0S303	Introduction of Low-dose Interleukin-2 into Epidural Space, Percutaneous Approach	Procedure	ICD-10-PCS
3E0S305	Introduction of Other Antineoplastic into Epidural Space, Percutaneous Approach	Procedure	ICD-10-PCS
3E0U305	Introduction of Other Antineoplastic into Joints, Percutaneous Approach	Procedure	ICD-10-PCS
3E0V305	Introduction of Other Antineoplastic into Bones, Percutaneous Approach	Procedure	ICD-10-PCS
3E0W305	Introduction of Other Antineoplastic into Lymphatics, Percutaneous Approach	Procedure	ICD-10-PCS
3E0Y305	Introduction of Other Antineoplastic into Pericardial Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
3E0Y705	Introduction of Other Antineoplastic into Pericardial Cavity, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
96401	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic	Procedure	CPT-4
96402	Chemotherapy administration, subcutaneous or intramuscular; hormonal anti-neoplastic	Procedure	CPT-4
96409	Chemotherapy administration; intravenous, push technique, single or initial substance/drug	Procedure	CPT-4
96411	Chemotherapy administration; intravenous, push technique, each additional substance/drug (List separately in addition to code for primary procedure)	Procedure	CPT-4
96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	Procedure	CPT-4

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)	Procedure	CPT-4
96416	Chemotherapy administration, intravenous infusion technique; initiation of prolonged chemotherapy infusion (more than 8 hours), requiring use of a portable or implantable pump	Procedure	CPT-4
96417	Chemotherapy administration, intravenous infusion technique; each additional sequential infusion (different substance/drug), up to 1 hour (List separately in addition to code for primary procedure)	Procedure	CPT-4
96420	Chemotherapy administration, intra-arterial; push technique	Procedure	CPT-4
96422	Chemotherapy administration, intra-arterial; infusion technique, up to 1 hour	Procedure	CPT-4
96423	Chemotherapy administration, intra-arterial; infusion technique, each additional hour (List separately in addition to code for primary procedure)	Procedure	CPT-4
96425	Chemotherapy administration, intra-arterial; infusion technique, initiation of prolonged infusion (more than 8 hours), requiring the use of a portable or implantable pump	Procedure	CPT-4
96440	Chemotherapy administration into pleural cavity, requiring and including thoracentesis	Procedure	CPT-4
96446	Chemotherapy administration into the peritoneal cavity via indwelling port or catheter	Procedure	CPT-4
96450	Chemotherapy administration, into CNS (eg, intrathecal), requiring and including spinal puncture	Procedure	CPT-4
96542	Chemotherapy injection, subarachnoid or intraventricular via subcutaneous reservoir, single or multiple agents	Procedure	CPT-4
96549	Unlisted chemotherapy procedure	Procedure	CPT-4
99.25	Injection or infusion of cancer chemotherapeutic substance	Procedure	ICD-9-CM
99.28	Injection or infusion of biological response modifier [BRM] as an antineoplastic agent	Procedure	ICD-9-CM
999.81	Extravasation of vesicant chemotherapy	Diagnosis	ICD-9-CM
A9534	Supply of radiopharmaceutical therapeutic imaging agent, I-131 tositumomab, per mCi	Procedure	HCPCS
A9545	Iodine I-131 tositumomab, therapeutic, per treatment dose	Procedure	HCPCS
C1084	Denileukin diftitox, 300 mcg, ontak iv	Procedure	HCPCS
C1086	Temozolomide, 5 mg, temodar	Procedure	HCPCS
C1166	Injection, cytarabine liposome, per 10 mg	Procedure	HCPCS
C1167	Injection, epirubicin HCl, 2 mg	Procedure	HCPCS
C1178	Injection, busulfan, per 6 mg	Procedure	HCPCS
C9004	Injection, gemtuzumab ozogamicin, per 5 mg	Procedure	HCPCS
C9012	Injection, arsenic trioxide, per 1 mg/kg	Procedure	HCPCS
C9017	Lomustine, 10 mg	Procedure	HCPCS
C9021	Injection, obinutuzumab, 10 mg	Procedure	HCPCS
C9024	Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine	Procedure	HCPCS
C9025	Injection, ramucirumab, 5 mg	Procedure	HCPCS
C9027	Injection, pembrolizumab, 1 mg	Procedure	HCPCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C9042	Injection, bendamustine HCl (Belrapzo), 1 mg	Procedure	HCPCS
C9044	Injection, cemiplimab-rwlc, 1 mg	Procedure	HCPCS
C9045	Injection, moxetumomab pasudotox-tdfk, 0.01 mg	Procedure	HCPCS
C9049	Injection, tagraxofusp-erzs, 10 mcg	Procedure	HCPCS
C9058	Injection, pegfilgrastim-bmez, biosimilar, (Ziextenzo) 0.5 mg	Procedure	HCPCS
C9062	Injection, daratumumab 10 mg and hyaluronidase-fihj	Procedure	HCPCS
C9064	Mitomycin pyelocalyceal instillation, 1 mg	Procedure	HCPCS
C9065	Injection, romidepsin, non-lyophilized (e.g. liquid), 1 mg	Procedure	HCPCS
C9066	Injection, sacituzumab govitecan-hziy, 2.5 mg	Procedure	HCPCS
C9069	Injection, belantamab mafodontin-blmf, 0.5 mg	Procedure	HCPCS
C9070	Injection, tafasitamab-cxix, 2 mg	Procedure	HCPCS
C9073	Brexucabtagene autoleucel, up to 200 million autologous anti-CD19 CAR positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose	Procedure	HCPCS
C9076	Lisocabtagene maraleucel, up to 110 million autologous anti-CD19 CAR-positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose	Procedure	HCPCS
C9078	Injection, trilaciclib, 1 mg	Procedure	HCPCS
C9080	Injection, melphalan flufenamide HCl, 1 mg	Procedure	HCPCS
C9081	Idecabtagene vicleucel, up to 460 million autologous anti-BCMA CAR-positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose	Procedure	HCPCS
C9082	Injection, dostarlimab-gxly, 100 mg	Procedure	HCPCS
C9083	Injection, amivantamab-vmjw, 10 mg	Procedure	HCPCS
C9084	Injection, loncastuximab tesirine-lpyl, 0.1 mg	Procedure	HCPCS
C9087	Injection, cyclophosphamide, (AuroMedics), 10 mg	Procedure	HCPCS
C9110	Injection, alemtuzumab, per 10 mg/ ml	Procedure	HCPCS
C9117	Ibritumomab tiuxetan	Procedure	HCPCS
C9118	Ibritumomab tiuxetan	Procedure	HCPCS
C9127	Injection, paclitaxel protein-bound particles, per 1 mg	Procedure	HCPCS
C9129	Injection, clofarabine, per 1 mg	Procedure	HCPCS
C9131	Injection, ado-trastuzumab emtansine, 1 mg	Procedure	HCPCS
C9205	Injection, oxaliplatin, per 5 mg	Procedure	HCPCS
C9207	Injection, bortezomib, per 3.5 mg	Procedure	HCPCS
C9210	Injection, palonosetron hydrochloride, per 250 mcg	Procedure	HCPCS
C9213	Injection, pemetrexed, per 10 mg	Procedure	HCPCS
C9214	Injection, bevacizumab, per 10 mg	Procedure	HCPCS
C9215	Injection, cetuximab, per 10 mg	Procedure	HCPCS
C9216	Injection, abarelix for injectable suspension, per 10 mg	Procedure	HCPCS
C9218	Injection, azacitidine, per 1 mg	Procedure	HCPCS
C9231	Injection, decitabine, per 1 mg	Procedure	HCPCS
C9235	Injection, panitumumab, 10 mg	Procedure	HCPCS
C9237	Injection, lanreotide acetate, 1 mg	Procedure	HCPCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C9239	Injection, temsirolimus, 1 mg	Procedure	HCPCS
C9240	Injection, ixabepilone, 1 mg	Procedure	HCPCS
C9243	Injection, bendamustine hcl, 1 mg	Procedure	HCPCS
C9252	Injection, plerixafor, 1 mg	Procedure	HCPCS
C9253	Injection, temozolomide, 1mg	Procedure	HCPCS
C9257	Injection, bevacizumab, 0.25 mg	Procedure	HCPCS
C9259	Injection, pralatrexate, 1 mg	Procedure	HCPCS
C9260	Injection, ofatumumab, 10 mg	Procedure	HCPCS
C9262	Fludarabine phosphate, oral, 1 mg	Procedure	HCPCS
C9265	Injection, romidepsin, 1 mg	Procedure	HCPCS
C9273	Sipuleucel-T, minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, including leukapheresis and all other preparatory procedures, per infusion	Procedure	HCPCS
C9276	Injection, cabazitaxel, 1 mg	Procedure	HCPCS
C9280	Injection, eribulin mesylate, 1 mg	Procedure	HCPCS
C9284	Injection, ipilimumab, 1 mg	Procedure	HCPCS
C9287	Injection, brentuximab vedotin, 1 mg	Procedure	HCPCS
C9289	Injection, asparaginase Erwinia chrysanthemi, 1,000 IU	Procedure	HCPCS
C9292	Injection, pertuzumab, 10 mg	Procedure	HCPCS
C9293	Injection, glucarpidase, 10 units	Procedure	HCPCS
C9295	Injection, carfilzomib, 1 mg	Procedure	HCPCS
C9296	Injection, ziv-aflibercept, 1 mg	Procedure	HCPCS
C9297	Injection, omacetaxine mepesuccinate, 0.01 mg	Procedure	HCPCS
C9414	Etoposide; oral, 50 mg, brand name	Procedure	HCPCS
C9415	Doxorubicin HCl, 10 mg, brand name	Procedure	HCPCS
C9416	BCG (intravesical) per instillation, brand name	Procedure	HCPCS
C9417	Bleomycin sulfate, 15 units, brand name	Procedure	HCPCS
C9418	Cisplatin, powder or solution, per 10 mg, brand name	Procedure	HCPCS
C9419	Injection, cladribine, per 1 mg, brand name	Procedure	HCPCS
C9420	Cyclophosphamide, 100 mg, brand name	Procedure	HCPCS
C9421	Cyclophosphamide, lyophilized, 100 mg, brand name	Procedure	HCPCS
C9422	Cytarabine, 100 mg, brand name	Procedure	HCPCS
C9423	Dacarbazine, 100 mg, brand name	Procedure	HCPCS
C9424	Daunorubicin, 10 mg	Procedure	HCPCS
C9425	Etoposide, 10 mg, brand name	Procedure	HCPCS
C9426	Floxuridine, 500 mg, brand name	Procedure	HCPCS
C9427	Ifosfamide, 1 gm, brand name	Procedure	HCPCS
C9428	Mesna, 200 mg, brand name	Procedure	HCPCS
C9429	Idarubicin HCl, 5 mg, brand name	Procedure	HCPCS
C9430	Leuprolide acetate, per 1 mg, brand name	Procedure	HCPCS
C9431	Paclitaxel, 30 mg, brand name	Procedure	HCPCS
C9432	Mitomycin, 5 mg, brand name	Procedure	HCPCS
C9433	Thiotepa, 15 mg, brand name	Procedure	HCPCS
C9437	Carmustine, brand name, 100 mg	Procedure	HCPCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
C9440	Vinorelbine tartrate, brand name, per 10 mg	Procedure	HCPCS
C9448	Netupitant 300 mg and palonosetron 0.5 mg, oral	Procedure	HCPCS
C9449	Injection, blinatumomab, 1 mcg	Procedure	HCPCS
C9453	Injection, nivolumab, 1 mg	Procedure	HCPCS
C9454	Injection, pasireotide pamoate long acting, 1 mg	Procedure	HCPCS
C9455	Injection, siltuximab, 10 mg	Procedure	HCPCS
C9472	Injection, talimogene laherparepvec, 1 million plaque forming units (PFU)	Procedure	HCPCS
C9474	Injection, irinotecan liposome, 1 mg	Procedure	HCPCS
C9475	Injection, necitumumab, 1 mg	Procedure	HCPCS
C9476	Injection, daratumumab, 10 mg	Procedure	HCPCS
C9477	Injection, elotuzumab, 1 mg	Procedure	HCPCS
C9480	Injection, trabectedin, 0.1 mg	Procedure	HCPCS
C9483	Injection, atezolizumab, 10 mg	Procedure	HCPCS
C9491	Injection, avelumab, 10 mg	Procedure	HCPCS
C9492	Injection, durvalumab, 10 mg	Procedure	HCPCS
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion	Procedure	HCPCS
G3001	Administration and supply of tositumomab, 450 mg	Procedure	HCPCS
G9835	Trastuzumab administered within 12 months of diagnosis	Procedure	HCPCS
G9837	Trastuzumab not administered within 12 months of diagnosis	Procedure	HCPCS
J0128	Injection, abarelix, 10 mg	Procedure	HCPCS
J0202	Injection, alemtuzumab, 1 mg	Procedure	HCPCS
J0207	Injection, amifostine, 500 mg	Procedure	HCPCS
J0594	Injection, busulfan, 1 mg	Procedure	HCPCS
J0640	Injection, leucovorin calcium, per 50 mg	Procedure	HCPCS
J0641	Injection, levoleucovorin, not otherwise specified, 0.5 mg	Procedure	HCPCS
J0642	Injection, levoleucovorin (Khapzory), 0.5 mg	Procedure	HCPCS
J0881	Injection, darbepoetin alfa, 1 mcg (non-ESRD use)	Procedure	HCPCS
J0885	Injection, epoetin alfa, (for non-ESRD use), 1000 units	Procedure	HCPCS
J0894	Injection, decitabine, 1 mg	Procedure	HCPCS
J0896	Injection, luspatercept-aamt, 0.25 mg	Procedure	HCPCS
J0897	Injection, denosumab, 1 mg	Procedure	HCPCS
J1020	Injection, methylprednisolone acetate, 20 mg	Procedure	HCPCS
J1030	Injection, methylprednisolone acetate, 40 mg	Procedure	HCPCS
J1040	Injection, methylprednisolone acetate, 80 mg	Procedure	HCPCS
J1050	Injection, medroxyprogesterone acetate, 1 mg	Procedure	HCPCS
J1051	Injection, medroxyprogesterone acetate, 50 mg	Procedure	HCPCS
J1094	Injection, dexamethasone acetate, 1 mg	Procedure	HCPCS
J1100	Injection, dexamethasone sodium phosphate, 1 mg	Procedure	HCPCS
J1190	Injection, dexrazoxane HCl, per 250 mg	Procedure	HCPCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
J1260	Injection, dolasetron mesylate, 10 mg	Procedure	HCPCS
J1380	Injection, estradiol valerate, up to 10 mg	Procedure	HCPCS
J1436	Injection, etidronate disodium, per 300 mg	Procedure	HCPCS
J1440	Injection, filgrastim (G-CSF), 300 mcg	Procedure	HCPCS
J1441	Injection, filgrastim (G-CSF), 480 mcg	Procedure	HCPCS
J1442	Injection, filgrastim (G-CSF), excludes biosimilars, 1 mcg	Procedure	HCPCS
J1446	Injection, TBO-filgrastim, 5 micrograms	Procedure	HCPCS
J1447	Injection, tbo-filgrastim, 1 mcg	Procedure	HCPCS
J1448	Injection, trilaciclib, 1 mg	Procedure	HCPCS
J1453	Injection, fosaprepitant, 1 mg	Procedure	HCPCS
J1626	Injection, granisetron HCl, 100 mcg	Procedure	HCPCS
J1627	Injection, granisetron, extended-release, 0.1 mg	Procedure	HCPCS
J1675	Injection, histrelin acetate, 10 mcg	Procedure	HCPCS
J1710	Injection, hydrocortisone sodium phosphate, up to 50 mg	Procedure	HCPCS
J1720	Injection, hydrocortisone sodium succinate, up to 100 mg	Procedure	HCPCS
J1725	Injection, hydroxyprogesterone caproate, 1 mg	Procedure	HCPCS
J1726	Injection, hydroxyprogesterone caproate, (Makena), 10 mg	Procedure	HCPCS
J1729	Injection, hydroxyprogesterone caproate, not otherwise specified, 10 mg	Procedure	HCPCS
J1930	Injection, lanreotide, 1 mg	Procedure	HCPCS
J1950	Injection, leuprolide acetate (for depot suspension), per 3.75 mg	Procedure	HCPCS
J1952	Leuprolide injectable, camcevi, 1 mg	Procedure	HCPCS
J2353	Injection, octreotide, depot form for intramuscular injection, 1 mg	Procedure	HCPCS
J2354	Injection, octreotide, nondepot form for subcutaneous or intravenous injection, 25 mcg	Procedure	HCPCS
J2405	Injection, ondansetron HCl, per 1 mg	Procedure	HCPCS
J2425	Injection, palifermin, 50 mcg	Procedure	HCPCS
J2430	Injection, pamidronate disodium, per 30 mg	Procedure	HCPCS
J2469	Injection, palonosetron HCl, 25 mcg	Procedure	HCPCS
J2502	Injection, pasireotide long acting, 1 mg	Procedure	HCPCS
J2505	Injection, pegfilgrastim, 6 mg	Procedure	HCPCS
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	Procedure	HCPCS
J2562	Injection, plerixafor, 1 mg	Procedure	HCPCS
J2650	Injection, prednisolone acetate, up to 1 ml	Procedure	HCPCS
J2783	Injection, rasburicase, 0.5 mg	Procedure	HCPCS
J2820	Injection, sargramostim (GM-CSF), 50 mcg	Procedure	HCPCS
J2860	Injection, siltuximab, 10 mg	Procedure	HCPCS
J2920	Injection, methylprednisolone sodium succinate, up to 40 mg	Procedure	HCPCS
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	Procedure	HCPCS
J3120	Injection, testosterone enanthate, up to 100 mg	Procedure	HCPCS
J3121	Injection, testosterone enanthate, 1 mg	Procedure	HCPCS
J3130	Injection, testosterone enanthate, up to 200 mg	Procedure	HCPCS
J3240	Injection, thyrotropin alpha, 0.9 mg, provided in 1.1 mg vial	Procedure	HCPCS
J3300	Injection, triamcinolone acetonide, preservative free, 1 mg	Procedure	HCPCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
J3301	Injection, triamcinolone acetonide, not otherwise specified, 10 mg	Procedure	HCPCS
J3305	Injection, trimetrexate glucuronate, per 25 mg	Procedure	HCPCS
J3315	Injection, triptorelin pamoate, 3.75 mg	Procedure	HCPCS
J3487	Injection, zoledronic acid (Zometa), 1 mg	Procedure	HCPCS
J3489	Injection, zoledronic acid, 1 mg	Procedure	HCPCS
J3590	Unclassified biologics	Procedure	HCPCS
J7506	Prednisone, oral, per 5 mg	Procedure	HCPCS
J7509	Methylprednisolone, oral, per 4 mg	Procedure	HCPCS
J7510	Prednisolone, oral, per 5 mg	Procedure	HCPCS
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	Procedure	HCPCS
J7684	Triamcinolone, inhalation solution, compounded product, administered through DME, unit dose form, per mg	Procedure	HCPCS
J8499	Prescription drug, oral, nonchemotherapeutic, NOS	Procedure	HCPCS
J8501	Aprepitant, oral, 5 mg	Procedure	HCPCS
J8510	Busulfan, oral, 2 mg	Procedure	HCPCS
J8520	Capecitabine, oral, 150 mg	Procedure	HCPCS
J8521	Capecitabine, oral, 500 mg	Procedure	HCPCS
J8530	Cyclophosphamide, oral, 25 mg	Procedure	HCPCS
J8540	Dexamethasone, oral, 0.25 mg	Procedure	HCPCS
J8560	Etoposide, oral, 50 mg	Procedure	HCPCS
J8562	Fludarabine phosphate, oral, 10 mg	Procedure	HCPCS
J8565	Gefitinib, oral, 250 mg	Procedure	HCPCS
J8600	Melphalan, oral, 2 mg	Procedure	HCPCS
J8610	Methotrexate, oral, 2.5 mg	Procedure	HCPCS
J8650	Nabilone, oral, 1 mg	Procedure	HCPCS
J8655	Netupitant 300 mg and palonosetron 0.5 mg, oral	Procedure	HCPCS
J8670	Rolapitant, oral, 1 mg	Procedure	HCPCS
J8700	Temozolomide, oral, 5 mg	Procedure	HCPCS
J8705	Topotecan, oral, 0.25 mg	Procedure	HCPCS
J8999	Prescription drug, oral, chemotherapeutic, NOS	Procedure	HCPCS
J9000	Injection, doxorubicin HCl, 10 mg	Procedure	HCPCS
J9001	Injection, doxorubicin HCl, all lipid formulations, 10 mg	Procedure	HCPCS
J9002	Injection, doxorubicin hydrochloride, liposomal, Doxil, 10 mg	Procedure	HCPCS
J9010	Injection, alemtuzumab, 10 mg	Procedure	HCPCS
J9015	Injection, aldesleukin, per single use vial	Procedure	HCPCS
J9017	Injection, arsenic trioxide, 1 mg	Procedure	HCPCS
J9019	Injection, asparaginase (Erwinaze), 1,000 IU	Procedure	HCPCS
J9020	Injection, asparaginase, not otherwise specified, 10,000 units	Procedure	HCPCS
J9021	Injection, asparaginase, recombinant, (Rylaze), 0.1 mg	Procedure	HCPCS
J9025	Injection, azacitidine, 1 mg	Procedure	HCPCS
J9027	Injection, clofarabine, 1 mg	Procedure	HCPCS
J9030	BCG live intravesical instillation, 1 mg	Procedure	HCPCS
J9031	BCG (intravesical) per instillation	Procedure	HCPCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
J9032	Injection, belinostat, 10 mg	Procedure	HCPCS
J9033	Injection, bendamustine HCl (Treanda), 1 mg	Procedure	HCPCS
J9034	Injection, bendamustine HCl (Bendeka), 1 mg	Procedure	HCPCS
J9035	Injection, bevacizumab, 10 mg	Procedure	HCPCS
J9036	Injection, bendamustine hydrochloride, (Belrapzo/bendamustine), 1 mg	Procedure	HCPCS
J9037	Injection, belantamab mafodontin-blmf, 0.5 mg	Procedure	HCPCS
J9039	Injection, blinatumomab, 1 mcg	Procedure	HCPCS
J9040	Injection, bleomycin sulfate, 15 units	Procedure	HCPCS
J9041	Injection, bortezomib (Velcade), 0.1 mg	Procedure	HCPCS
J9042	Injection, brentuximab vedotin, 1 mg	Procedure	HCPCS
J9043	Injection, cabazitaxel, 1 mg	Procedure	HCPCS
J9045	Injection, carboplatin, 50 mg	Procedure	HCPCS
J9047	Injection, carfilzomib, 1 mg	Procedure	HCPCS
J9050	Injection, carmustine, 100 mg	Procedure	HCPCS
J9055	Injection, cetuximab, 10 mg	Procedure	HCPCS
J9057	Injection, copanlisib, 1 mg	Procedure	HCPCS
J9060	Injection, cisplatin, powder or solution, 10 mg	Procedure	HCPCS
J9061	Injection, amivantamab-vmjw, 2 mg	Procedure	HCPCS
J9062	Cisplatin, 50 mg	Procedure	HCPCS
J9065	Injection, cladribine, per 1 mg	Procedure	HCPCS
J9070	Cyclophosphamide, 100 mg	Procedure	HCPCS
J9071	Cyclophosphamide (AuroMedics)	Procedure	HCPCS
J9080	Cyclophosphamide, 200 mg	Procedure	HCPCS
J9090	Cyclophosphamide, 500 mg	Procedure	HCPCS
J9091	Cyclophosphamide, 1 g	Procedure	HCPCS
J9092	Cyclophosphamide, 2 g	Procedure	HCPCS
J9093	Cyclophosphamide, lyophilized, 100 mg	Procedure	HCPCS
J9094	Cyclophosphamide, lyophilized, 200 mg	Procedure	HCPCS
J9095	Cyclophosphamide, lyophilized, 500 mg	Procedure	HCPCS
J9096	Cyclophosphamide, lyophilized, 1 g	Procedure	HCPCS
J9097	Cyclophosphamide, lyophilized, 2 g	Procedure	HCPCS
J9098	Injection, cytarabine liposome, 10 mg	Procedure	HCPCS
J9100	Injection, cytarabine, 100 mg	Procedure	HCPCS
J9110	Injection, cytarabine, 500 mg	Procedure	HCPCS
J9113	Cemiplimab-rwlc	Procedure	HCPCS
J9118	Injection, calaspargase pegol-mknl, 10 units	Procedure	HCPCS
J9120	Injection, dactinomycin, 0.5 mg	Procedure	HCPCS
J9130	Dacarbazine, 100 mg	Procedure	HCPCS
J9140	Dacarbazine, 200 mg	Procedure	HCPCS
J9144	Injection, daratumumab, 10 mg and hyaluronidase-fihj	Procedure	HCPCS
J9150	Injection, daunorubicin, 10 mg	Procedure	HCPCS
J9151	Injection, daunorubicin citrate, liposomal formulation, 10 mg	Procedure	HCPCS
J9153	Injection, liposomal, 1 mg daunorubicin and 2.27 mg cytarabine	Procedure	HCPCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
J9155	Injection, degarelix, 1 mg	Procedure	HCPCS
J9160	Injection, denileukin diftitox, 300 mcg	Procedure	HCPCS
J9170	Injection, docetaxel, 20 mg	Procedure	HCPCS
J9171	Injection, docetaxel, 1 mg	Procedure	HCPCS
J9173	Injection, durvalumab, 10 mg	Procedure	HCPCS
J9176	Injection, elotuzumab, 1 mg	Procedure	HCPCS
J9177	Injection, enfortumab vedotin-ejfv, 0.25 mg	Procedure	HCPCS
J9178	Injection, epirubicin HCl, 2 mg	Procedure	HCPCS
J9179	Injection, eribulin mesylate, 0.1 mg	Procedure	HCPCS
J9180	Epirubicin HCl, 50 mg	Procedure	HCPCS
J9181	Injection, etoposide, 10 mg	Procedure	HCPCS
J9182	Etoposide, 100 mg	Procedure	HCPCS
J9185	Injection, fludarabine phosphate, 50 mg	Procedure	HCPCS
J9190	Injection, fluorouracil, 500 mg	Procedure	HCPCS
J9198	Injection, gemcitabine hydrochloride, (Infugem), 100 mg	Procedure	HCPCS
J9200	Injection, floxuridine, 500 mg	Procedure	HCPCS
J9201	Injection, gemcitabine HCl, not otherwise specified, 200 mg	Procedure	HCPCS
J9202	Goserelin acetate implant, per 3.6 mg	Procedure	HCPCS
J9203	Injection, gemtuzumab ozogamicin, 0.1 mg	Procedure	HCPCS
J9204	Injection, mogamulizumab-kpkc, 1 mg	Procedure	HCPCS
J9205	Injection, irinotecan liposome, 1 mg	Procedure	HCPCS
J9206	Injection, irinotecan, 20 mg	Procedure	HCPCS
J9207	Injection, ixabepilone, 1 mg	Procedure	HCPCS
J9208	Injection, ifosfamide, 1 g	Procedure	HCPCS
J9209	Injection, mesna, 200 mg	Procedure	HCPCS
J9211	Injection, idarubicin HCl, 5 mg	Procedure	HCPCS
J9213	Injection, interferon, alfa-2a, recombinant, 3 million units	Procedure	HCPCS
J9214	Injection, interferon, alfa-2b, recombinant, 1 million units	Procedure	HCPCS
J9216	Injection, interferon, gamma 1-b, 3 million units	Procedure	HCPCS
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	Procedure	HCPCS
J9218	Leuprolide acetate, per 1 mg	Procedure	HCPCS
J9219	Leuprolide acetate implant, 65 mg	Procedure	HCPCS
J9223	Injection, lurbinectedin, 0.1 mg	Procedure	HCPCS
J9225	Histrelin implant (Vantas), 50 mg	Procedure	HCPCS
J9226	Histrelin implant (Supprelin LA), 50 mg	Procedure	HCPCS
J9227	Injection, isatuximab-irfc, 10 mg	Procedure	HCPCS
J9228	Injection, ipilimumab, 1 mg	Procedure	HCPCS
J9229	Injection, inotuzumab ozogamicin, 0.1 mg	Procedure	HCPCS
J9230	Injection, mechlorethamine HCl, (nitrogen mustard), 10 mg	Procedure	HCPCS
J9245	Injection, melphalan hydrochloride, not otherwise specified, 50 mg	Procedure	HCPCS
J9246	Injection, melphalan (Evomela), 1 mg	Procedure	HCPCS
J9247	Injection, melphalan flufenamide, 1 mg	Procedure	HCPCS
J9250	Methotrexate sodium, 5 mg	Procedure	HCPCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
J9260	Methotrexate sodium, 50 mg	Procedure	HCPCS
J9261	Injection, nelarabine, 50 mg	Procedure	HCPCS
J9262	Injection, omacetaxine mepesuccinate, 0.01 mg	Procedure	HCPCS
J9263	Injection, oxaliplatin, 0.5 mg	Procedure	HCPCS
J9264	Injection, paclitaxel protein-bound particles, 1 mg	Procedure	HCPCS
J9265	Injection, paclitaxel, 30 mg	Procedure	HCPCS
J9266	Injection, pegaspargase, per single dose vial	Procedure	HCPCS
J9267	Injection, paclitaxel, 1 mg	Procedure	HCPCS
J9268	Injection, pentostatin, 10 mg	Procedure	HCPCS
J9269	Injection, tagraxofusp-erzs, 10 mcg	Procedure	HCPCS
J9270	Injection, plicamycin, 2.5 mg	Procedure	HCPCS
J9271	Injection, pembrolizumab, 1 mg	Procedure	HCPCS
J9272	Injection, dostarlimab-gxly, 10 mg	Procedure	HCPCS
J9273	Tisotumab vedodin-tftv	Procedure	HCPCS
J9280	Injection, mitomycin, 5 mg	Procedure	HCPCS
J9281	Mitomycin pyelocalyceal instillation, 1 mg	Procedure	HCPCS
J9285	Injection, olaratumab, 10 mg	Procedure	HCPCS
J9290	Mitomycin, 20 mg	Procedure	HCPCS
J9291	Mitomycin, 40 mg	Procedure	HCPCS
J9293	Injection, mitoxantrone HCl, per 5 mg	Procedure	HCPCS
J9295	Injection, necitumumab, 1 mg	Procedure	HCPCS
J9299	Injection, nivolumab, 1 mg	Procedure	HCPCS
J9300	Injection, gemtuzumab ozogamicin, 5 mg	Procedure	HCPCS
J9301	Injection, obinutuzumab, 10 mg	Procedure	HCPCS
J9302	Injection, ofatumumab, 10 mg	Procedure	HCPCS
J9303	Injection, panitumumab, 10 mg	Procedure	HCPCS
J9304	Injection, pemetrexed (Pemfexy), 10 mg	Procedure	HCPCS
J9305	Injection, pemetrexed, NOS, 10 mg	Procedure	HCPCS
J9306	Injection, pertuzumab, 1 mg	Procedure	HCPCS
J9307	Injection, pralatrexate, 1 mg	Procedure	HCPCS
J9308	Injection, ramucirumab, 5 mg	Procedure	HCPCS
J9309	Injection, polatuzumab vedotin-piiq, 1 mg	Procedure	HCPCS
J9310	Injection, rituximab, 100 mg	Procedure	HCPCS
J9311	Injection, rituximab 10 mg and hyaluronidase	Procedure	HCPCS
J9312	Injection, rituximab, 10 mg	Procedure	HCPCS
J9313	Injection, moxetumomab pasudotox-tdfk, 0.01 mg	Procedure	HCPCS
J9315	Injection, romidepsin, 1 mg	Procedure	HCPCS
J9316	Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg	Procedure	HCPCS
J9317	Injection, sacituzumab govitecan-hziy, 2.5 mg	Procedure	HCPCS
J9318	Injection, romidepsin, nonlyophilized, 0.1 mg	Procedure	HCPCS
J9319	Injection, romidepsin, lyophilized, 0.1 mg	Procedure	HCPCS
J9320	Injection, streptozocin, 1 g	Procedure	HCPCS
J9325	Injection, talimogene laherparepvec, per 1 million plaque forming units	Procedure	HCPCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
J9328	Injection, temozolomide, 1 mg	Procedure	HCPCS
J9330	Injection, temsirolimus, 1 mg	Procedure	HCPCS
J9340	Injection, thiotepa, 15 mg	Procedure	HCPCS
J9348	Injection, naxitamab-gqgk, 1 mg	Procedure	HCPCS
J9349	Injection, tafasitamab-cxix, 2 mg	Procedure	HCPCS
J9350	Injection, topotecan, 4 mg	Procedure	HCPCS
J9351	Injection, topotecan, 0.1 mg	Procedure	HCPCS
J9353	Injection, margetuximab-cmkb, 5 mg	Procedure	HCPCS
J9354	Injection, ado-trastuzumab emtansine, 1 mg	Procedure	HCPCS
J9355	Injection, trastuzumab, excludes biosimilar, 10 mg	Procedure	HCPCS
J9356	Injection, trastuzumab, 10 mg and hyaluronidase-oysk	Procedure	HCPCS
J9357	Injection, valrubicin, intravesical, 200 mg	Procedure	HCPCS
J9358	Injection, fam-trastuzumab deruxtecan-nxki, 1 mg	Procedure	HCPCS
J9359	Loncastuximab tesirine-lpyl	Procedure	HCPCS
J9360	Injection, vinblastine sulfate, 1 mg	Procedure	HCPCS
J9370	Vincristine sulfate, 1 mg	Procedure	HCPCS
J9371	Injection, vincristine sulfate liposome, 1 mg	Procedure	HCPCS
J9375	Vincristine sulfate, 2 mg	Procedure	HCPCS
J9380	Vincristine sulfate, 5 mg	Procedure	HCPCS
J9390	Injection, vinorelbine tartrate, 10 mg	Procedure	HCPCS
J9395	Injection, fulvestrant, 25 mg	Procedure	HCPCS
J9400	Injection, ziv-aflibercept, 1 mg	Procedure	HCPCS
J9415	Daratumumab	Procedure	HCPCS
J9600	Injection, porfimer sodium, 75 mg	Procedure	HCPCS
J9999	Not otherwise classified, antineoplastic drugs	Procedure	HCPCS
Q0162	Ondansetron 1 mg, oral, FDA-approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 48-hour dosage regimen	Procedure	HCPCS
Q0166	Granisetron HCl, 1 mg, oral, FDA-approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 24-hour dosage regimen	Procedure	HCPCS
Q0167	Dronabinol, 2.5 mg, oral, FDA-approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 48-hour dosage regimen	Procedure	HCPCS
Q0168	Dronabinol, 5 mg, oral, FDA approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 48-hour dosage regimen	Procedure	HCPCS
Q0179	Ondansetron HCl 8 mg, oral, FDA approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 48-hour dosage regimen	Procedure	HCPCS
Q0180	Dolasetron mesylate, 100 mg, oral, FDA-approved prescription antiemetic, for use as a complete therapeutic substitute for an IV antiemetic at the time of chemotherapy treatment, not to exceed a 24-hour dosage regimen	Procedure	HCPCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
Q2017	Injection, teniposide, 50 mg	Procedure	HCPCS
Q2024	Injection, bevacizumab, 0.25 mg	Procedure	HCPCS
Q2025	Fludarabine phosphate, oral, 1 mg	Procedure	HCPCS
Q2043	Sipuleucel-T, minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF, including leukapheresis and all other preparatory procedures, per infusion	Procedure	HCPCS
Q2048	Injection, doxorubicin hydrochloride, liposomal, DOXIL, 10 mg	Procedure	HCPCS
Q2049	Injection, doxorubicin HCl, liposomal, imported Lipodox, 10 mg	Procedure	HCPCS
Q2050	Injection, doxorubicin HCl, liposomal, not otherwise specified, 10 mg	Procedure	HCPCS
Q2051	Injection, zoledronic acid, not otherwise specified, 1 mg	Procedure	HCPCS
Q2053	Brexucabtagene autoleucel, up to 200 million autologous anti-CD19 CAR positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose	Procedure	HCPCS
Q2054	Lisocabtagene maraleucel, up to 110 million autologous anti-CD19 CAR-positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose	Procedure	HCPCS
Q2055	Idecabtagene vicleucel, up to 460 million autologous B-cell maturation antigen (BCMA) directed CAR-positive T cells, including leukapheresis and dose preparation procedures, per therapeutic dose	Procedure	HCPCS
Q5101	Injection, filgrastim-sndz, biosimilar, (Zarxio), 1 mcg	Procedure	HCPCS
Q5111	Injection, pegfilgrastim-cbqv, biosimilar, (Udenyca), 0.5 mg	Procedure	HCPCS
Q5112	Injection, trastuzumab-dttb, biosimilar, (Ontruzant), 10 mg	Procedure	HCPCS
Q5113	Injection, trastuzumab-pkrb, biosimilar, (Herzuma), 10 mg	Procedure	HCPCS
Q5114	Injection, Trastuzumab-dkst, biosimilar, (Ogivri), 10 mg	Procedure	HCPCS
Q5115	Injection, rituximab-abbs, biosimilar, (Truxima), 10 mg	Procedure	HCPCS
Q5116	Injection, trastuzumab-qyyp, biosimilar, (Trazimera), 10 mg	Procedure	HCPCS
Q5117	Injection, trastuzumab-anns, biosimilar, (Kanjinti), 10 mg	Procedure	HCPCS
Q5118	Injection, bevacizumab-bvzr, biosimilar, (Zirabev), 10 mg	Procedure	HCPCS
Q5119	Injection, rituximab-pvvr, biosimilar, (RUXIENCE), 10 mg	Procedure	HCPCS
Q5120	Injection, pegfilgrastim-bmez, biosimilar, (ZIEXTENZO), 0.5 mg	Procedure	HCPCS
Q5122	Injection, pegfilgrastim-apgf, biosimilar, (Nyvepria), 0.5 mg	Procedure	HCPCS
Q5123	Injection, rituximab-arrx, biosimilar, (Riabni), 10 mg	Procedure	HCPCS
Q9978	Netupitant 300 mg and palonosetron 0.5 mg, oral	Procedure	HCPCS
Q9979	Injection, Alemtuzumab, 1 mg	Procedure	HCPCS
S0087	Injection, alemtuzumab, 30 mg	Procedure	HCPCS
S0088	Imatinib, 100 mg	Procedure	HCPCS
S0091	Granisetron HCl, 1 mg (for circumstances falling under the Medicare statute, use Q0166)	Procedure	HCPCS
S0108	Mercaptopurine, oral, 50 mg	Procedure	HCPCS
S0115	Bortezomib, 3.5 mg	Procedure	HCPCS
S0116	Bevacizumab, 100 mg	Procedure	HCPCS
S0119	Ondansetron, oral, 4 mg (for circumstances falling under the Medicare statute, use HCPCS Q code)	Procedure	HCPCS
S0145	Injection, PEGylated interferon alfa-2A, 180 mcg per ml	Procedure	HCPCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
S0146	Injection, pegylated interferon alfa-2b, 10 mcg per 0.5 ml	Procedure	HCPCS
S0156	Exemestane, 25 mg	Procedure	HCPCS
S0165	Injection, abarelix, 100 mg	Procedure	HCPCS
S0168	Injection, azacitidine, 100 mg	Procedure	HCPCS
S0170	Anastrozole, oral, 1 mg	Procedure	HCPCS
S0172	Chlorambucil, oral, 2 mg	Procedure	HCPCS
S0174	Dolasetron mesylate, oral 50 mg (for circumstances falling under the Medicare statute, use Q0180)	Procedure	HCPCS
S0176	Hydroxyurea, oral, 500 mg	Procedure	HCPCS
S0177	Levamisole HCl, oral, 50 mg	Procedure	HCPCS
S0178	Lomustine, oral, 10 mg	Procedure	HCPCS
S0179	Megestrol acetate, oral, 20 mg	Procedure	HCPCS
S0181	Ondansetron HCl, oral, 4 mg (for circumstances falling under the Medicare statute, use Q0179)	Procedure	HCPCS
S0182	Procarbazine HCl, oral, 50 mg	Procedure	HCPCS
S0187	Tamoxifen citrate, oral, 10 mg	Procedure	HCPCS
S0190	Mifepristone, oral, 200 mg	Procedure	HCPCS
S2107	Adoptive immunotherapy i.e. development of specific antitumor reactivity (e.g., tumor-infiltrating lymphocyte therapy) per course of treatment	Procedure	HCPCS
S9338	Home infusion therapy, immunotherapy, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem	Procedure	HCPCS
V58.11	Encounter for antineoplastic chemotherapy	Diagnosis	ICD-9-CM
V58.12	Encounter for antineoplastic immunotherapy	Diagnosis	ICD-9-CM
XW03351	Introduction of Blinatumomab Antineoplastic Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 1	Procedure	ICD-10-PCS
XW033B3	Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 3	Procedure	ICD-10-PCS
XW033C3	Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Peripheral Vein, Percutaneous Approach, New Technology Group 3	Procedure	ICD-10-PCS
XW033Q5	Introduction of Tagraxofusp-erzs Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW033S5	Introduction of Iobenguane I-131 Antineoplastic into Peripheral Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW04351	Introduction of Blinatumomab Antineoplastic Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 1	Procedure	ICD-10-PCS
XW043B3	Introduction of Cytarabine and Daunorubicin Liposome Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 3	Procedure	ICD-10-PCS
XW043C3	Introduction of Engineered Autologous Chimeric Antigen Receptor T-cell Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 3	Procedure	ICD-10-PCS
XW043Q5	Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
XW043S5	Introduction of Iobenguane I-131 Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW0DXL5	Introduction of Erdafitinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW0DXR5	Introduction of Venetoclax Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW0DXT5	Introduction of Ruxolitinib into Mouth and Pharynx, External Approach, New Technology Group 5	Procedure	ICD-10-PCS
XW0DXV5	Introduction of Gilteritinib Antineoplastic into Mouth and Pharynx, External Approach, New Technology Group 5	Procedure	ICD-10-PCS
Z51.1	Encounter for antineoplastic chemotherapy and immunotherapy	Diagnosis	ICD-10-CM
Z51.11	Encounter for antineoplastic chemotherapy	Diagnosis	ICD-10-CM
Z51.12	Encounter for antineoplastic immunotherapy	Diagnosis	ICD-10-CM
	Cancer-Related Surgery		
00500ZZ	Destruction of Brain, Open Approach	Procedure	ICD-10-PCS
00503ZZ	Destruction of Brain, Percutaneous Approach	Procedure	ICD-10-PCS
00504ZZ	Destruction of Brain, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
00570ZZ	Destruction of Cerebral Hemisphere, Open Approach	Procedure	ICD-10-PCS
00573ZZ	Destruction of Cerebral Hemisphere, Percutaneous Approach	Procedure	ICD-10-PCS
00574ZZ	Destruction of Cerebral Hemisphere, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
005B0ZZ	Destruction of Pons, Open Approach	Procedure	ICD-10-PCS
005B3ZZ	Destruction of Pons, Percutaneous Approach	Procedure	ICD-10-PCS
005B4ZZ	Destruction of Pons, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
005C0ZZ	Destruction of Cerebellum, Open Approach	Procedure	ICD-10-PCS
005C3ZZ	Destruction of Cerebellum, Percutaneous Approach	Procedure	ICD-10-PCS
005C4ZZ	Destruction of Cerebellum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
005D0ZZ	Destruction of Medulla Oblongata, Open Approach	Procedure	ICD-10-PCS
005D3ZZ	Destruction of Medulla Oblongata, Percutaneous Approach	Procedure	ICD-10-PCS
005D4ZZ	Destruction of Medulla Oblongata, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0061T	Destruction/reduction of malignant breast tumor including breast carcinoma cells in the margins, microwave phased array thermotherapy, disposable catheter with combined temperature monitoring probe and microwave sensor, externally applied microwave energy, including interstitial placement of sensor	Procedure	CPT-3
00B00ZZ	Excision of Brain, Open Approach	Procedure	ICD-10-PCS
00B03ZZ	Excision of Brain, Percutaneous Approach	Procedure	ICD-10-PCS
00B04ZZ	Excision of Brain, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
00B60ZZ	Excision of Cerebral Ventricle, Open Approach	Procedure	ICD-10-PCS
00B63ZZ	Excision of Cerebral Ventricle, Percutaneous Approach	Procedure	ICD-10-PCS
00B64ZZ	Excision of Cerebral Ventricle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
00B70ZZ	Excision of Cerebral Hemisphere, Open Approach	Procedure	ICD-10-PCS
00B73ZZ	Excision of Cerebral Hemisphere, Percutaneous Approach	Procedure	ICD-10-PCS
00B74ZZ	Excision of Cerebral Hemisphere, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
00BB0ZZ	Excision of Pons, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
00BB3ZZ	Excision of Pons, Percutaneous Approach	Procedure	ICD-10-PCS
00BB4ZZ	Excision of Pons, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
00BC0ZZ	Excision of Cerebellum, Open Approach	Procedure	ICD-10-PCS
00BC3ZZ	Excision of Cerebellum, Percutaneous Approach	Procedure	ICD-10-PCS
00BC4ZZ	Excision of Cerebellum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
00BD0ZZ	Excision of Medulla Oblongata, Open Approach	Procedure	ICD-10-PCS
00BD3ZZ	Excision of Medulla Oblongata, Percutaneous Approach	Procedure	ICD-10-PCS
00BD4ZZ	Excision of Medulla Oblongata, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
00T70ZZ	Resection of Cerebral Hemisphere, Open Approach	Procedure	ICD-10-PCS
00T73ZZ	Resection of Cerebral Hemisphere, Percutaneous Approach	Procedure	ICD-10-PCS
00T74ZZ	Resection of Cerebral Hemisphere, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
01.52	Hemispherectomy	Procedure	ICD-9-CM
01.53	Lobectomy of brain	Procedure	ICD-9-CM
01.59	Other excision or destruction of lesion or tissue of brain	Procedure	ICD-9-CM
01.6	Excision of lesion of skull	Procedure	ICD-9-CM
01150	Anesthesia for radical procedures for tumor of pelvis, except hindquarter amputation	Procedure	CPT-4
0135T	Ablation, renal tumor(s), unilateral, percutaneous, cryotherapy	Procedure	CPT-3
0184T	Excision of rectal tumor, transanal endoscopic microsurgical approach (ie, TEMS), including muscularis propria (ie, full thickness)	Procedure	CPT-3
01B30ZZ	Excision of Brachial Plexus, Open Approach	Procedure	ICD-10-PCS
01BL0ZZ	Excision of Thoracic Sympathetic Nerve, Open Approach	Procedure	ICD-10-PCS
0301T	Destruction/reduction of malignant breast tumor with externally applied focused microwave, including interstitial placement of disposable catheter with combined temperature monitoring probe and microwave focusing sensocatheter under ultrasound thermotherapy guidance	Procedure	CPT-3
0340T	Ablation, pulmonary tumor(s), including pleura or chest wall when involved by tumor extension, percutaneous, cryoablation, unilateral, includes imaging guidance	Procedure	CPT-3
0581T	Ablation, malignant breast tumor(s), percutaneous, cryotherapy, including imaging guidance when performed, unilateral	Procedure	CPT-3
06.2	Unilateral thyroid lobectomy	Procedure	ICD-9-CM
06.3	Other partial thyroidectomy	Procedure	ICD-9-CM
06.31	Excision of lesion of thyroid	Procedure	ICD-9-CM
06.39	Other partial thyroidectomy	Procedure	ICD-9-CM
06.4	Complete thyroidectomy	Procedure	ICD-9-CM
06.5	Substernal thyroidectomy	Procedure	ICD-9-CM
06.50	Substernal thyroidectomy, not otherwise specified	Procedure	ICD-9-CM
06.51	Partial substernal thyroidectomy	Procedure	ICD-9-CM
06.52	Complete substernal thyroidectomy	Procedure	ICD-9-CM
06.6	Excision of lingual thyroid	Procedure	ICD-9-CM
0600T	Ablation, irreversible electroporation; 1 or more tumors per organ, including imaging guidance, when performed, percutaneous	Procedure	CPT-3

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0601T	Ablation, irreversible electroporation; 1 or more tumors, including fluoroscopic and ultrasound guidance, when performed, open	Procedure	CPT-3
07T50ZZ	Resection of Right Axillary Lymphatic, Open Approach	Procedure	ICD-10-PCS
07T60ZZ	Resection of Left Axillary Lymphatic, Open Approach	Procedure	ICD-10-PCS
07T70ZZ	Resection of Thorax Lymphatic, Open Approach	Procedure	ICD-10-PCS
07T80ZZ	Resection of Right Internal Mammary Lymphatic, Open Approach	Procedure	ICD-10-PCS
07T90ZZ	Resection of Left Internal Mammary Lymphatic, Open Approach	Procedure	ICD-10-PCS
08.20	Removal of lesion of eyelid, not otherwise specified	Procedure	ICD-9-CM
08.23	Excision of major lesion of eyelid, partial-thickness	Procedure	ICD-9-CM
08.24	Excision of major lesion of eyelid, full-thickness	Procedure	ICD-9-CM
08BN0ZZ	Excision of Right Upper Eyelid, Open Approach	Procedure	ICD-10-PCS
08BN3ZZ	Excision of Right Upper Eyelid, Percutaneous Approach	Procedure	ICD-10-PCS
08BNXZZ	Excision of Right Upper Eyelid, External Approach	Procedure	ICD-10-PCS
08BP0ZZ	Excision of Left Upper Eyelid, Open Approach	Procedure	ICD-10-PCS
08BP3ZZ	Excision of Left Upper Eyelid, Percutaneous Approach	Procedure	ICD-10-PCS
08BPXZZ	Excision of Left Upper Eyelid, External Approach	Procedure	ICD-10-PCS
08BQ0ZZ	Excision of Right Lower Eyelid, Open Approach	Procedure	ICD-10-PCS
08BQ3ZZ	Excision of Right Lower Eyelid, Percutaneous Approach	Procedure	ICD-10-PCS
08BQXZZ	Excision of Right Lower Eyelid, External Approach	Procedure	ICD-10-PCS
08BR0ZZ	Excision of Left Lower Eyelid, Open Approach	Procedure	ICD-10-PCS
08BR3ZZ	Excision of Left Lower Eyelid, Percutaneous Approach	Procedure	ICD-10-PCS
08BRXZZ	Excision of Left Lower Eyelid, External Approach	Procedure	ICD-10-PCS
09500ZZ	Destruction of Right External Ear, Open Approach	Procedure	ICD-10-PCS
09503ZZ	Destruction of Right External Ear, Percutaneous Approach	Procedure	ICD-10-PCS
09504ZZ	Destruction of Right External Ear, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0950XZZ	Destruction of Right External Ear, External Approach	Procedure	ICD-10-PCS
09510ZZ	Destruction of Left External Ear, Open Approach	Procedure	ICD-10-PCS
09513ZZ	Destruction of Left External Ear, Percutaneous Approach	Procedure	ICD-10-PCS
09514ZZ	Destruction of Left External Ear, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0951XZZ	Destruction of Left External Ear, External Approach	Procedure	ICD-10-PCS
09530ZZ	Destruction of Right External Auditory Canal, Open Approach	Procedure	ICD-10-PCS
09533ZZ	Destruction of Right External Auditory Canal, Percutaneous Approach	Procedure	ICD-10-PCS
09534ZZ	Destruction of Right External Auditory Canal, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
09537ZZ	Destruction of Right External Auditory Canal, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
09538ZZ	Destruction of Right External Auditory Canal, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0953XZZ	Destruction of Right External Auditory Canal, External Approach	Procedure	ICD-10-PCS
09540ZZ	Destruction of Left External Auditory Canal, Open Approach	Procedure	ICD-10-PCS
09543ZZ	Destruction of Left External Auditory Canal, Percutaneous Approach	Procedure	ICD-10-PCS
09544ZZ	Destruction of Left External Auditory Canal, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
09547ZZ	Destruction of Left External Auditory Canal, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
09548ZZ	Destruction of Left External Auditory Canal, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0954XZZ	Destruction of Left External Auditory Canal, External Approach	Procedure	ICD-10-PCS
095K0ZZ	Destruction of Nasal Mucosa and Soft Tissue, Open Approach	Procedure	ICD-10-PCS
095K3ZZ	Destruction of Nasal Mucosa and Soft Tissue, Percutaneous Approach	Procedure	ICD-10-PCS
095K4ZZ	Destruction of Nasal Mucosa and Soft Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
095K8ZZ	Destruction of Nasal Mucosa and Soft Tissue, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
095KXZZ	Destruction of Nasal Mucosa and Soft Tissue, External Approach	Procedure	ICD-10-PCS
095M0ZZ	Destruction of Nasal Septum, Open Approach	Procedure	ICD-10-PCS
095M3ZZ	Destruction of Nasal Septum, Percutaneous Approach	Procedure	ICD-10-PCS
095M4ZZ	Destruction of Nasal Septum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
095M8ZZ	Destruction of Nasal Septum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
09B00ZZ	Excision of Right External Ear, Open Approach	Procedure	ICD-10-PCS
09B03ZZ	Excision of Right External Ear, Percutaneous Approach	Procedure	ICD-10-PCS
09B04ZZ	Excision of Right External Ear, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
09B0XZZ	Excision of Right External Ear, External Approach	Procedure	ICD-10-PCS
09B10ZZ	Excision of Left External Ear, Open Approach	Procedure	ICD-10-PCS
09B13ZZ	Excision of Left External Ear, Percutaneous Approach	Procedure	ICD-10-PCS
09B14ZZ	Excision of Left External Ear, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
09B1XZZ	Excision of Left External Ear, External Approach	Procedure	ICD-10-PCS
09B30ZZ	Excision of Right External Auditory Canal, Open Approach	Procedure	ICD-10-PCS
09B33ZZ	Excision of Right External Auditory Canal, Percutaneous Approach	Procedure	ICD-10-PCS
09B34ZZ	Excision of Right External Auditory Canal, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
09B37ZZ	Excision of Right External Auditory Canal, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
09B38ZZ	Excision of Right External Auditory Canal, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
09B3XZZ	Excision of Right External Auditory Canal, External Approach	Procedure	ICD-10-PCS
09B40ZZ	Excision of Left External Auditory Canal, Open Approach	Procedure	ICD-10-PCS
09B43ZZ	Excision of Left External Auditory Canal, Percutaneous Approach	Procedure	ICD-10-PCS
09B44ZZ	Excision of Left External Auditory Canal, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
09B47ZZ	Excision of Left External Auditory Canal, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
09B48ZZ	Excision of Left External Auditory Canal, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
09B4XZZ	Excision of Left External Auditory Canal, External Approach	Procedure	ICD-10-PCS
09BK0ZZ	Excision of Nasal Mucosa and Soft Tissue, Open Approach	Procedure	ICD-10-PCS
09BK3ZZ	Excision of Nasal Mucosa and Soft Tissue, Percutaneous Approach	Procedure	ICD-10-PCS
09BK4ZZ	Excision of Nasal Mucosa and Soft Tissue, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
09BK8ZZ	Excision of Nasal Mucosa and Soft Tissue, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
09BKXZZ	Excision of Nasal Mucosa and Soft Tissue, External Approach	Procedure	ICD-10-PCS
0B5C0ZZ	Destruction of Right Upper Lung Lobe, Open Approach	Procedure	ICD-10-PCS
0B5C3ZZ	Destruction of Right Upper Lung Lobe, Percutaneous Approach	Procedure	ICD-10-PCS
0B5C7ZZ	Destruction of Right Upper Lung Lobe, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0B5D0ZZ	Destruction of Right Middle Lung Lobe, Open Approach	Procedure	ICD-10-PCS
0B5D3ZZ	Destruction of Right Middle Lung Lobe, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0B5D7ZZ	Destruction of Right Middle Lung Lobe, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0B5F0ZZ	Destruction of Right Lower Lung Lobe, Open Approach	Procedure	ICD-10-PCS
0B5F3ZZ	Destruction of Right Lower Lung Lobe, Percutaneous Approach	Procedure	ICD-10-PCS
0B5F7ZZ	Destruction of Right Lower Lung Lobe, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0B5G0ZZ	Destruction of Left Upper Lung Lobe, Open Approach	Procedure	ICD-10-PCS
0B5G3ZZ	Destruction of Left Upper Lung Lobe, Percutaneous Approach	Procedure	ICD-10-PCS
0B5G7ZZ	Destruction of Left Upper Lung Lobe, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0B5H0ZZ	Destruction of Lung Lingula, Open Approach	Procedure	ICD-10-PCS
0B5H3ZZ	Destruction of Lung Lingula, Percutaneous Approach	Procedure	ICD-10-PCS
0B5H7ZZ	Destruction of Lung Lingula, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0B5J0ZZ	Destruction of Left Lower Lung Lobe, Open Approach	Procedure	ICD-10-PCS
0B5J3ZZ	Destruction of Left Lower Lung Lobe, Percutaneous Approach	Procedure	ICD-10-PCS
0B5J7ZZ	Destruction of Left Lower Lung Lobe, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0B5K0ZZ	Destruction of Right Lung, Open Approach	Procedure	ICD-10-PCS
0B5K3ZZ	Destruction of Right Lung, Percutaneous Approach	Procedure	ICD-10-PCS
0B5K7ZZ	Destruction of Right Lung, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0B5L0ZZ	Destruction of Left Lung, Open Approach	Procedure	ICD-10-PCS
0B5L3ZZ	Destruction of Left Lung, Percutaneous Approach	Procedure	ICD-10-PCS
0B5L7ZZ	Destruction of Left Lung, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0B5M0ZZ	Destruction of Bilateral Lungs, Open Approach	Procedure	ICD-10-PCS
0B5M3ZZ	Destruction of Bilateral Lungs, Percutaneous Approach	Procedure	ICD-10-PCS
0B5M7ZZ	Destruction of Bilateral Lungs, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0B9N00Z	Drainage of Right Pleura with Drainage Device, Open Approach	Procedure	ICD-10-PCS
0B9N0ZZ	Drainage of Right Pleura, Open Approach	Procedure	ICD-10-PCS
0B9N30Z	Drainage of Right Pleura with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0B9N40Z	Drainage of Right Pleura with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0B9N4ZZ	Drainage of Right Pleura, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0B9N80Z	Drainage of Right Pleura with Drainage Device, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0B9P00Z	Drainage of Left Pleura with Drainage Device, Open Approach	Procedure	ICD-10-PCS
0B9P0ZZ	Drainage of Left Pleura, Open Approach	Procedure	ICD-10-PCS
0B9P30Z	Drainage of Left Pleura with Drainage Device, Percutaneous Approach	Procedure	ICD-10-PCS
0B9P40Z	Drainage of Left Pleura with Drainage Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0B9P4ZZ	Drainage of Left Pleura, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0B9P80Z	Drainage of Left Pleura with Drainage Device, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0BBC0ZZ	Excision of Right Upper Lung Lobe, Open Approach	Procedure	ICD-10-PCS
0BBC3ZZ	Excision of Right Upper Lung Lobe, Percutaneous Approach	Procedure	ICD-10-PCS
0BBC4ZZ	Excision of Right Upper Lung Lobe, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BBC7ZZ	Excision of Right Upper Lung Lobe, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0BBD0ZZ	Excision of Right Middle Lung Lobe, Open Approach	Procedure	ICD-10-PCS
0BBD3ZZ	Excision of Right Middle Lung Lobe, Percutaneous Approach	Procedure	ICD-10-PCS
0BBD4ZZ	Excision of Right Middle Lung Lobe, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0BBD7ZZ	Excision of Right Middle Lung Lobe, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0BBF0ZZ	Excision of Right Lower Lung Lobe, Open Approach	Procedure	ICD-10-PCS
0BBF3ZZ	Excision of Right Lower Lung Lobe, Percutaneous Approach	Procedure	ICD-10-PCS
0BBF4ZZ	Excision of Right Lower Lung Lobe, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BBF7ZZ	Excision of Right Lower Lung Lobe, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0BBG0ZZ	Excision of Left Upper Lung Lobe, Open Approach	Procedure	ICD-10-PCS
0BBG3ZZ	Excision of Left Upper Lung Lobe, Percutaneous Approach	Procedure	ICD-10-PCS
0BBG4ZZ	Excision of Left Upper Lung Lobe, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BBG7ZZ	Excision of Left Upper Lung Lobe, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0BBH0ZZ	Excision of Lung Lingula, Open Approach	Procedure	ICD-10-PCS
0BBH3ZZ	Excision of Lung Lingula, Percutaneous Approach	Procedure	ICD-10-PCS
0BBH4ZZ	Excision of Lung Lingula, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BBH7ZZ	Excision of Lung Lingula, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0BBJ0ZZ	Excision of Left Lower Lung Lobe, Open Approach	Procedure	ICD-10-PCS
0BBJ3ZZ	Excision of Left Lower Lung Lobe, Percutaneous Approach	Procedure	ICD-10-PCS
0BBJ4ZZ	Excision of Left Lower Lung Lobe, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BBJ7ZZ	Excision of Left Lower Lung Lobe, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0BBK0ZZ	Excision of Right Lung, Open Approach	Procedure	ICD-10-PCS
0BBK3ZZ	Excision of Right Lung, Percutaneous Approach	Procedure	ICD-10-PCS
0BBK4ZZ	Excision of Right Lung, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BBK7ZZ	Excision of Right Lung, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0BBL0ZZ	Excision of Left Lung, Open Approach	Procedure	ICD-10-PCS
0BBL3ZZ	Excision of Left Lung, Percutaneous Approach	Procedure	ICD-10-PCS
0BBL4ZZ	Excision of Left Lung, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BBL7ZZ	Excision of Left Lung, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0BBM0ZZ	Excision of Bilateral Lungs, Open Approach	Procedure	ICD-10-PCS
0BBM3ZZ	Excision of Bilateral Lungs, Percutaneous Approach	Procedure	ICD-10-PCS
0BBM7ZZ	Excision of Bilateral Lungs, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0BBN0ZZ	Excision of Right Pleura, Open Approach	Procedure	ICD-10-PCS
0BBN3ZZ	Excision of Right Pleura, Percutaneous Approach	Procedure	ICD-10-PCS
0BBN4ZZ	Excision of Right Pleura, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BBN8ZZ	Excision of Right Pleura, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0BBP0ZZ	Excision of Left Pleura, Open Approach	Procedure	ICD-10-PCS
0BBP3ZZ	Excision of Left Pleura, Percutaneous Approach	Procedure	ICD-10-PCS
0BBP4ZZ	Excision of Left Pleura, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BBP8ZZ	Excision of Left Pleura, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0BCN0ZZ	Extirpation of Matter from Right Pleura, Open Approach	Procedure	ICD-10-PCS
0BCN3ZZ	Extirpation of Matter from Right Pleura, Percutaneous Approach	Procedure	ICD-10-PCS
0BCN4ZZ	Extirpation of Matter from Right Pleura, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BCP0ZZ	Extirpation of Matter from Left Pleura, Open Approach	Procedure	ICD-10-PCS
0BCP3ZZ	Extirpation of Matter from Left Pleura, Percutaneous Approach	Procedure	ICD-10-PCS
0BCP4ZZ	Extirpation of Matter from Left Pleura, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BDN0ZX	Extraction of Right Pleura, Open Approach, Diagnostic	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0BDN0ZZ	Extraction of Right Pleura, Open Approach	Procedure	ICD-10-PCS
0BDN3ZX	Extraction of Right Pleura, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0BDN3ZZ	Extraction of Right Pleura, Percutaneous Approach	Procedure	ICD-10-PCS
0BDN4ZX	Extraction of Right Pleura, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0BDN4ZZ	Extraction of Right Pleura, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BDP0ZX	Extraction of Left Pleura, Open Approach, Diagnostic	Procedure	ICD-10-PCS
0BDP0ZZ	Extraction of Left Pleura, Open Approach	Procedure	ICD-10-PCS
0BDP3ZX	Extraction of Left Pleura, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0BDP3ZZ	Extraction of Left Pleura, Percutaneous Approach	Procedure	ICD-10-PCS
0BDP4ZX	Extraction of Left Pleura, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0BDP4ZZ	Extraction of Left Pleura, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BHQ0YZ	Insertion of Other Device into Pleura, Open Approach	Procedure	ICD-10-PCS
0BHQ3YZ	Insertion of Other Device into Pleura, Percutaneous Approach	Procedure	ICD-10-PCS
0BHQ4YZ	Insertion of Other Device into Pleura, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BHQ7YZ	Insertion of Other Device into Pleura, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0BHQ8YZ	Insertion of Other Device into Pleura, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0BPQ00Z	Removal of Drainage Device from Pleura, Open Approach	Procedure	ICD-10-PCS
0BPQ01Z	Removal of Radioactive Element from Pleura, Open Approach	Procedure	ICD-10-PCS
0BPQ02Z	Removal of Monitoring Device from Pleura, Open Approach	Procedure	ICD-10-PCS
0BPQ0YZ	Removal of Other Device from Pleura, Open Approach	Procedure	ICD-10-PCS
0BPQ30Z	Removal of Drainage Device from Pleura, Percutaneous Approach	Procedure	ICD-10-PCS
0BPQ31Z	Removal of Radioactive Element from Pleura, Percutaneous Approach	Procedure	ICD-10-PCS
0BPQ32Z	Removal of Monitoring Device from Pleura, Percutaneous Approach	Procedure	ICD-10-PCS
0BPQ3YZ	Removal of Other Device from Pleura, Percutaneous Approach	Procedure	ICD-10-PCS
0BPQ40Z	Removal of Drainage Device from Pleura, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BPQ41Z	Removal of Radioactive Element from Pleura, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BPQ42Z	Removal of Monitoring Device from Pleura, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BPQ4YZ	Removal of Other Device from Pleura, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BPQ70Z	Removal of Drainage Device from Pleura, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0BPQ71Z	Removal of Radioactive Element from Pleura, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0BPQ72Z	Removal of Monitoring Device from Pleura, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0BPQ7YZ	Removal of Other Device from Pleura, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0BPQ80Z	Removal of Drainage Device from Pleura, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0BPQ81Z	Removal of Radioactive Element from Pleura, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0BPQ82Z	Removal of Monitoring Device from Pleura, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0BPQ8YZ	Removal of Other Device from Pleura, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0BTC0ZZ	Resection of Right Upper Lung Lobe, Open Approach	Procedure	ICD-10-PCS
0BTC4ZZ	Resection of Right Upper Lung Lobe, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BTD0ZZ	Resection of Right Middle Lung Lobe, Open Approach	Procedure	ICD-10-PCS
0BTD4ZZ	Resection of Right Middle Lung Lobe, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0BTF0ZZ	Resection of Right Lower Lung Lobe, Open Approach	Procedure	ICD-10-PCS
0BTF4ZZ	Resection of Right Lower Lung Lobe, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BTG0ZZ	Resection of Left Upper Lung Lobe, Open Approach	Procedure	ICD-10-PCS
0BTG4ZZ	Resection of Left Upper Lung Lobe, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BTH0ZZ	Resection of Lung Lingula, Open Approach	Procedure	ICD-10-PCS
0BTH4ZZ	Resection of Lung Lingula, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BTJ0ZZ	Resection of Left Lower Lung Lobe, Open Approach	Procedure	ICD-10-PCS
0BTJ4ZZ	Resection of Left Lower Lung Lobe, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BTK0ZZ	Resection of Right Lung, Open Approach	Procedure	ICD-10-PCS
0BTK4ZZ	Resection of Right Lung, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BTL0ZZ	Resection of Left Lung, Open Approach	Procedure	ICD-10-PCS
0BTL4ZZ	Resection of Left Lung, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BTM0ZZ	Resection of Bilateral Lungs, Open Approach	Procedure	ICD-10-PCS
0BTM4ZZ	Resection of Bilateral Lungs, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BWQ00Z	Revision of Drainage Device in Pleura, Open Approach	Procedure	ICD-10-PCS
0BWQ02Z	Revision of Monitoring Device in Pleura, Open Approach	Procedure	ICD-10-PCS
0BWQ0YZ	Revision of Other Device in Pleura, Open Approach	Procedure	ICD-10-PCS
0BWQ30Z	Revision of Drainage Device in Pleura, Percutaneous Approach	Procedure	ICD-10-PCS
0BWQ32Z	Revision of Monitoring Device in Pleura, Percutaneous Approach	Procedure	ICD-10-PCS
0BWQ3YZ	Revision of Other Device in Pleura, Percutaneous Approach	Procedure	ICD-10-PCS
0BWQ40Z	Revision of Drainage Device in Pleura, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BWQ42Z	Revision of Monitoring Device in Pleura, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BWQ4YZ	Revision of Other Device in Pleura, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0BWQ70Z	Revision of Drainage Device in Pleura, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0BWQ72Z	Revision of Monitoring Device in Pleura, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0BWQ7YZ	Revision of Other Device in Pleura, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0BWQ80Z	Revision of Drainage Device in Pleura, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0BWQ82Z	Revision of Monitoring Device in Pleura, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0BWQ8YZ	Revision of Other Device in Pleura, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0C500ZZ	Destruction of Upper Lip, Open Approach	Procedure	ICD-10-PCS
0C503ZZ	Destruction of Upper Lip, Percutaneous Approach	Procedure	ICD-10-PCS
0C50XZZ	Destruction of Upper Lip, External Approach	Procedure	ICD-10-PCS
0C510ZZ	Destruction of Lower Lip, Open Approach	Procedure	ICD-10-PCS
0C513ZZ	Destruction of Lower Lip, Percutaneous Approach	Procedure	ICD-10-PCS
0C51XZZ	Destruction of Lower Lip, External Approach	Procedure	ICD-10-PCS
0CB00ZZ	Excision of Upper Lip, Open Approach	Procedure	ICD-10-PCS
0CB03ZZ	Excision of Upper Lip, Percutaneous Approach	Procedure	ICD-10-PCS
0CB0XZZ	Excision of Upper Lip, External Approach	Procedure	ICD-10-PCS
0CB10ZZ	Excision of Lower Lip, Open Approach	Procedure	ICD-10-PCS
0CB13ZZ	Excision of Lower Lip, Percutaneous Approach	Procedure	ICD-10-PCS
0CB1XZZ	Excision of Lower Lip, External Approach	Procedure	ICD-10-PCS
0CB70ZZ	Excision of Tongue, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0CB73ZZ	Excision of Tongue, Percutaneous Approach	Procedure	ICD-10-PCS
0CB7XZZ	Excision of Tongue, External Approach	Procedure	ICD-10-PCS
0D11076	Bypass Upper Esophagus to Stomach with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D11079	Bypass Upper Esophagus to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1107A	Bypass Upper Esophagus to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1107B	Bypass Upper Esophagus to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D110J6	Bypass Upper Esophagus to Stomach with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D110J9	Bypass Upper Esophagus to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D110JA	Bypass Upper Esophagus to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D110JB	Bypass Upper Esophagus to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D110K6	Bypass Upper Esophagus to Stomach with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D110K9	Bypass Upper Esophagus to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D110KA	Bypass Upper Esophagus to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D110KB	Bypass Upper Esophagus to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D110Z6	Bypass Upper Esophagus to Stomach, Open Approach	Procedure	ICD-10-PCS
0D110Z9	Bypass Upper Esophagus to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D110ZA	Bypass Upper Esophagus to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D110ZB	Bypass Upper Esophagus to Ileum, Open Approach	Procedure	ICD-10-PCS
0D11476	Bypass Upper Esophagus to Stomach with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D11479	Bypass Upper Esophagus to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1147A	Bypass Upper Esophagus to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1147B	Bypass Upper Esophagus to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D114J6	Bypass Upper Esophagus to Stomach with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D114J9	Bypass Upper Esophagus to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D114JA	Bypass Upper Esophagus to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D114JB	Bypass Upper Esophagus to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D114K6	Bypass Upper Esophagus to Stomach with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0D114K9	Bypass Upper Esophagus to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D114KA	Bypass Upper Esophagus to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D114KB	Bypass Upper Esophagus to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D114Z6	Bypass Upper Esophagus to Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D114Z9	Bypass Upper Esophagus to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D114ZA	Bypass Upper Esophagus to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D114ZB	Bypass Upper Esophagus to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D11879	Bypass Upper Esophagus to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1187A	Bypass Upper Esophagus to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1187B	Bypass Upper Esophagus to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D118J9	Bypass Upper Esophagus to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D118JA	Bypass Upper Esophagus to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D118JB	Bypass Upper Esophagus to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D118K9	Bypass Upper Esophagus to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D118KA	Bypass Upper Esophagus to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D118KB	Bypass Upper Esophagus to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D118Z9	Bypass Upper Esophagus to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D118ZA	Bypass Upper Esophagus to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D118ZB	Bypass Upper Esophagus to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D12076	Bypass Middle Esophagus to Stomach with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D12079	Bypass Middle Esophagus to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1207A	Bypass Middle Esophagus to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1207B	Bypass Middle Esophagus to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D120J6	Bypass Middle Esophagus to Stomach with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D120J9	Bypass Middle Esophagus to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D120JA	Bypass Middle Esophagus to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D120JB	Bypass Middle Esophagus to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0D120K6	Bypass Middle Esophagus to Stomach with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D120K9	Bypass Middle Esophagus to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D120KA	Bypass Middle Esophagus to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D120KB	Bypass Middle Esophagus to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D120Z6	Bypass Middle Esophagus to Stomach, Open Approach	Procedure	ICD-10-PCS
0D120Z9	Bypass Middle Esophagus to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D120ZA	Bypass Middle Esophagus to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D120ZB	Bypass Middle Esophagus to Ileum, Open Approach	Procedure	ICD-10-PCS
0D12476	Bypass Middle Esophagus to Stomach with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D12479	Bypass Middle Esophagus to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1247A	Bypass Middle Esophagus to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1247B	Bypass Middle Esophagus to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D124J6	Bypass Middle Esophagus to Stomach with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D124J9	Bypass Middle Esophagus to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D124JA	Bypass Middle Esophagus to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D124JB	Bypass Middle Esophagus to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D124K6	Bypass Middle Esophagus to Stomach with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D124K9	Bypass Middle Esophagus to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D124KA	Bypass Middle Esophagus to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D124KB	Bypass Middle Esophagus to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D124Z6	Bypass Middle Esophagus to Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D124Z9	Bypass Middle Esophagus to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D124ZA	Bypass Middle Esophagus to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D124ZB	Bypass Middle Esophagus to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D12876	Bypass Middle Esophagus to Stomach with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0D12879	Bypass Middle Esophagus to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1287A	Bypass Middle Esophagus to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1287B	Bypass Middle Esophagus to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D128J6	Bypass Middle Esophagus to Stomach with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D128J9	Bypass Middle Esophagus to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D128JA	Bypass Middle Esophagus to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D128JB	Bypass Middle Esophagus to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D128K6	Bypass Middle Esophagus to Stomach with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D128K9	Bypass Middle Esophagus to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D128KA	Bypass Middle Esophagus to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D128KB	Bypass Middle Esophagus to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D128Z6	Bypass Middle Esophagus to Stomach, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D128Z9	Bypass Middle Esophagus to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D128ZA	Bypass Middle Esophagus to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D128ZB	Bypass Middle Esophagus to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D13076	Bypass Lower Esophagus to Stomach with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D13079	Bypass Lower Esophagus to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1307A	Bypass Lower Esophagus to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1307B	Bypass Lower Esophagus to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D130J6	Bypass Lower Esophagus to Stomach with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D130J9	Bypass Lower Esophagus to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D130JA	Bypass Lower Esophagus to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D130JB	Bypass Lower Esophagus to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D130K6	Bypass Lower Esophagus to Stomach with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D130K9	Bypass Lower Esophagus to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0D130KA	Bypass Lower Esophagus to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D130KB	Bypass Lower Esophagus to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D130Z6	Bypass Lower Esophagus to Stomach, Open Approach	Procedure	ICD-10-PCS
0D130Z9	Bypass Lower Esophagus to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D130ZA	Bypass Lower Esophagus to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D130ZB	Bypass Lower Esophagus to Ileum, Open Approach	Procedure	ICD-10-PCS
0D13476	Bypass Lower Esophagus to Stomach with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D13479	Bypass Lower Esophagus to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1347A	Bypass Lower Esophagus to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1347B	Bypass Lower Esophagus to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D134J6	Bypass Lower Esophagus to Stomach with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D134J9	Bypass Lower Esophagus to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D134JA	Bypass Lower Esophagus to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D134JB	Bypass Lower Esophagus to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D134K6	Bypass Lower Esophagus to Stomach with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D134K9	Bypass Lower Esophagus to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D134KA	Bypass Lower Esophagus to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D134KB	Bypass Lower Esophagus to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D134Z6	Bypass Lower Esophagus to Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D134Z9	Bypass Lower Esophagus to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D134ZA	Bypass Lower Esophagus to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D134ZB	Bypass Lower Esophagus to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D13876	Bypass Lower Esophagus to Stomach with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D13879	Bypass Lower Esophagus to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1387A	Bypass Lower Esophagus to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0D1387B	Bypass Lower Esophagus to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D138J6	Bypass Lower Esophagus to Stomach with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D138J9	Bypass Lower Esophagus to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D138JA	Bypass Lower Esophagus to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D138JB	Bypass Lower Esophagus to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D138K6	Bypass Lower Esophagus to Stomach with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D138K9	Bypass Lower Esophagus to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D138KA	Bypass Lower Esophagus to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D138KB	Bypass Lower Esophagus to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D138Z6	Bypass Lower Esophagus to Stomach, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D138Z9	Bypass Lower Esophagus to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D138ZA	Bypass Lower Esophagus to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D138ZB	Bypass Lower Esophagus to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D15074	Bypass Esophagus to Cutaneous with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D15076	Bypass Esophagus to Stomach with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D15079	Bypass Esophagus to Duodenum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1507A	Bypass Esophagus to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D1507B	Bypass Esophagus to Ileum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D150J4	Bypass Esophagus to Cutaneous with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D150J6	Bypass Esophagus to Stomach with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D150J9	Bypass Esophagus to Duodenum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D150JA	Bypass Esophagus to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D150JB	Bypass Esophagus to Ileum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D150K4	Bypass Esophagus to Cutaneous with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D150K6	Bypass Esophagus to Stomach with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D150K9	Bypass Esophagus to Duodenum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D150KA	Bypass Esophagus to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D150KB	Bypass Esophagus to Ileum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D150Z4	Bypass Esophagus to Cutaneous, Open Approach	Procedure	ICD-10-PCS
0D150Z6	Bypass Esophagus to Stomach, Open Approach	Procedure	ICD-10-PCS
0D150Z9	Bypass Esophagus to Duodenum, Open Approach	Procedure	ICD-10-PCS
0D150ZA	Bypass Esophagus to Jejunum, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0D150ZB	Bypass Esophagus to Ileum, Open Approach	Procedure	ICD-10-PCS
0D153J4	Bypass Esophagus to Cutaneous with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
0D15474	Bypass Esophagus to Cutaneous with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D15476	Bypass Esophagus to Stomach with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D15479	Bypass Esophagus to Duodenum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1547A	Bypass Esophagus to Jejunum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D1547B	Bypass Esophagus to Ileum with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D154J4	Bypass Esophagus to Cutaneous with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D154J6	Bypass Esophagus to Stomach with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D154J9	Bypass Esophagus to Duodenum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D154JA	Bypass Esophagus to Jejunum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D154JB	Bypass Esophagus to Ileum with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D154K4	Bypass Esophagus to Cutaneous with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D154K6	Bypass Esophagus to Stomach with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D154K9	Bypass Esophagus to Duodenum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D154KA	Bypass Esophagus to Jejunum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D154KB	Bypass Esophagus to Ileum with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D154Z4	Bypass Esophagus to Cutaneous, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D154Z6	Bypass Esophagus to Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D154Z9	Bypass Esophagus to Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D154ZA	Bypass Esophagus to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D154ZB	Bypass Esophagus to Ileum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D15876	Bypass Esophagus to Stomach with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D15879	Bypass Esophagus to Duodenum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1587A	Bypass Esophagus to Jejunum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0D1587B	Bypass Esophagus to Ileum with Autologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D158J6	Bypass Esophagus to Stomach with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D158J9	Bypass Esophagus to Duodenum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D158JA	Bypass Esophagus to Jejunum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D158JB	Bypass Esophagus to Ileum with Synthetic Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D158K6	Bypass Esophagus to Stomach with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D158K9	Bypass Esophagus to Duodenum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D158KA	Bypass Esophagus to Jejunum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D158KB	Bypass Esophagus to Ileum with Nonautologous Tissue Substitute, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D158Z6	Bypass Esophagus to Stomach, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D158Z9	Bypass Esophagus to Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D158ZA	Bypass Esophagus to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D158ZB	Bypass Esophagus to Ileum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1607A	Bypass Stomach to Jejunum with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160JA	Bypass Stomach to Jejunum with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0D160KA	Bypass Stomach to Jejunum with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0D160ZA	Bypass Stomach to Jejunum, Open Approach	Procedure	ICD-10-PCS
0D164ZA	Bypass Stomach to Jejunum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D168ZA	Bypass Stomach to Jejunum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0D1N0Z4	Bypass Sigmoid Colon to Cutaneous, Open Approach	Procedure	ICD-10-PCS
0D1N4Z4	Bypass Sigmoid Colon to Cutaneous, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D5U0ZZ	Destruction of Omentum, Open Approach	Procedure	ICD-10-PCS
0D5U3ZZ	Destruction of Omentum, Percutaneous Approach	Procedure	ICD-10-PCS
0D5U4ZZ	Destruction of Omentum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D5V0ZZ	Destruction of Mesentery, Open Approach	Procedure	ICD-10-PCS
0D5V3ZZ	Destruction of Mesentery, Percutaneous Approach	Procedure	ICD-10-PCS
0D5V4ZZ	Destruction of Mesentery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0D5W0ZZ	Destruction of Peritoneum, Open Approach	Procedure	ICD-10-PCS
0D5W3ZZ	Destruction of Peritoneum, Percutaneous Approach	Procedure	ICD-10-PCS
0D5W4ZZ	Destruction of Peritoneum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DB10ZZ	Excision of Upper Esophagus, Open Approach	Procedure	ICD-10-PCS
0DB13ZZ	Excision of Upper Esophagus, Percutaneous Approach	Procedure	ICD-10-PCS
0DB17ZZ	Excision of Upper Esophagus, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB20ZZ	Excision of Middle Esophagus, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0DB23ZZ	Excision of Middle Esophagus, Percutaneous Approach	Procedure	ICD-10-PCS
0DB27ZZ	Excision of Middle Esophagus, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB30ZZ	Excision of Lower Esophagus, Open Approach	Procedure	ICD-10-PCS
0DB33ZZ	Excision of Lower Esophagus, Percutaneous Approach	Procedure	ICD-10-PCS
0DB37ZZ	Excision of Lower Esophagus, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB40ZZ	Excision of Esophagogastric Junction, Open Approach	Procedure	ICD-10-PCS
0DB43ZZ	Excision of Esophagogastric Junction, Percutaneous Approach	Procedure	ICD-10-PCS
0DB44ZZ	Excision of Esophagogastric Junction, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DB47ZZ	Excision of Esophagogastric Junction, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB50ZZ	Excision of Esophagus, Open Approach	Procedure	ICD-10-PCS
0DB53ZZ	Excision of Esophagus, Percutaneous Approach	Procedure	ICD-10-PCS
0DB57ZZ	Excision of Esophagus, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB60Z3	Excision of Stomach, Open Approach, Vertical	Procedure	ICD-10-PCS
0DB60ZZ	Excision of Stomach, Open Approach	Procedure	ICD-10-PCS
0DB63Z3	Excision of Stomach, Percutaneous Approach, Vertical	Procedure	ICD-10-PCS
0DB63ZZ	Excision of Stomach, Percutaneous Approach	Procedure	ICD-10-PCS
0DB64Z3	Excision of Stomach, Percutaneous Endoscopic Approach, Vertical	Procedure	ICD-10-PCS
0DB64ZZ	Excision of Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DB67Z3	Excision of Stomach, Via Natural or Artificial Opening, Vertical	Procedure	ICD-10-PCS
0DB67ZZ	Excision of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB68Z3	Excision of Stomach, Via Natural or Artificial Opening Endoscopic, Vertical	Procedure	ICD-10-PCS
0DB68ZZ	Excision of Stomach, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DB70ZZ	Excision of Stomach, Pylorus, Open Approach	Procedure	ICD-10-PCS
0DB73ZZ	Excision of Stomach, Pylorus, Percutaneous Approach	Procedure	ICD-10-PCS
0DB77ZZ	Excision of Stomach, Pylorus, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB90ZZ	Excision of Duodenum, Open Approach	Procedure	ICD-10-PCS
0DB93ZZ	Excision of Duodenum, Percutaneous Approach	Procedure	ICD-10-PCS
0DB94ZZ	Excision of Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DB97ZZ	Excision of Duodenum, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DB98ZZ	Excision of Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DBE0ZZ	Excision of Large Intestine, Open Approach	Procedure	ICD-10-PCS
0DBE3ZZ	Excision of Large Intestine, Percutaneous Approach	Procedure	ICD-10-PCS
0DBE4ZZ	Excision of Large Intestine, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DBE7ZZ	Excision of Large Intestine, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DBE8ZZ	Excision of Large Intestine, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DBF0ZZ	Excision of Right Large Intestine, Open Approach	Procedure	ICD-10-PCS
0DBF3ZZ	Excision of Right Large Intestine, Percutaneous Approach	Procedure	ICD-10-PCS
0DBF4ZZ	Excision of Right Large Intestine, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DBF7ZZ	Excision of Right Large Intestine, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DBF8ZZ	Excision of Right Large Intestine, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DBG0ZZ	Excision of Left Large Intestine, Open Approach	Procedure	ICD-10-PCS
0DBG3ZZ	Excision of Left Large Intestine, Percutaneous Approach	Procedure	ICD-10-PCS
0DBG4ZZ	Excision of Left Large Intestine, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0DBG7ZZ	Excision of Left Large Intestine, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DBG8ZZ	Excision of Left Large Intestine, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DBGFZZ	Excision of Left Large Intestine, Via Natural or Artificial Opening With Percutaneous Endoscopic Assistance	Procedure	ICD-10-PCS
0DBH0ZZ	Excision of Cecum, Open Approach	Procedure	ICD-10-PCS
0DBH3ZZ	Excision of Cecum, Percutaneous Approach	Procedure	ICD-10-PCS
0DBH4ZZ	Excision of Cecum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DBH7ZZ	Excision of Cecum, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DBH8ZZ	Excision of Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DBK0ZZ	Excision of Ascending Colon, Open Approach	Procedure	ICD-10-PCS
0DBK3ZZ	Excision of Ascending Colon, Percutaneous Approach	Procedure	ICD-10-PCS
0DBK4ZZ	Excision of Ascending Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DBK7ZZ	Excision of Ascending Colon, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DBK8ZZ	Excision of Ascending Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DBL0ZZ	Excision of Transverse Colon, Open Approach	Procedure	ICD-10-PCS
0DBL3ZZ	Excision of Transverse Colon, Percutaneous Approach	Procedure	ICD-10-PCS
0DBL4ZZ	Excision of Transverse Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DBL7ZZ	Excision of Transverse Colon, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DBL8ZZ	Excision of Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DBLFZZ	Excision of Transverse Colon, Via Natural or Artificial Opening With Percutaneous Endoscopic Assistance	Procedure	ICD-10-PCS
0DBM0ZZ	Excision of Descending Colon, Open Approach	Procedure	ICD-10-PCS
0DBM3ZZ	Excision of Descending Colon, Percutaneous Approach	Procedure	ICD-10-PCS
0DBM4ZZ	Excision of Descending Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DBM7ZZ	Excision of Descending Colon, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DBM8ZZ	Excision of Descending Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DBMFZZ	Excision of Descending Colon, Via Natural or Artificial Opening With Percutaneous Endoscopic Assistance	Procedure	ICD-10-PCS
0DBN0ZZ	Excision of Sigmoid Colon, Open Approach	Procedure	ICD-10-PCS
0DBN3ZZ	Excision of Sigmoid Colon, Percutaneous Approach	Procedure	ICD-10-PCS
0DBN4ZZ	Excision of Sigmoid Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DBN7ZZ	Excision of Sigmoid Colon, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DBN8ZZ	Excision of Sigmoid Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DBNFZZ	Excision of Sigmoid Colon, Via Natural or Artificial Opening With Percutaneous Endoscopic Assistance	Procedure	ICD-10-PCS
0DBP0ZZ	Excision of Rectum, Open Approach	Procedure	ICD-10-PCS
0DBP4ZZ	Excision of Rectum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DBU0ZZ	Excision of Omentum, Open Approach	Procedure	ICD-10-PCS
0DBU3ZZ	Excision of Omentum, Percutaneous Approach	Procedure	ICD-10-PCS
0DBU4ZZ	Excision of Omentum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DBV0ZZ	Excision of Mesentery, Open Approach	Procedure	ICD-10-PCS
0DBV3ZZ	Excision of Mesentery, Percutaneous Approach	Procedure	ICD-10-PCS
0DBV4ZZ	Excision of Mesentery, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0DBW0ZZ	Excision of Peritoneum, Open Approach	Procedure	ICD-10-PCS
0DBW3ZZ	Excision of Peritoneum, Percutaneous Approach	Procedure	ICD-10-PCS
0DBW4ZZ	Excision of Peritoneum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DLP0CZ	Occlusion of Rectum with Extraluminal Device, Open Approach	Procedure	ICD-10-PCS
0DLP0DZ	Occlusion of Rectum with Intraluminal Device, Open Approach	Procedure	ICD-10-PCS
0DLP0ZZ	Occlusion of Rectum, Open Approach	Procedure	ICD-10-PCS
0DLP3CZ	Occlusion of Rectum with Extraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0DLP3DZ	Occlusion of Rectum with Intraluminal Device, Percutaneous Approach	Procedure	ICD-10-PCS
0DLP3ZZ	Occlusion of Rectum, Percutaneous Approach	Procedure	ICD-10-PCS
0DLP4CZ	Occlusion of Rectum with Extraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DLP4DZ	Occlusion of Rectum with Intraluminal Device, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DLP4ZZ	Occlusion of Rectum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DLP7DZ	Occlusion of Rectum with Intraluminal Device, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DLP7ZZ	Occlusion of Rectum, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DLP8DZ	Occlusion of Rectum with Intraluminal Device, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DLP8ZZ	Occlusion of Rectum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DQP0ZZ	Repair Rectum, Open Approach	Procedure	ICD-10-PCS
0DQP3ZZ	Repair Rectum, Percutaneous Approach	Procedure	ICD-10-PCS
0DQP4ZZ	Repair Rectum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DQP7ZZ	Repair Rectum, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DQP8ZZ	Repair Rectum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DT10ZZ	Resection of Upper Esophagus, Open Approach	Procedure	ICD-10-PCS
0DT14ZZ	Resection of Upper Esophagus, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DT17ZZ	Resection of Upper Esophagus, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DT18ZZ	Resection of Upper Esophagus, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DT20ZZ	Resection of Middle Esophagus, Open Approach	Procedure	ICD-10-PCS
0DT24ZZ	Resection of Middle Esophagus, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DT27ZZ	Resection of Middle Esophagus, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DT28ZZ	Resection of Middle Esophagus, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DT30ZZ	Resection of Lower Esophagus, Open Approach	Procedure	ICD-10-PCS
0DT34ZZ	Resection of Lower Esophagus, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DT37ZZ	Resection of Lower Esophagus, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DT38ZZ	Resection of Lower Esophagus, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DT40ZZ	Resection of Esophagogastric Junction, Open Approach	Procedure	ICD-10-PCS
0DT44ZZ	Resection of Esophagogastric Junction, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DT47ZZ	Resection of Esophagogastric Junction, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DT48ZZ	Resection of Esophagogastric Junction, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DT50ZZ	Resection of Esophagus, Open Approach	Procedure	ICD-10-PCS
0DT54ZZ	Resection of Esophagus, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DT57ZZ	Resection of Esophagus, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DT58ZZ	Resection of Esophagus, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DT60ZZ	Resection of Stomach, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0DT64ZZ	Resection of Stomach, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DT67ZZ	Resection of Stomach, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DT68ZZ	Resection of Stomach, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DT70ZZ	Resection of Stomach, Pylorus, Open Approach	Procedure	ICD-10-PCS
0DT74ZZ	Resection of Stomach, Pylorus, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DT77ZZ	Resection of Stomach, Pylorus, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DT78ZZ	Resection of Stomach, Pylorus, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DT90ZZ	Resection of Duodenum, Open Approach	Procedure	ICD-10-PCS
0DT94ZZ	Resection of Duodenum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DT97ZZ	Resection of Duodenum, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DT98ZZ	Resection of Duodenum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DTE0ZZ	Resection of Large Intestine, Open Approach	Procedure	ICD-10-PCS
0DTE4ZZ	Resection of Large Intestine, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DTE7ZZ	Resection of Large Intestine, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DTE8ZZ	Resection of Large Intestine, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DTF0ZZ	Resection of Right Large Intestine, Open Approach	Procedure	ICD-10-PCS
0DTF4ZZ	Resection of Right Large Intestine, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DTF7ZZ	Resection of Right Large Intestine, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DTF8ZZ	Resection of Right Large Intestine, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DTG0ZZ	Resection of Left Large Intestine, Open Approach	Procedure	ICD-10-PCS
0DTG4ZZ	Resection of Left Large Intestine, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DTG7ZZ	Resection of Left Large Intestine, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DTG8ZZ	Resection of Left Large Intestine, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DTGFZZ	Resection of Left Large Intestine, Via Natural or Artificial Opening With Percutaneous Endoscopic Assistance	Procedure	ICD-10-PCS
0DTH0ZZ	Resection of Cecum, Open Approach	Procedure	ICD-10-PCS
0DTH4ZZ	Resection of Cecum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DTH7ZZ	Resection of Cecum, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DTH8ZZ	Resection of Cecum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DTK0ZZ	Resection of Ascending Colon, Open Approach	Procedure	ICD-10-PCS
0DTK4ZZ	Resection of Ascending Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DTK7ZZ	Resection of Ascending Colon, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DTK8ZZ	Resection of Ascending Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DTL0ZZ	Resection of Transverse Colon, Open Approach	Procedure	ICD-10-PCS
0DTL4ZZ	Resection of Transverse Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DTL7ZZ	Resection of Transverse Colon, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DTL8ZZ	Resection of Transverse Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DTLFZZ	Resection of Transverse Colon, Via Natural or Artificial Opening With Percutaneous Endoscopic Assistance	Procedure	ICD-10-PCS
0DTM0ZZ	Resection of Descending Colon, Open Approach	Procedure	ICD-10-PCS
0DTM4ZZ	Resection of Descending Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DTM7ZZ	Resection of Descending Colon, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DTM8ZZ	Resection of Descending Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0DTMFZZ	Resection of Descending Colon, Via Natural or Artificial Opening With Percutaneous Endoscopic Assistance	Procedure	ICD-10-PCS
0DTN0ZZ	Resection of Sigmoid Colon, Open Approach	Procedure	ICD-10-PCS
0DTN4ZZ	Resection of Sigmoid Colon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DTN7ZZ	Resection of Sigmoid Colon, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DTN8ZZ	Resection of Sigmoid Colon, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DTNFZZ	Resection of Sigmoid Colon, Via Natural or Artificial Opening With Percutaneous Endoscopic Assistance	Procedure	ICD-10-PCS
0DTP0ZZ	Resection of Rectum, Open Approach	Procedure	ICD-10-PCS
0DTP4ZZ	Resection of Rectum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DTP7ZZ	Resection of Rectum, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0DTP8ZZ	Resection of Rectum, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0DTU0ZZ	Resection of Omentum, Open Approach	Procedure	ICD-10-PCS
0DTU4ZZ	Resection of Omentum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DX60Z5	Transfer Stomach to Esophagus, Open Approach	Procedure	ICD-10-PCS
0DX64Z5	Transfer Stomach to Esophagus, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DX80Z5	Transfer Small Intestine to Esophagus, Open Approach	Procedure	ICD-10-PCS
0DX84Z5	Transfer Small Intestine to Esophagus, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0DXE0Z5	Transfer Large Intestine to Esophagus, Open Approach	Procedure	ICD-10-PCS
0DXE4Z5	Transfer Large Intestine to Esophagus, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F190Z3	Bypass Common Bile Duct to Duodenum, Open Approach	Procedure	ICD-10-PCS
0F1G0ZC	Bypass Pancreas to Large Intestine, Open Approach	Procedure	ICD-10-PCS
0F500ZZ	Destruction of Liver, Open Approach	Procedure	ICD-10-PCS
0F503ZZ	Destruction of Liver, Percutaneous Approach	Procedure	ICD-10-PCS
0F504ZZ	Destruction of Liver, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F510ZZ	Destruction of Right Lobe Liver, Open Approach	Procedure	ICD-10-PCS
0F513ZZ	Destruction of Right Lobe Liver, Percutaneous Approach	Procedure	ICD-10-PCS
0F514ZZ	Destruction of Right Lobe Liver, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F520ZZ	Destruction of Left Lobe Liver, Open Approach	Procedure	ICD-10-PCS
0F523ZZ	Destruction of Left Lobe Liver, Percutaneous Approach	Procedure	ICD-10-PCS
0F524ZZ	Destruction of Left Lobe Liver, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F5D0ZZ	Destruction of Pancreatic Duct, Open Approach	Procedure	ICD-10-PCS
0F5D3ZZ	Destruction of Pancreatic Duct, Percutaneous Approach	Procedure	ICD-10-PCS
0F5D4ZZ	Destruction of Pancreatic Duct, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F5D7ZZ	Destruction of Pancreatic Duct, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0F5D8ZZ	Destruction of Pancreatic Duct, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0F5F0ZZ	Destruction of Accessory Pancreatic Duct, Open Approach	Procedure	ICD-10-PCS
0F5F3ZZ	Destruction of Accessory Pancreatic Duct, Percutaneous Approach	Procedure	ICD-10-PCS
0F5F4ZZ	Destruction of Accessory Pancreatic Duct, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F5F7ZZ	Destruction of Accessory Pancreatic Duct, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0F5F8ZZ	Destruction of Accessory Pancreatic Duct, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0F5G0ZZ	Destruction of Pancreas, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0F5G3ZZ	Destruction of Pancreas, Percutaneous Approach	Procedure	ICD-10-PCS
0F5G4ZZ	Destruction of Pancreas, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0F5G8ZZ	Destruction of Pancreas, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0FB00ZZ	Excision of Liver, Open Approach	Procedure	ICD-10-PCS
0FB03ZZ	Excision of Liver, Percutaneous Approach	Procedure	ICD-10-PCS
0FB04ZZ	Excision of Liver, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0FB10ZZ	Excision of Right Lobe Liver, Open Approach	Procedure	ICD-10-PCS
0FB13ZZ	Excision of Right Lobe Liver, Percutaneous Approach	Procedure	ICD-10-PCS
0FB14ZZ	Excision of Right Lobe Liver, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0FB20ZZ	Excision of Left Lobe Liver, Open Approach	Procedure	ICD-10-PCS
0FB23ZZ	Excision of Left Lobe Liver, Percutaneous Approach	Procedure	ICD-10-PCS
0FB24ZZ	Excision of Left Lobe Liver, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0FBD0ZZ	Excision of Pancreatic Duct, Open Approach	Procedure	ICD-10-PCS
0FBD3ZZ	Excision of Pancreatic Duct, Percutaneous Approach	Procedure	ICD-10-PCS
0FBD4ZZ	Excision of Pancreatic Duct, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0FBD7ZZ	Excision of Pancreatic Duct, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0FBD8ZZ	Excision of Pancreatic Duct, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0FBF0ZZ	Excision of Accessory Pancreatic Duct, Open Approach	Procedure	ICD-10-PCS
0FBF3ZZ	Excision of Accessory Pancreatic Duct, Percutaneous Approach	Procedure	ICD-10-PCS
0FBF4ZZ	Excision of Accessory Pancreatic Duct, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0FBF7ZZ	Excision of Accessory Pancreatic Duct, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0FBF8ZZ	Excision of Accessory Pancreatic Duct, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0FBG0ZZ	Excision of Pancreas, Open Approach	Procedure	ICD-10-PCS
0FBG3ZZ	Excision of Pancreas, Percutaneous Approach	Procedure	ICD-10-PCS
0FBG4ZZ	Excision of Pancreas, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0FBG8ZZ	Excision of Pancreas, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0FT00ZZ	Resection of Liver, Open Approach	Procedure	ICD-10-PCS
0FT04ZZ	Resection of Liver, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0FT10ZZ	Resection of Right Lobe Liver, Open Approach	Procedure	ICD-10-PCS
0FT14ZZ	Resection of Right Lobe Liver, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0FT20ZZ	Resection of Left Lobe Liver, Open Approach	Procedure	ICD-10-PCS
0FT24ZZ	Resection of Left Lobe Liver, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0FTD0ZZ	Resection of Pancreatic Duct, Open Approach	Procedure	ICD-10-PCS
0FTD4ZZ	Resection of Pancreatic Duct, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0FTD7ZZ	Resection of Pancreatic Duct, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0FTD8ZZ	Resection of Pancreatic Duct, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0FTF0ZZ	Resection of Accessory Pancreatic Duct, Open Approach	Procedure	ICD-10-PCS
0FTF4ZZ	Resection of Accessory Pancreatic Duct, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0FTF7ZZ	Resection of Accessory Pancreatic Duct, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0FTF8ZZ	Resection of Accessory Pancreatic Duct, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0FTG0ZZ	Resection of Pancreas, Open Approach	Procedure	ICD-10-PCS
0FTG4ZZ	Resection of Pancreas, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0G5G0ZZ	Destruction of Left Thyroid Gland Lobe, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0G5G3ZZ	Destruction of Left Thyroid Gland Lobe, Percutaneous Approach	Procedure	ICD-10-PCS
0G5G4ZZ	Destruction of Left Thyroid Gland Lobe, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0G5H0ZZ	Destruction of Right Thyroid Gland Lobe, Open Approach	Procedure	ICD-10-PCS
0G5H3ZZ	Destruction of Right Thyroid Gland Lobe, Percutaneous Approach	Procedure	ICD-10-PCS
0G5H4ZZ	Destruction of Right Thyroid Gland Lobe, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0G5K0ZZ	Destruction of Thyroid Gland, Open Approach	Procedure	ICD-10-PCS
0G5K3ZZ	Destruction of Thyroid Gland, Percutaneous Approach	Procedure	ICD-10-PCS
0G5K4ZZ	Destruction of Thyroid Gland, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0GBG0ZZ	Excision of Left Thyroid Gland Lobe, Open Approach	Procedure	ICD-10-PCS
0GBG3ZZ	Excision of Left Thyroid Gland Lobe, Percutaneous Approach	Procedure	ICD-10-PCS
0GBG4ZZ	Excision of Left Thyroid Gland Lobe, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0GBH0ZZ	Excision of Right Thyroid Gland Lobe, Open Approach	Procedure	ICD-10-PCS
0GBH3ZZ	Excision of Right Thyroid Gland Lobe, Percutaneous Approach	Procedure	ICD-10-PCS
0GBH4ZZ	Excision of Right Thyroid Gland Lobe, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0GBJ0ZZ	Excision of Thyroid Gland Isthmus, Open Approach	Procedure	ICD-10-PCS
0GBJ3ZZ	Excision of Thyroid Gland Isthmus, Percutaneous Approach	Procedure	ICD-10-PCS
0GBJ4ZZ	Excision of Thyroid Gland Isthmus, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0GTG0ZZ	Resection of Left Thyroid Gland Lobe, Open Approach	Procedure	ICD-10-PCS
0GTG4ZZ	Resection of Left Thyroid Gland Lobe, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0GTH0ZZ	Resection of Right Thyroid Gland Lobe, Open Approach	Procedure	ICD-10-PCS
0GTH4ZZ	Resection of Right Thyroid Gland Lobe, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0GTJ0ZZ	Resection of Thyroid Gland Isthmus, Open Approach	Procedure	ICD-10-PCS
0GTJ4ZZ	Resection of Thyroid Gland Isthmus, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0GTK0ZZ	Resection of Thyroid Gland, Open Approach	Procedure	ICD-10-PCS
0GTK4ZZ	Resection of Thyroid Gland, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0H50XZD	Destruction of Scalp Skin, Multiple, External Approach	Procedure	ICD-10-PCS
0H50XZZ	Destruction of Scalp Skin, External Approach	Procedure	ICD-10-PCS
0H51XZD	Destruction of Face Skin, Multiple, External Approach	Procedure	ICD-10-PCS
0H51XZZ	Destruction of Face Skin, External Approach	Procedure	ICD-10-PCS
0H52XZD	Destruction of Right Ear Skin, Multiple, External Approach	Procedure	ICD-10-PCS
0H52XZZ	Destruction of Right Ear Skin, External Approach	Procedure	ICD-10-PCS
0H53XZD	Destruction of Left Ear Skin, Multiple, External Approach	Procedure	ICD-10-PCS
0H53XZZ	Destruction of Left Ear Skin, External Approach	Procedure	ICD-10-PCS
0H54XZD	Destruction of Neck Skin, Multiple, External Approach	Procedure	ICD-10-PCS
0H54XZZ	Destruction of Neck Skin, External Approach	Procedure	ICD-10-PCS
0H55XZD	Destruction of Chest Skin, Multiple, External Approach	Procedure	ICD-10-PCS
0H55XZZ	Destruction of Chest Skin, External Approach	Procedure	ICD-10-PCS
0H56XZD	Destruction of Back Skin, Multiple, External Approach	Procedure	ICD-10-PCS
0H56XZZ	Destruction of Back Skin, External Approach	Procedure	ICD-10-PCS
0H57XZD	Destruction of Abdomen Skin, Multiple, External Approach	Procedure	ICD-10-PCS
0H57XZZ	Destruction of Abdomen Skin, External Approach	Procedure	ICD-10-PCS
0H58XZD	Destruction of Buttock Skin, Multiple, External Approach	Procedure	ICD-10-PCS
0H58XZZ	Destruction of Buttock Skin, External Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0H59XZD	Destruction of Perineum Skin, Multiple, External Approach	Procedure	ICD-10-PCS
0H59XZZ	Destruction of Perineum Skin, External Approach	Procedure	ICD-10-PCS
0H5AXZD	Destruction of Inguinal Skin, Multiple, External Approach	Procedure	ICD-10-PCS
0H5AXZZ	Destruction of Inguinal Skin, External Approach	Procedure	ICD-10-PCS
0H5BXZD	Destruction of Right Upper Arm Skin, Multiple, External Approach	Procedure	ICD-10-PCS
0H5BXZZ	Destruction of Right Upper Arm Skin, External Approach	Procedure	ICD-10-PCS
0H5CXZD	Destruction of Left Upper Arm Skin, Multiple, External Approach	Procedure	ICD-10-PCS
0H5CXZZ	Destruction of Left Upper Arm Skin, External Approach	Procedure	ICD-10-PCS
0H5DXZD	Destruction of Right Lower Arm Skin, Multiple, External Approach	Procedure	ICD-10-PCS
0H5DXZZ	Destruction of Right Lower Arm Skin, External Approach	Procedure	ICD-10-PCS
0H5EXZD	Destruction of Left Lower Arm Skin, Multiple, External Approach	Procedure	ICD-10-PCS
0H5EXZZ	Destruction of Left Lower Arm Skin, External Approach	Procedure	ICD-10-PCS
0H5FXZD	Destruction of Right Hand Skin, Multiple, External Approach	Procedure	ICD-10-PCS
0H5FXZZ	Destruction of Right Hand Skin, External Approach	Procedure	ICD-10-PCS
0H5GXZD	Destruction of Left Hand Skin, Multiple, External Approach	Procedure	ICD-10-PCS
0H5GXZZ	Destruction of Left Hand Skin, External Approach	Procedure	ICD-10-PCS
0H5HXZD	Destruction of Right Upper Leg Skin, Multiple, External Approach	Procedure	ICD-10-PCS
0H5HXZZ	Destruction of Right Upper Leg Skin, External Approach	Procedure	ICD-10-PCS
0H5JXZD	Destruction of Left Upper Leg Skin, Multiple, External Approach	Procedure	ICD-10-PCS
0H5JXZZ	Destruction of Left Upper Leg Skin, External Approach	Procedure	ICD-10-PCS
0H5KXZD	Destruction of Right Lower Leg Skin, Multiple, External Approach	Procedure	ICD-10-PCS
0H5KXZZ	Destruction of Right Lower Leg Skin, External Approach	Procedure	ICD-10-PCS
0H5LXZD	Destruction of Left Lower Leg Skin, Multiple, External Approach	Procedure	ICD-10-PCS
0H5LXZZ	Destruction of Left Lower Leg Skin, External Approach	Procedure	ICD-10-PCS
0H5MXZD	Destruction of Right Foot Skin, Multiple, External Approach	Procedure	ICD-10-PCS
0H5MXZZ	Destruction of Right Foot Skin, External Approach	Procedure	ICD-10-PCS
0H5NXZD	Destruction of Left Foot Skin, Multiple, External Approach	Procedure	ICD-10-PCS
0H5NXZZ	Destruction of Left Foot Skin, External Approach	Procedure	ICD-10-PCS
0H5QXZZ	Destruction of Finger Nail, External Approach	Procedure	ICD-10-PCS
0H5RXZZ	Destruction of Toe Nail, External Approach	Procedure	ICD-10-PCS
0HB0XZZ	Excision of Scalp Skin, External Approach	Procedure	ICD-10-PCS
0HB1XZZ	Excision of Face Skin, External Approach	Procedure	ICD-10-PCS
0HB2XZZ	Excision of Right Ear Skin, External Approach	Procedure	ICD-10-PCS
0HB3XZZ	Excision of Left Ear Skin, External Approach	Procedure	ICD-10-PCS
0HB4XZZ	Excision of Neck Skin, External Approach	Procedure	ICD-10-PCS
0HB5XZZ	Excision of Chest Skin, External Approach	Procedure	ICD-10-PCS
0HB6XZZ	Excision of Back Skin, External Approach	Procedure	ICD-10-PCS
0HB7XZZ	Excision of Abdomen Skin, External Approach	Procedure	ICD-10-PCS
0HB8XZZ	Excision of Buttock Skin, External Approach	Procedure	ICD-10-PCS
0HB9XZZ	Excision of Perineum Skin, External Approach	Procedure	ICD-10-PCS
0HBAXZZ	Excision of Inguinal Skin, External Approach	Procedure	ICD-10-PCS
0HBBXZZ	Excision of Right Upper Arm Skin, External Approach	Procedure	ICD-10-PCS
0HBCXZZ	Excision of Left Upper Arm Skin, External Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0HBDXZZ	Excision of Right Lower Arm Skin, External Approach	Procedure	ICD-10-PCS
0HBEXZZ	Excision of Left Lower Arm Skin, External Approach	Procedure	ICD-10-PCS
0HBFXZZ	Excision of Right Hand Skin, External Approach	Procedure	ICD-10-PCS
0HBGXZZ	Excision of Left Hand Skin, External Approach	Procedure	ICD-10-PCS
0HBHXZZ	Excision of Right Upper Leg Skin, External Approach	Procedure	ICD-10-PCS
0HBJXZZ	Excision of Left Upper Leg Skin, External Approach	Procedure	ICD-10-PCS
0HBKXZZ	Excision of Right Lower Leg Skin, External Approach	Procedure	ICD-10-PCS
0HBLXZZ	Excision of Left Lower Leg Skin, External Approach	Procedure	ICD-10-PCS
0HBMXZZ	Excision of Right Foot Skin, External Approach	Procedure	ICD-10-PCS
0HBNXZZ	Excision of Left Foot Skin, External Approach	Procedure	ICD-10-PCS
0HBQXZZ	Excision of Finger Nail, External Approach	Procedure	ICD-10-PCS
0HBRXZZ	Excision of Toe Nail, External Approach	Procedure	ICD-10-PCS
0HBT0ZZ	Excision of Right Breast, Open Approach	Procedure	ICD-10-PCS
0HBT3ZZ	Excision of Right Breast, Percutaneous Approach	Procedure	ICD-10-PCS
0HBT7ZZ	Excision of Right Breast, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0HBT8ZZ	Excision of Right Breast, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0HBTXZZ	Excision of Right Breast, External Approach	Procedure	ICD-10-PCS
0HBU0ZZ	Excision of Left Breast, Open Approach	Procedure	ICD-10-PCS
0HBU3ZZ	Excision of Left Breast, Percutaneous Approach	Procedure	ICD-10-PCS
0HBU7ZZ	Excision of Left Breast, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0HBU8ZZ	Excision of Left Breast, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0HBUXZZ	Excision of Left Breast, External Approach	Procedure	ICD-10-PCS
0HBV0ZZ	Excision of Bilateral Breast, Open Approach	Procedure	ICD-10-PCS
0HBV3ZZ	Excision of Bilateral Breast, Percutaneous Approach	Procedure	ICD-10-PCS
0HBV7ZZ	Excision of Bilateral Breast, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0HBV8ZZ	Excision of Bilateral Breast, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0HBVXZZ	Excision of Bilateral Breast, External Approach	Procedure	ICD-10-PCS
0HD2XZZ	Extraction of Right Ear Skin, External Approach	Procedure	ICD-10-PCS
0HD3XZZ	Extraction of Left Ear Skin, External Approach	Procedure	ICD-10-PCS
0HDQXZZ	Extraction of Finger Nail, External Approach	Procedure	ICD-10-PCS
0HDRXZZ	Extraction of Toe Nail, External Approach	Procedure	ICD-10-PCS
0HTQXZZ	Resection of Finger Nail, External Approach	Procedure	ICD-10-PCS
0HTRXZZ	Resection of Toe Nail, External Approach	Procedure	ICD-10-PCS
0HTT0ZZ	Resection of Right Breast, Open Approach	Procedure	ICD-10-PCS
0HTU0ZZ	Resection of Left Breast, Open Approach	Procedure	ICD-10-PCS
0HTV0ZZ	Resection of Bilateral Breast, Open Approach	Procedure	ICD-10-PCS
0J500ZZ	Destruction of Scalp Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0J503ZZ	Destruction of Scalp Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0J510ZZ	Destruction of Face Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0J513ZZ	Destruction of Face Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0J540ZZ	Destruction of Right Neck Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0J543ZZ	Destruction of Right Neck Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0J550ZZ	Destruction of Left Neck Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0J553ZZ	Destruction of Left Neck Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0J560ZZ	Destruction of Chest Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0J563ZZ	Destruction of Chest Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0J570ZZ	Destruction of Back Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0J573ZZ	Destruction of Back Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0J580ZZ	Destruction of Abdomen Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0J583ZZ	Destruction of Abdomen Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0J590ZZ	Destruction of Buttock Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0J593ZZ	Destruction of Buttock Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0J5B0ZZ	Destruction of Perineum Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0J5B3ZZ	Destruction of Perineum Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0J5C0ZZ	Destruction of Pelvic Region Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0J5C3ZZ	Destruction of Pelvic Region Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0J5D0ZZ	Destruction of Right Upper Arm Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0J5D3ZZ	Destruction of Right Upper Arm Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0J5F0ZZ	Destruction of Left Upper Arm Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0J5F3ZZ	Destruction of Left Upper Arm Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0J5G0ZZ	Destruction of Right Lower Arm Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0J5G3ZZ	Destruction of Right Lower Arm Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0J5H0ZZ	Destruction of Left Lower Arm Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0J5H3ZZ	Destruction of Left Lower Arm Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0J5J0ZZ	Destruction of Right Hand Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0J5J3ZZ	Destruction of Right Hand Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0J5K0ZZ	Destruction of Left Hand Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0J5K3ZZ	Destruction of Left Hand Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0J5L0ZZ	Destruction of Right Upper Leg Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0J5L3ZZ	Destruction of Right Upper Leg Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0J5M0ZZ	Destruction of Left Upper Leg Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0J5M3ZZ	Destruction of Left Upper Leg Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0J5N0ZZ	Destruction of Right Lower Leg Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0J5N3ZZ	Destruction of Right Lower Leg Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0J5P0ZZ	Destruction of Left Lower Leg Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0J5P3ZZ	Destruction of Left Lower Leg Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0J5Q0ZZ	Destruction of Right Foot Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0J5Q3ZZ	Destruction of Right Foot Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0J5R0ZZ	Destruction of Left Foot Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0J5R3ZZ	Destruction of Left Foot Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0JB00ZZ	Excision of Scalp Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0JB03ZZ	Excision of Scalp Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0JB10ZZ	Excision of Face Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0JB13ZZ	Excision of Face Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0JB40ZZ	Excision of Right Neck Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0JB43ZZ	Excision of Right Neck Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0JB50ZZ	Excision of Left Neck Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0JB53ZZ	Excision of Left Neck Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0JB60ZZ	Excision of Chest Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0JB63ZZ	Excision of Chest Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0JB70ZZ	Excision of Back Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0JB73ZZ	Excision of Back Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0JB80ZZ	Excision of Abdomen Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0JB83ZZ	Excision of Abdomen Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0JB90ZZ	Excision of Buttock Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0JB93ZZ	Excision of Buttock Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0JBB0ZZ	Excision of Perineum Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0JBB3ZZ	Excision of Perineum Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0JBC0ZZ	Excision of Pelvic Region Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0JBC3ZZ	Excision of Pelvic Region Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0JBD0ZZ	Excision of Right Upper Arm Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0JBD3ZZ	Excision of Right Upper Arm Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0JBF0ZZ	Excision of Left Upper Arm Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0JBF3ZZ	Excision of Left Upper Arm Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0JBG0ZZ	Excision of Right Lower Arm Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0JBG3ZZ	Excision of Right Lower Arm Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0JBH0ZZ	Excision of Left Lower Arm Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0JBH3ZZ	Excision of Left Lower Arm Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0JBJ0ZZ	Excision of Right Hand Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0JBJ3ZZ	Excision of Right Hand Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0JBK0ZZ	Excision of Left Hand Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0JBK3ZZ	Excision of Left Hand Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0JBL0ZZ	Excision of Right Upper Leg Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0JBL3ZZ	Excision of Right Upper Leg Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0JBM0ZZ	Excision of Left Upper Leg Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0JBM3ZZ	Excision of Left Upper Leg Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0JBN0ZZ	Excision of Right Lower Leg Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0JBN3ZZ	Excision of Right Lower Leg Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0JBP0ZZ	Excision of Left Lower Leg Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0JBP3ZZ	Excision of Left Lower Leg Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0JBQ0ZZ	Excision of Right Foot Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0JBQ3ZZ	Excision of Right Foot Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0JBR0ZZ	Excision of Left Foot Subcutaneous Tissue and Fascia, Open Approach	Procedure	ICD-10-PCS
0JBR3ZZ	Excision of Left Foot Subcutaneous Tissue and Fascia, Percutaneous Approach	Procedure	ICD-10-PCS
0K500ZZ	Destruction of Head Muscle, Open Approach	Procedure	ICD-10-PCS
0K503ZZ	Destruction of Head Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K504ZZ	Destruction of Head Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0K510ZZ	Destruction of Facial Muscle, Open Approach	Procedure	ICD-10-PCS
0K513ZZ	Destruction of Facial Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K514ZZ	Destruction of Facial Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0K520ZZ	Destruction of Right Neck Muscle, Open Approach	Procedure	ICD-10-PCS
0K523ZZ	Destruction of Right Neck Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K524ZZ	Destruction of Right Neck Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0K530ZZ	Destruction of Left Neck Muscle, Open Approach	Procedure	ICD-10-PCS
0K533ZZ	Destruction of Left Neck Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K534ZZ	Destruction of Left Neck Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0K540ZZ	Destruction of Tongue, Palate, Pharynx Muscle, Open Approach	Procedure	ICD-10-PCS
0K543ZZ	Destruction of Tongue, Palate, Pharynx Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K544ZZ	Destruction of Tongue, Palate, Pharynx Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0K550ZZ	Destruction of Right Shoulder Muscle, Open Approach	Procedure	ICD-10-PCS
0K553ZZ	Destruction of Right Shoulder Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K554ZZ	Destruction of Right Shoulder Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0K560ZZ	Destruction of Left Shoulder Muscle, Open Approach	Procedure	ICD-10-PCS
0K563ZZ	Destruction of Left Shoulder Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K564ZZ	Destruction of Left Shoulder Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0K570ZZ	Destruction of Right Upper Arm Muscle, Open Approach	Procedure	ICD-10-PCS
0K573ZZ	Destruction of Right Upper Arm Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K574ZZ	Destruction of Right Upper Arm Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0K580ZZ	Destruction of Left Upper Arm Muscle, Open Approach	Procedure	ICD-10-PCS
0K583ZZ	Destruction of Left Upper Arm Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K584ZZ	Destruction of Left Upper Arm Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0K590ZZ	Destruction of Right Lower Arm and Wrist Muscle, Open Approach	Procedure	ICD-10-PCS
0K593ZZ	Destruction of Right Lower Arm and Wrist Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K594ZZ	Destruction of Right Lower Arm and Wrist Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0K5B0ZZ	Destruction of Left Lower Arm and Wrist Muscle, Open Approach	Procedure	ICD-10-PCS
0K5B3ZZ	Destruction of Left Lower Arm and Wrist Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K5B4ZZ	Destruction of Left Lower Arm and Wrist Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0K5C0ZZ	Destruction of Right Hand Muscle, Open Approach	Procedure	ICD-10-PCS
0K5C3ZZ	Destruction of Right Hand Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K5C4ZZ	Destruction of Right Hand Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0K5D0ZZ	Destruction of Left Hand Muscle, Open Approach	Procedure	ICD-10-PCS
0K5D3ZZ	Destruction of Left Hand Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K5D4ZZ	Destruction of Left Hand Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0K5F0ZZ	Destruction of Right Trunk Muscle, Open Approach	Procedure	ICD-10-PCS
0K5F3ZZ	Destruction of Right Trunk Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K5F4ZZ	Destruction of Right Trunk Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0K5G0ZZ	Destruction of Left Trunk Muscle, Open Approach	Procedure	ICD-10-PCS
0K5G3ZZ	Destruction of Left Trunk Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K5G4ZZ	Destruction of Left Trunk Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0K5H0ZZ	Destruction of Right Thorax Muscle, Open Approach	Procedure	ICD-10-PCS
0K5H3ZZ	Destruction of Right Thorax Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K5H4ZZ	Destruction of Right Thorax Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0K5J0ZZ	Destruction of Left Thorax Muscle, Open Approach	Procedure	ICD-10-PCS
0K5J3ZZ	Destruction of Left Thorax Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K5J4ZZ	Destruction of Left Thorax Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0K5K0ZZ	Destruction of Right Abdomen Muscle, Open Approach	Procedure	ICD-10-PCS
0K5K3ZZ	Destruction of Right Abdomen Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K5K4ZZ	Destruction of Right Abdomen Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0K5L0ZZ	Destruction of Left Abdomen Muscle, Open Approach	Procedure	ICD-10-PCS
0K5L3ZZ	Destruction of Left Abdomen Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K5L4ZZ	Destruction of Left Abdomen Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0K5M0ZZ	Destruction of Perineum Muscle, Open Approach	Procedure	ICD-10-PCS
0K5M3ZZ	Destruction of Perineum Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K5M4ZZ	Destruction of Perineum Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0K5N0ZZ	Destruction of Right Hip Muscle, Open Approach	Procedure	ICD-10-PCS
0K5N3ZZ	Destruction of Right Hip Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K5N4ZZ	Destruction of Right Hip Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0K5P0ZZ	Destruction of Left Hip Muscle, Open Approach	Procedure	ICD-10-PCS
0K5P3ZZ	Destruction of Left Hip Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K5P4ZZ	Destruction of Left Hip Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0K5Q0ZZ	Destruction of Right Upper Leg Muscle, Open Approach	Procedure	ICD-10-PCS
0K5Q3ZZ	Destruction of Right Upper Leg Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K5Q4ZZ	Destruction of Right Upper Leg Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0K5R0ZZ	Destruction of Left Upper Leg Muscle, Open Approach	Procedure	ICD-10-PCS
0K5R3ZZ	Destruction of Left Upper Leg Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K5R4ZZ	Destruction of Left Upper Leg Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0K5S0ZZ	Destruction of Right Lower Leg Muscle, Open Approach	Procedure	ICD-10-PCS
0K5S3ZZ	Destruction of Right Lower Leg Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K5S4ZZ	Destruction of Right Lower Leg Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0K5T0ZZ	Destruction of Left Lower Leg Muscle, Open Approach	Procedure	ICD-10-PCS
0K5T3ZZ	Destruction of Left Lower Leg Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K5T4ZZ	Destruction of Left Lower Leg Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0K5V0ZZ	Destruction of Right Foot Muscle, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0K5V3ZZ	Destruction of Right Foot Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K5V4ZZ	Destruction of Right Foot Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0K5W0ZZ	Destruction of Left Foot Muscle, Open Approach	Procedure	ICD-10-PCS
0K5W3ZZ	Destruction of Left Foot Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0K5W4ZZ	Destruction of Left Foot Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KB00ZZ	Excision of Head Muscle, Open Approach	Procedure	ICD-10-PCS
0KB03ZZ	Excision of Head Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KB04ZZ	Excision of Head Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KB10ZZ	Excision of Facial Muscle, Open Approach	Procedure	ICD-10-PCS
0KB13ZZ	Excision of Facial Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KB14ZZ	Excision of Facial Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KB20ZZ	Excision of Right Neck Muscle, Open Approach	Procedure	ICD-10-PCS
0KB23ZZ	Excision of Right Neck Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KB24ZZ	Excision of Right Neck Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KB30ZZ	Excision of Left Neck Muscle, Open Approach	Procedure	ICD-10-PCS
0KB33ZZ	Excision of Left Neck Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KB34ZZ	Excision of Left Neck Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KB40ZZ	Excision of Tongue, Palate, Pharynx Muscle, Open Approach	Procedure	ICD-10-PCS
0KB43ZZ	Excision of Tongue, Palate, Pharynx Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KB44ZZ	Excision of Tongue, Palate, Pharynx Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KB50ZZ	Excision of Right Shoulder Muscle, Open Approach	Procedure	ICD-10-PCS
0KB53ZZ	Excision of Right Shoulder Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KB54ZZ	Excision of Right Shoulder Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KB60ZZ	Excision of Left Shoulder Muscle, Open Approach	Procedure	ICD-10-PCS
0KB63ZZ	Excision of Left Shoulder Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KB64ZZ	Excision of Left Shoulder Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KB70ZZ	Excision of Right Upper Arm Muscle, Open Approach	Procedure	ICD-10-PCS
0KB73ZZ	Excision of Right Upper Arm Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KB74ZZ	Excision of Right Upper Arm Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KB80ZZ	Excision of Left Upper Arm Muscle, Open Approach	Procedure	ICD-10-PCS
0KB83ZZ	Excision of Left Upper Arm Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KB84ZZ	Excision of Left Upper Arm Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KB90ZZ	Excision of Right Lower Arm and Wrist Muscle, Open Approach	Procedure	ICD-10-PCS
0KB93ZZ	Excision of Right Lower Arm and Wrist Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KB94ZZ	Excision of Right Lower Arm and Wrist Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KBB0ZZ	Excision of Left Lower Arm and Wrist Muscle, Open Approach	Procedure	ICD-10-PCS
0KBB3ZZ	Excision of Left Lower Arm and Wrist Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KBB4ZZ	Excision of Left Lower Arm and Wrist Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KBC0ZZ	Excision of Right Hand Muscle, Open Approach	Procedure	ICD-10-PCS
0KBC3ZZ	Excision of Right Hand Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KBC4ZZ	Excision of Right Hand Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KBD0ZZ	Excision of Left Hand Muscle, Open Approach	Procedure	ICD-10-PCS
0KBD3ZZ	Excision of Left Hand Muscle, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0KBD4ZZ	Excision of Left Hand Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KBF0ZZ	Excision of Right Trunk Muscle, Open Approach	Procedure	ICD-10-PCS
0KBF3ZZ	Excision of Right Trunk Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KBF4ZZ	Excision of Right Trunk Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KBG0ZZ	Excision of Left Trunk Muscle, Open Approach	Procedure	ICD-10-PCS
0KBG3ZZ	Excision of Left Trunk Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KBG4ZZ	Excision of Left Trunk Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KBH0ZZ	Excision of Right Thorax Muscle, Open Approach	Procedure	ICD-10-PCS
0KBH3ZZ	Excision of Right Thorax Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KBH4ZZ	Excision of Right Thorax Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KBJ0ZZ	Excision of Left Thorax Muscle, Open Approach	Procedure	ICD-10-PCS
0KBJ3ZZ	Excision of Left Thorax Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KBJ4ZZ	Excision of Left Thorax Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KBK0ZZ	Excision of Right Abdomen Muscle, Open Approach	Procedure	ICD-10-PCS
0KBK3ZZ	Excision of Right Abdomen Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KBK4ZZ	Excision of Right Abdomen Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KBL0ZZ	Excision of Left Abdomen Muscle, Open Approach	Procedure	ICD-10-PCS
0KBL3ZZ	Excision of Left Abdomen Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KBL4ZZ	Excision of Left Abdomen Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KBM0ZZ	Excision of Perineum Muscle, Open Approach	Procedure	ICD-10-PCS
0KBM3ZZ	Excision of Perineum Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KBM4ZZ	Excision of Perineum Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KBN0ZZ	Excision of Right Hip Muscle, Open Approach	Procedure	ICD-10-PCS
0KBN3ZZ	Excision of Right Hip Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KBN4ZZ	Excision of Right Hip Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KBP0ZZ	Excision of Left Hip Muscle, Open Approach	Procedure	ICD-10-PCS
0KBP3ZZ	Excision of Left Hip Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KBP4ZZ	Excision of Left Hip Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KBQ0ZZ	Excision of Right Upper Leg Muscle, Open Approach	Procedure	ICD-10-PCS
0KBQ3ZZ	Excision of Right Upper Leg Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KBQ4ZZ	Excision of Right Upper Leg Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KBR0ZZ	Excision of Left Upper Leg Muscle, Open Approach	Procedure	ICD-10-PCS
0KBR3ZZ	Excision of Left Upper Leg Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KBR4ZZ	Excision of Left Upper Leg Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KBS0ZZ	Excision of Right Lower Leg Muscle, Open Approach	Procedure	ICD-10-PCS
0KBS3ZZ	Excision of Right Lower Leg Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KBS4ZZ	Excision of Right Lower Leg Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KBT0ZZ	Excision of Left Lower Leg Muscle, Open Approach	Procedure	ICD-10-PCS
0KBT3ZZ	Excision of Left Lower Leg Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KBT4ZZ	Excision of Left Lower Leg Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KBV0ZZ	Excision of Right Foot Muscle, Open Approach	Procedure	ICD-10-PCS
0KBV3ZZ	Excision of Right Foot Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KBV4ZZ	Excision of Right Foot Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0KBW0ZZ	Excision of Left Foot Muscle, Open Approach	Procedure	ICD-10-PCS
0KBW3ZZ	Excision of Left Foot Muscle, Percutaneous Approach	Procedure	ICD-10-PCS
0KBW4ZZ	Excision of Left Foot Muscle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0KTH0ZZ	Resection of Right Thorax Muscle, Open Approach	Procedure	ICD-10-PCS
0KTJ0ZZ	Resection of Left Thorax Muscle, Open Approach	Procedure	ICD-10-PCS
0L500ZZ	Destruction of Head and Neck Tendon, Open Approach	Procedure	ICD-10-PCS
0L503ZZ	Destruction of Head and Neck Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L504ZZ	Destruction of Head and Neck Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L510ZZ	Destruction of Right Shoulder Tendon, Open Approach	Procedure	ICD-10-PCS
0L513ZZ	Destruction of Right Shoulder Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L514ZZ	Destruction of Right Shoulder Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L520ZZ	Destruction of Left Shoulder Tendon, Open Approach	Procedure	ICD-10-PCS
0L523ZZ	Destruction of Left Shoulder Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L524ZZ	Destruction of Left Shoulder Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L530ZZ	Destruction of Right Upper Arm Tendon, Open Approach	Procedure	ICD-10-PCS
0L533ZZ	Destruction of Right Upper Arm Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L534ZZ	Destruction of Right Upper Arm Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L540ZZ	Destruction of Left Upper Arm Tendon, Open Approach	Procedure	ICD-10-PCS
0L543ZZ	Destruction of Left Upper Arm Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L544ZZ	Destruction of Left Upper Arm Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L550ZZ	Destruction of Right Lower Arm and Wrist Tendon, Open Approach	Procedure	ICD-10-PCS
0L553ZZ	Destruction of Right Lower Arm and Wrist Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L554ZZ	Destruction of Right Lower Arm and Wrist Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L560ZZ	Destruction of Left Lower Arm and Wrist Tendon, Open Approach	Procedure	ICD-10-PCS
0L563ZZ	Destruction of Left Lower Arm and Wrist Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L564ZZ	Destruction of Left Lower Arm and Wrist Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L570ZZ	Destruction of Right Hand Tendon, Open Approach	Procedure	ICD-10-PCS
0L573ZZ	Destruction of Right Hand Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L574ZZ	Destruction of Right Hand Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L580ZZ	Destruction of Left Hand Tendon, Open Approach	Procedure	ICD-10-PCS
0L583ZZ	Destruction of Left Hand Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L584ZZ	Destruction of Left Hand Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L590ZZ	Destruction of Right Trunk Tendon, Open Approach	Procedure	ICD-10-PCS
0L593ZZ	Destruction of Right Trunk Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L594ZZ	Destruction of Right Trunk Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L5B0ZZ	Destruction of Left Trunk Tendon, Open Approach	Procedure	ICD-10-PCS
0L5B3ZZ	Destruction of Left Trunk Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L5B4ZZ	Destruction of Left Trunk Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L5C0ZZ	Destruction of Right Thorax Tendon, Open Approach	Procedure	ICD-10-PCS
0L5C3ZZ	Destruction of Right Thorax Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L5C4ZZ	Destruction of Right Thorax Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L5D0ZZ	Destruction of Left Thorax Tendon, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0L5D3ZZ	Destruction of Left Thorax Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L5D4ZZ	Destruction of Left Thorax Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L5F0ZZ	Destruction of Right Abdomen Tendon, Open Approach	Procedure	ICD-10-PCS
0L5F3ZZ	Destruction of Right Abdomen Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L5F4ZZ	Destruction of Right Abdomen Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L5G0ZZ	Destruction of Left Abdomen Tendon, Open Approach	Procedure	ICD-10-PCS
0L5G3ZZ	Destruction of Left Abdomen Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L5G4ZZ	Destruction of Left Abdomen Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L5H0ZZ	Destruction of Perineum Tendon, Open Approach	Procedure	ICD-10-PCS
0L5H3ZZ	Destruction of Perineum Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L5H4ZZ	Destruction of Perineum Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L5J0ZZ	Destruction of Right Hip Tendon, Open Approach	Procedure	ICD-10-PCS
0L5J3ZZ	Destruction of Right Hip Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L5J4ZZ	Destruction of Right Hip Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L5K0ZZ	Destruction of Left Hip Tendon, Open Approach	Procedure	ICD-10-PCS
0L5K3ZZ	Destruction of Left Hip Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L5K4ZZ	Destruction of Left Hip Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L5L0ZZ	Destruction of Right Upper Leg Tendon, Open Approach	Procedure	ICD-10-PCS
0L5L3ZZ	Destruction of Right Upper Leg Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L5L4ZZ	Destruction of Right Upper Leg Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L5M0ZZ	Destruction of Left Upper Leg Tendon, Open Approach	Procedure	ICD-10-PCS
0L5M3ZZ	Destruction of Left Upper Leg Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L5M4ZZ	Destruction of Left Upper Leg Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L5N0ZZ	Destruction of Right Lower Leg Tendon, Open Approach	Procedure	ICD-10-PCS
0L5N3ZZ	Destruction of Right Lower Leg Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L5N4ZZ	Destruction of Right Lower Leg Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L5P0ZZ	Destruction of Left Lower Leg Tendon, Open Approach	Procedure	ICD-10-PCS
0L5P3ZZ	Destruction of Left Lower Leg Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L5P4ZZ	Destruction of Left Lower Leg Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L5Q0ZZ	Destruction of Right Knee Tendon, Open Approach	Procedure	ICD-10-PCS
0L5Q3ZZ	Destruction of Right Knee Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L5Q4ZZ	Destruction of Right Knee Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L5R0ZZ	Destruction of Left Knee Tendon, Open Approach	Procedure	ICD-10-PCS
0L5R3ZZ	Destruction of Left Knee Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L5R4ZZ	Destruction of Left Knee Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L5S0ZZ	Destruction of Right Ankle Tendon, Open Approach	Procedure	ICD-10-PCS
0L5S3ZZ	Destruction of Right Ankle Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L5S4ZZ	Destruction of Right Ankle Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L5T0ZZ	Destruction of Left Ankle Tendon, Open Approach	Procedure	ICD-10-PCS
0L5T3ZZ	Destruction of Left Ankle Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L5T4ZZ	Destruction of Left Ankle Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L5V0ZZ	Destruction of Right Foot Tendon, Open Approach	Procedure	ICD-10-PCS
0L5V3ZZ	Destruction of Right Foot Tendon, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0L5V4ZZ	Destruction of Right Foot Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0L5W0ZZ	Destruction of Left Foot Tendon, Open Approach	Procedure	ICD-10-PCS
0L5W3ZZ	Destruction of Left Foot Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0L5W4ZZ	Destruction of Left Foot Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LB00ZZ	Excision of Head and Neck Tendon, Open Approach	Procedure	ICD-10-PCS
0LB03ZZ	Excision of Head and Neck Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LB04ZZ	Excision of Head and Neck Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LB10ZZ	Excision of Right Shoulder Tendon, Open Approach	Procedure	ICD-10-PCS
0LB13ZZ	Excision of Right Shoulder Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LB14ZZ	Excision of Right Shoulder Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LB20ZZ	Excision of Left Shoulder Tendon, Open Approach	Procedure	ICD-10-PCS
0LB23ZZ	Excision of Left Shoulder Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LB24ZZ	Excision of Left Shoulder Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LB30ZZ	Excision of Right Upper Arm Tendon, Open Approach	Procedure	ICD-10-PCS
0LB33ZZ	Excision of Right Upper Arm Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LB34ZZ	Excision of Right Upper Arm Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LB40ZZ	Excision of Left Upper Arm Tendon, Open Approach	Procedure	ICD-10-PCS
0LB43ZZ	Excision of Left Upper Arm Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LB44ZZ	Excision of Left Upper Arm Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LB50ZZ	Excision of Right Lower Arm and Wrist Tendon, Open Approach	Procedure	ICD-10-PCS
0LB53ZZ	Excision of Right Lower Arm and Wrist Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LB54ZZ	Excision of Right Lower Arm and Wrist Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LB60ZZ	Excision of Left Lower Arm and Wrist Tendon, Open Approach	Procedure	ICD-10-PCS
0LB63ZZ	Excision of Left Lower Arm and Wrist Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LB64ZZ	Excision of Left Lower Arm and Wrist Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LB70ZZ	Excision of Right Hand Tendon, Open Approach	Procedure	ICD-10-PCS
0LB73ZZ	Excision of Right Hand Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LB74ZZ	Excision of Right Hand Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LB80ZZ	Excision of Left Hand Tendon, Open Approach	Procedure	ICD-10-PCS
0LB83ZZ	Excision of Left Hand Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LB84ZZ	Excision of Left Hand Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LB90ZZ	Excision of Right Trunk Tendon, Open Approach	Procedure	ICD-10-PCS
0LB93ZZ	Excision of Right Trunk Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LB94ZZ	Excision of Right Trunk Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LBB0ZZ	Excision of Left Trunk Tendon, Open Approach	Procedure	ICD-10-PCS
0LBB3ZZ	Excision of Left Trunk Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LBB4ZZ	Excision of Left Trunk Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LBC0ZZ	Excision of Right Thorax Tendon, Open Approach	Procedure	ICD-10-PCS
0LBC3ZZ	Excision of Right Thorax Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LBC4ZZ	Excision of Right Thorax Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LBD0ZZ	Excision of Left Thorax Tendon, Open Approach	Procedure	ICD-10-PCS
0LBD3ZZ	Excision of Left Thorax Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LBD4ZZ	Excision of Left Thorax Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0LBF0ZZ	Excision of Right Abdomen Tendon, Open Approach	Procedure	ICD-10-PCS
0LBF3ZZ	Excision of Right Abdomen Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LBF4ZZ	Excision of Right Abdomen Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LBG0ZZ	Excision of Left Abdomen Tendon, Open Approach	Procedure	ICD-10-PCS
0LBG3ZZ	Excision of Left Abdomen Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LBG4ZZ	Excision of Left Abdomen Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LBH0ZZ	Excision of Perineum Tendon, Open Approach	Procedure	ICD-10-PCS
0LBH3ZZ	Excision of Perineum Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LBH4ZZ	Excision of Perineum Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LBJ0ZZ	Excision of Right Hip Tendon, Open Approach	Procedure	ICD-10-PCS
0LBJ3ZZ	Excision of Right Hip Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LBJ4ZZ	Excision of Right Hip Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LBK0ZZ	Excision of Left Hip Tendon, Open Approach	Procedure	ICD-10-PCS
0LBK3ZZ	Excision of Left Hip Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LBK4ZZ	Excision of Left Hip Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LBL0ZZ	Excision of Right Upper Leg Tendon, Open Approach	Procedure	ICD-10-PCS
0LBL3ZZ	Excision of Right Upper Leg Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LBL4ZZ	Excision of Right Upper Leg Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LBM0ZZ	Excision of Left Upper Leg Tendon, Open Approach	Procedure	ICD-10-PCS
0LBM3ZZ	Excision of Left Upper Leg Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LBM4ZZ	Excision of Left Upper Leg Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LBN0ZZ	Excision of Right Lower Leg Tendon, Open Approach	Procedure	ICD-10-PCS
0LBN3ZZ	Excision of Right Lower Leg Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LBN4ZZ	Excision of Right Lower Leg Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LBP0ZZ	Excision of Left Lower Leg Tendon, Open Approach	Procedure	ICD-10-PCS
0LBP3ZZ	Excision of Left Lower Leg Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LBP4ZZ	Excision of Left Lower Leg Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LBQ0ZZ	Excision of Right Knee Tendon, Open Approach	Procedure	ICD-10-PCS
0LBQ3ZZ	Excision of Right Knee Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LBQ4ZZ	Excision of Right Knee Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LBR0ZZ	Excision of Left Knee Tendon, Open Approach	Procedure	ICD-10-PCS
0LBR3ZZ	Excision of Left Knee Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LBR4ZZ	Excision of Left Knee Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LBS0ZZ	Excision of Right Ankle Tendon, Open Approach	Procedure	ICD-10-PCS
0LBS3ZZ	Excision of Right Ankle Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LBS4ZZ	Excision of Right Ankle Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LBT0ZZ	Excision of Left Ankle Tendon, Open Approach	Procedure	ICD-10-PCS
0LBT3ZZ	Excision of Left Ankle Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LBT4ZZ	Excision of Left Ankle Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LBV0ZZ	Excision of Right Foot Tendon, Open Approach	Procedure	ICD-10-PCS
0LBV3ZZ	Excision of Right Foot Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LBV4ZZ	Excision of Right Foot Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LBW0ZZ	Excision of Left Foot Tendon, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0LBW3ZZ	Excision of Left Foot Tendon, Percutaneous Approach	Procedure	ICD-10-PCS
0LBW4ZZ	Excision of Left Foot Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LT00ZZ	Resection of Head and Neck Tendon, Open Approach	Procedure	ICD-10-PCS
0LT04ZZ	Resection of Head and Neck Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LT10ZZ	Resection of Right Shoulder Tendon, Open Approach	Procedure	ICD-10-PCS
0LT14ZZ	Resection of Right Shoulder Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LT20ZZ	Resection of Left Shoulder Tendon, Open Approach	Procedure	ICD-10-PCS
0LT24ZZ	Resection of Left Shoulder Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LT30ZZ	Resection of Right Upper Arm Tendon, Open Approach	Procedure	ICD-10-PCS
0LT34ZZ	Resection of Right Upper Arm Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LT40ZZ	Resection of Left Upper Arm Tendon, Open Approach	Procedure	ICD-10-PCS
0LT44ZZ	Resection of Left Upper Arm Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LT50ZZ	Resection of Right Lower Arm and Wrist Tendon, Open Approach	Procedure	ICD-10-PCS
0LT54ZZ	Resection of Right Lower Arm and Wrist Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LT60ZZ	Resection of Left Lower Arm and Wrist Tendon, Open Approach	Procedure	ICD-10-PCS
0LT64ZZ	Resection of Left Lower Arm and Wrist Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LT90ZZ	Resection of Right Trunk Tendon, Open Approach	Procedure	ICD-10-PCS
0LT94ZZ	Resection of Right Trunk Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LTB0ZZ	Resection of Left Trunk Tendon, Open Approach	Procedure	ICD-10-PCS
0LTB4ZZ	Resection of Left Trunk Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LTC0ZZ	Resection of Right Thorax Tendon, Open Approach	Procedure	ICD-10-PCS
0LTC4ZZ	Resection of Right Thorax Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LTD0ZZ	Resection of Left Thorax Tendon, Open Approach	Procedure	ICD-10-PCS
0LTD4ZZ	Resection of Left Thorax Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LTF0ZZ	Resection of Right Abdomen Tendon, Open Approach	Procedure	ICD-10-PCS
0LTF4ZZ	Resection of Right Abdomen Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LTG0ZZ	Resection of Left Abdomen Tendon, Open Approach	Procedure	ICD-10-PCS
0LTG4ZZ	Resection of Left Abdomen Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LTH0ZZ	Resection of Perineum Tendon, Open Approach	Procedure	ICD-10-PCS
0LTH4ZZ	Resection of Perineum Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LTJ0ZZ	Resection of Right Hip Tendon, Open Approach	Procedure	ICD-10-PCS
0LTJ4ZZ	Resection of Right Hip Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LTK0ZZ	Resection of Left Hip Tendon, Open Approach	Procedure	ICD-10-PCS
0LTK4ZZ	Resection of Left Hip Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LTL0ZZ	Resection of Right Upper Leg Tendon, Open Approach	Procedure	ICD-10-PCS
0LTL4ZZ	Resection of Right Upper Leg Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LTM0ZZ	Resection of Left Upper Leg Tendon, Open Approach	Procedure	ICD-10-PCS
0LTM4ZZ	Resection of Left Upper Leg Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LTN0ZZ	Resection of Right Lower Leg Tendon, Open Approach	Procedure	ICD-10-PCS
0LTN4ZZ	Resection of Right Lower Leg Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LTP0ZZ	Resection of Left Lower Leg Tendon, Open Approach	Procedure	ICD-10-PCS
0LTP4ZZ	Resection of Left Lower Leg Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LTQ0ZZ	Resection of Right Knee Tendon, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0LTQ4ZZ	Resection of Right Knee Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LTR0ZZ	Resection of Left Knee Tendon, Open Approach	Procedure	ICD-10-PCS
0LTR4ZZ	Resection of Left Knee Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LTS0ZZ	Resection of Right Ankle Tendon, Open Approach	Procedure	ICD-10-PCS
0LTS4ZZ	Resection of Right Ankle Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LTT0ZZ	Resection of Left Ankle Tendon, Open Approach	Procedure	ICD-10-PCS
0LTT4ZZ	Resection of Left Ankle Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LTV0ZZ	Resection of Right Foot Tendon, Open Approach	Procedure	ICD-10-PCS
0LTV4ZZ	Resection of Right Foot Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0LTW0ZZ	Resection of Left Foot Tendon, Open Approach	Procedure	ICD-10-PCS
0LTW4ZZ	Resection of Left Foot Tendon, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0M510ZZ	Destruction of Right Shoulder Bursa and Ligament, Open Approach	Procedure	ICD-10-PCS
0M513ZZ	Destruction of Right Shoulder Bursa and Ligament, Percutaneous Approach	Procedure	ICD-10-PCS
0M514ZZ	Destruction of Right Shoulder Bursa and Ligament, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0M520ZZ	Destruction of Left Shoulder Bursa and Ligament, Open Approach	Procedure	ICD-10-PCS
0M523ZZ	Destruction of Left Shoulder Bursa and Ligament, Percutaneous Approach	Procedure	ICD-10-PCS
0M524ZZ	Destruction of Left Shoulder Bursa and Ligament, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0M530ZZ	Destruction of Right Elbow Bursa and Ligament, Open Approach	Procedure	ICD-10-PCS
0M533ZZ	Destruction of Right Elbow Bursa and Ligament, Percutaneous Approach	Procedure	ICD-10-PCS
0M534ZZ	Destruction of Right Elbow Bursa and Ligament, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0M540ZZ	Destruction of Left Elbow Bursa and Ligament, Open Approach	Procedure	ICD-10-PCS
0M543ZZ	Destruction of Left Elbow Bursa and Ligament, Percutaneous Approach	Procedure	ICD-10-PCS
0M544ZZ	Destruction of Left Elbow Bursa and Ligament, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0M550ZZ	Destruction of Right Wrist Bursa and Ligament, Open Approach	Procedure	ICD-10-PCS
0M553ZZ	Destruction of Right Wrist Bursa and Ligament, Percutaneous Approach	Procedure	ICD-10-PCS
0M554ZZ	Destruction of Right Wrist Bursa and Ligament, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0M560ZZ	Destruction of Left Wrist Bursa and Ligament, Open Approach	Procedure	ICD-10-PCS
0M563ZZ	Destruction of Left Wrist Bursa and Ligament, Percutaneous Approach	Procedure	ICD-10-PCS
0M564ZZ	Destruction of Left Wrist Bursa and Ligament, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0MB10ZZ	Excision of Right Shoulder Bursa and Ligament, Open Approach	Procedure	ICD-10-PCS
0MB13ZZ	Excision of Right Shoulder Bursa and Ligament, Percutaneous Approach	Procedure	ICD-10-PCS
0MB14ZZ	Excision of Right Shoulder Bursa and Ligament, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0MB20ZZ	Excision of Left Shoulder Bursa and Ligament, Open Approach	Procedure	ICD-10-PCS
0MB23ZZ	Excision of Left Shoulder Bursa and Ligament, Percutaneous Approach	Procedure	ICD-10-PCS
0MB24ZZ	Excision of Left Shoulder Bursa and Ligament, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0MB30ZZ	Excision of Right Elbow Bursa and Ligament, Open Approach	Procedure	ICD-10-PCS
0MB33ZZ	Excision of Right Elbow Bursa and Ligament, Percutaneous Approach	Procedure	ICD-10-PCS
0MB34ZZ	Excision of Right Elbow Bursa and Ligament, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0MB40ZZ	Excision of Left Elbow Bursa and Ligament, Open Approach	Procedure	ICD-10-PCS
0MB43ZZ	Excision of Left Elbow Bursa and Ligament, Percutaneous Approach	Procedure	ICD-10-PCS
0MB44ZZ	Excision of Left Elbow Bursa and Ligament, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0MB50ZZ	Excision of Right Wrist Bursa and Ligament, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0MB53ZZ	Excision of Right Wrist Bursa and Ligament, Percutaneous Approach	Procedure	ICD-10-PCS
0MB54ZZ	Excision of Right Wrist Bursa and Ligament, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0MB60ZZ	Excision of Left Wrist Bursa and Ligament, Open Approach	Procedure	ICD-10-PCS
0MB63ZZ	Excision of Left Wrist Bursa and Ligament, Percutaneous Approach	Procedure	ICD-10-PCS
0MB64ZZ	Excision of Left Wrist Bursa and Ligament, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0MT30ZZ	Resection of Right Elbow Bursa and Ligament, Open Approach	Procedure	ICD-10-PCS
0MT34ZZ	Resection of Right Elbow Bursa and Ligament, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0MT40ZZ	Resection of Left Elbow Bursa and Ligament, Open Approach	Procedure	ICD-10-PCS
0MT44ZZ	Resection of Left Elbow Bursa and Ligament, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0N5B0ZZ	Destruction of Nasal Bone, Open Approach	Procedure	ICD-10-PCS
0N5B3ZZ	Destruction of Nasal Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0N5B4ZZ	Destruction of Nasal Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0N5C0ZZ	Destruction of Sphenoid Bone, Open Approach	Procedure	ICD-10-PCS
0N5C3ZZ	Destruction of Sphenoid Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0N5C4ZZ	Destruction of Sphenoid Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0N5F0ZZ	Destruction of Right Ethmoid Bone, Open Approach	Procedure	ICD-10-PCS
0N5F3ZZ	Destruction of Right Ethmoid Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0N5F4ZZ	Destruction of Right Ethmoid Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0N5G0ZZ	Destruction of Left Ethmoid Bone, Open Approach	Procedure	ICD-10-PCS
0N5G3ZZ	Destruction of Left Ethmoid Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0N5G4ZZ	Destruction of Left Ethmoid Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0N5H0ZZ	Destruction of Right Lacrimal Bone, Open Approach	Procedure	ICD-10-PCS
0N5H3ZZ	Destruction of Right Lacrimal Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0N5H4ZZ	Destruction of Right Lacrimal Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0N5J0ZZ	Destruction of Left Lacrimal Bone, Open Approach	Procedure	ICD-10-PCS
0N5J3ZZ	Destruction of Left Lacrimal Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0N5J4ZZ	Destruction of Left Lacrimal Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0N5K0ZZ	Destruction of Right Palatine Bone, Open Approach	Procedure	ICD-10-PCS
0N5K3ZZ	Destruction of Right Palatine Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0N5K4ZZ	Destruction of Right Palatine Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0N5L0ZZ	Destruction of Left Palatine Bone, Open Approach	Procedure	ICD-10-PCS
0N5L3ZZ	Destruction of Left Palatine Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0N5L4ZZ	Destruction of Left Palatine Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0N5M0ZZ	Destruction of Right Zygomatic Bone, Open Approach	Procedure	ICD-10-PCS
0N5M3ZZ	Destruction of Right Zygomatic Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0N5M4ZZ	Destruction of Right Zygomatic Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0N5N0ZZ	Destruction of Left Zygomatic Bone, Open Approach	Procedure	ICD-10-PCS
0N5N3ZZ	Destruction of Left Zygomatic Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0N5N4ZZ	Destruction of Left Zygomatic Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0N5P0ZZ	Destruction of Right Orbit, Open Approach	Procedure	ICD-10-PCS
0N5P3ZZ	Destruction of Right Orbit, Percutaneous Approach	Procedure	ICD-10-PCS
0N5P4ZZ	Destruction of Right Orbit, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0N5Q0ZZ	Destruction of Left Orbit, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0N5Q3ZZ	Destruction of Left Orbit, Percutaneous Approach	Procedure	ICD-10-PCS
0N5Q4ZZ	Destruction of Left Orbit, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0N5R0ZZ	Destruction of Maxilla, Open Approach	Procedure	ICD-10-PCS
0N5R3ZZ	Destruction of Maxilla, Percutaneous Approach	Procedure	ICD-10-PCS
0N5R4ZZ	Destruction of Maxilla, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0N5T0ZZ	Destruction of Right Mandible, Open Approach	Procedure	ICD-10-PCS
0N5T3ZZ	Destruction of Right Mandible, Percutaneous Approach	Procedure	ICD-10-PCS
0N5T4ZZ	Destruction of Right Mandible, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0N5V0ZZ	Destruction of Left Mandible, Open Approach	Procedure	ICD-10-PCS
0N5V3ZZ	Destruction of Left Mandible, Percutaneous Approach	Procedure	ICD-10-PCS
0N5V4ZZ	Destruction of Left Mandible, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0N5X0ZZ	Destruction of Hyoid Bone, Open Approach	Procedure	ICD-10-PCS
0N5X3ZZ	Destruction of Hyoid Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0N5X4ZZ	Destruction of Hyoid Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NB00ZZ	Excision of Skull, Open Approach	Procedure	ICD-10-PCS
0NB03ZZ	Excision of Skull, Percutaneous Approach	Procedure	ICD-10-PCS
0NB04ZZ	Excision of Skull, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NB10ZZ	Excision of Frontal Bone, Open Approach	Procedure	ICD-10-PCS
0NB13ZZ	Excision of Frontal Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0NB14ZZ	Excision of Frontal Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NB30ZZ	Excision of Right Parietal Bone, Open Approach	Procedure	ICD-10-PCS
0NB33ZZ	Excision of Right Parietal Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0NB34ZZ	Excision of Right Parietal Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NB40ZZ	Excision of Left Parietal Bone, Open Approach	Procedure	ICD-10-PCS
0NB43ZZ	Excision of Left Parietal Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0NB44ZZ	Excision of Left Parietal Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NB50ZZ	Excision of Right Temporal Bone, Open Approach	Procedure	ICD-10-PCS
0NB53ZZ	Excision of Right Temporal Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0NB54ZZ	Excision of Right Temporal Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NB60ZZ	Excision of Left Temporal Bone, Open Approach	Procedure	ICD-10-PCS
0NB63ZZ	Excision of Left Temporal Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0NB64ZZ	Excision of Left Temporal Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NB70ZZ	Excision of Occipital Bone, Open Approach	Procedure	ICD-10-PCS
0NB73ZZ	Excision of Occipital Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0NB74ZZ	Excision of Occipital Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NBB0ZZ	Excision of Nasal Bone, Open Approach	Procedure	ICD-10-PCS
0NBB3ZZ	Excision of Nasal Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0NBB4ZZ	Excision of Nasal Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NBC0ZZ	Excision of Sphenoid Bone, Open Approach	Procedure	ICD-10-PCS
0NBC3ZZ	Excision of Sphenoid Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0NBC4ZZ	Excision of Sphenoid Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NBF0ZZ	Excision of Right Ethmoid Bone, Open Approach	Procedure	ICD-10-PCS
0NBF3ZZ	Excision of Right Ethmoid Bone, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0NBF4ZZ	Excision of Right Ethmoid Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NBG0ZZ	Excision of Left Ethmoid Bone, Open Approach	Procedure	ICD-10-PCS
0NBG3ZZ	Excision of Left Ethmoid Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0NBG4ZZ	Excision of Left Ethmoid Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NBH0ZZ	Excision of Right Lacrimal Bone, Open Approach	Procedure	ICD-10-PCS
0NBH3ZZ	Excision of Right Lacrimal Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0NBH4ZZ	Excision of Right Lacrimal Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NBJ0ZZ	Excision of Left Lacrimal Bone, Open Approach	Procedure	ICD-10-PCS
0NBJ3ZZ	Excision of Left Lacrimal Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0NBJ4ZZ	Excision of Left Lacrimal Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NBK0ZZ	Excision of Right Palatine Bone, Open Approach	Procedure	ICD-10-PCS
0NBK3ZZ	Excision of Right Palatine Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0NBK4ZZ	Excision of Right Palatine Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NBL0ZZ	Excision of Left Palatine Bone, Open Approach	Procedure	ICD-10-PCS
0NBL3ZZ	Excision of Left Palatine Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0NBL4ZZ	Excision of Left Palatine Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NBM0ZZ	Excision of Right Zygomatic Bone, Open Approach	Procedure	ICD-10-PCS
0NBM3ZZ	Excision of Right Zygomatic Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0NBM4ZZ	Excision of Right Zygomatic Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NBN0ZZ	Excision of Left Zygomatic Bone, Open Approach	Procedure	ICD-10-PCS
0NBN3ZZ	Excision of Left Zygomatic Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0NBN4ZZ	Excision of Left Zygomatic Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NBR0ZZ	Excision of Maxilla, Open Approach	Procedure	ICD-10-PCS
0NBR3ZZ	Excision of Maxilla, Percutaneous Approach	Procedure	ICD-10-PCS
0NBR4ZZ	Excision of Maxilla, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NBT0ZZ	Excision of Right Mandible, Open Approach	Procedure	ICD-10-PCS
0NBT3ZZ	Excision of Right Mandible, Percutaneous Approach	Procedure	ICD-10-PCS
0NBT4ZZ	Excision of Right Mandible, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NBV0ZZ	Excision of Left Mandible, Open Approach	Procedure	ICD-10-PCS
0NBV3ZZ	Excision of Left Mandible, Percutaneous Approach	Procedure	ICD-10-PCS
0NBV4ZZ	Excision of Left Mandible, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NBX0ZZ	Excision of Hyoid Bone, Open Approach	Procedure	ICD-10-PCS
0NBX3ZZ	Excision of Hyoid Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0NBX4ZZ	Excision of Hyoid Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NRT07Z	Replacement of Right Mandible with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0NRT0JZ	Replacement of Right Mandible with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0NRT0KZ	Replacement of Right Mandible with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0NRT37Z	Replacement of Right Mandible with Autologous Tissue Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
0NRT3JZ	Replacement of Right Mandible with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
0NRT3KZ	Replacement of Right Mandible with Nonautologous Tissue Substitute, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0NRT47Z	Replacement of Right Mandible with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NRT4JZ	Replacement of Right Mandible with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NRT4KZ	Replacement of Right Mandible with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NRV07Z	Replacement of Left Mandible with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0NRV0JZ	Replacement of Left Mandible with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0NRV0KZ	Replacement of Left Mandible with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0NRV37Z	Replacement of Left Mandible with Autologous Tissue Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
0NRV3JZ	Replacement of Left Mandible with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
0NRV3KZ	Replacement of Left Mandible with Nonautologous Tissue Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
0NRV47Z	Replacement of Left Mandible with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NRV4JZ	Replacement of Left Mandible with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NRV4KZ	Replacement of Left Mandible with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0NTC0ZZ	Resection of Sphenoid Bone, Open Approach	Procedure	ICD-10-PCS
0NTF0ZZ	Resection of Right Ethmoid Bone, Open Approach	Procedure	ICD-10-PCS
0NTG0ZZ	Resection of Left Ethmoid Bone, Open Approach	Procedure	ICD-10-PCS
0NTH0ZZ	Resection of Right Lacrimal Bone, Open Approach	Procedure	ICD-10-PCS
0NTJ0ZZ	Resection of Left Lacrimal Bone, Open Approach	Procedure	ICD-10-PCS
0NTK0ZZ	Resection of Right Palatine Bone, Open Approach	Procedure	ICD-10-PCS
0NTL0ZZ	Resection of Left Palatine Bone, Open Approach	Procedure	ICD-10-PCS
0NTM0ZZ	Resection of Right Zygomatic Bone, Open Approach	Procedure	ICD-10-PCS
0NTN0ZZ	Resection of Left Zygomatic Bone, Open Approach	Procedure	ICD-10-PCS
0NTP0ZZ	Resection of Right Orbit, Open Approach	Procedure	ICD-10-PCS
0NTQ0ZZ	Resection of Left Orbit, Open Approach	Procedure	ICD-10-PCS
0NTR0ZZ	Resection of Maxilla, Open Approach	Procedure	ICD-10-PCS
0NTT0ZZ	Resection of Right Mandible, Open Approach	Procedure	ICD-10-PCS
0NTV0ZZ	Resection of Left Mandible, Open Approach	Procedure	ICD-10-PCS
0NTX0ZZ	Resection of Hyoid Bone, Open Approach	Procedure	ICD-10-PCS
0P500ZZ	Destruction of Sternum, Open Approach	Procedure	ICD-10-PCS
0P503ZZ	Destruction of Sternum, Percutaneous Approach	Procedure	ICD-10-PCS
0P504ZZ	Destruction of Sternum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0P510ZZ	Destruction of 1 to 2 Ribs, Open Approach	Procedure	ICD-10-PCS
0P513ZZ	Destruction of 1 to 2 Ribs, Percutaneous Approach	Procedure	ICD-10-PCS
0P514ZZ	Destruction of 1 to 2 Ribs, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0P520ZZ	Destruction of 3 or More Ribs, Open Approach	Procedure	ICD-10-PCS
0P523ZZ	Destruction of 3 or More Ribs, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0P524ZZ	Destruction of 3 or More Ribs, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0P530ZZ	Destruction of Cervical Vertebra, Open Approach	Procedure	ICD-10-PCS
0P533ZZ	Destruction of Cervical Vertebra, Percutaneous Approach	Procedure	ICD-10-PCS
0P534ZZ	Destruction of Cervical Vertebra, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0P540ZZ	Destruction of Thoracic Vertebra, Open Approach	Procedure	ICD-10-PCS
0P543ZZ	Destruction of Thoracic Vertebra, Percutaneous Approach	Procedure	ICD-10-PCS
0P544ZZ	Destruction of Thoracic Vertebra, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0P550ZZ	Destruction of Right Scapula, Open Approach	Procedure	ICD-10-PCS
0P553ZZ	Destruction of Right Scapula, Percutaneous Approach	Procedure	ICD-10-PCS
0P554ZZ	Destruction of Right Scapula, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0P560ZZ	Destruction of Left Scapula, Open Approach	Procedure	ICD-10-PCS
0P563ZZ	Destruction of Left Scapula, Percutaneous Approach	Procedure	ICD-10-PCS
0P564ZZ	Destruction of Left Scapula, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0P570ZZ	Destruction of Right Glenoid Cavity, Open Approach	Procedure	ICD-10-PCS
0P573ZZ	Destruction of Right Glenoid Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0P574ZZ	Destruction of Right Glenoid Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0P580ZZ	Destruction of Left Glenoid Cavity, Open Approach	Procedure	ICD-10-PCS
0P583ZZ	Destruction of Left Glenoid Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0P584ZZ	Destruction of Left Glenoid Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0P590ZZ	Destruction of Right Clavicle, Open Approach	Procedure	ICD-10-PCS
0P593ZZ	Destruction of Right Clavicle, Percutaneous Approach	Procedure	ICD-10-PCS
0P594ZZ	Destruction of Right Clavicle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0P5B0ZZ	Destruction of Left Clavicle, Open Approach	Procedure	ICD-10-PCS
0P5B3ZZ	Destruction of Left Clavicle, Percutaneous Approach	Procedure	ICD-10-PCS
0P5B4ZZ	Destruction of Left Clavicle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0P5H0ZZ	Destruction of Right Radius, Open Approach	Procedure	ICD-10-PCS
0P5H3ZZ	Destruction of Right Radius, Percutaneous Approach	Procedure	ICD-10-PCS
0P5H4ZZ	Destruction of Right Radius, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0P5J0ZZ	Destruction of Left Radius, Open Approach	Procedure	ICD-10-PCS
0P5J3ZZ	Destruction of Left Radius, Percutaneous Approach	Procedure	ICD-10-PCS
0P5J4ZZ	Destruction of Left Radius, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0P5K0ZZ	Destruction of Right Ulna, Open Approach	Procedure	ICD-10-PCS
0P5K3ZZ	Destruction of Right Ulna, Percutaneous Approach	Procedure	ICD-10-PCS
0P5K4ZZ	Destruction of Right Ulna, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0P5L0ZZ	Destruction of Left Ulna, Open Approach	Procedure	ICD-10-PCS
0P5L3ZZ	Destruction of Left Ulna, Percutaneous Approach	Procedure	ICD-10-PCS
0P5L4ZZ	Destruction of Left Ulna, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0P5M0ZZ	Destruction of Right Carpal, Open Approach	Procedure	ICD-10-PCS
0P5M3ZZ	Destruction of Right Carpal, Percutaneous Approach	Procedure	ICD-10-PCS
0P5M4ZZ	Destruction of Right Carpal, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0P5N0ZZ	Destruction of Left Carpal, Open Approach	Procedure	ICD-10-PCS
0P5N3ZZ	Destruction of Left Carpal, Percutaneous Approach	Procedure	ICD-10-PCS
0P5N4ZZ	Destruction of Left Carpal, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0P5P0ZZ	Destruction of Right Metacarpal, Open Approach	Procedure	ICD-10-PCS
0P5P3ZZ	Destruction of Right Metacarpal, Percutaneous Approach	Procedure	ICD-10-PCS
0P5P4ZZ	Destruction of Right Metacarpal, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0P5Q0ZZ	Destruction of Left Metacarpal, Open Approach	Procedure	ICD-10-PCS
0P5Q3ZZ	Destruction of Left Metacarpal, Percutaneous Approach	Procedure	ICD-10-PCS
0P5Q4ZZ	Destruction of Left Metacarpal, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0P5R0ZZ	Destruction of Right Thumb Phalanx, Open Approach	Procedure	ICD-10-PCS
0P5R3ZZ	Destruction of Right Thumb Phalanx, Percutaneous Approach	Procedure	ICD-10-PCS
0P5R4ZZ	Destruction of Right Thumb Phalanx, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0P5S0ZZ	Destruction of Left Thumb Phalanx, Open Approach	Procedure	ICD-10-PCS
0P5S3ZZ	Destruction of Left Thumb Phalanx, Percutaneous Approach	Procedure	ICD-10-PCS
0P5S4ZZ	Destruction of Left Thumb Phalanx, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0P5T0ZZ	Destruction of Right Finger Phalanx, Open Approach	Procedure	ICD-10-PCS
0P5T3ZZ	Destruction of Right Finger Phalanx, Percutaneous Approach	Procedure	ICD-10-PCS
0P5T4ZZ	Destruction of Right Finger Phalanx, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0P5V0ZZ	Destruction of Left Finger Phalanx, Open Approach	Procedure	ICD-10-PCS
0P5V3ZZ	Destruction of Left Finger Phalanx, Percutaneous Approach	Procedure	ICD-10-PCS
0P5V4ZZ	Destruction of Left Finger Phalanx, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PB00ZZ	Excision of Sternum, Open Approach	Procedure	ICD-10-PCS
0PB03ZZ	Excision of Sternum, Percutaneous Approach	Procedure	ICD-10-PCS
0PB04ZZ	Excision of Sternum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PB10ZZ	Excision of 1 to 2 Ribs, Open Approach	Procedure	ICD-10-PCS
0PB13ZZ	Excision of 1 to 2 Ribs, Percutaneous Approach	Procedure	ICD-10-PCS
0PB14ZZ	Excision of 1 to 2 Ribs, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PB20ZZ	Excision of 3 or More Ribs, Open Approach	Procedure	ICD-10-PCS
0PB23ZZ	Excision of 3 or More Ribs, Percutaneous Approach	Procedure	ICD-10-PCS
0PB24ZZ	Excision of 3 or More Ribs, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PB30ZZ	Excision of Cervical Vertebra, Open Approach	Procedure	ICD-10-PCS
0PB33ZZ	Excision of Cervical Vertebra, Percutaneous Approach	Procedure	ICD-10-PCS
0PB34ZZ	Excision of Cervical Vertebra, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PB40ZZ	Excision of Thoracic Vertebra, Open Approach	Procedure	ICD-10-PCS
0PB43ZZ	Excision of Thoracic Vertebra, Percutaneous Approach	Procedure	ICD-10-PCS
0PB44ZZ	Excision of Thoracic Vertebra, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PB50ZZ	Excision of Right Scapula, Open Approach	Procedure	ICD-10-PCS
0PB53ZZ	Excision of Right Scapula, Percutaneous Approach	Procedure	ICD-10-PCS
0PB54ZZ	Excision of Right Scapula, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PB60ZZ	Excision of Left Scapula, Open Approach	Procedure	ICD-10-PCS
0PB63ZZ	Excision of Left Scapula, Percutaneous Approach	Procedure	ICD-10-PCS
0PB64ZZ	Excision of Left Scapula, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PB70ZZ	Excision of Right Glenoid Cavity, Open Approach	Procedure	ICD-10-PCS
0PB73ZZ	Excision of Right Glenoid Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0PB74ZZ	Excision of Right Glenoid Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PB80ZZ	Excision of Left Glenoid Cavity, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0PB83ZZ	Excision of Left Glenoid Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0PB84ZZ	Excision of Left Glenoid Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PB90ZZ	Excision of Right Clavicle, Open Approach	Procedure	ICD-10-PCS
0PB93ZZ	Excision of Right Clavicle, Percutaneous Approach	Procedure	ICD-10-PCS
0PB94ZZ	Excision of Right Clavicle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PBB0ZZ	Excision of Left Clavicle, Open Approach	Procedure	ICD-10-PCS
0PBB3ZZ	Excision of Left Clavicle, Percutaneous Approach	Procedure	ICD-10-PCS
0PBB4ZZ	Excision of Left Clavicle, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PBC0ZZ	Excision of Right Humeral Head, Open Approach	Procedure	ICD-10-PCS
0PBC3ZZ	Excision of Right Humeral Head, Percutaneous Approach	Procedure	ICD-10-PCS
0PBC4ZZ	Excision of Right Humeral Head, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PBD0ZZ	Excision of Left Humeral Head, Open Approach	Procedure	ICD-10-PCS
0PBD3ZZ	Excision of Left Humeral Head, Percutaneous Approach	Procedure	ICD-10-PCS
0PBD4ZZ	Excision of Left Humeral Head, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PBF0ZZ	Excision of Right Humeral Shaft, Open Approach	Procedure	ICD-10-PCS
0PBF3ZZ	Excision of Right Humeral Shaft, Percutaneous Approach	Procedure	ICD-10-PCS
0PBF4ZZ	Excision of Right Humeral Shaft, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PBG0ZZ	Excision of Left Humeral Shaft, Open Approach	Procedure	ICD-10-PCS
0PBG3ZZ	Excision of Left Humeral Shaft, Percutaneous Approach	Procedure	ICD-10-PCS
0PBG4ZZ	Excision of Left Humeral Shaft, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PBH0ZZ	Excision of Right Radius, Open Approach	Procedure	ICD-10-PCS
0PBH3ZZ	Excision of Right Radius, Percutaneous Approach	Procedure	ICD-10-PCS
0PBH4ZZ	Excision of Right Radius, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PBJ0ZZ	Excision of Left Radius, Open Approach	Procedure	ICD-10-PCS
0PBJ3ZZ	Excision of Left Radius, Percutaneous Approach	Procedure	ICD-10-PCS
0PBJ4ZZ	Excision of Left Radius, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PBK0ZZ	Excision of Right Ulna, Open Approach	Procedure	ICD-10-PCS
0PBK3ZZ	Excision of Right Ulna, Percutaneous Approach	Procedure	ICD-10-PCS
0PBK4ZZ	Excision of Right Ulna, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PBL0ZZ	Excision of Left Ulna, Open Approach	Procedure	ICD-10-PCS
0PBL3ZZ	Excision of Left Ulna, Percutaneous Approach	Procedure	ICD-10-PCS
0PBL4ZZ	Excision of Left Ulna, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PBM0ZZ	Excision of Right Carpal, Open Approach	Procedure	ICD-10-PCS
0PBM3ZZ	Excision of Right Carpal, Percutaneous Approach	Procedure	ICD-10-PCS
0PBM4ZZ	Excision of Right Carpal, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PBN0ZZ	Excision of Left Carpal, Open Approach	Procedure	ICD-10-PCS
0PBN3ZZ	Excision of Left Carpal, Percutaneous Approach	Procedure	ICD-10-PCS
0PBN4ZZ	Excision of Left Carpal, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PBP0ZZ	Excision of Right Metacarpal, Open Approach	Procedure	ICD-10-PCS
0PBP3ZZ	Excision of Right Metacarpal, Percutaneous Approach	Procedure	ICD-10-PCS
0PBP4ZZ	Excision of Right Metacarpal, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PBQ0ZZ	Excision of Left Metacarpal, Open Approach	Procedure	ICD-10-PCS
0PBQ3ZZ	Excision of Left Metacarpal, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0PBQ4ZZ	Excision of Left Metacarpal, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PBR0ZZ	Excision of Right Thumb Phalanx, Open Approach	Procedure	ICD-10-PCS
0PBR3ZZ	Excision of Right Thumb Phalanx, Percutaneous Approach	Procedure	ICD-10-PCS
0PBR4ZZ	Excision of Right Thumb Phalanx, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PBS0ZZ	Excision of Left Thumb Phalanx, Open Approach	Procedure	ICD-10-PCS
0PBS3ZZ	Excision of Left Thumb Phalanx, Percutaneous Approach	Procedure	ICD-10-PCS
0PBS4ZZ	Excision of Left Thumb Phalanx, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PBT0ZZ	Excision of Right Finger Phalanx, Open Approach	Procedure	ICD-10-PCS
0PBT3ZZ	Excision of Right Finger Phalanx, Percutaneous Approach	Procedure	ICD-10-PCS
0PBT4ZZ	Excision of Right Finger Phalanx, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PBV0ZZ	Excision of Left Finger Phalanx, Open Approach	Procedure	ICD-10-PCS
0PBV3ZZ	Excision of Left Finger Phalanx, Percutaneous Approach	Procedure	ICD-10-PCS
0PBV4ZZ	Excision of Left Finger Phalanx, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0PT00ZZ	Resection of Sternum, Open Approach	Procedure	ICD-10-PCS
0PT10ZZ	Resection of 1 to 2 Ribs, Open Approach	Procedure	ICD-10-PCS
0PT20ZZ	Resection of 3 or More Ribs, Open Approach	Procedure	ICD-10-PCS
0PT50ZZ	Resection of Right Scapula, Open Approach	Procedure	ICD-10-PCS
0PT60ZZ	Resection of Left Scapula, Open Approach	Procedure	ICD-10-PCS
0PT70ZZ	Resection of Right Glenoid Cavity, Open Approach	Procedure	ICD-10-PCS
0PT80ZZ	Resection of Left Glenoid Cavity, Open Approach	Procedure	ICD-10-PCS
0PT90ZZ	Resection of Right Clavicle, Open Approach	Procedure	ICD-10-PCS
0PTB0ZZ	Resection of Left Clavicle, Open Approach	Procedure	ICD-10-PCS
0PTC0ZZ	Resection of Right Humeral Head, Open Approach	Procedure	ICD-10-PCS
0PTD0ZZ	Resection of Left Humeral Head, Open Approach	Procedure	ICD-10-PCS
0PTF0ZZ	Resection of Right Humeral Shaft, Open Approach	Procedure	ICD-10-PCS
0PTG0ZZ	Resection of Left Humeral Shaft, Open Approach	Procedure	ICD-10-PCS
0PTH0ZZ	Resection of Right Radius, Open Approach	Procedure	ICD-10-PCS
0PTJ0ZZ	Resection of Left Radius, Open Approach	Procedure	ICD-10-PCS
0PTK0ZZ	Resection of Right Ulna, Open Approach	Procedure	ICD-10-PCS
0PTL0ZZ	Resection of Left Ulna, Open Approach	Procedure	ICD-10-PCS
0PTM0ZZ	Resection of Right Carpal, Open Approach	Procedure	ICD-10-PCS
0PTN0ZZ	Resection of Left Carpal, Open Approach	Procedure	ICD-10-PCS
0PTP0ZZ	Resection of Right Metacarpal, Open Approach	Procedure	ICD-10-PCS
0PTQ0ZZ	Resection of Left Metacarpal, Open Approach	Procedure	ICD-10-PCS
0PTR0ZZ	Resection of Right Thumb Phalanx, Open Approach	Procedure	ICD-10-PCS
0PTS0ZZ	Resection of Left Thumb Phalanx, Open Approach	Procedure	ICD-10-PCS
0PTT0ZZ	Resection of Right Finger Phalanx, Open Approach	Procedure	ICD-10-PCS
0PTV0ZZ	Resection of Left Finger Phalanx, Open Approach	Procedure	ICD-10-PCS
0Q500ZZ	Destruction of Lumbar Vertebra, Open Approach	Procedure	ICD-10-PCS
0Q503ZZ	Destruction of Lumbar Vertebra, Percutaneous Approach	Procedure	ICD-10-PCS
0Q504ZZ	Destruction of Lumbar Vertebra, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0Q510ZZ	Destruction of Sacrum, Open Approach	Procedure	ICD-10-PCS
0Q513ZZ	Destruction of Sacrum, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0Q514ZZ	Destruction of Sacrum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0Q520ZZ	Destruction of Right Pelvic Bone, Open Approach	Procedure	ICD-10-PCS
0Q523ZZ	Destruction of Right Pelvic Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0Q524ZZ	Destruction of Right Pelvic Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0Q530ZZ	Destruction of Left Pelvic Bone, Open Approach	Procedure	ICD-10-PCS
0Q533ZZ	Destruction of Left Pelvic Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0Q534ZZ	Destruction of Left Pelvic Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0Q540ZZ	Destruction of Right Acetabulum, Open Approach	Procedure	ICD-10-PCS
0Q543ZZ	Destruction of Right Acetabulum, Percutaneous Approach	Procedure	ICD-10-PCS
0Q544ZZ	Destruction of Right Acetabulum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0Q550ZZ	Destruction of Left Acetabulum, Open Approach	Procedure	ICD-10-PCS
0Q553ZZ	Destruction of Left Acetabulum, Percutaneous Approach	Procedure	ICD-10-PCS
0Q554ZZ	Destruction of Left Acetabulum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0Q560ZZ	Destruction of Right Upper Femur, Open Approach	Procedure	ICD-10-PCS
0Q563ZZ	Destruction of Right Upper Femur, Percutaneous Approach	Procedure	ICD-10-PCS
0Q564ZZ	Destruction of Right Upper Femur, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0Q570ZZ	Destruction of Left Upper Femur, Open Approach	Procedure	ICD-10-PCS
0Q573ZZ	Destruction of Left Upper Femur, Percutaneous Approach	Procedure	ICD-10-PCS
0Q574ZZ	Destruction of Left Upper Femur, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0Q580ZZ	Destruction of Right Femoral Shaft, Open Approach	Procedure	ICD-10-PCS
0Q583ZZ	Destruction of Right Femoral Shaft, Percutaneous Approach	Procedure	ICD-10-PCS
0Q584ZZ	Destruction of Right Femoral Shaft, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0Q590ZZ	Destruction of Left Femoral Shaft, Open Approach	Procedure	ICD-10-PCS
0Q593ZZ	Destruction of Left Femoral Shaft, Percutaneous Approach	Procedure	ICD-10-PCS
0Q594ZZ	Destruction of Left Femoral Shaft, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0Q5B0ZZ	Destruction of Right Lower Femur, Open Approach	Procedure	ICD-10-PCS
0Q5B3ZZ	Destruction of Right Lower Femur, Percutaneous Approach	Procedure	ICD-10-PCS
0Q5B4ZZ	Destruction of Right Lower Femur, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0Q5C0ZZ	Destruction of Left Lower Femur, Open Approach	Procedure	ICD-10-PCS
0Q5C3ZZ	Destruction of Left Lower Femur, Percutaneous Approach	Procedure	ICD-10-PCS
0Q5C4ZZ	Destruction of Left Lower Femur, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0Q5D0ZZ	Destruction of Right Patella, Open Approach	Procedure	ICD-10-PCS
0Q5D3ZZ	Destruction of Right Patella, Percutaneous Approach	Procedure	ICD-10-PCS
0Q5D4ZZ	Destruction of Right Patella, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0Q5F0ZZ	Destruction of Left Patella, Open Approach	Procedure	ICD-10-PCS
0Q5F3ZZ	Destruction of Left Patella, Percutaneous Approach	Procedure	ICD-10-PCS
0Q5F4ZZ	Destruction of Left Patella, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0Q5G0ZZ	Destruction of Right Tibia, Open Approach	Procedure	ICD-10-PCS
0Q5G3ZZ	Destruction of Right Tibia, Percutaneous Approach	Procedure	ICD-10-PCS
0Q5G4ZZ	Destruction of Right Tibia, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0Q5H0ZZ	Destruction of Left Tibia, Open Approach	Procedure	ICD-10-PCS
0Q5H3ZZ	Destruction of Left Tibia, Percutaneous Approach	Procedure	ICD-10-PCS
0Q5H4ZZ	Destruction of Left Tibia, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0Q5J0ZZ	Destruction of Right Fibula, Open Approach	Procedure	ICD-10-PCS
0Q5J3ZZ	Destruction of Right Fibula, Percutaneous Approach	Procedure	ICD-10-PCS
0Q5J4ZZ	Destruction of Right Fibula, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0Q5K0ZZ	Destruction of Left Fibula, Open Approach	Procedure	ICD-10-PCS
0Q5K3ZZ	Destruction of Left Fibula, Percutaneous Approach	Procedure	ICD-10-PCS
0Q5K4ZZ	Destruction of Left Fibula, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0Q5Q0ZZ	Destruction of Right Toe Phalanx, Open Approach	Procedure	ICD-10-PCS
0Q5Q3ZZ	Destruction of Right Toe Phalanx, Percutaneous Approach	Procedure	ICD-10-PCS
0Q5Q4ZZ	Destruction of Right Toe Phalanx, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0Q5R0ZZ	Destruction of Left Toe Phalanx, Open Approach	Procedure	ICD-10-PCS
0Q5R3ZZ	Destruction of Left Toe Phalanx, Percutaneous Approach	Procedure	ICD-10-PCS
0Q5R4ZZ	Destruction of Left Toe Phalanx, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0Q5S0ZZ	Destruction of Coccyx, Open Approach	Procedure	ICD-10-PCS
0Q5S3ZZ	Destruction of Coccyx, Percutaneous Approach	Procedure	ICD-10-PCS
0Q5S4ZZ	Destruction of Coccyx, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0QB00ZZ	Excision of Lumbar Vertebra, Open Approach	Procedure	ICD-10-PCS
0QB03ZZ	Excision of Lumbar Vertebra, Percutaneous Approach	Procedure	ICD-10-PCS
0QB04ZZ	Excision of Lumbar Vertebra, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0QB10ZZ	Excision of Sacrum, Open Approach	Procedure	ICD-10-PCS
0QB13ZZ	Excision of Sacrum, Percutaneous Approach	Procedure	ICD-10-PCS
0QB14ZZ	Excision of Sacrum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0QB20ZZ	Excision of Right Pelvic Bone, Open Approach	Procedure	ICD-10-PCS
0QB23ZZ	Excision of Right Pelvic Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0QB24ZZ	Excision of Right Pelvic Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0QB30ZZ	Excision of Left Pelvic Bone, Open Approach	Procedure	ICD-10-PCS
0QB33ZZ	Excision of Left Pelvic Bone, Percutaneous Approach	Procedure	ICD-10-PCS
0QB34ZZ	Excision of Left Pelvic Bone, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0QB40ZZ	Excision of Right Acetabulum, Open Approach	Procedure	ICD-10-PCS
0QB43ZZ	Excision of Right Acetabulum, Percutaneous Approach	Procedure	ICD-10-PCS
0QB44ZZ	Excision of Right Acetabulum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0QB50ZZ	Excision of Left Acetabulum, Open Approach	Procedure	ICD-10-PCS
0QB53ZZ	Excision of Left Acetabulum, Percutaneous Approach	Procedure	ICD-10-PCS
0QB54ZZ	Excision of Left Acetabulum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0QB60ZZ	Excision of Right Upper Femur, Open Approach	Procedure	ICD-10-PCS
0QB63ZZ	Excision of Right Upper Femur, Percutaneous Approach	Procedure	ICD-10-PCS
0QB64ZZ	Excision of Right Upper Femur, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0QB70ZZ	Excision of Left Upper Femur, Open Approach	Procedure	ICD-10-PCS
0QB73ZZ	Excision of Left Upper Femur, Percutaneous Approach	Procedure	ICD-10-PCS
0QB74ZZ	Excision of Left Upper Femur, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0QB80ZZ	Excision of Right Femoral Shaft, Open Approach	Procedure	ICD-10-PCS
0QB83ZZ	Excision of Right Femoral Shaft, Percutaneous Approach	Procedure	ICD-10-PCS
0QB84ZZ	Excision of Right Femoral Shaft, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0QB90ZZ	Excision of Left Femoral Shaft, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0QB93ZZ	Excision of Left Femoral Shaft, Percutaneous Approach	Procedure	ICD-10-PCS
0QB94ZZ	Excision of Left Femoral Shaft, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0QBB0ZZ	Excision of Right Lower Femur, Open Approach	Procedure	ICD-10-PCS
0QBB3ZZ	Excision of Right Lower Femur, Percutaneous Approach	Procedure	ICD-10-PCS
0QBB4ZZ	Excision of Right Lower Femur, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0QBC0ZZ	Excision of Left Lower Femur, Open Approach	Procedure	ICD-10-PCS
0QBC3ZZ	Excision of Left Lower Femur, Percutaneous Approach	Procedure	ICD-10-PCS
0QBC4ZZ	Excision of Left Lower Femur, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0QBD0ZZ	Excision of Right Patella, Open Approach	Procedure	ICD-10-PCS
0QBD3ZZ	Excision of Right Patella, Percutaneous Approach	Procedure	ICD-10-PCS
0QBD4ZZ	Excision of Right Patella, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0QBF0ZZ	Excision of Left Patella, Open Approach	Procedure	ICD-10-PCS
0QBF3ZZ	Excision of Left Patella, Percutaneous Approach	Procedure	ICD-10-PCS
0QBF4ZZ	Excision of Left Patella, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0QBG0ZZ	Excision of Right Tibia, Open Approach	Procedure	ICD-10-PCS
0QBG3ZZ	Excision of Right Tibia, Percutaneous Approach	Procedure	ICD-10-PCS
0QBG4ZZ	Excision of Right Tibia, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0QBH0ZZ	Excision of Left Tibia, Open Approach	Procedure	ICD-10-PCS
0QBH3ZZ	Excision of Left Tibia, Percutaneous Approach	Procedure	ICD-10-PCS
0QBH4ZZ	Excision of Left Tibia, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0QBJ0ZZ	Excision of Right Fibula, Open Approach	Procedure	ICD-10-PCS
0QBJ3ZZ	Excision of Right Fibula, Percutaneous Approach	Procedure	ICD-10-PCS
0QBJ4ZZ	Excision of Right Fibula, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0QBK0ZZ	Excision of Left Fibula, Open Approach	Procedure	ICD-10-PCS
0QBK3ZZ	Excision of Left Fibula, Percutaneous Approach	Procedure	ICD-10-PCS
0QBK4ZZ	Excision of Left Fibula, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0QBL0ZZ	Excision of Right Tarsal, Open Approach	Procedure	ICD-10-PCS
0QBL3ZZ	Excision of Right Tarsal, Percutaneous Approach	Procedure	ICD-10-PCS
0QBL4ZZ	Excision of Right Tarsal, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0QBM0ZZ	Excision of Left Tarsal, Open Approach	Procedure	ICD-10-PCS
0QBM3ZZ	Excision of Left Tarsal, Percutaneous Approach	Procedure	ICD-10-PCS
0QBM4ZZ	Excision of Left Tarsal, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0QBN0ZZ	Excision of Right Metatarsal, Open Approach	Procedure	ICD-10-PCS
0QBN3ZZ	Excision of Right Metatarsal, Percutaneous Approach	Procedure	ICD-10-PCS
0QBN4ZZ	Excision of Right Metatarsal, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0QBP0ZZ	Excision of Left Metatarsal, Open Approach	Procedure	ICD-10-PCS
0QBP3ZZ	Excision of Left Metatarsal, Percutaneous Approach	Procedure	ICD-10-PCS
0QBP4ZZ	Excision of Left Metatarsal, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0QBQ0ZZ	Excision of Right Toe Phalanx, Open Approach	Procedure	ICD-10-PCS
0QBQ3ZZ	Excision of Right Toe Phalanx, Percutaneous Approach	Procedure	ICD-10-PCS
0QBQ4ZZ	Excision of Right Toe Phalanx, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0QBR0ZZ	Excision of Left Toe Phalanx, Open Approach	Procedure	ICD-10-PCS
0QBR3ZZ	Excision of Left Toe Phalanx, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0QBR4ZZ	Excision of Left Toe Phalanx, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0QBS0ZZ	Excision of Coccyx, Open Approach	Procedure	ICD-10-PCS
0QBS3ZZ	Excision of Coccyx, Percutaneous Approach	Procedure	ICD-10-PCS
0QBS4ZZ	Excision of Coccyx, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0QT20ZZ	Resection of Right Pelvic Bone, Open Approach	Procedure	ICD-10-PCS
0QT30ZZ	Resection of Left Pelvic Bone, Open Approach	Procedure	ICD-10-PCS
0QT40ZZ	Resection of Right Acetabulum, Open Approach	Procedure	ICD-10-PCS
0QT50ZZ	Resection of Left Acetabulum, Open Approach	Procedure	ICD-10-PCS
0QT60ZZ	Resection of Right Upper Femur, Open Approach	Procedure	ICD-10-PCS
0QT70ZZ	Resection of Left Upper Femur, Open Approach	Procedure	ICD-10-PCS
0QT80ZZ	Resection of Right Femoral Shaft, Open Approach	Procedure	ICD-10-PCS
0QT90ZZ	Resection of Left Femoral Shaft, Open Approach	Procedure	ICD-10-PCS
0QTB0ZZ	Resection of Right Lower Femur, Open Approach	Procedure	ICD-10-PCS
0QTC0ZZ	Resection of Left Lower Femur, Open Approach	Procedure	ICD-10-PCS
0QTD0ZZ	Resection of Right Patella, Open Approach	Procedure	ICD-10-PCS
0QTF0ZZ	Resection of Left Patella, Open Approach	Procedure	ICD-10-PCS
0QTG0ZZ	Resection of Right Tibia, Open Approach	Procedure	ICD-10-PCS
0QTH0ZZ	Resection of Left Tibia, Open Approach	Procedure	ICD-10-PCS
0QTJ0ZZ	Resection of Right Fibula, Open Approach	Procedure	ICD-10-PCS
0QTK0ZZ	Resection of Left Fibula, Open Approach	Procedure	ICD-10-PCS
0QTL0ZZ	Resection of Right Tarsal, Open Approach	Procedure	ICD-10-PCS
0QTM0ZZ	Resection of Left Tarsal, Open Approach	Procedure	ICD-10-PCS
0QTN0ZZ	Resection of Right Metatarsal, Open Approach	Procedure	ICD-10-PCS
0QTP0ZZ	Resection of Left Metatarsal, Open Approach	Procedure	ICD-10-PCS
0QTQ0ZZ	Resection of Right Toe Phalanx, Open Approach	Procedure	ICD-10-PCS
0QTR0ZZ	Resection of Left Toe Phalanx, Open Approach	Procedure	ICD-10-PCS
0QTS0ZZ	Resection of Coccyx, Open Approach	Procedure	ICD-10-PCS
0R5C0ZZ	Destruction of Right Temporomandibular Joint, Open Approach	Procedure	ICD-10-PCS
0R5C3ZZ	Destruction of Right Temporomandibular Joint, Percutaneous Approach	Procedure	ICD-10-PCS
0R5C4ZZ	Destruction of Right Temporomandibular Joint, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0R5D0ZZ	Destruction of Left Temporomandibular Joint, Open Approach	Procedure	ICD-10-PCS
0R5D3ZZ	Destruction of Left Temporomandibular Joint, Percutaneous Approach	Procedure	ICD-10-PCS
0R5D4ZZ	Destruction of Left Temporomandibular Joint, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0R5E0ZZ	Destruction of Right Sternoclavicular Joint, Open Approach	Procedure	ICD-10-PCS
0R5E3ZZ	Destruction of Right Sternoclavicular Joint, Percutaneous Approach	Procedure	ICD-10-PCS
0R5E4ZZ	Destruction of Right Sternoclavicular Joint, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0R5F0ZZ	Destruction of Left Sternoclavicular Joint, Open Approach	Procedure	ICD-10-PCS
0R5F3ZZ	Destruction of Left Sternoclavicular Joint, Percutaneous Approach	Procedure	ICD-10-PCS
0R5F4ZZ	Destruction of Left Sternoclavicular Joint, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0R5G0ZZ	Destruction of Right Acromioclavicular Joint, Open Approach	Procedure	ICD-10-PCS
0R5G3ZZ	Destruction of Right Acromioclavicular Joint, Percutaneous Approach	Procedure	ICD-10-PCS
0R5G4ZZ	Destruction of Right Acromioclavicular Joint, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0R5H0ZZ	Destruction of Left Acromioclavicular Joint, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0R5H3ZZ	Destruction of Left Acromioclavicular Joint, Percutaneous Approach	Procedure	ICD-10-PCS
0R5H4ZZ	Destruction of Left Acromioclavicular Joint, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0R5J0ZZ	Destruction of Right Shoulder Joint, Open Approach	Procedure	ICD-10-PCS
0R5J3ZZ	Destruction of Right Shoulder Joint, Percutaneous Approach	Procedure	ICD-10-PCS
0R5J4ZZ	Destruction of Right Shoulder Joint, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0R5K0ZZ	Destruction of Left Shoulder Joint, Open Approach	Procedure	ICD-10-PCS
0R5K3ZZ	Destruction of Left Shoulder Joint, Percutaneous Approach	Procedure	ICD-10-PCS
0R5K4ZZ	Destruction of Left Shoulder Joint, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0R5L0ZZ	Destruction of Right Elbow Joint, Open Approach	Procedure	ICD-10-PCS
0R5L3ZZ	Destruction of Right Elbow Joint, Percutaneous Approach	Procedure	ICD-10-PCS
0R5L4ZZ	Destruction of Right Elbow Joint, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0R5M0ZZ	Destruction of Left Elbow Joint, Open Approach	Procedure	ICD-10-PCS
0R5M3ZZ	Destruction of Left Elbow Joint, Percutaneous Approach	Procedure	ICD-10-PCS
0R5M4ZZ	Destruction of Left Elbow Joint, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0R5N0ZZ	Destruction of Right Wrist Joint, Open Approach	Procedure	ICD-10-PCS
0R5N3ZZ	Destruction of Right Wrist Joint, Percutaneous Approach	Procedure	ICD-10-PCS
0R5N4ZZ	Destruction of Right Wrist Joint, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0R5P0ZZ	Destruction of Left Wrist Joint, Open Approach	Procedure	ICD-10-PCS
0R5P3ZZ	Destruction of Left Wrist Joint, Percutaneous Approach	Procedure	ICD-10-PCS
0R5P4ZZ	Destruction of Left Wrist Joint, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0RBC0ZZ	Excision of Right Temporomandibular Joint, Open Approach	Procedure	ICD-10-PCS
0RBC3ZZ	Excision of Right Temporomandibular Joint, Percutaneous Approach	Procedure	ICD-10-PCS
0RBC4ZZ	Excision of Right Temporomandibular Joint, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0RBD0ZZ	Excision of Left Temporomandibular Joint, Open Approach	Procedure	ICD-10-PCS
0RBD3ZZ	Excision of Left Temporomandibular Joint, Percutaneous Approach	Procedure	ICD-10-PCS
0RBD4ZZ	Excision of Left Temporomandibular Joint, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0RBJ0ZZ	Excision of Right Shoulder Joint, Open Approach	Procedure	ICD-10-PCS
0RBJ3ZZ	Excision of Right Shoulder Joint, Percutaneous Approach	Procedure	ICD-10-PCS
0RBJ4ZZ	Excision of Right Shoulder Joint, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0RBK0ZZ	Excision of Left Shoulder Joint, Open Approach	Procedure	ICD-10-PCS
0RBK3ZZ	Excision of Left Shoulder Joint, Percutaneous Approach	Procedure	ICD-10-PCS
0RBK4ZZ	Excision of Left Shoulder Joint, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0RBL0ZZ	Excision of Right Elbow Joint, Open Approach	Procedure	ICD-10-PCS
0RBL3ZZ	Excision of Right Elbow Joint, Percutaneous Approach	Procedure	ICD-10-PCS
0RBL4ZZ	Excision of Right Elbow Joint, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0RBM0ZZ	Excision of Left Elbow Joint, Open Approach	Procedure	ICD-10-PCS
0RBM3ZZ	Excision of Left Elbow Joint, Percutaneous Approach	Procedure	ICD-10-PCS
0RBM4ZZ	Excision of Left Elbow Joint, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0RBN0ZZ	Excision of Right Wrist Joint, Open Approach	Procedure	ICD-10-PCS
0RBN3ZZ	Excision of Right Wrist Joint, Percutaneous Approach	Procedure	ICD-10-PCS
0RBN4ZZ	Excision of Right Wrist Joint, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0RBP0ZZ	Excision of Left Wrist Joint, Open Approach	Procedure	ICD-10-PCS
0RBP3ZZ	Excision of Left Wrist Joint, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0RBP4ZZ	Excision of Left Wrist Joint, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0RQC0ZZ	Repair Right Temporomandibular Joint, Open Approach	Procedure	ICD-10-PCS
0RQC3ZZ	Repair Right Temporomandibular Joint, Percutaneous Approach	Procedure	ICD-10-PCS
0RQC4ZZ	Repair Right Temporomandibular Joint, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0RQD0ZZ	Repair Left Temporomandibular Joint, Open Approach	Procedure	ICD-10-PCS
0RQD3ZZ	Repair Left Temporomandibular Joint, Percutaneous Approach	Procedure	ICD-10-PCS
0RQD4ZZ	Repair Left Temporomandibular Joint, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0RRC07Z	Replacement of Right Temporomandibular Joint with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0RRC0JZ	Replacement of Right Temporomandibular Joint with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0RRC0KZ	Replacement of Right Temporomandibular Joint with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0RRD07Z	Replacement of Left Temporomandibular Joint with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0RRD0JZ	Replacement of Left Temporomandibular Joint with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0RRD0KZ	Replacement of Left Temporomandibular Joint with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0RTC0ZZ	Resection of Right Temporomandibular Joint, Open Approach	Procedure	ICD-10-PCS
0RTD0ZZ	Resection of Left Temporomandibular Joint, Open Approach	Procedure	ICD-10-PCS
0RTL0ZZ	Resection of Right Elbow Joint, Open Approach	Procedure	ICD-10-PCS
0RTM0ZZ	Resection of Left Elbow Joint, Open Approach	Procedure	ICD-10-PCS
0RUC07Z	Supplement Right Temporomandibular Joint with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0RUC0JZ	Supplement Right Temporomandibular Joint with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0RUC0KZ	Supplement Right Temporomandibular Joint with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0RUC37Z	Supplement Right Temporomandibular Joint with Autologous Tissue Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
0RUC3JZ	Supplement Right Temporomandibular Joint with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
0RUC3KZ	Supplement Right Temporomandibular Joint with Nonautologous Tissue Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
0RUC47Z	Supplement Right Temporomandibular Joint with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0RUC4JZ	Supplement Right Temporomandibular Joint with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0RUC4KZ	Supplement Right Temporomandibular Joint with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0RUD07Z	Supplement Left Temporomandibular Joint with Autologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0RUD0JZ	Supplement Left Temporomandibular Joint with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0RUD0KZ	Supplement Left Temporomandibular Joint with Nonautologous Tissue Substitute, Open Approach	Procedure	ICD-10-PCS
0RUD37Z	Supplement Left Temporomandibular Joint with Autologous Tissue Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
0RUD3JZ	Supplement Left Temporomandibular Joint with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
0RUD3KZ	Supplement Left Temporomandibular Joint with Nonautologous Tissue Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
0RUD47Z	Supplement Left Temporomandibular Joint with Autologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0RUD4JZ	Supplement Left Temporomandibular Joint with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0RUD4KZ	Supplement Left Temporomandibular Joint with Nonautologous Tissue Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0TB00ZZ	Excision of Right Kidney, Open Approach	Procedure	ICD-10-PCS
0TB03ZZ	Excision of Right Kidney, Percutaneous Approach	Procedure	ICD-10-PCS
0TB04ZZ	Excision of Right Kidney, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0TB07ZZ	Excision of Right Kidney, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0TB08ZZ	Excision of Right Kidney, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0TB10ZZ	Excision of Left Kidney, Open Approach	Procedure	ICD-10-PCS
0TB13ZZ	Excision of Left Kidney, Percutaneous Approach	Procedure	ICD-10-PCS
0TB14ZZ	Excision of Left Kidney, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0TB17ZZ	Excision of Left Kidney, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0TB18ZZ	Excision of Left Kidney, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0TB30ZZ	Excision of Right Kidney Pelvis, Open Approach	Procedure	ICD-10-PCS
0TB33ZZ	Excision of Right Kidney Pelvis, Percutaneous Approach	Procedure	ICD-10-PCS
0TB34ZZ	Excision of Right Kidney Pelvis, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0TB37ZZ	Excision of Right Kidney Pelvis, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0TB38ZZ	Excision of Right Kidney Pelvis, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0TB40ZZ	Excision of Left Kidney Pelvis, Open Approach	Procedure	ICD-10-PCS
0TB43ZZ	Excision of Left Kidney Pelvis, Percutaneous Approach	Procedure	ICD-10-PCS
0TB44ZZ	Excision of Left Kidney Pelvis, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0TB47ZZ	Excision of Left Kidney Pelvis, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0TB48ZZ	Excision of Left Kidney Pelvis, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0TBB0ZZ	Excision of Bladder, Open Approach	Procedure	ICD-10-PCS
0TBB3ZZ	Excision of Bladder, Percutaneous Approach	Procedure	ICD-10-PCS
0TBB4ZZ	Excision of Bladder, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0TBC0ZZ	Excision of Bladder Neck, Open Approach	Procedure	ICD-10-PCS
0TBC3ZZ	Excision of Bladder Neck, Percutaneous Approach	Procedure	ICD-10-PCS
0TBC4ZZ	Excision of Bladder Neck, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0TT00ZZ	Resection of Right Kidney, Open Approach	Procedure	ICD-10-PCS
0TT04ZZ	Resection of Right Kidney, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0TT10ZZ	Resection of Left Kidney, Open Approach	Procedure	ICD-10-PCS
0TT14ZZ	Resection of Left Kidney, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0TT20ZZ	Resection of Bilateral Kidneys, Open Approach	Procedure	ICD-10-PCS
0TT24ZZ	Resection of Bilateral Kidneys, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0TT30ZZ	Resection of Right Kidney Pelvis, Open Approach	Procedure	ICD-10-PCS
0TT34ZZ	Resection of Right Kidney Pelvis, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0TT37ZZ	Resection of Right Kidney Pelvis, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0TT38ZZ	Resection of Right Kidney Pelvis, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0TT40ZZ	Resection of Left Kidney Pelvis, Open Approach	Procedure	ICD-10-PCS
0TT44ZZ	Resection of Left Kidney Pelvis, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0TT47ZZ	Resection of Left Kidney Pelvis, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0TT48ZZ	Resection of Left Kidney Pelvis, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0TT60ZZ	Resection of Right Ureter, Open Approach	Procedure	ICD-10-PCS
0TT64ZZ	Resection of Right Ureter, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0TT67ZZ	Resection of Right Ureter, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0TT68ZZ	Resection of Right Ureter, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0TT70ZZ	Resection of Left Ureter, Open Approach	Procedure	ICD-10-PCS
0TT74ZZ	Resection of Left Ureter, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0TT77ZZ	Resection of Left Ureter, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0TT78ZZ	Resection of Left Ureter, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0TTB0ZZ	Resection of Bladder, Open Approach	Procedure	ICD-10-PCS
0TTB4ZZ	Resection of Bladder, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0TTB7ZZ	Resection of Bladder, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0TTB8ZZ	Resection of Bladder, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0TTC0ZZ	Resection of Bladder Neck, Open Approach	Procedure	ICD-10-PCS
0TTC4ZZ	Resection of Bladder Neck, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0TTC7ZZ	Resection of Bladder Neck, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0TTC8ZZ	Resection of Bladder Neck, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0TTD0ZZ	Resection of Urethra, Open Approach	Procedure	ICD-10-PCS
0TTD4ZZ	Resection of Urethra, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0TTD7ZZ	Resection of Urethra, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0TTD8ZZ	Resection of Urethra, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0U540ZZ	Destruction of Uterine Supporting Structure, Open Approach	Procedure	ICD-10-PCS
0U543ZZ	Destruction of Uterine Supporting Structure, Percutaneous Approach	Procedure	ICD-10-PCS
0U544ZZ	Destruction of Uterine Supporting Structure, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0U548ZZ	Destruction of Uterine Supporting Structure, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0U5C0ZZ	Destruction of Cervix, Open Approach	Procedure	ICD-10-PCS
0U5C3ZZ	Destruction of Cervix, Percutaneous Approach	Procedure	ICD-10-PCS
0U5C4ZZ	Destruction of Cervix, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0U5C7ZZ	Destruction of Cervix, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0U5C8ZZ	Destruction of Cervix, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0U5M0ZZ	Destruction of Vulva, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0U5MXZZ	Destruction of Vulva, External Approach	Procedure	ICD-10-PCS
0UB40ZZ	Excision of Uterine Supporting Structure, Open Approach	Procedure	ICD-10-PCS
0UB43ZZ	Excision of Uterine Supporting Structure, Percutaneous Approach	Procedure	ICD-10-PCS
0UB44ZZ	Excision of Uterine Supporting Structure, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0UB47ZZ	Excision of Uterine Supporting Structure, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0UB48ZZ	Excision of Uterine Supporting Structure, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0UBC0ZZ	Excision of Cervix, Open Approach	Procedure	ICD-10-PCS
0UBC3ZZ	Excision of Cervix, Percutaneous Approach	Procedure	ICD-10-PCS
0UBC4ZZ	Excision of Cervix, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0UBC7ZZ	Excision of Cervix, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0UBC8ZZ	Excision of Cervix, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0UBM0ZZ	Excision of Vulva, Open Approach	Procedure	ICD-10-PCS
0UBMXZZ	Excision of Vulva, External Approach	Procedure	ICD-10-PCS
0UT00ZZ	Resection of Right Ovary, Open Approach	Procedure	ICD-10-PCS
0UT04ZZ	Resection of Right Ovary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0UT07ZZ	Resection of Right Ovary, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0UT08ZZ	Resection of Right Ovary, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0UT0FZZ	Resection of Right Ovary, Via Natural or Artificial Opening With Percutaneous Endoscopic Assistance	Procedure	ICD-10-PCS
0UT10ZZ	Resection of Left Ovary, Open Approach	Procedure	ICD-10-PCS
0UT14ZZ	Resection of Left Ovary, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0UT17ZZ	Resection of Left Ovary, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0UT18ZZ	Resection of Left Ovary, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0UT1FZZ	Resection of Left Ovary, Via Natural or Artificial Opening With Percutaneous Endoscopic Assistance	Procedure	ICD-10-PCS
0UT20ZZ	Resection of Bilateral Ovaries, Open Approach	Procedure	ICD-10-PCS
0UT24ZZ	Resection of Bilateral Ovaries, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0UT27ZZ	Resection of Bilateral Ovaries, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0UT28ZZ	Resection of Bilateral Ovaries, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0UT2FZZ	Resection of Bilateral Ovaries, Via Natural or Artificial Opening With Percutaneous Endoscopic Assistance	Procedure	ICD-10-PCS
0UT40ZZ	Resection of Uterine Supporting Structure, Open Approach	Procedure	ICD-10-PCS
0UT44ZZ	Resection of Uterine Supporting Structure, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0UT47ZZ	Resection of Uterine Supporting Structure, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0UT48ZZ	Resection of Uterine Supporting Structure, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0UT50ZZ	Resection of Right Fallopian Tube, Open Approach	Procedure	ICD-10-PCS
0UT54ZZ	Resection of Right Fallopian Tube, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0UT60ZZ	Resection of Left Fallopian Tube, Open Approach	Procedure	ICD-10-PCS
0UT64ZZ	Resection of Left Fallopian Tube, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0UT70ZZ	Resection of Bilateral Fallopian Tubes, Open Approach	Procedure	ICD-10-PCS
0UT74ZZ	Resection of Bilateral Fallopian Tubes, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0UT90ZL	Resection of Uterus, Supracervical, Open Approach	Procedure	ICD-10-PCS
0UT90ZZ	Resection of Uterus, Open Approach	Procedure	ICD-10-PCS
0UT94ZZ	Resection of Uterus, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0UT97ZL	Resection of Uterus, Supracervical, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0UT97ZZ	Resection of Uterus, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0UT98ZL	Resection of Uterus, Supracervical, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0UT98ZZ	Resection of Uterus, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0UT9FZL	Resection of Uterus, Supracervical, Via Natural or Artificial Opening With Percutaneous Endoscopic Assistance	Procedure	ICD-10-PCS
0UT9FZZ	Resection of Uterus, Via Natural or Artificial Opening With Percutaneous Endoscopic Assistance	Procedure	ICD-10-PCS
0UTC0ZZ	Resection of Cervix, Open Approach	Procedure	ICD-10-PCS
0UTC4ZZ	Resection of Cervix, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0UTC7ZZ	Resection of Cervix, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0UTC8ZZ	Resection of Cervix, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0UTG0ZZ	Resection of Vagina, Open Approach	Procedure	ICD-10-PCS
0V500ZZ	Destruction of Prostate, Open Approach	Procedure	ICD-10-PCS
0V503ZZ	Destruction of Prostate, Percutaneous Approach	Procedure	ICD-10-PCS
0V504ZZ	Destruction of Prostate, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0V550ZZ	Destruction of Scrotum, Open Approach	Procedure	ICD-10-PCS
0V553ZZ	Destruction of Scrotum, Percutaneous Approach	Procedure	ICD-10-PCS
0V554ZZ	Destruction of Scrotum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0V55XZZ	Destruction of Scrotum, External Approach	Procedure	ICD-10-PCS
0V5S0ZZ	Destruction of Penis, Open Approach	Procedure	ICD-10-PCS
0V5S3ZZ	Destruction of Penis, Percutaneous Approach	Procedure	ICD-10-PCS
0V5S4ZZ	Destruction of Penis, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0V5SXZZ	Destruction of Penis, External Approach	Procedure	ICD-10-PCS
0V5T0ZZ	Destruction of Prepuce, Open Approach	Procedure	ICD-10-PCS
0V5T3ZZ	Destruction of Prepuce, Percutaneous Approach	Procedure	ICD-10-PCS
0V5T4ZZ	Destruction of Prepuce, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0V5TXZZ	Destruction of Prepuce, External Approach	Procedure	ICD-10-PCS
0VB50ZZ	Excision of Scrotum, Open Approach	Procedure	ICD-10-PCS
0VB53ZZ	Excision of Scrotum, Percutaneous Approach	Procedure	ICD-10-PCS
0VB54ZZ	Excision of Scrotum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0VB5XZZ	Excision of Scrotum, External Approach	Procedure	ICD-10-PCS
0VBS0ZZ	Excision of Penis, Open Approach	Procedure	ICD-10-PCS
0VBS3ZZ	Excision of Penis, Percutaneous Approach	Procedure	ICD-10-PCS
0VBS4ZZ	Excision of Penis, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0VBSXZZ	Excision of Penis, External Approach	Procedure	ICD-10-PCS
0VBT0ZZ	Excision of Prepuce, Open Approach	Procedure	ICD-10-PCS
0VBT3ZZ	Excision of Prepuce, Percutaneous Approach	Procedure	ICD-10-PCS
0VBT4ZZ	Excision of Prepuce, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0VBTXZZ	Excision of Prepuce, External Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0VT00ZZ	Resection of Prostate, Open Approach	Procedure	ICD-10-PCS
0VT04ZZ	Resection of Prostate, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0VT07ZZ	Resection of Prostate, Via Natural or Artificial Opening	Procedure	ICD-10-PCS
0VT08ZZ	Resection of Prostate, Via Natural or Artificial Opening Endoscopic	Procedure	ICD-10-PCS
0VT30ZZ	Resection of Bilateral Seminal Vesicles, Open Approach	Procedure	ICD-10-PCS
0VT34ZZ	Resection of Bilateral Seminal Vesicles, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0VT50ZZ	Resection of Scrotum, Open Approach	Procedure	ICD-10-PCS
0VT54ZZ	Resection of Scrotum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0VT5XZZ	Resection of Scrotum, External Approach	Procedure	ICD-10-PCS
0W190J4	Bypass Right Pleural Cavity to Cutaneous with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0W190JY	Bypass Right Pleural Cavity to Lower Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0W193J4	Bypass Right Pleural Cavity to Cutaneous with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
0W194J4	Bypass Right Pleural Cavity to Cutaneous with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W194JY	Bypass Right Pleural Cavity to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W1B0J4	Bypass Left Pleural Cavity to Cutaneous with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0W1B0JY	Bypass Left Pleural Cavity to Lower Vein with Synthetic Substitute, Open Approach	Procedure	ICD-10-PCS
0W1B3J4	Bypass Left Pleural Cavity to Cutaneous with Synthetic Substitute, Percutaneous Approach	Procedure	ICD-10-PCS
0W1B4J4	Bypass Left Pleural Cavity to Cutaneous with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W1B4JY	Bypass Left Pleural Cavity to Lower Vein with Synthetic Substitute, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0W9900Z	Drainage of Right Pleural Cavity with Drainage Device, Open Approach	Procedure	ICD-10-PCS
0W990ZZ	Drainage of Right Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0W9B00Z	Drainage of Left Pleural Cavity with Drainage Device, Open Approach	Procedure	ICD-10-PCS
0W9B0ZZ	Drainage of Left Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WB00ZZ	Excision of Head, Open Approach	Procedure	ICD-10-PCS
0WB03ZZ	Excision of Head, Percutaneous Approach	Procedure	ICD-10-PCS
0WB04ZZ	Excision of Head, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WB0XZZ	Excision of Head, External Approach	Procedure	ICD-10-PCS
0WB20ZZ	Excision of Face, Open Approach	Procedure	ICD-10-PCS
0WB23ZZ	Excision of Face, Percutaneous Approach	Procedure	ICD-10-PCS
0WB24ZZ	Excision of Face, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WB2XZZ	Excision of Face, External Approach	Procedure	ICD-10-PCS
0WB40ZZ	Excision of Upper Jaw, Open Approach	Procedure	ICD-10-PCS
0WB43ZZ	Excision of Upper Jaw, Percutaneous Approach	Procedure	ICD-10-PCS
0WB44ZZ	Excision of Upper Jaw, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WB4XZZ	Excision of Upper Jaw, External Approach	Procedure	ICD-10-PCS
0WB50ZZ	Excision of Lower Jaw, Open Approach	Procedure	ICD-10-PCS
0WB53ZZ	Excision of Lower Jaw, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0WB54ZZ	Excision of Lower Jaw, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WB5XZZ	Excision of Lower Jaw, External Approach	Procedure	ICD-10-PCS
0WB60ZZ	Excision of Neck, Open Approach	Procedure	ICD-10-PCS
0WB63ZZ	Excision of Neck, Percutaneous Approach	Procedure	ICD-10-PCS
0WB64ZZ	Excision of Neck, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WB6XZZ	Excision of Neck, External Approach	Procedure	ICD-10-PCS
0WBH0ZZ	Excision of Retroperitoneum, Open Approach	Procedure	ICD-10-PCS
0WBH3ZZ	Excision of Retroperitoneum, Percutaneous Approach	Procedure	ICD-10-PCS
0WBH4ZZ	Excision of Retroperitoneum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WBK0ZZ	Excision of Upper Back, Open Approach	Procedure	ICD-10-PCS
0WBK3ZZ	Excision of Upper Back, Percutaneous Approach	Procedure	ICD-10-PCS
0WBK4ZZ	Excision of Upper Back, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WBKXZZ	Excision of Upper Back, External Approach	Procedure	ICD-10-PCS
0WBL0ZZ	Excision of Lower Back, Open Approach	Procedure	ICD-10-PCS
0WBL3ZZ	Excision of Lower Back, Percutaneous Approach	Procedure	ICD-10-PCS
0WBL4ZZ	Excision of Lower Back, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WBLXZZ	Excision of Lower Back, External Approach	Procedure	ICD-10-PCS
0WBM0ZZ	Excision of Male Perineum, Open Approach	Procedure	ICD-10-PCS
0WBM3ZZ	Excision of Male Perineum, Percutaneous Approach	Procedure	ICD-10-PCS
0WBM4ZZ	Excision of Male Perineum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WBMXZZ	Excision of Male Perineum, External Approach	Procedure	ICD-10-PCS
0WBN0ZX	Excision of Female Perineum, Open Approach, Diagnostic	Procedure	ICD-10-PCS
0WBN0ZZ	Excision of Female Perineum, Open Approach	Procedure	ICD-10-PCS
0WBN3ZX	Excision of Female Perineum, Percutaneous Approach, Diagnostic	Procedure	ICD-10-PCS
0WBN3ZZ	Excision of Female Perineum, Percutaneous Approach	Procedure	ICD-10-PCS
0WBN4ZX	Excision of Female Perineum, Percutaneous Endoscopic Approach, Diagnostic	Procedure	ICD-10-PCS
0WBN4ZZ	Excision of Female Perineum, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WBNXZX	Excision of Female Perineum, External Approach, Diagnostic	Procedure	ICD-10-PCS
0WBNXZZ	Excision of Female Perineum, External Approach	Procedure	ICD-10-PCS
0WC90ZZ	Extirpation of Matter from Right Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WC93ZZ	Extirpation of Matter from Right Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0WC94ZZ	Extirpation of Matter from Right Pleural Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WCB0ZZ	Extirpation of Matter from Left Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WCB3ZZ	Extirpation of Matter from Left Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0WCB4ZZ	Extirpation of Matter from Left Pleural Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WCQ0ZZ	Extirpation of Matter from Respiratory Tract, Open Approach	Procedure	ICD-10-PCS
0WCQ3ZZ	Extirpation of Matter from Respiratory Tract, Percutaneous Approach	Procedure	ICD-10-PCS
0WCQ4ZZ	Extirpation of Matter from Respiratory Tract, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WH903Z	Insertion of Infusion Device into Right Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WH90YZ	Insertion of Other Device into Right Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WH933Z	Insertion of Infusion Device into Right Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0WH93YZ	Insertion of Other Device into Right Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0WH943Z	Insertion of Infusion Device into Right Pleural Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WH94YZ	Insertion of Other Device into Right Pleural Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WHB03Z	Insertion of Infusion Device into Left Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WHB0YZ	Insertion of Other Device into Left Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WHB33Z	Insertion of Infusion Device into Left Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0WHB3YZ	Insertion of Other Device into Left Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0WHB43Z	Insertion of Infusion Device into Left Pleural Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WHB4YZ	Insertion of Other Device into Left Pleural Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WHQ03Z	Insertion of Infusion Device into Respiratory Tract, Open Approach	Procedure	ICD-10-PCS
0WHQ0YZ	Insertion of Other Device into Respiratory Tract, Open Approach	Procedure	ICD-10-PCS
0WP900Z	Removal of Drainage Device from Right Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WP901Z	Removal of Radioactive Element from Right Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WP903Z	Removal of Infusion Device from Right Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WP90JZ	Removal of Synthetic Substitute from Right Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WP90YZ	Removal of Other Device from Right Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WP930Z	Removal of Drainage Device from Right Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0WP931Z	Removal of Radioactive Element from Right Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0WP933Z	Removal of Infusion Device from Right Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0WP93JZ	Removal of Synthetic Substitute from Right Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0WP93YZ	Removal of Other Device from Right Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0WP940Z	Removal of Drainage Device from Right Pleural Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WP941Z	Removal of Radioactive Element from Right Pleural Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WP943Z	Removal of Infusion Device from Right Pleural Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WP94JZ	Removal of Synthetic Substitute from Right Pleural Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WP94YZ	Removal of Other Device from Right Pleural Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WPB00Z	Removal of Drainage Device from Left Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WPB01Z	Removal of Radioactive Element from Left Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WPB03Z	Removal of Infusion Device from Left Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WPB0JZ	Removal of Synthetic Substitute from Left Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WPB0YZ	Removal of Other Device from Left Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WPB30Z	Removal of Drainage Device from Left Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0WPB31Z	Removal of Radioactive Element from Left Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0WPB33Z	Removal of Infusion Device from Left Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0WPB3JZ	Removal of Synthetic Substitute from Left Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0WPB3YZ	Removal of Other Device from Left Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0WPB40Z	Removal of Drainage Device from Left Pleural Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WPB41Z	Removal of Radioactive Element from Left Pleural Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WPB43Z	Removal of Infusion Device from Left Pleural Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WPB4JZ	Removal of Synthetic Substitute from Left Pleural Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WPB4YZ	Removal of Other Device from Left Pleural Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WPQ01Z	Removal of Radioactive Element from Respiratory Tract, Open Approach	Procedure	ICD-10-PCS
0WPQ03Z	Removal of Infusion Device from Respiratory Tract, Open Approach	Procedure	ICD-10-PCS
0WPQ0YZ	Removal of Other Device from Respiratory Tract, Open Approach	Procedure	ICD-10-PCS
0WW900Z	Revision of Drainage Device in Right Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WW901Z	Revision of Radioactive Element in Right Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WW903Z	Revision of Infusion Device in Right Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WW90JZ	Revision of Synthetic Substitute in Right Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WW90YZ	Revision of Other Device in Right Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WW930Z	Revision of Drainage Device in Right Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0WW931Z	Revision of Radioactive Element in Right Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0WW933Z	Revision of Infusion Device in Right Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0WW93JZ	Revision of Synthetic Substitute in Right Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0WW93YZ	Revision of Other Device in Right Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0WW940Z	Revision of Drainage Device in Right Pleural Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WW941Z	Revision of Radioactive Element in Right Pleural Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WW943Z	Revision of Infusion Device in Right Pleural Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WW94JZ	Revision of Synthetic Substitute in Right Pleural Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WW94YZ	Revision of Other Device in Right Pleural Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WWB00Z	Revision of Drainage Device in Left Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WWB01Z	Revision of Radioactive Element in Left Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WWB03Z	Revision of Infusion Device in Left Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WWB0JZ	Revision of Synthetic Substitute in Left Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WWB0YZ	Revision of Other Device in Left Pleural Cavity, Open Approach	Procedure	ICD-10-PCS
0WWB30Z	Revision of Drainage Device in Left Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0WWB31Z	Revision of Radioactive Element in Left Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0WWB33Z	Revision of Infusion Device in Left Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0WWB3JZ	Revision of Synthetic Substitute in Left Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS
0WWB3YZ	Revision of Other Device in Left Pleural Cavity, Percutaneous Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0WWB40Z	Revision of Drainage Device in Left Pleural Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WWB41Z	Revision of Radioactive Element in Left Pleural Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WWB43Z	Revision of Infusion Device in Left Pleural Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WWB4JZ	Revision of Synthetic Substitute in Left Pleural Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WWB4YZ	Revision of Other Device in Left Pleural Cavity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0WWQ01Z	Revision of Radioactive Element in Respiratory Tract, Open Approach	Procedure	ICD-10-PCS
0WWQ03Z	Revision of Infusion Device in Respiratory Tract, Open Approach	Procedure	ICD-10-PCS
0WWQ0YZ	Revision of Other Device in Respiratory Tract, Open Approach	Procedure	ICD-10-PCS
0X600ZZ	Detachment at Right Forequarter, Open Approach	Procedure	ICD-10-PCS
0X610ZZ	Detachment at Left Forequarter, Open Approach	Procedure	ICD-10-PCS
0X680Z1	Detachment at Right Upper Arm, High, Open Approach	Procedure	ICD-10-PCS
0X680Z2	Detachment at Right Upper Arm, Mid, Open Approach	Procedure	ICD-10-PCS
0X680Z3	Detachment at Right Upper Arm, Low, Open Approach	Procedure	ICD-10-PCS
0X690Z1	Detachment at Left Upper Arm, High, Open Approach	Procedure	ICD-10-PCS
0X690Z2	Detachment at Left Upper Arm, Mid, Open Approach	Procedure	ICD-10-PCS
0X690Z3	Detachment at Left Upper Arm, Low, Open Approach	Procedure	ICD-10-PCS
0X6D0Z1	Detachment at Right Lower Arm, High, Open Approach	Procedure	ICD-10-PCS
0X6D0Z2	Detachment at Right Lower Arm, Mid, Open Approach	Procedure	ICD-10-PCS
0X6D0Z3	Detachment at Right Lower Arm, Low, Open Approach	Procedure	ICD-10-PCS
0X6F0Z1	Detachment at Left Lower Arm, High, Open Approach	Procedure	ICD-10-PCS
0X6F0Z2	Detachment at Left Lower Arm, Mid, Open Approach	Procedure	ICD-10-PCS
0X6F0Z3	Detachment at Left Lower Arm, Low, Open Approach	Procedure	ICD-10-PCS
0X6J0Z4	Detachment at Right Hand, Complete 1st Ray, Open Approach	Procedure	ICD-10-PCS
0X6J0Z5	Detachment at Right Hand, Complete 2nd Ray, Open Approach	Procedure	ICD-10-PCS
0X6J0Z6	Detachment at Right Hand, Complete 3rd Ray, Open Approach	Procedure	ICD-10-PCS
0X6J0Z7	Detachment at Right Hand, Complete 4th Ray, Open Approach	Procedure	ICD-10-PCS
0X6J0Z8	Detachment at Right Hand, Complete 5th Ray, Open Approach	Procedure	ICD-10-PCS
0X6J0Z9	Detachment at Right Hand, Partial 1st Ray, Open Approach	Procedure	ICD-10-PCS
0X6J0ZB	Detachment at Right Hand, Partial 2nd Ray, Open Approach	Procedure	ICD-10-PCS
0X6J0ZC	Detachment at Right Hand, Partial 3rd Ray, Open Approach	Procedure	ICD-10-PCS
0X6J0ZD	Detachment at Right Hand, Partial 4th Ray, Open Approach	Procedure	ICD-10-PCS
0X6J0ZF	Detachment at Right Hand, Partial 5th Ray, Open Approach	Procedure	ICD-10-PCS
0X6K0Z4	Detachment at Left Hand, Complete 1st Ray, Open Approach	Procedure	ICD-10-PCS
0X6K0Z5	Detachment at Left Hand, Complete 2nd Ray, Open Approach	Procedure	ICD-10-PCS
0X6K0Z6	Detachment at Left Hand, Complete 3rd Ray, Open Approach	Procedure	ICD-10-PCS
0X6K0Z7	Detachment at Left Hand, Complete 4th Ray, Open Approach	Procedure	ICD-10-PCS
0X6K0Z8	Detachment at Left Hand, Complete 5th Ray, Open Approach	Procedure	ICD-10-PCS
0X6K0Z9	Detachment at Left Hand, Partial 1st Ray, Open Approach	Procedure	ICD-10-PCS
0X6K0ZB	Detachment at Left Hand, Partial 2nd Ray, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0X6K0ZC	Detachment at Left Hand, Partial 3rd Ray, Open Approach	Procedure	ICD-10-PCS
0X6K0ZD	Detachment at Left Hand, Partial 4th Ray, Open Approach	Procedure	ICD-10-PCS
0X6K0ZF	Detachment at Left Hand, Partial 5th Ray, Open Approach	Procedure	ICD-10-PCS
0X6L0Z0	Detachment at Right Thumb, Complete, Open Approach	Procedure	ICD-10-PCS
0X6L0Z1	Detachment at Right Thumb, High, Open Approach	Procedure	ICD-10-PCS
0X6L0Z2	Detachment at Right Thumb, Mid, Open Approach	Procedure	ICD-10-PCS
0X6L0Z3	Detachment at Right Thumb, Low, Open Approach	Procedure	ICD-10-PCS
0X6M0Z0	Detachment at Left Thumb, Complete, Open Approach	Procedure	ICD-10-PCS
0X6M0Z1	Detachment at Left Thumb, High, Open Approach	Procedure	ICD-10-PCS
0X6M0Z2	Detachment at Left Thumb, Mid, Open Approach	Procedure	ICD-10-PCS
0X6M0Z3	Detachment at Left Thumb, Low, Open Approach	Procedure	ICD-10-PCS
0X6N0Z0	Detachment at Right Index Finger, Complete, Open Approach	Procedure	ICD-10-PCS
0X6N0Z1	Detachment at Right Index Finger, High, Open Approach	Procedure	ICD-10-PCS
0X6N0Z2	Detachment at Right Index Finger, Mid, Open Approach	Procedure	ICD-10-PCS
0X6N0Z3	Detachment at Right Index Finger, Low, Open Approach	Procedure	ICD-10-PCS
0X6P0Z0	Detachment at Left Index Finger, Complete, Open Approach	Procedure	ICD-10-PCS
0X6P0Z1	Detachment at Left Index Finger, High, Open Approach	Procedure	ICD-10-PCS
0X6P0Z2	Detachment at Left Index Finger, Mid, Open Approach	Procedure	ICD-10-PCS
0X6P0Z3	Detachment at Left Index Finger, Low, Open Approach	Procedure	ICD-10-PCS
0X6Q0Z0	Detachment at Right Middle Finger, Complete, Open Approach	Procedure	ICD-10-PCS
0X6Q0Z1	Detachment at Right Middle Finger, High, Open Approach	Procedure	ICD-10-PCS
0X6Q0Z2	Detachment at Right Middle Finger, Mid, Open Approach	Procedure	ICD-10-PCS
0X6Q0Z3	Detachment at Right Middle Finger, Low, Open Approach	Procedure	ICD-10-PCS
0X6R0Z0	Detachment at Left Middle Finger, Complete, Open Approach	Procedure	ICD-10-PCS
0X6R0Z1	Detachment at Left Middle Finger, High, Open Approach	Procedure	ICD-10-PCS
0X6R0Z2	Detachment at Left Middle Finger, Mid, Open Approach	Procedure	ICD-10-PCS
0X6R0Z3	Detachment at Left Middle Finger, Low, Open Approach	Procedure	ICD-10-PCS
0X6S0Z0	Detachment at Right Ring Finger, Complete, Open Approach	Procedure	ICD-10-PCS
0X6S0Z1	Detachment at Right Ring Finger, High, Open Approach	Procedure	ICD-10-PCS
0X6S0Z2	Detachment at Right Ring Finger, Mid, Open Approach	Procedure	ICD-10-PCS
0X6S0Z3	Detachment at Right Ring Finger, Low, Open Approach	Procedure	ICD-10-PCS
0X6T0Z0	Detachment at Left Ring Finger, Complete, Open Approach	Procedure	ICD-10-PCS
0X6T0Z1	Detachment at Left Ring Finger, High, Open Approach	Procedure	ICD-10-PCS
0X6T0Z2	Detachment at Left Ring Finger, Mid, Open Approach	Procedure	ICD-10-PCS
0X6T0Z3	Detachment at Left Ring Finger, Low, Open Approach	Procedure	ICD-10-PCS
0X6V0Z0	Detachment at Right Little Finger, Complete, Open Approach	Procedure	ICD-10-PCS
0X6V0Z1	Detachment at Right Little Finger, High, Open Approach	Procedure	ICD-10-PCS
0X6V0Z2	Detachment at Right Little Finger, Mid, Open Approach	Procedure	ICD-10-PCS
0X6V0Z3	Detachment at Right Little Finger, Low, Open Approach	Procedure	ICD-10-PCS
0X6W0Z0	Detachment at Left Little Finger, Complete, Open Approach	Procedure	ICD-10-PCS
0X6W0Z1	Detachment at Left Little Finger, High, Open Approach	Procedure	ICD-10-PCS
0X6W0Z2	Detachment at Left Little Finger, Mid, Open Approach	Procedure	ICD-10-PCS
0X6W0Z3	Detachment at Left Little Finger, Low, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0XB20ZZ	Excision of Right Shoulder Region, Open Approach	Procedure	ICD-10-PCS
0XB23ZZ	Excision of Right Shoulder Region, Percutaneous Approach	Procedure	ICD-10-PCS
0XB24ZZ	Excision of Right Shoulder Region, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0XB30ZZ	Excision of Left Shoulder Region, Open Approach	Procedure	ICD-10-PCS
0XB33ZZ	Excision of Left Shoulder Region, Percutaneous Approach	Procedure	ICD-10-PCS
0XB34ZZ	Excision of Left Shoulder Region, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0XB40ZZ	Excision of Right Axilla, Open Approach	Procedure	ICD-10-PCS
0XB43ZZ	Excision of Right Axilla, Percutaneous Approach	Procedure	ICD-10-PCS
0XB44ZZ	Excision of Right Axilla, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0XB50ZZ	Excision of Left Axilla, Open Approach	Procedure	ICD-10-PCS
0XB53ZZ	Excision of Left Axilla, Percutaneous Approach	Procedure	ICD-10-PCS
0XB54ZZ	Excision of Left Axilla, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0XB60ZZ	Excision of Right Upper Extremity, Open Approach	Procedure	ICD-10-PCS
0XB63ZZ	Excision of Right Upper Extremity, Percutaneous Approach	Procedure	ICD-10-PCS
0XB64ZZ	Excision of Right Upper Extremity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0XB70ZZ	Excision of Left Upper Extremity, Open Approach	Procedure	ICD-10-PCS
0XB73ZZ	Excision of Left Upper Extremity, Percutaneous Approach	Procedure	ICD-10-PCS
0XB74ZZ	Excision of Left Upper Extremity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0XB80ZZ	Excision of Right Upper Arm, Open Approach	Procedure	ICD-10-PCS
0XB83ZZ	Excision of Right Upper Arm, Percutaneous Approach	Procedure	ICD-10-PCS
0XB84ZZ	Excision of Right Upper Arm, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0XB90ZZ	Excision of Left Upper Arm, Open Approach	Procedure	ICD-10-PCS
0XB93ZZ	Excision of Left Upper Arm, Percutaneous Approach	Procedure	ICD-10-PCS
0XB94ZZ	Excision of Left Upper Arm, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0XBB0ZZ	Excision of Right Elbow Region, Open Approach	Procedure	ICD-10-PCS
0XBB3ZZ	Excision of Right Elbow Region, Percutaneous Approach	Procedure	ICD-10-PCS
0XBB4ZZ	Excision of Right Elbow Region, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0XBC0ZZ	Excision of Left Elbow Region, Open Approach	Procedure	ICD-10-PCS
0XBC3ZZ	Excision of Left Elbow Region, Percutaneous Approach	Procedure	ICD-10-PCS
0XBC4ZZ	Excision of Left Elbow Region, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0XBD0ZZ	Excision of Right Lower Arm, Open Approach	Procedure	ICD-10-PCS
0XBD3ZZ	Excision of Right Lower Arm, Percutaneous Approach	Procedure	ICD-10-PCS
0XBD4ZZ	Excision of Right Lower Arm, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0XBF0ZZ	Excision of Left Lower Arm, Open Approach	Procedure	ICD-10-PCS
0XBF3ZZ	Excision of Left Lower Arm, Percutaneous Approach	Procedure	ICD-10-PCS
0XBF4ZZ	Excision of Left Lower Arm, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0XBG0ZZ	Excision of Right Wrist Region, Open Approach	Procedure	ICD-10-PCS
0XBG3ZZ	Excision of Right Wrist Region, Percutaneous Approach	Procedure	ICD-10-PCS
0XBG4ZZ	Excision of Right Wrist Region, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0XBH0ZZ	Excision of Left Wrist Region, Open Approach	Procedure	ICD-10-PCS
0XBH3ZZ	Excision of Left Wrist Region, Percutaneous Approach	Procedure	ICD-10-PCS
0XBH4ZZ	Excision of Left Wrist Region, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0XBJ0ZZ	Excision of Right Hand, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0XBJ3ZZ	Excision of Right Hand, Percutaneous Approach	Procedure	ICD-10-PCS
0XBJ4ZZ	Excision of Right Hand, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0XBK0ZZ	Excision of Left Hand, Open Approach	Procedure	ICD-10-PCS
0XBK3ZZ	Excision of Left Hand, Percutaneous Approach	Procedure	ICD-10-PCS
0XBK4ZZ	Excision of Left Hand, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0Y620ZZ	Detachment at Right Hindquarter, Open Approach	Procedure	ICD-10-PCS
0Y630ZZ	Detachment at Left Hindquarter, Open Approach	Procedure	ICD-10-PCS
0Y640ZZ	Detachment at Bilateral Hindquarter, Open Approach	Procedure	ICD-10-PCS
0Y6C0Z1	Detachment at Right Upper Leg, High, Open Approach	Procedure	ICD-10-PCS
0Y6C0Z2	Detachment at Right Upper Leg, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6C0Z3	Detachment at Right Upper Leg, Low, Open Approach	Procedure	ICD-10-PCS
0Y6D0Z1	Detachment at Left Upper Leg, High, Open Approach	Procedure	ICD-10-PCS
0Y6D0Z2	Detachment at Left Upper Leg, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6D0Z3	Detachment at Left Upper Leg, Low, Open Approach	Procedure	ICD-10-PCS
0Y6H0Z1	Detachment at Right Lower Leg, High, Open Approach	Procedure	ICD-10-PCS
0Y6H0Z2	Detachment at Right Lower Leg, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6H0Z3	Detachment at Right Lower Leg, Low, Open Approach	Procedure	ICD-10-PCS
0Y6J0Z1	Detachment at Left Lower Leg, High, Open Approach	Procedure	ICD-10-PCS
0Y6J0Z2	Detachment at Left Lower Leg, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6J0Z3	Detachment at Left Lower Leg, Low, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z0	Detachment at Right Foot, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z4	Detachment at Right Foot, Complete 1st Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z5	Detachment at Right Foot, Complete 2nd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z6	Detachment at Right Foot, Complete 3rd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z7	Detachment at Right Foot, Complete 4th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z8	Detachment at Right Foot, Complete 5th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0Z9	Detachment at Right Foot, Partial 1st Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0ZB	Detachment at Right Foot, Partial 2nd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0ZC	Detachment at Right Foot, Partial 3rd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0ZD	Detachment at Right Foot, Partial 4th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6M0ZF	Detachment at Right Foot, Partial 5th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z0	Detachment at Left Foot, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z4	Detachment at Left Foot, Complete 1st Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z5	Detachment at Left Foot, Complete 2nd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z6	Detachment at Left Foot, Complete 3rd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z7	Detachment at Left Foot, Complete 4th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z8	Detachment at Left Foot, Complete 5th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0Z9	Detachment at Left Foot, Partial 1st Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0ZB	Detachment at Left Foot, Partial 2nd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0ZC	Detachment at Left Foot, Partial 3rd Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0ZD	Detachment at Left Foot, Partial 4th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6N0ZF	Detachment at Left Foot, Partial 5th Ray, Open Approach	Procedure	ICD-10-PCS
0Y6P0Z0	Detachment at Right 1st Toe, Complete, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0Y6P0Z1	Detachment at Right 1st Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6P0Z2	Detachment at Right 1st Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6P0Z3	Detachment at Right 1st Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6Q0Z0	Detachment at Left 1st Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6Q0Z1	Detachment at Left 1st Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6Q0Z2	Detachment at Left 1st Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6Q0Z3	Detachment at Left 1st Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6R0Z0	Detachment at Right 2nd Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6R0Z1	Detachment at Right 2nd Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6R0Z2	Detachment at Right 2nd Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6R0Z3	Detachment at Right 2nd Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6S0Z0	Detachment at Left 2nd Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6S0Z1	Detachment at Left 2nd Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6S0Z2	Detachment at Left 2nd Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6S0Z3	Detachment at Left 2nd Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6T0Z0	Detachment at Right 3rd Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6T0Z1	Detachment at Right 3rd Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6T0Z2	Detachment at Right 3rd Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6T0Z3	Detachment at Right 3rd Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6U0Z0	Detachment at Left 3rd Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6U0Z1	Detachment at Left 3rd Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6U0Z2	Detachment at Left 3rd Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6U0Z3	Detachment at Left 3rd Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6V0Z0	Detachment at Right 4th Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6V0Z1	Detachment at Right 4th Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6V0Z2	Detachment at Right 4th Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6V0Z3	Detachment at Right 4th Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6W0Z0	Detachment at Left 4th Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6W0Z1	Detachment at Left 4th Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6W0Z2	Detachment at Left 4th Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6W0Z3	Detachment at Left 4th Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6X0Z0	Detachment at Right 5th Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6X0Z1	Detachment at Right 5th Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6X0Z2	Detachment at Right 5th Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6X0Z3	Detachment at Right 5th Toe, Low, Open Approach	Procedure	ICD-10-PCS
0Y6Y0Z0	Detachment at Left 5th Toe, Complete, Open Approach	Procedure	ICD-10-PCS
0Y6Y0Z1	Detachment at Left 5th Toe, High, Open Approach	Procedure	ICD-10-PCS
0Y6Y0Z2	Detachment at Left 5th Toe, Mid, Open Approach	Procedure	ICD-10-PCS
0Y6Y0Z3	Detachment at Left 5th Toe, Low, Open Approach	Procedure	ICD-10-PCS
0YB00ZZ	Excision of Right Buttock, Open Approach	Procedure	ICD-10-PCS
0YB03ZZ	Excision of Right Buttock, Percutaneous Approach	Procedure	ICD-10-PCS
0YB04ZZ	Excision of Right Buttock, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0YB10ZZ	Excision of Left Buttock, Open Approach	Procedure	ICD-10-PCS

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
0YB13ZZ	Excision of Left Buttock, Percutaneous Approach	Procedure	ICD-10-PCS
0YB14ZZ	Excision of Left Buttock, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0YB90ZZ	Excision of Right Lower Extremity, Open Approach	Procedure	ICD-10-PCS
0YB93ZZ	Excision of Right Lower Extremity, Percutaneous Approach	Procedure	ICD-10-PCS
0YB94ZZ	Excision of Right Lower Extremity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0YBB0ZZ	Excision of Left Lower Extremity, Open Approach	Procedure	ICD-10-PCS
0YBB3ZZ	Excision of Left Lower Extremity, Percutaneous Approach	Procedure	ICD-10-PCS
0YBB4ZZ	Excision of Left Lower Extremity, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0YBC0ZZ	Excision of Right Upper Leg, Open Approach	Procedure	ICD-10-PCS
0YBC3ZZ	Excision of Right Upper Leg, Percutaneous Approach	Procedure	ICD-10-PCS
0YBC4ZZ	Excision of Right Upper Leg, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0YBD0ZZ	Excision of Left Upper Leg, Open Approach	Procedure	ICD-10-PCS
0YBD3ZZ	Excision of Left Upper Leg, Percutaneous Approach	Procedure	ICD-10-PCS
0YBD4ZZ	Excision of Left Upper Leg, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0YBF0ZZ	Excision of Right Knee Region, Open Approach	Procedure	ICD-10-PCS
0YBF3ZZ	Excision of Right Knee Region, Percutaneous Approach	Procedure	ICD-10-PCS
0YBF4ZZ	Excision of Right Knee Region, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0YBG0ZZ	Excision of Left Knee Region, Open Approach	Procedure	ICD-10-PCS
0YBG3ZZ	Excision of Left Knee Region, Percutaneous Approach	Procedure	ICD-10-PCS
0YBG4ZZ	Excision of Left Knee Region, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0YBH0ZZ	Excision of Right Lower Leg, Open Approach	Procedure	ICD-10-PCS
0YBH3ZZ	Excision of Right Lower Leg, Percutaneous Approach	Procedure	ICD-10-PCS
0YBH4ZZ	Excision of Right Lower Leg, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0YBJ0ZZ	Excision of Left Lower Leg, Open Approach	Procedure	ICD-10-PCS
0YBJ3ZZ	Excision of Left Lower Leg, Percutaneous Approach	Procedure	ICD-10-PCS
0YBJ4ZZ	Excision of Left Lower Leg, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0YBK0ZZ	Excision of Right Ankle Region, Open Approach	Procedure	ICD-10-PCS
0YBK3ZZ	Excision of Right Ankle Region, Percutaneous Approach	Procedure	ICD-10-PCS
0YBK4ZZ	Excision of Right Ankle Region, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0YBL0ZZ	Excision of Left Ankle Region, Open Approach	Procedure	ICD-10-PCS
0YBL3ZZ	Excision of Left Ankle Region, Percutaneous Approach	Procedure	ICD-10-PCS
0YBL4ZZ	Excision of Left Ankle Region, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0YBM0ZZ	Excision of Right Foot, Open Approach	Procedure	ICD-10-PCS
0YBM3ZZ	Excision of Right Foot, Percutaneous Approach	Procedure	ICD-10-PCS
0YBM4ZZ	Excision of Right Foot, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
0YBN0ZZ	Excision of Left Foot, Open Approach	Procedure	ICD-10-PCS
0YBN3ZZ	Excision of Left Foot, Percutaneous Approach	Procedure	ICD-10-PCS
0YBN4ZZ	Excision of Left Foot, Percutaneous Endoscopic Approach	Procedure	ICD-10-PCS
11600	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter 0.5 cm or less	Procedure	CPT-4
11601	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter 0.6 to 1.0 cm	Procedure	CPT-4

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
11602	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter 1.1 to 2.0 cm	Procedure	CPT-4
11603	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter 2.1 to 3.0 cm	Procedure	CPT-4
11604	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter 3.1 to 4.0 cm	Procedure	CPT-4
11606	Excision, malignant lesion including margins, trunk, arms, or legs; excised diameter over 4.0 cm	Procedure	CPT-4
11620	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 0.5 cm or less	Procedure	CPT-4
11621	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 0.6 to 1.0 cm	Procedure	CPT-4
11622	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 1.1 to 2.0 cm	Procedure	CPT-4
11623	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 2.1 to 3.0 cm	Procedure	CPT-4
11624	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter 3.1 to 4.0 cm	Procedure	CPT-4
11626	Excision, malignant lesion including margins, scalp, neck, hands, feet, genitalia; excised diameter over 4.0 cm	Procedure	CPT-4
11640	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 0.5 cm or less	Procedure	CPT-4
11641	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 0.6 to 1.0 cm	Procedure	CPT-4
11642	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 1.1 to 2.0 cm	Procedure	CPT-4
11643	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 2.1 to 3.0 cm	Procedure	CPT-4
11644	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 3.1 to 4.0 cm	Procedure	CPT-4
11646	Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter over 4.0 cm	Procedure	CPT-4
11730	Avulsion of nail plate, partial or complete, simple; single	Procedure	CPT-4
11750	Excision of nail and nail matrix, partial or complete (eg, ingrown or deformed nail), for permanent removal;	Procedure	CPT-4
17.3	Laparoscopic partial excision of large intestine	Procedure	ICD-9-CM
17.31	Laparoscopic multiple segmental resection of large intestine	Procedure	ICD-9-CM
17.32	Laparoscopic cecectomy	Procedure	ICD-9-CM
17.33	Laparoscopic right hemicolectomy	Procedure	ICD-9-CM
17.34	Laparoscopic resection of transverse colon	Procedure	ICD-9-CM
17.35	Laparoscopic left hemicolectomy	Procedure	ICD-9-CM
17.36	Laparoscopic sigmoidectomy	Procedure	ICD-9-CM
17.39	Other laparoscopic partial excision of large intestine	Procedure	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
17260	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), trunk, arms or legs; lesion diameter 0.5 cm or less	Procedure	CPT-4
17261	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), trunk, arms or legs; lesion diameter 0.6 to 1.0 cm	Procedure	CPT-4
17262	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), trunk, arms or legs; lesion diameter 1.1 to 2.0 cm	Procedure	CPT-4
17263	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), trunk, arms or legs; lesion diameter 2.1 to 3.0 cm	Procedure	CPT-4
17264	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), trunk, arms or legs; lesion diameter 3.1 to 4.0 cm	Procedure	CPT-4
17266	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), trunk, arms or legs; lesion diameter over 4.0	Procedure	CPT-4
17270	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), scalp, neck, hands, feet, genitalia; lesion diameter 0.5 cm or less	Procedure	CPT-4
17271	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), scalp, neck, hands, feet, genitalia; lesion diameter 0.6 to 1.0 cm	Procedure	CPT-4
17272	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), scalp, neck, hands, feet, genitalia; lesion diameter 1.1 to 2.0 cm	Procedure	CPT-4
17273	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), scalp, neck, hands, feet, genitalia; lesion diameter 2.1 to 3.0 cm	Procedure	CPT-4
17274	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), scalp, neck, hands, feet, genitalia; lesion diameter 3.1 to 4.0 cm	Procedure	CPT-4
17276	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), scalp, neck, hands, feet, genitalia; lesion diameter over 4.0 cm	Procedure	CPT-4
17280	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), face, ears, eyelids, nose, lips, mucous membrane; lesion diameter 0.5 cm or less	Procedure	CPT-4
17281	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), face, ears, eyelids, nose, lips, mucous membrane; lesion diameter 0.6 to 1.0 cm	Procedure	CPT-4

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
17282	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), face, ears, eyelids, nose, lips, mucous membrane; lesion diameter 1.1 to 2.0 cm	Procedure	CPT-4
17283	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), face, ears, eyelids, nose, lips, mucous membrane; lesion diameter 2.1 to 3.0 cm	Procedure	CPT-4
17284	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), face, ears, eyelids, nose, lips, mucous membrane; lesion diameter 3.1 to 4.0 cm	Procedure	CPT-4
17286	Destruction, malignant lesion (eg, laser surgery, electrosurgery, cryosurgery, chemosurgery, surgical curettement), face, ears, eyelids, nose, lips, mucous membrane; lesion diameter over 4.0 cm	Procedure	CPT-4
17303	Chemosurgery (mohs' Micrographic Technique), First Stage, Fixed Tissue Technique, Including Removal Of All Gross Tumor And Application Of Fixative	Procedure	CPT-4
17304	Chemosurgery (Mohs micrographic technique), including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and complete histopathologic preparation including the first routine stain (eg, hematoxylin and eosin, toluidine blue); first stage, fresh tissue technique, up to 5 specimens	Procedure	CPT-4
17305	Chemosurgery (Mohs micrographic technique), including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and complete histopathologic preparation including the first routine stain (eg, hematoxylin and eosin, toluidine blue); second stage, fixed or fresh tissue, up to 5 specimens	Procedure	CPT-4
17306	Chemosurgery (Mohs micrographic technique), including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and complete histopathologic preparation including the first routine stain (eg, hematoxylin and eosin, toluidine blue); third stage, fixed or fresh tissue, up to 5 specimens	Procedure	CPT-4
17307	Chemosurgery (Mohs micrographic technique), including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and complete histopathologic preparation including the first routine stain (eg, hematoxylin and eosin, toluidine blue); additional stage(s), up to 5 specimens, each stage	Procedure	CPT-4
17310	Chemosurgery (Mohs micrographic technique), including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and complete histopathologic preparation including the first routine stain (eg, hematoxylin and eosin, toluidine blue); each additional specimen, after the first 5 specimens, fixed or fresh tissue, any stage (List separately in addition to code for primary procedure)	Procedure	CPT-4

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
17311	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), head, neck, hands, feet, genitalia, or any location with surgery directly involving muscle, cartilage, bone, tendon, major nerves, or vessels; first stage, up to 5 tissue blocks	Procedure	CPT-4
17312	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), head, neck, hands, feet, genitalia, or any location with surgery directly involving muscle, cartilage, bone, tendon, major nerves, or vessels; each additional stage after the first stage, up to 5 tissue blocks (List separately in addition to code for primary procedure)	Procedure	CPT-4
17313	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), of the trunk, arms, or legs; first stage, up to 5 tissue blocks	Procedure	CPT-4
17314	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), of the trunk, arms, or legs; each additional stage after the first stage, up to 5 tissue blocks (List separately in addition to code for primary procedure)	Procedure	CPT-4
17315	Mohs micrographic technique, including removal of all gross tumor, surgical excision of tissue specimens, mapping, color coding of specimens, microscopic examination of specimens by the surgeon, and histopathologic preparation including routine stain(s) (eg, hematoxylin and eosin, toluidine blue), each additional block after the first 5 tissue blocks, any stage (List separately in addition to code for primary procedure)	Procedure	CPT-4
18.29	Excision or destruction of other lesion of external ear	Procedure	ICD-9-CM
19125	Excision of breast lesion identified by preoperative placement of radiological marker, open; single lesion	Procedure	CPT-4
19160	Mastectomy, partial (eg, lumpectomy, tylectomy, quadrantectomy, segmentectomy);	Procedure	CPT-4
19162	Mastectomy, partial (eg, lumpectomy, tylectomy, quadrantectomy, segmentectomy); with axillary lymphadenectomy	Procedure	CPT-4
19180	Mastectomy, simple, complete	Procedure	CPT-4
19182	Mastectomy, subcutaneous	Procedure	CPT-4
19200	Mastectomy, radical, including pectoral muscles, axillary lymph nodes	Procedure	CPT-4
19220	Mastectomy, radical, including pectoral muscles, axillary and internal mammary lymph nodes (Urban type operation)	Procedure	CPT-4

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
19240	Mastectomy, modified radical, including axillary lymph nodes, with or without pectoralis minor muscle, but excluding pectoralis major muscle	Procedure	CPT-4
19260	Excision of chest wall tumor including ribs	Procedure	CPT-4
19271	Excision of chest wall tumor involving ribs, with plastic reconstruction; without mediastinal lymphadenectomy	Procedure	CPT-4
19272	Excision of chest wall tumor involving ribs, with plastic reconstruction; with mediastinal lymphadenectomy	Procedure	CPT-4
19294	Preparation of tumor cavity, with placement of a radiation therapy applicator for intraoperative radiation therapy (IORT) concurrent with partial mastectomy (List separately in addition to code for primary procedure)	Procedure	CPT-4
19301	Mastectomy, partial (eg, lumpectomy, tylectomy, quadrantectomy, segmentectomy);	Procedure	CPT-4
19302	Mastectomy, partial (eg, lumpectomy, tylectomy, quadrantectomy, segmentectomy); with axillary lymphadenectomy	Procedure	CPT-4
19303	Mastectomy, simple, complete	Procedure	CPT-4
19304	Mastectomy, subcutaneous	Procedure	CPT-4
19305	Mastectomy, radical, including pectoral muscles, axillary lymph nodes	Procedure	CPT-4
19306	Mastectomy, radical, including pectoral muscles, axillary and internal mammary lymph nodes (Urban type operation)	Procedure	CPT-4
19307	Mastectomy, modified radical, including axillary lymph nodes, with or without pectoralis minor muscle, but excluding pectoralis major muscle	Procedure	CPT-4
20982	Ablation therapy for reduction or eradication of 1 or more bone tumors (eg, metastasis) including adjacent soft tissue when involved by tumor extension, percutaneous, including imaging guidance when performed; radiofrequency	Procedure	CPT-4
20983	Ablation therapy for reduction or eradication of 1 or more bone tumors (eg, metastasis) including adjacent soft tissue when involved by tumor extension, percutaneous, including imaging guidance when performed; cryoablation	Procedure	CPT-4
21.30	Excision or destruction of lesion of nose, not otherwise specified	Procedure	ICD-9-CM
21.32	Local excision or destruction of other lesion of nose	Procedure	ICD-9-CM
21011	Excision, tumor, soft tissue of face or scalp, subcutaneous; less than 2 cm	Procedure	CPT-4
21012	Excision, tumor, soft tissue of face or scalp, subcutaneous; 2 cm or greater	Procedure	CPT-4
21013	Excision, tumor, soft tissue of face and scalp, subfascial (eg, subgaleal, intramuscular); less than 2 cm	Procedure	CPT-4
21014	Excision, tumor, soft tissue of face and scalp, subfascial (eg, subgaleal, intramuscular); 2 cm or greater	Procedure	CPT-4
21015	Radical resection of tumor (eg, sarcoma), soft tissue of face or scalp; less than 2 cm	Procedure	CPT-4
21016	Radical resection of tumor (eg, sarcoma), soft tissue of face or scalp; 2 cm or greater	Procedure	CPT-4
21034	Excision of malignant tumor of maxilla or zygoma	Procedure	CPT-4
21044	Excision of malignant tumor of mandible;	Procedure	CPT-4
21045	Excision of malignant tumor of mandible; radical resection	Procedure	CPT-4
21552	Excision, tumor, soft tissue of neck or anterior thorax, subcutaneous; 3 cm or greater	Procedure	CPT-4
21554	Excision, tumor, soft tissue of neck or anterior thorax, subfascial (eg, intramuscular); 5 cm or greater	Procedure	CPT-4
21555	Excision, tumor, soft tissue of neck or anterior thorax, subcutaneous; less than 3 cm	Procedure	CPT-4

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
21556	Excision, tumor, soft tissue of neck or anterior thorax, subfascial (eg, intramuscular); less than 5 cm	Procedure	CPT-4
21557	Radical resection of tumor (eg, sarcoma), soft tissue of neck or anterior thorax; less than 5 cm	Procedure	CPT-4
21558	Radical resection of tumor (eg, sarcoma), soft tissue of neck or anterior thorax; 5 cm or greater	Procedure	CPT-4
21601	Excision of chest wall tumor including rib(s)	Procedure	CPT-4
21602	Excision of chest wall tumor involving rib(s), with plastic reconstruction; without mediastinal lymphadenectomy	Procedure	CPT-4
21603	Excision of chest wall tumor involving rib(s), with plastic reconstruction; with mediastinal lymphadenectomy	Procedure	CPT-4
21930	Excision, tumor, soft tissue of back or flank, subcutaneous; less than 3 cm	Procedure	CPT-4
21931	Excision, tumor, soft tissue of back or flank, subcutaneous; 3 cm or greater	Procedure	CPT-4
21932	Excision, tumor, soft tissue of back or flank, subfascial (eg, intramuscular); less than 5 cm	Procedure	CPT-4
21933	Excision, tumor, soft tissue of back or flank, subfascial (eg, intramuscular); 5 cm or greater	Procedure	CPT-4
21935	Radical resection of tumor (eg, sarcoma), soft tissue of back or flank; less than 5 cm	Procedure	CPT-4
21936	Radical resection of tumor (eg, sarcoma), soft tissue of back or flank; 5 cm or greater	Procedure	CPT-4
22105	PART RESECT VERTEBRAL COMPONENT TUMOR; CERV	Procedure	CPT-4
22106	PART RESECT VERTEBRAL COMPONENT TUMOR; THORACIC	Procedure	CPT-4
22107	PART RESECT VERTEBRAL COMPONENT TUMOR; LUMBAR	Procedure	CPT-4
22900	Excision, tumor, soft tissue of abdominal wall, subfascial (eg, intramuscular); less than 5 cm	Procedure	CPT-4
22901	Excision, tumor, soft tissue of abdominal wall, subfascial (eg, intramuscular); 5 cm or greater	Procedure	CPT-4
22902	Excision, tumor, soft tissue of abdominal wall, subcutaneous; less than 3 cm	Procedure	CPT-4
22903	Excision, tumor, soft tissue of abdominal wall, subcutaneous; 3 cm or greater	Procedure	CPT-4
22904	Radical resection of tumor (eg, sarcoma), soft tissue of abdominal wall; less than 5 cm	Procedure	CPT-4
22905	Radical resection of tumor (eg, sarcoma), soft tissue of abdominal wall; 5 cm or greater	Procedure	CPT-4
23071	Excision, tumor, soft tissue of shoulder area, subcutaneous; 3 cm or greater	Procedure	CPT-4
23073	Excision, tumor, soft tissue of shoulder area, subfascial (eg, intramuscular); 5 cm or greater	Procedure	CPT-4
23075	Excision, tumor, soft tissue of shoulder area, subcutaneous; less than 3 cm	Procedure	CPT-4
23076	Excision, tumor, soft tissue of shoulder area, subfascial (eg, intramuscular); less than 5 cm	Procedure	CPT-4
23077	Radical resection of tumor (eg, sarcoma), soft tissue of shoulder area; less than 5 cm	Procedure	CPT-4
23078	Radical resection of tumor (eg, sarcoma), soft tissue of shoulder area; 5 cm or greater	Procedure	CPT-4
23200	Radical resection of tumor; clavicle	Procedure	CPT-4
23210	Radical resection of tumor; scapula	Procedure	CPT-4

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
23220	Radical resection of tumor, proximal humerus	Procedure	CPT-4
23221	Radical resection of bone tumor, proximal humerus; with autograft (includes obtaining graft)	Procedure	CPT-4
23222	Radical resection of bone tumor, proximal humerus; with prosthetic replacement	Procedure	CPT-4
24.4	Excision of dental lesion of jaw	Procedure	ICD-9-CM
24071	Excision, tumor, soft tissue of upper arm or elbow area, subcutaneous; 3 cm or greater	Procedure	CPT-4
24073	Excision, tumor, soft tissue of upper arm or elbow area, subfascial (eg, intramuscular); 5 cm or greater	Procedure	CPT-4
24075	Excision, tumor, soft tissue of upper arm or elbow area, subcutaneous; less than 3 cm	Procedure	CPT-4
24076	Excision, tumor, soft tissue of upper arm or elbow area, subfascial (eg, intramuscular); less than 5 cm	Procedure	CPT-4
24077	Radical resection of tumor (eg, sarcoma), soft tissue of upper arm or elbow area; less than 5 cm	Procedure	CPT-4
24079	Radical resection of tumor (eg, sarcoma), soft tissue of upper arm or elbow area; 5 cm or greater	Procedure	CPT-4
24150	Radical resection of tumor, shaft or distal humerus	Procedure	CPT-4
24151	Radical resection for tumor, shaft or distal humerus; with autograft (includes obtaining graft)	Procedure	CPT-4
24152	Radical resection of tumor, radial head or neck	Procedure	CPT-4
24153	Radical resection for tumor, radial head or neck; with autograft (includes obtaining graft)	Procedure	CPT-4
25071	Excision, tumor, soft tissue of forearm and/or wrist area, subcutaneous; 3 cm or greater	Procedure	CPT-4
25073	Excision, tumor, soft tissue of forearm and/or wrist area, subfascial (eg, intramuscular); 3 cm or greater	Procedure	CPT-4
25075	Excision, tumor, soft tissue of forearm and/or wrist area, subcutaneous; less than 3 cm	Procedure	CPT-4
25076	Excision, tumor, soft tissue of forearm and/or wrist area, subfascial (eg, intramuscular); less than 3 cm	Procedure	CPT-4
25077	Radical resection of tumor (eg, sarcoma), soft tissue of forearm and/or wrist area; less than 3 cm	Procedure	CPT-4
25078	Radical resection of tumor (eg, sarcoma), soft tissue of forearm and/or wrist area; 3 cm or greater	Procedure	CPT-4
25170	Radical resection of tumor, radius or ulna	Procedure	CPT-4
26111	Excision, tumor or vascular malformation, soft tissue of hand or finger, subcutaneous; 1.5 cm or greater	Procedure	CPT-4
26113	Excision, tumor, soft tissue, or vascular malformation, of hand or finger, subfascial (eg, intramuscular); 1.5 cm or greater	Procedure	CPT-4
26115	Excision, tumor or vascular malformation, soft tissue of hand or finger, subcutaneous; less than 1.5 cm	Procedure	CPT-4

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
26116	Excision, tumor, soft tissue, or vascular malformation, of hand or finger, subfascial (eg, intramuscular); less than 1.5 cm	Procedure	CPT-4
26117	Radical resection of tumor (eg, sarcoma), soft tissue of hand or finger; less than 3 cm	Procedure	CPT-4
26118	Radical resection of tumor (eg, sarcoma), soft tissue of hand or finger; 3 cm or greater	Procedure	CPT-4
26250	Radical resection of tumor, metacarpal	Procedure	CPT-4
26255	Radical resection, metacarpal (eg, tumor); with autograft (includes obtaining graft)	Procedure	CPT-4
26260	Radical resection of tumor, proximal or middle phalanx of finger	Procedure	CPT-4
26261	Radical resection, proximal or middle phalanx of finger (eg, tumor); with autograft (includes obtaining graft)	Procedure	CPT-4
26262	Radical resection of tumor, distal phalanx of finger	Procedure	CPT-4
27.42	Wide excision of lesion of lip	Procedure	ICD-9-CM
27.43	Other excision of lesion or tissue of lip	Procedure	ICD-9-CM
27043	Excision, tumor, soft tissue of pelvis and hip area, subcutaneous; 3 cm or greater	Procedure	CPT-4
27045	Excision, tumor, soft tissue of pelvis and hip area, subfascial (eg, intramuscular); 5 cm or greater	Procedure	CPT-4
27047	Excision, tumor, soft tissue of pelvis and hip area, subcutaneous; less than 3 cm	Procedure	CPT-4
27048	Excision, tumor, soft tissue of pelvis and hip area, subfascial (eg, intramuscular); less than 5 cm	Procedure	CPT-4
27049	Radical resection of tumor (eg, sarcoma), soft tissue of pelvis and hip area; less than 5 cm	Procedure	CPT-4
27059	Radical resection of tumor (eg, sarcoma), soft tissue of pelvis and hip area; 5 cm or greater	Procedure	CPT-4
27075	Radical resection of tumor; wing of ilium, 1 pubic or ischial ramus or symphysis pubis	Procedure	CPT-4
27076	Radical resection of tumor; ilium, including acetabulum, both pubic rami, or ischium and acetabulum	Procedure	CPT-4
27077	Radical resection of tumor; innominate bone, total	Procedure	CPT-4
27078	Radical resection of tumor; ischial tuberosity and greater trochanter of femur	Procedure	CPT-4
27079	Radical resection of tumor or infection; ischial tuberosity and greater trochanter of femur, with skin flaps	Procedure	CPT-4
27327	Excision, tumor, soft tissue of thigh or knee area, subcutaneous; less than 3 cm	Procedure	CPT-4
27328	Excision, tumor, soft tissue of thigh or knee area, subfascial (eg, intramuscular); less than 5 cm	Procedure	CPT-4
27329	Radical resection of tumor (eg, sarcoma), soft tissue of thigh or knee area; less than 5 cm	Procedure	CPT-4
27337	Excision, tumor, soft tissue of thigh or knee area, subcutaneous; 3 cm or greater	Procedure	CPT-4
27339	Excision, tumor, soft tissue of thigh or knee area, subfascial (eg, intramuscular); 5 cm or greater	Procedure	CPT-4
27364	Radical resection of tumor (eg, sarcoma), soft tissue of thigh or knee area; 5 cm or greater	Procedure	CPT-4
27365	Radical resection of tumor, femur or knee	Procedure	CPT-4

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
27615	Radical resection of tumor (eg, sarcoma), soft tissue of leg or ankle area; less than 5 cm	Procedure	CPT-4
27616	Radical resection of tumor (eg, sarcoma), soft tissue of leg or ankle area; 5 cm or greater	Procedure	CPT-4
27618	Excision, tumor, soft tissue of leg or ankle area, subcutaneous; less than 3 cm	Procedure	CPT-4
27619	Excision, tumor, soft tissue of leg or ankle area, subfascial (eg, intramuscular); less than 5 cm	Procedure	CPT-4
27632	Excision, tumor, soft tissue of leg or ankle area, subcutaneous; 3 cm or greater	Procedure	CPT-4
27634	Excision, tumor, soft tissue of leg or ankle area, subfascial (eg, intramuscular); 5 cm or greater	Procedure	CPT-4
27645	Radical resection of tumor; tibia	Procedure	CPT-4
27646	Radical resection of tumor; fibula	Procedure	CPT-4
27647	Radical resection of tumor; talus or calcaneus	Procedure	CPT-4
27880	Amputation, leg, through tibia and fibula;	Procedure	CPT-4
28039	Excision, tumor, soft tissue of foot or toe, subcutaneous; 1.5 cm or greater	Procedure	CPT-4
28041	Excision, tumor, soft tissue of foot or toe, subfascial (eg, intramuscular); 1.5 cm or greater	Procedure	CPT-4
28043	Excision, tumor, soft tissue of foot or toe, subcutaneous; less than 1.5 cm	Procedure	CPT-4
28045	Excision, tumor, soft tissue of foot or toe, subfascial (eg, intramuscular); less than 1.5 cm	Procedure	CPT-4
28046	Radical resection of tumor (eg, sarcoma), soft tissue of foot or toe; less than 3 cm	Procedure	CPT-4
28047	Radical resection of tumor (eg, sarcoma), soft tissue of foot or toe; 3 cm or greater	Procedure	CPT-4
28171	Radical resection of tumor; tarsal (except talus or calcaneus)	Procedure	CPT-4
28173	Radical resection of tumor; metatarsal	Procedure	CPT-4
28175	Radical resection of tumor; phalanx of toe	Procedure	CPT-4
28805	Amputation, foot; transmetatarsal	Procedure	CPT-4
28810	Amputation, metatarsal, with toe, single	Procedure	CPT-4
28820	Amputation, toe; metatarsophalangeal joint	Procedure	CPT-4
28825	Amputation, toe; interphalangeal joint	Procedure	CPT-4
31300	Laryngotomy (thyrotomy, laryngofissure), with removal of tumor or laryngocele, cordectomy	Procedure	CPT-4
31540	Laryngoscopy, direct, operative, with excision of tumor and/or stripping of vocal cords or epiglottis;	Procedure	CPT-4
31541	Laryngoscopy, direct, operative, with excision of tumor and/or stripping of vocal cords or epiglottis; with operating microscope or telescope	Procedure	CPT-4
31640	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with excision of tumor	Procedure	CPT-4
31641	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with destruction of tumor or relief of stenosis by any method other than excision (eg, laser therapy, cryotherapy)	Procedure	CPT-4
31785	Excision of tracheal tumor or carcinoma; cervical	Procedure	CPT-4
31786	Excision of tracheal tumor or carcinoma; thoracic	Procedure	CPT-4
32.20	Thoracoscopic excision of lesion or tissue of lung	Procedure	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
32.29	Other local excision or destruction of lesion or tissue of lung	Procedure	ICD-9-CM
32.3	Segmental resection of lung	Procedure	ICD-9-CM
32.30	Thoracoscopic segmental resection of lung	Procedure	ICD-9-CM
32.39	Other and unspecified segmental resection of lung	Procedure	ICD-9-CM
32.4	Lobectomy of lung	Procedure	ICD-9-CM
32.41	Thoracoscopic lobectomy of lung	Procedure	ICD-9-CM
32.49	Other lobectomy of lung	Procedure	ICD-9-CM
32.5	Pneumonectomy	Procedure	ICD-9-CM
32.50	Thoracoscopic pneumonectomy	Procedure	ICD-9-CM
32.59	Other and unspecified pneumonectomy	Procedure	ICD-9-CM
32.6	Radical dissection of thoracic structures	Procedure	ICD-9-CM
32.9	Other excision of lung	Procedure	ICD-9-CM
32503	Resection of apical lung tumor (eg, Pancoast tumor), including chest wall resection, rib(s) resection(s), neurovascular dissection, when performed; without chest wall reconstruction(s)	Procedure	CPT-4
32504	Resection of apical lung tumor (eg, Pancoast tumor), including chest wall resection, rib(s) resection(s), neurovascular dissection, when performed; with chest wall reconstruction	Procedure	CPT-4
32994	Ablation therapy for reduction or eradication of 1 or more pulmonary tumor(s) including pleura or chest wall when involved by tumor extension, percutaneous, including imaging guidance when performed, unilateral; cryoablation	Procedure	CPT-4
32998	Ablation therapy for reduction or eradication of 1 or more pulmonary tumor(s) including pleura or chest wall when involved by tumor extension, percutaneous, including imaging guidance when performed, unilateral; radiofrequency	Procedure	CPT-4
33120	Excision of intracardiac tumor, resection with cardiopulmonary bypass	Procedure	CPT-4
33130	Resection of external cardiac tumor	Procedure	CPT-4
34.09	Other incision of pleura	Procedure	ICD-9-CM
34.5	Pleurectomy	Procedure	ICD-9-CM
34.51	Decortication of lung	Procedure	ICD-9-CM
34.52	Thoracoscopic decortication of lung	Procedure	ICD-9-CM
34.59	Other excision of pleura	Procedure	ICD-9-CM
38211	Transplant preparation of hematopoietic progenitor cells; tumor cell depletion	Procedure	CPT-4
39220	Resection of mediastinal tumor	Procedure	CPT-4
42.4	Excision of esophagus	Procedure	ICD-9-CM
42.40	Esophagectomy, not otherwise specified	Procedure	ICD-9-CM
42.41	Partial esophagectomy	Procedure	ICD-9-CM
42.42	Total esophagectomy	Procedure	ICD-9-CM
42.51	Intrathoracic esophagoesophagostomy	Procedure	ICD-9-CM
42.52	Intrathoracic esophagogastrostomy	Procedure	ICD-9-CM
42.53	Intrathoracic esophageal anastomosis with interposition of small bowel	Procedure	ICD-9-CM
42.54	Other intrathoracic esophagoenterostomy	Procedure	ICD-9-CM
42.55	Intrathoracic esophageal anastomosis with interposition of colon	Procedure	ICD-9-CM
42.56	Other intrathoracic esophagocolostomy	Procedure	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
42.58	Intrathoracic esophageal anastomosis with other interposition	Procedure	ICD-9-CM
42.59	Other intrathoracic anastomosis of esophagus	Procedure	ICD-9-CM
42.61	Antesternal esophagoesophagostomy	Procedure	ICD-9-CM
42.62	Antesternal esophagogastrostomy	Procedure	ICD-9-CM
42.63	Antesternal esophageal anastomosis with interposition of small bowel	Procedure	ICD-9-CM
42.64	Other antesternal esophagoenterostomy	Procedure	ICD-9-CM
42.65	Antesternal esophageal anastomosis with interposition of colon	Procedure	ICD-9-CM
42.66	Other antesternal esophagocolostomy	Procedure	ICD-9-CM
42.68	Other antesternal esophageal anastomosis with interposition	Procedure	ICD-9-CM
42.69	Other antesternal anastomosis of esophagus	Procedure	ICD-9-CM
43.42	Local excision of other lesion or tissue of stomach	Procedure	ICD-9-CM
43.5	Partial gastrectomy with anastomosis to esophagus	Procedure	ICD-9-CM
43.6	Partial gastrectomy with anastomosis to duodenum	Procedure	ICD-9-CM
43.7	Partial gastrectomy with anastomosis to jejunum	Procedure	ICD-9-CM
43.8	Other partial gastrectomy	Procedure	ICD-9-CM
43.81	Partial gastrectomy with jejunal transposition	Procedure	ICD-9-CM
43.82	Laparoscopic vertical (sleeve) gastrectomy	Procedure	ICD-9-CM
43.89	Open and other partial gastrectomy	Procedure	ICD-9-CM
43.9	Total gastrectomy	Procedure	ICD-9-CM
43.91	Total gastrectomy with intestinal interposition	Procedure	ICD-9-CM
43.99	Other total gastrectomy	Procedure	ICD-9-CM
43611	Excision, local; malignant tumor of stomach	Procedure	CPT-4
45.7	Open and other partial excision of large intestine	Procedure	ICD-9-CM
45.71	Open and other multiple segmental resection of large intestine	Procedure	ICD-9-CM
45.72	Open and other cecectomy	Procedure	ICD-9-CM
45.73	Open and other right hemicolectomy	Procedure	ICD-9-CM
45.74	Open and other resection of transverse colon	Procedure	ICD-9-CM
45.75	Open and other left hemicolectomy	Procedure	ICD-9-CM
45.76	Open and other sigmoidectomy	Procedure	ICD-9-CM
45.79	Other and unspecified partial excision of large intestine	Procedure	ICD-9-CM
45.8	Total intra-abdominal colectomy	Procedure	ICD-9-CM
45.81	Laparoscopic total intra-abdominal colectomy	Procedure	ICD-9-CM
45.82	Open total intra-abdominal colectomy	Procedure	ICD-9-CM
45.83	Other and unspecified total intra-abdominal colectomy	Procedure	ICD-9-CM
45160	Excision of rectal tumor by proctotomy, transsacral or transcoccygeal approach	Procedure	CPT-4
45170	Excision of rectal tumor, transanal approach	Procedure	CPT-4
45171	Excision of rectal tumor, transanal approach; not including muscularis propria (ie, partial thickness)	Procedure	CPT-4
45172	Excision of rectal tumor, transanal approach; including muscularis propria (ie, full thickness)	Procedure	CPT-4
45180	EXC &/OR ELECTRODESICCAT MALIG TUMOR RECTUM	Procedure	CPT-4
45181	Excision And/or Electrodesiccation Of Malignant Tumor Of	Procedure	CPT-4

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
45190	Destruction of rectal tumor (eg, electrodesiccation, electrosurgery, laser ablation, laser resection, cryosurgery) transanal approach	Procedure	CPT-4
45336	SIGMOIDOSCOPY; ABLATE TUMOR MUCOSAL LESION	Procedure	CPT-4
46938	Cryosurgery of rectal tumor; malignant	Procedure	CPT-4
47370	Laparoscopy, surgical, ablation of 1 or more liver tumor(s); radiofrequency	Procedure	CPT-4
47371	Laparoscopy, surgical, ablation of 1 or more liver tumor(s); cryosurgical	Procedure	CPT-4
47380	Ablation, open, of 1 or more liver tumor(s); radiofrequency	Procedure	CPT-4
47381	Ablation, open, of 1 or more liver tumor(s); cryosurgical	Procedure	CPT-4
47382	Ablation, 1 or more liver tumor(s), percutaneous, radiofrequency	Procedure	CPT-4
47383	Ablation, 1 or more liver tumor(s), percutaneous, cryoablation	Procedure	CPT-4
47710	EXC BILE DUCT TUMOR W/REPR	Procedure	CPT-4
47711	Excision of bile duct tumor, with or without primary repair of bile duct; extrahepatic	Procedure	CPT-4
47712	Excision of bile duct tumor, with or without primary repair of bile duct; intrahepatic	Procedure	CPT-4
48.4	Pull-through resection of rectum	Procedure	ICD-9-CM
48.40	Pull-through resection of rectum, not otherwise specified	Procedure	ICD-9-CM
48.42	Laparoscopic pull-through resection of rectum	Procedure	ICD-9-CM
48.43	Open pull-through resection of rectum	Procedure	ICD-9-CM
48.49	Other pull-through resection of rectum	Procedure	ICD-9-CM
48.5	Abdominoperineal resection of rectum	Procedure	ICD-9-CM
48.50	Abdominoperineal resection of the rectum, not otherwise specified	Procedure	ICD-9-CM
48.51	Laparoscopic abdominoperineal resection of the rectum	Procedure	ICD-9-CM
48.52	Open abdominoperineal resection of the rectum	Procedure	ICD-9-CM
48.59	Other abdominoperineal resection of the rectum	Procedure	ICD-9-CM
48.6	Other resection of rectum	Procedure	ICD-9-CM
48.61	Transsacral rectosigmoidectomy	Procedure	ICD-9-CM
48.62	Anterior resection of rectum with synchronous colostomy	Procedure	ICD-9-CM
48.63	Other anterior resection of rectum	Procedure	ICD-9-CM
48.64	Posterior resection of rectum	Procedure	ICD-9-CM
48.69	Other resection of rectum	Procedure	ICD-9-CM
48.99	Other operations on rectum and perirectal tissue	Procedure	ICD-9-CM
49215	Excision of presacral or sacrococcygeal tumor	Procedure	CPT-4
50.22	Partial hepatectomy	Procedure	ICD-9-CM
50.29	Other destruction of lesion of liver	Procedure	ICD-9-CM
50.3	Lobectomy of liver	Procedure	ICD-9-CM
50.4	Total hepatectomy	Procedure	ICD-9-CM
50562	Renal endoscopy through established nephrostomy or pyelostomy, with or without irrigation, instillation, or ureteropyelography, exclusive of radiologic service; with resection of tumor	Procedure	CPT-4
50592	Ablation, 1 or more renal tumor(s), percutaneous, unilateral, radiofrequency	Procedure	CPT-4
50593	Ablation, renal tumor(s), unilateral, percutaneous, cryotherapy	Procedure	CPT-4
51.8	Other operations on biliary ducts and sphincter of oddi	Procedure	ICD-9-CM
51530	Cystotomy; for excision of bladder tumor	Procedure	CPT-4
51550	Cystectomy, partial; simple	Procedure	CPT-4

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
51555	Cystectomy, partial; complicated (eg, postradiation, previous surgery, difficult location)	Procedure	CPT-4
51565	Cystectomy, partial, with reimplantation of ureter(s) into bladder (ureteroneocystostomy)	Procedure	CPT-4
51570	Cystectomy, complete; (separate procedure)	Procedure	CPT-4
51575	Cystectomy, complete; with bilateral pelvic lymphadenectomy, including external iliac, hypogastric, and obturator nodes	Procedure	CPT-4
51580	Cystectomy, complete, with ureterosigmoidostomy or ureterocutaneous transplantations;	Procedure	CPT-4
51585	Cystectomy, complete, with ureterosigmoidostomy or ureterocutaneous transplantations; with bilateral pelvic lymphadenectomy, including external iliac, hypogastric, and obturator nodes	Procedure	CPT-4
51590	Cystectomy, complete, with ureteroileal conduit or sigmoid bladder, including intestine anastomosis;	Procedure	CPT-4
51595	Cystectomy, complete, with ureteroileal conduit or sigmoid bladder, including intestine anastomosis; with bilateral pelvic lymphadenectomy, including external iliac, hypogastric, and obturator nodes	Procedure	CPT-4
51596	Cystectomy, complete, with continent diversion, any open technique, using any segment of small and/or large intestine to construct neobladder	Procedure	CPT-4
51597	Pelvic exenteration, complete, for vesical, prostatic or urethral malignancy, with removal of bladder and ureteral transplantations, with or without hysterectomy and/or abdominoperineal resection of rectum and colon and colostomy, or any combination thereof	Procedure	CPT-4
52.2	Local excision or destruction of pancreas and pancreatic duct	Procedure	ICD-9-CM
52.21	Endoscopic excision or destruction of lesion or tissue of pancreatic duct	Procedure	ICD-9-CM
52.22	Other excision or destruction of lesion or tissue of pancreas or pancreatic duct	Procedure	ICD-9-CM
52.51	Proximal pancreatectomy	Procedure	ICD-9-CM
52.52	Distal pancreatectomy	Procedure	ICD-9-CM
52.53	Radical subtotal pancreatectomy	Procedure	ICD-9-CM
52.59	Other partial pancreatectomy	Procedure	ICD-9-CM
52.6	Total pancreatectomy	Procedure	ICD-9-CM
52.7	Radical pancreaticoduodenectomy	Procedure	ICD-9-CM
52204	Cystourethroscopy, with biopsy(s)	Procedure	CPT-4
52224	Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) or treatment of MINOR (less than 0.5 cm) lesion(s) with or without biopsy	Procedure	CPT-4
52234	Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) and/or resection of; SMALL bladder tumor(s) (0.5 up to 2.0 cm)	Procedure	CPT-4
52235	Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) and/or resection of; MEDIUM bladder tumor(s) (2.0 to 5.0 cm)	Procedure	CPT-4
52240	Cystourethroscopy, with fulguration (including cryosurgery or laser surgery) and/or resection of; LARGE bladder tumor(s)	Procedure	CPT-4
52339	Cystourethroscopy, with ureteroscopy and/or pyeloscopy (includes dilation of the ureter and/or pyeloureteral junction by any method); with resection of tumor	Procedure	CPT-4

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
52355	Cystourethroscopy, with ureteroscopy and/or pyeloscopy; with resection of ureteral or renal pelvic tumor	Procedure	CPT-4
54.4	Excision or destruction of peritoneal tissue	Procedure	ICD-9-CM
54530	Orchiectomy, radical, for tumor; inguinal approach	Procedure	CPT-4
54535	Orchiectomy, radical, for tumor; with abdominal exploration	Procedure	CPT-4
55.4	Partial nephrectomy	Procedure	ICD-9-CM
55.5	Complete nephrectomy	Procedure	ICD-9-CM
55.51	Nephroureterectomy	Procedure	ICD-9-CM
55.52	Nephrectomy of remaining kidney	Procedure	ICD-9-CM
55.54	Bilateral nephrectomy	Procedure	ICD-9-CM
55860	Exposure of prostate, any approach, for insertion of radioactive substance;	Procedure	CPT-4
55862	Exposure of prostate, any approach, for insertion of radioactive substance; with lymph node biopsy(s) (limited pelvic lymphadenectomy)	Procedure	CPT-4
55865	Exposure of prostate, any approach, for insertion of radioactive substance; with bilateral pelvic lymphadenectomy, including external iliac, hypogastric and obturator nodes	Procedure	CPT-4
57.6	Partial cystectomy	Procedure	ICD-9-CM
57.7	Total cystectomy	Procedure	ICD-9-CM
57.71	Radical cystectomy	Procedure	ICD-9-CM
57.79	Other total cystectomy	Procedure	ICD-9-CM
58140	Myomectomy, excision of fibroid tumor(s) of uterus, 1 to 4 intramural myoma(s) with total weight of 250 g or less and/or removal of surface myomas; abdominal approach	Procedure	CPT-4
58145	Myomectomy, excision of fibroid tumor(s) of uterus, 1 to 4 intramural myoma(s) with total weight of 250 g or less and/or removal of surface myomas; vaginal approach	Procedure	CPT-4
58146	Myomectomy, excision of fibroid tumor(s) of uterus, 5 or more intramural myomas and/or intramural myomas with total weight greater than 250 g, abdominal approach	Procedure	CPT-4
58575	Laparoscopy, surgical, total hysterectomy for resection of malignancy (tumor debulking), with omentectomy including salpingo-oophorectomy, unilateral or bilateral, when performed	Procedure	CPT-4
58952	Resection (initial) of ovarian, tubal or primary peritoneal malignancy with bilateral salpingo-oophorectomy and omentectomy; with radical dissection for debulking (ie, radical excision or destruction, intra-abdominal or retroperitoneal tumors)	Procedure	CPT-4
58957	Resection (tumor debulking) of recurrent ovarian, tubal, primary peritoneal, uterine malignancy (intra-abdominal, retroperitoneal tumors), with omentectomy, if performed;	Procedure	CPT-4
58958	Resection (tumor debulking) of recurrent ovarian, tubal, primary peritoneal, uterine malignancy (intra-abdominal, retroperitoneal tumors), with omentectomy, if performed; with pelvic lymphadenectomy and limited para-aortic lymphadenectomy	Procedure	CPT-4
60.4	Retropubic prostatectomy	Procedure	ICD-9-CM
60.5	Radical prostatectomy	Procedure	ICD-9-CM
60.62	Perineal prostatectomy	Procedure	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
60.69	Other prostatectomy	Procedure	ICD-9-CM
60200	Excision of cyst or adenoma of thyroid, or transection of isthmus	Procedure	CPT-4
60210	Partial thyroid lobectomy, unilateral; with or without isthmusectomy	Procedure	CPT-4
60212	Partial thyroid lobectomy, unilateral; with contralateral subtotal lobectomy, including isthmusectomy	Procedure	CPT-4
60220	Total thyroid lobectomy, unilateral; with or without isthmusectomy	Procedure	CPT-4
60225	Total thyroid lobectomy, unilateral; with contralateral subtotal lobectomy, including isthmusectomy	Procedure	CPT-4
60240	Thyroidectomy, total or complete	Procedure	CPT-4
60245	THYROIDECTOMY SUBTL/PART	Procedure	CPT-4
60246	THYROIDECTOMY; W/REMOV SUBSTERNAL THYROID GLAND	Procedure	CPT-4
60252	Thyroidectomy, total or subtotal for malignancy; with limited neck dissection	Procedure	CPT-4
60254	Thyroidectomy, total or subtotal for malignancy; with radical neck dissection	Procedure	CPT-4
60270	Thyroidectomy, including substernal thyroid; sternal split or transthoracic approach	Procedure	CPT-4
60271	Thyroidectomy, including substernal thyroid; cervical approach	Procedure	CPT-4
60545	Adrenalectomy, partial or complete, or exploration of adrenal gland with or without biopsy, transabdominal, lumbar or dorsal (separate procedure); with excision of adjacent retroperitoneal tumor	Procedure	CPT-4
60600	Excision of carotid body tumor; without excision of carotid artery	Procedure	CPT-4
60605	Excision of carotid body tumor; with excision of carotid artery	Procedure	CPT-4
61.3	Excision or destruction of lesion or tissue of scrotum	Procedure	ICD-9-CM
61510	Craniectomy, trephination, bone flap craniotomy; for excision of brain tumor, supratentorial, except meningioma	Procedure	CPT-4
61518	Craniectomy for excision of brain tumor, infratentorial or posterior fossa; except meningioma, cerebellopontine angle tumor, or midline tumor at base of skull	Procedure	CPT-4
61519	Craniectomy for excision of brain tumor, infratentorial or posterior fossa; meningioma	Procedure	CPT-4
61520	Craniectomy for excision of brain tumor, infratentorial or posterior fossa; cerebellopontine angle tumor	Procedure	CPT-4
61521	Craniectomy for excision of brain tumor, infratentorial or posterior fossa; midline tumor at base of skull	Procedure	CPT-4
61526	Craniectomy, bone flap craniotomy, transtemporal (mastoid) for excision of cerebellopontine angle tumor;	Procedure	CPT-4
61530	Craniectomy, bone flap craniotomy, transtemporal (mastoid) for excision of cerebellopontine angle tumor; combined with middle/posterior fossa craniotomy/craniectomy	Procedure	CPT-4
61545	Craniotomy with elevation of bone flap; for excision of craniopharyngioma	Procedure	CPT-4
61546	Craniotomy for hypophysectomy or excision of pituitary tumor, intracranial approach	Procedure	CPT-4
62164	Neuroendoscopy, intracranial; with excision of brain tumor, including placement of external ventricular catheter for drainage	Procedure	CPT-4
62165	Neuroendoscopy, intracranial; with excision of pituitary tumor, transnasal or trans-sphenoidal approach	Procedure	CPT-4

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
63275	Laminectomy for biopsy/excision of intraspinal neoplasm; extradural, cervical	Procedure	CPT-4
63276	Laminectomy for biopsy/excision of intraspinal neoplasm; extradural, thoracic	Procedure	CPT-4
63277	Laminectomy for biopsy/excision of intraspinal neoplasm; extradural, lumbar	Procedure	CPT-4
63278	Laminectomy for biopsy/excision of intraspinal neoplasm; extradural, sacral	Procedure	CPT-4
63280	Laminectomy for biopsy/excision of intraspinal neoplasm; intradural, extramedullary, cervical	Procedure	CPT-4
63281	Laminectomy for biopsy/excision of intraspinal neoplasm; intradural, extramedullary, thoracic	Procedure	CPT-4
63282	Laminectomy for biopsy/excision of intraspinal neoplasm; intradural, extramedullary, lumbar	Procedure	CPT-4
63283	Laminectomy for biopsy/excision of intraspinal neoplasm; intradural, sacral	Procedure	CPT-4
63285	Laminectomy for biopsy/excision of intraspinal neoplasm; intradural, intramedullary, cervical	Procedure	CPT-4
63286	Laminectomy for biopsy/excision of intraspinal neoplasm; intradural, intramedullary, thoracic	Procedure	CPT-4
63287	Laminectomy for biopsy/excision of intraspinal neoplasm; intradural, intramedullary, thoracolumbar	Procedure	CPT-4
63290	Laminectomy for biopsy/excision of intraspinal neoplasm; combined extradural-intradural lesion, any level	Procedure	CPT-4
64.2	Local excision or destruction of lesion of penis	Procedure	ICD-9-CM
65.3	Unilateral oophorectomy	Procedure	ICD-9-CM
65.31	Laparoscopic unilateral oophorectomy	Procedure	ICD-9-CM
65.39	Other unilateral oophorectomy	Procedure	ICD-9-CM
65.4	Unilateral salpingo-oophorectomy	Procedure	ICD-9-CM
65.41	Laparoscopic unilateral salpingo-oophorectomy	Procedure	ICD-9-CM
65.49	Other unilateral salpingo-oophorectomy	Procedure	ICD-9-CM
65.5	Bilateral oophorectomy	Procedure	ICD-9-CM
65.51	Other removal of both ovaries at same operative episode	Procedure	ICD-9-CM
65.52	Other removal of remaining ovary	Procedure	ICD-9-CM
65.53	Laparoscopic removal of both ovaries at same operative episode	Procedure	ICD-9-CM
65.54	Laparoscopic removal of remaining ovary	Procedure	ICD-9-CM
65.6	Bilateral salpingo-oophorectomy	Procedure	ICD-9-CM
65.61	Other removal of both ovaries and tubes at same operative episode	Procedure	ICD-9-CM
65.62	Other removal of remaining ovary and tube	Procedure	ICD-9-CM
65.63	Laparoscopic removal of both ovaries and tubes at same operative episode	Procedure	ICD-9-CM
65.64	Laparoscopic removal of remaining ovary and tube	Procedure	ICD-9-CM
67.2	Conization of cervix	Procedure	ICD-9-CM
67.32	Destruction of lesion of cervix by cauterization	Procedure	ICD-9-CM
67.33	Destruction of lesion of cervix by cryosurgery	Procedure	ICD-9-CM
67.39	Other excision or destruction of lesion or tissue of cervix	Procedure	ICD-9-CM
67.4	Amputation of cervix	Procedure	ICD-9-CM
68.3	Subtotal abdominal hysterectomy	Procedure	ICD-9-CM
68.39	Other and unspecified subtotal abdominal hysterectomy	Procedure	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
68.4	Total abdominal hysterectomy	Procedure	ICD-9-CM
68.41	Laparoscopic total abdominal hysterectomy	Procedure	ICD-9-CM
68.49	Other and unspecified total abdominal hysterectomy	Procedure	ICD-9-CM
68.5	Vaginal hysterectomy	Procedure	ICD-9-CM
68.51	Laparoscopically assisted vaginal hysterectomy (LAVH)	Procedure	ICD-9-CM
68.59	Other and unspecified vaginal hysterectomy	Procedure	ICD-9-CM
68.6	Radical abdominal hysterectomy	Procedure	ICD-9-CM
68.61	Laparoscopic radical abdominal hysterectomy	Procedure	ICD-9-CM
68.69	Other and unspecified radical abdominal hysterectomy	Procedure	ICD-9-CM
68.7	Radical vaginal hysterectomy	Procedure	ICD-9-CM
68.71	Laparoscopic radical vaginal hysterectomy [LRVH]	Procedure	ICD-9-CM
68.79	Other and unspecified radical vaginal hysterectomy	Procedure	ICD-9-CM
68.8	Pelvic evisceration	Procedure	ICD-9-CM
68.9	Other and unspecified hysterectomy	Procedure	ICD-9-CM
68540	Excision of lacrimal gland tumor; frontal approach	Procedure	CPT-4
68550	Excision of lacrimal gland tumor; involving osteotomy	Procedure	CPT-4
69.19	Other excision or destruction of uterus and supporting structures	Procedure	ICD-9-CM
69550	Excision aural glomus tumor; transcanal	Procedure	CPT-4
69552	Excision aural glomus tumor; transmastoid	Procedure	CPT-4
69554	Excision aural glomus tumor; extended (extratemporal)	Procedure	CPT-4
69970	Removal of tumor, temporal bone	Procedure	CPT-4
71.3	Other local excision or destruction of vulva and perineum	Procedure	ICD-9-CM
76.2	Local excision or destruction of lesion of facial bone	Procedure	ICD-9-CM
76.31	Partial mandibulectomy	Procedure	ICD-9-CM
76.39	Partial ostectomy of other facial bone	Procedure	ICD-9-CM
76.41	Total mandibulectomy with synchronous reconstruction	Procedure	ICD-9-CM
76.42	Other total mandibulectomy	Procedure	ICD-9-CM
76.45	Other total ostectomy of other facial bone	Procedure	ICD-9-CM
76.5	Temporomandibular arthroplasty	Procedure	ICD-9-CM
77.6	Local excision of lesion or tissue of bone	Procedure	ICD-9-CM
77.60	Local excision of lesion or tissue of bone, unspecified site	Procedure	ICD-9-CM
77.61	Local excision of lesion or tissue of scapula, clavicle, and thorax (ribs and sternum)	Procedure	ICD-9-CM
77.63	Local excision of lesion or tissue of radius and ulna	Procedure	ICD-9-CM
77.64	Local excision of lesion or tissue of carpals and metacarpals	Procedure	ICD-9-CM
77.65	Local excision of lesion or tissue of femur	Procedure	ICD-9-CM
77.66	Local excision of lesion or tissue of patella	Procedure	ICD-9-CM
77.67	Local excision of lesion or tissue of tibia and fibula	Procedure	ICD-9-CM
77.69	Local excision of lesion or tissue of other bone, except facial bones	Procedure	ICD-9-CM
77.8	Other partial ostectomy	Procedure	ICD-9-CM
77.81	Other partial ostectomy of scapula, clavicle, and thorax (ribs and sternum)	Procedure	ICD-9-CM
77.82	Other partial ostectomy of humerus	Procedure	ICD-9-CM
77.83	Other partial ostectomy of radius and ulna	Procedure	ICD-9-CM
77.84	Other partial ostectomy of carpals and metacarpals	Procedure	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
77.85	Other partial ostectomy of femur	Procedure	ICD-9-CM
77.86	Other partial ostectomy of patella	Procedure	ICD-9-CM
77.87	Other partial ostectomy of tibia and fibula	Procedure	ICD-9-CM
77.88	Other partial ostectomy of tarsals and metatarsals	Procedure	ICD-9-CM
77.89	Other partial ostectomy of other bone, except facial bones	Procedure	ICD-9-CM
77.9	Total ostectomy	Procedure	ICD-9-CM
77.90	Total ostectomy, unspecified site	Procedure	ICD-9-CM
77.91	Total ostectomy of scapula, clavicle, and thorax (ribs and sternum)	Procedure	ICD-9-CM
77.92	Total ostectomy of humerus	Procedure	ICD-9-CM
77.93	Total ostectomy of radius and ulna	Procedure	ICD-9-CM
77.94	Total ostectomy of carpals and metacarpals	Procedure	ICD-9-CM
77.95	Total ostectomy of femur	Procedure	ICD-9-CM
77.96	Total ostectomy of patella	Procedure	ICD-9-CM
77.97	Total ostectomy of tibia and fibula	Procedure	ICD-9-CM
77.98	Total ostectomy of tarsals and metatarsals	Procedure	ICD-9-CM
77.99	Total ostectomy of other bone, except facial bones	Procedure	ICD-9-CM
80.81	Other local excision or destruction of lesion of shoulder joint	Procedure	ICD-9-CM
80.82	Other local excision or destruction of lesion of elbow joint	Procedure	ICD-9-CM
80.83	Other local excision or destruction of lesion of wrist joint	Procedure	ICD-9-CM
80.92	Other excision of elbow joint	Procedure	ICD-9-CM
82.2	Excision of lesion of muscle, tendon, and fascia of hand	Procedure	ICD-9-CM
82.21	Excision of lesion of tendon sheath of hand	Procedure	ICD-9-CM
82.22	Excision of lesion of muscle of hand	Procedure	ICD-9-CM
82.29	Excision of other lesion of soft tissue of hand	Procedure	ICD-9-CM
82.3	Other excision of soft tissue of hand	Procedure	ICD-9-CM
83.3	Excision of lesion of muscle, tendon, fascia, and bursa	Procedure	ICD-9-CM
83.31	Excision of lesion of tendon sheath	Procedure	ICD-9-CM
83.32	Excision of lesion of muscle	Procedure	ICD-9-CM
83.39	Excision of lesion of other soft tissue	Procedure	ICD-9-CM
83.4	Other excision of muscle, tendon, and fascia	Procedure	ICD-9-CM
83.42	Other tenonectomy	Procedure	ICD-9-CM
83.49	Other excision of soft tissue	Procedure	ICD-9-CM
84.00	Upper limb amputation, not otherwise specified	Procedure	ICD-9-CM
84.01	Amputation and disarticulation of finger	Procedure	ICD-9-CM
84.02	Amputation and disarticulation of thumb	Procedure	ICD-9-CM
84.03	Amputation through hand	Procedure	ICD-9-CM
84.05	Amputation through forearm	Procedure	ICD-9-CM
84.07	Amputation through humerus	Procedure	ICD-9-CM
84.09	Interthoracoscapular amputation	Procedure	ICD-9-CM
84.10	Lower limb amputation, not otherwise specified	Procedure	ICD-9-CM
84.11	Amputation of toe	Procedure	ICD-9-CM
84.12	Amputation through foot	Procedure	ICD-9-CM
84.13	Disarticulation of ankle	Procedure	ICD-9-CM

Appendix C. List of Current Procedural Terminology, Fourth Edition (CPT-4), Current Procedural Terminology, Second Edition (CPT-2), Current Procedural Terminology, Third Edition (CPT-3), Healthcare Common Procedure Coding System (HCPCS), International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM), and International Classification of Diseases, Tenth Revision, Procedural Coding System (ICD-10-PCS) Codes Used to Define Exclusion Criteria in this Request

Code	Description	Code Category	Code Type
84.14	Amputation of ankle through malleoli of tibia and fibula	Procedure	ICD-9-CM
84.15	Other amputation below knee	Procedure	ICD-9-CM
84.17	Amputation above knee	Procedure	ICD-9-CM
84.19	Abdominopelvic amputation	Procedure	ICD-9-CM
84.91	Amputation, not otherwise specified	Procedure	ICD-9-CM
85.21	Local excision of lesion of breast	Procedure	ICD-9-CM
85.22	Resection of quadrant of breast	Procedure	ICD-9-CM
85.23	Subtotal mastectomy	Procedure	ICD-9-CM
85.4	Mastectomy	Procedure	ICD-9-CM
85.41	Unilateral simple mastectomy	Procedure	ICD-9-CM
85.42	Bilateral simple mastectomy	Procedure	ICD-9-CM
85.43	Unilateral extended simple mastectomy	Procedure	ICD-9-CM
85.44	Bilateral extended simple mastectomy	Procedure	ICD-9-CM
85.45	Unilateral radical mastectomy	Procedure	ICD-9-CM
85.46	Bilateral radical mastectomy	Procedure	ICD-9-CM
85.47	Unilateral extended radical mastectomy	Procedure	ICD-9-CM
85.48	Bilateral extended radical mastectomy	Procedure	ICD-9-CM
86.23	Removal of nail, nailbed, or nail fold	Procedure	ICD-9-CM
86.3	Other local excision or destruction of lesion or tissue of skin and subcutaneous tissue	Procedure	ICD-9-CM
86.4	Radical excision of skin lesion	Procedure	ICD-9-CM
D7440	excision of malignant tumor - lesion diameter up to 1.25 cm	Procedure	HCPCS
D7441	excision of malignant tumor - lesion diameter greater than 1.25 cm	Procedure	HCPCS
S2090	Ablation, open, one or more renal tumor(s); cryosurgical	Procedure	HCPCS
S2091	Ablation, percutaneous, one or more renal tumor(s); cryosurgical	Procedure	HCPCS
S2095	Transcatheter occlusion or embolization for tumor destruction, percutaneous, any method, using yttrium-90 microspheres	Procedure	HCPCS
S2210	Cryosurgical ablation (in situ destruction) of tumorous tissue, one or more lesions; liver	Procedure	HCPCS

Appendix D. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Exclusion Criteria in this Request

Generic Name/Nonproprietary	Brand Name/Proprietary
Chemotherapy	
BCG live	Theracys
BCG live	Tice BCG
Tositumomab Iodine-131 (with Maltose)	Bexxar 131 Iodine
abemaciclib	Verzenio
abiraterone acetate	Zytiga
abiraterone acetate	abiraterone
abiraterone acetate, submicronized	Yonsa
acalabrutinib	Calquence
ado-trastuzumab emtansine	Kadcyla
afatinib dimaleate	Gilotrif
aldesleukin	Proleukin
alectinib HCl	Alecensa
alemtuzumab	Campath
alpelisib	Piqray
altretamine	Hexalen
amifostine crystalline	Ethyol
amifostine crystalline	amifostine crystalline
amivantamab-vmjw	Rybrevant
anastrozole	Arimidex
anastrozole	anastrozole
anastrozole	anastrozole (bulk)
apalutamide	Erleada
arsenic trioxide	Trisenox
arsenic trioxide	arsenic trioxide
arsenic trioxide	arsenic trioxide (bulk)
asciminib hydrochloride	Scemblix
asparaginase	Elspar
asparaginase (Erwinia chrysanthemi)	Erwinase
asparaginase (Erwinia chrysanthemi)	Erwinaze
asparaginase Erwinia chrysanthemi (recombinant)-rywn	Rylaze
atezolizumab	Tecentriq
avapritinib	Ayvakit
avelumab	Bavencio
axicabtagene ciloleucel	Yescarta
axitinib	Inlyta
azacitidine	Onureg
azacitidine	Vidaza
azacitidine	azacitidine
belantamab mafodotin-blmf	Blenrep
belinostat	Beleodaq
belzutifan	Welireg
bendamustine HCl	Belrapzo
bendamustine HCl	Bendeka
bendamustine HCl	Treanda
bendamustine HCl	bendamustine
bevacizumab	Avastin
bevacizumab-awwb	Mvasi

Appendix D. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Exclusion Criteria in this Request

Generic Name/Nonproprietary	Brand Name/Proprietary
bevacizumab-bvzr	Zirabev
bexarotene	Targretin
bexarotene	bexarotene
bicalutamide	Casodex
bicalutamide	bicalutamide
binimetinib	Mektovi
bleomycin sulfate	Bleo 15K
bleomycin sulfate	bleomycin
blinatumomab	Blincyto
bortezomib	Velcade
bortezomib	bortezomib
bosutinib	Bosulif
brentuximab vedotin	Adcetris
brexucabtagene autoleucel	Tecartus
brigatinib	Alunbrig
busulfan	Busulfex
busulfan	Myleran
busulfan	busulfan
cabazitaxel	Jevtana
cabozantinib s-malate	Cabometyx
cabozantinib s-malate	Cometriq
calaspargase pegol-mknl	Asparlas
capecitabine	Xeloda
capecitabine	capecitabine
capmatinib hydrochloride	Tabrecta
carboplatin	Paraplatin
carboplatin	carboplatin
carfilzomib	Kyprolis
carmustine	BiCNU
carmustine	carmustine
carmustine in polifeprosan 20	Gliadel Wafer
cemiplimab-rwlc	Libtayo
ceritinib	Zykadia
cetuximab	Erbitux
chlorambucil	Leukeran
chlorambucil	chlorambucil (bulk)
cisplatin	cisplatin
cisplatin	cisplatin (bulk)
cladribine	Leustatin
cladribine	cladribine
clofarabine	Clolar
clofarabine	clofarabine
cobimetinib fumarate	Cotellic
copanlisib di-HCl	Aliqopa
crizotinib	Xalkori
cromolyn sodium	Gastrocrom
cromolyn sodium	cromolyn
cromolyn sodium	cromolyn (bulk)

Appendix D. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Exclusion Criteria in this Request

Generic Name/Nonproprietary	Brand Name/Proprietary
cyclophosphamide	cyclophosphamide
cyclophosphamide	cyclophosphamide (bulk)
cytarabine	cytarabine
cytarabine liposome/PF	DepoCyt (PF)
cytarabine/PF	cytarabine (PF)
dabrafenib mesylate	Tafinlar
dacarbazine	dacarbazine
dacomitinib	Vizimpro
dactinomycin	Cosmegen
dactinomycin	dactinomycin
daratumumab	Darzalex
daratumumab-hyaluronidase-fihj	Darzalex Faspro
darolutamide	Nubeqa
dasatinib	Sprycel
daunorubicin HCl	Cerubidine
daunorubicin HCl	daunorubicin
daunorubicin citrate liposomal	DaunoXome
daunorubicin/cytarabine liposomal	Vyxeos
decitabine	Dacogen
decitabine	decitabine
decitabine/cedazuridine	Inqovi
degarelix acetate	Firmagon
degarelix acetate	Firmagon kit w diluent syringe
denileukin diftitox	Ontak
dexrazoxane HCl	Totect
dexrazoxane HCl	Zinecard (as HCl)
dexrazoxane HCl	dexrazoxane HCl
diethylstilbestrol	diethylstilbestrol (bulk)
dinutuximab	Unituxin
docetaxel	Docefrez
docetaxel	Taxotere
docetaxel	docetaxel
dostarlimab-gxly	Jemperli
doxorubicin HCl	Adriamycin
doxorubicin HCl	Adriamycin PFS
doxorubicin HCl	doxorubicin
doxorubicin HCl pegylated liposomal	Doxil
doxorubicin HCl pegylated liposomal	Lipodox
doxorubicin HCl pegylated liposomal	Lipodox 50
doxorubicin HCl pegylated liposomal	doxorubicin, peg-liposomal
durvalumab	Imfinzi
duvelisib	Copiktra
elotuzumab	Empliciti
enasidenib mesylate	Idhifa
encorafenib	Braftovi
enfortumab vedotin-ejfv	Padcev
entrectinib	Rozlytrek
enzalutamide	Xtandi

Appendix D. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Exclusion Criteria in this Request

Generic Name/Nonproprietary	Brand Name/Proprietary
epirubicin HCl	Ellence
epirubicin HCl	epirubicin
erdafitinib	Balversa
eribulin mesylate	Halaven
erlotinib HCl	Tarceva
erlotinib HCl	erlotinib
estramustine phosphate sodium	Emcyt
etoposide	Toposar
etoposide	etoposide
etoposide	etoposide (bulk)
etoposide phosphate	Etopophos
everolimus	Afinitor
everolimus	Afinitor Disperz
everolimus	everolimus (antineoplastic)
exemestane	Aromasin
exemestane	exemestane
fam-trastuzumab deruxtecan-nxki	Enhertu
fedratinib dihydrochloride	Inrebic
floxuridine	floxuridine
floxuridine	floxuridine (bulk)
fludarabine phosphate	Fludara
fludarabine phosphate	Oforta
fludarabine phosphate	fludarabine
fluorouracil	Adrucil
fluorouracil	Carac
fluorouracil	Efudex
fluorouracil	Fluoroplex
fluorouracil	Tolak
fluorouracil	fluorouracil
fluorouracil	fluorouracil (bulk)
flutamide	Eulexin
flutamide	flutamide
fulvestrant	Faslodex
fulvestrant	fulvestrant
gefitinib	Iressa
gemcitabine HCl	Gemzar
gemcitabine HCl	gemcitabine
gemcitabine HCl in 0.9 % sodium chloride	Infugem
gemtuzumab ozogamicin	Mylotarg
gilteritinib fumarate	Xospata
glasdegib maleate	Daurismo
glucarpidase	Voraxaze
goserelin acetate	Zoladex
histrelin acetate	Vantas
hydroxyurea	Hydrea
hydroxyurea	hydroxyurea
hydroxyurea	hydroxyurea (bulk)
ibrutinib	Imbruvica

Appendix D. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Exclusion Criteria in this Request

Generic Name/Nonproprietary	Brand Name/Proprietary
idarubicin HCl	Idamycin PFS
idarubicin HCl	idarubicin
idecabtagene vicleucel	Abecma
idelalisib	Zydelig
ifosfamide	Ifex
ifosfamide	ifosfamide
ifosfamide/mesna	ifosfamide-mesna
imatinib mesylate	Gleevec
imatinib mesylate	imatinib
infigratinib phosphate	Truseltiq
inotuzumab ozogamicin	Besponsa
interferon alfa-2b,recomb.	Intron A
interferon alfa-n3	Alferon N
iobenguane iodine-131	Azedra Dosimetric
iobenguane iodine-131	Azedra Therapeutic
ipilimumab	Yervoy
irinotecan HCl	Camptosar
irinotecan HCl	irinotecan
irinotecan liposomal	Onivyde
isatuximab-irfc	Sarclisa
ivosidenib	Tibsovo
ixabepilone	Ixempra
ixazomib citrate	Ninlaro
kit for prep indium-111/ibritumomab tiuxetan/albumin human	Zevalin (In-111)
kit for prep yttrium-90/ibritumomab tiuxetan/albumin human	Zevalin (Y-90)
lapatinib ditosylate	Tykerb
lapatinib ditosylate	lapatinib
larotrectinib sulfate	Vitrakvi
lenalidomide	Revlimid
lenvatinib mesylate	Lenvima
letrozole	Femara
letrozole	letrozole
letrozole	letrozole (bulk)
leucovorin calcium	Calcium Folinate (leucovorin)
leucovorin calcium	leucovorin calcium
leuprolide acetate	Eligard
leuprolide acetate	Eligard (3 month)
leuprolide acetate	Eligard (4 month)
leuprolide acetate	Eligard (6 month)
leuprolide acetate	Lupron Depot
leuprolide acetate	Lupron Depot (3 month)
leuprolide acetate	Lupron Depot (4 month)
leuprolide acetate	Lupron Depot (6 Month)
leuprolide acetate	leuprolide
leuprolide acetate	leuprolide (bulk)
levamisole HCl	levamisole (bulk)
levoleucovorin	Khapzory
levoleucovorin calcium	Fusilev

Appendix D. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Exclusion Criteria in this Request

Generic Name/Nonproprietary	Brand Name/Proprietary
levoleucovorin calcium	levoleucovorin calcium
lisocabtagene maraleucel	Breyanzi
lisocabtagene maraleucel, CD4 component, 2 of 2	Breyanzi CD4 Component (2of 2)
lisocabtagene maraleucel, CD8 component, 1 of 2	Breyanzi CD8 Component (1of 2)
lomustine	CeeNU
lomustine	Gleostine
lomustine	lomustine
loncastuximab tesirine-lpyl	Zynlonta
lorlatinib	Lorbrena
lurbinectedin	Zepzelca
lutetium Lu 177 dotatate	Lutathera
margetuximab-cmkb	Margenza
mechlorethamine HCl	Mustargen
mechlorethamine HCl	Valchlor
mechlorethamine HCl	mechlorethamine (bulk)
medroxyprogesterone acetate	Depo-Provera
megestrol acetate	megestrol
megestrol acetate,micronized	megestrol acetate,micro (bulk)
melphalan	Alkeran
melphalan	melphalan
melphalan HCl	Alkeran (as HCl)
melphalan HCl	melphalan HCl
melphalan HCl/betadex sulfobutyl ether sodium	Evomela
melphalan flufenamide hydrochloride	Pepaxto
mercaptopurine	Purinethol
mercaptopurine	Purixan
mercaptopurine	mercaptopurine
mercaptopurine	mercaptopurine (bulk)
mesna	Mesnex
mesna	mesna
methotrexate	Xatmep
methotrexate	methotrexate (bulk)
methotrexate sodium	Rheumatrex
methotrexate sodium	Trexall
methotrexate sodium	methotrexate sodium
methotrexate sodium/PF	methotrexate sodium (PF)
methoxsalen	Uvadex
methoxsalen	methoxsalen (bulk)
midostaurin	Rydapt
mitomycin	Jelmyto
mitomycin	Mutamycin
mitomycin	mitomycin
mitomycin	mitomycin (bulk)
mitotane	Lysodren
mitotane	mitotane (bulk)
mitoxantrone HCl	Novantrone
mitoxantrone HCl	mitoxantrone
mobocertinib succinate	Exkivity

Appendix D. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Exclusion Criteria in this Request

Generic Name/Nonproprietary	Brand Name/Proprietary
mogamulizumab-kpkc	Poteligeo
moxetumomab pasudotox-tdfk	Lumoxiti
naxitamab-gqgk	Danyelza
necitumumab	Portrazza
nelarabine	Arranon
nelarabine	nelarabine
neratinib maleate	Nerlynx
nilotinib HCl	Tasigna
nilutamide	Nilandron
nilutamide	nilutamide
nintedanib esylate	Ofev
niraparib tosylate	Zejula
nivolumab	Opdivo
obinutuzumab	Gazyva
ofatumumab	Arzerra
olaparib	Lynparza
olaratumab	Lartruvo
omacetaxine mepesuccinate	Synribo
osimertinib mesylate	Tagrisso
oxaliplatin	Eloxatin
oxaliplatin	oxaliplatin
paclitaxel	paclitaxel
paclitaxel protein-bound	Abraxane
palbociclib	Ibrance
panitumumab	Vectibix
panobinostat lactate	Farydak
pazopanib HCl	Votrient
pegaspargase	Oncaspar
peginterferon alfa-2b	Sylatron
peginterferon alfa-2b	Sylatron 4-Pack
pembrolizumab	Keytruda
pemetrexed	Pemfexy
pemetrexed disodium	Alimta
pemigatinib	Pemazyre
pentostatin	Nipent
pentostatin	pentostatin
pertuzumab	Perjeta
pertuzumab-trastuzumab-hyaluronidase-zzxf	Phesgo
pexidartinib hydrochloride	Turalio
polatuzumab vedotin-piiq	Polivy
pomalidomide	Pomalyst
ponatinib HCl	Iclusig
porfimer sodium	Photofrin
pralatrexate	Folotyn
pralsetinib	Gavreto
procarbazine HCl	Matulane
procarbazine HCl	procarbazine HCl (bulk)
radium-223 dichloride	Xofigo

Appendix D. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Exclusion Criteria in this Request

Generic Name/Nonproprietary	Brand Name/Proprietary
ramucirumab	Cyramza
regorafenib	Stivarga
relugolix	Orgovyx
ribociclib succinate	Kisqali
ribociclib succinate/letrozole	Kisqali Femara Co-Pack
ripretinib	Qinlock
rituximab	Rituxan
rituximab-abbs	Truxima
rituximab-arrx	Riabni
rituximab-pvvr	Ruxience
rituximab/hyaluronidase, human recombinant	Rituxan Hycela
romidepsin	Istodax
romidepsin	romidepsin
ropeginterferon alfa-2b-njft	Besremi
rucaparib camsylate	Rubraca
ruxolitinib phosphate	Jakafi
sacituzumab govitecan-hziy	Trodelvy
samarium Sm 153 lexidronam	Quadramet
selinexor	Xpovio
selpercatinib	Retevmo
selumetinib sulfate/vitamin E TPGS	Koselugo
siltuximab	Sylvant
sipuleucel-T/lactated ringers solution	Provenge
sirolimus protein-bound	Fyarro
sodium butyrate	sodium butyrate (bulk)
sodium iodide-131	Hicon
sonidegib phosphate	Odomzo
sorafenib tosylate	Nexavar
sotorasib	Lumakras
streptozocin	Zanosar
strontium-89 chloride	Metastron
strontium-89 chloride	strontium-89 chloride
sunitinib malate	Sutent
sunitinib malate	sunitinib
tafasitamab-cxix	Monjuvi
tagraxofusp-erzs	Elzonris
talazoparib tosylate	Talzenna
talimogene laherparepvec	Imlygic
tamoxifen citrate	Soltamox
tamoxifen citrate	tamoxifen
tamoxifen citrate	tamoxifen (bulk)
tazemetostat hydrobromide	Tazverik
tebentafusp-tebn	Kimmtrak
temozolomide	Temodar
temozolomide	temozolomide
temsirolimus	Torisel
temsirolimus	temsirolimus
teniposide	Vumon

Appendix D. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Exclusion Criteria in this Request

Generic Name/Nonproprietary	Brand Name/Proprietary
teniposide	teniposide
tepotinib HCl	Tepmetko
thalidomide	Thalomid
thioguanine	Tabloid
thioguanine	thioguanine (bulk)
thiotepa	Tepadina
thiotepa	thiotepa
thiotepa	thiotepa (bulk)
tisagenlecleucel	Kymriah
tisotumab vedotin-tftv	Tivdak
tivozanib HCl	Fotivda
topotecan HCl	Hycamtin
topotecan HCl	topotecan
toremifene citrate	Fareston
toremifene citrate	toremifene
tositumomab (with maltose)	Bexxar Dosimetric
tositumomab (with maltose)	Bexxar Therapeutic
trabectedin	Yondelis
trametinib dimethyl sulfoxide	Mekinist
trastuzumab	Herceptin
trastuzumab-anns	Kanjinti
trastuzumab-dkst	Ogivri
trastuzumab-dttb	Ontruzant
trastuzumab-hyaluronidase-oysk	Herceptin Hylecta
trastuzumab-pkrb	Herzuma
trastuzumab-qyyp	Trazimera
tretinoin	tretinoin (antineoplastic)
trifluridine/tipiracil HCl	Lonsurf
trilaciclib dihydrochloride	Cosela
triptorelin pamoate	Trelstar
tucatinib	Tukysa
umbralisib tosylate	Ukoniq
uridine	uridine (bulk)
uridine triacetate	Vistogard
valrubicin	Valstar
valrubicin	valrubicin
vandetanib	Caprelsa
vandetanib	vandetanib
vemurafenib	Zelboraf
venetoclax	Venclexta
venetoclax	Venclexta Starting Pack
vinblastine sulfate	vinblastine
vincristine sulfate	Vincasar PFS
vincristine sulfate	vincristine
vincristine sulfate liposomal	Marqibo
vinorelbine tartrate	Navelbine
vinorelbine tartrate	vinorelbine
vismodegib	Erivedge

Appendix D. List of Generic/Nonproprietary and Brand/Proprietary Names of Medical Products Used to Define Exclusion Criteria in this Request

Generic Name/Nonproprietary	Brand Name/Proprietary
vorinostat	Zolinza
zanubrutinib	Brukinsa
ziv-aflibercept	Zaltrap

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Exposure Censoring Criteria in this Request

Generic Name	Brand Name
Other Antihypertensives	
aliskiren hemifumarate	Tekturna
aliskiren hemifumarate	aliskiren
aliskiren hemifumarate/amlodipine besylate	Tekamlo
aliskiren hemifumarate/amlodipine/hydrochlorothiazide	Amturnide
aliskiren hemifumarate/hydrochlorothiazide	Tekturna HCT
ambrisentan	Letairis
ambrisentan	ambrisentan
amlodipine besylate/benazepril HCl	Lotrel
amlodipine besylate/benazepril HCl	amlodipine-benazepril
amlodipine besylate/olmesartan medoxomil	Azor
amlodipine besylate/olmesartan medoxomil	amlodipine-olmesartan
atenolol/chlorthalidone	Tenoretic 100
atenolol/chlorthalidone	Tenoretic 50
atenolol/chlorthalidone	atenolol-chlorthalidone
azilsartan medoxomil	Edarbi
azilsartan medoxomil/chlorthalidone	Edarbyclor
benazepril HCl	Lotensin
benazepril HCl	benazepril
benazepril HCl/hydrochlorothiazide	Lotensin HCT
benazepril HCl/hydrochlorothiazide	benazepril-hydrochlorothiazide
bisoprolol fumarate/hydrochlorothiazide	Ziac
bisoprolol fumarate/hydrochlorothiazide	bisoprolol-hydrochlorothiazide
bosentan	Tracleer
bosentan	bosentan
candesartan cilexetil	Atacand
candesartan cilexetil	candesartan
candesartan cilexetil/hydrochlorothiazide	Atacand HCT
candesartan cilexetil/hydrochlorothiazide	candesartan-hydrochlorothiazid
captopril	captopril
captopril/hydrochlorothiazide	captopril-hydrochlorothiazide
clonidine HCl	Catapres
clonidine HCl	Nexiclon XR
clonidine HCl	clonidine HCl
clonidine HCl/chlorthalidone	Clorpres
doxazosin mesylate	Cardura
doxazosin mesylate	Cardura XL
doxazosin mesylate	doxazosin
enalapril maleate	Epaned
enalapril maleate	Vasotec
enalapril maleate	enalapril maleate
enalapril maleate/hydrochlorothiazide	Vaseretic
enalapril maleate/hydrochlorothiazide	enalapril-hydrochlorothiazide
eplerenone	Inspra
eplerenone	eplerenone
eprosartan mesylate	Teveten
eprosartan mesylate	eprosartan
eprosartan mesylate/hydrochlorothiazide	Teveten HCT

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Exposure Censoring Criteria in this Request

Generic Name	Brand Name
finerenone	Kerendia
fosinopril sodium	fosinopril
fosinopril sodium/hydrochlorothiazide	fosinopril-hydrochlorothiazide
guanabenz acetate	guanabenz
guanfacine HCl	Tenex
guanfacine HCl	guanfacine
hydralazine HCl	hydralazine
irbesartan	Avapro
irbesartan	irbesartan
irbesartan/hydrochlorothiazide	Avalide
irbesartan/hydrochlorothiazide	irbesartan-hydrochlorothiazide
isosorbide dinitrate/hydralazine HCl	BiDil
isoxsuprine HCl	isoxsuprine
lisinopril	Prinivil
lisinopril	Qbrelis
lisinopril	Zestril
lisinopril	lisinopril
lisinopril/dietary supplement,comb.10	Lytensopril
lisinopril/dietary supplement,comb.10	Lytensopril-90
lisinopril/hydrochlorothiazide	Prinzide
lisinopril/hydrochlorothiazide	Zestoretic
lisinopril/hydrochlorothiazide	lisinopril-hydrochlorothiazide
losartan potassium	Cozaar
losartan potassium	losartan
losartan potassium/hydrochlorothiazide	Hyzaar
losartan potassium/hydrochlorothiazide	losartan-hydrochlorothiazide
macitentan	Opsumit
mecamylamine HCl	Vecamyl
methyldopa	methyldopa
methyldopa/hydrochlorothiazide	methyldopa-hydrochlorothiazide
metoprolol succinate/hydrochlorothiazide	Dutoprol
metoprolol succinate/hydrochlorothiazide	metoprolol su-hydrochlorothiaz
metoprolol tartrate/hydrochlorothiazide	Lopressor HCT
metoprolol tartrate/hydrochlorothiazide	metoprolol ta-hydrochlorothiaz
metyrosine	Demser
metyrosine	metyrosine
minoxidil	minoxidil
moexipril HCl	Univasc
moexipril HCl	moexipril
moexipril HCl/hydrochlorothiazide	Uniretic
moexipril HCl/hydrochlorothiazide	moexipril-hydrochlorothiazide
nadolol/bendroflumethiazide	Corzide
nadolol/bendroflumethiazide	nadolol-bendroflumethiazide
olmesartan medoxomil	Benicar
olmesartan medoxomil	olmesartan
olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide	Tribenzor

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Exposure Censoring Criteria in this Request

Generic Name	Brand Name
olmesartan medoxomil/amlodipine besylate/hydrochlorothiazide	olmesartan-amlodipin-hcthiazid
olmesartan medoxomil/hydrochlorothiazide	Benicar HCT
olmesartan medoxomil/hydrochlorothiazide	olmesartan-hydrochlorothiazide
papaverine HCl	papaverine
perindopril arginine/amlodipine besylate	Prestalia
perindopril erbumine	Aceon
perindopril erbumine	perindopril erbumine
phenoxybenzamine HCl	Dibenzyline
phenoxybenzamine HCl	phenoxybenzamine
prazosin HCl	Minipress
prazosin HCl	prazosin
propranolol HCl/hydrochlorothiazide	propranolol-hydrochlorothiazid
quinapril HCl	Accupril
quinapril HCl	quinapril
quinapril HCl/hydrochlorothiazide	Accuretic
quinapril HCl/hydrochlorothiazide	quinapril-hydrochlorothiazide
ramipril	Altace
ramipril	ramipril
reserpine	reserpine
riociguat	Adempas
selexipag	Uptravi
sildenafil citrate	Revatio
sildenafil citrate	sildenafil (pulm.hypertension)
spironolactone	Aldactone
spironolactone	CaroSpir
spironolactone	spironolactone
tadalafil	Adcirca
tadalafil	Alyq
tadalafil	tadalafil (pulm. hypertension)
telmisartan	Micardis
telmisartan	telmisartan
telmisartan/amlodipine besylate	Twynsta
telmisartan/amlodipine besylate	telmisartan-amlodipine
telmisartan/hydrochlorothiazide	Micardis HCT
telmisartan/hydrochlorothiazide	telmisartan-hydrochlorothiazid
terazosin HCl	terazosin
trandolapril	Mavik
trandolapril	trandolapril
trandolapril/verapamil HCl	Tarka
trandolapril/verapamil HCl	trandolapril-verapamil
treprostinil diolamine	Orenitram
Contaminated Valsartan Products	
amlodipine besylate/valsartan	amlodipine-valsartan
amlodipine besylate/valsartan/hydrochlorothiazide	amlodipine-valsartan-hcthiazid
amlodipine/valsartan	amlodipine/valsartan
valsartan	valsartan
valsartan/hydrochlorothiazide	valsartan-hydrochlorothiazide

Appendix E. List of Generic and Brand Names of Medical Products Used to Define Exposure Censoring Criteria in this Request

Generic Name	Brand Name
valsartan/hydrochlorothiazide	valsartan/hydrochlorothiazide
Non-Contaminated Valsartan Products	
Valsartan	Valsartan
aliskiren/valsartan	Valturna
amlodipine besylate/valsartan	Exforge
amlodipine besylate/valsartan	amlodipine-valsartan
amlodipine besylate/valsartan/hydrochlorothiazide	Exforge HCT
amlodipine besylate/valsartan/hydrochlorothiazide	amlodipine-valsartan-hcthiazid
amlodipine/valsartan	amlodipine/valsartan
amlodipine/valsartan/hydrochlorothiazide	amlodipine/valsartan/hydrochlorothiazide
sacubitril/valsartan	Entresto
valsartan	Diovan
valsartan	valsartan
valsartan/hydrochlorothiazide	Diovan HCT
valsartan/hydrochlorothiazide	valsartan-hydrochlorothiazide
valsartan/hydrochlorothiazide	valsartan/hydrochlorothiazide
Unclassified Valsartan Products	
amlodipine besylate/valsartan	amlodipine-valsartan
amlodipine besylate/valsartan/hydrochlorothiazide	amlodipine-valsartan-hcthiazid
nebivolol HCl/valsartan	Byvalson
valsartan	valsartan
valsartan/hydrochlorothiazide	valsartan-hydrochlorothiazide

Appendix F. Specifications Defining Type 2 Parameters Used in this Request

The Center for Drug Evaluation and Research has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool [version 11.3.0] to estimate rates of valsartan utilization with in the Sentinel Distributed Database (SDD).

Query Period: May 1, 2012 - most recent available data (March 31, 2022)
Coverage requirement: Medical & Drug Coverage
Pre-Index Enrollment: 365 days
Enrollment Gap: 45 days
Age Group: 18-44, 45-64, 65-74, 75-84, 85+
Post-index enrollment requirement: 0
Stratifications: Year-Month, Age*Year-Month
Follow-up Time output categorization: 0-<1 year, 1-<2 years, 2-<3 years, 3-<4 years, 4-<5 years, 5+ years
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: Yes (for plus programming functionality)

Exposure/Event

Scenario	Index Exposure/ Event	Cohort definition	Washout period	Incident w/ respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Exposure episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor enrollment at evidence of
1	Any valsartan products	All valid index dates during query period (02)	0	n/a	n/a	30 days	30 days	Any	n/a	N	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *End of episode; *Switch to another antihypertensive
2	Contaminated valsartan products (Contaminated or recalled)	All valid index dates during query period (02)	0	n/a	n/a	30 days	30 days	Any	n/a	N	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *End of episode; *Switch to non-contaminated/branded valsartan category; *Switch to unclassified valsartan category; *Switch to another antihypertensive

Appendix F. Specifications Defining Type 2 Parameters Used in this Request

Scenario	Index Exposure/ Event	Cohort definition	Washout period	Incident w/ respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Exposure episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor enrollment at evidence of
3	Non-contaminated valsartan products (Non-contaminated or branded unclassified)	All valid index dates during query period (02)	0	n/a	n/a	30 days	30 days	Any	n/a	N	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *End of episode; *Switch to contaminated/recalled valsartan category; *Switch to unclassified valsartan category; *Switch to another antihypertensive
4	Any valsartan products	All valid index dates during query period (02)	365 (done via exclusion criteria)	All valsartan products	N	30 days	30 days	Any	n/a	N	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *End of episode; *Switch to another antihypertensive
5	Contaminated valsartan products (Contaminated or recalled)	All valid index dates during query period (02)	365 (done via exclusion criteria)	All valsartan products	N	30 days	30 days	Any	n/a	N	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *End of episode; *Switch to non-contaminated/branded valsartan category; *Switch to unclassified valsartan category; *Switch to another antihypertensive
6	Non-contaminated valsartan products (Non-contaminated or branded unclassified)	All valid index dates during query period (02)	365 (done via exclusion criteria)	All valsartan products	N	30 days	30 days	Any	n/a	N	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *End of episode; *Switch to contaminated/recalled valsartan category; *Switch to unclassified valsartan category; *Switch to another antihypertensive

Appendix F. Specifications Defining Type 2 Parameters Used in this Request

Scenario	Index Exposure/ Event	Cohort definition	Washout period	Incident w/ respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Exposure episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor enrollment at evidence of
7	Contaminated valsartan products (Contaminated or recalled)	All valid index dates during query period (02)	0	n/a	n/a	30 days	30 days	Any	n/a	N	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; (note: use plus programming to not censor on episode end date)
8	Contaminated valsartan products (Contaminated or recalled)	All valid index dates during query period (02)	0	n/a	n/a	30 days	30 days	Any	n/a	N	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *Switch to non-contaminated category; *Switch to unclassified valsartan category (note: use plus programming to not censor on episode end date)
9	Contaminated valsartan products (Contaminated or recalled)	All valid index dates during query period (02)	0	n/a	n/a	30 days	30 days	Any	n/a	N	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *End of Episode
10	Contaminated valsartan products (Contaminated or recalled)	All valid index dates during query period (02)	0	n/a	n/a	30 days	30 days	Any	n/a	N	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *End of Episode; *Switch to non-contaminated category; *Switch to unclassified valsartan category
11	Contaminated valsartan products (Contaminated or recalled)	All valid index dates during query period (02)	365 (done via exclusion criteria)	All valsartan products	N	30 days	30 days	Any	n/a	N	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; (note: use plus programming to not censor on episode end date)

Appendix F. Specifications Defining Type 2 Parameters Used in this Request

Scenario	Index Exposure/ Event	Cohort definition	Washout period	Incident w/ respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Exposure episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor enrollment at evidence of
12	Contaminated valsartan products (Contaminated or recalled)	All valid index dates during query period (02)	365 (done via exclusion criteria)	All valsartan products	N	30 days	30 days	Any	n/a	N	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *Switch to non-contaminated category; *Switch to unclassified valsartan category (note: use plus programming to not censor on episode end date)
13	Contaminated valsartan products (Contaminated or recalled)	All valid index dates during query period (02)	365 (done via exclusion criteria)	All valsartan products	N	30 days	30 days	Any	n/a	N	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *End of Episode
14	Contaminated valsartan products (Contaminated or recalled)	All valid index dates during query period (02)	365 (done via exclusion criteria)	All valsartan products	N	30 days	30 days	Any	n/a	N	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *End of Episode; *Switch to non-contaminated category; *Switch to unclassified valsartan category
15	Non-contaminated valsartan products (Non-contaminated or branded unclassified)	All valid index dates during query period (02)	0	n/a	n/a	30 days	30 days	Any	n/a	N	*Death; *Data Partner End Date; *Query End Date; *Disenrollment *Switch to contaminated/recalled valsartan category; *Switch to unclassified valsartan category (note: use plus programming to not censor on episode end date)

Appendix F. Specifications Defining Type 2 Parameters Used in this Request

Scenario	Index Exposure/ Event	Cohort definition	Washout period	Incident w/ respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Exposure episode extension	Care setting	Principal diagnosis position	Create Baseline Table?	Censor enrollment at evidence of
16	Non-contaminated valsartan products (Non-contaminated or branded unclassified)	All valid index dates during query period (02)	0	n/a	n/a	30 days	30 days	Any	n/a	N	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *End of Episode; *Switch to contaminated/recalled valsartan category; *Switch to unclassified valsartan category
17	Non-contaminated valsartan products (Non-contaminated or branded unclassified)	All valid index dates during query period (02)	365 (done via exclusion criteria)	All valsartan products	n/a	30 days	30 days	Any	n/a	N	*Death; *Data Partner End Date; *Query End Date; *Disenrollment *Switch to contaminated/recalled valsartan category; *Switch to unclassified valsartan category (note: use plus programming to not censor on episode end date)
18	Non-contaminated valsartan products (Non-contaminated or branded unclassified)	All valid index dates during query period (02)	365 (done via exclusion criteria)	All valsartan products	n/a	30 days	30 days	Any	n/a	N	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *End of Episode; *Switch to contaminated/recalled valsartan category; *Switch to unclassified valsartan category

ICD-9, ICD-10, HCPCS, and CPT codes are provided by Optum360.

NDC codes are checked against First Data Bank's FDB MedKnowledge®.

Appendix F. Specifications Defining Type 2 Parameters Used in this Request

The Center for Drug Evaluation and Research has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool [version 11.3.0] to estimate rates of valsartan utilization with in the Sentinel Distributed Database (SDD).

	Inclusion/Exclusion								
Scenario	Inclusion/ Exclusion	Criteria	Care setting	Principal diagnosis position	Evaulation period start	Evaluation period end	Exclude evidence of days supply if inclusion/exclusion evaluation period includes dispensings	Number of instances the criteria should be found in evaluation period	Forced supply to attach to dispensings
1	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1	n/a
2	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1	n/a
3	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1	n/a
4	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1	n/a
5	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1	n/a
6	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1	n/a
7	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1	n/a
8	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1	n/a
9	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1	n/a
10	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1	n/a
11	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1	n/a
12	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1	n/a

Appendix F. Specifications Defining Type 2 Parameters Used in this Request

Inclusion/Exclusion

Scenario	Inclusion/ Exclusion	Criteria	Care setting	Principal diagnosis position	Evaulation period start	Evaluation period end	Exclude evidence of days supply if inclusion/exclusion evaluation period includes dispensings	Number of instances the criteria should be found in evaluation period	Forced supply to attach to dispensings
13	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1	n/a
14	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1	n/a
15	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1	n/a
16	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1	n/a
17	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1	n/a
18	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1	n/a

ICD-9, ICD-10, HCPCS, and CPT codes are provided by Optum360.
NDC codes are checked against First Data Bank's FDB MedKnowledge®.

Appendix G. Specifications Defining Type 5 Parameters Used in this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool [11.3.0] to investigate the cumulative exposed days and cumulative exposed dose for valsartan products in the Sentinel Distributed Database (SDD), to inform the full analysis for cder_mpl1p_wp066.

Query period: May 1, 2012 to most recent available data (March 31, 2022)
Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 365
Post-index enrollment requirement: 0
Enrollment gap: 45
Age groups: 18-44, 45-64, 65-74, 75-84, 85+
Stratifications: n/a
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: No

Exposure

Scenario	Index Exposure	Cohort definition	Incident exposure washout period	Incident w/ respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment extension period	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:	Episode Duration Category	Cumulative Dose Category
1	Any Valsartan Products	Include all valid exposure episodes during query period (cohort def 02 using plus programming)	0	n/a	n/a	30 days	30 days	Any care setting	n/a	No	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *End of episode; *Switch to another antihypertensive	0-3 months, 4-6 months, 6 months-1 year, 1-1.5 years, 1.5-2 years, 2+ years	<=7300, 7301-14600, 14601-29200, 29201-43800, 43801-58400, 58401-116800, 116801-175200, 175201-233600, 233601+

Appendix G. Specifications Defining Type 5 Parameters Used in this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool [11.3.0] to investigate the cumulative exposed days and cumulative exposed dose for valsartan products in the Sentinel Distributed Database (SDD), to inform the full analysis for cder_mpl1p_wp066.

Query period: May 1, 2012 to most recent available data (March 31, 2022)
Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 365
Post-index enrollment requirement: 0
Enrollment gap: 45
Age groups: 18-44, 45-64, 65-74, 75-84, 85+
Stratifications: n/a
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: No

Exposure

Scenario	Index Exposure	Cohort definition	Incident exposure washout period	Incident w/ respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment extension period	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:	Episode Duration Category	Cumulative Dose Category
2	Contaminated valsartan products (Contaminated or recalled)	Include all valid exposure episodes during query period (cohort def 02 using plus programming)	0	n/a	n/a	30 days	30 days	Any care setting	n/a	No	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *End of episode; *Switch to non-contaminated/branded valsartan category; *Switch to unclassified valsartan category; *Switch to another antihypertensive	0-3 months, 4-6 months, 6 months-1 year, 1-1.5 years, 1.5-2 years, 2+ years	<=7300, 7301-14600, 14601-29200, 29201-43800, 43801-58400, 58401-116800, 116801-175200, 175201-233600, 233601+

Appendix G. Specifications Defining Type 5 Parameters Used in this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool [11.3.0] to investigate the cumulative exposed days and cumulative exposed dose for valsartan products in the Sentinel Distributed Database (SDD), to inform the full analysis for cder_mpl1p_wp066.

Query period: May 1, 2012 to most recent available data (March 31, 2022)
Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 365
Post-index enrollment requirement: 0
Enrollment gap: 45
Age groups: 18-44, 45-64, 65-74, 75-84, 85+
Stratifications: n/a
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: No

Exposure

Scenario	Index Exposure	Cohort definition	Incident exposure washout period	Incident w/ respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment extension period	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:	Episode Duration Category	Cumulative Dose Category
3	Non-contaminated valsartan products (Non-contaminated or branded unclassified)	Include all valid exposure episodes during query period (cohort def 02 using plus programming)	0	n/a	n/a	30 days	30 days	Any care setting	n/a	No	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *End of episode; *Switch to contaminated/recalled valsartan category; *Switch to unclassified valsartan category; *Switch to another antihypertensive	0-3 months, 4-6 months, 6 months-1 year, 1-1.5 years, 1.5-2 years, 2+ years	<=7300, 7301-14600, 14601-29200, 29201-43800, 43801-58400, 58401-116800, 116801-175200, 175201-233600, 233601+

Appendix G. Specifications Defining Type 5 Parameters Used in this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool [11.3.0] to investigate the cumulative exposed days and cumulative exposed dose for valsartan products in the Sentinel Distributed Database (SDD), to inform the full analysis for cder_mpl1p_wp066.

Query period: May 1, 2012 to most recent available data (March 31, 2022)
Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 365
Post-index enrollment requirement: 0
Enrollment gap: 45
Age groups: 18-44, 45-64, 65-74, 75-84, 85+
Stratifications: n/a
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: No

Exposure

Scenario	Index Exposure	Cohort definition	Incident exposure washout period	Incident w/ respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment extension period	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:	Episode Duration Category	Cumulative Dose Category
4	Any Valsartan Products	Include all valid exposure episodes during query period (cohort def 02 using plus programming)	365 (done via exclusion criteria)	All valsartan products	No	30 days	30 days	Any care setting	n/a	No	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *End of episode; *Switch to another antihypertensive	0-3 months, 4-6 months, 6 months-1 year, 1-1.5 years, 1.5-2 years, 2+ years	<=7300, 7301-14600, 14601-29200, 29201-43800, 43801-58400, 58401-116800, 116801-175200, 175201-233600, 233601+

Appendix G. Specifications Defining Type 5 Parameters Used in this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool [11.3.0] to investigate the cumulative exposed days and cumulative exposed dose for valsartan products in the Sentinel Distributed Database (SDD), to inform the full analysis for cder_mpl1p_wp066.

Query period: May 1, 2012 to most recent available data (March 31, 2022)
Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 365
Post-index enrollment requirement: 0
Enrollment gap: 45
Age groups: 18-44, 45-64, 65-74, 75-84, 85+
Stratifications: n/a
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: No

Exposure

Scenario	Index Exposure	Cohort definition	Incident exposure washout period	Incident w/ respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment extension period	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:	Episode Duration Category	Cumulative Dose Category
5	Contaminated valsartan products (Contaminated or recalled)	Include all valid exposure episodes during query period (cohort def 02 using plus programming)	365 (done via exclusion criteria)	All valsartan products	No	30 days	30 days	Any care setting	n/a	No	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *End of episode; *Switch to non-contaminated/branded valsartan category; *Switch to unclassified valsartan category; *Switch to another antihypertensive	0-3 months, 4-6 months, 6 months-1 year, 1-1.5 years, 1.5-2 years, 2+ years	<=7300, 7301-14600, 14601-29200, 29201-43800, 43801-58400, 58401-116800, 116801-175200, 175201-233600, 233601+

Appendix G. Specifications Defining Type 5 Parameters Used in this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool [11.3.0] to investigate the cumulative exposed days and cumulative exposed dose for valsartan products in the Sentinel Distributed Database (SDD), to inform the full analysis for cder_mpl1p_wp066.

Query period: May 1, 2012 to most recent available data (March 31, 2022)
Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 365
Post-index enrollment requirement: 0
Enrollment gap: 45
Age groups: 18-44, 45-64, 65-74, 75-84, 85+
Stratifications: n/a
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: No

Exposure

Scenario	Index Exposure	Cohort definition	Incident exposure washout period	Incident w/ respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment extension period	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:	Episode Duration Category	Cumulative Dose Category
6	Non-contaminated valsartan products (Non-contaminated or branded unclassified)	Include all valid exposure episodes during query period (cohort def 02 using plus programming)	365 (done via exclusion criteria)	All valsartan products	No	30 days	30 days	Any care setting	n/a	Yes	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *End of episode; *Switch to contaminated/recalled valsartan category; *Switch to unclassified valsartan category; *Switch to another antihypertensive	0-3 months, 4-6 months, 6 months-1 year, 1-1.5 years, 1.5-2 years, 2+ years	<=7300, 7301-14600, 14601-29200, 29201-43800, 43801-58400, 58401-116800, 116801-175200, 175201-233600, 233601+

Appendix G. Specifications Defining Type 5 Parameters Used in this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool [11.3.0] to investigate the cumulative exposed days and cumulative exposed dose for valsartan products in the Sentinel Distributed Database (SDD), to inform the full analysis for cder_mpl1p_wp066.

Query period: May 1, 2012 to most recent available data (March 31, 2022)
Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 365
Post-index enrollment requirement: 0
Enrollment gap: 45
Age groups: 18-44, 45-64, 65-74, 75-84, 85+
Stratifications: n/a
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: No

Exposure

Scenario	Index Exposure	Cohort definition	Incident exposure washout period	Incident w/ respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment extension period	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:	Episode Duration Category	Cumulative Dose Category
7	Contaminated valsartan products (Contaminated or recalled)	Include all valid exposure episodes during query period (cohort def 02 using plus programming)	0	n/a	n/a	30 days	30 days	Any care setting	n/a	No	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; (note: use plus programming to not censor on episode end date)	0-3 months, 4-6 months, 6 months-1 year, 1-1.5 years, 1.5-2 years, 2+ years	<=7300, 7301-14600, 14601-29200, 29201-43800, 43801-58400, 58401-116800, 116801-175200, 175201-233600, 233601+

Appendix G. Specifications Defining Type 5 Parameters Used in this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool [11.3.0] to investigate the cumulative exposed days and cumulative exposed dose for valsartan products in the Sentinel Distributed Database (SDD), to inform the full analysis for cder_mpl1p_wp066.

Query period: May 1, 2012 to most recent available data (March 31, 2022)
Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 365
Post-index enrollment requirement: 0
Enrollment gap: 45
Age groups: 18-44, 45-64, 65-74, 75-84, 85+
Stratifications: n/a
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: No

Exposure

Scenario	Index Exposure	Cohort definition	Incident exposure washout period	Incident w/ respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment extension period	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:	Episode Duration Category	Cumulative Dose Category
8	Contaminated valsartan products (Contaminated or recalled)	Include all valid exposure episodes during query period (cohort def 02 using plus programming)	0	n/a	n/a	30 days	30 days	Any care setting	n/a	No	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *Switch to unclassified valsartan category (note: use plus programming to not censor on episode end date)	0-3 months, 4-6 months, 6 months-1 year, 1-1.5 years, 1.5-2 years, 2+ years	<=7300, 7301-14600, 14601-29200, 29201-43800, 43801-58400, 58401-116800, 116801-175200, 175201-233600, 233601+

Appendix G. Specifications Defining Type 5 Parameters Used in this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool [11.3.0] to investigate the cumulative exposed days and cumulative exposed dose for valsartan products in the Sentinel Distributed Database (SDD), to inform the full analysis for cder_mpl1p_wp066.

Query period: May 1, 2012 to most recent available data (March 31, 2022)
Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 365
Post-index enrollment requirement: 0
Enrollment gap: 45
Age groups: 18-44, 45-64, 65-74, 75-84, 85+
Stratifications: n/a
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: No

Exposure

Scenario	Index Exposure	Cohort definition	Incident exposure washout period	Incident w/ respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment extension period	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:	Episode Duration Category	Cumulative Dose Category
9	Contaminated valsartan products (Contaminated or recalled)	Include all valid exposure episodes during query period (cohort def 02 using plus programming)	0	n/a	n/a	30 days	30 days	Any care setting	n/a	No	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *End of Episode	0-3 months, 4-6 months, 6 months-1 year, 1-1.5 years, 1.5-2 years, 2+ years	<=7300, 7301-14600, 14601-29200, 29201-43800, 43801-58400, 58401-116800, 116801-175200, 175201-233600, 233601+

Appendix G. Specifications Defining Type 5 Parameters Used in this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool [11.3.0] to investigate the cumulative exposed days and cumulative exposed dose for valsartan products in the Sentinel Distributed Database (SDD), to inform the full analysis for cder_mpl1p_wp066.

Query period: May 1, 2012 to most recent available data (March 31, 2022)
Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 365
Post-index enrollment requirement: 0
Enrollment gap: 45
Age groups: 18-44, 45-64, 65-74, 75-84, 85+
Stratifications: n/a
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: No

Exposure

Scenario	Index Exposure	Cohort definition	Incident exposure washout period	Incident w/ respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment extension period	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:	Episode Duration Category	Cumulative Dose Category
10	Contaminated valsartan products (Contaminated or recalled)	Include all valid exposure episodes during query period (cohort def 02 using plus programming)	0	n/a	n/a	30 days	30 days	Any care setting	n/a	No	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *End of Episode; *Switch to unclassified valsartan category	0-3 months, 4-6 months, 6 months-1 year, 1-1.5 years, 1.5-2 years, 2+ years	<=7300, 7301-14600, 14601-29200, 29201-43800, 43801-58400, 58401-116800, 116801-175200, 175201-233600, 233601+

Appendix G. Specifications Defining Type 5 Parameters Used in this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool [11.3.0] to investigate the cumulative exposed days and cumulative exposed dose for valsartan products in the Sentinel Distributed Database (SDD), to inform the full analysis for cder_mpl1p_wp066.

Query period: May 1, 2012 to most recent available data (March 31, 2022)
Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 365
Post-index enrollment requirement: 0
Enrollment gap: 45
Age groups: 18-44, 45-64, 65-74, 75-84, 85+
Stratifications: n/a
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: No

Exposure

Scenario	Index Exposure	Cohort definition	Incident exposure washout period	Incident w/ respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment extension period	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:	Episode Duration Category	Cumulative Dose Category
11	Contaminated valsartan products (Contaminated or recalled)	Include all valid exposure episodes during query period (cohort def 02 using plus programming)	365 (done via exclusion criteria)	All valsartan products	n/a	30 days	30 days	Any care setting	n/a	No	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; (note: use plus programming to not censor on episode end date)	0-3 months, 4-6 months, 6 months-1 year, 1-1.5 years, 1.5-2 years, 2+ years	<=7300, 7301-14600, 14601-29200, 29201-43800, 43801-58400, 58401-116800, 116801-175200, 175201-233600, 233601+

Appendix G. Specifications Defining Type 5 Parameters Used in this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool [11.3.0] to investigate the cumulative exposed days and cumulative exposed dose for valsartan products in the Sentinel Distributed Database (SDD), to inform the full analysis for cder_mpl1p_wp066.

Query period: May 1, 2012 to most recent available data (March 31, 2022)
Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 365
Post-index enrollment requirement: 0
Enrollment gap: 45
Age groups: 18-44, 45-64, 65-74, 75-84, 85+
Stratifications: n/a
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: No

Exposure

Scenario	Index Exposure	Cohort definition	Incident exposure washout period	Incident w/ respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment extension period	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:	Episode Duration Category	Cumulative Dose Category
12	Contaminated valsartan products (Contaminated or recalled)	Include all valid exposure episodes during query period (cohort def 02 using plus programming)	365 (done via exclusion criteria)	All valsartan products	n/a	30 days	30 days	Any care setting	n/a	No	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *Switch to unclassified valsartan category (note: use plus programming to not censor on episode end date)	0-3 months, 4-6 months, 6 months-1 year, 1-1.5 years, 1.5-2 years, 2+ years	<=7300, 7301-14600, 14601-29200, 29201-43800, 43801-58400, 58401-116800, 116801-175200, 175201-233600, 233601+

Appendix G. Specifications Defining Type 5 Parameters Used in this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool [11.3.0] to investigate the cumulative exposed days and cumulative exposed dose for valsartan products in the Sentinel Distributed Database (SDD), to inform the full analysis for cder_mpl1p_wp066.

Query period: May 1, 2012 to most recent available data (March 31, 2022)
Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 365
Post-index enrollment requirement: 0
Enrollment gap: 45
Age groups: 18-44, 45-64, 65-74, 75-84, 85+
Stratifications: n/a
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: No

Exposure

Scenario	Index Exposure	Cohort definition	Incident exposure washout period	Incident w/ respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment extension period	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:	Episode Duration Category	Cumulative Dose Category
13	Contaminated valsartan products (Contaminated or recalled)	Include all valid exposure episodes during query period (cohort def 02 using plus programming)	365 (done via exclusion criteria)	All valsartan products	n/a	30 days	30 days	Any care setting	n/a	No	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *End of Episode	0-3 months, 4-6 months, 6 months-1 year, 1-1.5 years, 1.5-2 years, 2+ years	<=7300, 7301-14600, 14601-29200, 29201-43800, 43801-58400, 58401-116800, 116801-175200, 175201-233600, 233601+

Appendix G. Specifications Defining Type 5 Parameters Used in this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool [11.3.0] to investigate the cumulative exposed days and cumulative exposed dose for valsartan products in the Sentinel Distributed Database (SDD), to inform the full analysis for cder_mpl1p_wp066.

Query period: May 1, 2012 to most recent available data (March 31, 2022)
Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 365
Post-index enrollment requirement: 0
Enrollment gap: 45
Age groups: 18-44, 45-64, 65-74, 75-84, 85+
Stratifications: n/a
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: No

Exposure

Scenario	Index Exposure	Cohort definition	Incident exposure washout period	Incident w/ respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment extension period	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:	Episode Duration Category	Cumulative Dose Category
14	Contaminated valsartan products (Contaminated or recalled)	Include all valid exposure episodes during query period (cohort def 02 using plus programming)	365 (done via exclusion criteria)	All valsartan products	n/a	30 days	30 days	Any care setting	n/a	No	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *End of Episode; *Switch to unclassified valsartan category	0-3 months, 4-6 months, 6 months-1 year, 1-1.5 years, 1.5-2 years, 2+ years	<=7300, 7301-14600, 14601-29200, 29201-43800, 43801-58400, 58401-116800, 116801-175200, 175201-233600, 233601+

Appendix G. Specifications Defining Type 5 Parameters Used in this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool [11.3.0] to investigate the cumulative exposed days and cumulative exposed dose for valsartan products in the Sentinel Distributed Database (SDD), to inform the full analysis for cder_mpl1p_wp066.

Query period: May 1, 2012 to most recent available data (March 31, 2022)
Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 365
Post-index enrollment requirement: 0
Enrollment gap: 45
Age groups: 18-44, 45-64, 65-74, 75-84, 85+
Stratifications: n/a
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: No

Exposure

Scenario	Index Exposure	Cohort definition	Incident exposure washout period	Incident w/ respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment extension period	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:	Episode Duration Category	Cumulative Dose Category
15	Non-contaminated valsartan products (Non-contaminated or branded unclassified)	Include all valid exposure episodes during query period (cohort def 02 using plus programming)	0	n/a	n/a	30 days	30 days	Any care setting	n/a	No	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *Switch to contaminated/recalled valsartan category; *Switch to unclassified valsartan category (note: use plus programming to not censor on episode end date)	0-3 months, 4-6 months, 6 months-1 year, 1-1.5 years, 1.5-2 years, 2+ years	<=7300, 7301-14600, 14601-29200, 29201-43800, 43801-58400, 58401-116800, 116801-175200, 175201-233600, 233601+

Appendix G. Specifications Defining Type 5 Parameters Used in this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool [11.3.0] to investigate the cumulative exposed days and cumulative exposed dose for valsartan products in the Sentinel Distributed Database (SDD), to inform the full analysis for cder_mpl1p_wp066.

Query period: May 1, 2012 to most recent available data (March 31, 2022)
Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 365
Post-index enrollment requirement: 0
Enrollment gap: 45
Age groups: 18-44, 45-64, 65-74, 75-84, 85+
Stratifications: n/a
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: No

Exposure

Scenario	Index Exposure	Cohort definition	Incident exposure washout period	Incident w/ respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment extension period	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:	Episode Duration Category	Cumulative Dose Category
16	Non-contaminated valsartan products (Non-contaminated or branded unclassified)	Include all valid exposure episodes during query period (cohort def 02 using plus programming)	0	n/a	n/a	30 days	30 days	Any care setting	n/a	No	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *End of Episode; *Switch to contaminated/recalled valsartan category; *Switch to unclassified valsartan category	0-3 months, 4-6 months, 6 months-1 year, 1-1.5 years, 1.5-2 years, 2+ years	<=7300, 7301-14600, 14601-29200, 29201-43800, 43801-58400, 58401-116800, 116801-175200, 175201-233600, 233601+

Appendix G. Specifications Defining Type 5 Parameters Used in this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool [11.3.0] to investigate the cumulative exposed days and cumulative exposed dose for valsartan products in the Sentinel Distributed Database (SDD), to inform the full analysis for cder_mpl1p_wp066.

Query period: May 1, 2012 to most recent available data (March 31, 2022)
Coverage requirement: Medical & Drug Coverage
Pre-index enrollment requirement: 365
Post-index enrollment requirement: 0
Enrollment gap: 45
Age groups: 18-44, 45-64, 65-74, 75-84, 85+
Stratifications: n/a
Envelope macro: Reclassify encounters during inpatient stay as inpatient
Freeze data: No
Exposure

Scenario	Index Exposure	Cohort definition	Incident exposure washout period	Incident w/ respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment extension period	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:	Episode Duration Category	Cumulative Dose Category
17	Non-contaminated valsartan products (Non-contaminated or branded unclassified)	Include all valid exposure episodes during query period (cohort def 02 using plus programming)	365 (done via exclusion criteria)	All valsartan products	n/a	30 days	30 days	Any care setting	n/a	No	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *Switch to contaminated/recalled valsartan category; *Switch to unclassified	0-3 months, 4-6 months, 6 months-1 year, 1-1.5 years, 1.5-2 years, 2+ years	<=7300, 7301-14600, 14601-29200, 29201-43800, 43801-58400, 58401-116800, 116801-175200, 175201-233600, 233601+
18	Non-contaminated valsartan products (Non-contaminated or branded unclassified)	Include all valid exposure episodes during query period (cohort def 02 using plus programming)	365 (done via exclusion criteria)	All valsartan products	n/a	30 days	30 days	Any care setting	n/a	No	*Death; *Data Partner End Date; *Query End Date; *Disenrollment; *End of Episode; *Switch to contaminated/recalled valsartan category;	0-3 months, 4-6 months, 6 months-1 year, 1-1.5 years, 1.5-2 years, 2+ years	<=7300, 7301-14600, 14601-29200, 29201-43800, 43801-58400, 58401-116800, 116801-175200, 175201-233600, 233601+

Appendix G. Specifications Defining Type 5 Parameters Used in this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool [11.3.0] to investigate the cumulative exposed days and cumulative exposed dose for valsartan products in the Sentinel Distributed Database (SDD), to inform the full analysis for cder_mpl1p_wp066.

Query period:	May 1, 2012 to most recent available data (March 31, 2022)
Coverage requirement:	Medical & Drug Coverage
Pre-index enrollment requirement:	365
Post-index enrollment requirement:	0
Enrollment gap:	45
Age groups:	18-44, 45-64, 65-74, 75-84, 85+
Stratifications:	n/a
Envelope macro:	Reclassify encounters during inpatient stay as inpatient
Freeze data:	No

Exposure

Scenario	Index Exposure	Cohort definition	Incident exposure washout period	Incident w/ respect to:	Exclude evidence of days supply if exposure washout includes dispensings	Treatment episode gap	Treatment extension period	Care setting	Principal diagnosis position	Create Baseline Table?	Censor treatment episode at evidence of:	Episode Duration Category	Cumulative Dose Category

NDC codes are checked against First Data Bank's FDB MedKnowledge®.

Appendix G. Specifications Defining Type 5 Parameters Used in this Request

The Center for Drug Evaluation and Research (CDER) has requested execution of the Cohort Identification and Descriptive Analysis (CIDA) tool [11.3.0] to investigate the cumulative exposed days and cumulative exposed dose for valsartan products in the Sentinel Distributed Database (SDD), to inform the full analysis for cder_mpl1p_wp066.

Inclusion/Exclusion Criteria

Scenario	Inclusion/ Exclusion group	Criteria	Care setting	Principal diagnosis position	Evaluation period start	Evaluation period end	Exclude evidence of days supply if inclusion/exclusion evaluation period includes dispensings	Number of instances the criteria should be found in evaluation period
1	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1
2	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1
3	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1
4	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1
5	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1
6	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1
7	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1
8	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1
9	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1
10	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1
11	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1

Appendix G. Specifications Defining Type 5 Parameters Used in this Request

Inclusion/Exclusion Criteria

Scenario	Inclusion/ Exclusion group	Criteria	Care setting	Principal diagnosis position	Evaluation period start	Evaluation period end	Exclude evidence of days supply if inclusion/exclusion evaluation period includes dispensings	Number of instances the criteria should be found in evaluation period
12	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1
13	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1
14	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1
15	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1
16	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1
17	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1
18	Cancer, Chemotherapy, Radiation, Cancer Surgery	Exclusion	Any	n/a	-365	-1	Evaluation period should search for evidence of days supply	1

NDC codes are checked against First Data Bank's FDB MedKnowledge®.

Appendix H. Design Diagram of Cohort Entry Requirements and Index Exposure



***Censoring Criteria**

1) Death
2) Data Partner End Date
3) Query End Date
4) Disenrollment
5) End of Episode
6) Switch to another antihypertensive
7) Switch to another valsartan category